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This book is dedicated to the non-human animals who suffer in the
name of science and whose destiny we are determined to change.
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Foreword
Peter Singer
From the time when I first became interested in the ethics of our treatment of
animals, I have always regarded the use of animals in research as a more difficult ethical issue than the use of animals for food. It is more difficult because
we have a wide range of tasty and nutritious food to eat, and it is obvious that
we can live healthy, flourishing lives without eating animals or animal products. It is true, sadly, that not everyone in the world has the luxury of being
able to choose what to eat. For the vast majority of people living in developed
countries, however, there is no need to eat animals or any animal products; and
the animal products they eat increase the risks to their health (see Chapter 4 in
this Volume). Those who continue to eat animals do it out of habit or because
they like the taste. On the other hand, some scientists tell us that to cease using
animals in biomedical research would greatly impede medical progress and,
in the long run, could lead to millions more premature deaths and additional
human suffering.
I am a philosopher, not a scientist, and my approach to issues relating to
animals has always been from an ethical perspective. Some people think that
taking an ethical approach to animal issues means that scientific claims about
the benefits of animal research are irrelevant because, even if research on animals could save many human lives, the end does not justify the means. That
is not how I see the issue. Although Kantians, and some other deontologists,
hold that the end does not justify the means, consequentialists regard the right
action as the one that will bring about the best consequences, so they hold that
the end can justify the means. I am a utilitarian, and utilitarianism is the bestknown form of consequentialism, so I share that view. As we can see from this
book, there is a case to be made for the view that continued animal research
could, in fact, be impeding scientific progress.
When it comes to protecting animals and giving proper consideration to
their interests, utilitarians have always been in the lead. Jeremy Bentham, the
founder of modern utilitarianism, wrote about animals, saying that, “The question is not, Can they reason? Nor, Can they talk? But, Can they suffer?”. Implicit
in the utilitarian emphasis on the capacity to suffer, and to experience pleasure, is the idea that all sentient beings have interests, and that similar interests should receive equal consideration, irrespective of race, sex, or species.
In contrast, the mainstream Abrahamic religions, Judaism, Christianity, and
Islam, all treat humans as entitled to use animals more or less as they wish,
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often seeing this as stemming from a divine grant of dominion over other animals. Christian teachings, from Augustine through Thomas Aquinas, and innumerable others on into the twentieth century, take this line. Kant also said
that we have no direct duties to animals, although the ground he gave for this
harsh position is that they are not self-conscious and, so, are merely means to
our ends. He does not explain why the absence of self-consciousness should
be a sufficient reason for denying that we have duties not to cause gratuitous
suffering to sentient beings.
Suppose that research on non-human animals turned out to yield misleading results, and only the use of one hundred human subjects, instead of the
one hundred animals, would lead to the cure that would save thousands of
lives. Defenders of animal research are loath to acknowledge that one implication of their defense of the use of animals in research might be that, in
some circumstances, it would be justifiable to use humans. One objection to
substituting humans for non-human animals would be that the greater self-
awareness of the humans means that they have more to lose and, so, would
suffer more from the knowledge that they are being experimented upon, than
would the non-human animals. But not all human beings have more selfawareness than non-human animals. Anencephalic infants do not, nor do people who are brain dead, or in a persistent vegetative state from which they will
never recover. The grounds on which Kant insisted that non-human animals
are merely means to our ends, rather than ends in themselves, would seem
to apply to these human beings as well. If they do not, why not? Should we
give preference to human beings, irrespective of their consciousness, merely
because they are biologically members of the species, Homo sapiens? How is
that different to giving preference to members of one race or gender, merely
because they are members of that race or gender? The institution of animal
experimentation is clearly based on speciesism. Chapters 14 to 20 in this Volume explore the difficulties in extrapolating findings from animals to humans.
These difficulties sharpen the question why we are willing to perform painful
or lethal experiments on non-human animals, who are clearly capable of suffering, while we are unwilling even to contemplate similar experiments on human beings, who are not capable of experiencing anything at all.
When I wrote Animal Liberation, which first appeared in 1975, it was shockingly easy to find accounts of horrific suffering inflicted on animals in the
course of experiments. These were not accounts written by animal rights activists (there were virtually none at the time anyway). They were written by the
researchers themselves and were published in leading scientific journals. All I
had to do to make the case that the interests of the animals were being utterly
disregarded was to quote from these journals, and I did so extensively. Since
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then, there has been progress in reducing animal suffering. European Union
Directive 2010/63/EU has been widely regarded as indicating that, at least in
the EU, pain and suffering is kept to a minimum, and animals are being replaced by non-animal-using methods wherever possible. The following pages
contain evidence that strongly suggests this is not the case. Particularly telling
are the observations, reported in Chapters 1 and 21 in this Volume, of abnormal
behavior and signs of stress in animals caused simply by living in standard
laboratory conditions. As these and other chapters show, even in Europe, there
is no ground for complacency about what happens to animals in science. The
situation is likely to be worse still in other countries. Nor should we neglect
the cost of using money in ways that are not maximally productive of benefits.
Chapter 10 explores the waste of United States public funds in research using
animals and asks whether the benefits achieved by such research are sufficient
to justify the cost.
This Volume, with its many distinct critical perspectives on research with
animals, is therefore very timely, particularly as I write this when Directive
2010/63/EU is under review. I hope it will transform discussion about the ethics and the science of research involving animals.

Preface
For close to a decade, I worked as a federal regulator, inspecting experiments
involving non-human animals (hereinafter referred to as animals) in Germany.
Because I had always been skeptical about the ethical and most of the scientific justifications given for conducting invasive research on animals, I felt
that as a veterinarian I should work within the current system to scrutinize
these practices and help improve the lives of individual animals used in the
name of s cience. By inspecting numerous animal laboratories and breeding
facilities, and assessing countless animal research proposals and their scientific outcomes (if they were published), I became exceedingly aware of the
considerable harms involved and the flaws of animal-based research on all
levels—ethical, scientific, legal, political, and economic.
Alongside my work as an inspector, I carried out a PhD project, assessing the
use of refinement, the last R of the 3Rs principles, in practice. Refinement refers
to methods that ought to reduce animal suffering in the laboratory. I focused
on experimental refinements in over 500 animal research applications comprising recovery surgical procedures from around Germany. My results show
that the majority of evaluated proposals did not take all possible measures
to avoid needless suffering. They confirm the trends found in structured and
systematic reviews of published animal studies from around the world. Being
a member of the competent authority, I frequently experienced its limits in
safeguarding animals due to the way it is set up: decentralized, understaffed,
and with limited resources.
Consequently, the political aims of reducing and replacing animals in
science have remained political claims; and authorities are unequipped to
ensure that only research projects that have a realistic potential to produce
benefits, which outweigh the harms inflicted on the animals, are granted licenses. The poor application of refinement methods in laboratories, and a
malfunctioning regulatory body emphasized, for me, the urgency for a paradigm change, away from using animals in science. Fortunately, in some areas
this change is already slowly happening. But to accelerate the shift, it is crucial
to appraise animal experimentation critically, from all angles, and to publicly
discuss the findings—a realization that led me to initiate this book project.
The 51 experts who contributed to this volume critically appraise current animal use in science, and they discuss innovative, human-relevant approaches to
advance the life sciences and to accelerate the shift towards the replacement
of animals in research, testing and education.
– Kathrin Herrmann
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I have more than a decade of experience in research and education, working
in animal welfare and animal protection. Originally, starting my career in zoos
and laboratories, I chose to specialize in animal behavior and welfare because
I felt that science had a role in improving the lives of animals used by these
industries. However, based on my personal experiences working in these environments and hand-rearing animals to be used for behavioral laboratory
research, my moral values shifted. With my increasing knowledge of animal
behavior and welfare, I realized that these industries were seriously flawed,
both scientifically and ethically. Increasingly, the scientific and educational research about animal behavior that I was exposed to on a daily basis informed
me that the animals I was working with should not be used for these purposes.
I now work as a Senior Scientific Researcher for an animal protection organization that promotes phasing out animal use in these industries, particularly in the areas of animals used in research, education, and entertainment.
The study of the behavior of all animals is fascinating; but only when the
animals can express their natural behavioral repertoire, under natural conditions. I t ruly believe that furthering our understanding of wild animal behavior through non-intrusive means can help those campaigning and lobbying for
greater animal protection, by enhancing appreciation for all species. Through
generating more public support and using indisputable scientific rationale,
which cannot be ignored, governments and policy makers can be influenced
to make progress towards ending the use of animals in these environments.
– Kimberley Jayne
We first met back in 2014, at the University of Exeter, during a workshop that
aimed to introduce perspectives from the humanities and social sciences to a
dialogue with practitioners and stakeholders across laboratory animal science
and welfare. Our mutual concerns about animals used in science led us to collaborate on this book project. Since we both work closely with researchers,
scholars, and campaigners, who are active in the fields of animal protection,
animal replacement technology, and ethical philosophy, the project rapidly
evolved into a 28 chapter-volume. Our aim is to not only transform science,
education, and policy into a more inclusive environment, but to continue to
work on projects that consider the impact of human behavior on all species.
This book may be eye-opening for some and encouraging for others. Its ultimate goal is to motivate everyone to work together in order to end the suffering
of our fellow animals.
– Kathrin Herrmann and Kimberley Jayne
Baltimore and London, August 2018
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Introduction
Legislative reforms around the world have insufficiently improved the protection of non-human animals (hereinafter referred to as animals). Directive
2010/63/EU of the European Parliament on the protection of animals used for
scientific purposes appears rather radical when compared to legislation in
other countries. The Directive promotes a paradigm change in articulating the
ultimate goal of the “full replacement of procedures on live animals for scientific and educational purposes as soon as it is scientifically possible” (Recital
10). Building on this principal vision of Directive 2010/63/EU, this book aims
to illustrate the current situation for animals used in research, testing, and
education and to give a future glimpse of what the end of their use may look
like. Aside from exploring current ethical challenges, scientific controversies
and economic and legal aspects related to animal experimentation, this book
discusses ways in which individuals, researchers, regulators, industry, and governments can all contribute to a paradigm change. It includes invited contributions from a range of multidisciplinary scholars, across many fields, who
share a vision for how a shift in current thinking can be achieved and how the
end of animal experiments can be accelerated. While some argue that full and
immediate abolishment of animal use is necessary to encourage science in the
direction of human-focused research, others discuss their vision in terms of
incremental steps towards the shared goal of total animal replacement. With
the intention of encompassing all animal use, this book considers the vision
of a paradigm shift at an international level, with the goal to find solutions for
this pressing problem that are motivated by a culture of compassion for all
animals.
The book starts out with a foreword by Peter Singer who has advocated for
the equality of human and other animal interests for several decades. The first
half of this book (Chapters 1–13) describes current debates surrounding the issues of using animals in science:
– The first section focuses on why and how to change the current paradigm.
Chapter 1 starts out from the last of the 3Rs, refinement, and its flawed application in practice. Chapters 2 and 3 address how to incorporate methods into the current system to prompt a move away from animal models.
Chapter 4 presents information on how people can engage in a paradigm
shift at an individual level, by adopting a disease preventing lifestyle.
– Section 2, which focuses on politics and legislation in animal experimentation, starts with a chapter on the importance of political campaigning
(Chapter 5), followed by a critique of how the 3R principles are applied by
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people working in animal research (Chapter 6). Chapter 7 reveals how having a political critique is of utmost importance.
– Section 3 debates the lack of transparency over animals used for experimentation, from the stakeholder perspectives of the animals (Chapter 8)
and animal protection groups (Chapter 9). Chapter 10 illustrates how public
funding is misappropriated for animal research.
– Section 4 discusses the ethics of using sentient individuals without their consent, including how humans decide upon their respective fates (Chapters 11
and 12) and their political objectification (Chapter 13).
The second half of the book (Chapters 14–28) analyzes the current practice
of using animals as scientific models, as well as already available animal-free
models:
– Section 5 begins with an overview of the lack of predictivity of animal
models over the history of their use (Chapter 14). Chapters 15 and 16 r eview
animal-derived research and its translation to human medical research.
Chapter 17 assesses the effectiveness of animal-based models for drug
testing and disease modeling. Chapter 18 expands on how animal-based
tests are harmful for humans. Chapter 19 reviews the significant increase
in use of genetically altered animals, and the impact of this on humandisease modeling. The section concludes with two chapters focusing
on the scientific and ethical concerns within specific areas of animal research, namely Alzheimer’s Disease (Chapter 20) and behavioral research
(Chapter 21).
– Section 6 shows how the future of animal-free research starts with humane
education and training for the next generation of researchers who have the
potential to change the direction that science takes. Chapter 22 focuses on
alternatives available for replacing animals used in biomedical and trauma
training, while Chapter 23 presents an example of how humane education
has been implemented.
– The final section shows how the paradigm is already shifting, commencing
with recent developments in animal-free test methods (Chapter 24). Chapter 25 exemplifies how in vitro and in silico methods are already being used
in certain areas of research. Chapter 26 presents the emerging organ on a
chip technology, its enormous future potential and its current limitations.
Chapter 27 critically highlights the need to remain cautious about hidden
animal use in replacement technologies, followed by the final Chapter 28,
which gives an outlook on the future of cruelty-free science and the great
promise it holds for animals and humans alike.
The book closes with an afterword by John Gluck, who shifted from being a
primate researcher to becoming a strong advocate for animals. Owing to the
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range of topics and the various backgrounds of our contributing authors, this
volume is intended for a wide prospective readership, offering a broad scope
into the key debates around the use of animals for experiments and education.
It is written not only for fellow scholars and scientists, but for the interested
public.
We are hopeful that this book will help to accelerate the already shifting
paradigm. Six decades after Russell and Burch published their, at the time, progressive ideas in the book “Principles of Humane Experimental Technique”, on
how to make science humane and rigorous, the time has come where it is impossible to ignore the facts: the flaws and shortcomings of the animal research
industry are evident, and the continued use of animal models is ethically and
scientifically less justifiable than ever before. This industry wastes intellectual,
scientific, and financial resources and causes harms not just to animals but
also to humans. With experiments on animals frequently showing little to no
benefit to the human species and, therefore, hindering the development of
treatments, and with costs borne by the animals used, we should finally accept the irreconcilable species differences. It is time to focus solely on robust,
human-relevant approaches, such as in silico and in vitro models, to conduct
human-focused science. For us to continue to evolve ethically as a species, we
need to stop causing further needless suffering and start generating a culture
of respect and compassion for all animals.

Think occasionally of the suffering of which you spare yourself the sight.
albert schweitzer
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Chapter 1

Refinement on the Way Towards Replacement:
Are We Doing What We Can?
Kathrin Herrmann

Freie Universität Berlin, Department of Veterinary Medicine, Institute of
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Introduction
[R]efinement is never enough, and we should always seek further for
reduction and if possible replacement.
russell and burch, 1959, Chapter 4

Russell and Burch introduced the principles of replacement, reduction, and
refinement of animal experimentation in 1959 in their groundbreaking book,
The Principles of Humane Experimental Technique, to eradicate inhumanity towards non-human animals (hereinafter referred to as animals). They utilized
the term inhumanity to indicate negative mental states experienced by animals
used in research and the procedures that cause such mental states. Their goal
was to avoid the use of animals wherever possible and to improve significantly
the treatment of the animals still deemed indispensable, while improving the
quality of scientific and medical research and testing (Russell and Burch, 1959).
Since the 1990s, the 3Rs have slowly gained more acceptance within the animal
research community. They have been recognized by organizations such as the
Council of Europe (1986) and the World Organisation for Animal Health (2018),
and they have been implemented in law in several countries, for example in
Germany and in the UK (Herrmann, Köpernik and Biedermann, 2009; Zurlo,
Rudacille and Goldberg, 1996).
Today, the principles are not only embedded in legislation in the E
 uropean
Union (EU) but around the world (Bayne et al., 2015). In the EU, Directive
2010/63/EU on the protection of animals used for scientific purposes came
into effect in 2013, thereby requiring all EU Member States to implement the
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3Rs fully. The EU Directive is more far-reaching compared to other legislation
since it promotes a strong shift away from animal experimentation, with its
goal being “full replacement of procedures on live animals for scientific and
educational purposes as soon as it is scientifically possible” (European Parliament, 2010, Recital 10). Furthermore, the EU Directive mandates that replacement should be the first priority, followed by reduction and then refinement
to be implemented if animal use is deemed absolutely unavoidable (European
Parliament, 2010, Recital 11). Russell and Burch (1959, Chapter 7) proposed the
following hierarchy: “Suppose, for a particular purpose, we cannot use replacing techniques. Suppose it is agreed that we shall be using every device of
theory and practice to reduce to a minimum the number of animals we have
to employ. It is at this point that refinement starts, and its object is simply to
reduce to an absolute minimum the amount of distress imposed on those animals that are still used.”
As a result of the incorporation of the 3Rs into legislation, which has mainly
been driven by ever-increasing societal concerns (cf. Clemence and Leaman,
2016; European Citizens’ Initiative, 2016; Jones, 2017; Pew Research Center,
2015, 2018), it would seem reasonable to expect changes within the research
industry, particularly replacement of animals with non-animal models. However, the cumulative effect of any such replacements has not prevented the
overall number of animals used from steadily increasing since the 2000s (European Commission, 2013; Taylor et al., 2008; Taylor and Rego, 2016). When looking at the 3Rs and their impact, it seems that refinement, the R of ultima ratio,
is receiving the most attention by the laboratory animal science c ommunity
(AALAS, n.d.; FELASA., 2016), especially in basic and applied research where
the majority of animals are utilized (in the EU, 65% of animals; cf. Daneshian
et al., 2015). A survey conducted with participants of laboratory animal science
training courses in four European countries found that refinement was seen as
more feasible and more pressing than replacement and reduction of animal
use (Franco, Sandøe and Olsson, 2018).
Due to this focus, the chapter starts by exploring the application of several
refinement methods in practice, commencing with current housing and husbandry standards and a discussion about the benefits of a “culture of care”,
followed by assessing important experimental refinements. To further assess the quality of animal-based research, it reviews necessary refinements
in planning, conduct, and reporting practices of animal studies. The chapter then moves on to look at feasible ways to reduce and replace animal use
by, first discussing tools to appraise animal studies whose application could
lead to a significant reduction of animal experiments and thus numbers of
animals used. It subsequently reflects on what the scientific community has
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been doing to move towards replacement of animals in research, testing, and
education. Finally, the chapter concludes with recommendations for steps to
be taken to work towards using non-animal, human-relevant approaches to
biomedical research and testing aimed to protecting human health.
2

Refinement of Animal Housing and Husbandry
Husbandry is a factor for contingent inhumanity in all types of experiment.
russell and burch, 1959, Chapter 4

Animals used in research, testing, and education spend their lives in a captive environment that is very different from their natural environment. Refined housing
gives animals the opportunity to cope with some of the stressors imposed by life
in the laboratory (Mason, 2006). Improving their living conditions by trying to
meet some of the animals’ basic behavioral needs is called environmental refinement or environmental enrichment (EE). Krech, Rosenzweig and Bennett (1960)
were the first to report biochemical changes in the brains of rats kept in a complex housing environment and augmented with daily exposure to novel items in
an open field. They coined the term EE when describing this paradigm (Benefiel,
Dong and Greenough, 2005). Environmental Enrichment is defined as “[a]ny
modification in the environment of captive animals that seeks to enhance the
physical and psychological well-being of the animals by providing stimuli which
meet the animals’ species-specific needs” (Baumans and van Loo, 2013). It includes complex social and inanimate object stimulation (Rosenzweig, 1966). Its
positive behavioral effects were first described in rats by Hebb in 1947, who
kept them as companion animals in his home. He observed that the rats living
in a more complex, stimulating environment learned better and more quickly
(Hebb, 1947). In addition to enhancing cognition, EE also promotes neuronal
activation, signaling and plasticity in a number of brain regions (Nithianantharajah and Hannan, 2006). In the beginning, research on EE was conducted primarily to assess changes in behavior and brain development. With the increased
concern for animal welfare and the establishment of animal welfare science as a
specific discipline, has EE been applied to improve the animals’ daily lives.
Aside from being driven by animal welfare and health concern, many eerelated research projects have also assessed the influence of poor housing conditions on research data. Garner (2005), van Praag, Kempermann and Gage
(2000), and Würbel (2001, 2007), among others, demonstrated that life in barren cages leads to abnormal brain development and to physiological and behavioral malfunction. Standard non- to little-enriched cages can cause a variety
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of abnormal behaviors, such as stereotypies (abnormal repetitive behaviour
patterns) (see e.g., Würbel and Stauffacher, 1994, 1996; Würbel, Stauffacher and
Holst, 1996) and inactivity while awake, observed for example in rhesus monkeys (Hennessy et al., 2014) and mice. Inactivity appears to be an alternative to
stereotypic behavior and indicates a depression-like state (Fureix et al., 2016).
Nonetheless, for a period of time, a number of laboratory animal scientists
strongly believed that standardizing the animals’ environment—by housing
animals in barren cages—was essential to control environmental variables
(e.g., Bayne, 2005; Eskola et al., 1999; Gärtner, 1999; Tsai et al., 2002, 2003, 2006).
The assumption was that standardization was crucial to minimize both variation in the data and the risk of obtaining conflicting results in replicate studies. Many laboratory animal scientists were concerned that implementing EE
would add undesirable variation to their responses to experimental treatments
(e.g., Bayne, 2005; Eskola et al., 1999; Gärtner, 1999; Tsai et al., 2002, 2003, 2006).
However, eight mouse strains kept under such uniform, standardized conditions, and tested on highly standardized behavioral tests in different laboratories, showed significant laboratory dependent variations (Crabbe, Wahlsten
and Dudek, 1999). Since then, studies by Augustsson et al. (2003), van de Weerd
et al. (2002), Wolfer et al. (2004), and Würbel (2007) have demonstrated that
housing conditions can be enriched without increasing variability in experimental results. Additional experiments using mice confirmed earlier research
findings that basic environmental enrichments (shelters and nesting material) can be used without compromising the research data (André et al., 2018).
Furthermore, this study showed that data from mice who had access to shelters and nesting material is comparable to previous data collected under barren housing conditions, consistent with earlier findings (see Augustsson et al.,
2003). The authors concluded that the influence of enrichment on research
outcomes was trivial, and that nesting material and shelters could be used without negative impact on study outcomes or loss of comparability to previous
data obtained from animals living in impoverished cages. (André et al., 2018).
In the future, rather than using more animals in new experiments on this topic, a systematic review (SR) could be undertaken to provide an overview of the
accessible evidence and new knowledge without further animal use. It would
also point out knowledge gaps and assess the quality and validity of the conducted animal studies (for more on SRs of animal experimentation, see e.g., Systematic Review Center for Laboratory Animal Experimentation, syrcle, n.d. a).
This so-called standardization fallacy (Würbel, 2000), the belief that homogenization of study populations (using the same strain, age, sex, weight,
housing conditions, etc.) is an essential part of good experimental design, appears to be one driver for the irreproducibility of results and for the lack of
external validity (Bailoo, Reichlin and Würbel, 2014). External validity is the
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extent to which experimental results can be used as a basis for generalizations
to other human and non-human animal populations in other environmental
conditions (van der Worp et al., 2010). This is why authors, including Richter,
Garner and Würbel (2009), Richter et al. (2010), Würbel (2000), and Würbel and
Garner (2007), promote systematic environmental heterogenization, which is
a “controlled and systematic variation of the properties of any given animal (or
animal population) and its environment within a single experiment” (Richter, 2017, p. 344). Voelk et al. (2018) compared 440 single- and multi-laboratory
preclincial animal studies that had used the same overall number of animals.
They compared effect size estimates and found that the studies conducted in
one laboratory only, in most cases did not predict effect size correctly, whereas multi-laboratory studies generated more consistent and accurate results.
Within-study standardization was identified as a major cause of poor reproducibility. Thus, Voelk et al. (2018) advocate for multi-laboratory design with
no increase of overall number of animals being necessary to enhance reproducibility and, potentially, external validity.
EE combined with systematic heterogenization contributes to improved
quality of animal experiments (Richter, Garner and Würbel, 2009; Richter
et al., 2010; Würbel, 2000; Würbel and Garner, 2007), whereas failure to provide
animals with living conditions that meet their species-specific needs jeopardizes both their welfare and experimental validity (e.g., Bailey, 2018; Balcombe,
2010; Bayne and Würbel, 2014; Garner, 2005; Messmer et al., 2014; Olsson et al.,
2003; Poole, 1997; Sherwin, 2004; Würbel, 2001, 2007; Würbel and Garner, 2007).
2.1
Examples of Environmental Refinement
An example of an extensively researched refinement method is providing mice
with various types and sufficient amounts of nesting material to build nests,
creating a microclimate needed for breeding and for preventing cold stress
(Gaskill et al., 2009, 2012; Gaskill and Garner, 2014; Hess et al., 2008). The thermoneutral zone of mice lies between 26°C and 34°C (Gordon, 1993); and standard temperatures in animal vivariums range between 20°C and 24°C. During
their inactive phase, mice prefer temperatures of 30°C–32°C (Gordon, 2012).
A proper nest is, therefore, essential for reducing cold stress, which not only
compromises animal well-being but also scientific data (Gaskill et al., 2009;
Karp, 2012; Messmer et al., 2014). Gaskill et al. (2013) additionally demonstrate
its negative effect on breeding performance. Nest building is a species-specific
behavior of mice, the absence of which can be used as an indicator of illness
(Gaskill and Pritchett-Corning, 2016). Another example involves gerbils, who
have a high motivation to dig, since they naturally build and live in burrows.
In standard laboratory conditions, where there is not enough substrate to dig
tunnels, gerbils show stereotypic digging behavior (Wiedenmayer, 1997). One
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solution, based on research conducted by Waiblinger and König (2004), is a
nesting box with an attached tunnel. The artificial burrow system seems to
help reduce stereotypic digging behavior.
Jirkhof (2015) found that housing conditions that meet the needs of mice
help them recover better and faster from experimental procedures. The influence of environment on diseases, such as cancer, has also been demonstrated;
for example, by Cao et al. (2010). In colon cancer and melanoma research,
mice living in an enriched environment showed reduced tumor growth and
increased remission compared to those living in a non-enriched environment
(Cao et al., 2010). Rabbits who received special positive attention from their
care givers showed a markedly increased resistance to the development of
atherosclerosis compared to rabbits who received no extra attention (Nerem,
Levensque and Cornhill, 1980).
2.2
Discussion on Environmental Refinement
It has been established that animals in a monotonous environment frequently display abnormal behaviors, such as stereotypies (Garner, 2005; Garner and Mason, 2002; Gross et al., 2012; Howerton, Garner and Mench, 2008;
Würbel and Stauffacher, 1994, 1996; Würbel, Stauffacher and Holst, 1996).
Furthermore, research has demonstrated the importance of environmental refinement, not only for animal welfare and for decreasing the negative
health effects of life in captivity, but for its benefits for research outcomes
in terms of their reliability, replicability, and validity (e.g., Abou-Ismail and
Mahboub, 2011; Garner, 2005; Weed and Raber, 2005).
Due, at least in part, to enforcement of animal protection laws, housing
conditions for laboratory animals have improved over the past decade. In the
EU, the Commission Recommendation of 18 June 2007 on guidelines for the
accommodation and care of animals used for experimental and other scientific purposes (Commission of the European Communities, 2007)—which was
later largely adopted by Directive 2010/63/EU (European Parliament, 2010,
Annex iii)—helped to enhance the captive environment of laboratory animals. However, exceptions to these minimum requirements may be demanded
by researchers for certain experiments. Examples include housing social species, such as rats, pigs, or non-human primates, individually and away from
their social groups; or not providing rodents with sufficient nesting material
and shelters, to allow easier and quicker monitoring. Yet, in most cases, a solution that considers the animals’ well-being and does not further compromise
their welfare could probably be found.
Moreover, it should be noted that the term most frequently used when talking about an improved living environment, environmental enrichment, can
be misleading, since it suggests that the standard cage conditions should be
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considered normal or species-typical. However, captive conditions have little in
common with the natural habitat of every single species used in research. For
example, Lahvis (2017) points out that the floor area in a standard mouse cage
is 280,000-times smaller than the animal’s natural home range. For rhesus macaques, he calculated it is 7 million-fold smaller. Along with the difference in the
size of the animals’ habitats, the stimulation provided in laboratories is also different from what animals encounter in their natural environments. Burghardt
(1996) argues that it would be more accurate to use the term controlled deprivation, since all captive environments deprive animals of some natural stimuli.
He points out that these restrictions have various, and oftentimes unpredictable, consequences for the welfare of captive animals (Burghardt, 1996, 1999).
In fact, a study by Gross et al. (2012) showed that around 12% of mice who lived
in enriched cages which contained nesting material, a shelter and a climbing
structure, still revealed stereotypic behavior. Moreover, evidence indicates that
when stereotypies are not observed, a potential reason could be that they are
only displayed when nobody is watching, e.g., in the nocturnal phase (Wells,
2017); or, since highly stereotypic animals seem to cope better than their
identically-treated conspecifics, non-stereotypic animals present an even
more abnormal, depression-like state as an alternative to stereotypic behavior
(Mason, 2006). It has been shown that sustained, uncontrolled stress can, at
least in some mouse strains, foster learned helplessness (Cabib, 2006).
2.3
Challenges in the Implementation of Refined Housing
The enforcement of animal protection laws has contributed to somewhat
improved housing conditions for laboratory animals over the past decade.
However, despite the mounting evidence of welfare and scientific problems
associated with standardized housing, the implementation of animal husbandry knowledge in laboratories has in the author’s experience been a major
and elusive challenge.
It is increasingly recognized that experimental animals experience serious
and repeated stress and distress, caused by life in the laboratory. Besides being
a welfare concern, there are multiple factors that adversely affect the animal’s
biological systems and thus the data collected from these animals (Bailey,
2018). Examples for stressors and thus potential influences on data, besides
the confinement itself, include ultrasonic noises (Baldwin, Primeau and Johnson, 2006; Turner et al., 2005), bedding material and cage cleaning (Burn et al.,
2006), handling, blood collection, and orogastric gavage (Balcombe, Barnard
and Sandusky, 2004), and the experimenters (Chesler et al., 2002) and their sex
(Baldwin, Primeau and Johnson, 2006; Sorge et al., 2014).
Numerous studies have shown that animals living in captive environments
are generally abnormal and unhealthy, as such environments change their
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behavior as well as immune, nervous, and endocrine functionality. Examples
include their altered response to infection (Gurfein et al., 2014), altered immune
response (Beura et al., 2016; Messmer et al., 2014), increased rates of obesity,
Type ii diabetes, high blood pressure, and premature death (Martin et al., 2010),
altered brain development (Bennett et al., 1964; Kempermann, Kuhn and Gage,
1997; Lewis et al., 2006; Rosenzweig and Bennett, 1969; Rosenzweig et al., 1962),
decreased strength and endurance (During et al., 2015), altered sleep, activity
patterns, and blood pressure (Martire et al., 2012), altered growth rates (Serrat,
King and Lovejoy, 2008), altered organ development, metabolic, growth, and
reproduction rates and behavior (Gordon, 2012), and enhanced tumor growth
(Cao et al., 2010; Li et al., 2015). As such, untreated control animals do not represent healthy individuals, since they are metabolically abnormal (Martin et al.,
2010). To date, there are only a few studies comparing wild versus confined animals, but they all show immense biological differences in physiology, such as
structure variation of the visual cortex among caged and free-roaming Norway
rats (Campi et al., 2011), lower levels of cholesterol in wild versus captive animals
(Schmidt et al., 2006), and immune system dissimilarities (Beura et al., 2016).
We must acknowledge that even if laboratory animal housing is enriched, it
cannot be enriched to an extent that it has no negative effect on the animal’s
welfare (e.g., Burghardt, 1996; Gross et al., 2012). Well-being can only be achieved
if the animal experiences positive welfare states, which require a responsive environment the animal can engage with. Studies show that animals prefer complex environments and are motivated to work for them (Anselme, Robinson
and Berridge, 2013; Sherwin et al., 2004). Current minimum legal requirements
for animal housing in the European Union, laid out in Directive 2010/63/EU,
are still insufficient in meeting all needs of all animals; although they are held
to be the most progressive in the world. As shown, problems of confinement
are manifold. Animals’ lives in captivity are monotonous and, therefore, lead
to boredom (Burn, 2017; Meagher and Mason, 2012), learned helplessness and
depression (Cabib, 2006; Špinka and Wemelsfelder, 2011), and abnormal behaviors. The effects pose serious welfare concerns and raise concerns about the
validity and translatability of data obtained from these unhealthy individuals.
2.4
Potential Improvements
In assuming an ethical responsibility to improve the lives of captive animals
(Gruen, 2014), the goal of husbandry refinement should be not only to reduce
stressors but to promote well-being. It is apparent that current housing conditions do not achieve that. One step towards improving animal housing is
to provide cages that allow for more natural behaviors. Makowska and Weary
(2016a) investigated the frequency of burrowing, climbing, and standing
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upright of rats held in pairs in standard (behaviorally restrictive) laboratory
cages in comparison with rats in cages allowing these behaviors (larger cages
with lower floors, filled with moist soil, holding five rats per cage) over a period
of 13 months. Although climbing bouts decreased with age, standing upright
and especially burrowing were still frequent behaviors in older rats. Stretching
is a corrective response to stiffness caused by immobility or positional stress
(Bertolucci, 2011). Makowska and Weary (2016a) found that standard-housed
rats performed 9 times more lateral stretches than rats housed in the seminaturalistic environment. The authors proposed that standard-housed rats
were stretching frequently in an attempt to alleviate stiffness from low mobility associated with standard housing. Improved welfare of the rats housed in
the semi-naturalistic cages was observed in an anticipatory behavior test that
assessed differences in reward sensitivity performed when the rats were 19 and
21 months old (Makowska and Weary, 2016b).
From the animals’ perspective, an even better approach would be the radical solution for housing refinement proposed by Lahvis (2017). Lahvis suggests
that research animals should live in the wild or at least roam freely in a large,
captive environment under naturalistic conditions. He is confident that with
available technologies (e.g., cameras, transponders, magnetometers, pressure
sensors, global positioning systems), this novel approach could be accomplished for many experiments. Lahvis (2017) advises that biomedical researchers should work together with behavioral ecologists to develop sufficiently
complex environments in order to ensure that test subjects produce scientific
data not influenced by husbandry.
3

A “Culture of Care” for Animals as Refinement

The term culture of care has frequently been referred to by members of the
laboratory animal science community to demonstrate “a commitment to
improving animal welfare, scientific quality, care of the staff and transparency for the stakeholders.” (Norecopa, 2016a). For instance, a working document on the development of a common education and training framework
to fulfill Directive 2010/63/EU requirements mentions the culture of care
numerous times (National Competent Authorities for the implementation
of Directive 2010/63/EU on the protection of animals used for scientific purposes, 2014). Individuals responsible for the welfare of animals should establish and maintain high standards to champion a culture of care among both
husbandry and scientific staff (European Commission, 2014). Entire sessions
at conferences have been dedicated to this topic, including sessions at the
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European Society for Alternatives to Animal Testing (eusaat) Congress in
2015 (eusaat, 2015) and at the 10th European World Congress on Alternatives
and Animal Use in the Life Sciences in Seattle in 2017 (von Aulock, 2017).
Reinhardt (2003, p. 123) identifies compassion for laboratory animals as a
refinement: “Kindness and concern for animals in the laboratory often have
been stigmatized as subjective, emotional qualities that can undermine the
‘objectivity’ of biomedical and psychological research.” However, since there
is evidence that the human-animal bond helps animals to cope with stressful
situations in the laboratory (Wolfle, 1987), compassion for laboratory animals
should not be dismissed as emotional and subjective but as a sound methodological base for scientifically valid animal-based research (see Mahoney,
1992; Reinhardt, 2003). Compassion implies an acute awareness of an animal’s
state of emotional, behavioral, and physical well-being and the urge to provide
them with the conditions essential for optimal well-being (Reinhardt, 2003).
According to Herzog, “there is every reason to believe that individuals who
care about their wards on a personal level actually treat the animals better.”
(2002, p. 30). Morton highlights that, ideally, the staff assessing pain in animals should have an empathetic attitude toward them (Morton, 2000). Such
a mindset can also be seen as a protection mechanism to control unrelated,
potentially data-influencing, variables (Reinhardt, 2003). Brown (2014) states,
“Although there are laws and regulations that govern working with research
animals, institutions involved in research, testing, and teaching using laboratory animals should strive to go beyond what is legally required and work to
establish a ‘culture of care’ to ensure animals are treated with compassion and
respect.” Brown highlights that this culture of care for animals not only benefits animals but the quality of science as well.
3.1
From Theory to Practice
How far a culture of care is being implemented on an institutional level is
unknown. Personal experiences of this author—as an inspector of animal
research institutions in Germany between 2007 and 2016 (Herrmann, 2013;
Herrmann and Ratsch, 2010; Maurin, 2012)—revealed differences regarding
the level of care for animals within the same institutions, with individual care
givers acting more or less compassionately towards their animals. An institutional culture of care agenda could not be identified.
The European Commission (EC) (2014) recommends the implementation of such a culture, and other countries have taken steps, in this direction.
For example, New Zealand’s National Animal Ethics Advisory Committee
guide is called A Culture of Care: A Guide for People Working with Animals
in Research, Testing, and Teaching (National Animal Ethics Advisory Committee, 2002). Several p
harmaceutical companies, such as Sanofi-Aventis
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and Merck (Klein and Bayne, 2007), and commercial breeding companies
(Brown, 2014) are reported to have established culture of care programs; however, no external review or assessment of these programs has been published.
3.2
Towards a Culture of Care and Compassion for Animals
There is potential for a positive impact of a culture of care on animal use and
welfare. But how can we implement such a culture? Schuppli et al. (2017) used
a new educational approach to test if exposure to socialized rats, who were
trained to fulfill several tasks, fostered compassion among animal experimenters. Six rats were trained using positive reinforcement techniques to, for example, jump onto a scale, or to lift objects. Participants observed these rats
and engaged with handling them. After the class, researchers (17) discussed
their feelings and reactions. Main findings included that all participants were
impressed by the rats’ abilities and the close relationship with their trainers.
They assumed that this positive animal-human interaction decreased stress in
the rats. However, various views existed in regard to potential effects on data.
The experimenters expressed unease about emotional difficulties in “sacrificing” their experimental animals after having bonded with them (Schuppli
et al., 2017). This highlights one of the major obstacles: When animal
researchers develop compassion for their research subjects, they face moral
difficulties (see Birke, Arluke and Michael, 2007; Gluck, 2016) and moral harms
(see Chapter 13 in this Volume, Johnson and Smajdor, 2019) just as animal caretakers and technicians do. However, this could be an important starting point
in moving towards a culture of compassion for all animals which could contribute to their replacement efforts.
4

Refinement of Experimental Procedures

There are several essential refinement methods to reduce the pain, distress,
anxiety, and suffering inflicted during the course of experimenting on the animals. Handling and restraint techniques are a source of potential distress and
anxiety (Balcombe, Barnard and Sandusky, 2004; Hurst and West, 2010;
Meijer et al., 2006); and these techniques have been investigated in experimental studies on stress (Johnson, Sharp and Miller, 2000). To avoid negative effects on behavior, tail handling of mice should be replaced by using tunnels
or cupping mice in the open hand (Gouveia and Hurst, 2013). These and other
non-aversive handling practices should be implemented industry-wide, since
they have been shown to reduce anxiety (Hurst and West, 2010) and optimize
the performance of mice in behavioral tests (Gouveia and Hurst, 2017). A recent
study by Clarkson et al. (2018) concluded that particular handling methods can
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not only cause anxiety, but they can also alter the hedonic value of reward.
Tail-handled mice demonstrated a decreased responsiveness to reward and,
potentially, a more depressive-like state compared to tunnel handled conspecifics (Clarkson et al., 2018).
For surgical procedures, basic experimental refinements include: proper
acclimatization of the animals to the room where anesthesia will be induced
(Flecknell, 2018a); optimal anesthesia, peri- and postoperative analgesia; and
adequate postoperative monitoring and care, including pain management
(Flecknell, 2016; Herrmann and Flecknell, 2018a). The application of humane
endpoints also prevents needless suffering. A humane endpoint (or “lessinhumane endpoint,” see Balls, 1999, p. 1) represents “[t]he earliest i ndicator in
an animal experiment of (potential) pain and/or distress that, within its scien‑
tific context and moral acceptability, can be used to avoid or limit adverse
effects by taking actions, such as humane killing, terminating the study, or alleviating the pain and distress.” (Hendriksen, Morton and Cussler, 2011, p. 344).
The way an animal is killed is another subject for refinement. Animal care
policies in many countries stipulate that death must be painless, and fear and
anxiety should be minimized (e.g., Charbonneau et al., 2010; European Parliament, 2010). Less inhumane killing comprises the use of the least distressing
and least painful methods that cause rapid loss of consciousness and subsequent death (see e.g., Leary et al., 2013).
The application of our steadily increasing knowledge on experimental refinements should benefit the over 115 million animals who are used annually in
research, testing, and education around the world (Knight, 2008; Taylor et al.,
2008). However, this benefit cannot be achieved unless the knowledge is translated into practice. In cases where research workers plan to use, for example,
less than optimal anesthesia or analgesia protocols, or do not provide other
standard veterinary practices, they need to scientifically justify this and demonstrate that the anticipated benefits of the experiments still outweigh the
harms inflicted upon the animals (Herrmann and Flecknell, 2018b). Due to the
multitude of available means, solutions can be found, in most cases, that help
prevent needless animal suffering (Herrmann and Flecknell, 2018a).
4.1
The Use of Experimental Refinements in Practice
Several structured and systematic literature reviews have given some insight
on certain experimental refinements, notably, killing methods (Pound and
Nicol, 2018; Uhlig et al., 2015) and the use of anesthetics and analgesics (Bertrand, Sandersen and Flecknell, 2018; Carbone and Austin, 2016; Coulter, Flecknell and Richardson 2009; Coulter et al., 2011; Pound and Nicol, 2018; Richardson,
and Flecknell, 2005; Stokes, Flecknell and Richardson, 2009; Uhlig et al., 2015).
For example, animal research involving surgical procedures carried out on
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diverse species and published in peer-reviewed journals has been analyzed
with regard to analgesic and anesthetic administration (Coulter et al., 2011;
Coulter, Flecknell and Richardson, 2009; Richardson and Flecknell, 2005).
Stokes, Flecknell and Richardson (2009) focused on studies conducted in two
time periods (2000–2001 and 2005–2006), assessing trends in the administration of analgesics and anesthetics to laboratory mice and rats undergoing surgical procedures. The study showed a trend of improvement in terms of safer
anesthetic regimens used in the later period examined; however, the findings
of this study and an earlier review assessing analgesic use in rodents (Richardson and Flecknell, 2005) show that there was still significant scope for refinement, especially with respect to perioperative care.
A systematic review of anesthesia, analgesia and euthanasia methods used
in anesthesiology, respiratory and critical care research in top-10 impact factor ranked journals journals pointed to insufficient reporting of experimental
studies with small laboratory mammals. Despite the poor reporting, the review
found shortcomings in the application of refinement (Uhlig et al., 2015). Another recent attempt to assess trends in pain management, this time in papers
published before 2011 and from 2014 to 2015, further confirmed that reporting
(and probably the use) of experimental refinement methods is still poor (Carbone and Austin, 2016). The review demonstrated that scientific publications
still cannot be relied upon to present a detailed description of analgesia and
anesthesia protocols, not to mention other experimental refinements.
Another approach employed by the author of this chapter, with Flecknell
(2018 a, b, c), was to retrospectively review proposals for authorization of basic
and applied animal research studies to learn which experimental refinements
were proposed. Over 500 applications submitted to the German competent
authorities in 2010 were reviewed. German law stipulates that all possible refinements that are planned in an animal study are described in detail in its proposal. The review’s goal was to evaluate the intended application of and, thus,
the awareness about possible refinements. Among other results, postoperative
analgesia was not proposed for 30% of surgeries; and, in the majority of cases,
its scientific necessity was not further discussed. Following 10% of procedures,
animals were to be given pain relieving medication only if the investigators
decided that it was necessary; however, structured assessments to detect pain
were absent (Herrmann and Flecknell, 2018a).
4.2
Discussion on Refinement of Experimental Procedures
Structured and systematic literature reviews and the work of this author found
strong indications for flaws in the administration of experimental refinement.
Refinement methods need to be fully employed in order to minimize stressors
that can lead to distress, such as suffering from postoperative pain, or living
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in a barren cage. The biological consequences of stress and distress compromise rigor, reliability, and relevance of data collected from these animals (see
Bailey, 2018 for a review on how stress of laboratory life and experimentation
can adversely affect research data). Animal researchers are responsible for the
animals they use (National Health and Medical Research Council, 2013). Thus,
they and their animal care staff should know enough about animal behavior
to properly assess the health and well-being of their test subjects. In the European Union, they are legally required to be skilled, educated, and equipped
to detect and relieve suffering accordingly (European Parliament, 2010,
Article 24).
There are several challenging areas of refined care and use that should be
addressed. For example, there is a need for automated, remote, 24/7 cage-side
monitoring to identify abnormal behavior, which is especially important when
assessing the welfare of genetically modified animals, as well as for prey species who tend to mask their medical condition or psychological state. Additionally, there is a need for further development and implementation of valid
pain-assessment techniques to determine the efficacy of treatment in the individual animal due to individual variations in pain response. While there is
necessity for further research into certain areas of experimental refinement, it
is essential that we apply the knowledge we already have, so that immediate
improvements in animal welfare can be achieved.
5

Refinement of Experimental Design, Conduct, and Reporting

There have been quality problems throughout medical and biomedical research (Begley and Ellis, 2012; Harris, 2017; Pound and Bracken, 2014; Prinz,
Schlange and Asadullah, 2011). “The scandal of poor medical research” with human subjects was discussed in a British Medical Journal (bmj) editorial in 1994
(Altman, 1994). A biostatistician took a prominent stance against the unethical
misuse of statistics (Altman, 1980). In a follow up 20 years later, another bmj editorial called, “Medical research—still a scandal,” concluded that matters have
become worse (Smith, 2014). It is apparent that the quality of in vivo research
with animal and human subject demands urgent improvement. Weaknesses in
design, conduct, and analysis of biomedical and public health research studies
yield misleading results and, thus, waste resources (Ioannidis et al., 2014). Since
legally-required animal data forms the basis of decisions to move forward to
human clinical trials, flawed animal research is additionally problematic.
Aside from evidence that many animal experiments that are performed
never get published (Scherer et al., 2018), a large part of what gets published is
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incorrect (e.g., Harris, 2017; Ioannidis, 2005; Freedman, Cockburn and Simcoe,
2015). Ioannidis (2005) argues that it is highly probable that most published
findings are indeed false. He drew his conclusion after conducting simulation
studies and SRs. He calculated that, at best, only one in three publications took
basic precautions to minimize bias (Ioannidis, 2005). Freedman, Cockburn
and Simcoe (2015) estimated that more than 50% of all preclinical studies in
the United States are unreliable, and that the financial damage of these irreproducible preclinical studies is US$28 billion per year. Their analysis revealed
that about 20% of the studies had an untrustworthy experimental design, one
quarter used media that contained contaminated cells and antibodies, and
in 18% of studies the data analysis was poor. All of these issues have contributed to the so-called reproducibility crisis in animal research (e.g., Aarts et al.,
2015; Baker, 2016; Begley and Ioannidis, 2015; Bracken, 2009; Collins and Tabak,
2014; Freedman, Cockbury and Simcoe, 2015; Ioannidis, 2005; Perel et al., 2007;
Pound et al., 2004; Pound and Bracken, 2014; Reichlin, Vogt and Würbel, 2016;
Scannel and Bosley, 2016; Würbel, 2016). A review of the literature by Bailoo,
Reichlin and Würbel (2014) strongly suggests that experimental design and
conduct of laboratory animal research are in need of improvement. A study
by Vogt et al. (2016) revealed that animal researchers working in Switzerland
do not apply basic principles of study design to avoid bias and do not properly
report their study outcomes. They also found that neither the Swiss regulatory
authority nor the international journals and their peer reviewers had adequate
knowledge to recognize these flaws.
In an attempt to improve the quality of research reports, several checklists
and guidelines have been put in place, such as Consolidated Standards of Reporting Trials (consort) and Standards for Reporting of Diagnostic Accuracy
(stard) for human clinical trials, Preferred Reporting Items for Systematic
reviews and Meta-Analyses (prisma) for SRs and meta-analyses, and Gold
Standard Publication Checklist (gspc), Animal Research: Reporting of In Vivo
Experiments (arrive) guidelines for animal research (Glasziou et al., 2014;
Hooijmans, Leenaars and Ritskes-Hoitinga, 2010) and HARRP, the harmonized
animal research reporting principles, which are a recent attempt by ICLAS
(International Council for Laboratory Animal Science) in harmonizing animal
research reporting to further improvements in the scientific rigor of animal
experiments (Osborne et al., 2018). The arrive guidelines (Kilkenny et al.,
2010) are the most widely known for reporting of animal-based experiments.
These guidelines have recently been complemented by the Planning Research
and Experimental Procedures on Animals: Recommendations for Excellence
(prepare) guidelines, which help to ensure quality when preparing animal
studies (Smith et al., 2017).
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The arrive guidelines were adopted by more than 1000 scientific journals,
and more than 20 funding agencies were expected to endorse them in 2010
(Baker et al., 2014; Enserink, 2017). Two years later, Baker et al. (2014) assessed
the degree to which they had been endorsed by reviewing journals, such as
Nature and PloS, and found that there was little improvement. The knowledge about and the use of reporting guidelines, such as the arrive guidelines, is still not widespread, as a study by Reichlin, Vogt and Würbel (2016)
has shown. Reichlin et al. asked animal experimenters in Switzerland to complete a questionnaire regarding their use of measures against risk of bias. Only
16% responded. The arrive guidelines were known by less than half (43.7%).
Furthermore, Carbone and Austin (2016) found no increase in reporting of analgesic use in the articles published in journals that had agreed to endorse the
arrive guidelines. Results of a recent randomized controlled trial of close to
1,700 scientists, who submitted papers to the scientific journal PLoS One, suggest that scientists are either ignoring the guidelines or are still unaware of
their existence. Another finding was that, even when an ARRIVE checklist was
completed, the correlating papers were actually not more compliant, which
may indicate that researchers do not know what is expected of them and why
providing this information is crucial, emphasizing the importance of proper
training (Enserink, 2017; Hair et al., 2018).
5.1
Sources of Bias in Animal-based Research
There is a large number of potential sources of bias in animal research. Not surprisingly, most published animal studies have some risk of bias (Macleod et al.,
2015). Safeguards to avoid bias in study design, conduct, and analysis include
randomization of treatment groups to eliminate systematic differences between them, blinding of investigator to treatment and to handling of data, and
reporting on sample size estimation (Macleod, 2011). Analytical errors may account for close to a quarter of the irreproducible studies (Freedman, Cockburn
and Simcoe, 2015); thus, knowledge about statistical methods is essential. Other suggested items for reporting include: a clear description of the hypotheses
tested or primary and secondary objectives of the study, housing and husbandry, including welfare-related assessments and interventions, adverse events,
and interpretation of results, taking into account the hypotheses/study objectives (Kilkenny et al., 2010). Part of the reproducibility and translatability crisis
is considered to be due to poor experimental design and conduct of animal
experiments (Bailoo, Reichlin and Würbel, 2014; Ioannidis, 2005; Macleod, 2011;
van der Worp, 2010; Würbel, 2016), including the influences of inappropriate
animal housing (Lahvis, 2017) and handling (Gouveia and Hurst, 2017), insufficient pain relief (Carbone and Austin, 2016; Herrmann and Flecknell, 2018a),
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as well as the absence of other refinements, such as careful monitoring, early
humane endpoints, and less inhumane killing methods to reduce pain, suffering, and distress (Herrmann and Flecknell, 2018b and 2018c). The other, and
perhaps larger, part is due to insurmountable species differences (Pound and
Bracken, 2014; Pound and Ritskes-Hoitinga, 2018), which Russell and Burch already discussed 60 years ago (1959, Chapter 5).
Another source of bias is selective reporting when publishing results of
animal experiments (Briel et al., 2013; Ioannidis, 2012; Landis et al., 2012; Lees
et al., 2012; Macleod et al., 2004; Pound and Bracken, 2014; Sena et al., 2010;
Tsilidis et al., 2013; Würbel, 2016). One problem relates to negative findings—
studies for which the original hypotheses were not proven. Some of these are
not published at all, which has long been recognized as a source of publication
bias. The second problem relates to studies that are reported incompletely. For
example, only the parts that demonstrate that the treatment is effective are
reported, with whole experimental groups excluded from reporting. This is selective outcome and analysis reporting bias (Ioannidis, 2012). These partially or
unreported studies may be repeated by others and thus represent an unnecessary waste of animal lives. Incomplete reporting of published findings makes it
impossible to replicate studies (Begley and Ellis, 2012). Because negative findings are often not published (Scherer et al., 2018), the value of published findings is over-estimated, which, in part, could explain some of the difficulties
in translating promising preclinical results into effective therapies for human
disease (Bath et al., 2009; Mergenthaler and Meisel, 2012; Sena et al., 2010).
Yet another pitfall is researchers’ freedom of flexibility in data collection,
analysis, and reporting, which dramatically increases false-positive rates in the
literature and, therefore, contributes to misleading animal research data and
overestimation of its significance. Regardless of the nominal endorsement of a
maximum false-positive rate of 5% (p ≤.05), standards for disclosing details of
data collected and analyzed make false positive results very likely ( Simmons,
Nelson and Simonsohn, 2011). The authors describe this as p-hacking. Oftentimes, an experimenter is more likely to find evidence that an effect exists
falsely than to find evidence that it does not correctly. This occurs because of
the investigators’ degree of freedom with regard to the amount of data collected and analyzed, the exclusion of certain observations made, the comparison or combination of conditions, the variables considered, and so forth. It
is uncommon for researchers to make these decisions before undertaking experiments. Their exploratory behavior is explained as ambiguity in how best
to make these decisions and the desire to find statistically significant results.
Confirmatory bias is another potential pitfall, since people tend to interpret ambiguous information in such a way that it supports a justifiable
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conclusion that matches their own aspirations (e.g., Dawson, Gilovich and Regan, 2002). HARKing (i.e., Hypothesizing After the Results are Known) (Kerr,
1998) is another common and problematic practice in science. Statistical tests
to differentiate true effects from random noise are designed for confirmatory
research, not exploratory research. Thus, when researchers change their a priori hypotheses after obtaining their results, this leads to false conclusions.
An additional area that urgently needs refinement is transparency and data
sharing to avoid publication bias and needless repetition of studies. Openness is a cornerstone of science and could help in reducing the reproducibility
problem science is facing (Errington et al., 2014; Harris, 2017; McNutt, 2014). It is
essential to discover and correct errors. The Food and Drug Administration Modernization Act of 1997 (fdama) (Food and Drug Administration, 2018) requires
scientists to register their hypotheses and endpoints in advance, if they plan to
run a clinical trial on potential new pharmaceutical drugs (ClinicalTrials.gov).
This new law went into effect in 2000. It also requires pharmaceutical companies to publish their results, thus, avoiding publication bias. Despite the insufficient enforcement of the law, as many scientists still do not report the results
of their studies (Harris, 2017), the indispensability of such provisions is demonstrated by the findings of a study conducted by Kaplan and Irvin (2015). They
assessed whether the fdama had any effect on study outcomes. Before the law
was in place, 57% of drugs or supplements showed benefits; after the law was
in place, 8% of the studies published confirmed their preregistered hypotheses
(Kaplan and Irvin, 2015). Such a prospective registration process is currently exceptional for animal-based studies, but it is unquestionably required in order
to enhance transparency, reduce selective reporting bias, and prevent duplication. The Center for Open Science, a nonprofit where researchers can register
their hypotheses a priori (https://cos.io) and Preclinical Trials, a platform for
registration at the outset of all types of animal studies (www.preclinicaltrials.
eu), will hopefully improve the current situation. An additional measure to improve transparency, and potentially reproducibility, is data sharing, which is a
requirement for publication by some major journals but many researchers still
refuse to share. By sharing data, errors can be discovered (e.g., Salzberg et al.,
2001). This is especially important in animal research, since it helps reduce the
number of animals used and sheds light on the real value of animal derived data.
5.2
Necessary Steps
The improved quality of human clinical trials was achieved by strategies to
minimize bias, a priori power analysis and further biostatistics, clear definition of the primary and secondary endpoints, data monitoring and auditing,
internationalization and inclusion of multiple centers, external steering committees and safety monitoring, rigid publication standards, trial registries, and
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more (Dirnagl and Fisher, 2012). The lessons learned from the improvement
of human clinical trial quality should be adopted by preclinical (Dirnagl and
Fisher, 2012) and all other biomedical research fields (Hartung, 2013), where
relevant and with appropriate changes, since flawed research is unscientific
and unethical. The ethical issues with research involving animals become extra
critical as needless animal suffering must be avoided, and as preclinical animal
data generally forms the basis for decisions whether to proceed to human clinical trials. Thus, in order to adhere to the 3Rs, the following efforts are crucial:
– Education and ongoing training of researchers in experimental design, statistical methods, and model selection (Justice and Dhillon, 2016).
– Close assistance in study design by institutional animal welfare bodies and
by biostatisticians.
– As a possible solution for the problem of false positives making their way
into the literature, some researchers suggest the p-value threshold should
be reduced to 0.005 (Chawla, 2017). Others say researchers should select and
justify p-value thresholds for their experiments, before collecting any data.
These levels should be based on factors such as the potential impact of a
discovery. These thresholds could then be evaluated via registered reports, a
type of scientific article in which methods and proposed analyses are peerreviewed before any experiments are conducted (Chawla, 2017).
– Transparency must be improved as it is crucial to document all anticipated
or exploratory steps in the study. Prospective registration of all animal studies with their hypotheses and endpoints is essential to prevent selectivereporting biases (Ioannidis, 2012) and avoid study duplications (Preclinical
Trials, n.d.).
– Disclosure and openness are critical elements of science for self-correction,
and they can help avoid poor practices, such as HARKing.
– The use of preparation and reporting guidelines, such as the prepare guidelines (Smith et al., 2017) combined with the arrive guidelines (Kilkenny
et al., 2010), should be a mandatory, legally required part of funding applications, project license applications, as well as publications. Education on how
to fill out the checklists and present the required information in the publication, as well as a focus on enforcement of compliance to both by journals, is
critical (Eisen, Ganley and MacCallum, 2014; Enserink, 2017; Hair et al., 2018;
Herrmann and Flecknell, 2018a).
– Raw data, analyses, and protocols must be made available to allow other
researchers to verify results. This can easily be achieved by using data repositories (e.g., https://datadryad.org or https://figshare.com).
– Reporting of all study outcomes to avoid traditional reporting bias and
selective outcome and analysis reporting bias should be mandatory (Ioannidis, 2012).
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– Retrospective assessments of animal studies (see Ec Expert Working Group
for Project Evaluation and Retrospective Assessment, 2013, pp. 28–32)
should be performed comprehensively and by independent experts; and all
results should be published to enhance transparency, minimize publication
bias, identify animal models lacking external validity, and, thus, improve future research.
– Mandatory data sharing so that other scientists can build on the work and
discover errors faster (cf. the error in the Human Genome Project discovered by Salzberg et al., 2001). Data sharing should be compulsory, especially
when research is publicly funded.
It is equally important that funding and regulatory bodies, animal ethics committees, animal welfare bodies, journal editors, and peer reviewers have a detailed knowledge of these topics in order to recognize flawed research studies.
This requires effective and thorough education and training of funders, animal
ethics and welfare committees, and regulatory body members on how to assess
animal research proposals (Vogt et al., 2016). Furthermore, in order to review
these applications in-depth, enough time and manpower are a prerequisite.
6

Refinement: Are We Doing What We Can?

As presented in this chapter, knowledge about and implementation of refinement of husbandry, experimental procedures and design, conduct, and reporting appears to still be patchy. Since adoption of refinement strategies has been
inconsistent, it would seem that rather than use additional animals to carry
out more refinement research, we should focus on the comprehensive application of existing refinements in animal laboratories as well as on reducing and
replacing animals.
6.1
But What about the Refinement of Animal Models?
Animal models ought to describe a biological phenomenon that the model
species has in common with the target species. Significance and validity, in
terms of the translatability of results produced in an animal model to the human condition, “depend on the selection of a suitable animal model,” writes
Hau (2008, p. 4), which is why comprehensive knowledge about comparative
anatomy and physiology is essential. A majority of animal models developed
with the expectation to study the origin, disposition, and treatment of human disorders and is created through experimental induction, genetic modification, or breeding of disease-causing mutations (Hau, 2008, p. 4). These
presumed predictive models are used to find treatments or to assess the toxicity of drugs and other chemicals (Hau, 2008). Hence, they cause conditions
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associated with pain and distress up to severe, long-lasting suffering for these
animals.
Some laboratory animal scientists focus on the refinement of animal models in an attempt to reduce the suffering caused. Examples for refinement recommendations of animal models include those described for mice and rats
who are utilized as models of ischemic stroke (Percie du Sert et al., 2017), for
rheumatoid arthritis (Hawkins et al., 2015), in experimental autoimmune encephalomyelitis (eae) (Wolfensohn et al., 2013a), as models and in procedures
involving seizures, convulsions, and epilepsy (Lidster et al., 2016; Wolfensohn
et al., 2013b), and as models of sepsis and septic shock (Lilley et al., 2015). If
the gathering of such recommendations does not involve additional harmful
animal experiments, and in case these guidelines are then applied in practice,
they could lead to an improvement of the individual animal’s life.
However, due to failure of numerous models to predict human outcomes
(e.g., Joffe et al., 2016; Mak, Evaniew and Ghert, 2014; Pharmaceutical Research
and Manufacturers of America, 2015, 2016), and due to limited funding, it
seems crucial to first assess carefully which research methods and models to
use. In the case of sepsis models, for example, there have been multiple publications highlighting the differences in human and mouse immunology (e.g.,
Mestas and Hughes, 2004; Rittirsch, Hoesel and Ward, 2007; Seok et al., 2013;
Shay et al., 2013; Payne and Crooks, 2007). After over 20 years of unsuccessful
research in this field, a number of scientists finally investigated why, out of
the approximately 150 new compounds that were developed for the treatment
of sepsis using mice, not one had beneficial effects for humans. They identified around 5,000 genes that are activated or deactivated by inflammation in
humans who suffered from sepsis, trauma, or burns. They went on to look for
the same genes in one commonly-used strain of mice and realized that there
was no correlation (Seok et al., 2013). As a consequence of the dissimilarity
of mouse and human immune systems, the entire field of sepsis research in
mice has been called into question, regarding its predictive value for humans.
Paradoxically, funding for this kind of animal research, which is also known for
causing severe levels of animal suffering, is still ongoing (Leist and Hartung,
2013). At the same time, human-based sepsis research has led to clinical trials
of effective therapies (van der Poll, 2012).
7

Reduction and Replacement: Are We Doing What We Can?

Most animal research is being justified as indispensable to furthering human
healthcare. However, despite measures being taken to improve the quality of
animal-based research, the translational success rate from animal studies to
Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

24

Herrmann

humans is low: Less than 12% of drugs entering clinical trials result in an approved medicine (Pharmaceutical Research and Manufacturers of America,
2015, 2016); and between 51% and 89% of preclinical studies are not reproducible (Freedman, Cockburn and Simcoe, 2015; Harthorne and Schachner, 2012).
There is an ongoing debate among scientists as to why animal models fail to be
predictive: Is this mainly due to poor scientific rigor and reporting, to species
differences, or to the fact that today we mainly deal with complex, oftentimes,
chronic ailments of which many are not well understood and, thus, impossible
to model in other animals?
As a consequence of the failure to translate findings to humans, new criteria for mouse models have been described (Justice and Dhillon, 2016). Hoping to enhance animal models of stroke, Dirnagl and Fisher (2012) call for
international, multicenter, preclinical Phase iii-type studies of promising
new ischemic stroke therapies in animals before moving to clinical trial. As
Phase iii studies would be based on prior studies and would use various strains
and species (Dirnagl and Fisher, 2012), as well as older animals with various comorbidities (e.g., diabetes mellitus, obesity, and hypertension) (Mergenthaler
and Meisel, 2012), the severity of these experiments and the numbers of animals involved would markedly rise. Of close to 100 interventions that improved
the outcome in animal stroke models, which were tested in clinical trials, only
one intervention improved the outcome in human patients (O’Collins et al.,
2006). Despite decades of research, most translational stroke trials that aim
to extrapolate basic research findings into clinical treatments, particularly in
the area of neuroprotection, have failed (Mergenthaler and Meisel, 2012). The
authors admit that, to date, there is no ideal animal model for stroke, and that
more complex models are needed to improve translational success in experimental stroke research (Mergenthaler and Meisel, 2012). Thus, at the time of
writing, Mergenthaler and his colleague Stachelscheid are developing human
stem cell-derived 2D and 3D models for stroke (vfa, 2017). Building on the latest in vitro research to model human brain development and disease, they plan
to employ a recently established protocol for generating 3D brain tissue, socalled cerebral organoids, from human pluripotent stem cells that can be applied to study a number of human brain diseases (Lancaster and Knoblich,
2014). Renner et al. (2017) further examined the development and potential
differentiation of cerebral organoids, which hold great potential to advance
human-relevant stroke research.
7.1
Potential for Reduction by Critical Appraisal of Animal Studies
Several unsuccessful animal models have been discussed, such as for Alzheimer disease (Cavanaugh, Pippin and Barnard, 2014; Pippin, Cavanaugh and
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Pistollato, 2019, Chapter 20 in this Volume; Pistollato et al., 2016), for stroke
(Shuaib et al., 2007; van der Worp et al., 2010), for tuberculosis (Fonseca et al.,
2017); for asthma (Mullane and Williams, 2014), for hiv/aids, for neurological,
menopausal human therapy, and for cancer research as well as drug development (Pippin, 2012). Since only disease models with high predictive validity are
likely to yield positive results and treatments for humans, it is critical to assess
the reliability, reproducibility, and validity of the animal model first. With the
overall low quality and predictive validity of the majority of research studies,
it has become evident that animal-based studies require rigorous evaluation
(Pound et al., 2004). A solid methodological approach would be to systematically review and to perform meta-analyses of animal studies, as SRs are seen by
experts in the field of evidence-based medicine as the highest level of medical
evidence (Hooijmans, Leenaars and Ritskes-Hoitinga, 2010).
7.1.1
Systematic Reviews (SRs)
A systematic review (SR) is a literature review that focuses on a specific question with the aim to identify and assess all relevant studies in order to generate
new, high-quality evidence. Thus, it enables evidenced-based decision making
(Norecopa, 2017). A SR may contain a meta-analysis. In a meta-analysis, the
results of a number of independent studies are statistically combined to calculate the average effect of studies addressing the same question, which may lead
to more reliable conclusions and may help to minimize needless duplication
of animal studies (Hooijmans et al., 2014a). SRs conform with the implementation of the 3Rs concept (Ritskes-Hoitinga, 2016), as their application leads to a
more evidence-based choice of animal models (e.g., de Vries et al., 2012; Sloff
et al., 2014; Zeeff et al., 2016). They help decrease unnecessary animal studies,
the evidence they produce should further responsible animal use, and they
increase scientific quality (van Luijk, 2016), as they are an excellent tool to
assess study quality by evaluating the internal, external, and construct validity
of the models. Internal validity is the degree to which the design, conduct, and
analysis of the experiment remove potential bias, so that the interpretation of
a causal relationship between an experimental treatment and variation in an
outcome measure is secured (Bailoo, Reichlin and Würbel, 2014). The extent to
which animal data gives a basis for generalization to other animal and human
populations, including other environmental circumstances, represents the external validity; and construct or predictive validity shows how good the model
is, the rate to which the sampling properties are representative for the entities
they ought to represent (Bailoo, Reichlin and Würbel, 2014; Würbel, 2017). An
example for a SR on internal validity is the study of Macleod et al. (2008) and
for construct validity, the work of Sena et al. (2010), both focusing on reasons
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for translational failure of experimental stroke. SRs are a significant tool to
identify quality issues with primary animal studies. For example, a recent SR
on the welfare implications of toe clipping and ear notching revealed that the
underlying animal experiments were too flawed to draw conclusions (Wever
et al., 2017). SRs are excellent to assess the risk of bias in animal studies and
thus to evaluate the reliability of the available evidence (van Luijk et al., 2014).
Perel et al. (2007) systematically reviewed the success of treatments in animals
and in humans, with head injury, hemorrhage, thrombosis due to acute ischemic stroke, acute ischemic stroke, and osteoporosis as well as preventive
medication in neonatal respiratory distress syndrome, with their applications
in humans with these impairments. Their conclusion was that the incongruity
between animal and human studies may be due to bias or to the failure of the
animal models to mimic clinical disease (Perel et al., 2007).
SRs of animal studies are still much less common than in the clinical setting,
where they are frequently used to make evidence-based decisions on healthcare; but awareness of the benefits of the utility of SRs of animal research has
been increasing (Hooijmans et al., 2014; van Luijk et al., 2014). The Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies (camarades) group, at the University of Edinburgh in the UK,
and the Systematic Review Center for Laboratory Animal Experimentation
(syrcle), at Radboud University Medical Center in the Netherlands, provide a
supporting framework for groups who are or want to get involved in the SR and
meta-analysis of data from experimental animal studies and offer advice and
training (camarades, 2014; syrcle, n.d. b). syrcle has published a step-bystep guide on how to identify all relevant animal studies (Norecopa, 2017), as
well as a tool similar to the Cochrane tool for assessing risk of bias in randomized clinical trials (Higgins et al., 2011), to assess the risk of bias in animal-based
studies (Hooijmans et al., 2014). It is important to receive proper training first,
as one needs to be aware of the pitfalls and limitations of these tools, and how
they can be misused and/or misleading (Gurevitch et al., 2018). Various types
of reporting biases, together with the limited methodological quality of some
studies on which meta-analyses and SRs are based, can impede their conduct
and interpretation (e.g., Benatar, 2007). When publication bias against negative animal studies exists, it will lead to an overestimate of the value of animal
studies. It is likely that if unpublished studies were to be included, then SRs
would show more studies with no effect in animals (Akhtar, Pippin and Sandusky, 2009). Checklists and tools have been proposed to help improve SRs and
meta-analyses (Hooijmans et al., 2014; Moher et al., 2009).
The use of SRs should be standard practice within animal-based research,
in the same way it has become a vital part of clinical research (Hooijmans,
Leenaars and Ritskes-Hoitinga, 2010; Hooijmans and Ritskes-Hoitinga, 2013;
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Pound and Bracken, 2014; Pound et al., 2004; Sandercock and Roberts, 2002).
SRs should be conducted prior to a new animal study to assess the validity of the proposed animal model and to avoid needless animal use (RitskesHoitinga and Wever, 2018). For example, in refinement research, SRs are an
efficient way to gather new high-quality data without having to experiment
on additional animals. As shown in this chapter, the implementation of new
knowledge about refinements to improve animal welfare has proven very
difficult. A prominent example is the use of carbon dioxide to kill animals.
Extensive research conducted on this welfare topic has produced overwhelming evidence against its use, but these findings still have not led to the abolishment of this common practice. At the time of writing, Turner et al. are
conducting a SR on the use of carbon dioxide as a killing method for mice and
rats. Their protocol (syrcle, n.d. c), as well as the protocols of others, are published on the syrcle website and, since 2018, protocols of SRs relevant to
human health can be registered at the international prospective register of
SRs, called prospero (https://www.crd.york.ac.uk/prospero/).
7.1.2
Other Retrospective Assessments
Conducting retrospective assessments (RAs) is a useful way to identify disease models and research methods that may be of limited value. Since 2013,
RAs are mandatory for certain animal studies in the European Union (European Parliament, 2010, Article 39). Members of the animal research inspectorates have been required to assess the outcomes of animal studies that were
classified as severe and/or use non-human primates. The animal researcher
has to submit the necessary documents so that the competent authority
can evaluate whether the study objectives were met, the actual harm inflicted, and whether the severity of procedures coincided with the prospective
assessments, and the number of animals used. In a ddition, the competent authorities must appraise any component that can advance the implementation
of the 3Rs (European Parliament, 2010, Article 39).
These RAs could be extremely effective in facilitating a critical review of the
use of animals in scientific procedures, if there are sufficient and qualified personnel to conduct them, as the EC’s aim with these RAs is to identify 3Rs improvements and enhance transparency to the public (EC Expert Working Group
for Project Evaluation and Retrospective Assessment, 2013). Publication of RA
results of all studies, including those that produced negative results and may
not be published elsewhere, would likely be of significant value. It would increase the knowledge base in a range of disciplines, reduce risks of duplication
of studies, and inform the design of future research (EC Expert Working Group
for Project Evaluation and Retrospective Assessment, 2013). However, only
about one sixth of all EU Member States agreed to make the RA results publicly
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available. This is not enough to meet the EC’s goals. To achieve maximum benefit, access to study results should be given not only to regulatory authorities but
to independent experts, in order for them to perform critical reviews of these
data. And all RA results have to be made publicly available. It is possible to do
so and still protect intellectual property by redacting and anonymizing certain
parts of the documentation.
7.1.3
Necessary Steps
As outlined earlier, the scientific and ethical justification for animal models
of human diseases depends on their providing an opportunity to investigate
disease biology and to determine potentially beneficial therapies for humans
(Benatar, 2007). Thus, only after an animal model has proven to have satisfactory predictive value for humans, should it be refined as much as possible to reduce pain, suffering, distress, and lasting harm. If proven of no value, it should
be abandoned. Such models should no longer receive regulatory approval nor
funding, nor should they be accepted by scientific journals. SRs and metaanalyses of animal models as well as RAs of all animal experiments performed by
independent experts would benefit animals and human patients, as they help
to identify flawed studies and to eliminate misleading, invalid models, and experimental designs. Such a rigid quality control of animal-based research would
most certainly lead to a significant reduction of animal use and, thus, to an increased effort to find more animal-free, robust, human biology-based models.
7.2

Is the Biomedical Research Industry Shifting away from Animal
Use?
The problem is that it hasn’t worked, and it’s time we stopped dancing
around the problem. […] We need to refocus and adapt new methodologies for use in humans to understand disease biology in humans.
zerhouni, former head of the US National Institutes of Health, quoted in
McManus, 2013

There is growing recognition that instead of focusing efforts on trying to refine animal experiments, a primary focus on human-relevant data is needed
(Collins, 2011; Giri and Bader, 2015; Langley et al., 2015, 2017; Zerhouni, 2014),
as a significant challenge that medical research is facing today is the understanding and possible treatment of chronic, complex diseases of which
many are not well understood and, thus, cannot be modeled in other animals
(Tsukamoto, 2016). Tsukamoto asks in a Drug Discovery Today editorial: “How
can we replicate human diseases that develop later in life and/or result from
a prolonged unhealthy lifestyle, far beyond the lifespan of rodent animals?
What makes us expect that the outcomes from carefully controlled animal
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experiments can be duplicated in patients with substantial heterogeneity
across various aspects (age, gender, genetics, lifestyle, disease stage, etc.)?”
Transgenic mice commonly used as disease models, oftentimes contain multiple copies of presumed disease-causing transgenes, and it is dubious “whether phenotypes seen in mice as a result of this ‘genetic exaggeration’ have any
relevance to the corresponding human diseases” (Tsukamoto, 2016). Zerhouni
(2014) calls for a new approach that redirects the drug-development paradigm
that commences with the patient to explore the genetic foundation of molecular changes inherent to human pathophysiology.
As Russell and Burch remarked in 1959, “refinement is never enough, and
we should always seek further for reduction and if possible replacement”
(Chapter 4). Since 1959, we have gathered immense knowledge about animals
and their consciousness, which has led to the public acknowledgment by a
group of prominent neuroscientists that other animals are conscious too: The
Cambridge Declaration on Consciousness (Low, 2012). Since 1959, the technology revolution has also immensely changed the field of life sciences and,
hence, provides us with the tools to move away from using animals (Langley
et al., 2015, 2017).
Current legislation, reflecting societal concerns, as well as the scientific failures of animal research should function to drive research, testing, and education away from using live animals. Some areas of education and training are
already using animal-free teaching approaches, for ethical reasons and educational advances (see e.g., Bones et al., 2019, Chapter 23; Pawlowski et al., 2019,
Chapter 22 in this Volume). In the area of chemical-toxicity testing, some progress has already been made in finding advanced non-animal methods, initiated,
for example, through the pioneering Toxicology in the 21st Century (Tox21), a US
federal initiative (National Research Council, 2007; National Toxicity Program,
2004; Rovida et al., 2015; Zurlo, 2012). However, the general tendency in toxicology is to introduce new methods without eradicating all the old (animal-based)
ones (Rovida et al., 2015). Still, the acceptance of animal-free alternatives by
regulators without additional animal-based tests, in the pharmaceutical and
food-toxicity testing fields, should be possible when proven scientifically qualified for the specific context of use. However, awareness and acceptance of
scientically-valid, non-animal methods is still low among regulators as well as
research workers (Ramirez et al., 2015).
The high failure rate of drugs in the clinical phase (Begley and Ellis, 2012;
Food and Drug Administration, 2004; Hutchinson and Kirk, 2011; Kola and
Landis, 2004; Olson et al., 2000) indicates not only poor scientific quality and
cognitive bias but also that animals are not good models for humans (e.g.,
Greek and Kramer, 2019, Chapter 17 in this Volume; Kramer and Greek, 2018;
Knight, 2019, Chapter 14 in this Volume; Leist and Hartung, 2013); and the same
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applies to food-safety testing in animals (Rovida et al., 2015). Already back in
2000, an eye-opening report (Olson et al., 2000) was published about the results of a multinational pharmaceutical company survey, which served to better understand the concordance of the toxicity of pharmaceuticals in humans
compared with other animals. The weakness of animal studies to predict the
human toxicity of drugs became apparent, as results revealed a human toxicity
concordance rate of 71% when tested in multiple rodent as well as non-rodent
species. When they compared humans with rodent species only, there was a
43% correlation; humans compared with non-rodent species showed a 63%
match. Drug toxicity studies in animals are long-lasting and, hence, may cause
severe suffering; and they are frequently not predictive for effects in humans
(Hartung, 2009).
Cumulative knowledge is essential for scientific progress. Thus, there is
increasing awareness of the importance of data sharing and collaboration to
shift the paradigm away from using unsound animal models for drug toxicity
testing. The human toxome project, a systematic mapping of the entirety of
toxicity pathways, is ongoing in the area of chemical risk assessment. Rovida
et al. (2015) suggested that this project should be extended to include the assessment of efficacy and adverse effects of drugs and food ingredients. Continued reliance on animal models appears implausible to enhance the current poor rate of clinical approval of new treatments. This is why Humane
Society International initiated the Biomedical Research for the 21st Century
(BioMed21) Collaboration. The BioMed21 Collaboration is working internationally with health experts, regulatory and research agencies, funding
bodies, and others to develop innovative research roadmaps that focus on
understanding human disease pathophysiology.The goal is to further this humanfocused approach to studying, preventing, and treating disease (BioMed
21 Collaboration, n.d.). A central recommendation of the BioMed21 2015
workshop was to use the Adverse Outcome Pathway (aop) concept in biomedical research. aop, an important concept in toxicology, describes a logical
sequence of causally-linked biological events that lead from the first action of a
compound to an eventual adverse effect on human health (Langley et al., 2017).
Furthermore, it was recommended that technological advances should be combined in human-specific tools and models. The importance of funding these
new approaches was highlighted as well as the need for faster validation and
acceptance by the scientific community, funding bodies, and scientific journals, who mostly still postulate the use of animals (Langley et al., 2015, 2017).
BioMed21 is a rare example for a non-animal-based approach in the area of
applied research, which—together with the field of basic research—uses the
majority of animals. Overall, there is little evidence that these fields are reducing the use of animals, as the 3Rs posit we must. Quite the contrary: Animal use
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has been increasing in the new century (Taylor and Rego, 2016), mainly due to
an increasing generation and use of genetically altered animals (Bailey, 2019,
Chapter 19 in this Volume; Carbone, 2004; Ormandy, Schuppli and Weary, 2009;
Ram, 2019, Chapter 15 in this Volume), which has, in recent years, been fueled
by excitement over new technologies, such as crispr, an easier genetic modification technique that will most probably lead to a further steep increase in
animal numbers and species modified (Bailey, 2019). These new technologies,
however, have not kept their promise of improving translation between animal
models and human health, as they have failed to increase the efficiacy and the
safety of drugs (Hunter, 2011). For a detailed discussuion on the scientific and
ethical issues of the genetic modification of animals, see Chapter 19 in this
Volume (Bailey, 2019).
7.2.1
Funding
Progress in the development of replacement methods seems to be limited
most by the availability of funds. Some governments and non-governmental organizations around the world are providing scarce funding, especially when
compared to funds available for biomedical and life research as a whole. It is
unclear how much of the annual worldwide funds—an estimated US$100 billion for biomedical research alone (Chalmers and Glasziou, 2009) and up to
US$240 billion for all the life sciences (Røttingen et al., 2013)—are currently
used for research centered around the use of animals, as it is not differentiated
in the statistics (e.g., in Germany, bmbf, 2017). Daneshian (2016) estimated
that in 2015, funds for projects with animals in Germany, including animal research facilities, were about €1920 million; funds for replacement methods
ranged around €6.45 million. These financial means, mainly derived from German taxes, are distributed in opposition to Germany’s declared political goal of
working towards replacement of animal use at the national level (bmel, 2015)
as well as the EU level (European Parliament, 2010, Recital 10).
In preclinical human model development, the Tissue Chips for Disease Modeling and Efficacy Testing initiative, funded by US National Center for A
 dvancing
Translational Sciences (ncats) of the National Institutes for Health (nih), is
a rare example. Its goal is to explore human microphysiological systems as potential facilitators of drug development in numerous disease areas. Its budget is approximately US$15 million, annually, for 13 two-year projects (ncats,
2017); while nih, being the biggest funder and research organization in the
world, has annual funds of about US$39 billion for medical research alone
(nih, 2019). The EU framework program for research and innovation, Horizon 2020 (European Commission, n.d.), has, at the time of writing, supported
16 research projects devoted to alternative methods to animal testing, with a
total of €90 million (European Parliament, 2017). The main research activities
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are targeted towards developing complex in silico and in vitro human-based
systems for better and more cost-effective safety and efficacy testing of chemicals, nanoparticles, vaccines, and drugs (European Parliament, 2017).
Between 1981 and 2015, the German Federal Ministry for Education and Research (Bundesministerium für Bildung und Forschung, bmbf) gave €160 million in funding for over 500 3Rs research projects. Aside from not exclusively
funding replacement projects, the funds dedicated to the 3Rs were sparse; for
example, in the 6-year period between 2010 and 2015, less than €20 million
were available (bmbf, 2016). The UK National Centre of the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) is the largest funder
of such research in the United Kingdom (Burden et al., 2015). Between 2004 and
2014, NC3Rs awarded 200 grants worth approximately US$54 million (Burden
et al., 2015); the annual overall budget of NC3Rs is approximately €11.2 million
(NC3Rs, n.d. d). In contrast, the German national 3Rs center, Zentrum zum
Schutz der Versuchstiere (Bf3R), has an annual budget of €1.5 million to run all
of its operations (Bundesinstitut für Risikobewertung, 2016) and provides approximately €350,000 to external replacement and refinement research groups
per year (Bundesinstitut für Risikobewertung, 2018). Replacement research
has to compete with refinement research for these limited funds (bmbf, 2016;
NC3Rs, n.d. a).
A donor that exclusively provides money for the first R is the cosmetic company Lush, which in 2012 established the Lush Prize in collaboration with the
UK not-for-profit group, Ethical Consumer Research Association (Redmond,
2019, Chapter 27 in this Volume). Lush provides £250,000 in funding each year
for the main prize categories, with additional funds for regional awards in Asia
and the Americas (Lush Prize, n.d.). An example for a charity providing some
funding is People for the Ethical Treatment of Animals (peta) International Science Consortium (pisc), which, in June 2017, awarded funding to develop four
in vitro exposure systems to researchers from institutions in the United Kingdom, United States, and Belgium that are leaders in the development of nonanimal methods to test the toxicity of airborne substances (peta International
Science Consortium, n.d. a). pisc assists with funding where promising in vitro or in silico techniques require further development or validation in order
to gain regulatory acceptance. pisc focuses on toxicology and until, 2017, it
has contributed about €2.9 million towards improving and implementing
non-animal research methods (peta International Science Consortium, n.d.
b). The Alternatives Research & Development Foundation (ardf) funds and
promotes the development and validation of non-animal methods in biomedical research, product testing, and education and has provided US$3.25 million
in funds since 1993 (Alternatives Research & Development Foundation, 2018).
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The US National Anti-Vivisection Society (navs) provides some grants through
the International Foundation for Ethical Research (ifer) for early career scientists to develop humane, human-relevant alternatives that replace animal
use (navs, 2018). Overall, there are a few local and international initiatives and
prizes but most focus on animal testing, while non-animal approaches in basic
and applied research lag behind. Moreover, to ensure the field of animal-free,
human-based research methods and approaches is continually and substantially growing, increased, stable governmental funding must be provided.
7.2.2
Education and Training
Another obstacle in shifting the current research paradigm is the limited availability of educational and training courses on animal-free methods and approaches in all areas of biomedical science, but especially in basic and applied
research, since current available guidance documents and databases as well as
courses almost exclusively focus on testing alternatives. There are some efforts
being made to improve experimental design, conduct, and reporting; for example, online resources are available at some of the national 3Rs centers, such
as at Norecopa, Norway’s National Consensus Platform for the advancement of
the 3Rs (Norecopa, 2016b) and the UK NC3Rs (NC3Rs, n.d. b, c), since quality
issues of biomedical research has become apparent.
By EU law, the researcher must be well informed about state-of-the-art
developments in the field of investigation, and animals must only be used if
all possible alternatives are considered to be inadequate (EC Joint Research
Centre, 2013). The EC Joint Research Centre’s EU Reference Laboratory for
Alternatives to Animal Testing – European Centre for the Validation of Alternative Methods (eurl ecvam) Search Guide (EC Joint Research Centre, 2013)
and Data Base Service on Alternative Methods to animal experimentation
(DB-alm) (EC Joint Research Centre, 2017) ought to assist with the search for
alternatives to animal use. However, even for experts in the respective field,
it is a lengthy and difficult task, as existing search systems do not support the
necessary search strategies.
Altertox Academy, formerly caat Academy, offers hands-on training, but
primarily for toxicologists, in human-relevant alternative methods and technologies (Altertox Academy, 2018). Education and training courses, mandatory
for all animal researchers in the EU, include one animal-free methods module
(e.g., felasa B courses), but of a 40 hour felasa B course, about one hour is
dedicated to replacements, and generally only alternatives used in toxicology
testing are covered (e.g., Berliner Kompaktkurse, 2017, p. 23). In 2016, the University of California (UC) San Diego offered a course that introduces participants to the available non-animal research methods, their efficacy, and how to
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identify and implement them. It covered more areas than just regulatory toxicology (UC San Diego, 2018). However, detailed courses with extensive modules for all areas of the biomedical sciences currently do not exist.
7.2.3
Search Engine for Alternative Methods
What is urgently needed—aside from specific education and training
courses—is an unbiased, freely available search engine that is able to find
correlations regarding scientific purpose between animal experiments and
alternative methods and, at the same time, 3Rs-relevant deviances in the
methodologies (in vitro versus in vivo). Scientists from the Leibniz Institute
for Social Sciences (gesis) and the German Federal Institute for Risk Assessment (Bundesinstitut für Risikobewertung, BfR) have laid the foundation for
such a search engine, using machine learning. The project is called smafira,
which stands for “smart feature-based interactive ranking algorithm.” The goal
of smafira is to develop automated but mechanistically transparent search
procedures that focus on such deviations and, thus, to provide an improved
automatic support to search for non-animal methods (fisaonline, n.d.). This
search engine will drastically reduce the number of documents scientists have
to go through (gesis, n.d.). A first version of the smafira search engine is
anticipated to be available in the second half of 2019 (Daniel Butzke, BfR, personal communication, January 2019).
8

Ways to Work Towards Replacement

Directive 2010/63/EU, a progressive animal protection legislation in the field,
sums up some important steps that have to be taken to work towards a paradigm shift, when it states (emphasis added): “The availability of alternative
methods is highly dependent on the progress of the research into the development of alternatives. […] the Commission and the Member States should
contribute through research and by other means to the development and
validation of alternative approaches.” (Recital 46). Article 47 declares: “The
Commission and the Member States shall contribute to the development
and validation of alternative approaches which could provide the same or
higher levels of information as those obtained in procedures using animals
[…], and they shall take such other steps as they consider appropriate to encourage research in this field. […] Member States should, at national level,
ensure the promotion of alternative approaches and the dissemination of
information […]”.
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8.1
Political Engagement
The needed political engagement that Directive 2010/63/EU demands from its
Member States to move towards an animal-free world of scientific experimentation was made a priority by the Dutch government in 2016. The Netherlands
National Committee for the protection of animals used for scientific purposes
(NCad) has developed a vision and plan of action for moving away from laboratory animal use. The Dutch goal is to phase out the utilization of animals in
a number of fields by 2025, namely in regulatory testing of chemicals, food ingredients, pesticides and (veterinary) medicines, and biological products, such
as vaccines (NCad, n.d.). The Committee also plans to steadily reduce animal
involvement in regulatory preclinical research and basic research: “If we are to
make the transition to non-animal research methods, we must make a paradigm shift away from existing mindsets and practices” (NCad, n.d., p. 3), a task
which seems to be impossible without political involvement. The Dutch strategy holds the potential to act as a driver for other countries to follow this path.
8.2
Legislative Change
There is a need for regulators who are brave to move legislative change forward. The reason for the continued use of animals for regulatory testing is
legislative, as existing policies require that new drug candidates are tested on
animals before they can be assessed in human clinical trials, regardless of the
fact that these animal tests are often unreliable in assessing safety and efficacy
in humans (Greek and Kramer, 2019, Chapter 17 in this Voume). These regulations need to be amended according to scientific knowledge, and serious efforts need to be made to accelerate the development of advanced, humane,
and human-relevant models (Archibald, Coleman and Drake, 2019, Chapter 18
in this Volume).
8.3
Redeployment of Funds
Absolutely essential for the paradigm change towards advanced, animal-free
science and better healthcare is the redirection of funding. The limited funding for replacement research, oftentimes, has to compete with refinement
research (e.g., bmbf, 2016; NC3Rs, n.d. a). These scarce funds should be used
to further human biology-based approaches. Also, regarding taxpayers’ money,
the national governments, arguably, have the responsibility to use the funds in
the name of a society that has repeatedly voiced that more needs to be done
to replace animals in science. Moreover, our society is ethically evolving, with
evidence of dwindling acceptance for animal suffering in the name of science. And it is being increasingly acknowledged that the continued reliance
on animal models is unlikely to improve significantly the currently poor rate of
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clinical approval of new treatments. Thus, animal-based research also contributes to resources being wasted (Harris, 2017; Ioannidis et al., 2014; Keen, 2019,
Chapter 10 in this Volume).
Aside from redeploying funds, partially to preclinical human-relevant disease research (Langley et al., 2017) and to clinical rather than basic research
(Pound and Bracken, 2014), a large part of funding should be dedicated to disease prevention efforts. To combat the increasing prevalence of dementia, for
example, human-focused, non-animal models and methods, such as computational methods, advanced brain imaging techniques, and epidemiological
studies should be given funding preference (Pistollato et al., 2016). Another
extremely important area of disease prevention is basic public healthcare
(Marks, 2012) as well as nutrition and lifestyle education. In addition, funds
should also be used for pollution control, as pollution is currently found to be
the largest environmental cause of disease and premature death around the
world (Landrigan et al., 2017). The World Health Organization (who) estimated that around 3 million people die prematurely every year due to air pollution
alone (Watts et al., 2017). In 2015, diseases caused by pollution were responsible
for about 16% (9 Mio.) of all human deaths worldwide, which is three times
more than deaths from tuberculosis, malaria, and aids combined and 15 times
more than all wars and other means of violence together (Landrigan et al.,
2017).
8.4
Education and Training
Education as well as re- and ongoing training about how to conduct state-ofthe-art science and report it properly, as well as education on research ethics
and bioethics are crucial. They enable students and scientists to gain a solid
grounding in science based on non-animal models, while sincerely embracing the hierarchy of the 3Rs. Such learning objectives should be made available and should be mandatory for everyone planning to work or working in
biomedical science. Education and retraining are the most important means
to move away from the current thought culture and practice of animal use towards a new, humane research paradigm.
8.5
Scientific Collaboration
As Russell and Burch observed in 1959, “As we shall see, replacement is widely
used in some fields, while in others it is very far from being exploited to the
full, if at all. Moreover, such developments have been largely empirical, and
largely independent of each other” (Chapter 5). At the moment, 3Rs experts
are divided into replacement experts, on the one hand, and refinement experts, on the other. Animal welfare bodies and national committees in the
EU (Directive 2010/63/EU, Recital 48), for example, are supposed to advise
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s cientists about the application of the 3Rs but seem to have little to no knowledge about available replacements and novel animal-free approaches to scientific questions (van Luijk et al., 2012; van Luijk et al., 2013). To achieve the
ultimate goal in shifting the focus from refinement of animal use to replacement of animal use the animal research community needs to engage with replacement experts. National 3Rs centers should be equipped with a majority of
experts in replacement methods, and a close collaboration between replacement experts and animal researchers appears crucial in moving towards animal replacement. To accelerate the development of new human biology-based
approaches, a multidisciplinary approach is essential for bringing together the
newest technologies and experts from various disciplines (Langely et al., 2017;
Noor, 2019, Chapter 25 in this Volume).
9

Final Remarks

Looking into the future of animal-based science, Carbone (2004) wrote that
morality and politics will continue to be the drivers for replacement research.
Since the introduction of the principles, it has been widely held that animal researchers have an ethical responsibility to minimize any pain, distress, fear, suffering, and harm caused to animals when keeping them confined and utilizing
them for invasive experiments without their consent. To apply the knowledge
gained through animal welfare and refinement research is good veterinary and
scientific practice, but it is not a substitute for reduction and replacement of
animal experimentation. Indeed, Balls warned “that refinement can be used
as a convenient way of showing commitment to the 3Rs, while ensuring that
animal experimentation is seen as respectable and can be allowed to continue,
while the fundamental ethical questions raised by it are avoided” (2010, p. 21).
Thus, we have to be on guard that refinement is not used as a whitewashing
tool, but its full application, which is an ethical imperative, must be guaranteed during the transition to human-relevant, animal-free methodologies.
Aside from extensive flaws in the way the majority of animals are housed
and treated, and the poor conduct and reporting of many animal studies, the
general lack of transparency around the use of animals in research as well as
the low rate of critical appraisal of animal experiments are apparent. These
failings have led to incorrect data and an overestimation of their significance
(Cohen, 2018). Unnecessary harm inflicted upon these animals and, in the case
of medical research, the harms done to patients who suffer from adverse reactions to drugs that were tested safe in animals or who are urgently waiting
for treatments are serious issues that need to be addressed. A commitment to
adhere to the 3Rs and to good scientific practice as well as to address societal
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concerns about the use of animals in science would require a strong shift away
from animals towards the use of human-relevant approaches.
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Introduction

Over time, the interpretation of science has occasionally been corrupted by
vested interest groups, be they financially motivated or ego driven. Scientific
consensus and widespread public beliefs usually catch up with the evidence,
but this can take a very long time and often costs lives. The use of non-human
animals in biomedical research and testing is a scientific endeavor and, as such,
can and should be evaluated in light of the best science currently available.
But facts that have been accepted in all areas of science are routinely ignored
or called into question by well-funded, vested interest groups, compromising
the scientific integrity of biomedical research. History is replete with examples
of practices deemed scientifically viable in one era, but later abandoned as
more facts about the material universe were discovered. There are also many
instances of practices being rejected by the scientific establishment, in spite
of the fact that they were valid based on scientific criteria. In this chapter, we
discuss why science is important in the context of animal modeling, how scientific positions are currently evaluated through the peer-review process, and
how an evaluation of the science of animal modeling should be conducted
now. We reach the conclusion that, in order to formally evaluate the scientific
viability of animal modeling, a debate is urgently needed with experts in the
relevant fields of science reviewing pro and con arguments written in position
papers.
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Context

The use of non-human animals in science, in general, and in biomedical research and testing, in particular, has historically been controversial. Formal
objections to the practice emerged as early as the seventeenth century, primarily based on moral objections (Franco, 2013). The peak controversy, perhaps,
began with the popularization of the animal rights movement, circa 1975. Welfare concerns aside, there are many stakeholders with vested interests in the
continued use of non-human animals in research. First, many scientists and
nonscientists worldwide are employed, either directly or indirectly, due to the
use of non-human animals in biomedical science, with jobs spanning both
private-sector and publicly-funded entities. The volume and variety of entities
that conduct and/or fund animal-based research complicates any attempt to
quantify the dollar magnitude of associated expenditures; but a conservative
estimate indicates that at least US$10 billion is spent annually on animal-based
research and testing in the United States, only taking account of funds originating from the National Institutes of Health (Monastersky, 2008). If one considers other grant-funding sources and private-sector sources, both in the US and
in the many other countries where non-human animals are used, the amount
spent annually is likely many orders of magnitude more than this conservative
figure.
Of course, human nature is such that people generally oppose technological
changes which may render their own employment obsolete or may otherwise
interfere with their personal objectives. Furthermore, people may even be reluctant to embrace technological change that simply alters the specific tasks
they undertake in completing their work. For instance, scholarly researchers
who have entire laboratories devoted to animal modeling may be reluctant to
consider adopting non-animal-based research methods if doing so might require the development of new tools, jeopardizing their publishing prospects
or their ability to continue training graduate students to emulate the type
of research they have always undertaken. That is, it takes time and effort for
people to develop new skills, and people are naturally averse to changes that
might require that they do so. Additionally, universities and other research institutions rely on research grant overhead fees as a form of revenue to help
cover the administrative costs of running their organizations. When a sizeable
portion of that overhead-fee revenue stream originates from grants that fund
animal-based research, executives and even employees at those institutions
may be reluctant to consider a future free of animal modeling. A researcher at
Columbia University wrote that one reason animal modeling continues is due
to the “frailties of human nature. Too many eminent laboratories and illustrious researchers have devoted too much of their time to studying malignant
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diseases in mouse models, and they’re the ones reviewing one another’s grants
and deciding where the nih [National Institutes of Health] money gets spent.
They’re not prepared to concede that mouse models are basically valueless for
most cancer therapeutics” (Raza, 2015, p. 232).
In recognition that a wide variety of conflicts of interest can influence
scholarly researchers, including non-monetary, Nature Research journals, for
example, require authors “to declare any competing financial and/or nonfinancial interests,” including “present or anticipated employment by any organization that may gain or lose financially through this publication”; unpaid
memberships or advisory positions; writing or consulting for an educational
company; and other considerations (see Nature Research, 2011). Because of
vested interests—whether monetary, emotional, or philosophical—the outcome of any change in the animal-model paradigm has the potential to affect
many people adversely, some of whom are represented by societies, lobbyists, nonprofits, nongovernmental organizations, and other groups that may
be keen to attract media attention to promote their agendas. Consequently,
vested interests can interfere with the adoption of progressive policies and
behaviors.
The social and political atmosphere surrounding animal use is similar to that
of other science-based controversies (or in some cases, p
 seudo-controversies),
such as vaccines, global warming, and genetically modified organisms (gmos).
There are typically advocates on both sides of such issues, and it is often the
case that one needs an advanced science background to understand the relevant issues. Thus, the general public, and even some scientists, may not be
able to determine rightly which side the scientific facts actually support. The
more money at stake in any given debate (e.g., the interests of the oil and
coal industries in the context of the global warming controversy), the more
propaganda will likely emerge, potentially confounding the public’s ability to
understand and evaluate the facts. Even when there is scientific consensus
because of overwhelming evidence—as there is on the overall effectiveness
of vaccines, the safety of gmos in terms of human health, and the existence of
global warming—the opposition can be so well funded and prone to promoting unscientific points of view that the general public can almost be forgiven
for incorrectly believing there exists real controversy on these points.
Regarding the use of non-human animals to model human responses to
drugs and diseases, articles questioning the scientific viability of the practice
began appearing in the scientific literature in the 1980s. These critiques have
taken various forms and, unfortunately, have included arguments that appear
on the surface to be science-based, but are in fact not valid science-based attacks. The first four of the following five points list the most common themes
of these attacks, and we provide a brief explanation of why each argument
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lacks merit. The fifth point represents a valid objection to animal modeling, by
which we mean the objection is logical and is based on scientific facts. In the
discussion that follows, we make frequent reference to the concept of predictive value. We refer the reader to the empirical evidence section of Chapter 17
(in this volume), for a detailed discussion of the mathematical calculation of
numerical predictive value. Briefly, predictive value is an important metric by
which a test or methodology correctly identifies an outcome or condition in
humans. The specific threshold by which a particular modality is deemed to
have an acceptably high predictive value varies by context. In medicine, where
lives lie in the balance, one could argue that nothing short of 100% is acceptable. In some cases, even drugs tested with modalities that offer predictive value as high as 99.9% have been pulled from the market due to life-threatening
consequences. In practice, animal models have predictive value below 50%,
making them less informative than a coin flip and rendering them of no practical use in predicting human outcomes. Given the poor predictive value of animal modeling, Kramer and Greek (2019) propose existing drug development
and disease research resources ought to be redirected towards personalized
medicine, a new field which offers the promise of 100% predictive value due to
its basis in each patient’s own unique genetic makeup.
We now turn to listing the most common critiques of the use of non-human
animals to model human responses to drugs.
1.
The methodology of the experiment was poor, and, therefore, animal modeling should be abolished. This argument is invalid because implicit within
the argument is the false premise that if the methodology had been good
then that would have reflected well on the viability of the entire paradigm of animal modeling. Of course, the use of good or bad methodology in a given experiment is not sufficient for making general statements
about whether animal modeling should be abolished overall.
2. The history of medical science has not been as dependent on animal modeling as we have been led to believe, and, therefore, animal modeling should
be abolished. This argument is invalid. Whether or not the current state
of modern medical science was dependent on researchers having used
animal models in the past has no bearing on whether the continued use
of non-human animals is vital. Decisions about any future use of animal
models should be based on modern scientific knowledge about whether
animal models have predictive value for human outcomes, taking into account information that may not have been available or considered when
past decisions were made.
3. Review articles conclude that specific non-human animal species have not
been vital to various medical developments, and, thus, animal modeling
should be abolished. This argument is not valid. Even if it were true that
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specific non-human animal species were not essential parts of specific
medical advancements, this would not be a sound basis for evaluating
whether the overall use of animal models has predictive value for human
outcomes.
4. There are now alternatives to using non-human animals, and, therefore, animal modeling should be abolished. There exist alternatives to many uses
of non-human animals in science but not others. Currently, for example,
there are no toxicity tests that have high enough predictive value for humans. Nor can we ethically instrument the human brain the way we do
in non-human animals. The position in this point is further weakened by
the fact that it does not address whether animal modeling is scientifically
viable in the first place, nor does it offer a scientific theory to tie together
areas where animal use is successful and areas where it is not.
5. The paradigm of animal modeling is not scientifically viable for predicting
human response to drugs and diseases, and, thus, animal models should
not be used to predict human response to drugs and diseases. In contrast to
the previous four points, this particular point is based on critical thinking, logic, and scientific facts; and, hence, it is a valid scientific argument.
Scientific knowledge from complexity science and evolutionary biology,
supported by empirical evidence, establishes that animal modeling does
not have predictive value for human outcomes. Past research in these
areas was summarized by authors, including Greek and Rice (2012), LaFollette and Shanks (1996), LaFollette and Shanks (1998), and Shanks
and Greek (2009), forming the basis for trans-species modeling theory
(tsmt): “While trans-species extrapolation is possible when perturbations concern lower levels of organization or when studying morphology
and function on the gross level, one evolved, complex system will not
be of predictive value for another when the perturbation affects higher
levels of organization” (Greek and Hansen, 2013a, p. 245).
In Chapter 17 in this volume, Greek and Kramer (2019) discuss tsmt in great
depth. Briefly, tsmt draws on established knowledge in evolutionary biology and complex systems science to draw the conclusion that animal models
cannot be predictive of human response to drugs and disease. We refer the
interested reader to Chapter 17 for further details. tsmt is the only scientific
argument that invalidates using animal models to predict human response to
perturbations that occur at higher levels of organization. tsmt is also the only
critique of animal modeling that both explains past apparent successes and
failures and why future reliance on animal models will lead to continued significant failures in predicting human responses (Greek, 2014; Greek and Hansen, 2013a,b; Greek and Menache, 2013; Greek and Rice, 2012; Jones and Greek,
2013). Unlike tsmt, points 1–4 above do not offer any definitive resolution to
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the animal modeling controversy; indeed, many animal modeling advocates
agree with various aspects of these points. Furthermore, points 1–4 offer no
scientific evaluation of the problem, nor do they make reference to science to
support their assertions. Point 5, in contrast, is based on valid scientific foundations, and, hence, we focus here on tsmt as the only viable opposition to
the paradigm of animal modeling.
tsmt is a theory and, like all scientific theories, it is consistent with the
following definition from the National Academies of Sciences, Engineering,
and Medicine (2017): “In everyday usage, “theory” often refers to a hunch or
a speculation. When people say, “I have a theory about why that happened,”
they are often drawing a conclusion based on fragmentary or inconclusive
evidence. The formal scientific definition of theory is quite different from the
everyday meaning of the word. It refers to a comprehensive explanation of
some aspect of nature that is supported by a vast body of evidence”. Stated
differently, fact-supported theories should not be guesses but, instead, must
be reliable accounts of the real world. To that end, the facts associated with
evolution and complex systems have been established beyond doubt by observation and experiments. Furthermore, there is extensive empirical evidence
from animal modeling to support tsmt. Additionally, tsmt is characterized
by consilience—it agrees with facts from other fields. It is also falsifiable and
generalizable, and it offers predictions for future outcomes. tsmt fulfills all of
the qualifications for a scientific theory.
In this chapter, we suggest a peer-reviewed debate process by which scientists and society, in general, could formally evaluate the scientific validity of
the statement in point 5 and, in so doing, could resolve the deep disagreement
about the predictive value of animal modeling. This process could have been
applied in the past and lethal errors would consequently have been avoided.
It could also be applied to other science-based controversies facing society.
The peer-reviewed debate we recommend is not a panacea appropriate for
all disagreements. Many disputes in life (and even those relating to the use of
non-human animals in certain contexts) do not center on science but rather
arise due to fundamental differences in opinion, which are rooted in ideology.
However, the process we propose is appropriate for settling controversies related to science, such as those that arise in the context of using animal models
as predictors of human outcomes.
3

Why Science Is Important

The use of non-human animals in science and science education is not confined to biomedical research and testing where predictive value is touted as an
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Nine categories of animal use in science and research (Greek and Shanks, 2009)

Non-human animals are used as predictive models of humans for research
into such diseases as cancer and aids.
Non-human animals are used as predictive models of humans for testing
drugs or other chemicals.
Non-human animals are used as “spare parts”, such as when a person
receives an aortic valve from a pig.
Non-human animals are used as bioreactors or factories, such as for the
production of insulin or monoclonal antibodies or to maintain the supply
of a virus.
Non-human animals and animal tissues are used to study basic physiological principles.
Non-human animals are used in education to educate and train medical
students and to teach basic principles of anatomy in high school biology
classes.
Non-human animals are used as a modality for ideas or as a heuristic
device, which is a component of basic science research.
Non-human animals are used in research designed to benefit other animals of the same species or breed.
Non-human animals are used in research in order to gain knowledge for
knowledge sake.

o bjective. There are, in fact, many categories of animal use, as shown in Table 2.1,
some of which do not lean on predictive value as a determining factor for using
non-human animals.
In general, it may be possible to justify the use of non-human animals associated with Categories 3–9 based on scientific grounds, without reliance
on predictive value for perturbations that occur at higher levels of organization. For instance, one can make a logical argument, with valid reference to
science, to support the claim that human lives may be saved by using tissue
retrieved from an animal (Category 3) or to make the claim that one can learn
about the broad structure of lungs in mammals by examining the lungs of rats
(Category 6). (This does not rule out the possibility that, in some cases, there
may also be valid scientific objections; for example, the risk of facilitating the
cross-species transmission of viruses.) Furthermore, there may exist valid
ethical objections to the use of non-human animals in specific instances of
Categories 3–9. We leave aside possible objections such as these for the purposes of this discussion and focus, instead, exclusively on scientific arguments
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regarding utility. L ikewise, using some non-human animals in order to learn
more about other animals of the same species is scientifically uncontroversial
in veterinary medical research. However, it is not scientifically justifiable to use
non-human animals in the context of Categories 1 and 2, for reasons based in
complex systems science and evolutionary biology (for more details on complex systems science and evolutionary biology, see Chapter 17, the above-cited
papers regarding tsmt, and the references therein).
Nevertheless, the literature is filled with cases where researchers make
(baseless) claims that animal models have predictive value for human outcomes in the context of drugs and diseases. For example, the widely-used
Handbook of Laboratory Animal Science states: “[An] important group of animal models is employed as predictive models. These models are used with the
aim of discovering and quantifying the impact of a treatment, whether this
is to cure a d isease or to assess toxicity of a chemical compound” (Hau, 2003,
p. 2). A highly cited article in Clinical Cancer Research states: “gems [genetically engineered mice] closely recapitulate the human disease and are used
to predict human response to a therapy, treatment or radiation schedule […]
gems that faithfully recapitulate human brain tumors and will likely result in
high-quality clinical trials with satisfactory treatment outcomes and reduced
drug toxicities” (Fomchenko and Holland, 2006, p. 5296). The popular textbook, Animal Models in Toxicology (Gad, 2007), states: “Biomedical sciences’
use of animals as models [is to] help understand and predict responses in
humans, in toxicology, and pharmacology […] [B]y and large animals have
worked exceptionally well as predictive models for humans” (Preface). “Animals have been used as models for centuries to predict what chemicals and
environmental f actors would do to humans […] The use of animals as predictors of potential ill effects has grown since that time” (p. 2). “If we correctly identify toxic agents (using animals and other predictive model systems)
in advance of a product or agent being introduced into the marketplace or
environment, generally it will not be introduced” (p. 3). These are but a few
of the many instances where researchers make vastly over-reaching claims
about the prediction value of animal models. A balanced assessment of
the overall evidence shows, instead, that animal models, for all practical
purposes, do not have predictive value for human responses to drugs and
diseases.
Further to that point, the medical literature contains many papers that
show, based on the (standard) statistical concept of predictive value, that there
is no basis to continue using non-human animals to predict human response
to drugs and diseases (Greek, 2014; Greek and Greek, 2010; Greek and Hansen,
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2013a; Greek, Pippus and Hansen, 2012b; Greek and Rice, 2012; Greek, Shanks
and Rice, 2011b; Shanks and Greek, 2009; Shanks, Greek and Greek, 2009). Since
advocates of animal modeling appeal to the predictive value argument to justify their use of non-human animals, the onus is on those advocates to clearly
establish predictive value. Yet, such evidence based on predictive value, which
may support of the use of animal models, is notably absent from the scientific
literature. That evidence is also absent from the legally binding documents that
the Institutional Animal Care and Use Committees and funding bodies, such
as the National Institutes of Health (nih) in the US, require animal modelers
to sign, testifying that their projects have a reasonable expectation to translate
to humans. The lack of evidence is a direct consequence of the fact (shown by
the studies cited above, and, in turn, the many studies they cite) that responses
to perturbations, such as drugs and diseases, in an animal have effectively no
predictive value for responses in humans.
The fact that animal models do not have predictive value for human responses has several important implications, including the following:
1.
The extent to which the general public supports the use of non-human
animals in research rests on an assumption that the outcome of the research benefits humans directly. For example, writing in Nature, Giles
states: “public opinion is behind animal research only if it helps develop
better drugs.” (2006, p. 981) Since animal models do not have predictive
value for human outcomes, their use should be abandoned.
2. Continuing to use non-human animals in the absence of predictive value
wastes time and money (see Chapter 10) which could instead be devoted
to scientifically valid pursuits.
3. Various members of the pharmaceutical industry and various scientists
have acknowledged the failure of the animal model for predicting human responses to drugs and diseases (Arrowsmith, 2011a,b; Ennever,
Noonan and Rosenkranz, 1987; Fletcher, 1978; Food and Drug Administration, 2004; Johnson et al., 2001; Kola and Landis, 2004; Kummar et al.,
2007; Lumley, 1990; Morgan et al., 2012; Seok et al., 2013; van Meer et al.,
2012). Nevertheless, there is a widespread belief among lawmakers and
members of the public that animal models cannot be abandoned until
“alternatives” have been developed. The logic behind this belief is specious. To demonstrate this, we offer the following thought experiment.
Imagine if regulators were to choose which drugs to endorse for human
use based on a simple coin flip (e.g., heads, we allow humans to use a
given drug; tails, we do not). Such an approach would do nothing to ensure the safety or efficacy of drugs reaching the market. This is because
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coin flips do not have predictive value for determining human responses
to drugs. Consequently, it would make no sense to continue using coin
flips to choose drugs until an alternative to coin flips could be identified.
Likewise, animal models do not have predictive value in determining human responses to drugs, and their use must be halted independent of
whether an alternative exists.
4. Animal-based research lacks predictive value for human responses to
drugs and diseases, and, thus, it is reckless to continue to justify the use
of animal models with myths about protecting humans in clinical trials
or learning about human disease. Abundant theoretical and empirical
evidence has established unequivocally that the animal model does not
have predictive value for humans and indeed cannot. Thus, the only scientifically valid conclusion is to stop attempting to use animal models
to predict outcomes for humans. See Kramer and Greek (2018) for an
extensive discussion of the many ways various groups of human stakeholders, including but not limited to patients, are directly harmed by the
continued use of animal models.
While the vested interests we described earlier have served as an obstacle to
acceptance of the fact that animal models do not have predictive value for
human responses, the truth has, nevertheless, been acknowledged in the scientific literature, on occasion. For example, Markou, Chiamulera, Geyer, Tricklebank (of Eli Lilly) and Steckler (of Johnson and Johnson) state: “Despite great
advances in basic neuroscience knowledge, the improved understanding of
brain functioning has not yet led to the introduction of truly novel pharmacological approaches to the treatment of central nervous system (cns) disorders.
This situation has been partly attributed to the difficulty of predicting efficacy
in patients based on results from preclinical studies [mainly animal studies,
although in vitro would also be included in preclinical studies] […] Few would
dispute the need to move away from the concept of modeling cns diseases in
their entirety using animals” (Markou et al., 2009, p. 74). Additional examples
include: Alini et al. (2008); Arrowsmith (2011a, b); Begley (2003a, b); Butler
(2008); Contopoulos-Ioannidis, Ntzani and Ioannidis (2003); Crowley (2003);
Dragunow (2008); Editorial (2010, 2012); Ferdowsian and Beck (2011); Geerts
(2009); Grant, Green and Mason (2003); Hackam and Redelmeier (2006);
Hampton (2006); Höerig and Pullman (2004); Holmes, Solari and Holgate
(2011); Hurko and Ryan (2005); Ioannidis (2004); Jin and Wang (2003); Johnston
(2006); Kaste (2005); Langley (2014); Ledford (2008, 2012); Leslie (2010); Liebman (2005); Lindl, Voelkel and Kolar (2005); Mankoff et al. (2004); Marincola
(2003); Markou et al. (2009); Mullane and Williams (2012); Pammolli, Magazzini and Riccaboni (2011); Philips (2004); Pound et al. (2004); Pound and Bracken
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(2014); Reynolds (2012); Rosenberg (2003); Rothwell (2006); Sena et al. (2007);
Smith (1987); van der Worp et al. (2010); Xiong, Mahmood and Chopp (2013);
and Zerhouni (2005).
Further evidence that animal models are extremely limited in what they
can inform, regarding druggable targets and future cures, comes from a comment in the American Journal of Medicine about Contopoulos-Ioannidis et al.’s
(2003) article:
The article by Contopoulos-Ioannidis et al. in this issue of the Journal
addresses a much-discussed but rarely quantified issue: the frequency
with which basic research findings translate into clinical utility. The authors performed an algorithmic computer search of all articles published
in six leading basic science journals (Nature, Cell, Science, the Journal of
Biological Chemistry, the Journal of Clinical Investigation, the Journal Experimental Medicine) from 1979 to 1983. Of the 25,000 articles searched,
about 500 (2%) contained some potential claim to future applicability
in humans, about 100 (0.4%) resulted in a clinical trial, and, according to
the authors, only 1 (0.004%) led to the development of a clinically useful
class of drugs (angiotensin-converting enzyme inhibitors) in the 30 years
following their publication of the basic science finding. They also found
that the presence of industrial support increased the likelihood of translating a basic finding into a clinical trial by eightfold.[…] Still, regardless
of the study’s limitations, and even if the authors were to underestimate
the frequency of successful translation into clinical use by 10-fold, their
findings strongly suggest that, as most observers suspected, the transfer
rate of basic research into clinical use is very low.
crowley, 2003, p. 503

Note that of the 101 articles that formed the primary focus of Crowley’s study,
about 64% were animal studies. An Editorial (2010, p. 499) in Nature supports
the above position:
The readers of Nature should be an optimistic bunch. Every week we
publish encouraging dispatches from the continuing war against disease
and ill health. Genetic pathways are unravelled, promising drug targets
are identified and sickly animal models are brought back to rude health.
Yet the number of human diseases that can be efficiently treated remains
low—a concerning impotency given the looming health burden of the
developed world’s ageing population. The uncomfortable truth is that scientists and clinicians have been unable to convert basic biology a dvances
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into therapies or resolve why these conversion attempts so often don’t
succeed. Together, these failures are hampering clinical research at a time
when it should be expanding.
Given the vast amount of money that funds animal-based research and testing, the many hours of human effort that are devoted to these pursuits, and
the reliance of all humans whose well-being relies on scientific knowledge for
maintaining health and treating disease, there is an urgent need for unbiased,
expert scientists to assess the predictive value of animal models. We propose
a debate for this purpose, and we now turn to outlining the parameters for
ensuring such a debate is sound.
4

How to Evaluate Scientific Arguments

Science is a process of observing the material universe, possibly conducting
experiments related to those observations, and ultimately ascertaining facts.
According to E.O. Wilson (1999, p. 58): “Science […] is the organized, systematic
enterprise that gathers knowledge about the world and condenses the knowledge
into testable laws and principles.” Often, time will determine whether a given
scientist’s conclusions are representative of the material universe. But in the
interim, the best method for separating fact from fiction involves the peerreview process. The peer-review process uses experts in specific areas of science to evaluate the work of others and to determine whether the research and
conclusions of that research are reliable enough to be published in a science
journal for dissemination to a broad readership.
The peer-review process of scientific journals works as follows. A number of
experts are asked to review a submission to the journal and determine (among
other factors):
– whether the submission is in accordance with known facts about our current scientific understanding
– whether the terms and assumptions are consistent with proper usage
– whether the methodology is appropriate
– whether the statistics were correctly calculated
– whether or not there are flaws in the authors’ reasoning
– whether the findings are likely to be of interest to the scientific community,
policy makers, and/or the general public.
This process is not foolproof, but under the appropriate circumstances, it is
usually capable of separating potential facts from sheer nonsense. Depending on the contents of the submission, experts from several different areas
of science may be asked to review the submission and judge the part of the
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s ubmission that falls under his or her area of expertise. We propose that something akin to this peer-review process should be employed in order to evaluate
the scientific viability of using one species to predict response for another in
the context of developing drugs and treating diseases.
The peer-review process has been used repeatedly to resolve disputes in
many scientific settings, for instance at conferences where select scholars presented evidence for and against a particular position in front of an audience of
other experts in the field. A consensus is sought, if not in terms of who is right,
at least in terms of which statements can be taken as fact and which must still
be taken as conjecture. However, many controversies in science have, instead,
been left to simply play out on their own without interference in the form of
peer review. Some of these events have had lethal consequences. For example,
in 1847, Ignaz Semmelweis introduced the idea that the unwashed hands of
medical students and physicians spread the disease known as puerperal fever,
an infection related to child bearing. Despite the fact that his patients demonstrated a reduced mortality rate after he and his students began washing
their hands, his colleagues ostracized him, and his idea died along with many
more patients. Had experts been convened to study and debate the evidence,
antiseptic techniques would have been developed much sooner and many
mothers’ lives would have been saved (Ataman, Vatanoğlu-Lutz, and Yıldırım,
2013). Other prominent examples of scientific breakthroughs being ignored include the following: Barbara McClintock’s idea of jumping genes, transposons,
was ignored by a mostly male establishment in biology. McClintock could not
even find a publisher for her research. Darwin’s theory of evolution was almost
forgotten in the early twentieth century. Alfred Wegener’s idea of continental
drift was ignored because he did not propose a mechanism for the notion.
Science has also allowed nonsense to go unchallenged until someone publicly proved the status quo wrong or, occasionally, until disaster occurred. Some
cases persisted simply because no one exhibited the courage to disrupt the status quo; unfortunately, history is full of such examples. The Columbia disaster
of 2003 occurred because the craft was allowed to launch despite engineers
knowing there were problems with the tiles (Langewiesche, 2003). Similarly,
the space shuttle Challenger disaster of 1986 was caused by engineers ignoring a problem with the O-rings. Descartes’ unsubstantiated assertions convinced society that non-human animals were not sentient, and some members
of society are still clinging to that position. Smoking was defended by some
physicians for years because they were employed by the tobacco industry
(Jackler, 2015). Scientific consensus can also be wrong. For instance, Earth contraction theory was wrong and was eventually replaced by Wegener’s movement of continents and eventually plate tectonics. Newton was shown to be
partially wrong by Einstein’s theory of relativity. Some of Einstein’s objections
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to quantum mechanics turned out to be wrong. The notion that ulcers were
relieved by decreasing anxiety and drinking milk was abandoned after Marshall proved that ulcers were the result of an infectious disease, and research
revealed that milk actually stimulated acid production in the stomach. Peerreview, d ebate, and the convening of experts at conferences, all played a role
in ensuring that obsolete scientific views were replaced by positions rooted in
modern knowledge.
Science has historically advanced slowly and by consensus, which is why
Planck (1949, pp. 33–34) stated: “A new scientific truth does not triumph by
convincing its opponents and making them see the light, but rather because its
opponents eventually die, and a new generation grows up that is familiar with
it.” Reaching consensus slowly and methodically can have its advantages in certain contexts; but when lives are at stake, as was the case with Semmelweis and
is the case with using animal models to predict human outcomes, a slow pace is
not acceptable. The debate we propose can help expedite the formal evaluation
of conflicting views and is especially appropriate for facilitating d iscussions
about complex topics with foundations that span multiple disciplines.
5

Peer-reviewed Debate

We propose to borrow elements of the process used in peer-reviewed science
journals and implement them in a debate format to evaluate the scientific issues surrounding the use of animal models, specifically, to resolve whether
non-human animals have a high predictive value in terms of modeling human
response to drugs and diseases. The scientific literature contains an abundance
of articles that ought to convince a scientifically-minded reader that animal
models do not have predictive value for human response to drugs and diseases; a small sampling includes, Arrowsmith (2011a, b); Crowley (2003); Greek
(2012, 2016); Greek and Greek (2010); Greek and Hansen (2012, 2013a); Greek,
Hansen and Menache (2011a); Greek and Menache (2013); Greek, Menache and
Rice (2012b); Greek and Rice (2012); Greek, Shanks and Rice (2011b); Hurko and
Ryan (2005); Jones and Greek (2013); Marincola (2003); Mullane and Williams
(2012); Shanks and Greek (2008, 2009); and Shanks, Greek and Greek (2009).
We propose the debate as a supplement to the existing literature, not only to
help promote scientific consensus but also to reach a much broader audience
of interested parties, including members of the general public.
A formal debate, sponsored by a government or major science organization and with implications for future funding and legislation, would compel
the animal model community to participate and address the problems with
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animal modeling. Engaging in less formal debates, including traditional oral
debates organized by university departments or student groups (as we have
done frequently; see Sandgren and Greek, 2007; Skolnick and Greek, 2005), has
far less scope for effecting a change in consensus views about animal modeling.
The reasons for this are many, including the fact that layperson members of the
audience typically do not understand the science (and there are typically no
expert judges present to help the audience evaluate the debaters’ positions); if
there are judges present, their expertise may not span all the areas of science
that are pertinent to a full and careful evaluation of animal modeling; and time
and format constraints prevent the debaters from going into sufficient detail to
substantiate their cases. We propose a formal debate that would address these
issues, permitting a fair evaluation of both sides of the debate. We recommend
the following rules for the debate:
1.
The subject of the debate will be the position that animal models have
insufficient predictive value for human response to perturbations that
occur at higher levels of organization (e.g., human response to drugs
and diseases) and the implication that the vast majority of animal use
in science, in general, and research and testing, in particular, should
cease.
2. Each side of the debate will be represented by a single individual who
is recognized as an expert by the public and the scientific community.
That individual may, in turn, consult any number of experts for input and
guidance.
3. A single person or a group of not more than three people will be appointed as moderator(s) of the debate.
4. A panel of scientists who are experts in the relevant fields will act as
judges and will evaluate the positions put forward by the debaters. These
panel members may come from academia or industry and must be recognized as experts by the public and the scientific community. In all, 12–20
scientists will be selected to serve on the expert panel, and their collective expertise will span and encompasses the following fields:
a.	clinical medicine, in general, as well as infectious diseases, cancer,
heart diseases, and neurology
b. statistics
c.	
evolutionary biology, including evolutionary and developmental
biology
d. clinical research
e. drug development
f. personalized medicine
g. basic research
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h.	complexity theory (expert(s) should come from the math or physics
department of a university)
i.	critical thinking, the history of the science behind medical discoveries, and philosophy of science, in general (expert(s) should have extensive training and credentials in science as well as the stated areas).
The judges and moderator(s) must have no vested interests in the outcome of the debate, including any of the following:
a.	a direct financial interest in the outcome of the debate, such as currently receiving money for conducting or facilitating animal-based
research
b.	a significant indirect financial interest that arises from animal-based
research or testing
c.	an indirect vested interest, such as having, at least in-part, made one’s
reputation through having conducted research using non-human
animals
d.	an indirect financial interest in the form of having a first-degree relative or spouse who currently receives or formerly received funding for
animal-based research or testing
e.	a philosophical or emotional interest in the use of non-human animals
in research and testing, such as well-known figures from the animal
protection movement or pro-vivisection/pro animal-use movement.
The debate itself will consist of the following steps:
a.	The debaters, panel members, and moderators will agree on a set
of panel members, textbooks, or position papers that specify basic
principles of science and critical thinking. Any disagreements will be
settled by the expert in the relevant area prior to the proceeding with
next steps and will be disclosed by the moderator(s) in the last step
of the debate. This will encourage all parties to play fairly, as the communications will be a matter of record.
b. Each of the debaters will submit a written position paper.
c.	If the judges have questions or comments about the position papers, they will compile them and submit them to the appropriate
debater(s).
d.	Each debater will have the option to respond in writing to the set of
judges’ questions/comments.
e.	The judges will render their judgement after evaluating the position
papers and (if appropriate) responses. The judges’ evaluations must
be based on the validity of each side’s position, as stated in the position paper and responses to questions, and each side’s adherence to
the rules of engagement. In evaluating this set of information, each
judge must verify (based on their respective area of expertise) w
 hether
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the provided evidence supports the debaters’ claims and whether
the arguments and reasoning in the position papers are sound and
valid.
f.	The judges will compile a list of claims made in each side’s position
paper which were rejected by the judges as false or unsubstantiated,
as well as instances in each position paper which were deemed by the
judges to be inconsistent with the agreed-upon principles of critical
thinking and science. Advance knowledge that these disclosures will
occur, will encourage all parties to play fairly, because all of their statements will be a matter of record.
g.	The full proceedings, including the names of all participants, the
position papers, the judges’ questions and comments, the debater’s
responses, the judges’ final decision, and the disclosures described
above will all be published in a scholarly outlet, such as an open-
access journal.
6

Conclusion

Science has evolved since the time when animal modelers first began using
non-human animals in earnest in the nineteenth century. But never have experts convened to formally examine the evidence for and against the continued
use of non-human animals. The debate we propose for this purpose, conducted in public and judged by unbiased experts, is long overdue. There is no argument in modern society about whether scientists should receive funding to
develop a perpetual motion machine; this is because science has established
that such a device cannot exist. Analogously, society’s continued investment
in animal modeling can and should be evaluated based on its scientific merit.
Given the fact that governments and businesses devote scarce resources and
vast sums of money to the enterprise of using animal models to predict human
responses to drugs and diseases, and the fact that human lives are at stake,
there is an urgent need to evaluate whether science supports the continuation of this practice. The debate we propose would serve as a significant step
forward to that end.
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Introduction
Article 23 of European Union (EU) Directive 86/609/EEC required that Member States promote the development and validation of alternative technologies
and stated that the European Commission (EC) “shall report before the end of
1987 on the possibility of modifying tests and guidelines” (European Parliament,
1986, Article 23). This Directive was replaced by Directive 2010/63/EU on the protection of animals used for scientific purposes, which now requires that Member
States develop and validate alternative approaches much more precisely and
specifies that the ultimate objective is the “full replacement of procedures on live
animals for scientific and educational purposes, as soon as it is scientifically possible to do so” (European Parliament, 2010, Recital 10). However, having followed
the initiatives of Member States for more than 30 years, we see that d evelopments
to replace animal experiments occur more by accident than by design. Directive 2010/63/EU has not changed this either. This chapter explores the reasons
why the development and approval of animal-free methods are not advancing
more quickly, and why the numbers of animals used is not declining despite the
development of new methods. Undoubtedly, there are complex, multifactorial
reasons behind this. Our analysis leads us to the heart of the matter. There is no
master plan and there are no responsible project managers who effectively pursue the objectives of Directive 2010/63/EU at a national or EU level.
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In 2015, we started collating individual measures in order to tackle the problems we encounter in our day-to-day work as an animal rights organization,
defining five categories (or pillars). We were encouraged to pursue our ideas
by developments in the United States through concepts, such as Toxicology in
the 21st Century—A Vision and a Strategy (Tox21) (Krewski et al., 2010), as well
as by the EU ban on the marketing of cosmetics tested on animals, which came
into force in 2013. During this time, the Netherlands National Committee for
the protection of animals used for scientific purposes (NCad) presented its
plan, Transition to Non-Animal Research, referred to here as the NCad report
(NCad, 2016a), becoming the first EU member state to present a road map for
phasing out animal procedures and stimulating innovation without laboratory
animals. Unfortunately, no EU Member State, so far, has publicly spoken out in
favor of the Dutch initiative. On the contrary, its timeline has been criticized as
being unrealistic, risking the safety of medical treatment, and hampering basic
research. Only the government of the Brussels-Capital Region has put forward
a plan to phase out animal experiments along the lines of the NCad report.
Member States should show more support for such initiatives, which aspire to
achieve the goal of full replacement stated in Directive 2010/63/EU. At the EU
level, unfortunately, there is neither an overall strategy for phasing out the use
of animals for scientific purposes nor for monitoring the implementation of
the paradigm shift. It is important that changes take place, but how they take
place is subject to debate.
Writing from the point of view of a German animal rights organization, the
main focus of this chapter is Germany. Although Germany claims to be especially committed to developing animal-free methods, it ranks among the highest in terms of animal experiments in the EU, together with France and the
United Kingdom.
1

Part 1: How Seriously Do Member States Take the Tasks and
Obligations Stated in Directive 2010/63/EU?

A master plan to end animal experiments requires suitable resources for effectively reducing animal experiments and increasing market-ready animal-free
methods. In the following we discuss steps towards that final goal.
On 1 December 2016, the Netherlands became the first EU Member State
to present a road map for “phasing out animal procedures and the promotion of innovation without laboratory animals” (NCad, 2016a, p. 3). They are
convinced that some uses of animals—currently required by law for safety
testing of chemicals, food additives, pesticides, and (veterinary) medicines as
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well as the commercial launch of biological products (e.g., vaccines)—can be
phased out by 2025, while maintaining existing safety levels. However, their
road map recommends that regulatory pre-clinical tests for the registration
of new biological substances/products not be phased out by 2025 because
there is a lack of replacement methods. Similarly, animal experiments in
the field of “curiosity-driven” (NCad, 2016a, p. 38) basic research is not to be
terminated by 2025 because there is a basic right to freedom of research;
and, as no one knows the subject of research in advance, animal experiments cannot be easily replaced with new animal-free methods. Therefore,
it has been necessary to implement 10-year plans for each individual area
of research. In the case of animal experiments in applied and translational
research (implementation of preclinical research in clinical development),
which are also not to be phased out by 2025, the development of replacement methods is to be accelerated. The aim is to reduce significantly the use
of laboratory animals for education and t raining. The planning encompasses
transition objectives, transition strategy, and management of the transition.
There is every indication that the NCad report, commissioned by the former
Minister for Agriculture, Martijn van Dam, has laid out solid project planning with the goal of effecting system change from animal use to animal-free
procedures.
This type of planning should have been initiated at an EU-wide level in
2013 when Directive 2010/63/EU came into effect, requiring the phasing out
of animal procedures and the acceleration of innovation without laboratory animals. While no Member State has publicly spoken out in favor of the
Dutch initiative, the German research association, Deutsche Forschungsgemeinschaft (dfg) and the Allianz der Wissenschaftsorganisationen (Alliance of Science and Research Organizations) issued a critical assessment of
the plan, calling its timeline unrealistic and claiming it would endanger the
safety of medical treatment and hamper basic research (BfR, 2017a). According to our organization (People for Animal Rights Germany—Federal Association against V
 ivisection), a good master plan has the following attributes:
it includes all stakeholders, including the scientific community, industry, and
animal rights/welfare organizations; it has robust monitoring to assess the
paradigm shift towards animal-free science; and it has an active commitment
of all stakeholders to implement the plan. The master plan for an end to animal experiments requires suitable resources that purposefully pursue this end
by reducing animal experiments and increasing market-ready animal-free
methods.
The master plan’s foundation rests on five pillars:
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Pillar 1: Increased Research Funding for Animal-free Methods Is
Necessary
Here we refer to animal-free research in the field of applied and basic research.
This research field includes methods that can replace animal testing in regulatory animal tests (in a narrow sense). The budget for animal-free research
methods should be drastically increased, with the EU and its Member States
implementing their own funding programs for replacement methods. Germany, for example, is not a suitable role model: at present, “system-changing”
replacement methods compete with 
“system-maintaining” refinement
and reduction methods, because the three options are funded by the same
programs.
The EU needs to increase the budget for funding animal-free research. In the
current funding period, only one program that is dedicated to replacement,
EU-ToxRisk, is funded. This European collaborative project is funded by
the EU Framework Program for Research and Innovation, Horizon 2020. The
project started on January 1, 2016 and will last for six years. It currently has
only €30 million at its disposal (EU-ToxRisk, 2016), with 39 participating
groups. By comparison, during the last funding period, the EU Seventh Framework Program provided the project cluster, seurat-1, with €50 million in
funding for work towards the replacement of in vivo systemic d ose-toxicity
testing (which ran until December 2016)—much more than the current
funding.
Special funding programs are essential for creating ready-for-series technologies, i.e., mass production in large amounts with a lower product prize;
for example, the characteristics and viability of current cell systems must be
improved to recreate the functions of the natural organ as accurately as possible; current organoid biotechnology needs to replicate the behavior of organs
more closely; and the functions of the capillary system and immune system
still need to be modeled.
National and European budgets, especially for validation studies, are
also necessary and the EU Reference Laboratory for Alternatives to Animal
Testing—European Centre for the Validation of Alternative Methods (eurl
e cvam) (eurl ecvam, 2017a) should be provided with adequate resources.
This demands a great deal of work. Validation and qualification of the new in
vitro systems have been discussed in several workshops across the US. These
workshops were hosted by the American Institute for Medical and Biological Engineering (aimbe) and the National Institutes of Health (nih) at the
nih campus in Bethesda, Maryland. Representatives of the eurl e cvam
and of some European start-ups also took part. The participants determined
1.1
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the need for a broader definition of validation for the integration of new
platform technologies into preclinical safety evaluation. The new in vitro
systems, such as the chip technologies (cell and tissue platforms, microelectrode systems with connected measuring devices), biomarkers, and the quality of cell and tissue types derived from human stem cells were also seen as
needing evaluation in terms of safety for preclinical applications and efficacy. The pharmaceutical industry, which is the primary customer of the
new multi-organ on a chip systems, should also be more involved (aimbe,
2013).
The EU Member States need to support the concept of Tox21, developed in
the US (Krewski et al., 2010). The concept’s goal is to provide a new basis for risk
and safety assessments of substances and products (i.e., regulatory toxicology),
using new techniques that are human-specific; and to promote the use of animal tests only in exceptional cases (see also the Integrated Approaches to Testing and Assessment adopted by the Organization for Economic Cooperation
and Development, oecd, 2017). The oecd now includes 35 countries around
the world, across North and South America, Europe, and Asia.
A research focus is also needed on the implementation of cell culture media
ready for practical application and for which no animals suffer, i.e., without the
use of fetal bovine serum (see Redmond, 2018, in this Volume). Researchers in
the US have been able to work with serum-free media in a defined system since
1995 (Schaffner et al., 1995).
Pillar 2: Animal-free Methods in Teaching and Scientific Research
Have to Be Expanded
The goal of Pillar 2 is to establish academic chairs—with corresponding personnel and financial resources for research and teaching and regular professorships—for animal-free research methods, courses of study in the life sciences that do not use animals, a broad range of papers not based on the use of
animals, and an increased number of theses and higher qualifications, with a
focus on animal-free methods.
In Germany, for example, individual chairs in some federal states or Bundesländer (Baden-Württemberg, Berlin, Hesse, and North Rhine-Westphalia) have
been established to develop methods to replace animal use. Researchers are
thus able to offer students a perspective to get closer to the topic and to prepare their theses with non-animal methods. However, there are still only a few
chairs in some federal states. There is need for courses of study that address
scientific questions using new animal-free methods. So far, students in life
sciences courses, such as biology or human medicine, must, with few exceptions, participate in courses that use animals. Furthermore, where platforms
1.2

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

How Can the Final Goal of Completely Replacing Animal

93

for alternatives to animal tests have been set up, the scientists involved usually investigate 3Rs methods (replacement, reduction, and refinement), which
means that the scarce resources are spread across all three areas. Instead, the
platforms’ financial resources need to be e xclusively available for replacement
methods.
The situation is similar in other European Countries. There are a few national centers for alternatives to animal use, such as, the Finnish Centre for
Alternative Methods, which teaches only animal-free replacement methods.
In the private sector, Altertox Academy (formerly the Center for Alternatives
to Animal Testing Academy) offers training for young scientists in replacement methods. Others national centers, such as the Danish 3Rs-Center, the
Swedish Toxicology Science Research Center, or the Romanian Center for Alternative Test Methods, were founded to implement the mission of Directive
2010/63/EU and teach not only the replacement of animal use but also reduction and refinement. The range of programs of study for animal-free methods
(full replacement) should be expanded. It should be possible to choose courses
of studies at European universities that will enable students to do research and
develop methods without using animals.
Pillar 3: Bans on Animal Testing Must Be Consolidated and
Expanded
Since its review in November 2017, Article 58 of Directive 2010/63/EU has barely led to sufficient improvements for laboratory animals. In the next review, the
EC must take into account any progress made in the field of a lternative methods that may lead to an end to the use of animals, in particular non-human
primates. The first step should be to repeal Article 55 of Directive 2010/63/EU,
which allows Member States to provide exceptions from the regulations protecting non-human primates (European Parliament, 2010); it also allows exceptions from Article 2, which stipulates that procedures not be performed on
animals if they involve severe pain, suffering, or distress. Therefore, with the
approval of the EC, Member States may, for example, use monkeys in experiments that involve severe pain, suffering, or distress.
Further bans should be introduced, including: a ban on patenting genetically altered animals; and a full ban on animal tests for household products
and their components, including banning the sale of such goods (analogous to
the existing provisions for cosmetic products) is essential.
Viable European and national competency centers should be established,
with the following tasks: creating transparency for the public, monitoring adherence to EU animal welfare law, and setting up information offices for all
stakeholders.
1.3
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Closer cooperation/collaboration with scientists and agencies in the US,
which is more advanced in technological development. The US regulatory
authorities are also not hesitant to search for and accept new animal-free
methods. Even pharmaceutical and chemical companies think that the EC
should be more orientated towards American models, such as the Food and
Drug Administration (fda) and the Environmental Protection Agency (epa)
(Ettel, 2018). Another example is the new Interagency Coordinating Committee on the Validation of Alternative Methods plan (National Toxicology Program, 2018).
1.3.1
Suggestions for Implementing Existing EU Law
The EC Department, Directorate-General for Environment, should have a European competency center, for monitoring adherence to EU law and providing up-to-date information on pain, suffering/distress, and fear as well as on
animal-free testing methods and other information relevant to this range of
topics.
These additional tasks could also be integrated into existing structures, such
as eurl ecvam’s EU Network of Laboratories for the Validation of Alternative Methods (EU-netval), under the umbrella of the EC Directorate-General
for Environment. So far, EU-netval comprises laboratories in individual EU
Member States that conduct validation studies and assess the reliability and
relevance of new animal-free methods (EU-netval, 2018). The European validation authority, eurl ecvam, could also focus on transparency for the public, provide information offices for all stakeholders, and monitor adherence to
EU animal welfare law. It is also vital that a negative list be introduced that will
stand up in court, defining tests that may no longer be conducted for ethical
reasons.
The establishment of national competency centers as central institutions
for informing and educating all stakeholders involved is also necessary. At a
national level, these tasks could be completed by the EU National Committees
in the Member States. The national information structures established thus far,
in accordance with Article 49 of Directive 2010/63/EU, have laid the foundation for such tasks.
The competency centers would be responsible for developing lists of criteria
for assessing whether applications for animal experiments fulfill legal requirements, criteria that are lacking, thus far, but are necessary. This requires practicable assessment criteria for qualifying/quantifying the n
 ecessity, benefits,
and ethical justifiability of the animal procedure as well as specifying the level
of distress. The competency centers should also offer education schemes for all
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stakeholders. To this end, it would be necessary to develop content and performance records. We recommend developing an education scheme for animalfree testing methods, analogous to the courses of the Federation for Laboratory
Animal Science Associations (felasa, n.d.).
Practical, user-friendly databases should be set up to allow reliable and
uncomplicated referencing of animal-free methods.
The approving authorities and monitoring agencies in the Member States
should be provided with adequate finances, expertise, and staff.
Steps must be taken to ensure that the Member States implement the requirements set out in Directive 2010/63/EU, without exception. In Germany, for
example, although stipulated by Directive 2010/63/EU, the approving authorities currently do not have a comprehensive right for evaluation when assessing
applications for animal procedures, due to a decision made by the Higher Administrative Court Bremen (Oberverwaltungsgericht Bremen, 2012). Directive
2010/63/EU stipulates that project evaluation should consist of six evaluation
points (European Parliament, 2010, Article 38, Section 2, Subsections a–f). It
should include an evaluation of the project objectives, the predicted scientific
benefits or educational value, and the severity of the procedures, and a harmbenefit analysis of whether the suffering, pain, and distress inflicted on the animals is justified by the expected outcome, in light of ethical considerations and
the ultimate benefit to human beings, animals, or the environment.
Pillar 4: Success Monitoring of the Increase of Animal-free
Methods and the Reduction of Animal Experiments Is of Particular
Importance
This pillar is especially important. It stands for the need for quality management, as it entails control measures that systematically document the progress
of the paradigm shift. Unlike the other pillars, there are no approaches, as yet,
to achieve this goal; they have to be established from the start. D
 efinitive parameters should be determined for quantifying and qualifying the reduction of
animal experiments and the increase in animal-free methods. A retrospective
assessment for all animal tests conducted and the publication of their data
crucial. Directive 2010/63/EU expressly provides for such a retrospective assessment (European Parliament, 2010, Article 39).
1.4

1.5
Pillar 5: Complementary Measures Are Necessary
Complementary measures comprise drastically shortening the time needed
for assessing and approving animal-free research methods; researching animal experiment models in order to de-validate them; and introducing a class
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a ction suit for animal welfare in the EU and its Member States, as well as providing adequate resources for law enforcement authorities.
Moving from the development of an animal-free method to its implementation in the regulatory framework, which would lead to a broader range of
applications, has taken too long. Periods of 12 to 15 years, or even longer, have
been a matter of course (Hartung, 2015). There is a lack of financial support
for proof-of-concept studies as well as pre-validation and validation studies, so
that developers spend a great deal of time seeking financial support. In addition, regulatory authorities become involved in this process at too late a stage
(Hohensee and Brüning, 2016; Schöffl et al., 2000).
According to NCad and other researchers, there is a “growing focus on Synthesis of Evidence”, the experimental design and critical reviewing of existing animal models (Cronin, 2017, p. 39; NCad, 2016a; Varga et al., 2010). Just as
the new animal-free methods must be validated, it is also necessary for animal
testing to undergo systematic review.
Greater demand for national and international coordination of the promotion and acceleration of validation, regulatory acceptance, and implementation
of animal-free methods (NCad, 2016a).
2

Part 2: How Has the Change of Course Been Pursued So Far—
Nationally, in the EU, and Internationally?

Directive 63/2010/EU provides for a long-term withdrawal from all animal
experiments. Nevertheless, for many researchers, the development of
replacement methods has not been the priority it should be. It still has a niche
existence. Although some research groups focus on replacement, research and
budgets at both the national and European levels are too low and should be
embedded in a higher-level context. Here, more efforts are necessary.
2.1
Setting up Committees in Accordance with Directive 2010/63/EU
With Directive 2010/63/EU, the EU and its Member States have set the longterm goal of ending animal experimentation and promoting the development
of replacement methods for animal experiments. The Directive must be enacted in national law by all Member States. The amended German Animal Welfare
Act (Tierschutzgesetz) took effect in July 2013, and the new Animal Welfare Laboratory Animal Regulation (Tierschutz-Versuchstierverordnung) took e ffect in
August 2013. However, while opportunities for achieving a higher level of animal protection should have been put in place, they were forfeited. Although
the necessary legal basis exists in primary law, a maximum limit for pain or suffering in animal experiments, and a ban on increasing animal e xperiments, by
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eliminating the exemption clauses, were not enforced in German law (Peters
and Stucki, 2012). Furthermore, the comprehensive right of project evaluation
pursuant to Article 36 of Directive 2010/63/EU was not implemented and was,
instead, replaced by a qualified plausibility check (Hildermann, 2015).
Article 49 of Directive 2010/63/EU states that all EU Member States must
establish National Committees for the protection of animals used for scientific purposes (European Parliament, 2010). In Germany, this role is performed
by the Federal Institute of Risk Assessment (BfR), which has established the
German Centre for the Protection of Laboratory Animals (Bf3R), located at
the BfR, as set out in the amendment of the German Animal Welfare Act that
took effect on July 13, 2013 (BfR, 2017b). According to Paragraph 45 of the German Animal Welfare Laboratory Animal Regulation, the National Committee
advises the competent authorities and animal welfare committees on matters
regarding the acquisition, breeding, accommodation, or care of vertebrates
and cephalopods (as defined in Paragraph 1, Section 1 of the Regulation); or the
use of vertebrates and cephalopods in animal experiments. The National Committee also advises the competent authorities, in accordance with Paragraph
46 of the Regulation, on matters regarding alternatives to animal experiments
(Bundesministerium für Justiz und Verbraucherschutz, 2017).
The German Centre for the Protection of Laboratory Animals (Bf3R) was
founded in the context of the animal welfare initiative (“Tierwohlinitiative”)
of the German Federal Ministry of Food and Agriculture (bmel) in 2015.
While before the establishment of the Bf3R, the Centre for Documentation
and Evaluation of Alternatives to Animal Experiments (zebet) was of central
importance, it has now been integrated into the Bf3R as one of five areas of
competence. The competence areas are research and development of methods to reduce pain and suffering of laboratory animals (refinement); the National Committee; development of alternatives in the field of toxicology; and
coordination of research funding. The last two areas of competence were
formerly tasks of zebet. However, the tasks of all competence areas are predominantly performed by Experimental Toxicology and zebet (BfR, 2017b).
Therefore, alternative methods are investigated, developed, and validated in
accordance with the 3R principles. Thereby, the focus has shifted from the development of replacement methods for animal experiments towards the 3Rs.
Today, refinement and reduction of animal use is treated of, at least, equivalent
importance.
2.2
Has Funding Been Increased in Recent Years?
2.2.1
Funding on a National Level (Germany)
Although an increasing number of projects are funded on a national level, those
who conduct research in replacement methods criticize that disproportionate
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funding for animal experiments and an exaggerated perception of their importance has led to a decades-long neglect of the development of replacement
methods and a reticence to promote them actively (Baumgartl-Simons, 2017;
Leist, 2016).
Programs for the Development of Animal-free Methods: The Funding
Has to Be Shared with Refinement Methods
In Germany, projects are funded mostly by the German Federal Ministry of
Education and Research (Bundesministerium für Bildung und Forschung,
bmbf). bmbf, Bf3R, and the set Foundation together provide approximately
€5.7 million per year in funding for research into the development of replacement and complementary methods for animal experiments based on the 3R
principles. A few German federal states have established funding programs of
their own, including Baden-Württemberg, which provides €400,000 per year;
and Rhineland-Palatinate, €70,000 every two years (see Table 3.1). Some individual projects, such as postgraduate programs, are funded by the German
research association, dfg; however, this funding is not dedicated to the development of animal-free methods and, therefore, is not listed here.
Note: This table presents an overview, not an official empirical survey.
On a state level, in Germany, it seems that an expansion of research associations and professorial chairs has slowly begun. Some federal states have
established research associations or professorial chairs and are providing initial funding for a finite period. For example, Baden-Württemberg funds the Doerenkamp-Zbinden Chair of in vitro Toxicology and Biomedicine/Alternatives
to Animal Experimentation with €200,000 to €400,000 annually. However,
most of this funding is combined with research for the 3Rs as a whole, so funding for replacement methods alone cannot be quantified. For example, Berlin
may soon take over the Berlin-Brandenburg research platform (BB3R), with
an integrated postgraduate program; and it plans to establish an institute for
alternatives to animal experiments, with €8.6 million, at the Charité University School of Medicine Berlin (Der Regierende Bürgermeister—Senatskanzlei
Berlin, 2017). The current bmbf funding has expired and negotiations for funding on a state level are currently in progress. In Frankfurt, a professorship for
pharmaceutical technology has been established, with 3R methods as its main
research focus. During the next five years, €200,000 will be made available to
be shared with another chair for refinement methods. Lower Saxony finances
the research initiative R2N—Replace and Reduce, with €4.5 million. North
Rhine-Westphalia is funding the Centrum für Ersatzmethoden zum Tierversuch (cerst-nrw), a center for replacement methods for animal experimentation, with €500,000 per year for a period of five years.
2.3
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Table 3.1

Funding for the development of animal-free methods in Germany

A. Chairs and platforms
Federal state

Subject

Designation

BadenWürttemberg

Chair

The Doerenkamp- 200,000–
Zbinden Chair
400,000 per
of in-vitro
annum
Toxicology and
Biomedicine

BadenWürttemberg

Berlin

3Rs platform/
Research
Association

Federal
Ministry of
Education
and Research
(bmbf)

Hesse

Chair

BerlinBrandenburg
research
platform BB3R
with integrated
graduate
education
Chair of
pharmaceutical
technology

Lower Saxony

Research
Association

North RhineWestphalia

Chair

R2N, replace
and reduce in
Lower Saxony;
replacement and
complementary
methods for
trend-setting
biomedical
research
Centrum für
Ersatzmethoden
zumTierversuch
(cerst-nrw)

Amount (€)

92,000
(2014–2016),
negotiations
at state level
to continue

Financed by

200,000 per
annum (5
years)

Hesse/
Johanna
Quandt
Foundation
4.5 million (4 Lower Saxony
years)

500,000 per
annum

North RhineWestphalia
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Table 3.1

B.

Funding for the development of animal-free methods in
Germany (cont.)

Project funding

Germany-wide Development,
proof-onconcept

BadenWürttemberg

RhinelandPalatine

Development,
proof-onconcept

Approaches
for the
development of
replacement and
complementary
methods for
animal use

5.7 million
per annum

Development of 400,000 per
replacement and annum
complementary
methods for
animal use
Development, Development of 70,000/24
proof-on-conceptreplacement and months
complementary
methods for animal
use

Federal
Ministry of
Education
and Research/
Federal
Institute
of Risk
Assessment/
set Foundation
BadenWürttemberg

RhinelandPalatine

Since 1981, the bmbf has funded 530 projects for the development of 3R methods (bmbf, 2016). The annual budget totals €5 million (although applicants
for funding from this bmbf research budget, and for research prizes awarded
for the development of alternatives to animal experiments, include developers of refinement methods for animal experiments, i.e. animal experimenters).
So far, more than €170 million in funding has been provided in this area (Hohensee and Brüning, 2016). However, a 2011 study published by the Fraunhofer
Institute for Systems and Innovation Research showed that about 30 per cent
of the projects funded between 1981 and 2000 focused on refinement (Hüsing
et al., 2011). In addition, few institutions or projects receive sufficient funding.
For example, the BfR simultaneously supports about ten working groups for
up to three years, each with an average of €35,000 per year. By comparison, the
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development of the in vitro pyrogen test required €6 million from development
to implementation. The working group needed €400,000 per year (Thomas
Hartung, personal communication, August 2016). Numerous applicants compete for the low project funds. The funding amount of about €5.7 million from
the bmbf, set foundation, and Federal Institute of Risk Assessment is far too
small, with no budget available for pre-validation and v alidation studies. Since
the developers of refinement methods can also apply for these funds, even less
money is available. Funding for refinement methods should have its own budget. The half-hearted funding is intended to give the impression that Germany
actively supports the development of new animal-free methods. However, it is
not an expression of the decision to phase out animal experiments, instead, it
slows down the development.
2.4
Additional Programs
There are a few complementary funding programs to the main program,
Alternatives to Animal Experiments, such as e:Bio-Innovative Competition
Systems Biology, which runs until 2020. Systems biology unites complex highthroughput experiments with mathematical modeling of the obtained data,
to develop models to predict complex biological processes on cellular, tissue, and organ levels as well as in the entire organism (bmbf, 2011). One of
the complementary programs, BioÖkonomie 2030-GO-Bio, aims to further
develop innovative research topics in the field of life sciences to the point
of making these available for economic implementation, like innovative
start-ups (Bundesministerium für Wirtschaft und Energie, 2017). This is interesting for organ on a chip technology developments intended for market
launch.
2.4.1
Funding Transregional/On a European Level
There are also a few programs financed by more than one EU Member State,
such as InnoSysTox—Innovative Systems Toxicology for Alternative to Animal
Testing, a €3 million project financed jointly by Germany and the N
 etherlands
(ZonMw, 2017). The application deadline was December 2014. Another program is the translational funding initiative, Multilateral Collaboration in
Computational Neuroscience: Germany—US—Israel—France (bmbf, 2015a).
The EU-wide budget is unknown. In Germany, €90,000 – €225,000 in funding was available for a three-year term. The application deadline for the first
run was November 2016. However, as previously noted, across the EU there is
currently only one program financed by the EU’s funding framework Horizon
2020 dealing with animal-free issues, EU-ToxRisk, which deals with feasibility
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studies for methods that most urgently need to be developed in toxicology. In
EU-ToxRisk, 39 project participants must share a budget of €30 million.
The research guidelines that define what methods are most urgent are set
out by the scientists themselves, and not by the EC. This was the case with project cluster seurat-1 (seurat-1, 2013), which received €25 million in funding
from both the EU and the industrial association, Cosmetics Europe. C
 osmetics
Europe also contributes to the funding for EU-ToxRisk (amount unknown)
(Cosmetics Europe, 2017). Especially urgent areas of research should be stipulated, and the development of animal-free methods must have priority. At the
EU level, scientists seem to agree on the methods in most urgent need of development; but in Germany, there is no agency that decides which methods
need to be developed and provided with preferential funding. Apparently, a
particular bone of contention is whether it is better to fund all research indiscriminately, in the spirit of scientific freedom or originality, or to demand
specific research into solutions for important questions (Hohensee, 2015). In
the case of achieving the end goal of full replacement, as set out in Directive
2010/63/EU, the answer is clear: Research developments should not be funded
indiscriminately, but rather clear priorities are necessary, with replacement of
foremost importance.
2.4.2
Funding on an International Level
The US was the first country to take decisive steps towards ending animal experiments, with the concept Tox21 (National Center for Advancing Translational Sciences, ncats, 2017a). Tox21 is a collaboration among the nih, fda,
epa, and the National Toxicology Program at the National Institute of Environmental Health Sciences, with the goal of achieving better assessment of the
toxicity of substances by using faster and more efficient human-specific methods in high-throughput technologies. To this end, fit-for-purpose cell models
have been developed; and a high-throughput apparatus has been set up, which
scans the gene expressions in human cells for alterations after they have been
exposed to the test substance. The epa has established its own National Center for Computational Toxicology, in which prediction models are developed
based on the new results (Committee on Toxicity Testing and Assessment of
Environmental Agents, 2007; ncats, 2017b).
A number of organ on a chip start-ups, most of them from the US, have
been established to produce lab-scale prototypes. Zhang and Radisic (2017) described the most important 29 start-ups, dividing their work into groups: startups developing barrier functions, start-ups developing tissue-interface on a
chip, and start-ups developing parenchymal-tissue on a chip. The first scientist
to envision the possibility and pioneer the practice of quantitatively-simulating
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molecular and cellular biological systems, with in vitro devices was Professor Michael L. Shuler of Cornell University, New York (Hurelcorp, 2018). Together with Professor James J. Hickman of the University of Central Florida,
Shuler founded the start-up, hesperos, in 2014 (hesperos, 2017). Hickman
developed the first serum-free media for hippocampal neuron cultures in
1995 (Schaffner et al., 1995) and published the first readouts of electrical and
mechanical functions of neurons in 1998 (Ravenscroft et al., 1998). Together
with Shuler and others, Hickman integrated cardiac, muscle, neuronal, and liver modules in a microphysiological system, under continuous flow conditions
in a serum-free defined medium, utilizing a pump-free platform (Oleaga et al.,
2016). So far, hesperos has successfully tested six organs on a chip (Miller,
2017).
TissUse, a German spin-off from the Technical University of Berlin, was
founded by Dr. Uwe Marx in 2010. The initial focus of this company was on
the development of two-organ and four-organ models. Today, like hesperos,
their ultimate goal is to develop a human on a chip, integrating at least 10 organ-like tissue constructs of human origin. Instead of using a gravity-driven
flow, like Hesperos, the TissUse platform contains a built-in micropump, driven by an external pneumatic controller. A second microfluidic circuit ensures
drainage of the fluid excreted through a kidney’s epithelial cell layer. The fourorgan chip with intestine, liver, skin, and kidney is already available and can
be co-cultured for up to 28 days (Maschmeyer et al., 2015). The Wyss Institute
for Biologically Inspired Engineering at Harvard University in Boston has produced 19 university start-ups (Wyss Institute, 2018) and is known for its organ
on a chip developments. One of the current research results is a pulmonary
thrombosis model on a chip. The research was co-financed by the Defense Advanced Research Projects Agency (darpa), Janssen Pharmaceuticals (Jain et
al., 2018), and funding from ncats (ncats, 2018).
The Center for Alternatives to Animal Testing (caat) was founded in 1981 by
Alan Goldberg, a professor at Johns Hopkins University in Baltimore. caat was
then financed by the American Cosmetic Toiletry and Fragrance Association
(ctfa), which was interested in the development of replacement methods
for testing their products (caat, n.d. a). caat’s goal is to create fundamental
knowledge regarding possible methods for replacing tests using whole organisms (i.e. living animals) with alternative methods in the development and
testing of commercial and therapeutic products. caat established its own
in vitro toxicology laboratory in 1985. In 1988, the cosmetics company, Avon,
financed the first program for replacing animal experiments in the field of contact allergies. Since 1989, caat has also been supported by government agencies and, as of 1992, by the epa. caat-Europe, at the University of Konstanz in
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Germany, the European equivalent to caat in the us (caat-US), was founded
in 2009. caat coordinates transatlantic relations between the US and Europe
in the field of animal-free methods, by bringing together international stakeholders in congresses and workshops on various topics of non-animal research
(Universität Konstanz, 2018). On information days, the public is informed
about the latest developments in this field. Both caat-US and caat-Europe
in Germany train young scientists in new animal-free methods (caat, n.d. b).
Expanding education and research towards science without animal
experiments is crucial, as only a small group of researchers currently work on
replacement methods. Despite the aforementioned funded individual professorial chairs, there is still no way of completing a course of studies that would
equip students with the professional capacity to develop alternatives to animal experiments. In order to complete a thesis at one of the newly established
chairs (see above), the student must first have studied one of the more common
courses of studies, such as biology, medicine, veterinary medicine, biochemistry, pharmaceutics, toxicology, or biophysics, which, for the most part, continue to use animals for training (satis, 2017a). Only very few tertiary institutions
allow the use of alternatives to animal dissection on ethical grounds. Instead,
tolerance towards alternatives to the use of animals in training courses has
decreased, depending on the course organizers’ attitude. Only four German
State Higher Education Acts (North Rhine-Westphalia, Hesse, Saarland, and
Bremen) allow the right to decline using animals on ethical grounds (satis,
2017b). Most students quickly get used to using animals because they do not
want to belong to a fringe group, without prospects of gaining a professional
foothold, or they want to keep their options open. The lack of opportunities
for attaining qualifications in animal-free courses of studies leads to a lack of
qualified young scientists in the area of animal-free methods, so that funding bodies sometimes argue that the reticence in providing finances results
from insufficient scientific standards (Hohensee, 2015). The lack of political
will means that the subject continues to go in circles.
2.5
The Time-consuming Validation Process
The time taken for the validation and approval of animal-free testing methods urgently needs to be shortened. The broadening of funding by the bmbf
program, Alternatives to Animal Testing, to include strategies for implementing newly developed methods as replacements for animal experiments
(bmbf, 2015b, Module ii), is a first step in the right direction; but it is by no
means enough. Validation studies, in particular, are extremely expensive and
time-consuming and go through the bottleneck of the European validation
authority, eurl ecvam, which has limited capacities. There are simply not
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enough resources. If a validation study is successfully conducted, the process
of r ecommendation by eurl ecvam begins with consultations with different
committees, including the Preliminary Assessment of Regulatory Relevance
(parere) and the eurl ecvam Stakeholder Forum (estaf) (eurl ecvam,
2017b). eurl ecvam then consults with other EC committees, as well as the
other international partners for validation and cooperation on the development of alternative test methods. The general public and companies, who
would ultimately implement the development, are given time to submit comments. Only after a long period of time is a Test Guideline drafted, and the
method is then included in the annexes of the relevant statutory regulation.
This sometimes requires 10 years (Hohensee, 2016a). There are, however, instances where the inventor is not interested in validation because it would tie
up resources; for example, Ulrich Stock, who developed a borosilicate chamber
with a blood-like solution to test heart valves under human-like conditions in
2011 (personal communication, November 2011). Here an agency is needed to
oversee proceedings.
3

Part 3: Why Are There Insufficient Animal-free Test Methods and in
Which Areas?

In Which Areas Are There Insufficient Animal-free Test Methods and
Why?
In this section, we focus on the field of toxicology alone. Relevant animal-free
methods in the field of toxicology could also be applied to other areas. There
has been great progress in the development of replacement methods in the
area of local toxicity testing (e.g., skin and eye tests), where many animal experiments have already been replaced (AltTox, 2016). However, there are still
no replacement methods for long-term studies of the organism as a whole, for
example, in the area of inhalation toxicity or tests for reproductive damage
and damage caused to offspring. The development of replacement methods
for testing environmental toxicity is also only rudimentary.
The goal of the holistic approach is to be able to depict the entire o rganism
in a simplified and miniaturized form. This is a complicated process because
individual organs, their biology, and their interactions within the body are
highly complex. In order to replace this complex organism in experiments, scientists aim to create a human on a chip, in which all the vital human organs
are combined on a chip of miniaturized scale of about 1:10,000. At present,
about eight miniaturized organs can be simulated and interconnected (Ingber,
2017). However, to construct a human surrogate for drug screening, scientists
3.1
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are convinced that it will not be necessary to replicate a perfect human body
but simply to provide a better predictive model than animal models (Wang
et al., 2016). For such simplified models, many different technical approaches
have been developed; for example, according to chip fabrication techniques,
medium composition, delivery systems of media, nutrients, oxygen, metabolites, and so forth, have a strong influence on the quality of cell or organ cultures and the results. Wang et al. (2016) provide an exploratory overview of
current d evelopments in multi-organ systems and their pro and cons. Since
each start-up presently holds only a piece of the entire puzzle, the authors
recommend that the multiple companies should be motivated to join forces to
combine their techniques and patents, thereby fostering the continued evolution of more advanced products. In many cases, the viability of organoid system cultures cannot, currently, be guaranteed for long-term investigations.
Depending on the laboratory, there are groups whose cell systems can be
utilized for just one week (Hohensee, 2017) and others for three months (Epithelix, 2017). These differences may result from the organs’ different needs and
the difficulties of recreating miniaturized human organs, especially in the case
of such vital organs as the liver or kidneys. Wang et al. (2016) discuss the need
for a common culture medium, with full chemical definition, as a blood surrogate that can maintain the viability and function of various organ models
and by the use of extracellular matrices can influence the reproducibility and
physiologically-realistic ratio of liquid to cell volumes in the (multi-) organ on
a chip system.
Methods in the field of inhalation toxicology are advanced with superficial
and deeper respiratory epithelium in vitro and with, in some cases, a viability
or usability of more than a month (Epithelix, 2017). Lung models have been
in use for quite some time (Esch, Bahinski and Huh, 2015; Huh et al., 2010).
One method, having achieved general approval, is currently undergoing a
validation study in Germany (Hoffmann et al., 2017). However, it was initially
intended for replacing animal experiments in the area of acute toxicity. Developments in the area of long-term toxicity are not as advanced and are being
explored in a feasibility study within the framework of the EU project cluster,
EU-ToxRisk (EU-ToxRisk, 2016).
Recreating a reproductive tract in a multifluidic system is a particular challenge. Some advancements have already been made, such as the development of 3D cell culture models of animal Fallopian tubes, in which embryos
can even develop in the “tubular fluid” (Chen et al., 2017). There are models
of the vagina and in vitro test systems with ectocervical cells and fibroblasts,
which have been developed to test substances for their irritant, toxic, or endocrine disruptive effects (Ayehunie et al., 2016; Landry et al., 2016). An artificial
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reproductive cycle has also been created, using murine ovarian follicles in vitro, to investigate the mechanisms of reduced fertility (Zhu et al., 2016). First
steps have been taken to culture parts of female ovaries, using human follicles,
to study the maturation processes (Laronda et al., 2014). There are also initial
developments for studying the hormonal cycle, using human ovarian tissue as
well as mice and human follicles (Skory et al., 2015). More advanced is a system
(evatar) to simulate the 28-day hormone profile of the female reproductive
tract to study its influence on reproductive tissue (Xiao et al. 2017). However,
due to species differences between mice and humans, the use of murine tissue
can only be a first step. The goal is to construct models with human-specific
tissue material (for an overview see Eddie et al., 2015). A repro-on a chip could
be used in the future to recreate mechanistic developments and disorders in
the development of the reproductive organs in the field of basic and applied
research but not reproductive behavioral disorders or detrimental effects on
offspring. Other solutions would have to be found for these. The project cluster
EU-ToxRisk is also conducting feasibility studies in the field of developmental and reproductive toxicology (EU-ToxRisk, 2016). Unfortunately, hormonal
regulation (feedback loops with hypothalamus, adenohypophysis, and thyroid,
which affect the tissues) and immune defense, which would allow the modulation of a miniature human on a chip, are lacking.
What is appealing about this human on a chip technology is that automation could rapidly shorten the time and cost of development by using large
rooms filled with robotic systems to simultaneously run tests on a multitude
of chips, with different concentrations of a variety of substances, without the
disruption of human factors (e.g., introduction of bacteria, measuring errors,
or pipetting errors). This would facilitate more targeted, cheaper, and faster
development and production and make it more attractive for industry.
3.2
Why Aren’t Developments Progressing More Quickly in Germany?
The development of animal-free methods primarily depends on the advancement of knowledge (Linz School of Education, 1999; Schmiel, 2006) as well
as other factors, such as efficient methods of investigation and measurement,
high-performance research facilities with a workplace environment conducive
to creativity, innovative staff, and, most significantly, sufficient funds. The following observations regarding these factors are restricted to Germany.
3.2.1
Powerful Methods of Investigation and Measurement
Modern molecular biological and biochemical methods, insights into cell culture, stem cell research, chip technology, omics technologies, computers of
high performance, algorithms, potent imaging techniques, and bioprinters
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have considerably advanced the development of animal-free testing methods
(bmbf, 2016; dfg, 2017). While these powerful methods should also be available
to universities and other research facilities, they would involve considerable
cost. Several facilities are currently known to need money for 3D bioprinters in
order to advance research on non-animal replacements, including the Institute
of Veterinary Anatomy of the Free University Berlin. It is possible that some
research remains at a certain level of development due to lack of instruments.
This situation has been recognized by the German Research Foundation (dfg,
2017). The problem could be addressed by establishing decentralized method
centers, whose services would be available to all authorized research institutes.
Collaborations with extramural institutes (e.g., Fraunhofer Institutes) also
need to be facilitated and, perhaps, expanded.
3.2.2

High-performance Research Facilities with a Workplace
Environment Conducive to Creativity
In addition to up-to-date research topics, the workplace environment is also
important for the research staff, for example, in terms of hierarchy, recognition, and interdisciplinary collaboration. Recent years have seen progress
in this regard. New university courses have also been introduced, some of
which are suitable for the development of replacement methods for animal
experiments, such as Medical Biotechnology (Technische Universität Berlin,
TU-Berlin, 2017), Biomedical Computing (xStudy SE, 2017a), Life Science Engineering (Hochschule für Technik und Wirtschaft Berlin, htw-Berlin, 2017),
Biomedical Engineering (xStudy SE, 2017b), and Biochemistry and Molecular
Biology (Universität Bayreuth, 2018). There are increasingly more student exchanges between international partner universities (xStudy SE, 2017a).
3.2.3
Innovative Staff
Understandably, aspiring students and postgraduates, among others, are influenced by their career prospects when choosing suitable fields of study. This
choice involves assessing how much return they can actually get on their investment in their course of studies. The best employees go to institutes with
the best reputations (“everyone wants to go to Harvard”); institutes that do the
best research, who are best known, that have significant influence in the scientific community, that are not economically threatened, and that pay their
staff well. For this reason, attractive degree courses in the area of animal-free
methods are needed (e.g., Medical Biotechnology at TU-Berlin). There should
also be a climate of internationality, enabling an exchange of know-how and
strategic thinking in problem solving. At present, there are professorial chairs
in Germany, where one can learn animal-free research and testing methods;
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however, entire courses of studies are not available. Students often must work
with animals or animal organs because they must first complete a standard
syllabus (e.g., biology), after which they can attend single courses or complete their theses at the newly installed chairs, in places such as Frankfurt,
Düsseldorf, and Konstanz (Buchmann Institute for Molecular Life Sciences,
2017; Hohensee; 2016b; University of Konstanz, 2018).
3.2.4
More Capital from the Corporate Sector Is Necessary
Sufficient capital is important. The development of animal-free test methods
in Germany is largely financed by state funding. This means that the risks involved with research and development are borne by society (taxpayers), whilst
the returns on successfully developed technologies benefit all stakeholders. It
would, therefore, make sense to provide not only national and European funding but also more capital from the corporate sector. European organizations,
such as Cosmetics Europe and the European Partnership for Alternative Approaches to Animal Testing (epaa), are good examples (Cosmetics Europe,
2017; epaa, 2017). Tax relief for companies that invest in research has been demanded for many years and should be implemented (Verband der Chemischen
Industrie, 2017). In the US, there are more ambitious programs leading to better and more innovative scientific outputs. ncats at nih and darpa recently
funded a US$150 million program for grants in the field of toxicity testing, drug
efficacy evaluation, and disease modeling (Wang et al., 2016). It seems that
there is a strong motivation to make the new systems successfully applicable.
In Europe, there are no such programs available. Funding programs are fragmented into small individual measures with much smaller budgets. So far, only
the Netherlands has clearly expressed its intentions. Other Member States are
reserved, expressing themselves at best behind closed doors and referring to
their cooperation within the framework of their National Committees. Many
researchers who use animal methods likely have little interest in the success of
the Dutch plan. Such reservation by Member States could be a barrier towards
the success of the plan.
4

Part 4: The Netherlands Makes a Name for Itself

4.1
Why Is the NCad Report a Good Template for a Paradigm Shift?
As of May 2017, NCad has published 108 documents, demonstrating its success (NCad, 2016a); however, the Netherland’s former Minister of Agriculture,
Martijn van Dam, ambitiously pursued “the final goal of full replacement” as
set out in Recital 10 of Directive 2010/63/EU (European Parliament, 2010). The
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manner in which Dutch politics has responded to the initiative is truly sensational. On April 8, 2016, the Dutch Minister of Agriculture requested that
NCad Chairman, Herman Koëter, develops a phase-out timeline for procedures involving animal use. The plan, Transition to Non-Animal Research, was
published on December 15, 2016 (NCad, 2016a). The history of its development
is as interesting and groundbreaking as the plan itself.
4.2
The Development of the NCad Report
The NCad plan is not the result of a whim but rather the product of years
of expert preparation, in which all stakeholders were involved. In June 2014,
the Dutch Ministry of Economic Affairs commissioned the expert group, The
Think Tank on Supplementary Financing for Alternatives to Animal Testing
(De Denktank Aanfullende financierung alternatieven voor dierproeven), to
develop recommendations for additional funding for the development of “innovations without laboratory animals” (NCad, 2016a, p. 42,). The Think Tank
presented its 140-page report, In Transition! The Netherlands leads the way in
laboratory animal-free innovations, in October 2015 (Henneman et al., 2015).
Based on this report, on April 8, 2016, the Minister of Agriculture, Martijn van
Dam, assigned NCad the task of presenting a strategy for phasing out animal
procedures. Van Dam specified that the strategy should involve the National
Institute of Public Health and Environmental Protection (Rijksinstituut voor
Volksgezondheid en Milieu Netherlands, rivm). rivm has significant expertise in toxicity testing and is both national and international coordinator for
3Rs methods. van Dam instructed NCad to name specific phasing-out targets
and stated that the legally required toxicity tests should be phased out within
10 years, which would reduce the number of animals used in experiments by
10% in the Netherlands. He also emphasized the goal, formulated in the Think
Tank’s recommendations, that the Netherlands become the world leader in
laboratory animal-free innovations by 2025 (NCad, 2016b).
NCad conducted two expert workshops on June 9 and July 7, 2016 in cooperation with the rivm (NCad, 2016a, p. 13). In August 2016, the LinkedIn
group, Towards a Future of Scientific Progress Without the Use of Experimental
Animals, was founded (Koëter, 2016). As of November 17, 2016, the group had
245 members, but unfortunately it delivered little of substance (NCad, 2016a,
p. 51). A public consultation was held on September 8, 2016 in Den Haag, where
a broad range of organizations commented on specific recommendations,
such as “It is possible to move away from the regulatory animal procedures
within the next ten years” (NCad, 2016a, p. 51). The report, Transition to NonAnimal Research, was presented to van Dam and published on December 15,
2016.
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4.3
What Facts and Figures Are Named in the Phase-out Timetable?
In its report, NCad divided animal experiments into different areas and assessed the possibility of reducing them by 2025. The Netherlands aims to be an
international leader in the field of innovation without laboratory animals by
2025 and sees a realistic chance of achieving this goal. Areas and possibilities
of reduction, as noted in the NCad report, are:
1.
Regulatory tests:
–	“The use of laboratory safety testing for chemicals, food additives, pesticides, and (veterinary) medicines can be phased out by 2025 whilst
maintaining the existing safety level” (NCad, 2016a, pp. 3, 17).
–	“The use of laboratory animals in regulatory tests for the release of
biological products, such as vaccines, will be phased out by 2025 whilst
maintaining the existing safety level” (NCad, 2016a, pp. 17–18).
–	Regulatory preclinical tests associated with the registration of new
biological substances/products cannot be phased out by 2025. “At this
stage, however, due to the complex composition of these products and
generally complex mechanism of action, the regulatory preclinical
research associated with the registration of new biopharmaceuticals
(such as vaccines or monoclonal antibodies) cannot be phased out at
the same pace” (NCad, 2016a, pp. 17–18).
2. Basic scientific and medical research:
–	Animal experiments in the field of “curiosity-driven basic research
cannot be phased out by 2025. Therefore, individual ten-year plans are
necessary for each area of research” (NCad, 2016a, p. 15). The complex
procedures and interactions in an organism as a whole cannot be simulated at the current time.
–	“Within the field of fundamental scientific research, the reduction or
phasing out of the use of animals is not realistic in the short term in all
areas of research” (NCad, 2016a, p. 18).
3. Applied and translational research:
–	While animal experiments in applied and translational research (implementation of preclinical research in clinical development) cannot
be phased out by 2025, the development of replacement methods can
be accelerated. This includes investing more in human-specific models and less in animal models. The Netherlands aims to become “an
international leader” in this respect (NCad, 2016a, p. 19).
4. Education and training:
–	“By focusing on animal-free practices and actively reflecting on the use
of laboratory animals in education, the use of laboratory animals for education and training can be significantly reduced” (NCad, 2016a, p. 19).
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Transition Objectives, Transition Strategy and Management of the
Transition
NCad has found that there is a realistic chance of completely phasing out
animal experiments in the areas of regulatory safety tests (for chemicals,
food additives, pesticides, and veterinary and human medical products) and
regulatory tests for the release of biological products (e.g., vaccines) by 2025.
This requires a transition strategy and management of the transition. The development will not take place on its own. Therefore, we strongly recommend
the development of NCad´s transition objectives, transition strategy, and program for transition management.
4.4

4.4.1
Transition Objectives
The transition objectives refer to a paradigm shift away from existing mindsets and practices, which are combined with animal use, to a strong focus on
innovations without laboratory animals. In regulatory research, this means a
significant reduction in the use of laboratory animals; in the field of basic research, the development of a ten-year vision for each area; and in the field of
applied and translational research, more rapid progress, for example, through
the development of human models for human diseases. Furthermore, the use
of animals in education and training can be significantly reduced (NCad, 2016a,
pp. 3–4).
4.4.2
Transition Strategy
NCad has stated that the following is necessary for a good transition strategy:
– the use of human data
– international cooperation for a new approach to risk assessment
– multidisciplinary cooperation on the development and approval of replacement methods
– monitoring of the evaluation and dissemination of replacement methods
– monitoring and evaluation of the reduction of animal procedures (since
the contribution replacement methods make towards the reduction of the
number of animals used in the Netherlands cannot currently be proven)
– development of an innovation index for replacement methods (data
warehouse, directory) in collaboration with other countries (NCad, 2016a,
p. 24).
4.4.3
Transition Management
The NCad report states that the key to success is (international) collaboration
among all stakeholders. The Minister for Agriculture would have the guiding
role but also involve other ministries. The existing Interdepartmental Working
Group on Alternatives to Animal Procedures would be transformed into an
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Interdepartmental Management Group, with the involvement of representatives from several ministries. The Management Group would draft an agenda
for the new replacement methods that need to be developed in consultation
with all stakeholders.
4.5
Evaluation and Conclusions
An analysis of the 108 reports that led to the decisions presented in the NCad
report, showed that the phase-out timeline is not an unrealistic idea. The
phase-out timeline is based on the results of two years of intense consultation
and work, involving representatives of stakeholders from the fields of science,
applied research, contract research, laboratory animal science, medicine,
replacement of animal testing, and animal welfare (NCad, 2016c, p. 2). The
phase-out timeline was developed with all participating groups; as such, the
road map is certainly ambitious but by no means unrealistic. It is, therefore,
disconcerting that other EU Member States have either ignored or rejected the
Dutch plan, and none have expressed support.
5

The Way Forward

What has to be done to rigorously pursue the “phasing out of animal procedures and the stimulation of innovation without laboratory animals” (NCad,
2016a, p. 3)? With the NCad report, Transition to Non-Animal Research, the
Netherlands has not only presented an opinion but has developed a concept for purposefully affecting a paradigm shift. The NCad report contains
clear transition objectives, a transition strategy, and a program for transition
management. Our association, People for Animal Rights Germany, proposes
that the following can be achieved, based on the Dutch concept and including our five pillars and our demand for a master plan for phasing out animal
experiments:
–
The EU Member States’ National Committees (European Parliament,
2010, Article 49) should endorse the NCad plan. The national responsible
ministers (especially the ministers responsible for the animal welfare,
science, and research portfolios) should advocate for the adoption of the
NCad concept, to encourage the governments of the Member States to
implement the Dutch plan in their own countries. Parallel to this, we recommend that the responsible national ministers vote in their respective
Councils of Ministers to support the NCad plan at an EU level.
–
Based on the national governmental resolutions and the resolutions of
the EU Council of Ministers, the EC should adopt the NCad concept as a
principle for action for reducing animal testing and funding animal-free
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procedures. Political action is also urgently needed to stop the different
stakeholders working against each other.
–
These objectives can be achieved by the EU Members States’ ministers
responsible for the animal welfare, science, and research portfolios, by
developing a new approach to assessing the risks posed by substances
and asserting this internationally beyond the EU. The pivotal issue is the
actual risk (risk assessment) and not the substances’ overall hazard potential (hazard assessment) (NCad, 2016a, p. 20).
–	In the short term, the Netherlands intends to compile a priority list for
areas of regulatory testing that lack animal-free methods. Other EU
Member States should actively support the Netherlands in compiling this
list. The EU Member States and the EC should then approve funding programs for these procedures. Funding programs should only be available
for animal-free testing methods and provide continuous funding, from
development to final validation.
–	It is necessary that the responsible ministers in the EU Member States
optimize the validation process. The results of methods to be validated
must be compared with human data and not with data from animal experiments (NCad, 2016a). The time needed for the validation process
should also be shortened.
–	The responsible ministers in the EU Member States should agree on the
introduction of a monitoring system for quality assurance during the
transition process, which would monitor the development and application of animal-free procedures and the phasing out of animal procedures,
allowing timely intervention in the case of negative developments.
–	The Dutch Minister of Economic Affairs will set up sub-domains in order
to draw up ten-year plans for the different areas of basic research. The
plans will name realistic objectives for “innovations without laboratory
animals” (NCad, 2016a, p. 3). This task is a particular challenge, as basic
research has, until now, been regarded as sacrosanct. This makes it all
the more important that all EU Member States actively participate in the
drawing up of these plans.
6

Final Remarks

We strongly recommend transforming the current plan, Transition to Non-
Animal Research, proposed by NCad, from an uncoordinated single process
to a targeted joint project, in which all stakeholders stand behind the same
goals and actively pursue them based on an overall plan. The NCad report describes crucial objectives: ending animal procedures for regulatory tests; listing
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and prioritizing the animal-free procedures that need to be developed; and
drawing up ten-year plans for phasing out animal procedures in the different
areas of basic research. Under the leadership of politics, the principles that
underlie the NCad report should be implemented in the EU Member States,
supported by the EC, and ideally in step with international regulatory authorities and scientific bodies. The implementation should be ensured by national
and international project management, accompanied by a monitoring system,
and made transparent to the public. A joint pursuit of the Dutch concept by
the other EU Member States would work towards achieving the goal of Recital
10 of Directive 2010/63/EU to replace animals for scientific and educational
purposes. This requires a common will and joint preparation of individual
plans in European (or even international) workshops with all major stakeholders, in particular science, industry, and public authorities. The successful
phase out of animal testing in the field of cosmetics, which is gradually taking place worldwide, as well as current multi-organ on a chip developments
across many countries, have shown that it is possible to achieve these goals
together.
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1

Introduction

Animal experiments are commonly conducted to understand human diseases
and responses to treatment. As decades of research indicate, the use of nonhuman animals (hereinafter referred to as animals) to translate the side effects,
benefits, and impact of medications and treatments on the human body has
been demonstrated to be ineffective; while billions of animals and humans
have suffered (Shanks, Greek and Greek, 2009). Due to misleading safety and
efficacy data from animal experiments, humans are often prescribed medications that may not be as effective or as safe as the patient, or even physician,
may have been led to believe (Akhtar, 2015).
In the United States alone, over 820,000 animals were used for research in
2016. This number does not include many species, including mice, rats and
aquatic animals, under the Animal Welfare Act (United States Department of
Agriculture, usda, 2017). It is estimated that up to 100 million mice and rats are
used for research purposes in the US each year (Carbone, 2004). A number of
species of farm animals are also used in research for the purpose of enhancing
the agricultural industry. However, from an ethical standpoint, experimenting
on animals subjects them to cruelty, costs billions of dollars a year, and often does not provide sufficient results to ensure human safety (Akhtar, 2015).
A major reason that animal studies are ineffective is that human bodies are very
different physiologically from other animals, including the way we develop diseases and how we absorb nutrients. Many advances have been made to create
alternatives to animal testing, which are being adopted by scientists interested
in innovative methods in research; and, yet, the use of animals for therapeutic
testing is on the rise. To attain more accurate data regarding human health,
there are no substitutes for human population- and clinical studies, particularly for lifestyle-related diseases, which may not be relevant to non-humans. This
chapter addresses how we can make decisions towards disease prevention and
reduce the demand for prescription drugs and, in turn, reduce animal research
and testing, through the adoption of a whole foods, plant-based diet, which has
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demonstrated to minimize and, in some cases reverse, lifestyle-related disease.
The chapter focuses on conditions that can be preventable, where medication
is avoidable, as opposed to conditions that require management with medical
intervention.
2

The Unwanted Effects of Prescription Drugs

The use of medications to treat human diseases, while often a necessity, can also
lead to a range of complications. About 4.5 million outpatient and emergency
visits occur in the US each year for adverse drug reactions (Sarkar et al., 2011). Of
those who are hospitalized, an additional 840,000 patients are given drugs that
cause serious adverse reactions during their hospital stay (Light, 2014). In total,
about 2.74 million Americans are impacted by complications from prescription
drugs each year, and this does not account for the impact of over-the-counter
medications (Light, 2014). Even proper use of prescription drugs may lead to
death. The European Commission estimates that adverse reactions from prescription drugs cause almost 200,000 deaths a year in Europe (Light, 2014). In
the US, an average of 128,000 deaths occur from properly prescribed medications annually. Combined, around 328,000 patients, in the US and Europe, die
from properly prescribed prescription drugs each year (Light, 2014).
The global rise in chronic diseases has resulted in an increase in the research,
development, and testing of prescription medication to address and stabilize
conditions, such as type 2 diabetes, cancer, and heart disease. The Centers for
Disease Control and Prevention (cdc) describes chronic diseases and conditions (e.g., heart disease, stroke, cancer, type 2 diabetes, obesity, and arthritis),
among the most common, costly, and often preventable health issues in the US
(cdc, 2017a). The rise in new prescription drugs on the market and increased
consumption, due to an increase in lifestyle-related diseases, has resulted in an
increase in animal research and testing. For example, according to the US Food
and Drug Administration (fda), new treatments are studied on laboratory animals to first determine potential toxicity before they can be tried on humans
(fda, 2014). These experiments identify side effects and the impact of medications on animals, but do not produce a complete or accurate translation of the
medication’s function and reaction in humans, including their effectiveness,
toxicity, and side effects. Many people with chronic diseases take prescription
drugs to better manage their conditions and achieve a better quality of life, although prescription drugs, especially for chronic conditions, often do not cure
diseases or address their root causes. Prescription drugs are typically intended
to alleviate symptoms or slow the advancement of a disease, and they may
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even prolong life, but their side effects may require additional medications
that can negatively impact patients’ quality of life. Prescription medications
can also lead to dependency and drug overdoses (National Institute on Drug
Abuse, 2017). In the US alone, there has been a spike in opioid use and dependency, and among 47,055 drug related deaths in 2014, 28,647 (60.9%) involved
an opioid (Rudd et al., 2016).
3

The Cost of Chronic Disease

While prescription drugs can prolong and improve patients’ quality of life,
they also lead to rising costs for patients and public healthcare systems. The
United Kingdom (UK) spends £446 million, annually, of its National Health
Service (nhs) budget on adverse drug reactions (Specialist Pharmacy Service,
2014). Unlike the UK, the US government does not provide a universal healthcare coverage plan, though it spends substantial funds towards healthcare. US
residents with multiple chronic conditions often face extensive out-of-pocket
costs for their care, including higher costs for prescription drugs (cdc, 2016a).
The high cost of multiple prescriptions, paired with undesirable side effects
and reduced quality of life, is a common issue among those living with chronic
diseases. Our aging population is growing and the prevalence of risk factors,
such as poor diet, obesity, and inactivity, are contributing factors to the prevalence of multiple chronic conditions in young people, adults, and the elderly.
Obesity is among the top risk factors, mainly because it is directly linked to
conditions, such as heart disease, stroke, type 2 diabetes, and certain types of
cancer; these conditions are among the leading causes of preventable death
and the most expensive to conditions treat (cdc, 2017a). Globally, we are facing an obesity epidemic; 36% of the world’s population is overweight or obese
(The gbd 2015 Obesity Collaborators, 2017). In the US, 70.7% of the adult population, 20 years and older, is either overweight or obese; and 37.9% are obese
(cdc, 2017a, 2017c).
The burden of multiple chronic conditions affects 1 in 4 Americans, and
that number increases to 3 in 4 over the age of 65 (cdc, 2016a). Treating
chronic diseases, mental health, and associated high risk behaviors, accounts
for 86% of the US government’s $2.7 trillion annual healthcare expenditures
(cdc, 2017b). The US government spends more on healthcare than any other developed country, yet they experience the lowest life expectancy (Commonwealth Fund, 2015). A recent epidemiological study of the eating habits
of more than 536,000 people linked meat consumption with increased death
rates from nine major diseases, including cancer, heart disease, respiratory
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d iseases, stroke, diabetes, kidney disease, and liver disease (Etemadi et al.,
2017). We should invest more funding and resources in a national, comprehensive, chronic d isease-prevention approach and address policy, including corporate policies, to improve food creation and distribution standards, systems,
and environments. It is with such changes that we can impact the masses and
see a decline in new incidences of chronic diseases. Focusing on preventive
medicine would allow for further research and application of human-relevant
non-animal testing methods, since many chronic conditions that require treatment are influenced by human lifestyle choices. Research on the treatment
of lifestyle-related conditions needs to focus on the human and the human
lifestyle to be more effective. This focus could lead to a reduced demand for
new lifestyle medications and may allow for greater application of innovative,
non-animal methods in disease research and testing, consequently, reducing
the number of animals used in these experiments. The concept of personalized medicine relies on the fact that humans are different from animals, and
we need to rely on human-based research, using predictive human-based testing models, to tailor medicine effectively to the human population (Greek,
Menache and Rice, 2012). It is possible to adopt a diet that benefits the health
of humans and reduces or avoids the suffering of animals, including animals
killed for consumption, animals involved in agricultural research, and animals
used for research and testing of drug interventions and diseases. A whole food,
plant-based diet, free from animal products, has been shown to be the most
nutritious for our health; while it simultaneously avoids animal suffering and
improves the sustainability of our environment and the planet.
4

Why Eat a Plant-based Diet?

4.1
Health
An abundance of research indicates that a whole foods, plant-based diet is effective in preventing and, in some cases, reversing chronic diseases. The US’s
Academy of Nutrition and Dietetics states that appropriately planned vegetarian and vegan, diets can be healthful and nutritionally adequate and may
provide health benefits for the prevention and treatment of certain diseases
(Melina, Craig and Levin, 2016). The British Association of Dietetics aligns with
this statement, and states that a well-planned vegan diet supports healthy living for all ages and stages, including pregnancy, lactation, infancy, childhood,
adolescence, older adulthood; and for athletes (British Dietetic Association,
2017; Melina, Craig and Levin, 2016). Eating a plant-based diet can help reduce
the risk of, and possibly prevent, chronic conditions, such as ischemic heart

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

128

Vyas

disease, type 2 diabetes, hypertension, certain types of cancer, and obesity
(Melina, Craig and Levin, 2016). Research in this field has not gone unnoticed,
and the US’s largest managed care organization, Kaiser Permanente, recommends healthy eating in the form of a plant-based diet, as the first line of treatment against chronic diseases (Tuso, Ismail and Bartolotto, 2013). According to
Kaiser Permanente, this diet should include plant foods in their whole form,
especially vegetables, fruits, legumes, and seeds and nuts (in smaller amounts).
For the greatest health benefits, this diet limits or eliminates animal products.
Total fats, such as oils, are generally restricted (Tuso, Ismail and Bartolotto,
2013). In summary, to achieve optimum health whole, plant-based foods are
encouraged, while meats, dairy, eggs, and all refined processed foods (including refined sugars) are discouraged. Similarly, the American Medical Association has called for the availability of healthful plant-based meals in schools,
food assistance programs, and hospitals. They request that hospitals across the
US reduce the availability of sugar-sweetened beverages and eliminate processed meats, in addition to including plant-based meals to improve the health
of patients, staff, and visitors (Berg, 2017).
4.2
Antibiotic Resistance
An additional health concern associated with consumption of animals and
their products, is antibiotic resistance. Animals raised in factory farms are often treated with sub-therapeutic antibiotics to promote growth or reduce the
spread of infections among animals, due to the high concentration of animals
in confined spaces. Long periods of exposure to antibiotics in animals may
lead bacteria to become resistant and survive, and there is strong evidence that
antibiotic use in animal livestock can lead to resistant infections in humans
(cdc, 2016b). Furthermore, large numbers of animals are used for research
and testing of antibiotic resistance, contributing to the number of animals affected by human lifestyle choices. Over 400,000 American residents become ill
from antibiotic-resistant foodborne bacteria every year (cdc, 2016d). The top
five pathogens that result in hospital stays in the US are salmonella, norovirus,
campylobacter, Toxoplasma, and E. coli (cdc, 2016c). Antibiotic resistance is
at the forefront of public health issues because it makes illnesses, which were
once easily treated with antibiotics, more difficult to cure and more expensive
to treat (cdc, 2016b). Humans can contract these infections in a number of
ways: (1) Consuming contaminated meat could lead to an infection in humans;
(2) Bacteria contaminants in the environment via infected stool can spread to
produce through irrigated contaminated water; or (3) Bacteria can contaminate our water supply (cdc, 2016b). All animals carry bacteria in their intestines, and when they are slaughtered, these bacteria can contaminate meat
or other animal products, whether antibiotic resistant bacteria or not (cdc,
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2016b). Antibiotic resistant bacteria from animals can also contaminate nonanimal produce but using care, by washing your hands and produce prior to
consuming it, can reduce your risk of food borne illness (US Department of
Health and Human Services, n.d.).
Eating health-promoting foods along with physical activity and stress management can help lead to overall well-being. Healthy eating and physical activity
both contribute to keeping us healthy, and it is important to remember that
while both are crucial, physical activity cannot undo the effects of a poor diet
(Malhotra, Noakes and Phinney, 2015). Mental and emotional health are also
important to our overall well-being and eating a diet rich in plants may play a
role in accomplishing this balance. Research has shown that a plant-based diet
not only reduces the risk of chronic diseases but also helps to boost overall
mood and reduce anxiety, depression, and fatigue (Agarwal et al., 2015). Choosing to consume more plant-based foods can positively impact your health,
both physically and mentally.
4.3
Animals in Our Food System
Eating a plant-based diet can also help reduce the contraction of illnesses
caused by animal consumption while reducing harm to animals. While millions of animals are harmed each year from animal experimentation, in 2008,
it was estimated that over 66 billion land animals were killed globally each year
for human consumption (Food and Agriculture Organization of the United Nations, 2014). Farmed animals are not only used for human consumption; many
are subject to experimentation under the premise of increasing production
and the effectiveness of their use for human consumption (usda Agricultural
Research Service, n.d.). The findings from these experiments are intended to
maximize products or outputs from these animals, which can lead to additional animal suffering due to the increased burden. Approximately US$1.4 billion
was spent on American agricultural animal research in 2016; US$900 million in
public funds and US$500 million by private industry (Keen, 2019, Chapter 10 in
this Volume).
To meet the demand for human consumption, billions of animals are
raised on industrial factory farms or Concentrated Animal Feeding Operations
(cafos), and the land area where animals congregate is often amongst feed,
manure and urine, dead animals, and production operations (usda National
Resources Conservation Services, n.d.). cafos often lack direct sunlight and
restrict movement due to the large number of animals held in a confined space
to meet consumer demand; these animals may be caged, chained, or tethered.
Confinement and lack of outdoor access often contribute to boredom and
stress in animals, as they are unable to stretch, self-groom, or even turn their
Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

130

Vyas

bodies, which results in physical and psychological distress (Overcash, 2011).
Manure can often be found on animals and this waste is often the source of
infectious bacteria, such as E. coli and Salmonella, which affect human populations through contaminated food and water, contributing further to disease
(The pew Charitable Trusts, 2008). This further adds to the use of more antibiotics for both humans and farm animals.
cafos are typically large, with at least 1,000 large animals, such as cattle
bred for beef. By definition, a cafo equals 1,000 head of beef cattle, 700 dairy
cows, 2,500 swine weighing more than 55 pounds, 125,000 broiler chickens, or
82 thousand laying hens, confined to the site for over 45 days out of the year
(usda National Resources Conservation Services, n.d.). Most farmed animals
spend their lives in these conditions. Approximately 98% of the meat in the
US comes from cafos on an annual basis, including approximately 31 million
cattle and calves, 120 million pigs, 450 million hen-laying chickens, 9 billion
chickens raised for meat, and 250 million turkeys that are killed for human consumption (usda National Agricultural Statistics Service, 2017; 2016). Industrialized factory farming of animals began in the US over 50 years ago to increase
efficiencies, and since then other countries have followed suit. In fact, the UK
now has close to 800 mega farms, with similar concentrations and conditions
to the US cafos (Wasley and Davies, 2017). The number of land animals killed
for human consumption sheds light on the scale of global animal suffering, but
the suffering does not end with land animals. The number of aquatic or sea animals killed for food each year is in the trillions, and whether farmed or caught
from the wild, their suffering is often severe (Brooke and Mood, 2013). About
50% of the word’s fish for consumption comes from fish farms (Food and Agriculture Organization of the United Nations, 2016). Much like cafos, the goal
of maximizing profits leads to high density fish farms or aquaculture that are
often breeding grounds for diseases that enter the water and the human food
chain, requiring further research for antibiotics (McKeown and Halweil, 2009).
4.4
Sustainability and Our Environment
Plant-based diets are more environmentally sustainable and use fewer natural resources than diets based on animal products (Melina, Craig and Levin,
2016). Raising animals for food not only has significant impact on the suffering
of animals, it has dire consequences for our environment as well. Worldwide,
animal agriculture contributes to 14.5% of human-produced greenhouse gas
emissions, which is more than all emissions from transportation, including
planes, trains, and vehicles (Food and Agriculture Organization of the United
Nations, 2013). In addition, pesticides, such as glyphosate, sprayed on crops fed
to livestock are linked to water contamination. The world’s demand for animal
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agriculture has resulted in the loss of pastures, including rainforests, to raise
livestock. Industrial animal agriculture is the leading cause of overfishing, the
destruction of wildlife, deforestation, and the depletion of freshwater resources (United Nations, n.d.). In addition, cattle ranching, due to deforestation,
leads to carbon dioxide emissions, loss of biodiversity, soil degradation, and
water pollution (Food and Agriculture Organization of the United Nations,
n.d.). Growing crops to feed livestock is another burden on the environment.
Global agriculture accounts for 30% of greenhouse gas emissions, with a high
percentage from animal agriculture and the grains grown to raise them (usda,
2010). In fact, a third of the world’s cereal harvest is fed to factory farmed animals (Compassion in World Farming, 2017). Globally, we could potentially feed
3 billion people with these grains rather than raise animals to be killed for
human consumption (Compassion in World Farming, 2017). In the US, consumers eat more meat per capita than any other country in the world, and the
hidden consequences of this consumption cost US$400 billion a year, accounting for negative effects on the environment and human health (Simon, 2013a).
Discussions so far have presented a number of reasons for eating a plantbased diet—for health, including reducing antibiotic resistance, to support
the environment, to reduce animal suffering, and reduce food insecurity. However, how do we transition to a more healthful diet that reduces the burden
on animals used for experiments, and what are some of the major barriers to
eating more healthfully? The following sections address what we can do at the
individual level, the challenges we face at the systems, policy, and environmental levels, and how these challenges impact our individual choices to eat more
health-promoting foods.
5

Making the Shift

5.1
The Individual Level—Your Choices Matter
Every day we make choices on what we eat. Are the foods we consume healthpromoting or disease-promoting? Making the choice to consume more
health-promoting foods, particularly a whole foods, plant-based diet, with
minimally processed or added sugar, increases our ability to control our own
health. Eating more plant-based, whole foods can lead to improvements in
blood pressure, cholesterol, and blood sugar and may lead to weight loss (Tuso
et al., 2013). Addressing these risk factors with food as medicine can be a first line
of defense against chronic diseases and may allow you to stave off or reduce the
use of expensive life-long medications and/or invasive medical procedures. Individual choices also impact demand in our food supply. For example, consumer
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demand for plant-based milks has increased e xponentially, and almond milk
sales have grown by 250% in the past five years (Nielsen, 2016). In addition,
36% of American consumers prefer plant-based milks over traditional dairy
(Nutrition Business Journal, 2015). In contrast, the traditional milk market has
decreased by more than $1 billion (Nielsen, 2016). In fact, the reduced demand
for dairy has resulted in the US federal government purchasing a surplus of 11
million pounds of cheese for US$20 million, to feed participants enrolled in food
assistance programs due to a 30-year high surplus (usda, 2016).
The shift in consuming more plant-based foods is on the rise, especially
among the millennial and Z generations. In an age where younger generations have always had access to the internet and are accustomed to gaining
information quickly, individuals are often more aware of the foods they eat.
Among their top concerns about food are sustainability, animal welfare, and
the healthfulness of food. Building awareness of where our food comes from
and how it was produced is an important aspect of educating the masses. Being informed and making decisions on what you eat and how that impacts
your personal health, animals, and the environment is empowering. At the
individual level, the consumer can have an impact on reducing the need for
animals in research on animal farming and testing of drugs for lifestyle-related
diseases. Making a choice to purchase more whole plant-based foods puts
money towards foods that are more sustainable, better for your health, and
free of animal cruelty.
6

Challenges to Healthful Eating

Our diets have significantly changed over the past 50 years, and more so over
the past 25 years, due to changes in farming practices and increased consumption of processed foods, meat, dairy, and eggs (Food and Agriculture Organization of the United Nations, 2017). At the same time, the number of animals
used for disease research and the treatment of lifestyle-related diseases has
also grown. We have choices in what we eat, but our choices are often influenced by a number of external factors.
6.1
Advertising
Food and beverage companies spend significant resources on promoting their
products and often target children and adolescents. Research shows that advertising to children is an effective tactic to impact their food choices and
attitudes towards food; and as most food advertising promotes unhealthy
foods, its impact is negative. In 2012, the fast food industry spent US$4.6 billion
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on advertising, and children and teens were one of their primary audiences
(Harris et al., 2013). Recent research from the Heart and Stroke Foundation of
Canada reveals that “over 90% of food and beverage product ads viewed by
kids and teens online are for unhealthy products, and collectively kids between
the ages of 2 and 11 see 25 million food and beverage ads a year on their top 10
favorite websites” (Heart and Stroke Foundation of Canada, 2017, p. 8). Exposure to these advertisements may lead to an increase in poor food choices, possibly contributing to the development of obesity and chronic diseases.
6.2
Funding Scientific Studies
Large food corporations have large budgets for advertising and many also
spend millions of dollars funding scientific research. Research has shown that
industry sponsorship of studies often leads to bias in research outcomes (BesRastrollo et al., 2013). For example, The Coca-Cola Company funds scientists
and organizations to promote physical activity, as the main driver to reducing
obesity, rather than focusing on diet. Examples of funding recipients, include
the National Parks and Recreation Association, Boys and Girls Club of America, and the Morehouse School of Medicine, Inc. (The Coca-Cola Company,
n.d.). The Coca-Cola Company has also been known to use the influence of
food industry representatives over scientific entities and medical associations
to guide the debate in the interest of the food industry (Sacks, G. et al., 2017).
Large food corporations provide funding to healthcare and nutrition focused
organizations as well. By funding scientists and organizations, corporations
influence research to focus on physical activity, for example, as the primary
contributing factor in obesity rather than diet and healthful eating. A recent
study found that 95 national health organizations in the US, including medical
and public health institutions that focus on obesity prevention, received funding from either The Coca-Cola Company or PepsiCo from 2011–2015 (Aaron
and Siegel, 2017). The Academy of Nutrition and Dietetics, the US’s national
association representing dieticians, has corporate sponsors, including CocaCola, Kraft Foods, Nestlé, Kellogg, the National Dairy Council, National Cattleman’s Beef Association, ConAgra foods, and General Mills, many of which also
provide continuing education credits for attending their educational sessions
(Simon, 2013b). Corporate influence over healthcare organizations, scientists,
and dieticians, in addition to the advertising and marketing of unhealthy
foods, can influence the messages we receive from those we consider experts
and lead to confusion about health-promoting foods, consequently, influencing our choices in favor of unhealthful foods.
Food companies have also been found to use animal experimentation to
develop new ingredients or test the effectiveness of their food products in
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improving health. Animal experiments are conducted with the purpose of
making health claims about their food products and generally result in ending animals’ lives. Nestlé, Danone, and Yakult are among a few companies that
have experimented on animals. Nestlé provides information to consumers on
their approach to animal experimentation on their company website (Nestlé,
n.d.). Major companies are also expanding their research approaches to include non-animal approaches to ensure consumer safety.
6.3
Access to Healthy Food
Unhealthy foods are profusely advertised in underserved populations, and
research shows that people with lower socioeconomic status and communities of color are more likely to have access to an abundance of unhealthy fast
foods and less access to healthy foods. Many of these communities are food
deserts, where grocery stores or supermarkets are not in close proximity (PolicyLink and The Food Trust, 2013). Unfortunately, the grocery or corner stores
in these neighborhoods often show a disparity in the quality, variety, quantity,
and price of healthy foods they offer (PolicyLink and The Food Trust, 2013).
For those receiving government funding, the US’s Supplemental Nutrition Assistance Program (snap), formerly called food stamps, provides recipients with
funds/credit to be used towards the purchase of food; and the snap programs
pays retailers for the amount of food purchased. Currently, the snap program
does not have a health focus, and funds can be used to purchase meat; dairy
products; candy; energy drinks; and, essentially, any food product (usda Food
and Nutrition Services, 2017). Studies have shown that, in some cases, snap
participants have worse diets and may be more likely to be obese than nonparticipants (Condon et al., 2015).
6.4
Government and Food
There are a multitude of initiatives focused on countering the obesity epidemic led by government funded surveillance and public health programs, nongovernment organizations, and healthcare organizations and their affiliates.
Public health programs are not funded at the same the level as the food industry’s programs, nor are they able to use government funds to lobby for better policies. Public health agencies dedicate significant resources to promote
healthy behaviors, but the traditional food and beverage industries have much
larger budgets to counteract these efforts. In 2016, food and beverage companies spent over US$31 million on lobbying to establish legislation to protect
or improve the sales of their products or to fight against legislation that could
impact their bottom line (Center for Responsive Politics, 2016).
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6.5
Subsidies
The United States Department of Agriculture (usda) leads public policy on
food, agriculture, natural resources, rural development, nutrition, and related
issues (usda, n.d. a). The top focal areas of the usda are to support farmers
and ranchers, in addition to administering nutrition assistance programs, providing nutrition education, and creating dietary guidelines every five years, in
conjunction with the United States Department of Health and Human Services (usda, n.d. b). The multiple roles the usda plays are often viewed with scrutiny, since the usda creates guidelines on what Americans should eat, while
supporting the promotion of and financial incentives for farmers of the commodities outlined in their dietary recommendations. For example, the usda
recommends the consumption of the following four food groups for a balanced
diet: vegetables, fruits, grains, and proteins and three servings of dairy a day
(ChooseMyPlate, n.d.). However, dairy products contain significant amounts of
cholesterol and saturated fat, and cheese is the number one source of saturated
fat in the American diet (National Cancer Institute Epidemiology and Genomics
Research Program, n.d.; Physicians Committee for Responsible Medicine, n.d. b).
There are a number of plant-based sources that have equivalent calcium to
dairy, or even higher; and consumption of dairy has been shown to have little
or no impact on bone health. Indeed, some studies have shown that increased
dairy consumption is linked to increased fractures (Schooling, 2014). Furthermore, calcium needs can be met by eating plant-based foods instead (usda
Food Composition Databases, n.d.). The usda also recommends choosing lean
or low-fat meat and poultry and mentions that processed meats have added
sodium; but it fails to mention that processed meats are considered a Group 1
carcinogenic food, linked to colorectal cancer; and that red meat was identified
as a probable carcinogenic by the World Health Organization (World Health
Organization International Agency for Research on Cancer, 2015). Red meat is
also linked to increased rates of cardiovascular disease (Pan et al., 2012). Due
to its close ties to major stakeholders (i.e., dairy, meat, and egg industries), the
usda would have to consider the economic impact of their actions should
they deem these foods unnecessary for a healthy American diet. Recommendations for the Dietary Guidelines are made by researchers and experts in the
field of nutrition, but the guidelines appear to include foods not present in
these recommendations, such as some forms of dairy and meat (Heid, 2016).
Although research supports a plant-forward or plant-based diet, the usda is
in a precarious position, since it is heavily influenced by lobbying (perhaps
even data manipulation) by major stakeholders from the meat, dairy, and egg
industries (Heid, 2016).
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Dairy and animal agriculture are among the commodities that receive the
highest subsidies from the government. The US government provides subsidies to farmers and ranchers for commodity crops and livestock, with corn
and soy at the top of the list. 63% of food subsidies support crops grown
for feed or livestock, of which corn and soy are a major proportion (Physicians Committee for Responsible Medicine, n.d. a). About 20% of subsidies
support grains for human consumption; 15% support crops, such as sugars,
or crops that become sweeteners, starch, oil, and alcohol for human consumption; and 2% support fruits, vegetables, legumes, and nuts for human
consumption (Physicians Committee for Responsible Medicine, n.d. a). This
may seem alarming. More money is spent on subsidies to provide farm animals
with feed or to raise livestock than for direct human consumption. Yes, that is
correct. Furthermore, the dairy program alone received US$5.6 billion in subsidies from 1995–2014 (Environmental Working Group, n.d.). Governmental
subsidies saved the animal agriculture industry US$35 billion from 1995–2005
(Physicians Committee for Responsible Medicine, n.d. a). The breakdown of
subsidy allocation is significant because it reflects a misalignment between
healthy eating guidance and financial government incentives. to support
healthy eating by the government.
In the US, all taxpayers contribute to subsidies that impact their health and
environment and contribute to animal suffering. Around 20 billion in tax dollars are used annually to support agriculture subsidies and insurance, a bulk of
which goes towards crops for livestock feed (US Government Accountability
Office, 2017). US taxpayers contribute to funding for animal experimentation
as well. Approximately 47% of the research budget of the National Institutes
of Health includes an animal experimentation component, which results in
US$12 billion–US$14.5 billion spent by taxpayers on animal experimentation
annually (Pankevich et al., 2012). In addition to subsidies, the usda oversees
Research and Promotion programs, otherwise known as check-off programs,
that support agriculture commodities voted on by farmers. These programs
allow the government to use funding for private commercial goals, including
advertising campaigns and research on the nutritional quality of agriculture
commodities, without highlighting any particular producer or brand (National
Agricultural Law Center, n.d.). The goal of these checkoff programs is to help
improve the market position of chosen commodities by expanding markets,
increasing demand, and developing new uses and markets (National Agricultural Law Center, n.d.). Examples of check-off programs include, “Got Milk?”;
“Beef—It’s What’s for Dinner”; and “Pork, The Other White Meat.” Research
and promotion check-off programs fund the beef, milk, dairy, lamb, and poultry commodity groups, totaling approximately US$560 million per year (Simon,
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2013a). Ultimately, the money spent on livestock research is for the purpose of
increasing meat, dairy, and egg consumption.
6.6
Policy Shifts
Subsidies are not unique to the US, and similar programs providing financial
incentives, especially for animal agriculture, exist in the European Union and
Australia, among others. With the marketing efforts the food industry targets
at children and adults, and the subsidies and indirect funds that animal agriculture receives to promote their products and protect their bottom line, the
barriers to healthy eating are increasingly apparent. Animal products, such as
meat, dairy, and eggs are artificially viewed as cheaper alternatives to plantbased foods, which are healthier and cause less harm to the environment or to
animals. Subsidies should be re-visited to assess the need for these programs;
and, if they are deemed necessary, they should align with more health promoting commodities used for human consumption. Some progress is being made,
for example, the American Medical Association has called on the federal government to provide snap recipients with incentives for purchasing healthful
foods, in an effort to improve their diets (Berg, 2017). snap retailers receive reimbursement for selling healthful foods but not for foods that promote disease.
This shift could lead to more retailers stocking fresh produce, whole grains,
beans, nuts, and seeds and healthy plant-based packaged foods. This call on
the government should be further explored and implemented to improve access to healthful foods for snap recipients and underserved communities.
Creating a healthier food environment is an important step in improving
access to healthy foods. Policies need to address widespread advertising of unhealthy foods, especially in lower income neighborhoods, while increasing the
availability of healthful foods and creating healthier food standards for government assistance programs, such as snap and food pantries. In addition, the Dietary Guidelines should reflect current evidenced-based-research and include
sustainable sources of food. The government should consider increasing support of farmers that grow plant-based crops, using sustainable farming practices, and offer support to farmers in declining animal agriculture industries to
transition their skills, equipment, land, and training to farm plant-based crops,
which are thriving, are considered health promoting foods, do not cause harm
to animals, and are grown sustainably.
How we look at what constitutes as food is important. Based on centuries
of research, we know that eating a diet rich in vegetables, fruits, whole grains,
legumes, and nuts in small portions, is good for our health. The tobacco movement has had significant successes in raising awareness of its harmful health
effects; and, with system and policy changes, such as implementing taxes on
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the sale of tobacco products, it has contributed to the decline in tobacco use.
Though policy shifts are challenging to implement, and for tobacco these
shifts took decades, the current foods systems across the globe may benefit
from adopting proven strategies from the tobacco movement and tailoring
them to combat lifestyle-related diseases. By removing subsidies for unhealthful foods, their true cost will be reflected in their price, which alone may create changes in purchasing behavior. The result of removing subsidies for, and
possibly implementing taxes on, these foods could lead to a significant reduction in greenhouse gases, hundreds of thousands human lives saved each year
from reductions in meat, dairy, and egg consumption (Nature Climate Change,
2016); as well as a reduction in the need for involving animals in research on
agriculture and lifestyle-related diseases. In the meantime, individual lifestyle
choices can go a long way to prevent the human, animal, and environmental
harms caused by animal agriculture.
7

The Gap—Medical Training and Nutrition

When we are ill, we visit our physician in hopes that they will provide a solution
to fix our ailment. Physicians are seen as the go-to source when we are feeling
unwell, and rightfully so; they are required to attend numerous years of schooling, pass extremely difficult qualifying exams, and undergo years of training,
with long hours in residency and fellowship programs. Based on this extensive
training, we assume that physicians are the best source for nutritional advice
as well. The surprising fact is that most physicians receive very little nutrition
education in their training (on average 20 hours or less) (Krebs and Primak,
2006). The lack of training they receive in medical school does not lend itself to
using food as medicine or as the first line of treatment in combatting chronic
diseases (Devries et al., 2014). Non-animal technologies, such as the organ on
a chip, are contributing to the development of personalized medicine, which
can benefit lifestyle disease research. In addition to nutrition training, we also
need more training in animal-free research and development and in animalfree education and training (cf. e.g., Bones et al., 2019, Chapter 23; Herrmann,
2019, Chapter 1; Pawlowski et al., 2019, Chapter 22 in this Volume).
While physicians do not receive sufficient training in nutrition, they receive
rigorous training in treating diseases with prescription medications in medical
school and during their residency (Kshirsagar and Vu, 2016). Pharmaceutical companies reach out directly to physicians to market and provide education on their company’s pharmaceutical drugs (Kshirsagar and Vu, 2016). This
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 arketing entails gifts, sponsored lunches, promotional items, direct mailings,
m
consultations, and samples. Many of the pharmaceutical companies spend
more on marketing and promotion than on research and development. Research shows that marketing to physicians often results in an increase in their
prescribing the promoted pharmaceuticals (Goodman, 2001). There has also
been an increase in direct marketing to consumers by pharmaceutical companies (fda, 2015). Policy reform should take into account the ethics of these
practices, since consumers, like physicians, can be influenced by pharmaceutical marketing to seek out promoted medications that may not align with
evidence-based science. What is more, the pharmaceutical industry is one of
the main contributors to animal experimentation.
Since physicians are not traditionally trained in the use of a whole foods,
plant-based diet to prevent or reverse disease, the status quo of prescribing
medications to address symptoms or risk factors for a condition(s) continues.
Physicians may have dieticians, nurses, health educators, or health coaches on
staff that provide more in-depth nutrition education; but physicians should
receive additional training on the benefits of eating a whole foods, plant-based
diet to improve health. Increasing the requirements for nutrition education
and ensuring physicians are paid for these efforts would be a step towards
progress (Greger, 2013).
8

A Plant-based Future

This chapter provides a snapshot of our current food climate and how eating
a whole foods, plant-based diet can help improve our health, reduce our demand for prescription drugs for lifestyle-related diseases, reduce the associated intensity of animal-based disease research (for human and agricultural
diseases), avoid contributing to farm animal suffering, and protect our environment. Eating a whole foods, plant-based diet can save billions of dollars in
personal healthcare costs, as well as costs associated with antibiotic resistance
and disease research. It can reduce greenhouse gases and offset the grains
used for livestock, to diversify crops and feed millions of people without food
security.
Educating populations about the origins of our food and how the choices
we make when deciding what goes in our mouth not only impacts our own
bodies but the environment and billions of animals. That said, education must
be associated with changes to policies and an environment that supports the
production and distribution of health promoting foods. This should include
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removing subsidies for disease promoting foods, providing incentives to purchase health promoting foods, and creating environments where healthful
foods are easily accessible.
To better serve our populations, physicians need more education and
training on the role of nutrition in disease prevention while in medical school and through continued training in nutrition research. A shift is
needed—the gold standard of using animals in identifying appropriate prescription drugs for humans must be revaluated and the focus must shift to
advancing non-animal research methods that are more accurate and humanrelevant (Akhtar, 2015). Animal-free technologies that help develop personalized medicine should be encouraged as well. We must invest in human and
clinical studies that reflect human responses to disease rather than relying
on results from animal studies. Advocates for non-animal research methods
need to continue to build awareness of the benefits and effectiveness of
non-animal research and testing methods for helping those suffering from
lifestyle-related diseases, while we continue our efforts to improve the population health of our nations.
At an individual level, by opting for a whole foods, plant-based diet, we can
help reduce the need for new prescription drugs to treat illnesses and can benefit from advances in animal-free pathways for biomedical research to save
animals, our health, the economy, and our environment.
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Political Campaigning: Where Scientific and Ethical
Arguments Meet Public Policy
Emily McIvor

Science Policy Advisor, People for the Ethical Treatment of Animals
(peta). London, United Kingdom

1

Introduction

The ambition of the paradigm shift we seek is vast, and the obstacles we face
are intractable. For anyone opposing the use of non-human animals (hereinafter referred to as animals) in research and testing, the story has been the
same from the start. Legitimate concern for animals has been all-too-easily
dismissed as misguided sentimentality, and powerful vested interests have
claimed scientific, economic, and moral superiority. But the ground is shifting.
Animal researchers accept the need to provide scientific justification for their
choices, and the protection of animals is increasingly recognized as a public
good. Concern among citizens has been translated into hard-and-fast rules,
and scientific advances have added weight to the growing demand for change.
In deciding how best to achieve the paradigm shift, the question for animal
advocates is how to create the greatest change in the shortest time possible.
This chapter deals with political campaigning at the European Union (EU)
level, since the adoption of the first EU Directive on the protection of animals
used for scientific purposes, and focuses on the main political developments
of the past two decades. Historically, much was made of a perceived choice
between presenting ethical or scientific arguments; both are powerful drivers,
providing evidence that existing practice is flawed. Other chapters in this Volume describe aspects of those approaches in detail; similarly, the question of
whether to focus on the 3Rs or replacement only is also covered elsewhere. In
this chapter, a pragmatic policy focus is necessary to explore how scientific
and ethical objectives can be pursued in order to move forward in the political arena, making full use of existing structures and creating new opportunities. The stakes are high. Our vision requires a revolution in science and in the
way animals are treated. Twenty-first century technology should not depend
on inhumane practices, just as modern economies should not depend on the
destruction of the environment or the exploitation of workers.
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Before proposing future strategies, it is useful to reflect briefly on the current situation. In the EU, Directive 2010/63/EU requires Member States to
apply the 3Rs and encourages the further development of new 3R methods
and techniques. Research funding programs identify the replacement of animal models as scientific and policy objectives; and several publicly funded
national centers are now dedicated to developing, validating, and promoting
alternative methods. The EU Reference Laboratory for Alternatives to Animal Testing, the European Centre for the Validation of Alternative Methods
(eurl-ecvam) has, among its duties and tasks, the remit to coordinate and
promote the development and use of alternatives to procedures in the areas
of basic and applied research and regulatory testing (European Parliament,
2010, Directive 2010/63/EU, Annex vii). Each of these achievements has come
about because of pressure from citizens and animal advocacy organizations,
and each has created a momentum of its own so that further progress is inevitable. At the same time, the number of animals used in scientific procedures
in the EU appears to be increasing (Taylor and Rego, 2016); and animal use is
robustly defended by powerful commercial, academic, and charitable organizations. It is legal to restrain conscious non-human primates (nhps), so they
are unable to move at all for long periods, and to poison animals to death by
applying toxic chemicals to their skin. The scientific revolution is undoubtedly
underway, and Directive 2010/63/EU identifies animal welfare as a “value of
the Union” (European Parliament, 2010, Recital 2); but current practice has not
caught up.
2

The Politics of Animal Experimentation: An Overview

The development of current European regulatory frameworks can be seen as
the culmination of a series of historical confrontations between animal users and advocates (Lyons, 2011). By identifying five “critical junctures”, including the adoption of the United Kingdom’s Cruelty to Animals Act in 1876, the
Royal Commission of 1912, and the adoption of the Animals (Scientific Procedures) Act in 1986 (UK’s transposition of Directive 1986/609 eec; Council of the
European Communities, 1986), Lyons (2011) traces the evolution, from a largely
self-regulating, animal user community to the current regulatory regime. The
relevance to our situation is the analysis of power exercised by those who defend animal use. Through early critical junctures, the power to decide whether
animal use is justified, to control access to information, and to entrench an establishment view that the use of animals is essential to medical progress, was

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

Political Campaigning

153

firmly placed in the hands of animal users. Only later, with adoption of the
1986 Act, did the necessity for greater public and political scrutiny gain broad
support.
Lyons describes key elements of various positions held, including this analysis of an animal use ideology (2011, pp. 360–361):
– It claims that animal welfare is secondary to research goals
– It considers animal experimentation necessary, and hence permissible,
in the pursuit of knowledge without immediate or foreseeable human
benefit
– It is opposed to utilitarian scrutiny of experimentation proposals
– It supports professional self-regulation and opposes lay interference in animal experimentation.
This is contrasted with an animal welfare belief system:
– It believes that animal welfare should be given significant weight in policy
making
– It believes that proposals for harmful uses of animals should be subject to
independent utilitarian analysis
– It considers animal experimentation necessary, and hence permissible, only
to satisfy urgent and pressing human needs
– It supports the requirement of lay control to ensure consideration of wider
public and animal interests.
And an animal rights philosophy:
– It posits that all sentient animals have inherent value and share human interest in avoiding suffering
– It claims that the fundamental rights of protection from torture, killing, and
enslavement should, therefore, extend beyond the human species to other
sentient animals
– It argues for the abolition of animal experimentation.
In the political arena, the welfare belief system often achieves consensus, and
politicians can usually gain majority support for measures appearing to balance competing interests. Furthermore, a welfare agenda represents valuable
middle-ground when the positions of different interest groups seem so far
apart as to be irreconcilable.
Efforts to create a level playing field between industry and civil society
groups have proved effective at the EU level (Persson, 2007); but in terms of
numbers alone, leaving aside financial resources, industry and animal user
groups are better represented than animal advocacy organizations. The
UK Home Office public consultation on the European Commission’s (EC)
proposal to revise Directive 86/609/EEC received only 19 responses from animal
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welfare organizations out of a total of 87 submissions, including 33 from
academic institutions and 17 from representative bodies (Home Office,
2010). An associated imbalance, concerning access to scientific and political decision makers (Lyons, 2011), again risks leaving animal advocacy organizations severely outdone. However, public opinion is also an important
element of the debate, and animal advocacy organizations have been effective in demonstrating that public concern for animals must be taken into
consideration.
Polling commissioned by the European Coalition to End Animal Experiments (eceae) on the revision of Directive 86/609/EEC—conducted by
YouGov (2009) in the UK, France, Germany, Italy, Sweden and the Czech
Republic—found that public opinion was not consistent with the EC’s legislative proposal; for example, substantial majorities in all countries surveyed favored a ban on experiments causing pain or suffering to nhps (House of Lords,
2009). UK Government surveys exploring attitudes to animal research (Clemence and Leaman, 2016; Leaman, Latter and Clemence, 2014) note varying degrees of public support or opposition, depending on the phrasing of questions.
There was a slight increase, between 2014 and 2016, in respondents who supported a ban on the use of any animals in research, from 23% to 26%. The 2016
survey also found that 59% of people disagreed with the statement “it does not
bother me if animals are used in scientific research”, showing concern for animals among a clear majority of respondents. The difference, in policy terms,
between the abolitionist view (represented by the UK’s 26%) and a gradualist
approach is significant; but there is strong agreement (74% of respondents)
with the statement that more work is needed on alternatives to using animals
in scientific research.
In terms of the wider political debate, even though detailed discussions
about animal care and use tend to emphasize differences among stakeholder
organizations rather than areas of agreement, promoting the replacement of
animal procedures is compatible with all three of the belief systems identified
above. Arguing for the increased uptake of human biology-based technologies
in biomedical research is not new; but in an era of rapidly developing science
and divergent opinion concerning other aspects of the debate, its importance
cannot be overestimated. Because of the need for policy makers to arbitrate
between opposing views, and the broad appeal of the alternatives’ message,
a major benefit of effective political lobbying is, therefore, ensuring that the
replacement of animal procedures is promoted to the greatest extent possible.
This cannot come at the expense of trying to improve conditions for the animals that are used, but it is a powerful driver towards achieving the paradigm
shift.
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Directive 2010/63/EU

The adoption of EU legislation provides multiple access points, and the EC
encourages interest group participation in order to meet the objective of
connecting the EU more closely to citizens (Persson, 2007). This objective
was amply demonstrated during the lengthy process through which Directive
1986/609/EEC was revised and Directive 2010/63/EU came into being. While
the revision was underway, the EC adopted an Interinstitutional Agreement on
Better Law-making (European Commission, 2003, 2003/C321/01), strengthening
pre-legislative consultation processes and requiring impact assessments. These
access points, while often appearing to delay the process, ensured v aluable evidence was gathered, informing both the legislative proposal and further political negotiations. Studies, including the scientific Opinion by the European
Food Safety Authority’s Animal Health and Animal Welfare Panel (ahaw), and
findings from the Technical Expert Working Group convened by the EC, created useful evidence and opportunities for further interventions the following
years.
The legislative proposal—when finally published in 2008—irritated those
defending animal use and, although representing a considerable improvement
on previous legislation, it also failed to satisfy animal advocates. The UK animal
user community, coming together under the auspices of joint Bioscience Sector
position papers, identified several areas of concern, including the proposal to
protect certain invertebrate species, limits on use of nhps, and burdensome
bureaucracy. The organizations also raised concerns that the draft Directive
would undermine UK and European competitiveness, noting that “As well as
problems with the content, the wording throughout the Directive requires significant review for scientific accuracy and internal consistency” (Bioscience
Sector, 2009, p. 2). While generally supporting the application of the 3Rs, the
groups opposed creation of national structures to assist in the validation of
new 3R methods, claiming that: “The proposals for National Reference Laboratories are unnecessary and infeasible and would not be effective at developing
alternative methods. They would divert research funding away from research
which might not only develop alternatives but further benefit biomedical discoveries” (Bioscience Sector, 2009, p. 39).
But by the end of the political negotiation, the new legislation, Directive
2010/63/EU, included a handful of promising elements, alongside several measures that are weaker in terms of animal protection, than those contained in
the EC’s original proposal. Central to the achievements for animal protection
lobbyists is Recital 10 (European Parliament, 2010), which specifies that “this
Directive represents an important step towards achieving the final goal of full
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replacement of procedures on live animals for scientific and educational purposes as soon as it is scientifically possible to do so.” In response to proactive
EU-wide campaigning for greater prominence to the replacement of animal
experiments and for the inclusion of basic and applied animal research in the
remit of eurl ecvam, EU Member States are now required to promote development and use of alternatives, establish a single contact point to receive
information about new methods, join an EU-wide network of contact points,
and require new projects to be authorized only when alternatives have been
considered. Campaigns to ensure regular “thematic reviews” on areas, such as
the replacement of experiments on nhps, were partially successful (Article 58);
and Recital 10 states that the Directive should be “reviewed regularly in light
of evolving science and animal protection measures” (European Parliament,
2010). Emphasis on the use of existing alternative techniques and the further
development of new methods is strengthened by requirements for project
evaluations, increased transparency, and, most importantly, the retrospective
assessment of all projects using nhps and projects involving procedures classified as “severe” (Article 39).
4

Ending Cosmetics Animal Testing: 20 Years and Counting…

Nowhere is the importance of procedural access points and the willingness of
legislators to respond to the wishes of citizens more visibly demonstrated than
in the 20-year struggle to end animal testing of cosmetics and the sale of newly
animal-tested cosmetics ingredients in the EU. Without detailing every one of
the (numerous) twists and turns it took to see the 2013 ban enter into force, one
hard-fought measure deserves special mention: the requirement for a full political negotiation in the event of any attempt to delay implementation of the
final 2013 deadline. Although the sale ban had been agreed on in 1993 and was
due to be implemented in 1998, the EC was permitted, under the 6th Amendment to the Cosmetics Directive (European Commission, 1993), to delay it until
2000 and then to 2002, on the grounds that replacement tests were not fully
developed. The delays were agreed on through the comitology process, offering a lower level of access than a full political debate. However, further delays
were not permitted beyond the 2002 deadline, by which time a new legislative
proposal was published, triggering a full political negotiation before further
delays could be adopted.
The point of interest for campaigners is that within the 7th Amendment
(European Commission, 2003), new wording deliberately prevented any further delay without a legislative proposal being debated and voted upon by
the European Parliament and Council. The 2009 phase of the sale ban gave no
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 rovision for any kind of delay, on any grounds; and the final 2013 phase could
p
only be delayed by new legislation. Creating the requirement for another access point—a 2013 renegotiation in the event that animal tests had not been
replaced—was the key compromise that satisfied both industry and animal
advocates. As the 2013 deadline approached, the EC opted to implement the
ban and avoid any further accusations that they were ignoring the wishes of
citizens. However, nothing is safe until full animal replacement is achieved,
and although animal organizations rightly view an end to cosmetics animal
testing as a political objective, achievable in the absence of alternatives being in place, loopholes putting our achievements at risk are relatively easily
disguised. Perceived ambiguities concerning the terms of the ban have led to
legal challenges, underlining the need for constant vigilance. Had the wording
of Article 13 of the Cosmetics Directive been tighter (European Commission,
2009, Regulation (EC)1223/2009), we could have avoided the threat of further
challenges.
On the day the European Parliament’s Environment Committee debated
their second reading position, a front-page article in the UK’s Independent
newspaper revealed behind-the-scenes lobbying by a major company to ensure ambiguity persisted, and loopholes were not closed (Woolf, 2002). The
article was handed to Members of the European Parliament (meps) and while
some unhelpful caveats remained, the final wording saw the Parliament successfully overcome opposition from EU Member States and adopt measures
that would ban animal testing for cosmetics, and phase in the ban on selling
newly animal-tested cosmetics ingredients (Osborn, 2002). The cosmetics campaign and resulting legislation also emphasize the importance of consensusbuilding around the need to replace animal tests. The 1993 legislation triggered
increased efforts to replace animal methods and resulted in valuable contributions from industry, Member States, and the EC. eurl ecvam became a worldleader in validating alternatives, and the EU entered the twenty-first century
expressing a clear aspiration to replace outdated, failing animal methods.
5

reach, Chemical Testing and Transforming Toxicology

The political negotiation of Registration, Evaluation, Authorisation and Restriction of Chemicals (reach), the EU Chemicals Regulation (European Commission, 2006, Regulation (EC) 1907/2006), forced stakeholders with different
aims to work together. A direct confrontation between industry (who favored
lower costs and regulatory burdens) and environmental groups (who called
for expensive animal testing and rigorous regulatory processes) left animal
advocates needing to tread carefully. However, the animal protection agenda
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was in no danger of being ignored. Calculations regarding the number of animal tests that could be required by reach—varying initially from 9.5 million
to 45.8 million (Institute for Environment and Health, 2001)—hit the headlines; but there was an associated danger of animal welfare arguments being
co-opted by those simply wanting to reduce test costs. Politicians, more likely
to favor environmental concerns, were also those with the strongest policies on
animal protection; so a simple alignment with industry would have been highly problematic. Policies on data-sharing and transparency helped to forge links
between animal and environmental groups, but the most important development concerned the recognition that animal tests represented outdated science. As the discussions progressed, all players acknowledged that because the
future EU chemicals policy would be dependent on animal testing, it was impossible to ignore either the animal welfare or scientific case for replacement.
Between 2001 and 2003 the tone of the European debate around toxicity
testing shifted. Publication of the eceae report, The Way Forward: A NonAnimal Testing Strategy for Chemicals (European Coalition to End Animal Experiments, 2003) was pivotal in defining the debate for decades to come. The
eceae argued that in an ideal situation, there would be no need to make a
choice between saving animals and protecting people. Replacing animal tests
provided a win/win solution. New non-animal tests could be better, cheaper,
and faster; and reliance on outdated animal tests would waste money and potentially confound those seeking decisive regulatory action. The conclusion
of the reach negotiation in 2006 saw several meaningful animal welfare demands enshrined in legislation, with “promotion of alternative methods for
assessment of hazards of substances” becoming one of three objectives of the
legislation, listed in Article 1.
The political shift, which started with tentative statements from radical
Green Party politicians about the scientific need to replace animal tests, grew
to represent the mainstream view of the European Parliament and Council. By
the time meps of the center left had picked up the new rhetoric, a convincing
case had been made, and at first reading the European Parliament’s environmental committee voted for an entirely non-animal testing approach under
reach (Committee on the Environment, Public Health and Food Safety, 2005),
marking a significant call on all concerned to do more to replace animal tests.
Again, consensus around the need to replace animal methods achieved overwhelming support, and a central requirement of reach is that animal testing
should only be carried out as a last resort.
The legislative gains enshrined in reach built on past success concerning
replacement, including the application and development of 3R methods, as
mentioned in Directive 1986/609/EEC and required by the 1993 Cosmetics
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 irective, and broke new ground by requiring rapid updating of legislation in
D
response to new methods becoming available. What these legal requirements
did not do was ensure that regulators and the European Chemicals Agency
(echa) apply the rules without constant pressure from campaigners, culminating in several rulings against echa by the EU Ombudsman for failing to
meet regulatory requirements relating to avoidance of animal testing (peta
UK, 2014; echa, 2015).
6

2001–2003: Paradigm Shift Meets Parliament

The fifth term of the European Parliament (1999–2004) saw meps from across
the political divide join forces to push the replacement agenda through legislative debates, Reports and Parliamentary Questions. The fact that reach
and the 7th Amendment to the Cosmetics Directive were on the Parliamentary agenda at the same time, and the EC was working to revise Directive
1986/609/EEC, made for more urgency. The EC/Industry collaboration, the European Partnership for Alternatives to Animal Testing (epaa), was established
during this period, providing a forum in which companies could combine resources and expertise and demonstrate their commitment to implementation
of the 3Rs. The epaa has achieved a number of notable successes, including
the study that informed changes to Annex viii of reach, ensuring that acute
toxicity studies, using the dermal route, can be waived in most circumstances
(epaa, 2014).
In the midst of these political activities, the need for an accelerated
process to achieve international adoption of the Organisation for Economic
Co-operation and Development (oecd) Test Guidelines was recognized. The
International Coalition for Animal Protection in oecd Programs (icapo)
was formed (icapo, n.d.), allowing scientific experts working for international animal protection organizations, to participate in global efforts to
implement the 3Rs. The structure of icapo has, helpfully, required organizations to maintain a single point of contact with the oecd and to collaborate
with each other. To complete the picture, EU Framework Program (FP) funding decisions were taking a positive direction. Under FP6 (2002–2006), 21
projects to advance animal-free methods were funded, with a total of over
€63 million, and contained wording—thanks to the European Parliament—
concerning the need to replace toxicity testing on animals (European Parliament, 2002, Decision 1513/2002/EC). In this context, during the first years of
the twenty-first century, several advances were made, the results of which are
still playing out.
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Post-2010/63/EU: EU Lobbying and the Global Challenge

During the negotiation of Directive 2010/63/EU, information about the intentions of industry and the animal user community crept into the public domain. In the absence of replacement science successfully displacing
animal research, the future for animals could look very bleak indeed. In
2009, the UK House of Lords Select Committee on the European Union SubCommittee D (Environment and Agriculture) held an inquiry and reported
to Parliament (HL 164 2009–2010). During the evidence sessions, questions
were posed about the potential for higher welfare standards in the EU to
drive animal use abroad. While there was clear evidence that an EU research base holds several advantages for companies, several contributions
were worrying.
Evidence presented in the Memorandum by the Bioscience Sector (House
of Lords, 2009) notes the existence of “substantial competition from countries, such as China, India, and Singapore in developing infrastructure to
undertake animal research, which includes not just routine toxicity tests but
also R & D” (p. 21); and states that “commercial investment [is] increasing
faster in countries outside the EU, such as the US, China and India” (p. 19).
During the oral evidence session, industry representatives described the
experience that “most major pharmaceutical companies are now investing
in Asia” (p. 43), with decisions being “influenced very strongly, particularly,
by access to non-human primates and developing the Asian market with
particular reference to China” (p. 43). One representative went on to describe new facilities in Shanghai, which will focus on cancer research and
collaboration with a Chinese institution dedicated to constructing a specific
nhp facility.
The view that higher EU welfare standards are unlikely to contribute in
the short term to this shift is broadly supported, but the expectation of industry is that growing markets and longer-term projections are contributing
to the expansion of animal facilities in countries not governed by EU standards. The fear is not so much that companies will fail to keep pace with,
for example, EU standards of housing and care, but that in countries with
less rigorous legislation, less attention will be paid to severity limits, reporting, and transparency. This global expansion does not, however, mean that
EU political campaigning is any less important. Increased scientific scrutiny,
such as that required by European legislation, along with funding for the development of alternatives, is driving global change. We cannot protect nhp
in Chinese research facilities, but we can hold the science behind nhp use to
account.
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8

The EC’s Scientific Committee Opinions on nhp Use, 2009 and 2017

Use of nhps in the EU is highly controversial. Years of public campaigning has
raised awareness of nhp suffering and sentience (Jennings, 2010); and the 2007
European Parliamentary Declaration, which called for a timetable for replacing all use of nhps (European Parliament, 2007, P6_TA(2007)0407) led to the
inclusion of proposals to limit nhp use in the EC’s legislative proposal of 2008.
Alongside this, the EC requested a series of Opinions from its scientific committees concerning the potential to replace nhp use.
Animal advocates have, repeatedly, found the process by which the Opinions
have been formulated frustrating and biased. Contributors tend to be nhp users
rather than biomedical researchers who use non-animal methods. In the most
recent Opinion, released by the Scientific Committee on Health Environmental
and Emerging Risks (scheer) (scheer, 2017), the Committee argues in favor
of continued nhp use, while failing to acknowledge key reviews on the ineffectiveness of nhps as a model for humans or reviews on advances in alternative
animal-free methods. Nevertheless, the Committee made a handful of recommendations, including that systematic reviews should be undertaken and the
“psychological effect” on nhps should be better assessed (though this latter recommendation could lead to further research on nhp laboratory welfare).
9

The Citizens’ Initiative: Stop Vivisection

In this context, it is not hard to see why campaigners have continued to call
for an outright ban on all animal experiments. The Lisbon Treaty of 2009 introduced a process by which European citizens can initiate activity by the EC,
including proposals for new legislation, if a petition receives one million signatures collected in seven EU Member States within one year (the European
Citizens’ Initiative, European Commission, 2011). The third successful Citizens’
Initiative, Stop Vivisection, registered in 2012, called on the EC to “abrogate directive 2010/63/EU on the protection of animals used for scientific purposes
and to present a new proposal that does away with animal experimentation
and instead makes compulsory the use—in biomedical and toxicological research—of data directly relevant for the human species” (European Citizens’
Initiative, 2016). The Citizens’ Initiative demonstrated, again, EU-wide support
for ending the use of animals in research and testing, raised awareness among
policy makers, and generated new commitments from the EC. The European
Parliament hearing on the Citizens’ Initiative gave meps the opportunity to listen to arguments first-hand and question experts (European Parliament, 2015).
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The EC’s 2015 Communication responding to Stop Vivisection (C(2015) 3773)
identified four action points:
(1) Acceleration of progress in the 3Rs through knowledge sharing
(2) Development, validation, and implementation of new alternative
approaches
(3) Enforcement of compliance with the 3Rs principle and alignment of relevant sector legislation
(4) Engagement in a dialogue with the scientific community.
The EC’s response concluded by welcoming “the mobilisation of citizens in
support of animal welfare” stating that “the Citizens’ Initiative has provided
an opportunity to critically examine how the EU can reinforce its efforts in
moving from animal to non-animal based research and testing” (European
Commission, 2015, p. 10). However, there is no evidence that relevant decisionmaking bodies, such as Member State National Committees, referred to in Directive 2010/63/EU, are making the necessary adjustments.
Action 4 committed the EC to organize a scientific conference titled NonAnimal Approaches – The Way Forward, which, although supported by a
wider-than-usual audience of stakeholders, was boycotted by the organizers
of the Stop Vivisection Citizens’ Initiative, who later made a complaint to the
EU Ombudsman, considering that “the [European] Commission had given
an inadequate response to the initiative and the detailed proposals put forward in the context of the initiative”. The Ombudsman rejected the complaint
(EU Ombudsman, 2017); but the substance of the Initiative remains active,
and is an important milestone for policy makers at all levels of EU decision
making.
10

Conclusion

Scientific progress does not necessarily equate to changes in practice, in public
policy, or in legislation; but political progress can drive science. For this reason alone, effective political strategies are essential. The paradigm shift can
be accelerated by improvements in transparency, reporting, and protection of
animals as well as by increasing levels of scientific scrutiny, funding, and political will. Experience gained at the EU level demonstrates that when public
opinion—backed by convincing evidence and practical proposals—can be effectively presented, policy makers are required to balance competing interests
and promote workable solutions. In the field of research on animals, this often
results in increased efforts to replace animal experiments. Public opinion surveys indicate that legislators have not yet created laws that adequately address
citizens’ concerns; but continuing public and political pressure has ensured
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new initiatives are likely and further access points, in terms of influencing the
regulatory agenda, are open to advocacy groups.
Developing a coherent political strategy on the basis of either science or animal protection alone is fraught with difficulties. Heated debate, and regulatory
systems attempting to balance animal suffering with expected outcomes have
forced animal advocates into the scientific arena and scientists to respond to
welfare requirements. Those campaigning for a paradigm shift are gaining scientific weight and credibility, and new technologies are unstoppable.
So, what will end the use of animals in experiments in the shortest possible time? Using the experience gained over the past twenty years of EU-level
campaigning, it seems sensible to accept that widely different approaches and
organizations all have their place. Welfare advocates who work only with industry can achieve a great deal; the promoters of the Citizens’ Initiative, Stop
Vivisection, caused the EC to set new goals and attempt to create consensus
between stakeholders holding radically different views, and EU-level coalitions of national advocacy groups, together with a handful of international
organizations, through dogged scrutiny of implementation procedures, maintain public and political pressure. The need for legislators and regulators to
demonstrate a willingness to hear the views of a range of stakeholders has allowed animal advocates to find a voice at all levels of political processes and to
work with other campaign groups, industry, and academia to promote shared
objectives.
The experience of political campaigning described above is offered in the
hope that the paradigm shift happens sooner rather than later. The following overview of the points described above and lessons learned may also be
of use:
Political Campaigning:
– Make use of all procedural access points, remembering that early intervention works best.
– Work across political divides and with all stakeholders to understand the
full range of opinions and differing viewpoints.
– Join expert groups, share expertise, and try to avoid duplicating the work of
other, similar organizations.
– Understand the agenda of your opponents and check the meaning of wording that seems unclear. Loopholes can be avoided if spotted early enough.
– Create new access points. Always work for regular reviews, reports, and further studies.
– Find ways to increase transparency. From ensuring all animals are counted to sophisticated prospective and retrospective reviews, transparency is
essential.
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– Appreciate the work of consensus-based entities. Where there is consensus,
meaningful progress should be achievable.
Amplifying Our Message:
– Animal advocacy organizations working together are more likely to succeed. We have seen this through icapo and in the political arena. Sharing
material early on and avoiding duplication is more likely to ensure initiatives are successful.
– Formulating joint positions with other organizations, such as environment,
health, patient, and industry groups, amplifies our message.
– Coalitions and umbrella groups are helpful but need to demonstrate the extent of their supporter base, for example, by directly linking politicians with
national organizations and the citizens they represent.
The question of global versus national or regional campaigning answers itself.
We need to work at every level, in every forum, using all peaceful, evidencebased, effective means available to us. From handing out leaflets in the street
to funding studies by researchers to expose failing animal models of disease, every contribution is valuable and is helping to achieve the paradigm
shift.
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1

Introduction: Widespread Acceptance and Regulatory Failure of
the 3Rs

Few other issues have prompted as many legislators to adopt legal instruction
on the “proper” use of non-human animals (hereinafter referred to as animals)
in medical and scientific research. Today, the 3Rs (replacement, reduction, and
refinement of animals in scientific procedures) are globally accepted by a vast
majority of states (Blattner, 2014); and prominent international organizations,
such as the World Organisation for Animal Health (Terrestrial Animal Health
Code, 2018, Article 7(8)(3)) and the Council of Europe (Convention for the
Protection of Vertebrate Animals Used for Experimental and Other Scientific
Purposes, 1986, Articles 6(2), 7 and 8). Widespread acceptance of the 3Rs is a
notable achievement, since animal law is a relatively young field of law, and attitudes about the human-animal relationship diverge sharply across societies.
As progressive as this established body of law appears, the rules governing research on animals—especially the 3R maxim that dominate this legal
landscape—suffer from regulatory failure. First, and most importantly, despite widespread commitment to replace and reduce animals in research,
the number of animals used for experimental purposes worldwide is now the
same as it was in the 1980s (the number dropped in the 1990s and 2000s but
has been rising ever since; Bayne et al., 2015, p. 3; European Commission, 2013;
Taylor, 2013; Taylor et al., 2008; Taylor and Rego, 2016). Second, though the
principle of refinement demands that the severity of experiments be diminished, countries are reporting a rising number of research procedures done
on animals who are forced to endure the most severe experiments (e.g., Neue
Zürcher Zeitung, 2016). There is reason to believe that refinement, which seeks
to ameliorate the conditions of animals used for a research procedure, fails to
fulfill their basic welfare needs. For example, pursuant to the United States’
Guide for the Care and Use of Laboratory Animals, a pig who weighs up to
50kg can be housed for up to five years on 15 square feet (0.9m2), without any
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access to the outside (National Research Council Institute for Laboratory Animal Research, 2011). The Guide states that thereby “animals can turn around
and move freely without touching food or water troughs, have ready access to
food and water, and have sufficient space to comfortably rest away from areas
soiled by urine and feces” (p. 63). On 15 square feet, however, a pig cannot
possibly exhibit normal behavior. No human of the same weight is expected
to behave naturally in a 0.9m2 elevator and certainly not for a period of five
years. Overall, this overview of the achievements of the 3Rs suggests that both
in qualitative and in quantitative terms, adopting the 3Rs has not decreased
animal suffering.
At the same time, societal demands for better protection of animals are
more common than ever before (European Commission, 2016). According to
the most recent polls, citizens are increasingly concerned about the welfare of
animals used in science and agree that more needs to be done to replace their
use (Clemence and Leaman, 2016; European Citizen’s Initiative, 2016; Funk and
Rainie, 2015; Jones, 2017). Despite these demands and the reasonable doubts
they cast on the potential of the 3Rs to lead to the ultimate replacement of animals in research (see below), the 3Rs continue to be a popular policy tool for
legislators and research facilities that use them as an example of their efforts
to ameliorate the suffering of animals in research. The worldwide acceptance
and simultaneous failure of the 3Rs seem to have turned the maxim, intentionally or not, into a means of whitewashing the images of those profiting from
research vis-à-vis the public: scientists, research industries, and regulators.
In light of these developments, this chapter takes a functional-comparative
approach to scrutinize whether and how we can meet the rising societal demands for replacement. It specifically examines whether the 3Rs bear the potential of meeting this goal, and if so, what reforms are necessary, or whether
the 3Rs should instead be abrogated.
2

Abrogating the 3Rs?

The widespread acceptance of the 3Rs, alongside their simultaneous failure,
forces us to ask whether the 3Rs should be retired. In 2015, people across the European Union (eu) launched the European Citizens’ Initiative, Stop Vivisection,
and expressed, with over 1,150,000 signatures, their desire for a paradigm shift
away from the use of animals. The European Citizens’ Initiative is a p
 olitical
means at the eu level that makes it possible for 1 million citizens to participate
in developing eu strategies, by prompting the European Commission (ec) to
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propose a legislative act. The Stop Vivisection initiative demanded the use of
animals for research purposes be abolished, which would have necessitated
abrogating Directive 2010/63/EU (European Parliament, 2010), and with it,
the 3Rs. The ec responded to the initiative by issuing a communication that
effectively ignored these demands, arguing that the Directive also had replacement as a long-term goal, but that animal research cannot be banned because,
“a ban […] would likely export the biomedical research and testing outside
the eu to countries where welfare standards may be lower and more animals
may be needed to achieve the same scientific result” (European Commission,
2015, p. 3). As an alternative to the proposed abrogation, the ec promised that
it would speed up the expected progress of the 3Rs by sharing knowledge, developing and validating new alternatives, strengthening enforcement, and
entering a dialogue with the scientific community, for example, by organizing a conference devoted to this issue (see Holley et al., 2016, on knowledge
sharing in the eu). Undoubtedly, these steps may help to enforce Directive
2010/63/EU more effectively, but they do not respond to the criticism that
the 3Rs suffer from structural deficits that lead to the perpetuation of animal use in science. In effect, the steps envisaged by the Commission, like the
3Rs as they stand, are unlikely to bring about the full replacement of animal
models.
Given these economic fears and political constraints that continue to inform the debate on the replacement of animals in research, it may be more effective to use the worldwide acceptance of the 3Rs as a foundation for working
towards a paradigm change, through a foot-in-the-door strategy. Theoretically,
the 3Rs have many advantages over other types of regulatory approaches.
They are simple and intelligible, easily understandable, and catchy. They enjoy a general application, paired with refined conceptualization (compared
to the very general objective of avoiding unnecessary animal suffering that
leaves even more room for interpretation). The 3Rs take an integrative approach by incentivizing innovation, accommodating the interests of various
stakeholders, and not discrediting the purposes of research, such as finding
causes, treatments, and cures for diseases or enabling novel scientific insights.
The 3Rs consider the sentience and suffering of animals a baseline and respond to the needs of animals beyond physiological suffering, such as their
needs for social interaction and mental stimulation. Based on the hypothesis
that the 3Rs are theoretically expedient, it is worth exploring the potential of
this principle to mature into a more viable concept for the future of animal
law, in particular with regard to its capacity to preempt the use of animals in
research.
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Reform Proposal 1: Reverse Hierarchy of the 3Rs

Most countries claim that a minimum number of animals should be used to
obtain scientific knowledge, but the language of the replacement principle
is regularly laxer than that of refinement. For example, in the eu, Directive
2010/63/EU determines that “Member States shall ensure that, wherever possible, a scientifically satisfactory method or testing strategy, not entailing
the use of live non-human animals, shall be used instead of a procedure”
(emphasis added, European Parliament, 2010, Article 4). But given that the
Directive fails to determine the probability of possible alternatives, how accessible they ought to be, and the need to invest into them, the norm fails to
incentivize researchers to divest from animal research. According to Article
13 of Directive 2010/63/EU, replacement is only necessary if alternatives are
recognized under eu law. In addition, legislators often do not necessarily
mean replacement in an absolute sense when they call for replacement measures; instead, the use of seemingly less sentient animals, like rodents or fish,
are readily accepted as a form of replacement (e.g., German Animal Welfare
Act 2006, Section 7a(2)(5); India Prevention of Cruelty to Animals Act, Animal Welfare Board of India, 1982, Prevention of Cruelty to Animals Act, 1982,
Section 7(2)(e); us Guide for the Care and Use of Laboratory Animals, National
Research Council, 2011, p. 5; Scientific Committee on Health Environmental
and Emerging Risks, SCHEER, 2017, p. 15).
This clearly runs counter to Russell and Burch’s (1959) definition of replacement as “any scientific method employing non-sentient material” (Chapter 5)
and fails to give those animals, whose capacity to sentience is still disputed,
the benefit of the doubt (challenging the view that non-human animals lower
on the zoological scale lack sentience: Tomasik, 2014). Such lax provisions give
ample room for regulatees to avoid actual replacement, and they increase the
possibility that certain research procedures may never be replaced. Given the
lax practice in replacement and strong accentuation towards reduction and refinement, there seems to be an implicit hierarchical understanding of the 3Rs
that gives refinement and reduction priority over replacement (Gerritsen, 2015,
p. 38). The marginalization of replacement is especially disconcerting if one
looks at the 3Rs from an “animal use” perspective, as seen in Table 6.1.
It is this framework that allows animal researchers to discharge their duties under the 3Rs by engaging in refinement (and marginal reduction) alone.
The political and legal preoccupation with refinement and reduction shifts the
focus away from where it should be, i.e., on replacement. So, if we continue to
accept that legislators and institutions simply refine and marginally reduce the
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Table 6.1

Refinement and reduction support the use of animals for research procedures
and only replacement bears the potential of phasing out animal research in the
long term.

Use of animals

Refinement

Reduction

Replacement

+

+

−

use of animal models—only replacing them “wherever practical” and thereby
conceiving themselves as fulfilling their 3R duties—we will end up perpetuating the use of animals in experiments. Contrary to what many practice, the 3Rs
ought, however, be interpreted to mandate that replacement be given primary
consideration. As the above-mentioned polls show, citizens’ opinions increasingly pressure legislators to come up with a workable plan to phase out the
use of animals in research, which necessitates insisting on the replacement of
animals in research (see also Goldberg and Locke, 2004). To bring about this
paradigmatic change, the 3Rs should be understood hierarchically, where the
first goal is replacement, the second reduction, and the third refinement. The
imperative for this reversal is based on a historical, teleological, and evolutionary interpretation.
A historical interpretation of the 3Rs relies on Russell and Burch’s foundational work on the principle. Russell and Burch, the founders of the 3Rs, clearly
stated that the humanitarian problem lies in the severity with which animals
encounter stress and the high number of animals affected, and that the very
purpose of the 3Rs is to tackle these (Russell and Burch, 1959, p. 93; Blattner,
2014). Russell and Burch further stated that “refinement is never enough, and
we should always seek further for reduction and if possible replacement”
(Chapter 4). Because replacement does not appear to be a priority of the 3Rs
even though it is an explicit goal of the tripartite principle, the law must give
more weight to this element when it applies the principle in the future.
A teleological interpretation also suggests that the law must reverse the hierarchy of the 3Rs. Indications of this interpretation already exist under current
legislation. The Council of Europe’s Convention for the Protection of Vertebrate
Animals used for Experimental and other Scientific Purposes states in its preamble that its parties are “[r]esolved to limit the use of animals for experimental and other scientific purposes with the aim of replacing such use […]
in particular by seeking alternative measures and encouraging the use of these
alternative measures” (Council of Europe, 1986). In Directive 2010/63/EU,
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the eu expressed its wish to, “achiev[e] the final goal of full replacement of
procedures on live animals for scientific and educational purposes” (European Parliament, 2010, Recital 10). If we interpret the 3Rs based on these
stated purposes, replacement must be our top priority. Article 4 of Directive
2010/63/EU, which details the 3R commitments, begins by stating the duty
of replacement and, thereby, implies a reverse hierarchical understanding of
the principle, as well. Article 13 of the Directive further guides the choice
of methods in the scientific and educational use of animals and—unlike the
previous regulation, Directive 86/609/EEC (Council of the European Communities, 1986)—does not require replacement methods to be “reasonably,
and practically available” (Article 7(2)). Instead, replacement methods are
recognized as non-animal methods or testing strategies, even if they are not
reasonably and practically available. This wording change, strictly interpreted,
means alternatives should be required even where they are costly, have never been used by the researcher, or are not available at the researcher’s home
institution.
The polls introduced herein show that the global community has never
been more concerned about animals’ well-being than it is today. As a consequence of this burgeoning global conscience, we are witnessing the rise of the
general principle of animal welfare, which is developing into a norm of customary international law (Bowman, Davies, and Redgwell, 2010, p. 678; Brels,
2012, p. 37; Sykes, 2014; Trent et al., 2005, p. 77). International documents and
the laws of over 60 states worldwide make clear the general moral commitment and the legal requirement that animals be treated humanely and spared
suffering (Blattner, 2016, pp. 304–308). The general principle of animal welfare
underlines the goal of animal protection as an intrinsic interest of animals. In
other words, the suffering of animals matters to the law because it matters to
animals (Bolliger, Richner, and Rüttimann, 2011, p. 24–25, n. 14; Leondarakis,
2001, p. 29). Importantly, the general principle of animal welfare not only mandates proper treatment of animals while using them; it also encompasses the
aspiration of states to preempt any violation of their intrinsic interests.
Another global principle that requires regulatory frameworks to shift emphasis on animal replacement is the precautionary principle. The p
 recautionary
principle commonly applies in decision-making processes and entails that,
where there are threats of serious or irreversible damage, lack of full scientific
certainty shall not be used as a reason to postpone cost-effective measures to
prevent damage. The prime application of the precautionary principle is in environmental law where it covers animals who form an integral part of an ecosystem (Montreal Protocol on Substances that Deplete the Ozone Layer, 1987;
United Nations, 1992, Article 8h, 14(1)(d); United Nations General A
 ssembly,
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1992, Article 15; World Charter for Nature, 1982, Article 12(b)). But, as the ec
states, “in practice, [the] scope [of the precautionary principle] is much wider,
and specifically where preliminary objective scientific evaluation indicates
that there are reasonable grounds for concern that the potentially dangerous
effects on the environment, human, animal or plant health may be inconsistent with the high level of protection chosen for the Community” (Commission of the European Communities, 2000; see also World Health Organization,
1994, Article 5(7)). The precautionary principle demands that we err on the
side of caution to prevent dangerous effects on animal health, replacing animals in research rather than regulating and, thus, perpetuating their use by
refinement and reduction. We must thus decide in favor of animals wherever
and whenever actions impair, or likely will impair, their physical and psychological health and life (Gerick, 2005, p. 213; Kuhlau et al., 2011). An evolutionary interpretation, based on the general principle of animal welfare and the
precautionary principle therefore indicates that replacement should be given
primary consideration among the 3Rs.
4

Reform Proposal 2: Qualitative Balances of Interests, Harm-Benefit
Analyses, and Proportionality Tests

Even if replacement is given absolute preference, the 3Rs are still likely to fail
because in most jurisdictions they enjoy only relative validity. Researchers do
not refine the conditions of animals, do not reduce the number of animals
used, and do not replace animals as the primary research model (even where
alternatives exist) if human interests justify that decision. The Swiss Animal
Welfare Act 2005, for example, states that “[p]ain, suffering or harm may be
inflicted on or anxiety caused to a non-human animal only if this is unavoidable for the purpose of the experiment” (Article 20(1)). The issue here is that
the purpose of the experiment is the only determinant in deciding whether
animal suffering is unavoidable, or so-called necessary. The suffering inflicted on animals during experimentation is seen as a prima facie harm, but its
justifiability—and hence its legality—is fully determined by the purpose of
the experiment. Animals’ interests in not suffering, by contrast, do not enter
the judgment on necessity.
The Swiss Animal Welfare Act seems to have taken a step in the right direction by further providing that animal experimentation is impermissible “if, in
relation to the anticipated gain in knowledge, it inflicts disproportionate pain,
suffering or harm [on the animal]” (emphasis added, Article 19(4)). Similarly, under the United Kingdom’s Animals (Scientific Procedures) Act 1986, the

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

Rethinking the 3Rs: From Whitewashing to Rights

175

 nimals in Science R
A
 egulation Unit will assess whether the harms caused by an
experiment are “justified by the expected outcome” (emphasis added, Section
5B(3)(d)). This is also the case with Article 38(1)(b) of Directive/2010/63/EU
(European Parliament, 2010). These and other laws claim that they determine
the legality of an experiment conducted on animals not only by evaluating the
necessity of an experiment but by weighing all interests at hand. Such norms
bring to application what is sometimes known as the balance of interest tests,
harm-benefit analyses, or the proportionality principle.
Pursuant to these tests, animal experiments are evaluated in a two-step procedure. Regulators require the purpose of an experiment to be indispensable
(final indispensability), and they require the means to achieve this end to be
indispensable (instrumental indispensability or harm-benefit analysis) (Peters, 2012, p. 34ff.; e.g., German Animal Welfare Act 2006, Section 7(1)(1); Swiss
Animal Welfare Act 2005, Article 17). Final indispensability is an analysis of the
purpose and legitimacy of an experiment, which answers the if question. Instrumental indispensability, on the other hand, answers the how and largely
refers to the principle of proportionality (e.g., German Animal Welfare Act,
2006, Section 7(1)(2)). The proportionality analysis includes the elements of
suitability (means must be able to achieve desired ends), necessity (no milder
means are available to achieve the end), and proportionality strictu sensu (Bolliger and Rüttimann, 2015, pp. 71–73). This final proportionality, strictu sensu
evaluation includes a duty to diligently balance interests affected by the act at
hand and conforms to the harm-benefit analysis (Ferrari and Gerritsen, 2015,
p. 140) but with respect to means as opposed to ends.
Let us turn to final indispensability first. Before weighing interests, decisionmaking bodies usually follow a system that classifies expected harms inf
licted on animals. For example, there is a five-step classification system in
Canada (Canadian Council on Animal Care, 2011), in New Zealand (New Zealand Government, 2010, Section 2(1)), and in Israel (Kolman et al., 2014, pp.
202–203), a four-tiered scheme in Singapore (National Advisory Committee for
Laboratory Animal Research, 2004, Article 5(4)(2)(b)) and the eu (European
Parliament, 2010, Articles 15 and 16); and the Philippines has a three-step pain
categorization system (Philippines Law on the Use of Animals in Research, 1999,
Article 5(2)). Most of these classification schemes determine harm or pain levels based on the severity of a procedure or its duration, or a combination of the
two. Article 15 of Directive 2010/63/EU, for example, assesses projects as nonrecovery, mild (short-term mild pain, suffering, or distress), moderate (shortterm moderate or long-lasting mild pain, suffering, or distress), and severe
(severe or long-lasting moderate pain, suffering, or distress) (European Parliament, 2010). To best evaluate harm, psychological spheres of animals must also
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be considered b ecause inducing fear or anxiety in an animal negatively affects
their well-being (e.g., Council of Europe, 1979, preamble; Swiss Animal Welfare
Act, 2005, Article 3(b)(4)).
In contrast to harms, benefits are neither classified nor categorized. For
instance, in the uk, where stricter harm-benefit analyses are said to prevail
(Perry, 2007, p. 43), benefits are described in a very broad manner, by answering
questions such as, what data or products may be acquired by the work, what
scientific questions will be answered, what knowledge gaps will be filled, who
will benefit from the work, and how and when the benefits will accrue. Quite
telling in this respect is the need for scientists to “[e]xplain why the benefits
go beyond ‘it would be nice to know’” (uk Home Office, 2014, p. 126; see also
European Parliament, 2010, Article 38(2)(a); uk Home Office, 2016, pp. 9–11).
Scientifically speaking, to offer benefits, a research project must produce recognizable results of scientific value (e.g., Austrian Animal Welfare Act, 2004,
Section 4(3)(a)). From a societal perspective, however, only socially desirable
objectives can be pursued in an experiment. Saving labor, time and costs or
duplicating research cannot, prima facie, be weighed against animals’ interests
(e.g., German Animal Welfare Act, 2006, Section 7a(2)(5)).
Though these rules on final indispensability serve an important purpose
and help prevent the most unnecessary and atrocious research procedures,
they effectively leave untouched the great bulk of research. For example, the
societal objectives of curing diseases or producing new scientific knowledge
typically operate as a carte blanche that legitimate every form of animal exploitation and give the 3Rs only relative validity. But simply dropping the
words cancer research cannot and should not automatically justify the use of
animals. We must introduce a scheme that evaluates the importance of the
research, its contribution to the expected goal, and the likelihood of its success; and we must be wary of approving research projects that simply ensure
a research facility’s survival and the preservation of jobs, while perpetuating
the exploitation of animals (arguing that “[c]onducting animal experiments
is a convenient and highly effective way for these researchers to gain career
prestige and job security, and for the universities who employ them to obtain
lucrative research grants. There is a quid pro quo relationship between research
institutions and those giving the grants”, Greek and Greek, 2004, p.25). No
research that goes beyond “it would be nice to know” is, by itself, morally or
legally weighty enough to justify the immense suffering of animals in research.
Peters (2015) proposes categorizing human interests into small, moderate,
and great benefits to introduce a level field for evaluating human benefits
versus animal harms (p. 97). Having precise knowledge about both burdens
and benefits allows us to weigh more systematically the importance of the interests at hand, and makes it more obvious when marginal scientific interests
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seek to trump animals’ fundamental interests in life and bodily and mental
integrity.
A further failing within harm-benefit evaluations is that the tests are regularly affected by referring to the legal tools that encapsulate those interests,
rather than by the interests themselves. Scholars and individuals around the
world have frequently exposed the risks of endowing humans with rights,
while endowing animals only with protections. When experiments are evaluated, rights of humans, such as the freedom of research (e.g., Council of Europe, 1950, Article 10) or the freedom to choose an occupation and the right to
engage in work (e.g., European Convention, 2000, Article 15), are juxtaposed
against (animal) protections (e.g., the 3Rs). The fact that certain interests are
legally recognized either as rights or as protections, establishes a disparate
and unequal footing for the affected parties. Protections are effectively undermined when confronted with rights in a balance of interests, because they
are a weaker legal tool. Consequently, protections only take effect where the
rights of humans leave room for them. The Swiss Animal Welfare Act (2005) is
a prime example of this automatic trumping. It requires anyone who handles
animals to ensure their well-being “as far as the intended purpose allows”
(Article 4(1)(b)). This not only renders research quintessentially a utilitarian
endeavor; but, more notably, it creates a structural deficit to the detriment
of animals. The balance of interests ends up being merely perfunctory and
legitimizes, in essence rubber-stamps, the exploitation of animals (Ferrari and
Gerritsen, 2015, p. 140; Gerritsen, 2015, p. 38).
A prime example of the inherent deficiency created by rights versus protection is the German state objective of animal protection. Prior to the amendment of Article 20a of German Basic Law, scholars viewed the German Basic
Law as a “constant obstacle” (Evans, p. 326) to the effective protection of animals
and were hopeful that the constitutionalization of animal protection, even
if it would not create justiciable rights, would put animal protection on par
with constitutional rights, as regards governmental value judgments (Gerick,
2005, p. 120). Judiciary practice established since the norm’s amendment in
2002, however, shows that the state objective is regularly subordinated to constitutional rights (German Administrative Court, 2006; German Constitutional
Court, 2009; German Constitutional Court, 2006; see further Eisen and Stilt,
2017, note 25). The deficiency again is that the balances of interests do not
even examine the interests that underlie legal tools. They fail, for example, to
acknowledge that what we may be balancing are interests in not being tortured versus interests in making economic profit. Instead, these tests balance
interests only with reference to legal tools that protect those interests (rights
versus protections)—a practice that structurally favors all human interests in
using animals, over all interests of animals in not being used.
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The first step towards ensuring a less biased balance of interests is to clearly
differentiate between a scientific evaluation of whether animals are required
to obtain a scientific result, and an ethical evaluation of whether it is morally
justifiable in each individual case to inflict a certain kind of suffering upon an
animal for a certain kind of desired objective. The second step to reforming
these tests is leveling the position of competing interests, by establishing a reliable framework for a qualitative and non-speciesist balance of interests. Such
a qualitative balance of interests demands that identical interests be viewed
identically, regardless of the holder of the interest, i.e., be it the interests of humans or the interests of animals (Ferrari and Gerritsen, 2015, p. 139; Robertson,
2015, p. 102). Balancing qualities of the interests at stake should, in principle,
prevent marginal research interests from trumping interests in bodily integrity.
5

Reform Proposal 3: Animal Rights

Why Reverse Hierarchies and Upgraded Balances of Interests Do Not
Suffice
Even if replacement is considered the primary aim of the 3Rs, and even if we
considerably revamp the balance of interests test, the 3Rs will likely continue to
fail. The odds against this test are so high because its logic is flawed. The golden
standard in animal experimentation is the animal model. The animal model
poses ethical problems, has never been validated as a research method, and
is strongly criticized for lacking sufficient predictive value to draw inferences
about human models (e.g., Baker, 2016; Bailey, Thew and Balls, 2014; Greek and
Menache, 2013; Knight, 2011; McIvor, 2019, Chapter 5 in this Volume). Despite
these apparent flaws and the structural deficiencies of the animal model, u
 nder
the 3Rs, a non-animal model not only needs to be as “effective” as the a nimal model,
but (unlike the animal model) it actually needs to work. As Greek points out, this
means we are “[w]aiting to abandon a test that does not work until we can
find one that does” (Greek, 2015). A recently published report by the Scientific Committee on Health Environmental and Emerging Risks (scheer) on the
need for non-human primates in research even posits that alternative models,
which are to be validated against existing animal models, will require—from
a legal perspective—using more animals in the validation process (scheer,
2017, pp. 20, 56). The odds are thus high that the 3Rs will perpetuate the use of
animals in research. A final and crucial lex ferenda change that may overturn
this deeply ingrained imbalance requires restructuring protections as rights.
5.1

5.2
Prohibitions as Rights?
Some scholars argue that animals already have at least some rights by arguing
that prohibitions are negative freedom rights of animals. Section 85 paragraph 1
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of the New Zealand Animal Welfare Act (1999), for example, provides that
“[n]o person may carry out any research, testing, or teaching involving the use
of a non-human hominid unless such use has first been approved by the Director-General and the research, testing, or teaching is carried out in accordance
with any conditions imposed by the Director-General” (Section 85(1)). From
the general prohibition on using hominids for research, testing, or teaching,
some infer that hominids have the right not to be infringed in their life and
bodily and mental integrity. Wagman and Liebman (2011), for example, argue
that “the ban on certain conduct seems to grant the affected animals the ‘right’
to be free of such conduct. Because of animals’ status as property in every jurisdiction, those rights are naturally limited” (pp. 261; see also McCausland, 2014,
p. 27; Robertson, 2015, pp. 3, 5; Sunstein, 2004, p. 99; Waldau, 2011).
If we look at the laws that regulate research on animals, there are several
prohibitions that could be posited as negative freedom rights. According to
Article 8(2) and (3) of Directive 2010/63/EU, there is a prohibition of the use
of great apes and non-human primates for research purposes (cf. European
Parliament, 2010, Recital 18). Exceptions are stated in Article 8(2)(a) and (b) for
non-human primates and in Article 55(2) for great apes. The Australian Policy
on the Use of Non-Human Primates for Scientific Purposes (National Health and
Medical Research Council, 2003), which declares that research on great apes
is legal under narrow conditions, is also sometimes considered to enshrine a
freedom right of great apes to not be used in research. Similar prohibitions/
rights exist in Austria, Belgium, the Netherlands, Sweden, Switzerland, the uk,
and other states (Goldner, 2014). Another type of negative freedom right can be
seen in the EU-wide prohibition of experiments that result in severe pain, suffering, or distress for animals and which are likely to be long-lasting (European
Parliament, 2010, Article 15(2)). However, these prohibitions are undermined
when Member States choose to allow such procedures temporarily (European Parliament, 2010, Article 55(2)–(3)). Member states may, however, decline
to adopt exceptions, which scholars support by arguing that certain levels of
suffering should not be permitted under any circumstances, regardless of any
likely or aspired benefits (Zurlo, Rudacille and Goldberg, 1996). Another type
of prohibition is the ban on subjecting vertebrates to research without anesthesia when experiments result in serious injuries (European Parliament, 2010,
Article 14(1), Sentence 2). Prohibitions may also preclude certain purposes
from justifying animal use in research. Under Puerto Rican law, for example,
animal experiments are prohibited if they are done for educational purposes
(e.g., Puerto Rico Animal Welfare Act, 2008, Article 19(b); see also Swiss Animal
Welfare Ordinance, 2008, Article 138(2)).
Prohibitions are a major step forward for animals, making certain species of animals unavailable to human disposition. In this sense, prohibitions
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e ffectively preempt balances of interests: None of the specified procedures
are prima facie available to be overridden by human interests. But these prohibitions apply only to a minority of animals (e.g., to iconic or endangered
animals) and continue to be undermined by broad exceptions, which in turn
promote the continuing use of a majority of animals in research.
5.3
The Need for Animal Rights
The whole idea that the duties of some can be translated into the rights of
others (to whom the duty is owed); and, thus, that prohibitions are negative
freedom rights of animals, is disputed in legal scholarship (Curnutt, 2001,
pp. 19ff., 26ff.; Raspé, 2013, p. 282). Contrary to Wagman and Liebman’s perspective is the view that specified norms are prohibitions, no more, no less. Rights
are only established by unequivocally identifying them as such (e.g., “hominids
have a right to life and a right to bodily and mental integrity”). Instead of opting for limited prohibitions that are undermined by numerous and sweeping
exceptions, the only way to begin attending to the fundamental interests of
animals is to establish rights for them. Rights are those rare tools that ensure
that interests are qualitatively balanced, and that the balance is egalitarian and
non-speciesist. As Peters (2016) argues: “[A]nimal rights would allow a fair balancing in which the proper value of fundamental animal interests (such as the
interest to live) could be integrated. Animal rights would therefore preclude
the current routine sacrifice of fundamental animal interests in favor of trite
human interests” (p. 49). The demand for fundamental rights for animals is
neither utopian nor far-fetched; it is the only option available to move away
from our prevailing perfunctory consideration of animals. Particularly in research, where balance of interest tests prevail, establishing rights for animals
is indispensable if we seriously want to start envisaging an end to their use in
experimentation.
Another notable aspect about rights is that they ensure that rights holders
have a sphere of absolute unavailability. In human rights law, this is known
as the very substance of a right that may not be restricted or impaired in any
way (e.g., European Economic Community, 1957, Article 2; Swiss Constitution,
1999, Article 36(4)). Because animals, under the laws of most states, are denied rights, human interests in exploiting animals take categorical precedence
over their most fundamental interests, such as life and freedom. Introducing
a sphere of inviolability for the most fundamental interests that animals possess is necessary, if we want to truly take their interests seriously and live up to
our recognition of their intrinsic value (Peters, 2015, p. 72). A number of laws
already recognize that the interests of animals matter because these interests
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matter to them, i.e., that animals have to be protected for their own sake. The
Dutch Animal Welfare Act (Wet dieren 2011) in this context expresses “recognition of the intrinsic value of the animal” (preamble). Directive 2010/63/EU
(European Parliament, 2010) enshrines that “[a]nimals have an intrinsic value
which must be respected” (Recital 10) and that they “should always be treated
as sentient creatures” (Recital 12). The intrinsic value of animals is also recognized under German law (German Animal Welfare Act, 2006, Section 1); and
the preamble to the Latvian Animal Protection Law (1999) states that “[t]he
ethical obligation of humankind is to ensure the welfare and protection of all
species of animals, because every unique being is in itself of value”. Article 3
litera a of the Swiss Animal Welfare Act (2005) speaks of the “[i]nherent worth
of the animal that has to be respected”. Thailand’s Ethical Principles and Guidelines for the Use of Animals (National Research Council of Thailand, 1999) states
that “[a]nimal users are to be aware of the value of life of animals” (Principle 1),
and that “animal users need to be aware that animals are living beings just as
humans are living beings” (Principle 4). The recognition of the intrinsic value
of animals is not only ethically relevant, but it carries legal implications (Peters,
2015, p. 70) and should result in rights that protect these individuals’ core interests. Recent case law in India shows that animal rights are on the rise and that
they are readily implementable. The High Court of Kerala (2000) declared:
“[L]egal rights shall not be the exclusive preserve of the humans which has to be
extended beyond people thereby dismantling the thick legal wall with humans
all on one side and all animals on the other side” (N.R. Nair and Ors v. Union
of India (uoi) and Ors, 2000); and, “animals are born with an equal claim for
life without any cruelty to them. Perhaps if this right was given proper recognition by the human-beings, there would have been no necessity to bring on the
statute book of the said Act” (People for Animals and Ors. v. State of Goa and
Ors, 1997).
Establishing rights, and thereby an essence of inviolability, has a number
of implications. Akin to Principle 5 of the Nuremberg Code (1949), experiments will not be conducted, “where there is an a priori reason to believe that
death or disabling injury will occur” because it violates the core content of a
right to life and bodily and mental integrity. And analogous to Principle 8 of
the Helsinki Declaration (World Medical Association, 2013), the primary purpose of medical research to generate new knowledge cannot take precedence
over the rights and interests of individual research subjects. Today, the duty
to rehabilitate animals—sometimes known as the fourth R—could be taken
as a useful starting point in this respect. Recital 14 of Directive 2010/63/EU
states that methods should avoid death (of animals) as an endpoint. Killing
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an animal used for a research experiment is only permitted if they remain in
or have recurrent moderate or severe pain, suffering, distress, or lasting harm
(European Parliament, 2010, Article 17(2); Government of India, Ministry of
Environment and Forests, 2007, Annex 6). Article 17 paragraph 3 of Directive
2010/63/EU further states: “Where an animal is to be kept alive, it shall receive
care and accommodation appropriate to its state of health.” India’s Guidelines
on the Regulation of Scientific Experiments on Animals determine that “investigators are responsible for the aftercare and/or rehabilitation of animals after
experimentation” (Government of India, Ministry of Environment and Forests,
2007, Annex 6). If states today are willing to determine that death of animals
used in research should be avoided, it is not unreasonable to consider the possibility that they will grant animals a right to life in the future. Thereby, the
rehoming duty would be explicitly reframed as a manifestation of a right to
life, akin to Principle 5 of the Nuremberg Code (1949). A deficiency of current
rehoming provisions, however, is that researchers are nudged to use the method that causes lasting moderate and severe pain, so they can put the animal
down without having to care for or accommodate them after the conclusion
of the experiment. To counter these unwarranted disincentives, the costs of
aftercare and/or rehabilitation of animals post-experimentation should be
budgeted as a part of research costs when an application is filed (as required
by Government of India, Ministry of Environment and Forests, 2007, Annex 6,
Principle 4).
5.4
A Paradigm Shift?
Animal rights implemented in law would create a paradigm shift because
they offer specific advantages over protections. Instead of merely establishing specific and context-dependent prohibitions, rights operate more broadly
and are less determinate. This confers advantages to the rights holder, because
rights are applicable in a myriad of situations. For example, a right to bodily and mental integrity applies to the general question of whether use of an
animal in research is justified. If the answer is yes, then the question must be
asked whether and how this right can be guaranteed in research (e.g., by carrying out research that does not inflict any form of suffering, including death).
Moreover, animals are empowered by rights because they, by being actionable,
grant them access to stronger legal tools of enforcement (Edmundson, 2014,
pp. 345ff., 350; Goldner, 2014, p. 53ff.). Only the enforced duty of others to respect the right in question renders its worthiness palpable (Edmundson, 2014,
p. 360). Establishing a right of animals to life and bodily and mental integrity
would stop perpetuating the use of animals for research and enable us to achi
eve the primary goal of the 3Rs: the ultimate replacement of animal models.
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While funding animal-free alternatives will undoubtedly contribute to this
goal, as well (see e.g., Swiss Animal Welfare Act, Article 22(2); European Parliament, 2010, Recital 46), only a paradigm change in the law of animals in
research will stop incentivizing research facilities to continue experimenting on animals and will start enabling them to put all their efforts into finding ethically sound (and more scientifically sound) alternatives to the use of
animals.
If industries cannot now devise alternatives to animal models, then certain
types of research procedures simply should not be carried out until we find
alternatives. When the Helsinki Declaration (World Medical Association, 2013)
came into force, legislators deemed acceptable the burden of looking for alternative models to research on humans. The same change of research procedure is, on the basis of a non-speciesist ethic, reasonable to demand from
industries that currently rely on animal models. This route is not utopian but
was taken by lawmakers before, such as when the eu decided to give full effect to the Cosmetics Directive (European Commission, 2013, p. 3). When discussing the p
 otential postponement of the 2013 marketing ban on cosmetics,
since replacement methods for all animal models were not yet available, the
ec argued that postponing the ban would “diminish determination to swiftly
develop alternative test methods. Past experience demonstrates clearly that
animal testing provisions in the cosmetics legislation have been a key accelerator in relation to the development of alternative methods and have sent
a strong signal far beyond the cosmetics sector and far beyond Europe” (European Commission, 2013, p. 6). Instead of conceiving rights for animals as a
scientific regression, industries will be incentivized to finally spur innovation
towards ethically sound and economically accessible alternatives.
The eu Cosmetics Directive has had a positive spill-over effect into other areas of animal experimentation, alongside further national bans on cosmetics
testing, including Australia (Australian Government, Department of Health,
2018), India (Government of India, Ministry of Health and Family Welfare,
2005, Section 148C), Israel (Israeli Cruelty to Animals Law 1994, Article 2(d);
prohibiting cutting into live tissue), Guatemala (Guatemalan Animal Welfare
Act 2017, Article 54), New Zealand (New Zealand Animal Welfare Act 1999,
Section 84A), South Korea (South Korea Animal Protection Law 2007; in force
2019), and Taiwan (Business Cosmetics, 2016). In September 2016, the Dutch
parliament changed its policy on animal research law in an unprecedented
way. The parliament passed a motion to phase out all experiments on nonhuman primates and declared that by 2025, it aims to operate by testing methods that do not make use of animals. The policy areas in which the use of
animals must be phased out until 2025 include regulatory testing of chemicals,
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food ingredients, pesticides and (veterinary) medicines and biological products, such as vaccines. In the areas of fundamental research, applied and
transitional research, as well as education and training, by contrast, no such
specific reference date has been announced. The government’s next step is for
the Dutch National Committee for the Protection of Animals Used for Scientific Purposes (NCad, 2016) to plan a schedule that phases out experiments on
animals (which applies to all of the above areas). NCad clearly puts emphasis
on innovation and the development of new research methods rather than the
abrogation of animal research; yet, its move is historical and will hopefully set
a precedent for other states to follow. These developments show that the unavailability of animals for research does not equate with an end to research
and advances for human benefit but instead, it heralds the beginning of an
ethically and scientifically sound future for research. If devised as rights instead of bans, these regulatory changes would create more secure and justiciable ground for animals and could enable us to work more effectively towards a
paradigm change in research.
6

Concluding Remarks

The 3Rs are a primary example of regulatory failure, and yet the concept
enjoys an unparalleled acceptance among states and research institutions
worldwide. Instead of abrogating the 3Rs (which is demanded by a growing number of citizens), it would be better to leverage the 3Rs’ widespread
acceptance to enable regulators to fulfil their unachieved regulatory goals
and meet the growing demands of citizens for a more just relationship with
animals.
This chapter proposed means of bringing about paradigm change, that, although few, are powerful. First, regulators must reverse the hierarchy of the
3Rs, based on a historical, teleological, and evolutionary interpretation, with
replacement taking precedence. Second, regulators must introduce qualitative
balances of interests, so identical interests are viewed identically, regardless of
the interest holder. As a result, marginal scientific or prestige interests cannot
trump interests in life and bodily and mental integrity. Third, animals must be
accorded explicit rights to life and bodily and mental integrity, based on our
legal commitment to protect them for their own sake (intrinsic animal protection), for the following reasons: rights grant more power to rights holders
than interests do to interest holders, rights require special justification, give
effective weight to animal interests in balancing tests, make the core interests
of animals inviolable to human exploitation, and operate broadly. Although
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rights will preclude undertaking many research practices that are currently
conducted on animals, they spur innovation and help make research more effective and accessible. As the ec (2013) stated with respect to cosmetics, “the
possible risks from the 2013 marketing ban can be turned into an opportunity
for the Union to set an example of responsible innovation […] with positive
impact beyond Europe” (p. 6). The very same opportunities are available to us
in research more generally if we begin to embark on a road of innovation and
progress.
If these adjustments are incorporated, we anticipate that the 3Rs can offer a valuable approach to overturning the deeply ingrained default rule of
animal experimentation and to incrementally phase out the use of animals
in research. But “[f]ully reaping the potential of alternative methods is a
challenging endeavor that will require a shift in thinking of all involved” (European Commission, 2013, p. 6; inertia of continued animal use is acknowledged in Innovate uk, 2015, p. 14). Legislators must empower scientists and
research institutions to take the full replacement road by designing the best
possible legal framework for it and by giving them the necessary financial incentives and education to pursue replacement, instead of holding them morally responsible for the continued use of animals, which is in fact a regulatory
failure.
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1

Introduction

Generally, an animal experiment can be defined as an intervention on an
animal, which causes suffering, harm, and distress, for scientific purposes. In
this definition, animal experiments differ from more general scientific investigations concerning animals, such as observational studies in the wild in the
fields of ethology or conservation, in which animals are involved but may not
be harmed. Nowadays, the use of the term vivisection, in the case of animal experiments, is very controversial. This term originally referred to the cutting of
living bodies for scientific purposes and has a long conceptual history (Maehle,
1992). In ancient times, it was used for referring to experiments on animals
as well as on humans. Only in modern times, it became a colloquial term for
all animal experiments and was much used by opponents in the nineteenth
century, as the criticism of animal experiments became organized in a political movement (Maehle, 1990). Many opponents to animal experiments, nowadays, use the term deliberately in a political sense, connecting to past animal
protection movements (e.g., the international Citizens’ Initiative Stop Vivisection, cf. Rippe, 2009). Animal experimenters, on the other hand, oppose the
term on the grounds that there is no chirurgical exploration of living animals
in experiments (e.g., German Research Foundation, dfg, 2016).
Currently, animals are used in different ways for scientific purposes: they
are used in basic research; in education in a variety of biomedical disciplines,
including veterinary medicine; as so-called disease models, to mimic different
diseases, mostly human ones; as test subjects in different test settings; in veterinary medicine; in behavioral and cognitive ethological studies; as bioreactors to produce fluids or bodily parts which contain therapeutic substances
for human beings (i.e., “gene-pharming”); and as sources of cells, tissues, and
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organs for human transplantation. Although the capturing, handling, transporting, confining, and breeding of animals are relevant parts of the practice
of animal experimentation, they are not explicitly indicated in many laws as
animal experiments. This constitutes a problem because these practices cause
major distress in animals. Furthermore, the act of breeding animals for scientific purposes, which has become unavoidable (with rare exceptions), since
it ensures the standardization and reproducibility of experimental results (cf.
Ferrari, 2008), must be considered an ethical issue. In the practice of animal
experimentation, individuals are materially formed in their identity as experimental living beings. These animals are often born with specific characteristics suited to scientific experiments (see Linzey and Linzey, 2015). The fact that
breeding is not classified as an animal experiment affects the perception of the
suffering and the number of animals used for research. For example, in experiments that make use of genetically altered animals, many individuals are used
for the realization and maintenance of a, so-called, transgenic animal line, and
are not counted in the statistics. Furthermore, many transgenic lines are bred
in commercial facilities to be ready for use, so that scientists can order them
from a catalogue.
This chapter offers a framework for building a convincing critique of animal
experimentation. In order to do so, it first explores the framework that justifies
animal experiments in the current debate, which relies both on scientific and
ethical arguments. It then analyzes the main arguments developed to oppose
animal experiments, in terms of epistemic and ethical arguments. Although
valuable, these arguments present some pitfalls when considered separately.
The chapter concludes that a convincing critique of animal experimentation
must be political.
2

How Is the Practice of Animal Experiments Currently Justified?

Although animal experiments are carried out all over the world, in most cases
their use is not mandatory. Their main goal is to protect human beings, though
protecting non-human animal health and the environment are also goals. This
chapter presents the argument that the obligation to perform animal experiments comes from a commonly accepted experimental culture, which is justified on the basis of ethical and epistemic arguments relating to human gains.
In the writings which justify animal experiments, often the need to protect
human safety is of primary concern. The apparent unavoidability of animal
experiments is explained, first through reference to historical arguments and,
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second, through the irreducibility of, so-called, in vivo experiments to other
methods (e.g., in vitro, in silico, or computer modelling). For example, the Royal
Society (2004) has argued that almost every medical achievement in the twentieth century relied on the use of animals in some way. The German Research
Foundation (dfg, 2016), in its paper on animal experiments, maintains that
even sophisticated computers are unable to model interactions between molecules, cells, tissues, organs, organisms, and the environment. It is argued that
animal experiments result from a cost-benefit-analysis, in which the costs for
animals have to be balanced with the benefits for the protection of human
health and the environment.
The Principles of Humane Experimental Technique (Russell and Burch, 1959)
is one of the first documents on the ethical rationale of animal experiments
and has become a milestone in the politics of alternative methods. Russell
and Burch formed the basis for a new applied science that would improve or
substitute the treatment of laboratory animals, while advancing the quality
of science in studies that use animals. They claimed that this science must be
inspired by the three principles of replacement, reduction, and refinement with
regard to the use of animals. It is important to note that Russell and Burch’s
intent was ethical, but their methods were descriptive and empirical, not normative. Russell and Burch were inspired by the goal, stated by the Universities
Federation for Animal Welfare (ufaw) in the United Kingdom, to promote, socalled, humane behavior, consisting of reducing pain and fear inflicted upon
animals (Tannenbaum and Bennett, 2015). The method of replacing, reducing,
or refining the use of animals in studies was defined as an empirical approach.
According to this method, inhumanity was associated with physical or psychological distress, unnecessary or avoidable pain, fear, stress, anxiety, and bodily discomfort. However, for Russell and Burch, the goal of lessening distress
(inhumanity) in scientific procedures was always subordinate to the goals of
conducting science and achieving scientific and medical progress. Russell and
Burch, indeed, were not criticizing the use of animals in research as such, but
promoted methods to reduce and, whenever possible, eliminate animal distress consistent with the conduct of sound science. Although the concept of
alternatives was not present in their 1959 book, the 3Rs have been the foundation for the development of alternative methods, which were formally introduced by Smyth (1978) in Alternatives to Animal Experiments (see Tannenbaum
and Bennet, 2015). Smyth defined an alternative as any change in experimental
methods that results in the application of the 3Rs. Since then, there has been
an ongoing debate on the different definitions of these principles and how to
apply them to scientific procedures (see e.g., Tannenbaum and Bennett, 2015);
but the core of the message remains in favor of animal experiments. Indeed,
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more recently, Russell described the word alternative as “unfortunate” because
it suggests only 1R (Russell, 2005).
The justification of animal experiments has been explained in the clearest
and strongest manner in the case of biomedical research. One of the most
quoted documents is the Nuremberg Code, which followed the Nuremberg
Trials after World War ii. The Nuremberg Code states that, “The experiment
should be so designed and based on the results of animal experimentation and a knowledge of the natural history of the disease or other problem under study that the anticipated results will justify the performance
of the experiment” (Shuster, 1997, p. 1436). Another widely used document
is the Declaration of the World Medical Association on the Ethical Principles
for Medical Research Involving Human Subjects, first formulated in Helsinki in
1964 (World Medical Association, 1964). This Declaration was formulated as
a response to the monstrous threats to humanity during World War ii, and
it defined the role of animal experiments prior to human exposure: “Medical
research involving human subjects must conform to generally accepted scientific principles, be based on a thorough knowledge of the scientific literature,
other relevant sources of information, and adequate laboratory and, as appropriate, animal experimentation. The welfare of animals used for research
must be respected”. Now known as the Helsinki Declaration, it establishes the
ethical obligation to carry out animal experiments when results from these
experiments are necessary and unavoidable at a given time by the scientific
community.
In 2010, inspired by the Helsinki Declaration, which changed the landscape
of human experimentation, a group of scientists (approximately 4500 individuals, at the time of writing) formulated the Basel Declaration (2010) “to further
advance the implementation of ethical principles such as the 3Rs whenever
animals are being used and to call for more trust, transparency and communication on the sensitive topic of animals in research”. The Basel Declaration
states the necessity of animal experiments to meet fundamental scientific
challenges (such as human and non-human animal diseases and protection of
the environment), and that the necessity will remain in the foreseeable future
for biomedical research. The first principle of the Basel Declaration is “to respect and protect the animals entrusted to us and not inflict unnecessary pain,
suffering, or harm to them by adhering to highest standards of experimental
design and animal care”. This is very similar in scope and intent to the 3Rs.
The principles that follow provide specific care in particular scientific practices, such as the creation and use of genetically modified animals or the use of
animals in education (Basel Declaration, 2010). The German Research Foundation (dfg) explains the ethics of animal experimentation through, so-called,
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patho-inclusive ethics, which they define as follows: “It is not only reconcilable
with valuing human interests over those of sentient animals but also with the
position that other human interests, such as life and health, knowledge gain,
and pleasure may justify causing distress to animals. Moreover, this view does
not preclude the killing of animals, but it does demand that the killing should
not cause fear or suffering, if possible” (dfg, 2016, p. 43).
In these texts, the argument that justifies animal research relies on the
ethical obligation of a profession, which considers the performance of animal
experiments the best scientific standard. In other words, the standard of accepting and promoting some animal experiments is described as a scientific
standard, since animal experiments are considered the epistemically best way
to achieve certain goals. In addition, the commitment of maintaining good
animal welfare is an ethical concern but always subordinate to that of the best
science. However, it is not only the professional obligation of scientists to use
the best standards at a given time which justifies animal experiments. The professional obligation is based on a more general framework on human-animal
relationships, which is anthropocentric at its core. It is a form of (unqualified)
speciesism, i.e., the unjustified disadvantageous treatment or consideration
of those who do not belong to, or are not categorized as belonging to, a certain species (or group of species). Richard Frey (2005) refers to this position
as guided by the “argument from benefit” that is derived from utilitarianism,
which justifies the infliction of pain on animals to serve different goals, and is
combined with speciesism, which states that a species belonging (i.e. human)
justifies a different ethical treatment. Indeed, in the case of animals, the costbenefit-analysis is accepted; whereas, in the case of humans, it is not: “utilitarianism for animals, Kantianism for people,” as Nozick (1974, p. 39) put it. Cohen
(1986) offers a similar defense for animal experiments. Contesting the idea of
animal rights because animals lack the capacity to make moral claims, Cohen
has argued that we have a strong duty to conduct such experiments to alleviate
human suffering and extend human lives.
In summary, defense of animal research is derived from a combination of
scientific reasons (the best possible standard at a given time), the ethical obligation of scientists as a professional community (to respect the best possible
standards), and speciesism. Although the arguments for animal experiments
are accepted by many in society, particularly in terms of regulations and experimental practice, arguments against animal experiments have a long history
and have been articulated in different texts and campaigns worldwide. The
following sections distinguish between two main arguments against animal
experimentation, epistemic (also called, epistemic antivivisectionism) and ethical (also called, ethical antivivisectionism).
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The Epistemic Critique of Animal Experiments

At the core of the epistemic critique of animal experiments is the idea that
such experiments are bad science. Bad is used as a synonym for inefficient, scientifically wrong, or misleading. This kind of critique has a long history. Between the third and fourth centuries, bce, the empiric school of the Ancient
Greek rejected the study of anatomical and physiological vivisection, due both
to its cruelty and the belief that pain and death would distort the normal appearance of internal organs. In more recent times, some animal welfare and
animal rights organizations and philosophers have used examples from the
history of biomedical experimentation, and retrospective studies on the influence of animal experiments in human medicine, to criticize the practice. The
Italian philosopher, Croce (2000), coined the term, scientific antivivisectionism
(antivivisezionismo scientifico), as a rejection of the idea of the transferability
of results from one species to another. According to this rationale, modern
animal models are of limited use and can even be dangerous because the data
produced are not easily translatable to humans (Croce, 2000; Gericke and Reinke, 2011; cf. Pappworth, 1968).
For LaFollette and Shanks (1996) and Greek and Greek (2003) the idea of
the unavoidability of animal experiments is misleadingly taken as the “gold
standard” within the scientific community. At the center of this critique is the
deconstruction of the claim that animal experiments in biomedicine are predictive of human conditions. LaFollette and Shanks (2004; 2006) provide a critique of the use of animal models based on evolutionary theory. They observe
that phylogenetically related animals have different mechanisms to achieve
the same biological functions, a phenomenon they call “causal-functional
asymmetry”. This phenomenon renders cross-species extrapolations as causal
explanations impossible. Knowledge of relevant causal differences, i.e., causal
dis-analogies (with respect to mechanisms and pathways), which compromise the usefulness of analogical reasoning, is necessary; however, this knowledge is only possible retrospectively, once a property has already been tested
on different species. LaFollette and Shanks (1996) argue that the defense of
animal experimentation relies on a scientifically misleading interpretation
of the epistemic role of animal models in biomedical research. They explain
that this defense is a product of Claude Bernard’s legacy, which is based on
a hypothetical-deductivist method in biomedicine, coupled with a rejection
of statistical laws. Bernard assumed that clinical medicine (including epidemiological studies) could never be a genuine science and believed in the interchangeability of species to test clinical hypotheses (LaFollette and Shanks,
1996).
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The argument defending the unavoidability of animal experiments is based
on the confusion between what are known as causal-analogic models (cams)
and hypothetical animal models (hams). Historically, some animal experiments were consistent with hypothetical-deductive methods, in that they were
useful to gain knowledge. However, in the present day, with scientific and technical advancements in alternative methods, the potential of molecular biology
(together with proteomics and genomics, among others), as well as computer
models, animal models have become obsolete and poor scientific practice.
As a result, scientists who promote animal models are not adhering to good
scientific practice, and continued use of animal models may prevent the attainment of human-relevant results. This critique is apparent in the current
debate on the promotion of alternative methods within regulatory toxicology.
For example, Hartung (2013) has spoken of “toxic ignorance” and the necessity
for a paradigm shift in the twenty-first century that moves away from animal
use and embraces new non-animal technologies.
The epistemic critique of animal experiments is supported by considerable
literature from retrospective studies, which have established the poor clinical value of animal models (Pound et al., 2004). Though beyond the scope of
this chapter, this literature reaches a sobering conclusion that, in many cases,
animal experiments show poor methodological quality, problems with evaluation, and limitations of false-positive or false-negative results. Furthermore,
there is a visible lack of consistency between the results of animal models and
clinical trials, as well as a significant lack of transferability of results (Akhtar,
2015; Knight, 2011). This demonstrates the need for a retrospective evaluation
and critical appraisal of the benefits of animal experiments to facilitate a paradigm shift towards non-animal and human-relevant approaches.
4

The Ethical Critique of Animal Experiments

The ethical critique of animal experiments is derived from reflection on the
moral status of animals as sentient beings: animal experiments impose suffering and death, so that the animals’ interests are systematically violated.
Hence, this practice is not justified, regardless of its “utility”. This kind of critique can be traced to the seventeenth and eighteenth centuries, when a rise
in movements opposing cruelty to animals occurred, and men of letters in
England denounced the brutality of animal experiments and openly opposed
the Cartesian view of animals as automata (Maehle, 1990). The ethical critique of animal experiments explicitly denounces speciesism: “There is only
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one serious moral defense of vivisection. That defense proceeds as follows.
Human beings are better off because of vivisection. […] One thing should be
immediately obvious. The benefits argument has absolutely no logical bearing on the debate over animal rights. Clearly, all that the benefits argument
could possibly show is that vivisection on nonhuman animals benefits human
beings. What this argument cannot show is that vivisecting animals for this
purpose is morally justified. Whether animals have rights is not a question
that can be answered by saying how much vivisection benefits human beings”
(Regan, 2004, p. 174).
The ethical critique attacks the cost-benefits of the animal model in two
ways: first, the thesis of inviolable animal rights (right to life and prohibition
of the infliction of suffering) intrinsically excludes the institutionalization of a
cost-benefit calculation (see Donaldson and Kymlicka, 2011). Second, because
the ethical critique denounces that in animal experiments two incomparable
magnitudes are compared: the direct, intentional, present infliction and killing
of animals and the elaboration of methods to reach future anticipated knowledge that can principally serve to protect humans. In other words, a conflict
situation is constructed. Such attempts are part of a long-term strategy for the
further development of scientific goals (Wolf, 1988), by which (perhaps) the
suffering of some persons (or some animals) can be prevented; and they cannot, therefore, be viewed as a conflict of interest. In the institutionalized practice of animal experiments, animals are born to be experimental tools, they are
bred for a purpose, and their biological nature is formed through the identity
given to them by human use. If we recognize animals as bearers of fundamental rights, we cannot permit the institutionalization of a cost-benefit measure
that violates their life and causes them suffering. The practice of animal experimentation is intrinsically unethical as it forges animals’ identity, puts them
in confinement, restricts their species-specific traits, and kills them.
5

The Strengths and Pitfalls of the Epistemic and Ethical Critiques

Both the epistemic and the ethical arguments have a long history in the critique of animal experiments. However, to facilitate a paradigm shift towards
ending animal experiments, one must understand the weaknesses of these
approaches. The epistemic critique of using animals strikes the scientific justification of animal experiments at its core, because it argues that these methods are simply not the best scientific standards at a given time. The rejection
of professional standards is a strong claim because, as previously explained,
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the argument in favor of animal experiments is built on professional ethics, in
which ethical obligations are derived from epistemic standards. However, in
an anti-speciesist framework, the apparent force of the epistemic argument
becomes a weakness. The epistemic critique is often too general and runs the
risk of making the same mistake as its opponents. There are cases in which
knowledge can be transferred from animals to human beings. Since this critique contests a pro-animal experiment position on an empirical level, it runs
the risk of failure in cases that animal models may be valuable. LaFollette and
Shanks’ (1994) critique of the predictability of animal models is based on biomedical research; however, when applied to the field of basic research, as well
as cases of species-specific veterinary medicine, their argument is weaker (LaFollette and Shanks, 1996). The experimental system in basic research centers
on discovering new fields and new uses of knowledge. This characteristic, on
the one hand, can permit the elaboration of more complex alternative methods that mimic dynamics and biological properties in efficient ways; however,
on the other hand, it also leads to the establishment of new fields and new uses
attached to animals.
The second problem with the epistemic critique to animal experiments is
that the rejection of speciesism appears to be subordinate to the argument of
utility. The epistemic critique is directed towards the benefit side of the costbenefit-analysis but not the analysis in itself. The largest part of intended benefits is human gain. As previously discussed, the protection of human health
is the highest priority in the justification of animal use. Therefore, when discussing animal experiments with a rationale, it is close to impossible to reject
them. It is important to note that scientists often acknowledge the limitations
of their work and express rather modest claims in terms of the applicability of
the outcomes of their studies. Nevertheless, they maintain that animal use is
necessary and important.
The ethical critique of animal experiments offers a strong case against animal experiments, because it refuses to use a cost-benefit model, which prioritizes human gains. However, the ethical critique is, at times, accused of not
explicitly addressing the potential loss of knowledge from renouncing animal
experiments. This is apparent in the accelerated development of non-animal
alternatives since the European ban on cosmetic testing on animals: “Past experience demonstrates clearly that animal testing provisions in the cosmetics
legislation have been a key accelerator in relation to the development of alternative methods and have sent a strong signal far beyond the cosmetics sector
and far beyond Europe” (European Commission, 2013, p. 6). The human spirit
is creative and to renounce particular strategies encourages other pathways of
discovering and working.
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Conclusion: For a Political Critique of Animal Experimentation

Why are animal experiments considered by some as fundamental and important even though they have limitations? It is impossible to answer this
question with reference to empirical results alone. This question is more relevant to values and social goals. The praxis of animal research, of each kind
of experimental practice, is a practice in a given time and space in society,
and it is a reflection of epistemic and ethical values. Scientific practices are
not free of ethical values because: (1) they use limited cognitive and financial resources (and thus it is always a matter of choice in which direction
these resources should go); and (2) research activities reflect our values; that
is, what we are willing to do in a society, what we consider as an acceptable
means to reach an end. When we accept the infliction of pain on and killing
of sentient beings, we embrace these values as a society. This is apparent in
the justification framework of the Declaration of Helsinki. Since the carrying
out of animal research is a matter of a professional ethics (despite the possibility of adjustments if, for example, the experiments are not designed properly),
once these experiments meet current scientific standards, it is more difficult
to criticize them. Therefore, as long as the infliction of harm on animals is
justified, as long as animals are ontologically thought of as “research tools”,
animal use continues. Thus, overconfidence in animal experiments as scientific
techniques is profoundly linked with an instrumental view of animals and life
in general.
The fundamental decision on the acceptability of the infliction of suffering
and the killing of animals is a reflection of a social order and, of course, not
solely a matter of empirical evidence. As a result, the necessity or inevitability
of a scientific experiment is always a product of decisions and negotiations in
a society. In the case of human clinical trials, there are also considerations of
possible benefits and costs (in term of risks for the patient); but the situation
is fundamentally different because the life and well-being of human beings is
considered more significant than those of animals. For example, in the ethical literature about human clinical trials, the language used to contest some
experiments is fundamentally different, and it often refers to vulnerabilities
and possible abuses of particular populations and groups. The vulnerability of
animals, in contrast, is simply taken for granted in the experimental system.
Inasmuch as the idea of human exceptionalism is a political idea (ideology),
the possibility of strictly distinguishing epistemic reasons from ethical reasons
permits a division of moral labor (e.g., “I conduct science and do not engage
with ethical problems, it is not in my field of expertise”), which is highly problematic and, therefore, rejected for human clinical trials.
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The dispute on animal experiments cannot be a dispute on (objective) benefits; it is a dispute on what we as a society want to justify as practices and how
we treat the living beings who are a part of it. Science and its practices are a
social project. Can humankind benefit from animal abuse? This fundamental
political nature of the category of necessity calls for a political critique of animal experiments, a critique that combines both the ethical and the epistemic
critical arguments, acknowledging the non-neutrality of scientific decisions.
An ethical critique to animal use is weaker, if it is not combined with a critique of the system of experimentation, i.e. the epistemic culture of animal
experiments. At the same time, the epistemic critique should free itself from
the reference to the category of utility as if it were solely a matter of scientific
evidence; resulting in an impasse in front of scientific papers which recognize
the limitations of animal models and their perceived importance at the same
time, depending on the mechanisms investigated. As previously noted, the
choice of renouncing animal experiments in favor of non-animal methods is
fundamentally a political choice; this choice should be accompanied by the
development of infrastructures and programs to serve as incentives for scientific advancement, and by a new ethos of the scientific community. While
these needs have been previously recognized by authors defining animal use
as poor science (e.g., LaFollette and Shanks, 1996; Greek and Greek, 2003), it is
also important to recognize the political nature of the category of necessity in
the experimental practice.
A political critique of animal use strives to substitute the epistemic and
ethical culture of animal experiments with a culture of compassion and solidarity, independent of the species-belonging. A political critique of animal experimentation rejects the fundamental subjugation of animal interests “just
because they are animals” and openly argues for the establishment of a different ethical culture. In order to be effective, the political critique must admit
that it is necessary to give up certain pathways to knowledge while, at the
same time, establishing a system in which it is possible to research and develop technologies without violating the fundamental interests and rights of
animals.
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1

Introduction

The use of non-human animals (hereinafter referred to as animals) in research
and testing is a widely accepted practice in many industries. Millions of animals each year are subjected to painful procedures that include everything
from physical mutilation to drug addiction. According to the United States
Department of Agriculture (usda), over 820,812 animals were experimented
on in the United States in 2016 (usda, 2017), though this count does not include rats, mice, or birds, and dubiously relies solely on the self-reporting of
laboratories (Humane Society of the United States, 2011; Keen, 2019, Chapter
10 in this Volume). Estimates suggest that a more accurate count – one that
includes rats, mice, and birds – brings the number closer to 25 million total
animals used in the United States (Humane Society of the United States, 2013).
These numbers raise many questions, not least of which is whether this practice is prima facie immoral. But this is not the broader question that I address
in this chapter. Instead, I look at the continued use of animals for experiments
from the point of view of business ethics, in particular, through the lens of
stakeholder theory. Specifically, I argue that animals as research subjects are
stakeholders in the corporations that practice animal experimentation, and
this status demands that their interests be considered with the interests of
other stakeholders.
Importantly, while this chapter discusses issues of interest to a broader philosophy audience, it is, nonetheless, situated in a volume whose purpose is, in
part, to motivate practical paradigm change in the way that animal advocates
think about their work. Not unlike other scholars, my own work is shaped by my
personal experiences: I am a philosopher by training and an animal advocate
outside the walls of the academy, so my concern for animals is both theoretical
and pragmatic. As such, the practical import of this chapter speaks most obviously to people like me, i.e., advocates who are also academics. In p
 articular,
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arguing for the stakeholder status of animals in research corporations gives
advocates (both academic and traditional) a new tool to use in the fight for the
proper consideration of animal interests. It brings the c onversation—in an organic and relevant way—to a group of people who would have likely remained
uninformed of the issue, and offers defenders of animal interests the opportunity to employ a general method of advocacy that has historically been very
successful.
The argument in this chapter proceeds as follows. To begin, I discuss the
broad and narrow interpretations of the stakeholder view, and I argue that the
narrow view offers a more practical framework for making business decisions.
Following this, I will show that, while no iteration of stakeholder theory ever
directly identifies animals as stakeholders, the inclusion of research animals
in this category is as self-evident as the inclusion of employees; minimally,
this demands that the moral manager properly considers the interests that research animals have in not suffering. I then contend that if research animals
really are stakeholders, and if their interests really are more urgent than the
interests of other stakeholders, then the presumed legitimacy of animal experimentation needs to be reevaluated. Finally, in the last section i offer some
responses to three potential objections to the arguments put forth in this chapter. Ultimately, I conclude that, from the point of view of stakeholder theory,
animal experimentation, especially when it inflicts suffering on animal subjects, is not justifiable.
2

Narrow and Broad Interpretations of the Stakeholder View

Stakeholder theorists claim that the purpose of the corporation is to harmonize
the interests of the stakeholders, though there is not widespread agreement on
how to identify stakeholders (Goodpaster, 1991, p. 66). Indeed, Mitchell et al.
(1997) have catalogued 27 different conceptions of the stakeholder, including
some of the following:
A stakeholder is/stakeholders are:
– a person or group, “which the organization is dependent on for its continued survival” (Freeman and Reid, 1983, p. 91; Mitchell et al., 1997, p. 858)
– a person or group, “that benefit[s] from or are harmed by, and whose rights
are violated or respected by, corporate actions.” (Evan and Freeman, 1988,
p. 79; Mitchell et al., 1997, p. 858)
– “constituents who have a legitimate claim on the firm […] established
through the existence of an exchange relationship” and who supply “the
firm with critical resources (contributions) and in exchange each expects
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its interests to be satisfied” (Hill and Jones, 1992, p. 133; Mitchell et al. 1997,
p. 858)
– a person or group “having some legitimate, non-trivial relationship with an
organization [such as] exchange transactions, action impacts, and moral responsibilities” (Brenner, 1993, p. 205; Mitchell et al., 1997, p. 858)
– “the firm is significantly responsible for their well-being, or they hold a
moral or legal claim on the firm” (Langtry, 1994, p. 433; Mitchell et al., 1997,
p. 858)
– and “persons or groups with legitimate interests in procedural and/or substantive aspects of corporate activity.” (Donaldson and Preston, 1995, p. 85;
Mitchell et al., 1997, p. 858).
The most frequently cited stakeholder theorist, Edward Freeman (1984), describes a stakeholder as "any group or individual who can affect or is affected
by the achievement of the organization’s objectives” (p. 46). Of course, like
many of the others, this definition is vague, and much is left to interpretation.
But, broadly construed, this definition commonly includes the government,
the environment, and many third-party associations (e.g., the suppliers of a
supplier), in addition to the commonly recognized stakeholder groups: owners, suppliers, employees, customers, and local community. On this, the wide
interpretation, the category of stakeholder is quickly rendered unruly and insignificant, as it can be expanded to include just about any person or group
(for the origin of this distinction, see Freeman and Reed, 1983). As Orts and
Strudler (2002, p. 218) note, “virtually anyone and anything can ‘affect or be
affected’ by the decisions and actions of business enterprise. Expansive views
of relevant ‘stakeholders’ tend easily to become so broad as to be meaningless
and so complex as to be useless.” Clearly then, we are in need of a refined understanding of the concept of stakeholder.
One such definition proposes that stakeholders be identified as those
groups, “who are vital to the survival and success of the firm” (Evan and Freeman 1998, p. 58), or who are “definitional to the firm” (Freeman et al., 2002, p.
31). According to this narrow view, stakeholders are much easier to identify,
thus, making this view more workable from a management standpoint. Surely,
though, one might argue that by limiting the account of stakeholders to the
narrow interpretation, we risk overlooking groups and entities that deserve
consideration when business decisions are made. But, importantly, stakeholder status is not the sole identifier of moral considerability. For example, Orts
and Strudler (2002, p. 221) state that businesses have moral obligations to obey
the law, even if it conflicts with stakeholder interests.
Of course, neither the narrow nor the wide view of stakeholder identification is without its difficulties. The most obvious difficulty, for both, is that
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r egardless of how stakeholders are identified, complications arise in balancing
the claims and interests of the various stakeholder groups, as stakeholder identification alone does not address which claims or interests are the most important, at what time. Nonetheless, going forward, I adopt a narrow interpretation
of stakeholder identification, as the broad view renders the moral manager
impotent in their decision-making. Indeed, the narrow view is most widely
defended by stakeholder theorists and is most widely adopted by managers
(e.g., see Mitchell et al., 1996, and references therein). Even so, it is not the
purpose of this chapter to defend one conception of stakeholder identification over another. Rather, my goal is much less lofty: it is simply to show that
even according to the narrow conception of stakeholder (and so presumably
also the wide conception), animals who are experimented on can be properly
construed as stakeholders in the corporations that conduct these experiments.
As such, their interests cannot be disregarded.
3

Research Animals, Stakeholders, Suffering, and Compassion

3.1
Research Animals as Stakeholders
As noted, the narrow interpretation of stakeholder restricts stakeholders to
those groups “who are definitional to the firm” (p. 31, Freeman et al., 2002).
This interpretation is commonly thought to include customers, suppliers, financiers, employees, and parts of the local community. However, given the
fact that many businesses rely heavily on research animals to bring products
to market, then these animals are very likely stakeholders too, analogous to
suppliers and/or employees. Consider, for instance, the use of animals in the
Draize eye irritancy test, an experiment that is used by an array of companies
to evaluate how irritating a particular substance is. (Notably, the use of this
test has decreased, as it was banned for use in cosmetics testing in the eu,
India, Israel, and New Zealand, though it is still used quite often in the us and
elsewhere (Cruelty Free International, 2017). In this test, animals (typically
rabbits) may be unable to move for days while chemicals are applied to their
eyes, and usually the animal subjects are given no more than a topical anesthetic, so long as it does not interfere with the experiment. Sometimes these
tests result in infection and/or tissue damage that is so severe that the animal
is rendered blind (Humane Society International, n.d.). If these animals cannot be re-used in future tests (because of the damage done by previous tests)
they are killed, usually by being suffocated, having her neck broken, or by being decapitated (Humane Society of the United States, 2018). Without the information this test supplies, many companies would be unwilling or unable to
bring their p
 roducts to market. Therefore, it may be said that the animals on
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whom the Draize test and other such tests rely are central to the successes of
the companies that depend on these practices.
Like human employees, research animals offer a very specific type of labor,
without which the company would potentially suffer severe financial penalties. These animals are sometimes subjected to painful tests for years at a time
without any form of relief or compensation. They are forced to give their freedom, their health, their well-being, and their lives to these companies. And like
the suppliers of a company, animal subjects of experimentation provide the
business with the raw materials and services that it needs to make its product;
but in the case of the laboratory animals, the materials that are being supplied
are the bodies and lives of the animal subjects. Without these “materials”, companies would not be able to perform the Draize tests or similar experiments.
As such, research animals are stakeholders, even on the narrow conception, in
the companies that use them. They are, like an employee or supplier, integral
to the operations of the firm, and so, accordingly, their interests must be considered as any other stakeholder’s interests would.
Importantly, establishing that research animals are stakeholders does not
help in the identification of the relevant interests deserving of consideration,
nor does it tell us how to balance these interests against other stakeholder
claims; though, to be clear, this ambiguity does not mean that we are justified
in subordinating non-human animal interests to human interests. There are
likely to be many workable routes for identifying and managing stakeholder
interests, but for brevity, I focus on one possible way to identify the interests
that matter in this context, and I will likewise propose one way that we might
commensurate the interests of competing stakeholder groups.
3.2
Commensurating Stakeholder Interests: Suffering and Compassion
The phrase to have an interest means that something (A) has welfare or
well-being, such that, “having or doing X would (or we think it would) benefit A, that having or doing X would make a contribution to A’s well-being”
(Regan, 1983, p. 88). Based on this understanding, animals, at the very least,
have a basic and fundamental interest in not suffering, and they probably also
have interests in enjoying their lives and avoiding untimely deaths (though,
for the purpose of this chapter, I refrain from relying on the latter two). The
interest in not suffering is, as Singer and Bentham point out, a prerequisite
for having any other interests, and so it is prior to and more urgent than any
other interests (Singer, 2002, p. 7). This establishes one possible way to balance stakeholder interests: the more foundational and urgent the interest, the
more heavily it is weighted. To be sure, the experiments that animals are subjected to in research laboratories are directly and obviously contrary to their
interest in not suffering. Furthermore, given the fundamental nature of this
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interest, and the systematic way in which it is violated, its proper consideration is likely much more urgent and pressing than the consideration of other
legitimate stakeholder concerns and so should be prioritized by the decision
maker.
Of course, it might be argued that engaging in medical research in which animals are used as test subjects helps us to take account of a sick person’s interest in not suffering, an interest that may be just as urgent as the interest of the
laboratory animal. Let us assume for the sake of argument that this is true, i.e.,
that medial research on animals is the only way in which the cures and treatments for some illnesses will ever be discovered. If this is the case, then when
we choose not to engage in animal research, are we then also choosing to ignore
the interest that sick people have in not suffering? Put in the context of business
ethics, the moral manager may be torn between causing suffering to animals
and potentially preventing suffering that would otherwise happen to h
 umans,
and refusing to impose suffering on animals but allowing sick people to suffer. This is a complex moral issue, but one possible way to navigate through
this terrain is to think about those qualities that we would expect the moral
manager to have and then explore how those qualities may direct them in this
situation.
Surely, one important quality of the moral manager would be compassion.
Indeed, Solomon (1999, Chapter 3) lists compassion as one among many of
the business virtues, explaining that the directive of compassion is to relieve
suffering: “Within the corporation, compassion is often called for […] Compassion, of course, can be expensive […] but what is less obvious is the enormous
expense of not having or expressing compassion, in further lost time and the
distraction that comes of suffering through hardship alone, in the insecurity
and consequent lack of devotion of not only the employee in question but
of everyone around, in seething resentment. Compassion, like caring, is not
merely a humanizing embellishment in the otherwise businesslike life of a
corporation. It is essential to the very life of that corporation as a human community.” While Solomon beautifully articulates the importance of compassion
towards employees as humans, notably absent from this characterization is
concern for animal suffering. It is unclear how Solomon thinks that the moral
manager should consider animals’ interests in not suffering, but regardless of
Solomon’s own position, the principle of equality requires that, “suffering be
counted equally with like suffering—in so far as rough comparisons can be
made—of any other being” (Singer, 2008, p. 37). This is a basic principle of fairness, and to violate it on the basis of one’s race, gender, or even species would
be arbitrary and wrong. Therefore, the moral manager should be concerned
not just with the suffering of the humans in their corporate community, but
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also with the animals in their corporate community; this is what fairness and
compassion demand.
So, the question is now: Can the virtue of compassion help us to mitigate
the conflict between the human interest in not suffering and the animal interest in not suffering, as described above? I think so. Consider this dilemma, as
explored by Simmons (2016, p. 113):
What is the compassionate thing to do in this case? It seems ambiguous
since one can be compassionate to humans by promoting their interests
in continued life. I contend, however, that to refrain from killing animals,
even at the potential cost of failing to benefit human health, is the more
fully compassionate thing to do. To kill animals in order to save human
lives entails offensively (i.e., aggressively) and intentionally causing harm
to others without their consent. Indeed, it is an act of aggression, violence, and domination, even if done to help others […] [T]o intentionally,
offensively inflict harm on another shows, to some degree, a lack of concern for the other’s welfare […] On the other hand, to refrain from killing
animals, at the potential cost of not saving human lives, need not show
any lack of concern for human welfare. It is not offensively causing harm
to humans; it is merely failing to help them.
Importantly, Simmons (2016) argues that failing to mitigate the harms suffered
by the humans that result from their diseases is not actually the result of moral
indifference, nor the result of intentionally wanting the humans to suffer. Instead, “A fully compassionate person aims to prevent harm to individuals but
will not offensively, intentionally inflict harm on others in the process of doing
so” (p. 114). If Simmons is correct, then the moral manager will not allow the
infliction of suffering on animals for the sake of preventing human suffering.
Of course, the case above assumes that there will always be a conflict
between the animal interest in not suffering and the human interest in not
suffering. But, this is a false dichotomy. This supposed conflict rests on two
assumptions: first, that medical research nearly always results in cures or treatments that can effectively alleviate human suffering; and second, that the relief of human suffering can only be achieved by inflicting suffering on animals.
Neither of these assumptions is valid. Research has actually shown that animal
experiments done with the purpose of extrapolating results relevant to human
health are notoriously ineffective. Pharmaceuticals tested on animals have a
90% failure rate (Pharmaceutical Research and Manufacturers of America,
2015; 2016); this means that they are certified safe from animal studies, then
fail in human clinical trials or once they reach the market. Additionally, there
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are many non-animal testing methods that can be used in place of animal experimentation. These include, but are not limited to: epidemiological studies
(studies of human populations); clinical research; bioinformatics (statistical
evaluation of biology); systems biology (studies of interaction between biological systems); tissue engineering (a combination of engineering principles
and biology); microfluidics (organ on a chip); in vitro (human cell and tissue
cultures) research; in silico (computer-based) techniques; stem cell methods;
genetic methods; advanced imaging technologies; and safe human-based studies (see Chapters in Part 7 in this Volume: Hartung, 2019; Noor, 2019; Taylor,
2019; Wilkinson, 2019). As such, there are ways to relieve human suffering that
do not demand that we inflict suffering on animals. We can conclude, then,
that it is unlikely (though not impossible) that the interest humans and nonhuman animals have in not suffering will not conflict as obviously or as regularly as commonly thought.
3.3
Summary
In this section I have argued that, by definition, research animals can be categorized as stakeholders in businesses that engage in animal experimentation
or testing. In most cases of animal experimentation, the interest being violated
is the animal’s interest in not suffering, an interest that is, more often than not,
more urgent than the interests of competing stakeholders. And, furthermore,
in taking the virtue of compassion seriously, the moral manager can mitigate
conflicts that arise between two groups of stakeholders that may both have
an interest in not suffering; in particular, compassion demands that we do
not intentionally cause harm to one group, even if we do it to prevent harm
to another group. As such, stakeholder theory demands that, at a minimum,
managers have a moral imperative to stop animal experimentation that inflicts
suffering on animal subjects.
4

Objections

In this final section, I address some potential objections to my argument.
Objection 1: Aren’t There Laws in Place that Already Protect the
Interests of Animal Subjects?
Those familiar with the practice of animal experimentation may be tempted to claim that advocating for the interests of animals as stakeholders is
unnecessary, since there are already laws and regulations in place that serve
4.1
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to protect the interests of animal subjects. One such law, in the us, is the us
Animal Welfare Act (awa) (1966, last amended 2013). In fact, the awa does set
minimal requirements for the care of certain animal species used in laboratories, ensuring that they have water, food, and shelter. Even so, these minimal
standards fail to adequately protect an animal’s interest in not suffering; and
further, simple adherence to the awa is not an appropriate tool for gauging if
an animal’s interest in not suffering has actually been respected. To begin, the
Act only demands adequate food, shelter, and water be provided outside the
demands of the experiment; that is, as a matter of experimentation, animals
can be denied these things and, worse, for sustained periods of time. Indeed,
it is not uncommon for animals to be subjected to radiation exposure; shock
therapy; exposure to nerve gas; mutilation; social isolation; drug overdose and
addiction; starvation and dehydration; oxygen deprivation; surgery without
anesthesia; poisoning; induction of psychopathology, including depression (in
higher primates); deprivation studies; extreme temperature exposure; toxicity
tests; and immersion and injection studies (Singer, 2002, Chapter 2). Second,
the Act does not cover mice, rats, birds, or reptiles; so, these animals—the animals who comprise the majority of laboratory animals—are not guaranteed
any protections (us Animal Welfare Act, 1966, last amended 2013). And finally,
the Act presumes that experimentation on animals is actually acceptable, thus
subordinating the interests of animals from the outset, as do all similar regulations. Clearly then, simply adhering to the Animal Welfare Act (or similar rules
in other countries) does not guarantee that a company has rightfully considered the interests of its animal test subjects. As such, there is good reason to
identify research animals as stakeholders.
4.2
Objection 2: What About the Other Stakeholders?
What if taking this argument seriously meant that a company had to shut its
doors? This is an important concern, but I think we can address it by first thinking about a less controversial case. Consider a world in which multi-national
corporations that rely on child labor were forced to actually take the interests
of their child laborers into consideration, minimally, the children’s interests in
not suffering. For some corporations, taking these interests seriously may only
require making some changes, e.g., finding new laborers, relocating plants, removing some products from the market. But for other corporations, respecting
these interests may mean that they have to halt their operations completely.
Would we, should we, object to these closures? In doing so, would we not be
saying that the protection of the fundamental interests that the children have
in not suffering (among other interests) is not as important as the survival of
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the corporation? This seems to be an indefensible claim: a concern for maximizing profits does not trump all other concerns. This is not to say that the
profit interests of the other stakeholders are not important or serious, but rather, the urgency of the interests being violated in this case gives priority to the
children. Put more generally, in instances in which there is a serious and systematic violation of basic interests, we should be comfortable with the closure
of companies that rely on these violations for their continuation. This holds
whether the interests in question stem from human or non-human stakeholders, as fairness demands that we give equal consideration for equal interests.
Of course, this assumes that the animal experimentation and financial success are necessarily linked, meaning that corporations will disappear without
the ability to engage in animal experimentation. But, this is absolutely not the
case, since viable alternatives to animal testing exist or can be developed. In
fact, many companies have already moved towards this change (many were
forced in this direction as a result of the eu ban on cosmetics implemented in
2013). And even other companies have, from their inception, made it part of
their mission statement to avoid cruel animal experimentation. The continued success of such companies (and the industries in which they are situated)
shows that businesses can remain financially viable without experimenting
on animals. So, forgoing animal experimentation does not necessitate that
a business close its doors, and this means that the reduction and eventual
elimination of animal experimentation would not necessarily conflict with
the interests that the other stakeholders have in the financial success of their
corporations.
Objection 3: Why Business Ethics? (Or, What is the Practical Import of
this Argument for the Animal Advocate?)
One might wonder what value a business ethics approach to this issue offers,
given that so many moral theorists have already convincingly argued that
animal experimentation is, in most cases, wrong (e.g., DeGrazia, 1996; Regan,
1983; Singer, 2002). Likewise, animal advocates may wonder how this argument
practically advances the movement to see the interests of research animals
properly protected. As an academic and an advocate, I see these two concerns
as inextricably linked, and I strongly believe that the stakeholder approach to
considering animal interests is a tool that can be employed in the academy and
in the social/political space where traditional advocacy occurs.
Perhaps, unsurprisingly, I agree that there are many compelling arguments
that successfully condemn the practice of animal experimentation. Even so,
there are several reasons why framing this issue from the point of view of business ethics can be helpful. First, it seems quite obvious—especially in light of
4.3
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the arguments developed above—that laboratory animals are stakeholders
in the institutions that practice animal experimentation. And yet, nowhere
in the vast stakeholder literature are these particular animals referenced or
acknowledged. Occasionally, a theorist will consider the possibility of the environment as a stakeholder, and so by default the wild animals who live in the
environment become stakeholders in a way, but animals confined to a life in
a laboratory are never mentioned (e.g., Bowie, 2009; Orts and Strudler, 2002).
This seems to me a serious oversight, and so, academically, this subject deserves
consideration. But, beyond the rather obvious scholarly omission, business students are unlikely to be taught animal ethics in business school, and it is similarly unlikely that they are required to take courses in ethical theory. Instead, they
may be required to take a course in business ethics, where they study stakeholder and stockholder theory, the various forms of contracts, sexual harassment/
discrimination, and the like. These issues are undoubtedly important; however,
given the moral urgency surrounding the practice of animal experimentation,
it is likewise very important to discuss the rightness or wrongness of using animals as test subjects, especially with those who will be in a position to benefit
from the practice. Notably, discussing the morality of animal experimentation
by exploring the argument that animals are stakeholders allows, in a very natural and cohesive way, business students to think about the use of animals as
test subjects, using language and ideas that they are already familiar with and
comfortable using, and so this approach offers business students both substantive and directive guidance in considering animal interests. Furthermore, exposing business students to this way of thinking is crucially important, since, in
the very near future, many of them may be in a position to make decisions that
reflect a real moral concern for animal subjects in a way that other people will
never have the opportunity to do (there are only so many of us that will manage laboratories and the like). Thus, I see this argument as giving the academic
advocate a route to introducing concern for laboratory animals in a way that
utilizes a framework that is already accepted by the typical business student.
In addition, it is also worth noting that, historically speaking, the general
method of arguing for stakeholder status is typically a part of any successful route to having an oppressed or exploited group’s interests properly considered. Even if the technical language of stakeholder is not employed, one
way to interpret the historical inclusion of many stakeholder groups is as a
fight to have stakeholder status properly recognized. Several examples fit this
characterization, including the restriction on child laborers in the late Industrial Revolution and, more recently, the movement to properly recognize
the interests of adjunct professors at universities in the us (at some institutions, at least). In these cases and others like them, the moral arguments for
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stakeholder status preceded the adoption of legal safeguards that formalized
limits on what could be done to these groups in the name of maximizing profits. Many students of business are taught not just to respect these limits legally,
but to understand why they are so important. Indeed, many such principles
are built into professional codes of ethics and corporate mission statements,
both of which help to influence corporate cultures and set expectations for
managers. This general sort of social evolution gives us good reason to believe
that classifying animals as stakeholders can be understood as a natural extension of the principles and guidelines that many business people and corporations already adhere to and endorse, and that real protections for research
animals (as real protections for any other stakeholder group) do not necessarily have to be interpreted as completely and arbitrarily contrary to the profitability of the business.
Finally, and perhaps obviously, my argument could easily be extended to
corporations that raise animals for food or use animals in entertainment; any
use of animals for the sake of profit-making automatically qualifies them as
stakeholder, and so, as such, they should be afforded the rights and considerations of these groups. This means that the case made above will have applicability for animal advocates in ways that extend far beyond the moral and legal
consideration of animals used for research and testing.
5

Conclusion

I have argued that research animals are analogous to a company’s e mployees
and/or suppliers and can thus be considered stakeholders according to the
narrow conception of stakeholder identification. If this categorization is correct, then businesses have an obligation to consider the interests of these
animals, including, minimally, their interests in avoiding suffering. In addition, I have argued that the interest in not suffering is very likely more urgent
and fundamental than the legitimate interests of the other stakeholder groups
and so should be treated as such. Therefore, according to stakeholder theory,
corporations should refrain from using animals as test subjects, especially
when such testing inflicts suffering on the animal subjects. Moreover, beyond
offering an interesting theoretical claim, the arguments in this chapter give
advocates (both academic and traditional) a new tool to use in the fight for
the proper consideration of animal interests by making the issue relevant to
a broader audience. It brings the conversation in a pertinent and topical way
to a group of people who would have likely remained uninformed of the topic
and offers advocates the opportunity to employ a method of advocacy that
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has h
 istorically been very successful. There are, then, both moral and practical reasons for including research animals as stakeholders in corporations that
engage in animal research and testing.
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Introduction
Transparency involves communicating meaningful information (e.g.
data or details of decision-making processes) to audiences, openly and
honestly, with the intention of informing, enabling understanding and
meeting responsibilities of accountability.
yeates and reed, 2015, p. 504

It has been argued that citizen stakeholders would be well served by greater
transparency. The Transparency Register of the European Union (eu) (2016),
for example, states that “Transparency is […] a key part of encouraging
European citizens to participate more actively in the democratic life of the
eu”. But why is transparency in non-human animal (hereinafter referred to as
animal) research desirable, or indeed vital? Hadley (2012) argues that the public finance much animal research but do not know what impact their taxes
and donations have on animals. Furthermore, he suggests that, since “people
enjoy the benefits of animal research when they consume pharmaceuticals or
undergo surgical procedures that prolong or improve the quality of their lives,
it seems reasonable to inform them of the costs to animals for which their consumer choices are to some extent causally responsible” (Hadley, 2012, p. 105).
Good governance is another reason for transparency in animal research. Thus,
McLeod and Hobson-West suggest that one of the key themes “in the science
governance literature is the linking of transparency and public trust (or mistrust)” (2015, p. 792). Varga et al. concur that “more transparency will increase
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public confidence in the appropriate conduct and regulation of animal research and therefore help to maintain public acceptance” (2010, p. 500).
Some in the research community have supported increased transparency
to improve the public’s understanding of animal research and boost its acceptability. “Underpinning this idea is a belief that animal rights advocates
use public ignorance to benefit their cause. Thus, the only way to counter the
damage done to the animal research community’s public image is to increase
the lay community’s understanding of research practices” (O’Sullivan, 2006,
p. 6). In contrast, animal advocates emphasize the importance of public debate
and awareness of the reality of research animals to improve animal welfare
and to work towards an end of animal experimentation. In general, animal advocates are confident that the more the public knows about animal research,
the less it will be willing to sanction it. In their public pronouncements, then,
both researchers and animal advocates consider increased transparency to be
in their own best interest (O’Sullivan, 2006). The critical issue is what information should be available and given focus.
Most people know nothing or little about animal research. For example,
an opinion poll, commissioned by Humane Research Australia (hra) in 2013,
found that 43% of Australians were not aware that animals are used in experimental research in Australia (Humane Research Australia, 2016a). Few people who live in countries where animal experiments occur know much detail
about the numbers and species of animals used, the types of procedures they
endure, or the pain and suffering involved (Hadley, 2012), as well as the ineffectiveness of using animals as models for humans. The public is interested,
however, in these details. A public consultation in the United Kingdom—to
which animal activists and scientists were not invited—found public support
for openness and interest in a wide range of key information (Ipsos MORI,
2013). Information of interest includes, for example, details about animal use
(e.g., organizations that use animals, numbers and percentages of animal species used, severity of procedures, how animals are killed, and whether there
are non-animal alternatives); information about genetically altered animals;
outcomes for animals, such as levels of suffering, with examples and images of
typical procedures; more information about alternatives to animal use; and reports on finished projects from an animal welfare point of view. Furthermore,
people asserted the animal research sector “should subject itself to external
scrutiny by those who have an interest in the animals’ welfare, rather than by
those who have a vested financial or scientific interest in the research being
carried out” (Ipsos MORI, 2013, p. 37). A later Ipsos MORI poll found that 42%
of respondents perceive uk organizations that use animals for research as
“secretive” (Clemence and Leaman, 2016, p. 2).
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In countries, such as Australia and those of the European Union (eu), researchers collect data of interest to the public, but there are differences, as
we explore below, in the regulations governing disclosure and the format of
the information. Over the past decade, some animal research institutions have,
seemingly, made efforts to promote their work and provided information beyond what is legally required. Examples include, the Concordat on Openness
on Animal Research (Understanding Animal Research, n.d.), a group of more
than 100 universities, charities, commercial companies, research councils, umbrella bodies, and learned societies in the uk that have agreed to be more open
about their use of animals in research; and the Basel Declaration, signed by
scientists and institutions who aspire to speak openly about their work with
the public (Basel Declaration, 2011). The Basel Declaration is, however, in large
part merely an agreement to abide by legal requirements already governing
animal research.
Governments and regulators may also attempt to be more open. For example, in 2015, the uk Government expressed a commitment to increase openness and transparency in animal research with the intention of “giving the
public new tools and opportunities to understand how and why such research
is carried out and to scrutinize the steps being taken to minimize suffering and
find alternatives” (Home Office Department for Business Innovation and Skills
and Department of Health, 2015, p. 7). It has been obvious, however, that such
openness is selective and “can be viewed as grease in the apparatus of animal
experimentation, as a unifying ingredient that permits maintenance of status
quo in human/animal relations and preserves existing institutional public/science relations” (Holmberg and Ideland, 2012, p. 354). Holmberg and Ideland
observed that the public debate on animal experimentation is constrained by
selective openness and by the motivation to enlighten an uninformed public,
hoping to gain public acceptance. Thus, they argue, selective openness permits
the maintenance of the status quo and preserves existing institutional relations between scientists and the public.
Funding for biomedical research in Australia is substantial. In 2017, the
National Health and Medical Research Council (nhmrc) committed more
than aud$877 million to fund health and medical research (in 2016, more
than aud$828 million; in 2015, more than aud$896; and in 2014, more than
aud$780 million) (nhmrc, 2018). Australian biomedical research is generally
regarded as being of high quality, and it uses many animals. According to information provided by nhmrc staff to hra, 34% of grant applications in 2015 indicated the use of animals in their research (personal communication, March
2016). In this chapter, we detail attempts by Australia’s largest and most active
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anti-vivisection organization, Humane Research Australia (hra), to test the
professions of openness and obtain more information than is publicly available about animal research. hra is a non-profit organization that challenges
the use of animal experiments and promotes more humane and scientifically
valid non-animal methods of research. Both authors are on hra’s management
committee. hra is abolitionist in aim, but one of its medium-term strategies
is to raise public awareness and highlight the failures of the regulatory system,
particularly those of animal ethics committees and state animal welfare laws.
In this chapter, we contrast the Australian situation with the eu system, discuss impediments to disclosure, and advocate that reform of animal research
regulations in Australia and the eu be focused around these impediments.
Furthermore, we provide some suggestions on how reform could be achieved.
We argue that such reform and our advocacy will lead to increased scrutiny,
which in turn will lead to greater reduction and replacement of animals used
in research.
2

Transparency in Australia

Animal research in Australia is guided by the nhmrc’s Australian Code for the
Care and Use of Animals for Scientific Purposes (the Code): “The purpose of
the Code is to promote the ethical, humane and responsible care and use of
animals for scientific purposes. The Code provides an ethical framework and
governing principles to guide decisions and actions of all those involved in the
care and use of animals for scientific purposes. The Code details the responsibilities of investigators, animal carers, institutions and animal ethics committees (aecs), and all people involved in the care and use of animals, and
describes processes for accountability” (nhmrc, 2013, p. 1).
Under the Australian federal system, responsibility for animal welfare is
delegated to the states, and all states and territories have incorporated the
Code into state legislation. While being part of a self-regulatory system,
the Code “receives its regulatory power by adoption under the state’s delegated animal welfare legislation, or through administrative controls, for example
referral to it in licenses issued to research establishments” (Whittaker, 2014,
p. 3). In the absence of federal regulatory power, statutory provisions relating
to animals used in research vary between jurisdictions. Central to the Code is
the commitment to minimize harm, pain, and distress to animals used in the
laboratory and other research or teaching situations, and “balancing whether
the potential effects on the wellbeing of the animals involved is justified by the
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 otential benefits to humans, animals or the environment” (nhmrc, p. 1). Balp
ancing is to be achieved by applying the 3Rs: replacement (not using animals
where possible); reduction (reducing the number of animals used); and refinement (minimizing negative impact on the animals). However, many terms
used in the Code are imprecise or undefined (e.g., regularly, suitable, adequate,
necessary). While the Code requires that research activities must balance
whether the potential effects on the well-being of the animals involved are
justified by the potential benefits to humans, there is no explicit requirement
that the potential benefits for humans outweigh certain impacts on animals,
such as pain and death. This leaves the balancing wide open to interpretation.
Animal ethics committees (aecs) are essential to the implementation of
the Code. All projects and activities that involve the care and use of animals
for scientific purposes are subject to ethical review, approval, and monitoring
by an aec. aecs are composed of a chairperson, a veterinarian, a scientist or
teacher, with experience relevant to the institution’s activities, a person with
a background and commitment to animal welfare, and an independent community member. Additional members can be appointed, but animal welfare
representatives and community members must, together, represent at least
one-third of the aec membership.
2.1
Animal Use Data
Unlike many other countries, Australia does not maintain a national collection
of animal use data. Moreover, collection and reporting methods vary between
states/territories, and delays in making data available can extend up to five
years (personal communication, hra staff, March 2017). Some states and territories do not collect relevant data at all. It is ironic that the only national statistics in Australia are those collated and published by hra, an anti-vivisectionist
organization. hra gathers annual statistics from the states/territories and
makes them available on its website (Humane Research Australia, 2016b). The
latest available statistics, at the time of writing, are from 2016 and are only
from four states. On the basis of the most recent and previous statistics, hra
estimates that the total number of animals used in Australia in 2016 was over 9
million (Humane Research Australia, 2016c). The information from the states
is presented in different formats, using different categories. Not all states collect all of the data recommended by the Code. For example, New South Wales
does not collect data from schools, and in Western Australia reporting on research using fish and cephalopods is not mandatory. Due to the discrepancies
in data, it is impossible to paint an accurate picture of animal use in research
and teaching in Australia. hra’s estimates are approximate, in part based on
averages, and conservative.
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2.2
hra Attempts to Obtain Animal Research Information
As an animal advocacy organization, hra has made systematic attempts to
break through the confusing and varied policies on transparency across the
Australian states. We make requests to relevant institutions and often follow
up with a Freedom of Information (foi) application, if unsuccessful. Under
Australian Commonwealth and state law, government agencies cannot refuse
requests by the public for access to information they hold, unless there are
good grounds, such as national security or the privacy of individuals, for not
doing so. In general, there is a presumption that the public has a right to information. As a result, an foi request can be a powerful tool. Examples of
information disclosed recently include details of sexual assaults at Australian
universities, incident logs from Australia’s offshore detention centers, and statistics relating to arrests at Melbourne airport concerning prohibited items.
Agencies are not always cooperative, however, as we detail in the next section.
hra asks for documents and reports and information about incidents in
laboratories and associated facilities that come to our attention, such as details
on the unexpected deaths of two non-human primates at a breeding colony
in New South Wales in 2015. In some cases, hra has asked for a review from
the state foi Commissioner. Generally, because our efforts are more targeted,
informed, and sustained, hra finds more information than is available in the
public domain or that individuals could expect to discover. Many requests for
information, however, are refused. Agencies give a variety of reasons, many of
which are not convincing, and skirt their responsibility, outlined in the previous paragraph, to be transparent; reasons include, for example, that the agency
does not hold the information nor does it know who holds it, retrieving the
information would be an unwarranted use of resources, or “it is generally understood that this information will not become public” (personal communication, May 2014).
2.3
Animal Ethics Committee (aec) Material
Like many animal advocates (e.g., O’Sullivan, 2006; Varga et al., 2010; Whittaker,
2014), at hra we believe available information about animal research should
enable members of the public to make judgments about whether the use of
animals is justified given what was done to them, the benefits realized, and the
lack of alternatives to realize the benefits. Uncontroversially, we view this as
THE ethical question to ask from a utilitarian perspective, the standard ethical
framework in which judgments about human use of animals are usually made.
hra’s primary target, then, is to find information about particular research
projects. To enable a judgment about justification, we view the following details as essential:
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1.
The project proposal
2. Purpose and predicted benefits
3. Detailed consideration of non-animal alternatives
4. Animal species and numbers
5. Impacts on the animals
6. Fate of the animals once the project has been completed
7. Realized benefits of the research.
With the exception of realized benefits of the research, all details about a project are already documented. In Australia, the Code requires they be part of the
application process. Although the Code allows some flexibility of implementation, as it does in many matters, most aec project forms that we were able to
access strictly conform to these requirements (e.g., University of Melbourne
Office, n.d.). All details then, which in our view are sufficient to make a judgment about justification at the project level, should already exist in various
records, reports, and databases. However, we cannot verify whether this collection and compilation of information is always carried out and how well it
is done. We cannot verify compliance because these details are not publicly
accessible.
Other information we view as important for judging the current level and
nature of animal experimentation in Australia is also unavailable for public
viewing. These data include summary statistics collected by the states and territories from the aecs (“animal use returns”); and efforts by institutions and
other license holders to reduce animal use, as described in the annual aec
reports. hra’s success rate in gaining access to aec documents, by directly requesting them, has been disappointing. For example, we contacted all major
Australian universities to ask for their annual aec reports for a range of years.
Only in one case did we receive a positive response. In all other cases, we either
did not receive a response or the request was refused on the grounds that it
was not the practice of the institution concerned to make this material public.
Requests for project applications (even redacted versions), progress reports,
and final reports were also not granted.
2.4
License Holder Names
In 2014, an foi request was pursued on appeal to the foi Commissioner in
Victoria. The request was for the names of the license holders, the institutions,
and other bodies that are licensed to undertake animal research. The request,
by one of the authors on behalf of hra, did not ask for the names of individuals; and this was made explicit in the application. A typical license holder
is not a person, but an institution, such as a university or part of a university. hra has an interest in these details, both to gauge the number and range
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(e.g., public versus private) of animal research in the state and to guide our
search for publications, which is the most definitive way in which we can establish that particular research has taken place in Australian institutions. We
are aware of many of the license holders already, both because of publications
found independently and the nature of the institutions, such as universities
and research hospitals. Some of these institutions put information about license holders or their aecs on a website. As hra stressed in its original request
and in subsequent appeals, we were not interested in nor seeking to identify
any individuals, whether they be institution administrative staff or researchers.
Although our request for the license holder names seems uncontroversial, it was refused. In its decision, the department cited four sections in the
Freedom of Information Act (1982, last amended 2017), which can be applied
to exempt information sharing. Two sections relate to confidential business
and commercial details; one to the disclosure of “the personal affairs of [...]
person[s]”; and the last to the case where disclosure of a document would or
would, likely, “endanger the lives or physical safety of persons […] who have
provided confidential information in relation to the enforcement or administration of the law” (Freedom of Information Act, 1982, last amended 2017,
31(1)(e)). Somewhat surprisingly, on appealing this decision, the foi Commissioner dismissed each ground for exemption except the last. Thus, of all
the reasons given by the department’s foi officer for not making the license
holder names public, only the exemption relating to the physical security of
individuals was upheld. Such inconsistency in the treatment of requests for
information about animal research from Australian regulators is fairly typical
in hra’s experience.
In its submission to the foi Commissioner, the department’s evidence that
revealing license holders would endanger individuals, consisted solely of the
claim that, in a previous foi request, two license holders had concerns about
being identified, as they had been the target of threats, disruptive action, and
property damage from protesters in the past (foi Commissioner, personal
communication, September 2014). hra does not find it credible that the security concerns of two out of all license holders in Victoria (hra estimates this
number to be between 50 and 100) were enough to reject the request. We were
not provided with any evidence of the claims made by the licensees, and our
attempts to verify the incidents with a further foi request to the Australian
Federal Police were not successful. Violence against animal laboratories and
infiltrations are rare and have decreased markedly over the past 20 years.
In another sign of inconsistent regulation and policy, this time at the state
level, license holder information from other states in Australia has been made
available to us on request. In Queensland, the register of scientific animal use
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(Queensland Government Department of Agriculture and Fisheries, 2014)
can, by law, be inspected by any member of the public. License information
is even more accessible in Tasmania, via a website (Tasmanian Government,
Department of Primary Industries Parks Water and Environment, 2017). These
differences between states call into question the Victorian foi Commissioner’s ruling. If security and risk to individuals are not an issue in other states,
why would they be a problem peculiar to Victoria? In 2015, a further foi application was submitted (after responsibility had been transferred to a different department), asking again for the license holder names. The request was
refused on the same grounds, including those previously disallowed by the foi
Commissioner.
3

Transparency in the European Union

3.1
Concordat on Animal Research
The Concordat on Openness on Animal Research is an initiative that aims to
make animal research more transparent in the uk. It came into effect in 2014.
More than 100 signatories on the Concordat have made a commitment to:
– Being clear about when, how, and why they use animals in research
– Enhancing communications with the media and the public about their research using animals
– Being proactive in providing opportunities for the public to find out about
research using animals
– Reporting on progress annually and sharing their experiences.
The efforts of the parties to meet their commitments vary widely. Some only
have a web page describing the institution’s efforts in implementing the 3Rs,
ethical reviews, and animal welfare standards. Others provide detailed examples of animal research, such as case studies. Some signatories have published
the minutes of the Animal Welfare and Ethical Review Body (awerb) meetings
on their websites. The 2017 Concordat Annual Report (Williams, 2017) makes
particular mention of these new efforts at openness. The minutes we accessed
were, however, all in a redacted and abbreviated form and, crucially, contained
little evidence or detail of ethical review (e.g., University of Nottingham, n.d.).
Individual protocol information is lacking, making it difficult to determine
what will be done to the animals. The University of Cambridge awerb minutes, for example, routinely redact the title of project for new and existing
licenses (University of Cambridge, 2018). Signatories to the Concordat tend
to stress the benefits of animal research, generally, and the importance and
necessity of their own researchers’ work in particular; while downplaying the
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pain and suffering caused to animals and the number of animal deaths. Unsuccessful research and negative findings are not reported (Pound and Blaug,
2016).
The Ipsos MORI poll finding, mentioned above, that respondents equated
transparency of the animal research sector with its willingness to subject itself
to external scrutiny by those interested in animal welfare, was not honored in
the Concordat (Pound and Blaug, 2016). This is despite the fact that the poll was
commissioned by uar, the group responsible for establishing the Concordat.
These omissions are significant; but the Concordat, nonetheless, seems a step
in the right direction that Australia could follow. There is always the chance
that there could be more balanced disclosure over time, not least because of
pressure from animal advocates. In Australia, we have nothing even remotely
similar to the Concordat. Rather than promoting their animal research, institutions are much more interested in concealing it. Given our previous experience with innocuous requests, such as the names of license holders described
above, we expect there would be resistance on the grounds of security. The uk
experience, however, suggests this fear would be unfounded: “When the Concordat was developed there was considerable concern cited about the risks of
openness and a fear that transparency would bring researchers into physical
danger. The information provided by signatory institutions about their communications activities since May 2014 indicates clearly that this has not been
the case” (Williams, 2015, p. 4).
Non-technical Summaries (nts) and Retrospective Assessments
(ras)
Non-technical summaries (nts) of animal research are mandated by the eu
Directive 2010/63/EU (European Parliament, 2010, Article 43). nts provide
information on the objectives of a project; predicted harm and benefits and
the number and types of animals to be used; and a demonstration of compliance with the requirement of replacement, reduction, and refinement. nts are
anonymous and do not contain the names and addresses of the user and its
personnel. eu Member States are required to publish the summaries, including any updates. In the uk, the Home Office has published summaries on its
website since 2014.
While the summaries include answers to the crucial questions about any
animal research project, which enable an ethical assessment of harms and
benefits to be considered, there is variety in the detail and quality of the information provided. There are, however, some uniformities and generic responses, which are unsatisfactory. In response to the question why animals need to
be used and non-animal methods cannot, project applicants routinely claim
3.2
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that they must develop in vivo models because in vitro models are inadequate
to model the disease, condition, or cell interactions being investigated. With
respect to refinement, researchers typically respond with a statement that the
methods and procedures are designed to minimize suffering. Invariably, there
is an additional statement that anesthesia will be given where required, and
that the animals will be constantly monitored for signs of pain and distress
and killed if these reach moderate severity. Applicants often comment that
achievement of the aims of the research limits the minimization of suffering
possible.
Directive 2010/63/EU requires retrospective assessments (ras) of projects
using non-human primates and projects involving procedures classified as severe. eu Member States may require ras for additional types of projects as
well. However, including an ra of a completed project in the nts is optional.
We found no mention of an ra in any of the nts we examined (including
summaries of projects using non-human primates and involving severe procedures). In the uk, ras of projects approved by the Home Office are currently under review and will be published in due course. The British Animals in
Science Regulation Unit also plans for nts to be updated with ras (personal
communications of Kathrin Herrmann with the Animals in Science Regulation Unit, June 2017). In Australia, we view an initiative like the provision of
nts, with all its deficiencies, as worthwhile. The categories of information provided are similar to those we would like to see publicly available in Australia,
notwithstanding, the lack of clarity regarding the extent of retrospective assessment at this time.
There are, however, several obstacles to the implementation of nts and ras
in Australia, which do not apply in the eu. First, in the eu, research animal legislation is mostly national rather than state based. To provide summaries of all
animal research projects in Australia would require the agreement and cooperation of all state departments, an objective never easily achieved. Second, Australian state government departments do not license projects, institutions do.
Investigators are required by the Code to be “competent” in the care and use of
animals, but the Code does not state explicitly who makes that judgment. The
aecs approve or license projects. Yet, some tentative moves have been made in
this direction. As early as 2003, the Australian and New Z
 ealand Council for the
Care of Animals in Research and Teaching (2007, pp. 5–6) drafted a proposal
for, what it termed, lay summaries of animal research to be published. The format for the summaries was as follows:
– Provide the context of the study by way of a brief background
– Describe the aim of the study
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– State the necessity of using animals for the study with consideration of
alternatives
– Describe the outcomes of the study.
A proposal was sent to a number of aecs in New Zealand for comment (the
authors are not aware of a similar survey in Australia). Of the 34 who responded, 21 were not supportive, four had reservations, and nine were supportive.
Concerns raised included, intellectual property, confidentiality, and the cost
of compliance. Some respondents thought lay summaries would provide
ammunition for animal activists. It was also not unexpected that those engaged in “low impact” animal research were, in general, more in favor of the
summaries.
4

Beyond Selective Openness

A large section of the public does not feel well informed about animal research (Clemence and Leaman, 2016; Humane Research Australia, 2016a).
Citizens are divided over animal research (Funk and Rainie, 2015; Jones,
2017) and want more transparency (Ärzte gegen Tierversuche, n.d.). As we
have argued, increased transparency is needed as part of good governance
and accountability. In the following, we propose steps to reform the current
system.
4.1
A Register of All Publicly Funded Animal Research Projects
A recent report by the United Nations Secretary-General’s High-Level Panel on
Access to Medicines called for governments to require, “the unidentified data
on all completed and discontinued clinical trials be made publicly available
in an easily searchable public register” (United Nations, 2016, p. 37), including
study designs and protocols, data sets, test results, and anonymity-protected
patient data. The current lack of transparency of clinical trials, it is argued, undermines the ability of clinicians, researchers, and patients to make informed
decisions about treatments. We argue that the same applies to animal research.
To minimize publication and selective reporting biases (Ioannidis, 2012) and to
improve accountability to the public, the quality of research, and the effectiveness and safety of new drugs and other treatments, raw data and full protocols
of research projects using animals have to be made publicly available before
the research starts. A first initiative is taken by the website PreclinicalTrials
.org which provides an international online platform to register protocols
for preclinical animal studies (PreclinicalTrials, n.d.). The preregistration of
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a nimal studies would also allow experts to advise on available non-animal
methods. On completion of the research, we need to know what the research
has contributed, and how that is balanced with the suffering of the animals
used (Knight, 2011; Lund, Lassen and Sandoe, 2012; Lund et al., 2014). The nts,
as they currently exist in the eu, will not deal with the problem of duplicated
research and the unnecessary use of animals because they provide only limited information.
4.2
Cost-benefit Analysis
A cost-benefit analysis underpins animal research regulation in most countries. For example, Directive 2010/63/EU on the protection of animals used for
scientific purposes (European Parliament, 2010) requires that the likely harm
to an animal should be balanced against the expected benefits of the project.
A similar, but considerably weaker, criterion appears in the Australian Code,
stipulating that the potential effects on the well-being of animals involved
in a project be justified by the potential benefits for humans, animals, or the
environment.
Proponents of animal research claim that research involving animals has
contributed to human clinical knowledge, but there are few systematic reviews
of human clinical utility. Those that do exist show poor human utility of animal models for toxicity testing and the development of clinical interventions
(Knight, 2011; see also Archibald, Coleman and Drake, 2019, Chapter 18; Greek
and Kramer, 2019, Chapter 17; Knight, 2019, Chapter 14; and Ram, 2019, Chapter
15 in this Volume). Scant research exists on how the public views the tension
between animal costs and human benefits. A group of researchers in Denmark
(Lund et al., 2014) explored this topic in focus groups and an online survey.
They found that respondents used cost-benefit approaches in their reasoning,
even those who strongly supported or rejected animal research. Animal pain
and research purpose were of greater importance in balancing the costs and
benefits than the species of the animals. At present, researchers may inform us
about the potential benefits of animal research projects; but we need more, as
Knight (2011) argues: “To assess the degree to which experimental objectives
were successfully met, the costs incurred by research animals, and to inform
future research strategy and further experimental licensing decisions, retrospective evaluation of experiments should be mandatory where such experiments are considered likely to result in significant costs to laboratory animals
or to public finances, or significant human benefits” (p. 293).
The harm-benefit calculation is at the heart of the ethical assessment of
animal research. In the uk, it is conducted by the Home Office when researchers apply for a project license. In Australia, the animal ethics committee makes
the determination. In both jurisdictions, there is very little evidence that any
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research proposal fails to pass ethical assessment; the purported benefits are
always judged to outweigh the costs to the animals (Pound and Blaug, 2016;
Russell, 2012). In the uk, there is a detailed description of the methodology
used to calculate costs and benefits. The Australian states have similar, though
less comprehensive, guides. In both cases, there is fudging on the crucial question of how to weigh or balance harms against costs. The Home Office guide,
for example, considers the process as ultimately a value-laden judgment and
often subjective. In neither instance can the completed cost-benefit assessments of the Animals in Science Regulation Unit (uk) and the aec (Australia)
be viewed by the public.
4.3
Ethical Reproducibility
Although researchers and animal ethics committees are directed to balance
the likely harm to the animals against the expected benefits of the project, the
public does not know how, or even whether, this occurs. Anderson et al. (2013)
pointed out that descriptions of research ethics methods in published papers
are minimally informative, and authors are not required to publish them. They
suggest that ethical reproducibility requires reporting the concrete features of
study design that deal with the specific ethical challenges of a research study.
They propose the following guidelines for reporting:
– Report strategies used to avoid or replace the use of animals in research that
has the potential to cause them harm
– Report improvements to procedures and husbandry that minimize actual
or potential pain, suffering, distress, or lasting harm and/or improve animal
welfare in situations in which the use of animals is unavoidable
– Report methods that minimize animal use and enable researchers to obtain
comparable levels of information from fewer animals.
Furthermore, Anderson et al. (2013) argue that ethics reporting should be guided by the principles of transparency (i.e., reporting sufficient detail to enable
readers to assess and reproduce the research ethics methods used) and proportionality (i.e., providing detail at a level that is proportionate to the ethical
complexity and risk to animals).
4.4
Development of Non-animal Methods and Training
If they are serious about the implementation of the 3Rs, government funding bodies need to provide support and dedicated resources for the development of non-animal methods, and researchers need training in up-to-date
non-animal methods (see Herrmann, 2019 Chapter 1 in this Volume). In Australia, the government body that funds biomedical research, the nhmrc, does
not dedicate funding, specifically, to the development of animal-free research
methods.
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4.5
Additional Considerations for Australia
In Australia, animal experimenters, their institutions, and federal and state/
territory governments provide far less information of interest to the public
about animal research than in eu countries. As a first step, we propose that
already existing information be made publicly available, without identifying
details. This would include the records of aec meetings; aec annual reports to
their institutions; licensed institutions’ annual reports to their state/territory
government; and institutions’ reports of aec external reviews, which are, according to the Code, to be undertaken at least every four years. Monitoring the
care and use of animals is one of the responsibilities of the aecs. According
to the Code, it is left to them to determine the timing and frequency of inspections. Facility inspections may also be undertaken by state governments.
Again, reports about facility inspections exist but the information is not publicly available.
Furthermore, the nhmrc, as the largest funding-body of biomedical research, is the appropriate organization to make the details of funded animal
research available. The nhmrc already provides lists of funded projects (nhmrc, 2018). However, from the project descriptions in these lists, it is unclear
whether the research uses animals. It should be easy to add this detail. The
next step would involve achieving consistency of reporting. An independent
animal welfare office at the federal level would be suitable to take on this task.
However, so far, Australia does not have such an independent organization.
Consistency of reporting would involve consistent categories across all states/
territories for animal species, purposes of use, and severity of procedures (Bain
and Debono, 2013).
Transparent reporting as part of the research community’s accountability
to the public and funders requires additional information. Hadley (2012) notes
that animal use data are collected by researchers and intended for the public
record but are rarely given meaningful media exposure. Hadley suggests that
animal researchers provide concise summaries of their projects to journalists and public relations practitioners. We propose that Australia develops a
practice similar to the one implemented in the eu, where non-technical, plain
language summaries are published online and accessible to the public. We suggest these summaries clearly describe what happens to animals undergoing
procedures in a way that the public can understand. This type of openness
would provide the public with a more impartial way to evaluate the animals’
experiences against the intended benefits of the research conducted upon
them.
Bain and Debono call for a “national statistics compilation that systematically reports on the degree of 3Rs implementation” (2013, p. 215). Given that the
3Rs are central to the Code, and aecs are already asking a number of questions
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regarding the implementation of the 3Rs, such a compilation would contribute
to accountability and transparency of animal research. Furthermore, it would
provide benchmark information on how patterns of animal use are changing
over time. At present, scant information is provided about the living environments of animals in laboratories, such as enrichment, opportunities to express
species-specific behaviors, and whether individual animals are kept in i solation
from other animals. This is of interest to the public and could be provided on
a website, as some research institutions in the eu already do. Transparency
is central to the scientific method and ethical conduct. We trust that genuine
transparency will lead to greater scrutiny of animal research projects, which
in turn will lead to greater reduction and replacement of animals in research.
5

Conclusion

It is argued, at times, that greater transparency can help the cause of both sides
of the animal research debate (Hadley, 2012; O’Sullivan, 2006). Critics have also
sought more information to expose the injustice of what is done to animals in
the laboratory. On the other side, initiatives such as the Concordat (uk) and
the nts (eu) are viewed by at least some in the research community as opportunities to show the importance of their work and to counter the claims of animal advocates. On balance, though, critics more urgently demand openness
than users. Those engaged in animal experimentation do so legally and do not
have to convince regulators or funders that they are not doing anything wrong.
To deal with public opinion, the default strategy in many countries, including
Australia, has been to keep the public largely ignorant.
To date, improved transparency, since the introduction of Directive
2010/63/EU, has not yet led to better implementation of the 3Rs; and, overall,
the number of animals used in research has not decreased. We hope, nonetheless, that more openness will be seen in Europe, spread to other countries, and
lead to a paradigm change. If this comes about, the public will see:
– More disclosure of impacts, pain, deaths, and fate of animals (in particular,
information about the levels of impact by research purpose)
– More unnecessary studies revealed, such as duplicated research, studies for
which non-animal alternatives are available, or studies that are trivial and
should not have been undertaken
– More clues regarding trends, such as the use of donated greyhounds, increasing use of transgenic animals, including non-human primates, or
xenotransplantation
– Information on return on investment and transferability of results to
humans.
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At Humane Research Australia, we are convinced that when this kind of information is revealed, public opinion will swing against animal experimentation.
There is also no doubt that we would use such data to continue our advocacy
for more ethical and human-relevant research.
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1

Background
To kill an error is as good a service as, and sometimes even better than,
the establishing of a new truth or fact.
charles darwin, 1879

Biomedical and agricultural animal research uses millions of experimental
animals and dozens of animal species each year by choice, precedent, or regulatory mandate in basic and applied life science research and toxicity testing of
drugs, chemicals, and consumer products. Animal research is a large component of the international us$270 billion government-subsidized, biomedical
industrial ecosystem (Chakma et al., 2014). In the United States (us) and presumably elsewhere, about half of these funds support animal research and
testing (Institute of Medicine and National Research Council, 2012). Each
year at least 115 million experimental animals (mostly mice and likely a significant underestimate) are used worldwide (Akhtar, 2015). The status quo animal research environment provides “ecosystem services” to a large number of
inter-dependent “species”, including governments, academia, biotechnology,
agri-food and pharmaceutical industries, and publishers. Losers in this system
are the conscripted animals (for “labor”) and taxpayers (for “capital”).
Animal research squanders precious public and private monies directly, indirectly, by opportunity cost, and by unintended negative consequences. There
is no doubt that biomedical and agricultural animal research have delivered
societal dividends. Nevertheless, the questionable benefit-cost ratio and the
unquestionable negative repercussions of animal research are enormous for
taxpayers, patients, and the public at large. Precise animal research investments
and attendant waste are impossible to ascertain, in part because the research
community and the us government obfuscate financial and animal use data.
However, estimated us tax dollars wasted on animal use in b iomedical and
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agricultural research range, conservatively, from us$5 billion to us$9 billion
per year. Even though exact monetary and animal use data are u
 nobtainable,
in this chapter I use the best available, if imprecise, estimates. The estimates
themselves are arguable, yet the underlying conclusions remain valid.
2

Biomedical Animal Research

Animal experiments are of two types: basic (e.g., investigation of biological
phenomena and animal models) and applied (e.g., drug research and development (R&D), and toxicity and safety testing). Applied research can also be
preclinical (e.g., molecular biology, cell culture, animal models) or clinical
(e.g., human drug or vaccine efficacy trials). The preclinical research goal in
animal experimentation is to generate candidate drugs, bio-medical technology or devices and diagnostic tests to evaluate downstream for clinical testing and possibly commercialization, a laboratory-to-patient process called
translation. Preclinical research also entails toxicity testing of drugs, vaccines,
chemicals, cosmetics, and other consumer products, usually in mice and dogs.
Veterinary biomedical animal research is structured essentially the same as its
human counterpart albeit on a much smaller scale. The desired outcome of
preclinical research, mostly performed by government and academia, are scientific papers, the currency (along with grant funds) of research success. The
desired outcome of applied research, mostly performed by biotechnology and
pharmaceutical firms, are patented biomedical products that reflect successful
translation and new revenue streams. Public acceptance of animal research,
especially if invasive and painful, is contingent on substantial human benefits
and fiscal accountability. Unfortunately, taxpayers often support animal research
under the false hype of “breakthrough” animal model-based medical progress.
Most preclinical research is publicly funded. The us National Institutes of
Health (nih), the world’s largest biomedical research organization with a 2019
budget of us$39.2 billion, emphasizes infectious diseases and oncology (nih,
2019). The biotechnology and pharmaceutical sectors favor product development and commercialization (e.g., bio-engineered drugs, vaccines and clinical
trials for cancer, analgesics, anti-diabetic drugs, and some rare diseases). The
public sector generally relies more on animals than the private sector. However, the private sector depends indirectly on publicly funded animal research
as a pipeline for candidate drugs or technologies to convert into marketable
biomedical products (Dorsey et al., 2009; Moses et al., 2015).
Tax-supported animal research and testing is conducted or sponsored by
several us agencies, especially the nih. Federal laws mandate animal testing
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of pharmaceuticals, vaccines, and other chemicals to assess their safety and
efficacy. The Environmental Protection Agency and the Food and Drug Administration (fda) are appropriated vast funds for animal testing. Other us
agencies that require and/or conduct animal testing include the Department
of A
 griculture (usda), the Consumer Product Safety Commission, the Department of Defense, the National Institute of Environmental Health Sciences,
and the Department of Transportation. The private sector has decreased animal testing in some areas, especially in pharmaceuticals (due to high cost and
animal model failure) and in cosmetics (due to consumer pressure). However,
millions of animals are still used annually by private industry for internal or
regulatory safety and efficacy testing of agrochemicals, vaccines and other biologics, and chemicals in consumer products (61.8%; us$71 billion). Private industry is followed by the us government (31.5%; us$45 billion) nonprofits and
charities (3.8%; us$4.4 billion), and academia (3.0%; us$3.5 billion). About
us$56.4 billion (49%) is spent on preclinical research, with the nih providing
most funding. About 47% of preclinical research uses animals, of which 51%
to 89% is flawed. Thus, us$14 billion to us$25 billion (9 million to 15 million
out of 17 million laboratory animals) of us animal research is wasted (Freedman, Cockburn and Simcoe, 2015; Moses et al., 2015; National Anti-Vivisection
Society, 2018).
2.1
Many Animals
Precise animal numbers utilized in us biomedical research are unknown because the large majority (at least 95%) are exempt from the monitoring, care,
and reporting requirements of the usda’s Animal Welfare Act (awa). Mice,
rats, birds, and fish are exempt. As a result, it is impossible to know how many
mice and rats are used each year for research in the us, for what purposes,
and the pain and/or distress these animals experience because this data is not
gathered or reported (American Anti-Vivisection Society, 2017). The usda reported 820,812 awa-covered animal species used for research, testing, teaching, and experimentation in 2016. About 40% of these animals were reported
to be subjected to painful procedures, some with and some without anesthesia or analgesia (usda, 2017). However, this usda awa data (animal numbers,
species, painful procedures, etc.) is facility self-reported and thus unverified.
It is estimated that roughly 95% of the animals used in us laboratories are
mice and rats. Assuming relative species use comparability of European Union
data on vertebrate animals (i.e., mice, rats, birds, fish, and all cold-blooded
animals), and an awa non-exempt research animal population of 821,000,
about 16 million mice are used annually. However, the estimated us research
mouse population varies between 10 million and 100 million animals, many
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g enetically engineered (Guarino, 2015). Mouse numbers are growing rapidly
(Goodman, Chandna and Roe, 2015). Extrapolation from Goodman, Chandna
and Roe’s study estimates the us research mouse population at 86 million.
2.2
The Biomedical Industrial Complex
The biomedical industrial complex is an international multi-billion-dollar
business. Animal experimentation in the biomedical industrial complex (bic)
is pervasive, secretive, profitable, and government-sanctioned. The term “industrial complex” is from the famous and prescient 1961 farewell speech by
us President Dwight Eisenhower to “beware the military industrial complex”,
the semi-opaque, complicated “dark state” network of relationships between
governments, the armed forces and the corporate military/security sector
that supplies them. Like the military industrial complex, the biomedical industrial complex is an impenetrable, taxpayer-money driven eco-system,
where the stated bio-medical and public health missions are sometimes subservient to more self-serving ones (Orzechowski, 2012). This does not impugn
or discredit most animal researchers, who usually have good, if misguided,
intentions.
There are innumerable inter-dependent bic beneficiaries. These include
millions of investigators (salaries, prestige), thousands of universities and
foundations (overhead, patents, jobs), hundreds of funding organizations
(jobs, power), numerous biotechnology and pharmaceutical corporations
(jobs, profits, patents, products) and venture capitalists (return on investment,
roi). Moreover, there is a vast subtler army of allied industries (e.g., equipment, reagent and animal suppliers, consultants, bureaucrats, veterinarians,
regulators, and publishers).
Like all taxpayer subsidized enterprises affiliated with human medicine,
prices for products and services are highly inflated. Animal suppliers breed
animals, from genetically engineered mice to monkeys, to satisfy researcher
demands. A New Zealand white rabbit can cost us$350, a monkey us$8,000.
In 2010, the Jackson Laboratory sold 2.9 million mice for a revenue of us$98.7
million. Suppliers of feed, cages, and equipment have profitable businesses. A
mouse treadmill may cost us$10,000. The us scientific publishing industry generates us$10 billion in annual revenue (Jarvis and Williams, 2016). Biomedical
research, with or without animals, is particularly lucrative for us universities
who charge overhead (facilities and administrative fees) on every research dollar, typically at a 50% rate. About 80% (us$29.8 billion/year) of nih’s us$37.3
billion annual funding is awarded to universities and research institutes as extramural competitive grants. Academic “administrative costs” consume one in
three research grant dollars, approximately us$9.3 billion (one-fourth) of the
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entire nih budget. Overhead primarily pays high university executive salaries
and building depreciation costs and only marginally supports research and investigators. By comparison, typical overhead (fixed costs) for a private us business is approximately 23% of sales, salaries, and benefits, inclusive.
3

The Failure of the Animal Model Paradigm in Biomedical Research
The problem is that it [animal research] hasn’t worked, and it’s time we
stopped dancing around the problem […] We need to refocus and adapt
new methodologies for use in humans to understand disease biology in
humans […] You’ve lost the debate if you lose sight of the taxpayers and
the patients.
zerhouni, former head of the us nih, in McManus, 2013

The cornerstone of modern biomedical investigation is animal experimentation, but this practice is in the midst of an existential crisis. Up to 88% of
preclinical biomedical experiments, especially those involving animals, are invalid, i.e. derived candidate drugs or vaccines are clinically ineffective or toxic
(Freedman et al., 2015; Bock, 2016). This results from poor experimental practices intertwined with the abject failure of synthetic disease in animals, from mice
to chimpanzees, to serve as more than skin-deep human disease surrogates.
Animal research has always been ethically contested, but there is now indisputable evidence of animal model failure to recapitulate human disease and provide clinical value (Pound and Blaug, 2016). Public support for animal research
is dropping. From 2009 to 2014, Americans opposing animal use in scientific research increased from 43% to 50% (Pew Research Center, 2015). Failed animal
models are the root cause of disappointing and diminishing returns on biomedical investments. Poorly designed preclinical animal studies lead to downstream
expensive but fruitless clinical trials, exposing people to false hopes, potentially
harmful drugs, or withheld beneficial treatments. Poorly conducted studies produce unreliable findings and suffering in millions of animals, nullifying the social and moral justification of laboratory animal use (Pound and Bracken, 2014).
4

Failure and Waste in Preclinical Animal Research

4.1
Of Mice Not Men: Animals Are Not People
Hundreds of thousands of peer-reviewed publications are based on the assumption that human-animal similarities enable knowledge from “animal
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models” to be extrapolated to people. The belief is entrenched in scientific
funding agencies and animal experimentalists. However, even if animal research is conducted faultlessly, animal models have limited success in predicting human clinical outcomes because of inherent evolutionary, genomic,
epi-genomic, physiological, and other human-animal differences. Human diseases are artificially induced in animals but fail to reproduce the complexity of
human ailments. Animal models are typically generated through genetic manipulation, surgical intervention, or injection of foreign substances, producing ailments with signs similar to a human disease. A common current mouse
cancer model harvests human tumor cells, grows them in a petri dish and then
transplants tumor tissue beneath the skin of immuno-compromised mice,
so that the mice avatars cannot reject the implanted tumors. These so-called
patient-derived xenografts are then exposed to drugs whose killing efficiency
and toxicity profiles are extrapolated to treat “personalized” human cancers.
The cancer research community published an extraordinary 361,693 experimental studies and journal papers according to a PubMed database search I
conducted on 8 August 2018 using the terms “Mice” and “Cancer”. PubMed was
unable to identify how many successful anti-cancer mouse drugs became fdaapproved for human use but that number is certainly miniscule. Billions of lost
dollars clearly show that mice as human disease surrogates are no more analogous than artificially flavored grape drink is to fine French wine. The chimpanzee, who shares 99% of its dna sequence with humans and should best predict
human outcomes, has largely failed as an animal model, certainly in dozens of
hiv vaccine trials over the past three decades (Bailey, 2008). A 1% dna difference apparently outweighs a 99% similarity.
5

Irreproducibility

Science has two aims: to be reproducible (confirmatory) and to contribute to
cumulative knowledge (discovery). Confirmatory science has higher value because it defines scientific truth, i.e. the non-repeatable is false. An estimated
51% to 89% of preclinical animal research (us$13.3 billion to us$23 billion) is
unreliable (see Table 10.1).
About 1.5 million biomedical scientific papers are published per year.
Irreproducible but published animal research constitutes severe literature pollution, leading other researchers to follow false leads, amplifying waste (see
Figure 10.1).
Some cogent and expensive examples of non-repeatable animal experiments are shown in Table 10.2.
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Table 10.1 Annual us biomedical and agricultural R&D
investment and estimated wasted animal research monies

Source

Total research
Total basic
investment: basic, or precliniapplied, preclini- cal (assume
cal,
49% of
and clinical
total)a

Total animal
(assume 47%
of preclinical)b

Wasted
money due to
flawed animal
research
(assume 51%
to 89% failure
rate)a

Biomedical—basic/preclinical and applied/clinicala
All
Industry

Government
Non-profits
and charities
Academia

us$124 billion
(100%)
us$71 billion
(61.8%)

us$56 billion us$26 billion

us$45 billion
(31.5%)
us$4.4 billion
(3.8%)

us$22 billion us$10.4 billion

us$3.5 billion
(3%)

us$1.7 billion us$800 million

us$34.8
billion

us$16.4 billiond

us$2.2 billion us$1.1 billion

Animal agriculture—basic and appliedc
All

us$1.4 billion
(100%)

us$686
millione

us$686 million

Industry

us$500 million
(36%)

us$245
million

us$245 million

Government us$900 million
(64%)

us$441
million

us$441million

All 2017 biomedical and agricultural animal research
All

us$125.4 billion us$61.5
billion

us$28.9 billion

us$13.3–
us$23 billion
us$8.4–
us$14.6
billion
us$5.3–
us$9.3 billion
us$560–
us$970
million
us$410–
us$700
million

us$350–
us$611
million
us$125–
us$218
million
us$225–
us$393
million

us$14.7–
us$25.7
billion
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Total research
Total basic
investment: basic, or precliniapplied, preclini- cal (assume
cal,
49% of
and clinical
total)a

Total animal
(assume 47%
of preclinical)b

Industry

us$71.5 billion

us$35 billion us$16.6 billion

Government us$45.9 billion

us$22.4 billion us$10.5 billion

251

Wasted
money due to
flawed animal
research
(assume 51%
to 89% failure
rate)a
us$8.5–
us$14.8
billion
us$5.3–us$9.3
billion

a
b
c
d

Freedman et al., 2015
National Anti-Vivisection Society, 2018
Clancy, Fugile and Heisey, 2016
Probably an overestimate, as industry has a downstream clinical research focus and relies
much less on upstream animal research than government or academia.
e Since animal models are rarely used or needed in agricultural animal research, total basic
research and total animal research dollars are assumed to be the same.

The most alarming exemplar of irreproducibility is a 2012 Amgen study that
reproduced key findings in only six of 53 (11%) landmark preclinical cancer
papers, mostly from mouse models, published in premier scientific journals
(Begley and Ellis, 2012). nih director Francis Collins recently wrote, “A growing
chorus of concern, from scientists and laypeople, contends that the complex
system for ensuring the reproducibility of biomedical research is failing and
is in need of restructuring […] Preclinical research, especially work that uses
animal models, seems to be the area that is currently most susceptible to reproducibility issues” (emphasis added, Collins and Tabak, 2014). Why do we continue to spend so much on flawed animal models that lack validity, resilience, and
repeatability?
6

Non-publishable Research and Publication Bias

A hypothesized treatment in an animal model may be ineffective or toxic, a
“failure” considered a “negative result”. Scientists do not want to submit, and
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Preclinical (animal)

Clinical (human)

Failure to
translate

Invalid animal
disease models

Animal model
failure

Unpublishable or
negative results

Publication bias against
negative results
Figure 10.1

Findings published but
irreproducible and unsound

Pollution of bio-medical
literature

The animal model of human disease as a major driver of wasted
money and translational failure in biomedical research.

journals do not want to publish negative findings because they lack the prestige
of novel discoveries. This leads to unnecessary repetition of failed (unknown)
research, amplifying wasted money. Published animal trials overestimate by
30% the likelihood of treatment success because of “missing” unpublished
negative findings (Sena et al., 2010).
Unpublished or unpublishable results bias the biomedical literature, favoring positive over negative findings and leading to duplicate studies that
unnecessarily endanger animal and human subjects and waste resources.
Clinical trials funded by nih (almost exclusively based on the false animal-ashuman paradigm) and registered within ClinicalTrials.gov (clinicaltrials.gov),
an n ih-run trial registry and results database, showed that fewer than half
of 635 nih funded clinical trials between 2005 and 2008 were published in a
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Table 10.2 Examples of non-repeatable animal experiments

Research field

Repeatability
failure

Drug discovery: Cancer,
women’s health,
cardiovascular

Bayer reports 43
us$67 milliona
of 67 (65%) new
drug targets failed
to repeat academic
journal findings.
50% of published Many millions
academic studies
in top-tier journals
cannot be repeated
with same conclusions by industrial
labs.
Amgen researcher us$53 milliona
unable to reproduce
the findings in 47 of
53 (89%) landmark
cancer papers from
top journals.

Drug discovery:
All biomedical
disciplines

Drug discovery:
Cancer

Estimated wasted
money

Reference

Mullard, 2011; Begley and Ellis, 2012

Osherovich, 2011

Begley and Ellis,
2012

a Cost to repeat preclinical work in industrial labs varies from us$500,000 to us$2 million per
compound and three to 24 months. I used a value of us$1 million per drug target (see Freedman, Cockburn and Simcoe, 2015).

peer reviewed biomedical journal within 30 months of trial completion. Furthermore, those that were published omitted key, usually detrimental, details
(Ross et al., 2012). A 2016 study of 4347 interventional clinical trials across
51 us academic medical centers reported dissemination of results within 24
months of c ompletion ranging from 16.2% to 55.3%. This occurred in spite
of a 2008 (unenforced) federal law requiring reporting of clinical trial results
within 12 months of completion or termination with a (never applied) $10,000
per day fine for non-compliance (Chen et al., 2016). My current home institution, the University of Nebraska, is the most flagrant violator of clinical
trial reporting among academic institutions, disclosing less than 20% of clinical trial findings from 2015 to 2017 (Pillar and Bronshtein, 2018). En toto, the
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non-transparent delayed or non-reporting of human clinical trials represents
the dual wasteful and unethical suffering of many thousands of laboratory
animals, the compromised safety and squandered sacrifice of thousands of
participant human subjects and a total disregard for public accountability to
us taxpayers.
7

Failure to Translate: Downstream Human Clinical Consequences
of Flawed Animal Research
The history of cancer research has been a history of curing cancer in the
mouse. We have cured mice of cancer for decades and it simply didn’t
work in humans. We need to acknowledge the fact that use of animals
will not make us better scientists, but bitter scientists.
richard klausner, former director of the us National Cancer Institute, 1998, in
mandal and parija, 2013

As the above quote attests, animal model failure has been well known for
decades at the highest levels. Animal experiments have contributed to
understanding mechanisms of disease and normal animal physiology and biochemistry. However, their record in predicting effectiveness, toxicity of treatment, or preventive strategies in human trials is dismal. In fact, clinical trials
are essential precisely because animal studies do not predict with sufficient
certainty what will happen in people (van der Worp et al., 2010). The pharmaceutical industry bemoans the near empty pipeline over the past 30 years of
new drugs that enter and survive the clinical trial gauntlet to gain fda approval. Serious biases in animal studies makes it nearly impossible to rely on animal
data to predict whether or not an intervention will be toxic or have a favorable
clinical benefit-risk ratio in humans (Ioannidis, 2012). Excessive translational
risk occurs even though there has never been more public and private money,
trained researchers, and better infrastructure, facilities, and biotechnological
tools (e.g., “humanized” mice) than at present. Nearly all candidate drugs derived from preclinical research, entailing immense expenditures and use of
animal models in which the drugs work well against artificially-induced disease, fail in human trials (Kaur, Sidhu and Singh, 2016). Well-known examples
of animal model-to-human clinical failure, costing billions of public and private dollars, are shown in Table 10.3.
Drivers of translation failure include:
– Irreproducibility: For decades, the pharmaceutical industry has internally
replicated preclinical research findings, published or otherwise, as standard
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Table 10.3 Examples of non-translatable clinical science based on laboratory animal
research, mostly mouse models. The drugs or other interventions “worked” (nontoxic, clinically effective) in animal models but were abandoned for use in people
due to toxicity or lack of therapeutic efficacy

Research field

Repeatability failure

Type 1 diabetes All 195 methods that
prevented or delayed
development of type 1
diabetes in mice failed in
people.
Human im30–40 vaccines in approx.
mune-deficien- 90 clinical trials, involvcy virus (hiv): ing more than 20,000
pre-clinical,
human volunteers, failed;
and Phase i, ii all vaccines worked in
and iii vaccine non-human primates,
trials
especially chimpanzees
injected with hiv; one
vaccine increased human
hiv risk.
Alzheimer’s dis- 300 different intervenease: preclinical tions reported effective
in mice, clinical in the amyloid precursor
trials in people mouse model; none effective in human trials. Of
1,200 clinical trials, only
5 drugs approved, which
treat symptoms but not
disease progression.
Ischemic stroke Two of 500 neuroprotective interventions against
stroke successful in human clinical trials; one of
the two beneficial drugs
was aspirin.

Estimated wasted Reference
money
Billions

Roep, Atkinson
and Herrath,
2004

Billions; not one Bailey, 2008
hiv vaccine fdaapproved after 30
years

Billions

Zahs and Ashe
2010; Cavanaugh, Pippin and
Barnard, 2014

Billions

van der Worp
et al., 2010

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

256

keen

Table 10.3 Examples of non-translatable clinical science based on laboratory animal
research, mostly mouse models. The drugs or other interventions “worked” (nontoxic, clinically effective) in animal models but were abandoned for use in people
due to toxicity or lack of therapeutic efficacy (cont.)

Research field

Inflammation
and sepsis

Repeatability failure

Estimated wasted Reference
money

150 clinical trials that
Billions
tested candidate agents
intended to block the
inflammatory response all
worked in mice; all failed
in critically ill patients.
Amyotrophic
100 potential drugs in
Billions
lateral sclerosis established animal models,
(als)
of which eight entered clinical trials with thousands
of people, failed. Clinical
trials of 24 compounds in
51 studies of 13,000 als
patients, found 1 beneficial
compound.

Seok et al., 2013

Perrin, 2014; Petrov
et al., 2017

operating procedure to validate drug targets and initiate internal drug discovery. Non-repeatable results have been disappointing and expensive (see
Table 10.2). The pharmaceutical industry has heavily divested and decreased
reliance on animals because each translational failure causes significant
losses of invested capital. European drug companies decreased animal use
by 25% from 2005 to 2008 (Pound and Bracken, 2014).
– False positive animal model success: Industry researchers must give up when
a drug is poorly absorbed, unsafe, or does not work. Only five in 5,000 compounds that enter preclinical testing make it to human testing. Only one of
the five is safe and effective enough to be marketed (fda, 2017). More than
90% of promising new compounds fail when tested in humans because
they are ineffective or toxic, even though each drug performed well in prior
multi-species animal tests.
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– False negative toxicity (iatro-epidemics): Severe unintended human harms
and billions of dollars in damages occur when fda-approved drugs are
non-toxic in laboratory animals but cause serious, sometimes fatal iatro—
(medically caused) epidemics after marketplace entry. These adverse drug
reactions may cause 100,000 us deaths annually, although this is likely a
highly inflated number (Lazarou, Pomeranz and Corey, 1998). The fda
Adverse Events Reporting System (faers) is a computerized information
database designed to support the agency’s post-marketing safety surveillance program for all approved drug and therapeutic biologic products. The
faers contains almost 16 million reports of adverse events and reflects data
from 1969 to 2018, suggesting limitations to the validity of animal drug or
biologics toxicity screening (fda, 2018). For example:
– The arthritis drug rofecoxib (Vioxx) was safe in eight studies in African
green monkeys and five other animal species but caused 140,000 heart attacks and 60,000 to 100,000 deaths before withdrawal in 2004. Merck paid
us$950 million to settle damages in 2011 (Pippin, 2012).
– Analysis of 780 chemical agents listed in a cancer database found the
positive predictivity of animal bioassays, for a definite or probable human carcinogen, to be 20% (Knight, 2007). In addition to risking human
welfare from the low predictability of animal bioassays, each assay requires up to millions of dollars and years to execute (Akhtar, 2015).
– The diet drug, fen-phen (fenfluramine-phentermine), worked well as
an appetite suppressant in rats without toxicity. However, this popular
drug damaged heart valves and caused pulmonary hypertension in some
people in the 1990s. The fda withdrew it in 1997. The drug’s maker settled
damage claims for us$3.75 billion (Kolata, 1997; Morrow, 1999).
– False positive drug toxicity: Just as ineffective and dangerous drugs are approved based on erroneous safety in animals, useful drugs may be toxic in
animals but safe for people. Aspirin was patented in 1900, decades before
mandated animal testing. When later evaluated, aspirin produced birth
defects in mice, rats, guinea pigs, rabbits, cats, dogs, sheep, and monkeys.
Post-approval toxicity of penicillin (killed guinea pigs) and tamoxifen (liver
cancer in rats) was absent in people. If the animal toxicity were known, these
safe drugs would unlikely be on the market today (Akhtar, 2015).
– Costs of failed clinical trials: Clinical human research relies on and extends
preclinical animal research. Unsound animal research leads to precarious
clinical research outcomes. The fda drug approval process is stringent and
tightly controlled and consists of four phases (Phase i to Phase iv). Phase i:
Is the drug safe in healthy people?; Phase ii: Does the drug work in patients?;
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Phase iii: Pivotal trials: How does the drug compare to existing treatments?;
Phase iv: Post-marketing surveillance: What unknown drug effects (good or
bad) happen? Only one in 5000 to 10,000 new chemical compounds derived
from preclinical testing proceed to Phase i (Akhtar, 2015). Phase transition
success rates are: Phase i to Phase ii: 63%; Phase ii to Phase iii: 31%; Phase
iii to new drug approval: 85%. The overall success rate from Phase i to fdaapproval is 9.6% (Batelle, 2015).
The immense attrition of drugs entering human clinical trials has made big
pharma cautious, even skeptical, of preclinical animal research. In 2013, the
average time and cost to develop a new drug was 10 years and us$2.6 billion
(Batelle, 2015). Candidate drugs that fail anywhere in the clinical trial process,
prior to fda-approval, still lose millions of dollars. Drug development losses
are recouped as higher prices for pharmaceuticals already on the market.
Promising preclinical animal studies that require extensive time, labor, and
money rarely translate into successful human therapies. The overwhelming
preclinical tendency to use animal models, in spite of their near universal
translation failure, invokes the “law of the hammer”, a cognitive bias involving over-reliance on a familiar tool (Kaplan, 1964). Abraham Maslow (1966)
said, “I suppose it is tempting, if the only tool you have is a hammer, to treat
everything as if it were a nail”. The laboratory mouse is certainly a worn-out
bio-hammer.
8

Animal Agriculture Research: Less Money, Fewer Animals, but
Great Waste All the Same

According to the usda, in 2016, approximately 80,000 farm animals (pigs,
sheep, goats, and cattle) were used in animal testing or biomedical research.
This excludes federal government owned agricultural-research animals who
are awa exempt (approximately 50,000 animals). About us$1.4 billion was
spent on us agricultural animal research in 2016, including us$900 million in
public funds (mostly usda) and us$500 million by private industry (Clancy,
Fuglie and Heisey, 2016) (see Table 10.1). Animal agriculture research has approximately 1% of the budget and uses approximately 0.8% of the animals
used in biomedical research. Since experiments are performed directly on the
target livestock species, animal research in agriculture has the distinct advantage of not relying on animal models.
8.1
The Animal Agriculture Industrial Complex
Animal agricultural research is a cog in the large industrial agri-business ecosystem. It directly and indirectly supports an entourage of scientists, government
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agencies, livestock commodity groups, lobbyists, and the animal health, feed
and other allied industries (Twine, 2012). The dominant raison d’être of livestock research is to benefit people via support of the industrial (“factory farm”
or “prison”) paradigm, i.e. intensively managed and densely confined pigs,
feedlot beef cattle, dairy cattle, and poultry (Imhoff, 2010). There are three
common aims:
– To optimize so called production efficiency of meat, milk and eggs i.e. generate
the greatest output with the fewest inputs. Three tools accomplish this: genetic selection, feed efficiency and animal health, writ large, including growth
promoting drugs, disease suppressing antibiotics and numerous vaccines.
– To maximize consumption of animal agriculture products.
– To address unintended consequences of industrial animal agriculture (e.g.,
food safety risk, zoonotic pathogens, antibiotic resistance, and pollution
from animal wastes).
9

Case Studies in Wasted Money from Animal Research
The Mad Cow Disease iatro-pandemic and new variant Creutzfeldt-Jakob
Disease (nvCJD): The best feed for cows … is cows!
“The road to hell is paved with good intentions”
Saint Bernard of clairvaux, 1150

Because feed is the greatest expense in raising livestock (65%–75% of total
cost), there is an ongoing quest to lower feed costs. A dominant research goal is
to increase feed efficiency (feed inputs/outputs of growth, eggs or milk). Feed
efficiency research focuses on: (1) drugs (hormones and antibiotics); (2) genetic
selection; (3) better nutrition; and (4) low cost “waste products” as feedstuffs.
While corn and soybeans are mainstays in us industrialized livestock rations, less savory ingredients also become animal feeds, especially to meet
expensive protein needs. Only 60% of a slaughtered cow is edible (i.e. suitable as human food). The remaining “inedible” 40% (including hides, bones,
entrails, lungs, spleens, hooves, fat and gristle, and fetuses, among others),
known euphemistically as “by-products”, are not permitted to be used as
human food. They can, however, be used in livestock and poultry feeds and pet
foods. Rendering plants transform slaughter by-products and animals that are
unsuitable for human consumption into animal feed products using grinding,
cooking, and pressing processes. Livestock are fed rendered animal fat and protein from slaughtered food animals and their wastes, including chicken feathers, egg shells, poultry litter (bedding and feces), blood, hair, bone m
 arrow, pig
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manure, and rumen ingesta. So called “4D” animals (dead, dying, diseased,
disabled) also become livestock feed and pet foods. Cost driven same-species
feeding (cannibalism) is common and industry-supported in livestock and
poultry in most countries (Denton et al., 2005).
Meat and bone meal (mbm, dried and ground), also known as “animal flour”,
was a small-scale livestock feed for much of the twentieth century. The Agricultural Research Service, the internal usda research arm, studied feeding
bovine mbm to dairy cattle in the 1960s (Brundage and Sweetman, 1963). However, commercial rendering, industry-sponsored research at the University of
Nebraska-Lincoln, in the early 1980s, discovered the “by-pass protein effect”
when cattle are fed high protein mbm from dead cattle (Rampton and Stauber,
1997). Proteins from rendered bovine mbm, unlike plant proteins, withstand
rumen microbial digestion and are delivered intact to the small intestine, maximizing growth and lactation in high-yield dairy cattle. Additional Universitysponsored research confirmed the mbm by-pass protein effect, resulting in
many peer-reviewed papers (e.g., Stock et al., 1981; Santos et al., 1998). It should
be no surprise that rumen microbes, evolutionarily designed over millions of
years to digest forage, are unable to digest mbm, completely foreign nutrients.
By analogy, humans would have a difficult time digesting sawdust. By the mid1980s, mbm bypass protein was widely accepted, especially in Western Europe,
as a dairy cattle protein source. mbm use in animal feed was heavily dependent
on its price relative to the price of alternative ingredients (e.g., soybeans) with
similar nutrient values.
However, this anti-nature Faustian bargain of high milk production in exchange for cannibalism resulted, starting in the mid-1980s, in the bovine spongiform encephalopathy (bse, “Mad Cow”) pandemic. This new fatal prion
(infectious protein) disease spread to cattle eating prion-contaminated bovine
mbm, amplified by “recycling” rendered cattle that died of bse into even more
prion-contaminated mbm. In Britain, 185,000 live cattle were bse-infected,
4.4 million were slaughtered during the 1986–1998 eradication program, and
perhaps a million bse-infected cattle entered the human food chain. Cattle
in 30 countries were infected. Thousands of European dairy farmers lost their
livelihoods (Brown et al., 2001). Since the 1996 discovery that bse was transmissible to humans from eating prion-contaminated beef, at least 231 persons
in 13 c ountries died from new variant Creutzfeldt-Jakob Disease (nvCJD), the
zoonotic manifestation of bse (Maheshwari et al., 2015). Since the first us bse
case in 2003, the us cattle industry has forfeited billions of dollars from lost
exports, decreased product value, lower consumption, and new regulatory burdens. This tragic mbm cow cannibalism story shows that “production efficiency” research can have incredible negative sequelae and vividly demonstrates
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the myth of so-called peer-reviewed sound science. Unfortunately, the bse
experience has not completely tempered the feeding of animal protein to
herbivores.
Livestock Research at the usda us Meat Animal Research Center (us
marc)
I worked at the usda Agricultural Research Service of the Meat Animal Research Center (marc) in Nebraska from 1988 to 2014 in various veterinary
clinical and research positions for the usda and the University of NebraskaLincoln (unl). The usda and unl jointly operate marc, the world’s largest
livestock research center. It has a federal appropriation of us$22 million per
year, plus approximately us$5 million in annual revenue from livestock sales,
a cumulative us$1.3 billion budget over the half century it has existed. marc
is essentially a 55 square mile (14,200 hectare) ranch surrounding a research
campus. Each year, marc’s 6,800 brood cows raise 6,000 calves, 600 sows produce 14,000 piglets, and 2,800 ewes birth 5,000 lambs; 35,000 animals in total.
Almost all Agricultural Research Service livestock and meat research is directed toward helping large producers and processors. In particular, much current
Agricultural Research Service research addresses the untended negative consequences of industrial animal agriculture, for example food safety risk, zoonotic
pathogens, drug residues, antibiotic resistance and pollution from animal
wastes.
A former marc Director told me directly that since an executive branch
agency (such as the Agricultural Research Service) cannot lobby Congress (the
Hatch Act of 1939), he would tell the livestock trade and lobbying associations
what research marc wanted to do. These associations would then lobby Congress on marc’s behalf, often resulting in new funding for marc, frequently as
budgetary earmarks. In return, marc would (and still does) perform taxpayersubsidized research directly addressing pressing priority livestock and meat
industry concerns.
Thus, in addition to its multi-million dollar federal research budget, marc
performs targeted research on behalf of, or funded by, livestock commodity groups. For example, the National Cattlemen’s Beef Association (ncba),
a trade association and lobbying group for mostly large us beef producers
and slaughter processors, has a very close and decades-long association with
marc. The ncba funded at least 52 research projects at marc between 1999
and 2017. These included one project in genetic selection, nine in meat quality,
and 42 in beef safety (zoonotic bacteria and antibiotic resistance). Each ncba
proposal typically provides funding of us$100,000 for one year and does not
cover marc labor or equipment costs. Thus, this represents a us$5.2 million
9.1
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ncba research investment in marc over 18 years (National Cattlemen’s Beef
Association, 2017). However, since marc provides “free” labor (~80% of the
cost of research), this $5.2 million industry “investment” in marc signifies a
taxpayer gift of at least $20.8M to the ncba over 18 years, an impressive return
in investment. The North American Meat Institute, a meat and poultry trade
association representing meat packers and processors is also a frequent funder
of industry research at marc.
marc’s mission is to apply science and technology for red meat production
efficiency to benefit consumers, producers, and animal agri-business, with a
genetic selection focus. Among livestock producers, animal scientists, and beef
geneticists, marc is a world-famous, nih-Mayo Clinic equivalent for red meat
livestock R&D. Like all industrial livestock based-systems, marc achieves “production efficiency” using three tools:
– Genetic selection: Choose a desirable and heritable production trait (e.g.,
many offspring; large muscles) and vigorously (hyper) select for this attribute over many generations.
– Feed efficiency: Maximize via genetic selection and/or experimental lowcost feeds. For example, in the early 1980s, marc scientists fed high pH
cement kiln dust (a by-product of cement manufacturing) to feedlot steers,
sheep, and pigs as a calcium feed supplement and to buffer the dangerously acidic rumen or stomach pH of animals fed high-energy corn rations (Wheeler et al., 1981; Pond et al., 1982). Cement kiln dust is the finegrained, solid, highly alkaline waste removed from cement kiln exhaust
gas by air pollution control devices. Toxicity led to abandonment of these
experiments.
– “Factory farm-acology”: Use drugs to improve feed efficiency and promote
fast lean growth, such as anabolic steroids (hormone implants), antibiotics, ionophores, and beta-agonists (repartitioning agents that convert fat to
muscle) (Petersen, 2012). The cumulative drug effects are rapid growth and
maximized lean muscle mass.
As a cogent example of marc funding of industry research, usda and unl
investigated the growth and “welfare” (body temperature and mobility) effects of zilpaterol, a beta-agonist growth promotant, on marc feedlot steers
(Boyd et al., 2015). Zilpaterol is a failed human asthma drug whose undesirable
human side effect of turning fat into muscle was a very desirable outcome in
cattle. This drug is approved for use in livestock in only five countries (Centner,
Alvey and Stelzleni, 2014). Zilpaterol was voluntarily removed from the market by Merck in 2013 due to serious animal welfare concerns. This zilpaterol
research at marc, tri-funded by usda, unl and the Nebraska Beef C
 ouncil,
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not surprisingly reported no welfare problems in using this fat-to-muscle
repartitioning agent. Of interest in this marc feedlot study are: (1) all nine
authors were livestock scientists; no person with animal or livestock welfare
training or expertise was part of the study; (2) an unreferenced and invalidated meat industry-developed 5-level ordinal lameness scoring metric was
employed (Tyson mobility scoring, Tyson Foods, Springdale, ak) and; (3) evaluators were not blinded as to treatment group, a dominant source of experimental bias.
I will recount three examples of marc research principles in action, all with
animal welfare repercussions and massive waste of taxpayer dollars.
9.2
Twinner Beef Cattle
Rationale: Cows usually have one offspring. The natural twinning rate in cattle
is 1%–2%. Production efficiency would double if cows had twins instead of
singlets.
Results: From 1981 until 2011, the twinning rate in a marc herd rose to approximately 50% (1.6 calves per cow) via intense genetic selection.
Problems: (1) It is bio-unnatural for cows to have twins, fighting against millions of years of evolution favoring singlets; (2) Dystocia, C-sections, mastitis,
early calf deaths, and sterile female calves.
Outcome: The project was abandoned after 30 years and approximately 100
million tax dollars. There was no market for twinning cows. Most farmers cull
cows with twins due to the well-known problems described above. A beef geneticist said in 2016, “There are animals in this world that God made to have
twins or triplets; cows are made to have one” (Simmons, 2016).
9.3
“Double muscled” Beef Cattle
Rationale: Cattle with more muscle mass have greater productivity. Belgium
blue cattle can have a mutant myostatin gene, causing skeletal muscles to grow
continuously, producing massive animals.
Results: marc scientists co-identified the myostatin gene mutation as causative for double muscling and developed a test for its genetic selection worldwide. Production efficiency experiments conducted over many years produced
cattle with very large muscle mass.
Problems: Dystocia, low fertility, low stress and heat tolerance, poor calf
viability.
Outcome: The project started in 1997 and was abandoned after many years
and millions of tax dollars. There is no market for these cattle (Elstein and
Peabody, 2004; Bassett, 2009).
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9.4
“Easy care” Sheep
Rationale: The us commodity sheep industry is becoming extinct. In 2015,
there were less than 5 million sheep, a 91% decline since 1950. Labor is costly.
Solution: Increase sheep production efficiency by developing a cross-bred
fecund breed. This “easy care” sheep has hair (since us wool has negative economic value) and births twins or triplets. Use brutal neo-Darwinian selection
via hands-off husbandry to select sheep that raise lambs, who require minimal
labor, feed inputs, and human attention.
Results: From 2002 to 2017, approximately 1,500 easy care ewes gave birth to
3,000–5,000 lambs per year. Rather than the usual summer pasture and winter
shed housing and lambing, “easy care” sheep were kept on isolated pastures
year-round without shelter or shade. Shepherds were prohibited, by experimental protocol, from intervening to care for ewes or lambs in need. Ewes that
survived and reared lambs under these heinous conditions were considered
“successfully genetically selected”.
Problems: Predictably, human-dependent domestic sheep treated like wild
sheep faired very poorly. Lamb mortality ranged from 10% to 50% per year
(normal rates are 1%–5%). Over 15 years, 15–20 thousand lambs died (the expected number was 1,200) from coyote predation, starvation, exposure, abandonment, dystocia, and disease.
Outcome: Like the Twinner cattle, the “easy care” sheep project used intense long-term genetic selection in an anti-nature, poor welfare manner to
attempt to create a product without commercial demand. The easy (“No”) care
sheep research failed completely, unsurprisingly, to reach its scientific goal
of a new sheep breed with low labor needs. Over 15 years, the project spent
approximately 15 million tax dollars. No scientific papers resulted from this
work.
These three marc projects share several commonalities:
– Intense genetic selection created or attempted to create a livestock product
no one wanted where production efficiency at all (animal and taxpayer) costs
was the focus.
– Genetics were used as a biological hammer to select for abnormal, exaggerated, or unnatural traits that were both costly and harmful to livestock
well-being.
– Projects were internally and non-competitively funded for decades with
millions of tax dollars.
– marc livestock, like all federal government-owned agricultural research
livestock, are awa-exempt and subject to almost no internal or external animal welfare oversight which are mandated for other us research animals.
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The industrial animal agriculture system does not merit research funding
from the public treasury, as exemplified by the decades of failed and unnecessary research and multi-millions of wasted tax dollars at marc. It is almost
impossible to justify research support for an unsustainable system that produces Mad Cow disease, antimicrobial resistance, pollution from livestock
wastes, food-borne pathogens (e.g., E coli O157), and horrible livestock and
poultry welfare. “Cheap” factory-farmed eggs, beef, pork and chicken enabled
by intensive agricultural animal research are incredibly expensive (Pew Charitable Trusts, 2008).
10

Conclusions
Publicity is justly commended as a remedy for social and industrial diseases. Sunlight is said to be the best of disinfectants; electric light the
most efficient policeman.
louis d. brandeis, 1914

It is an economic and ethical imperative to reduce wasted money and animals used in us biomedical and agricultural animal research. These imperatives are unlikely to manifest in the current animal research environment due
to perverse incentives. Complete transparency (e.g., costing, specific animal
usage, outcomes, evidence of translational success, mandatory public reporting of all government funded research regardless of results) in both the
public and private domains will likely be the most effective driver of fiscal
responsibility and refining (minimizing experimental suffering), reducing
(minimizing animal numbers), and replacing (with non-animal alternatives)
research animal use. This will require, at a minimum, sustained public pressure, policy and regulatory changes (e.g., removal of species or institutional
exemptions from the awa), adequate resourcing, and enforced (new or old)
legislation.
Animal research is losing its immunity from criticism or challenge. However, it is a multi-billion-dollar industry in which government, academia and
private business have high financial stakes (Pound and Bracken, 2014). It is
critical to recognize that wasted money in animal research is only germane
to laboratory animals and to people excluded from the animal research industrial complex (i.e., taxpayers, patients, investors, and consumers). To those
within the animal research ecosystems, there is no waste or cost, only sustenance and benefit. This is a major reason why wasteful, unproductive, and even
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c ounterproductive use of research animals not only continues but is fiercely
defended despite obvious limitations and dangers. Supporters of animal research rely on expert opinion (one of the least valid types of evidence) and
the occasional translational success story. Opponents have billions of wasted
dollars, millions of scientific papers, and decades of evidence against their
continued use. Government sponsored animal experiments may continue because they are taxpayer-subsidized and incentivized. The pharmaceutical and
biotechnology industries may reduce laboratory animal use in drug discovery
and development, because they cannot invest heavily in such an unreliable
methodology. Unfortunately, scientific precedent, legal liability concerns, and
regulatory approval mandates will ensure enormous use of laboratory animals
in the private sector to assess safety of drugs, medical devices, biologics, chemicals, and consumer products and to test vaccines (for potency and by batch),
at least in the near term or until regulatory requirements change.
Available and emerging non-animal research approaches and technologies
can provide better return on investment, more valid and valuable findings, and
better human well-being outcomes and save billions of taxpayer dollars and
millions of animal lives (D’Urbino, 2016). Goals should include:
– Abandoning molecular reductionism (e.g., as manifested in genetically
modified or “gene knock out” mice).
– Investigating complex naturally-occurring disease in humans and animals
instead of artificial and incongruent animal models.
– Implementing more in vitro (human or animal cell-based assays) and in
silico (computer modeling) technologies.
– Resourcing development, validation, and regulatory acceptance of nonanimal alternatives (e.g., the Interagency Coordinating Committee on the
Validation of Alternative Methods, iccvam (National Toxicology Program,
2018)).
– Defunding public biomedical research that uses animal disease models.
– Eliminating non-competitive internal government research funding and
halving extramural grant overhead rates.
– Discontinuing the failed research focus in agriculture on industrial livestock “production efficiency” in favor of humane sustainable agricultural
research.
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Introduction
The true rule in determining to embrace or reject anything is not whether
it has any good in it, but whether it has more of evil than of good. Few
things are wholly evil or wholly good. Almost everything is a composite of
the two, so that our best judgement of the predominance between them
is continually demanded.
abraham lincoln, June 20, 1848, in a speech to the United States (us) House
of Representatives on Internal Improvements, suggesting an approach to decision
making in ethically complex situations

Few would disagree with the ethical contention that if cruelty to animals is
not wrong, then nothing is wrong. In fact, it is not only wrong, but in most
states in the us, it is a crime, a felony no less. And yet, intentionally inflicting
pain and suffering upon animals, which meets Webster’s definition of cruelty,
is routinely countenanced when vivisection (from the Latin vivi, to be alive,
and secare, to cut) is performed under license for biomedical research. Deciding to embrace, or reject, or limit animal research demands our best ethical
judgment; and it is complicated by factual disputes over the extent to which
it benefits human health. Three issues combining facts and ethics need to be
considered. First, to what extent does animal research deliver on its promise
to improve human health? Second, if the goal of public investment (e.g., tax
dollars spent by the National Institute of Health, nih) on animal research is to
improve human health, are we getting sufficient return for the billions spent,

© Lawrence A. Hansen and Kori Ann Kosberg, ���9 | doi:10.1163/9789004391192_012
This is an open access chapter distributed under the terms of theKathrin
prevailing
cc-by-nc License at the time
Herrmann and Kimberley Jayne - 978-90-04-39119-2
of publication.
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

276

Hansen and Kosberg

or might the money be better directed towards human-based research or implementing healthcare interventions of proven efficacy? Third, since opinions
about ends justifying means will vary, who should decide if animal research is
ethically justified: the scientists who perform it or representatives of the public
at large, who pay for it?
In the us, the biomedical academic research establishment, as currently
constituted, empowers animal researchers to determine what animal experimentation is allowed. But this represents an obvious conflict of interest, since
the researchers’ livelihoods depend on continuing animal use, and their attitudes about the ethical justifications for vivisection are a priori set in stone, as
evidenced by their career choices. Shifting the ethical paradigm about animal
experimentation will require transferring decision-making authority about animal use in science from the animal researchers who carrying out experiments
to the public who finances them and who may be less inclined to approve any
and all use of animals in experimentation.
2

To What Extent Does Animal Research Improve Human Health?

It is axiomatic, even reflexive, for proponents of animal research to contend
that virtually every medical achievement of the last century has depended directly
or indirectly on research with animals. But it may be wise to consider the source
of such a sweeping proclamation. The quotation traces back to a 1994 article in
The Physiologist, a journal heavily invested in publishing animal research, entitled “The importance of animals in biomedical and behavioral research” where
it appears as a bold assertion unaccompanied by any substantiating evidence
(Matthews, 2008, p. 95). Does this claim bear up under empirical scrutiny in
the modern era of evidence-based medicine?
A recently published summary of systematic reviews investigating the relevance of animal based research to human medicine (Pound and Bracken,
2014) provides a comprehensive consideration of the topic. The authors conclude that animal research is plagued by poor quality, typically fails to address
internal and external validity, lacks randomization and blinding, engages in
selective analysis and outcome reporting, and suffers from publication bias,
all resulting in overstatements about the validity of entire bodies of research.
An even more exhaustively referenced review article on the use of animals in
medical science research cites multiple studies documenting the failure of animal models to translate into human benefit in hiv/aids, stroke, cancer, spinal
cord injury, traumatic brain injury, cardiovascular disease, diabetes, and menopausal hormonal therapy (Pippin, 2013). A prescient earlier analysis by Crowley
in 2003 (Sung et al., 2003) had already established that out that of 25,000 basic
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research articles published in the top 6-ranked journals for basic research, only
one was associated with a clinically useful new drug in 30 years of publication. The dismal track record of animal research leading to improved human
health has been succinctly summarized in yet another study (Tsilidis et al.,
2013) reviewing data from the Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies, which concludes that bias in
animal studies makes it nearly impossible to rely on most animal data to predict whether or not an intervention will have a favorable clinical benefit-risk
ratio in human subjects.
Poor study design contaminated by bias doubtlessly contributes to the irrelevance of most animal research to medical progress. But a deeper, fatal flaw
in the entire animal research paradigm may be its assumption that evolutionary continuity between humans and other animals allows valid cross-species
extrapolation, essentially a presupposition that what we learn to be true in
one species will be true in another (Ioannidis, 2012). Evolutionary continuity
can account for the success of animal model extrapolations early in the history of physiology, as when William Harvey, a seminal figure in the development of medicine and physiology, correctly deduced the closed-circuit nature
of h
 uman blood flow after observing it in non-human animals. But that was
in 1628; in the modern era of personalized medicine, when patients’ tumors
are characterized with chromosomal scanning and cancer gene panels to
identify specific mutations directing individualized chemotherapy, the notion that mice represent furry pocket-sized models of humans seems scientifically quaint. Non-human animals are not simplified versions of humans, as
the word model implies, but are rather evolved systems, differently complex
in their own right. Small differences in initial conditions of a complex system,
such as diverging regulation and expression of genes, modifier genes, or posttranslational protein processing can result in two superficially similar systems
(human and non-human animals), exhibiting vastly different responses to the
same experimental manipulations (Greek and Shanks, 2009).
If forced to concede by meta-analyses that most animal experimentation
bears no clinical fruit, animal researchers defend it by arguing that its critics are insufficiently appreciative of the contributions made by vivisection to
our cumulative fund of biomedical knowledge (Carbone, 2012), not only as a
curiosity-driven, fact-finding quest for knowledge, but as it applies to the understanding and progression of human disease. This argument justifies a nimal
research as basic rather than applied science. How can opponents of animal research ever know that in the fullness of time an insight into basic biology
derived from an animal experiment of no relevance to human health, at the
time it was performed, might not, someday, be important to improving health?
This rhetorical contention is nebulous enough to be impossible to refute, since
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no one knows the future. Any and all research is justified by this argument,
and it implies that no ethical balancing of pain and suffering cost to experimental animals against the expectation of human health gain should even be
attempted. Basic research that uses animals will continue to find new facts
about basic biology, as it has in the past. But to conflate finding new facts with
advances in human health as ethical justification for animal research is a disingenuous bait and switch.
3

What Is the Cost to Benefit Ratio of Spending on Animal Research
to Improve Health?

Dawning awareness of the failure of most animal based research to benefit human health is reflected in commentary from the current and a former head of
the nih, the agency in charge of funding biomedical research in the us, with
a us$39 billion budget in 2019 (nih, 2019). Francis Collins, the present head of
the nih, wrote, “The use of animal models for therapeutic development and
target validation is time consuming, costly, and may not accurately predict efficacy in humans. As a result, many clinical compounds are carried forward only
to fail in phase ii or phase iii clinical trials: many others are probably abandoned because of the shortcomings of the [animal] model” (Collins, 2011, p.
3). Concerning the same failure of animal models, a former nih director, Elias
Zerhouni, commented more memorably, “We have moved away from studying
human disease in humans. We all drank the Kool-Aid on that one [transgenic
mouse models], me included […] The problem is that it hasn’t worked, and
it’s time we stopped dancing around the problem […] We need to refocus and
adapt new methodologies for use in humans to understand disease biology in
humans” (McManus, 2013).
Among such innovative new methodologies for studying human diseases
in humans are organotypic cultures that combine cellular constituents to
replicate entire tissues and tumor environments, allowing cellular, subcellular, and molecular biological experiments historically performed on animals
to instead be conducted on the species of interest — humans. Bacterial production of insulin has replaced its traditional extraction from bovine or swine
pancreas, and chromatography is used to determine drug purity and dosage
rather than animal usage (Doke and Dhawale, 2015). Human stem cells are another modern research modality being utilized to study human diseases and
develop drugs to combat them. Experimental techniques converging on the
goal of personalized medicine include pharmacogenomics and genetic (gene
chip) m
 icroarrays. These wet bench innovations are complimented by advanced non-invasive imaging methods, such as positron emission tomography,
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a ccelerator mass spectroscopy, and magnetic resonance imaging. These and
many other human-species relevant research methods may be far more likely
than discredited animal models to advance health.
Proponents of animal research often invoke the ultimate goal of reducing
human disease morbidity and mortality as justification for the pain and suffering inherent in animal experimentation. In truth, however, if that is the goal,
then from a global health perspective, we would be getting a much better return on healthcare investment by sparing the animals and spending the money
on soap and hand-washing. Every year, respiratory infections and diarrhea kill
more than 3.5 million children under the age of 5, and that death toll could
be cut in half simply with soap and hand-washing. One study found 50% less
pneumonia and 53% fewer cases of diarrhea in families given soap and encouraged to wash their hands (Luby et al., 2005). A meta-analysis of similar studies
of diarrhea alone concluded that hand washing reduced its incidence by 42%–
47%, and that promoting hand washing could save a million lives a year (Curtis
and Carincross, 2003). No one expects the us research establishment to redirect any of its funding toward hand washing in the cause of global healthcare
or health justice, since the lives to be saved are outside the us. Nevertheless,
ethical justification for animal research, as a means for improving human
health, should be viewed with some skepticism when far more directly effective, less expensive, and ethically unproblematic means for saving millions of
children’s lives are immediately at hand but underutilized because of spending
priorities.
4

When Is Animal Research Stewardship and When Is It Despotism?

Stewardship is the careful and responsible management of something entrusted to one’s care. The concept has Judeo-Christian roots but has acquired a
secular meaning in an environmental context, embraced by many with no religious faith at all. Originally, stewardship was an obligation imposed upon humankind by God, when granting humanity dominion over the rest of creation.
As is often the case with the exercise of power, this dominion of humans over
animals has not worked to the animals’ advantage. For millennia, the prevailing human ethos has been instrumentalism, the belief that animals exist for us,
to serve our interests and wants. This attitude stems from moral anthropocentrism, the conviction that humans, set above animals by divine edict, should
always have absolute priority in our moral reasoning about animal use. While
this Judeo-Christian tradition has been hard on animals, at least in theory, obligations of stewardship accompanying dominion should temper our treatment
of animals even as we use them for our own ends.
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The concept of stewardship persists in altered form, as society has become
progressively less religious and more secular, challenging traditional assumptions about humanity’s divinely ordained special status in creation. The fact of
human dominion remains, even if attributed to evolutionary happenstance,
and is recognized in an atheist scientific worldview, now often expressed by
the term homocene or anthropocene to describe a human dominated natural
world (Schwagerl and Crutzen, 2014). A secularized version of stewardship
endures too, transformed into an ethical environmentalism in which our obligation is to preserve the ecological habitability of the planet we inherited
for future generations to enjoy. One ramification of ecological rather than religious stewardship is the recognition that humans are part of rather than over
and above the rest of nature. As Darwin initially observed, and subsequent
evolutionary biology has confirmed, human and non-human animals are fundamentally more alike than dissimilar (Darwin, 1859). Beyond shared biology,
behavioral research shows that many animals exhibit traits once presumed
to be uniquely human, including sympathy, empathy, cooperation, a sense of
fairness and justice, and a very humanlike capacity for future oriented cognition (Roberts, 2012). The privileged moral status humans continue to assign
ourselves is ethically arbitrary and self-serving, more an example of humans
as rationalizing than rational creatures, enlisting our intellectual nimbleness
in the service of our desires.
Animal researchers should consider themselves doubly obligated by a contemporary secular sense of stewardship. First, society pays for what they do;
and the poor translation of most animal research into human health benefits,
which is what the public thinks that it is buying, is a failure of financial stewardship. Second, stewardship in a secular scientific age requires a rebalancing of
the ethical scales we use in determining what kind of animal use is justifiable.
Science informs us that animals are sentient beings like ourselves, capable of
pleasure and pain (Griffin and Speck, 2004). They are not just property or tools;
they have their own interior life deserving of respect. If a more highly sophisticated capacity for ethical reasoning and morality is what sets humans apart
from other animals, then ethical reasoning and morality must always guide us
in how we treat them. Cruel basic science, rather than medically relevant experiments performed on empathy-inspiring species, may seem to be the easy
case to make against animal research as poor ethical stewardship. Nevertheless, decades of protests, focused on such seemingly easy cases to make, have
not, for example, stopped neurophysiological visual tracking research on Rhesus macaques in which they undergo coil implants in both eyes, holes drilled
into their skulls for recording electrode placements, and head immobilization surgeries in which screws, plates, and bolts are implanted in their heads.
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F ollowing these procedures, the monkeys are dehydrated to provide, what the
researchers call, a “work ethic”, so that they will visually track a moving object
for a sip of water reward, while tied into a restraining chair with their heads
bolted into an immobilizing frame. First impressions are accurate in recognizing animal cruelty, and most of us cannot even bear to look at pictures of
these monkeys with bolted heads and electrode-implanted brains being put
through their paces in a desperate attempt to get a life sustaining sip of water;
but despite ethical revulsion to an easy case of animal cruelty, this research has
continued for decades (Ramachandran and Lisberger, 2005); and cats, another
favored species, are being treated similarly (Yartsev, 2009), as well as mice (Guo
et al., 2014). Making animals suffer this intensely, in pursuit of a basic science
research agenda, merely because we can, because we have the power of total
control over them, is more despotism than stewardship. “Might makes right” is
not an ethical argument.
5

Who Decides if Ends Justify Means in the Ethics of Animal
Research?

Animal researchers occupy one end of an ethical opinion spectrum. They
have concluded that the hypothetical expanding of scientific knowledge justifies the means they employ, and that the suffering inflicted on experimental
animals is acceptable in the pursuit of a greater good. At the opposite pole
are animal rights activists, who believe that cruelty to animals is wrong, period, and that no scientific ends can justify means that entail animal pain
and suffering. Public opinion polling informs us that most people occupy an
ethical middle ground, with approval of animal research contingent upon
animals not suffering too much, and only in the service of research likely to
benefit human health. 51% of Americans believe medical testing on animals
is morally acceptable (Jones, 2017); and 65% of the United Kingdom public
supports medical testing in the absence of an alternative model (Clemence
and Leaman, 2016). People also express different attitudes towards animal
use, depending on the species involved, and are less supportive of research
using dogs, cats, and non-human primates than of research with mice, rats,
and fish (Ormandy and Schuppli, 2014). 48% of people in the uk believe it is
acceptable to use rats in medical research to benefit people, while only 16%
approve of using dogs (Clemence and Leaman, 2016). So, how are these ethical
differences arbitrated in academic research centers at present? And who gets
to decide, in specific instances of proposed animal use, if the end justifies the
means?
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In the us, federal laws and regulations that govern animal use in research
stem from public outrage over cruelty to animals destined for research laboratories exposed in a life magazine article in 1966, which prompted the us Congress to pass the Laboratory Animal Welfare Act. Subsequently renamed the
Animal Welfare Act (awa), and repeatedly amended in the decades since, it is
administered by the Department of Agriculture (usda). A 1985 awa amendment and the Health Research Extension Act, also passed in 1985 and administered under Public Health Service (phs) Policy on Humane Care and Use of
Laboratory Animals rules, both mandated the establishment of Institutional
Animal Care and Use Committees (iacucs) at all facilities performing biomedical research on animals (Levin and Reppy, 2015). Minimum iacuc membership requirements, initially set forth in the awa, balanced public bioethical
concerns and scientific expertise, stipulating a three-member committee to
include a laboratory animal veterinarian, a committee chair, and one member who is not affiliated in any way with the institution and is not an animal
user, who would represent general community interests in the treatment of
animals. The minimum phs iacuc requirements were similarly balanced,
stipulating a minimum of five persons, including an institutional laboratory
veterinarian, an animal researcher, a member unaffiliated with the institution,
and a member whose primary concern was not in the scientific arena (e.g., an
ethicist, lawyer, or clergy member) (Hansen, 2013).
The founding directives for iacuc memberships would have created iacucs
that reflected public concern for laboratory animal welfare and performed
ethical cost-benefit analyses of proposed animal research, with approval contingent upon a balancing of animal pain and suffering against a reasonable
expectation of resultant human benefit. However, institutions heavily incentivized by grant funding attached to animal research realized that the usda
and phs dictates for iacuc membership were only minimum requirements
which did not limit the numbers of additional animal researchers who could
be appointed to the committees, tipping their balance to ensure approval of
all animal research protocols. They also recognized that, unlike the European
Union Directive instituted to address the same bioethical issues in animal research (Directive 2010/63/EU, European Parliament, 2010), neither of the two
us regulatory requirements set for iacucs specifically mandated an ethical
review of animal research protocols prior to their authorization (Levin and
Reppy, 2015).
Consequently, expanded iacucs now averaging 23 members rather than
three or five, are heavily skewed towards animal researchers (67%) and institutional veterinarians whose livelihoods depend on animal research (15%),
and 93% of iacuc chairs are animal researchers (Hansen, 2013). Predictably,
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iacucs in which 82% of members and 93% of chairs have vested interests
in continuing animal research approve essentially all proposed animal experiments set before them. 98% of proposed animal experiments are approved
according to the most comprehensive analysis available (Plous and Herzog,
2001), without considering an ethical balancing of animal harm against human health gain. An expert on how iacucs function, and a longtime defender
of the system, writes plainly, “Few people realize that virtually nothing is prohibited by the Animal Welfare Act, so long as it can be justified to the iacuc.
Nor do iacucs, by and large, function by rejecting animal protocols when the
ethical costs are too high […] [R]ejection of protocols is not what iacucs do
[…] [E]ven painful animal experiment may be allowed […] any research protocol may be approved […] regardless of any weighing of the potential benefits”
(Carbone, 2004).
This institutionalized blanket endorsement of all animal use disregards the
public’s attitude of contingent approval of animal research, heavily qualified by
concerns over limiting suffering, promises of resultant disease treatments, and
avoidance of experimentation on favored species, i.e. dogs, cats, and primates
(Henry and Roarke, 2009; Swami, Furnah, and Christopher, 2008). An example
iacuc ruling from the University of California, San Diego (ucsd), in 2001, illustrates how disconnected the system is from public bioethics. Hundreds
of San Diego physicians signed an anti-dog lab petition, urging the Medical
School to end dog vivisection and euthanasia teaching exercises in a freshman
pharmacology course. These physicians knew from professional experience
that killing dogs was unnecessary in becoming a doctor and so filed an appeal
to the ucsd iacuc, pointing to phs guidelines requiring a good-faith effort to
replace animal labs in education and research, once alternatives became available. The signatories to the anti-dog lab petition reasoned that since 95% of
schools taught the course without killing dogs (Hansen and Boss, 2002), it must
be unnecessary for ucsd to do so. The official response of the ucsd iacuc
was that vivisection and euthanasia of dozens of dogs in those labs raised no
animal welfare issues. This seemed like Orwellian newspeak to the doctors, and
public protests followed. Finally, after sufficient adverse publicity, the ucsd
Faculty Council and School of Medicine Department Chairs ended the unnecessary dog vivisections, accomplishing what the iacuc should have done
years before; that is, “respect society’s concerns regarding the welfare of animal
subjects” (Hansen, 2013, p. 188), as was stipulated in the awa amendment of
1985, creating the iacuc system.
So, the answer to the question, who decides if ends justify means in the ethics
of animal research? is—animal researchers. But the word decide is misleading
in this context, if it is taken to imply the result of a deliberative process that
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could have more than one outcome, as when a jury decides to acquit or convict a defendant. The animal researcher dominated iacucs have determined
a priori that experimental animals are of so little ethical worth compared to
the value they place on hypothetically increasing scientific knowledge that the
ends always justify the means. Decisions from committees of wolves arbitrating the fate of sheep would be less predictable.
6

How Could Research Ethics Be Better Aligned with Public Concern
for Animal Welfare?

The iacuc system fails to address ethical issues in animal research which are
of concern to the public, because it is dominated by those whose livelihoods,
careers, and professional identities are dependent upon the unfettered continuation of animal experimentation. It is asking too much of human nature
to expect that committees of animal researchers could set aside their conflicts
of interest, inclination to groupthink, and conscious and unconscious biases
to look at the ethics of animal use in research as does society at large. Ethical constraints on how animals are treated in research have always been externally imposed on an, oftentimes, resistant biomedical establishment. The
latter’s ingenuity in evading such constraints is seen not only in its stacking
of the iacuc membership deck with animal researchers, but also by its successful lobbying effort to amend the AWA in 2002, so as to exclude from its
protections mice and rats who comprise 99% of the animals used in research
laboratories (Farm Security and Rural Investment Act, 2002). Even the few favored species of greatest ethical concern to the public, i.e. primates, dogs, and
cats, supposedly covered by the nominal protections of the awa, are routinely
subject to medically irrelevant basic science experimentation, which most
people would consider cruelty, if it were performed on themselves or their pet
dogs or cats.
Two possible solutions to the disconnect between society’s nuanced and
qualified attitude towards animal research and the iacuc’s philosophy of
“anything goes” are worth considering, both of which would work towards
achieving the paradigm shift in ending animal experimentation. First, the AWA
could be amended to restore its initially intended balance b etween researchers
and members representing societal interest in animal welfare. A second more
definitive approach would be a legal ban on research using primates, dogs,
and cats, leaving researchers with 99% of the animals they are using currently,
and respecting the public’s ethical qualms about the suffering of their favored
species. One precedent for how protecting favored species may succeed is the
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constraint recently imposed on chimpanzee research by the nih, in response
to a report from the Institute of Medicine Committee on the Necessity of the
Use of Chimpanzees in Biomedical and Behavioral Research (Kahn, 2014). If
one species of non-human animals can be set off limits to vivisection, solely
because of ethical concerns, it raises hopes that others may follow, which is
why the constraints were so strongly opposed by animal researchers not using chimpanzees, fearing this precedent may be the thin edge of an ethical
wedge. As for legally banning companion animal research, the fact that in 2014
Americans spent over us$50 billion on their dogs and cats may indicate that
there is a deep, yet untapped, reservoir of potential political support for such
legislation.
7

Summary and Conclusions

Paradigm shifts in science occur when new theories make more accurate and
reproducible predictions than old ones about empirically observed natural phenomena or experimental results. When the term paradigm shift is applied to the
ethics of animal experimentation, the concept becomes less scientifically literal, and understanding how ethically seismic paradigm shifts occur in human
history is challenging. Once they have occurred, however slow their incubation,
they are codified into laws reflecting an altered ethical consensus. Slavery was
once legal, now it is not; women now have equality under the law with men, but
through most of human history they did not. Changing the ethical paradigm
about animal experimentation requires both a scientific analysis of its lack of efficacy in improving human health, and an ethical appeal to broaden our sphere
of compassion for our fellow sentients. If successful, such a paradigm change will
ultimately outlaw any animal experimentation that causes pain and suffering.
From a purely scientific perspective, multiple meta-analyses indicate that
animal based research only rarely translates into improved human health. This
failure of to benefit human health can result from poor study design as well as
intrinsic evolutionary differences, precluding the extrapolation of results from
one species to another; but regardless of its cause, this failure undercuts a major
ethical justification for inflicting harm on animals in biomedical research. nih
directors past and present recognize the low yield of animal research in benefitting human health and recommend shifting funding priorities towards new
methodologies for use in humans to understand disease biology in humans (McManus, 2013). From a global healthcare perspective, and considering the ethics
of healthcare justice, money spent on basic science animal research, if diverted
to implementing healthcare interventions of proven efficacy, could save many
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millions more human lives. Legal constraints were imposed on animal research
by us Congress in response to public outrage over exposés of animal abuse, resulting in the Laboratory Animal Welfare Act in 1966 and the mandated creation
of iacucs in 1985 to address public concerns about laboratory animal welfare.
However, iacucs, as currently constituted, are dominated by animal researchers who have determined, a priori, to approve any and all use of animals in
biomedical research, without regard to public ethical concerns about limiting
animal suffering, which species are used, and relevance to human health.
Because animal researchers now control the use of animals in experimentation, any paradigm change will require wrestling authority away from them and
investing it in a broader range of ethical stakeholders, specifically the public
and its elected representatives who are more inclined than career vivisectors
to weigh the ethical cost to human benefit of animal experimentation. The ban
on chimpanzee vivisection, despite the opposition of animal experimenters,
may represent a template for moral progress toward the hoped-for paradigm
shift. If public empathy for our fellow primates can overcome the resistance
of the biomedical academic establishment to banning chimpanzee research,
it is cause for optimism that a similar approach to other favored species, such
as dogs and cats, may generate an ethical momentum, like falling dominoes,
towards finally expanding the circle of human compassion to encompass all
creatures capable of pain and suffering.
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1

Introduction: “Don’t Be Emotional, Let’s Focus on the Facts”

The fact that countries all over the world continue to develop new regulations for experimentation on non-human animals testament that this practice raises many doubts. Our aim in this chapter is to show that one important
type of doubt should receive more attention: a particular type of moral doubt
that could play a pivotal role in the ethical review of animal experiments. We
assume that there are a range of emotions that indicate morally complex or
problematic situations. When one or all of these emotions are experienced,
we say that someone is experiencing moral doubt. To illustrate this point, we
introduce the concept of moral doubt in the context of review processes, as
they are legally required in the European Union (eu). Independent evaluation
committees review animal research proposals to advise competent authorities
whether applications for animal experiments comply with the legal standards.
We chose the case of Germany as an example to explain what these committees decide upon and the degree to which their decisions may be influenced
by emotions. We develop the argument that acknowledging emotional moral
doubt throughout the review process, in specific ways, may have the positive
effect of fostering paradigm change in animal experimentation, as envisioned
in Directive 2010/63/EU (European Parliament, 2010).
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Review Processes between Technical Checks and Ethical Advice:
Lessons Learned from the German Practice

European animal welfare and protection laws regulate ethical conflict surrounding animal experimentation in the following way: They require that
experiments be authorized based on a harm-benefit analysis and that the
principles of the 3Rs (replacement, reduction, and refinement) be implemented, as outlined in Directive 2010/63/EU (European Parliament, 2010,
Recital 11 and Article 4). Moreover, “animals should always be treated as sentient c reatures and their use in procedures should be restricted to areas which
may ultimately benefit human or animal health, or the environment” (European Parliament, 2010, Article 12). This is the extant ethical consensus, which
is reflected in national legislations. We argue that review processes have two
functions: a technical function to ensure that this consensus is implemented
(technical function); and a normative function to identify new reasons for ethical concern (ethical function).
2.1
Evaluation Committees as Legal Advisors in European Animal Law
Under European Union legal harmonization, eu Member States have intro
duced review processes (rps) to evaluate whether applications comply with
legal standards. Since information on the many different rps is scarce, we must
rely on Silva et al. (2015), who collected and confirmed data from 20 Member
States. However, all Member States have implemented some form of rp. In
cases where information is available, Member States require that the opinion
of an external evaluation committee must be taken into account by the competent authorities (Silva et al., 2015). The required expertise in such committees
varies: most eu Member States require knowledge in technical, medical, or
natural sciences as well as veterinary health and welfare. Some Member States
require legal expertise (e.g., Finland, Poland, Denmark); others require expertise in ethics (e.g., Belgium, Estonia, Netherlands) or alternatives to animal
experimentation (e.g., Latvia, Netherlands). In some states, representatives of
interest groups are nominated, such as animal protection (e.g., Poland, Croatia,
Sweden); p
 atients (e.g., Denmark and Poland); or general society, as represented by lay persons (e.g., Portugal and the United Kingdom) (see Silva et al., 2015).
Despite the differences in expertise, any RP fulfills two functions. First, to
evaluate what applicants describe as the scientific purpose of their experiments, with regards to their plausibility. Part of this plausibility check is an
evaluation of whether common means to reduce suffering (refinement) are
in place; and whether the smallest necessary number of non-human animals
is used (reduction). We call this the technical function. However, it is widely
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acknowledged that the implementation of Directive 2010/63/EU expects RPs
to do more, namely to provide an ethical evaluation independent from the
applicant (Hirt, Maisack and Moritz, 2016; Maisack, 2016; Peters and Stucki,
2014). This includes weighing alternatives, including animal-free alternatives
(replacement). Indeed, if technical or science-based checks were the only
function, there would be no need to include representatives of interest groups
or ethical expertise in the committees. Hence, the second ethical function of
independent committees is to advise the respective authority on a compelling
harm-benefit analysis, including the “indispensability” of a planned experiment. We return to this point below because, given the way committees actually work and applicants approach them, the issue is more complex. In theory,
at least in cases of severe harm to non-human animals, authorities have to be
“satisfied” with the “sufficient importance” of an experiment in order to allow
it, as specified in the European Treaty Series (ets 123) (1986, Article 9).
In cases of substantial conflict of interest, pluralist democracies enable representatives of interest groups to negotiate in parliament in order to achieve
compromises that benefit the common good (Fraenkel, 2011). The outcome of
such discussions usually leads to a normative decision, in the form of a law, to
be enforced by executive forces (e.g., competent authorities). The institutional
approach implicit in Article 9 of the ets (1986) is different because enforcement and normative decisions go hand in hand. Competent authorities in EU
countries have to weigh the interests of non-human animals and researchers
on a case-by-case basis and, by doing so, implement the law, while allowing for
different interpretations. Hence, the weighing process is transferred from the
legislative to the executive power. Since this can be problematic, external evaluation committees were introduced to include the contributions of experts
and representatives of interest groups, as mentioned above (Silva et al. 2015).
For example, in Germany and the United Kingdom, RPs were introduced in
1986 (Biedermann, 2009).
The ethical RP is important when it comes to research competition within the EU. Member states have “a certain flexibility to maintain national
rules aimed at more extensive protection of animals” if the functioning of
the internal market is not affected (see European Parliament, 2010, Directive
2010/63/EU, Article 7). Presumably, an economized medical and pharmaceutical sector will allocate its research where regulation is low and animal protection measures are least costly. Consequently, if a country uses the right to
impose more extensive animal protection measures than those agreed upon at
EU level, applicant institutions (e.g. international pharmaceutical companies)
may look for other countries where regulations are less extensive. This is why
the work of RPs is an important instrument in working towards a paradigm
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change in animal e xperimentation, as requested by EU law; and this is why a
harmonization of RPs, as a means to secure implementation of EU regulations,
may be desirable as well. In what follows, we discuss some of the shortcomings
of the German RP in order to draw conclusions for improving RPs in general.
The German “Ethics Committees”: Ethical Review or Technical
Plausibility Checks?
According to most recent reports, over 2.8 million non-human vertebrates
were used for scientific purposes in 2017 (Bundesministerium für Landwirtschaft
und Ernährung, 2018) which makes Germany Europe’s second highest user of
non-human animals for research purposes (Cruelty Free International, 2016).
We now turn to the situation of the RP in this country to see how the ethical and technical functions are implemented and to understand some of its
complicating factors. The German animal protection law, Tierschutzgesetz
(TierSchG 2006, last amended in 2017), requires that competent authorities assess the indispensability of experiments (Section 7a); and that they be assisted
by external committees (TierSchG 2006, Section 15) in reviewing the animal
research proposals. These are the German rps. The declared intent was that
these committees would support authorities with expert knowledge, and that
animal protection organizations would be given the opportunity to propose
members (Deutscher Bundestag Drucksache 10/3158, 1985). The majority of
the members have to possess expertise in medicine, veterinary medicine, or
natural sciences (Tierschutz-Versuchstierverordnung, TierSchVersV 2013, Section 42(1)). These members may conduct or may have conducted animal experiments themselves; and one third of the members should represent animal
protection organizations (TierSchVersV 2013, Section 42(2)). Therefore, committee m
 embers from animal protection organizations are the minority (Hirt,
Maisack and Moritz, 2016). Moreover, although the law makes reference to the
need for ethical justification (TierSchG 2006, Section 7a(2)(3)) and for ethical
expertise (TierSchG 2006, Section 9(1)), what it means is unclear. The fact that
members of the committee work under strict confidentiality (presumably in
order to protect personnel involved in the research, their families, and the
animals themselves) adds to the lack of transparency; the public cannot be
consulted on questions where the normative consensus is, arguably, in flux. Efforts have been made, post factum, to make basic information regarding authorized experiments easily accessible to the interested public (see https://www
.animaltestinfo.de); however, the public, who are increasingly willing to stop
certain experiments to protect animals (Eurobarometer, 2005; European Citizens’ Initiative, 2016; Greenpeace Magazin, 2003), have no say in the matter.
Another complicating factor is the potential tension between animal a dvocates
2.2

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

Beyond Plausibility Checks

293

and scientists in the committees, which makes an open-minded examination
of individual cases difficult. As noted above, unresolved conflicts over animal
experimentation at the legal level are, in part, decided on a case-by-case-basis
in the committees. At the same time, committee work is supposed to be based
on objective standards of evaluation. In practice, it is often unclear who adheres to what standards of debate; and, as a result, work in the committees
can oscillate between the search for ethical truth and the quest for political
compromise. The final decision on the approval of an application does not
have to be unanimous. Six members (normally) have to vote for the decision
to be considered by the authorities, who eventually decide whether to grant or
prohibit the research. Committee work is voluntary, with little reimbursement
for time invested. While medical or veterinary researchers may be permitted
to work on applications during working hours, other members are not always
able to do so and are thus clearly disadvantaged.
Finally, the problem of finding animal-free alternatives to a proposed experiment remains. While it is incumbent upon the applicant to show that no such
alternatives exist, this is often done by a simply stating that that is the case.
While committee members are not supposed to be co-researchers, they will
do what they can to find out whether that is true. At the same time, they can
hardly be experts in all relevant animal research fields. For example, a research
consortium proposed to test inequity aversion in mammals, including humans
(Bundesinstitut für Risikobewertung, 2015). Not entirely without irony, the idea
was to use rats (next to marmosets and tamarins) because of their highly social
nature; and it was explicitly stipulated that, in the long run, results from this
experiment would allow adaptations in human society that increase prosocial
behavior and cooperation. It was also expected that the experiment would
promote better protection for non-human animals who, socially, can prove to
be much more complex creatures than expected. Six-hundred and four rats
were to be confined in standard laboratory cages, and they would be killed at
the end of the experiment. Harms inflicted on the non-human animals further included separation of individuals from their group (fear); injection of
hormones; and handling. The applicant had to show that there were no nonanimal alternatives for the experiment, and that results could not be obtained
through observance of the behavior of free living non-human animals. However, one would need to be an expert in behavioral animal sciences and animal
cognition to prove this assumption right or wrong. Given that committees do
not specialize in certain themes or research topics, it would be a coincidence if
a committee member knew the issues involved well enough. And even if such
an expert happened to be a member of the group, they would need sufficient
time to establish a compelling, suitable alternative to refuse the application.
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Note that emotions arguably play a role in the assessment of this experiment;
anger and incredulity regarding the supposed transferability of results or the
disregard for research in the social, political, and/or economic sciences would
likely have occurred. After all, humans are not 70kg rats, in terms of their metabolism, and certainly the complex conditions of inequity present in human
societies and the ways in which they can be dealt with cannot be modelled
using rats in a cage.
Thus, we can see how the fact that it is often difficult to prove that alternatives exist practically reduces the application of the 3Rs to two, namely, reduction of animals involved and refinement, i.e., applying all methods and means to
reduce pain, distress, harm, and suffering (see Herrmann, 2019, Chapter 1 in this
Volume). However, simply living under laboratory conditions is distressing for
the animals and raises ethical questions. Hence, we argue that such a reduced
evaluation does not meet the ethical principle of the German animal protection
law, which states that “experiments on vertebrates and cephalopods may only
be conducted, if the expected pain, suffering and harm is ethically justifiable
regarding the purpose of the experiment.” (TierSchG 2006, Section 7a(2)(3)).
There is, then, a serious tension at the heart of the RP. Although the public
is led to believe that ethical justification plays an important role in committee work—colloquially known as ethics committees in Germany (Hirt, Maisack,
and Moritz, 2016)—the RP practically disregards real ethical alternatives and
focuses on minor technical adaptations. Convincing RPs would necessarily involve a much more careful evaluation of the intended infliction of harm on
animals, in light of the expected benefits of and possible alternatives to the
experiment. In order to achieve this, we propose careful consideration of emotional sensitivities surrounding animal experiments.
There are good reasons to assume that emotions are important in identifying and clarifying ethical questions. Instead of singling out one emotion in
particular, we suggest calling the experience of a range of potentially conflicting emotions when confronted with animal experiments moral doubt. While
we explain this idea in more detail below, we emphasize that the distinction
between ethical and technical assessment is not always straightforward. Consider, for example, the so called, severity assessment of animal suffering. The
estimated individual condition of animals during an experiment can hardly
be conducted without an empathetic understanding of the animals’ minds;
for it is the empathetic engagement with a suffering animal that motivates
the individual to alleviate the harm done to them (Aaltola, 2012; Gruen, 2015).
Therefore, one cannot assess the urgency to alleviate the suffering—and that
precisely must be the idea of a severity assessment—without any empathetic
engagement. However, despite their obvious importance in moral and political
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life, the role of emotions in ethical inquiry surrounding animal experiments
has not been clarified. In the tradition of animal protection in Germany, emotions have been ignored and even treated as unprofessional, non-scientific
threats. Calls for more sobriety include the explicit demand that emotions
ought to be suppressed (see von Gall, 2016). A similar culture of debate can be
assumed to surround the current RP in Germany. This shows that, in order to
assess the potential of RP to foster paradigm change, the connection between
genuine ethical review and mere technical checks is highly relevant.
In 2012, the administrative court in Bremen ruled that competent authorities
only need to ensure “qualified plausibility checks” of the experiments and may
refrain from ethical assessment of harms and benefits (Higher Administrative
Court Bremen, 2012, p. 16). Although this ruling has come under juridical critique and does not meet the requirements of Directive 2010/63/EU (Maisack,
2016; Peters and Stucki, 2014), it mirrors a tendency to focus on technical checks
and to neglect more extensive ethical review in current RP practice. This tendency is reinforced by institutional factors, including, but not limited to, the
dominance of life scientists in the committees, no proper compensation, lack
of time, and the unresolved question of how to better include expertise on
non-animal alternatives. Nevertheless, the public is under the impression that
competent authorities do everything to seek ethical advice, and that no animal
is killed without compelling reason.
3

Emotions in Inquiry and the Case for Moral Doubt in Ethical
Review Processes

Now that we have highlighted the tensions surrounding the RP, what is the
role of emotions here? Why should a particular form of emotional experience, namely what we term moral doubt, be at the heart of a well-functioning
ethical review? And how can we achieve concrete improvements of the
committees—such as, integrating committee work with the political process,
or greater transparency of animal testing where committee members are allowed to voice their concerns publicly—if we take moral doubt seriously?
Emotions, in general, suffer from the stigma of being irrational (Midgley,
1983, Chapter 3). This is true in the context of the RP as well. If committee
members show too much empathy for animals, they are at risk of being charged
with anthropomorphism; they may be accused of being unprofessional if they
get angry about something that may very well deserve an angry response, such
as the general sloppiness of an application; the lack of standard forms of refinement (Herrmann, 2019, Chapter 1 in this Volume); or even the presence
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of a palpable contempt for the RP itself. For members who are asked to repress or ignore such emotional responses, this can lead to self-censorship and
alienation from the process. While we know of no official qualitative study of
committee work, our own experience and unofficial reports substantiate the
suspicion that the dynamics of these committees may be analogous to dynamics that have been problematized under the concept of epistemic injustice
(Fricker, 2007). Epistemic injustice occurs when prejudice operates in ways
that lead some knowers to discard the testimony of others for epistemically
irrelevant reasons, as in the case of a white jury not believing the testimony of
a black person or a man not believing a woman. In both cases, the individual’s
epistemic competence is doubted because of a problematic prejudice: that
people of color/women are not trustworthy. Experiencing this injustice is considered a harm that can have alienating effects. We argue that something very
similar can occur when people who express their moral doubts in emotional
terms are regarded as less reliable because of the prejudice that emotions are
necessarily irrational. Moreover, in the committee as a whole, it may lead to
polarization, and, importantly, to an incomplete grasp of the problem at hand.
In what follows, we suggest a more constructive role for emotions in such inquiries. Although, at times, disturbing and difficult to experience, emotions
are both important sources of information about moral values and intellectual
virtues (Hookway, 1993), i.e., dispositions to react to information with hope, interpret them charitably, or experience the proverbial love of truth. All of these
are easily dismissed and ignored to the detriment of the RP.
Emotions, Value Recognition, and the Framework of Directive
2016/63/EU
While precise philosophical reconstruction is a matter of debate, an important
connection is often assumed between emotions and values and our motivations to do something about values (e.g., Deonna and Teroni, 2015; Tappolet,
2016; Kriegel, 2015). To doubt, for example, by shaking your head and calling x
unbelievable, crucially involves a hesitation to continue business as usual and
a refusal to accept x as normal, good evidence, or appropriate; to say that x is
disgusting or abhorrent is to identify x as predicated by a negative value that
motivates a range of actions aimed at changing the situation. Emotions can
also act as signals to others (van Kleef, 2009), about what you think or what you
are likely to do next, a warning to others or a request for them to attend to a
situation more closely. Such evaluations and suggestions regarding what to do
are, of course, preliminary and are, at times, affected by other emotions. Your
trust in the good intentions of other committee members may lead you to drop
3.1
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an issue that angered you. Emotions still need to be taken seriously for inquiries to go well, since they help create a complete picture of the circumstances
of the inquiry you find yourself in (Hookway, 2003; Szigeti 2013). To suppress all
emotions, such as disgust, shame, or fear when entering a committee meeting
(or a laboratory, for that matter) on account of professionalism is irresponsible
because you may fail to notice things that are indeed disgusting, shameful, or
scary. These evaluations are not projected upon a supposedly value-neutral,
factual situation. Rather, they are part of human practices and objects of inquiry that people must eventually agree upon. To the extent that science, by
virtue of being a practice as well, is far from being value neutral (Douglas, 2009;
Longino, 1990), it is desirable that a sense of moral integrity is restored at the
heart of the highly problematic practice of animal research. Such integrity is
minimally defined by the fact that it operates with meaningful moral concepts
and value judgments, a core tenet of pragmatism (Putnam, 2010).
Thus, there is a factual component to the question of whether something
is, for example, cruel or not; and to rid oneself of emotional sensitivity makes
it unlikely to discover this. It is important to mention that such sensitivity is
already numbed at the level of the analytical terms at the committee members’
disposal. This is symptomatic of the misleading, objectifying language that surrounds animal testing (Crary, 2016). To give an example, committee work relies
on a severity classification that defines categories of animal suffering, ranging
from low to high: non-recovery, mild, moderate, and severe. However, the allegedly lowest category of severity, which most experiments imply, is the killing of
animals at the end of the experiment, despite the fact that many of them could
live much longer. At the same time, Directive 2016/63/EU requests an acknowledgement of the “intrinsic value of life” of animals (see European Parliament,
2010, Annex v). Similar knowledge of value and commitments are expected by
the German animal protection law (TierSchG 2006, Section 1; TierSchVersV 2013,
Annexes 2.2, 3.2). The tension between ethical rhetoric and reality provokes
emotions and calls for intense debate about cruelty. The same is true for many
other cases. For example, the deprivation of social partners for up to 24 hours
is classified as mild. While most companion dogs are not left to endure prolonged separation from their social partners, why should it be okay for a rat not
to know where her cagemates are for a much longer period of time? These examples only scratch the surface of the issue at hand, and we are not even close
to evaluating questions involving intentional pain and suffering inflicted on
animals. However, the fact that legitimate doubts already appear at this point
supports the claim that more ethical inquiries are needed to foster change in
the current system.
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3.2
Exercising Moral Doubt in the Context of Animal Testing
We have discussed the disruptive nature of doubt, disgust, anger, and the
like. Here, we illustrate the moral doubt that can arise concerning animal experiments. We follow the tradition of philosophical pragmatism, in that we
propose a problem-driven, generally science-friendly approach to reasoning
that subscribes to fallibilism and contextualism and maintains that there is
no fundamental dichotomy between facts and values (Putnam, 1994), to name
the pragmatist tenets that are important to our topic. Accordingly, we suppose
that problems occur when our habits to think and to act break down, i.e. when
we experience inconsistencies. If, for example, I experience distress from the
use of an animal for the purpose of x, believing that x is unproblematic, my
doubt by virtue of experiencing the creature’s distress is a sign that the practice
is not unproblematic. Ideally, I would pause and reflect. My goal is to establish
a belief that will not be easily questioned by future experience, for instance: “I
shall not use any an animal for purpose x” or “Purpose x is unproblematic, but I
need to change the situation for the animal in ways that eliminate the distress.”
Emotions that occur in the context of animal experimentation include disgust,
anger, compassion, and hope (to name but a few). When we experience one
of these emotions, or a mix of them, in ways that demand that we pause and
reflect, we experience moral doubt that can help us evaluate issues of animal
experimentation.
It is important to note that doubts also need to be taken seriously when
someone else expresses them, i.e. if I fail to find anything problematic in what
I am doing, but someone else alerts to me to potential ethical problems that I
may not have noticed (Trout, 2010). This reinforces the issue of diversity in sensitivities within the committees. If I have had to train myself to ignore moral
doubts that I may otherwise experience, in order to pursue my career by experimenting on animals, I must rely on someone else’s emotional sensitivity
whose moral doubt is intact. This is needed at multiple stages, assuming that
any inquiry includes acknowledgement of a problematic situation, clarification of what the problem really is, determination of possible solutions, and (hypothetical) reasoning and the testing of the solution (Dewey, 1938, Chapter 6).
Moral doubt is relevant because it functions as a sign that there is a problem.
Moreover, it can entail suggestions as to what the problem may be. Finally,
emotions are involved in suggesting solutions that are deemed morally appropriate (Fesmire, 2003). They can act as intellectual virtues, such as courage or
conscientiousness; and they will play a role both in the hypothetical reasoning
and, ideally, in the evaluation of whether the problem has been solved well.
However, emotions are not necessarily constructive. While, for example,
empathy and anger over injustice done to rats, which are part of testing
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inequity aversion, are appropriate, it is easy to see how high hopes regarding
the research proposal or feelings of loyalty towards the applicant can lead the
RP astray. It is also important to note that the secrecy surrounding committee
work can lead to cowardice in addressing the concerns that arise in the committees, or in public, for fear of risk to one’s career. We have already noted the
desirability of restoring moral integrity at the heart of science and addressing the values and value conflicts that arise in inquiry, for which we currently
lack appropriate concepts. We propose that committees need to be sensitive to
the way in which language surrounding animal experiments obstructs ethical
complexities. Committee members need to approach rhetoric within applications cautiously, evaluate experiments at face value, and ensure that the ethical function of the RP is taken seriously. In this, the so-called pragmatic maxim
can be of help. It asks us to elucidate concepts in terms of their conceivable
effects, which in ethics should be understood as finding the right words (Cojocaru, under review). This can help criticize the emptiness of the word ethics used in legal documents as well as describe the problems committees are
actually dealing with. Systematically applying the pragmatic maxim can help
steer through a sea of jargon and euphemisms and render the specific context
under evaluation more precise. Emphasizing that the language we use to speak
about animals and their suffering matters, because it habituates us to think
and act in certain ways, shows that the application of the 3Rs touches upon
more than simple technicalities; and that they are about scientific and moral
integrity much more than about plausibility based on the assumption that science is value-free.
In summary, we suggest that the integration of moral doubt into RPs can
achieve two things. First, it may lead to a more conscientious adaptation of
animal protection, already envisioned in Directive 2010/63/EU, by challenging both the relative neglect of the ethical dimension of the RP compared to
technical checks and the moral numbness of people planning, conducting,
evaluating, and overseeing the experiments. Since the pragmatist methodology emphasizes the importance of learning from errors and insists on the evaluation of tested solutions, a retrospective evaluation of projects that have been
granted authorization would be highly desirable as part of the RP. Second, it is
likely that some questions of animal testing will not be resolved within the RP,
specifically those that are already unanswerable within the existing framework
or those that arise when a regulatory framework itself is questionable. When
doubt cannot be resolved, the practice should not proceed, so that important
opportunities to inquire into value conflicts are not missed. While this may
not sound very pragmatic, the principle of living doubt may provide a moral
compass whenever a, so-called, dilemma between erring on the side of caution
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and scientific progress is construed. Any such rhetoric, which, it should be noted, manipulates emotion, should be held in check; and where doubts prevail,
members of the RP must suspend judgment; integrate all possible sources of
information to get a clear picture of the problem at hand; and engage in public
debate, not as moral experts who explain supposed necessities to a sentimental public, but with an intellectually honest request for help.
4

Concluding Comments

Competent authorities throughout the EU face the challenge of ethically
evaluating animal experiments, and Directive 2010/63/EU demands that

applications be evaluated by third parties other than the applicant. Expert
committees may be a suitable model for this purpose, as long as the basic principles of their work are submitted to democratic control. One way or another,
experts will have to deal with emotions when deciding on the life and death
of countless, sentient animals. The way in which experts deal with their own
emotions and those of others is likely to impact their decisions. The question, then, is not whether but how this influence occurs. While we stress that
no comprehensive study of experts’ actual emotional regulation has been
conducted, in this c hapter, we provide an answer to the normative question,
whether c ompetent authorities and experts have good reason to articulate and
acknowledge clearly their emotional moral concerns and consider them as relevant for decision-making. The answer is, yes. We base this answer on a philosophical account of emotional functioning. Moral doubts signal problems
in particular situations, say something about the nature of the problem, and
push for solutions. In our case, the problem is the suffering of millions of animals subjected to experiments that will hypothetically improve human life—a
definitive moral cost for an uncertain benefit. If the RP does not provide room
to find the right words when articulating these emotional signs, the problem-
solving potential is lost. We argue that acknowledging, and not suppressing
and ignoring, moral doubts can foster the envisioned paradigm change in animal experimentation. In order to enable such an optimistic perspective, a variety of conditions need to be fulfilled.
In cases where a substantial debate cannot resolve a conflict, the RP should
be able to communicate concrete, open-questions to political or legal decision
makers. RPs are impeded by lack of clarity in the implementation of vague
legal norms, such as the prohibition of unnecessary suffering. The public and
the legislator need to know about the unanswered questions that follow from
these impediments and push for solutions. Interaction should also exist at the
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academic level. In cases where doubts about suitable alternatives to an animal
experiment exist, applications need to be forwarded to experts on the topic
in question, even if they are not part of the committees. Given the variety of
research topics, even a medical scientist cannot evaluate any topic in medicine. Aware of such problems in the RP, educational bodies can also take on
pivotal issues in moral training. Evaluation committees may not be the only
institutions to inform the RP. Non-governmental organizations (ngos) traditionally play a central role in informing public decision-making about the
plurality of different interests, and this work has to be transparent. It is questionable whether scientists in evaluation committees really are independent
from special interests and solely rely in their decisions on objective and ethical
accounts. A clarification of the vested interests involved in legal decisions can
be stipulated by ngos. Moreover, in order to evaluate the evaluations, it is important to review systematically all the research projects that were granted
authorization; for example, did they achieve what they had promised, and
what happened to the animals involved? More direct monitoring and publication of this data could also help assess whether, for example, the severity classifications help in practice. Such post-hoc evaluations may be both the source
and legitimation of moral doubts regarding similar projects in the future.
The tension between the current practice of animal experimentation and
the ethical value of unnecessary suffering, hopefully, provokes emotions. Indeed, ethical review must be based on facts. However, given the many uncertainties and problems surrounding the RP, above all, one thing is clear: there is
a strongly felt sense that we need non-animal alternatives in research. Ignoring
this and continuing to participate in an inherently dubitable practice impedes
reasonable solutions. Finding the right words when expressing moral doubts
is a technical skill to inform legal decision making, and we currently disregard
this skill at the expense of our moral and scientific integrity.
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1

Introduction

Most research on non-human animals (hereinafter referred to as animals) involves clear harms for the animals used, either as a direct result of research
protocols or by virtue of the conditions under which the animals are kept. Arguably, however, although these harms are widely acknowledged, they have
not motivated significant change to the practice of animal research. In this
chapter, we focus on the damage to humans that can result from animal experimentation and how this may act as an alternative driver of change.
Humans employed in animal research, whether inside animal housing or
the laboratory, confront significant stress as a result of what they routinely do
as part of their job, as well as by virtue of how that work is received by “outsiders” to animal research. These workplace stressors can result in physical and
psychological harms. It is well known that human patients may also be harmed
as a consequence of the epistemological shortcomings of research undertaken
on animals, which fails to translate to human clinical settings. Whilst we will
briefly discuss these kinds of physical and psychological harms, our primary
focus is the moral injury that can result from the practice of animal research.
Moral injury occurs when a disregard of someone’s well-being causes them
harm. Typically, this is understood to encompass the kind of moral wrong that
may arise from systematic injustices or from criminal or violent acts. However,
moral injury is increasingly recognized as a problem for the perpetrators as
well as the victims of certain acts. Moral injury, thus, also occurs when a person
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is complicit in activities that they feel are morally wrong or transgressive. Moral injury as a phenomenon, in this sense, is well established in military situations, where personnel may undertake or witness actions that would be illegal
or immoral in other settings.
Using arguments derived from the work of Axel Honneth (2006), we show
that animal research involves an institutionalized failure to recognize nonhuman animals that not only reifies animals but the human persons engaged
in this process, diminishing the scope of their moral agency and causing moral
injury. In this chapter, we begin by briefly articulating the harms to animals in
research and the more conventional harms to humans that can arise as a result
of animal research, before making a case for the ethical damage wrought by
the failures of recognition inherent within the system of animal research. We
conclude with a brief outline of our approach as a means of effecting change
in animal research.
2

Harms to Animals in Research

It is widely acknowledged that animals frequently suffer harms when used in
interventional biomedical research directed at human clinical benefit. These
harms may be the direct result of research protocols or relate to the conditions
in which animals are housed. Animals can experience pain and discomfort
when used in toxicology testing, the development of pharmaceuticals, vaccine
development, diagnostic techniques, and surgical research. The intervention
itself may be the source of distress, or, if the research protocol demands it,
prior infliction of an alien disease or condition on the animal may be a source
of suffering. Animals used in biomedical research are routinely killed at the
completion of a protocol or series of protocols. Although arguments can be
made that, in itself death may not amount to a harm for non-humans, the
manner in which animals are killed can be a source of concern, and there is
disagreement over what constitutes humane euthanasia (Hawkins et al., 2016).
Housing can be another source of harm for animals in research, since the environment in which animals are kept may negatively impact their well-being.
Housing that is inexpensive, easy to handle, and clean may not provide the
best environment to meet the needs of animals. Animals may be harmed by
lack of access to conspecifics and adequate stimulation, the intrusion of light
and noise, inappropriate cage design, and so on (National Health and Medical
Research Council, 2013). Although most of these harms are well known, arguably, they have not motivated significant change in the practice of research.
For the remainder of this chapter, we focus instead on harms to humans from
animal research, which have received relatively little attention.
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Harms to Humans — Physical

For some time, it has been acknowledged that there are epistemological problems in translating results obtained from animal experiments into human
clinical benefit. A number of reasons can be cited for this failure, including,
differences in physiology and metabolism between human and non-human
animals (LaFollette and Shanks, 1996); poorly conducted and inappropriately
evaluated animal experiments (Perel et al., 2007; Pound et al., 2004); and animal stress due to many of the environmental factors identified above (e.g. small
cage size, boredom, high levels of noise, etc.), which in turn has impact on
physiology and the reliability of scientific data obtained from animals (Akhtar,
Pippin and Sandusky, 2008; Baldwin, Primeau and Johnson, 2006; Burwell and
Baldwin, 2006; also see in this Volume: Herrmann, 2019; Jayne and See, 2019).
Irrespective of the reasons behind failures in translation, the consequences
are significant for human patients and those who work with animals. First, patients may receive treatment that is inappropriate and harmful, if such treatments have “passed” animal testing but remain dangerous to humans (Pound
and Bracken, 2014). In these cases outcomes may include a heightened risk of
morbidity or mortality. There are also opportunity costs associated with pursuing one form of intervention rather than another. Second, patients may not
receive treatments that could be beneficial, if they have “failed” animal tests,
i.e. the development of potentially fruitful interventions for humans may be
cut short by unsuccessful animal trials (Pound and Bracken, 2014). In addition,
research findings in animals, which have no validity for humans, can lead to
the misdirection of future financial resources and research efforts (Pound and
Bracken, 2014). The resources of funders, researchers, and human trial participants may be effectively wasted in pursuit of what amounts to futile lines of
inquiry. These resources would be better spent on different treatments or different forms of research, such as clinical trials, epidemiological studies, and
computer modelling, rather than on animal research.
Those who work in animal research are also at risk of harm. Exposure to
workplace stressors is associated with a range of negative outcomes (Britt
et al., 2016). People who are directly involved with animal research, whether
inside animal housing or the laboratory, face challenging issues in relation to
the animals in their care. These workers may witness or directly cause animals
to experience discomfort, pain, and suffering as part of an experimental protocol. They may be required to infect animals with a disease, or impair their
function in some way, or euthanize them at the completion of the experimental protocol. Research workers can experience a range of negative feelings
and health impacts (physiological, psychological, and social) as a result of
their involvement in research. During their work, some may experience guilt,
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 neasiness, or frustration, as well as grief at the death of an animal in their care
u
(American Association for Laboratory Animal Science, 2003). The culture of
secrecy that cloaks much animal research limits discussion of these challenges
by workers, exacerbating the problems experienced.
For those who work as animal carers or as laboratory technicians, these
difficulties may be particularly pressing. Those who are employed to look after animals, rather than carry out the research per se, have frequently chosen
their careers based on a love of animals; as such, they experience the harms
to animals in research as especially distressing (Birke, Arluke and Michael,
2007). Furthermore, these individuals may not have been routinized to animal
research in the same way as those who have trained as researchers, so they may
lack the coping mechanisms that may assist in addressing these issues (Birke,
Arluke and Michael, 2007). There is limited discussion of these harms in the literature. In the remainder of this chapter, we focus on an even more neglected
area of harm to humans involved in animal research, namely, moral harm.
4

Harms to Humans — Moral

In order to make effective use of animals in research, those who work with
them must, to some extent, treat them as objects: objects of scientific interest. In order to do this, the subjectivity of the animal is disregarded or denied.
Its value comes not from what is intrinsic to it but from what others deem to
be useful. The animal is controlled, monitored, manipulated, and measured in
ways that, as we have suggested, often cause harm. This is not the same as, for
example, deliberate cruelty, sadism, or vindictiveness. The intention is not usually to cause suffering but to achieve some other goal, for which the a nimal’s
suffering is a necessary prerequisite or side effect. The animal is merely a means
to a scientific end, and those who are involved in the research must ensure that
they are able to view animals in this narrow way and treat them accordingly.
The treatment of human beings as objects or as mere means to scientific
ends is uncontroversially regarded as morally problematic. The validity of the
animal model aside, whether it is morally wrong to use animals in this way
depends partly on what moral theory one subscribes to. Most of those who
find it acceptable to use animals for research base their reasoning on the idea
that animals have a different moral status from human beings. Accordingly,
much of the debate about animal rights has revolved around the question of
what capacities are necessary or sufficient for full moral status, and whether
animals have these capacities (Bastian et al., 2012; DeGrazia, 1996; Singer, 2013).
However, we suggest that there are moral problems associated with the use of
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animals in research, regardless of their moral status. This is because, in order
to make use of them, we have to adopt a particular stance towards them that
requires a subjugation or diminution of our own moral agency. We can choose
to treat animals as subjects or as objects for our use. When we choose the latter option, we reify them. Reification is a term with a complex political and
philosophical history. For the purposes of our discussion, we build primarily
on Honneth’s use of the term (2006).
5

What Is Reification and How Does It Relate to Other Moral
Concepts?

Reification is a disposition or a mode of relating to others that can be a product of systems and institutions that compel people to behave in certain ways,
to treat others as mere things. It is, as Axel Honneth (2006) puts it, a social
pathology (p. 92). The concept of reification has some resonance with Kant’s
formula of humanity. Kant insists that we should never treat other human
beings as mere means to our own ends, but always as ends in themselves.
Reification also has some resonance with the concepts of commodification,
objectification and inattention. Elisabeth Anderson (1990), for example, discusses the commodification of women’s labor in surrogacy. Commodification
is bad, she says, because it is mistaken. We fail to value the commodified
person and this is an error. The woman is inappropriately used — treated
as a thing — rather than respected. Anderson’s view suggests that there are
fixed moral categories, and that we sometimes make mistakes in determining
how to categorize others. This implies that commodification is not intrinsically wrong, only when we commodify the wrong entity. This is what occurs
in surrogacy, according to Anderson, whereas she may not think it wrong to
commodify animals used in research. We employ Honneth’s (2006) approach
to argue a broader and more agnostic view. Given that we are sometimes
uncertain of how to respond to others, and we know that we are fallible and
self-interested, to cultivate a commodifying disposition may be intrinsically,
morally problematic.
Reification has similarities with what Kathie Jenni calls, vices of inattention
(2003). Jenni argues that it is through inattention that people who are horrified
when they know about factory farming, nevertheless, eat meat and try to avoid
thinking about the horrors involved in its production. Similar claims may be
made with regard to our reluctance to think about or discuss animal research.
Again, this suggests a specifically epistemological kind of problem: we lack
knowledge because we choose to look away instead of properly observing.
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In Anderson’s (1990) account too, we make an epistemological mistake in miscategorizing certain others. However, focusing on accidents, lack of attention,
and epistemological mistakes does not adequately capture the very deliberate
aspects of what occurs in animal research. It is for this reason that we find
reification a more compelling descriptor of the situation.
What is involved in animal research is not accidental. Indeed, reification
goes hand in hand with a very specific form of attention, certainly in science.
It is a reifying attention that denies not only the non-thing-ness of the object of research, but also the moral agency of the researcher, since the moral
relationship between researcher and research object is fixed by institutional
and external factors. The researcher cannot choose to relate to the animal as a
non-thing, at least not without sacrificing the scientific mantle.
In developing his understanding of reification, Honneth (2006) discusses
Lukács’ view of a world where caring has been subverted and replaced with
a pathological tendency towards reification (Lukács, 1971). Honneth rejects
the concept of care as the counterpart of reification, in favor of the term recognition. The phenomenon of reification and the means of addressing it are
central to our purposes, as we examine the ways in which animals are used in
research. Reification, according to Axel Honneth, is a deadening tendency that
distorts our ability to relate to the world around us. “[T]he subject is no longer
empathetically engaged in interaction with its surroundings but is instead
placed in the perspective of a neutral observer, psychically and existentially
untouched by its surroundings” (2006, pp. 98–99).
Reification is not inherent in specific actions but in a conjunction of the
action and disposition/intention. For this reason, there is no single means
by which we can point at a class of actions and say they are always wrong.
However, as we have suggested, it seems fairly clear that the scientific gaze is
likely to be a reifying one, even before any action has been taken. Indeed, doing
nothing can be compatible with reifying, if the reason for doing nothing is that
one regards the entity that is being ignored as a mere thing; for example, if one
fails to rescue an animal from a burning building.
It should be clear from our discussion so far that reification is deeply risky
for those who are reified. Whether human or animal, their interests, suffering,
and subjectivity are likely to go unnoticed or to be systematically devalued.
But the moral problems stemming from reification are not limited, specifically,
to the harm that it may cause to those who are reified. This is of particular
importance to our analysis of the human harms engendered through animal
research. Many people believe that provided certain standards of welfare are
met, and research protocols are subjected to ethical review, animal research is
not in itself unethical. However, animals remain research objects, and their life
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and well-being are precarious, since at the discretion of the researcher, they
may be harmed or euthanized. Indeed, one of the clearest indications that research animals are reified is the fact that, once their value to an experiment is
over, they are generally terminated. Animals will usually fight to preserve their
existence; but the intrinsic value of an animal’s life to the animal itself is not
sufficient, in the research context, to allow it to live. We suggest that animal
research will remain morally problematic even if issues of welfare continue to
be improved, precisely because the harm suffered by research animals is only
a subset of the problem. As long as research involves the reification of other
animals, it will cause moral difficulties for those engaged in this research. It
is here that the concept of reification is particularly significant in helping us
move away from limited questions concerning the capacities or moral status
of animals. From Honneth’s perspective, this is irrelevant in at least one important sense. “The things we encounter in our everyday dealings with the world
must also be regarded as entities to which we relate in an inappropriate way
when we apprehend them merely neutrally and according to external criteria”
(2006, p. 132).
6

Reification and Moral Injury

We have outlined the ways in which animal research involves the reification
of animals. However, a key part of our argument is that this, in turn, impacts
the people responsible for working with such animals. Reification, aside from
anything else, is a diminution, denial, or abrogation of moral agency. This can
work in two ways. First, the reifier denies that the entity in question is anything
other than a thing. Second, the very process of reification reflects back on the
moral agent. The person, who has the capacity to be a moral agent, comes to
feel and act as though this were not the case through reifying both their own
moral agency and the entities that they encounter.
This kind of situation may lead individuals into difficulties regarding whether to continue to do work they find troubling. For example, some of those who
work in the animal house and as laboratory technicians construe themselves as
a type of intermediary between scientific researchers and animals, advocating
and protecting the latter (Birke, Arluke and Michael, 2007). This sets up a kind
of cognitive dissonance, which can be exacerbated by pressure from within the
organization. For example, informal advice to management from the American Association for Laboratory Animal Science (2003) suggests supervisors
remind workers that “if they cannot perform an assigned task, someone else
will be required to do so” (p. 3). This means that individuals who care for the
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animals they work with, and who have built a rapport with them, can become
caught in a cycle whereby they feel personally obliged and institutionally pressured to persevere with this work in spite of the personal cost.
Staff who do care about the animals they work with are themselves being reified by systemic and institutional pressures. The moral agency that
enables them to relate to the animal, to have a view as to how and whether
something should be done, may be stultified over time. Habermas also identifies this problem — that of our capacity to reify ourselves — calling it the
“self-instrumentalization of the species” (2014). While Habermas was not concerned with animal research, he, nevertheless, offers a clear illustration of the
phenomenon he was concerned with. In seeking to instrumentalize other species, we simultaneously do the same to ourselves.
7

Loss of Moral Agency Leads to Moral Injury

The use of animals in research requires a narrowing of the social sphere, to exclude some entities or to limit the ways in which the interests of these entities
can serve to restrict our freedoms to act on them. In this way, moral agency is
constrained. In addition, the nature of scientific work often means that people
carry out procedures that have been defined and required by others, so that
moral implications, in relation to animals, may be doubly removed from the
individual’s own sense of moral autonomy or agency. There are some parallels
here with the known problem of desensitization: those who cannot successfully desensitize themselves to animal suffering are unlikely to thrive in jobs
that require animal research. Therefore there is an inbuilt incentive for scientists and researchers to seek to desensitize themselves actively, by reframing
their moral relationship with the animals (Capaldo, 2004).
We hypothesize that habitually narrowing the scope of moral concern is a
source of moral injury to those who do it. Institutions and workplaces often
require this kind of narrowing. For example, to promote efficiencies, effort is
expended on an ever-smaller circle of those who matter. Thus, workers may
find themselves told to ignore the mold on the tomatoes in the burgers, or to
give parents misleading feedback on their children’s reports, or to prioritize
the management’s targets above any other concern they have relating to the
patient (Smajdor, 2013). There are many areas of modern life, maybe even most
workplaces, where the demands of efficiency are such that reification seems
inescapable. To this extent, the situation of those involved in animal research
may not be significantly different from those working in factories or universities or engaged in other sorts of scientific or laboratory work. However, there
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is an important additional factor that feeds into the mix here. There are some
people whose occupations also involve intensely, ethically-charged decisions
or practices. These include those working as military personnel, medical professionals, and — we would argue — those involved in animal research.
The damaging effects of breaking strong moral taboos have previously been
discussed in the context of military and medical personnel. For example, both
medics and military personnel are more likely to witness, bring about, or be
involved in the death of other human beings. Both are required to perform actions that cause harm to other individuals. Both may have to overcome feelings
of repugnance for what they do and to attempt to distance themselves from
normal human responses (Howe, Smajdor and Stöckl, 2012; Smajdor, Salter and
Stöckl, 2010). For these reasons and others, medical and military personnel are
at risk of moral injury (Litz et al., 2009; Steenkamp et al., 2011), and a variety
of strategies have been developed in order to encourage institutions and individuals to identify these risks and deal with them. It may not be immediately
obvious that one can draw parallels between animal researchers and soldiers
or medics; but, in fact, proximity with death and witnessing or causing trauma
is likely to be part of all of these worlds, as is the need to function within h
 ighly
complex and hierarchical systems. These systems impose their own moral
demands and codes, which frequently conflict with the norms and expectations of society. In these circumstances, a combination of strong social taboo
attached to the activity, reification, loss of agency, and the ethical complexity
of the role lends itself to a far higher risk of moral injury.
It is routinely accepted in modern societies that killing and harming animals is prima facie wrong. Indeed, to participate in activities such as these
is usually against the law and/or regarded as immoral, unless carried out by
designated people. Even, or especially, in developed Western societies, whose
farming practices and research activities require that animals are used, killed,
or harmed, members of the public are not commonly involved in these practices. What this means is that, just as doctors or members of the military are
engaged in breaking taboos, so too are people whose roles involve using or
harming animals. Animal researchers must contain their “normal” feelings, to
some extent, and refrain from “normal” moral and social judgements just as
soldiers do. Shifting between different moral contexts can, in itself, be a risk
for moral injury. The switch from war to civilian life is well recognized as a
source of stress, and this shift is one that animal researchers may undergo on
a lesser scale every day. In some senses, animal research is even more morally
taboo than military service. Soldiers can be, and often are, viewed as heroes. In
the contemporary environment, it is hard to envisage the same possibility for
animal researchers (Birke, Arluke and Michael, 2007, however, note that some
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pro-research campaigns seek to cast researchers as heroes for saving patients,
especially children). Furthermore, soldiers are often regarded as paradigmatic
examples of powerful, attractive men. It is not generally thought shameful to
be a soldier. Nor would one expect to have to keep this secret. Yet, away from
their colleagues, some animal researchers might feel shame, social stigma, and
exclusion based on what they do. As a result, they may feel impelled to keep the
nature of their work secret. Again, this taboo bears particularly on laboratory
technicians as opposed to researchers, since for the former group working with
animals in research constitutes the entirety of their role (Birke et al., 2007).
Aside from the elements of cognitive dissonance or shame attached to animal research, which is perhaps a result of its problematic moral status in society, moral injury may arise in this context from a more direct and personal
feeling of being involved in wrongdoing. Again, this has parallels with military
situations. Moral injury can result from witnessing or being complicit in acts
that one feels to be wrong. One does not have to be a perpetrator of the act
in question in order to be damaged by it. A sense of helplessness, or perception of being disempowered by the structures and systems within which one
works, can lead to situations where one’s moral agency comes under threat.
Over time, this leads to a gradual hardening, or dissociation, as individuals
try to protect themselves from the sense of wrongdoing and become passive
and disempowered. If this dissociation is effective, a person may cease to feel
distress but may, nevertheless, continue to be damaged physiologically and
psychologically (Kammeyer-Mueller, Simon and Rich, 2010; Litz et al., 2009).
8

Addressing the Problem of Reification

Several strategies and remedies could be devised to limit or ameliorate reification and its associated moral harms in the context of animal experimentation. For example, universities, hospitals, and other institutions where animal
research takes place could better acknowledge the kind of stresses and pressures placed on their workers and implement policies to support resilience,
perhaps akin to those adopted in the military setting. Although this may help
workers cope with the issues they confront (which is not insignificant), it does
not seem to get to the heart of the problem, namely, that biomedical research
requires the reification of animals and, in turn, the humans who work with
them. Another strategy may be to radically transform the practice of research
in such a way that the harms to animals are minimized and their intrinsic value and subjectivity acknowledged. This could be facilitated by adopting the
animals-as-patients model argued for elsewhere (Johnson and Degeling, 2012).
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Animal patients shift the balance of harms to benefits for animals in research
and address some of the epistemological worries about the failure of animal
research to translate into human clinical benefit. A move towards regarding
animals as patients could represent one point along the way to a paradigm
shift in animal research. This, if successful, would radically alter the relationship between researchers and participants. It would no longer be necessary for
researchers to distance themselves from the animals’ suffering, and, as with
research involving humans, the moral value of the research participant would
be an inbuilt aspect of the process.
It seems to us that, as with other major social shifts on complex issues, there
will not be a single knock down argument or historical, political, or economic
circumstance that will provoke change in animal research. Rather, change will
occur when a number of arguments and factors come together that all support a new direction. We hope to have shown that there is a new argument
that can be mounted against animal research, one that is grounded in an
acknowledgement of the moral harms to humans that can result from involvement in animal experimentation. Contributing an argument that appeals to
human self-interest and does not depend on problematic attempts to establish
the moral status of animals or on reducing animals to their welfare, is, we hope,
promising and able to further gird a move away from the current, deeply problematic, practice of animal research.
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1

A Growing Tradition of Laboratory Animal Use

Researchers have sought to understand the mechanisms of human health and
disease, for as long as the latter has existed. Serious interest in the structure
and functioning of the human body has been evident at least since the ancient
Greeks. However, the investigations of Greek physicians into human anatomy
and physiology were greatly hampered by social taboos about dissecting human corpses (von Staden, 1989). But non-human animals (hereinafter referred
to as animals), were not so revered or feared. Some dissected their corpses,
while others, such as Alcmaeon of Croton (sixth–fifth century, bce), practiced surgical or other invasive procedures on the living (Court, 2005; Maehle
and Tröhler, 1990), and conducted some of the first animal experiments ever
recorded.
Almost two millennia passed before such social dogmas were seriously questioned. The Renaissance heralded a new era of scientific inquiry, during which
Flemish physician and surgeon Vesalius (1514–1564) began to source human
cadavers for dissection illegally. He discovered that a number of anatomical
structures believed to exist, following animal dissections, were unexpectedly
absent in humans. His highly accurate anatomical descriptions challenged the
authoritative texts of classical authors (O’Malley, 1964).
Throughout the seventeenth century the spirit of scientific inquiry grew and
with it, experimentation on living animals. Some surgical investigations and
demonstrations that predated anesthesia were infamously cruel and caused
widespread social controversy. However, French philosopher, René Descartes
(1596–1650), famously rebutted such critiques, claiming that animals were
merely mindless automata, i.e., “machine-like” (Descartes, 1989); their cries
were of no greater moral consequence than the squeals of a p
 oorly-oiled
machine.
Nevertheless, by the end of the seventeenth century, the question of animal
suffering and the acceptability of such procedures had become an i ncreasingly
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prominent moral and social concern (Maehle and Tröhler, 1990). Jeremy Bentham (1748–1832), famously asked, “The question is not, Can they reason? nor,
Can they talk? but, Can they suffer?” (Bentham, 1823, Chapter 17, footnote).
And his concerns have been echoed by many others since.
By the beginning of the nineteenth century, a revolution had begun within
medicine. Growing awareness of the poor effectiveness of many traditional
therapies led to investigations focused on understanding disease etiology
(causation) and pathogenesis (progression), with the intention of increasing
diagnostic and prognostic accuracy and treatment efficacy. The use of animals
as investigative models increased in the second half of the nineteenth century,
often in highly-invasive research and still predating most forms of anesthesia
or analgesia. Increasing social unease about such research led to widespread
opposition in Europe, and especially Britain, where organizations, such as the
National Anti-Vivisection Society (navs), founded 1875, (navs, 2012) and the
British Union for the Abolition of Vivisection, founded 1898, (now Cruelty Free
International, n.d.), were established to campaign against it. The Cruelty to
Animals Act (1876) entered into force, becoming the first legislation to regulate
animal experiments (Franco, 2013).
In the latter part of the twentieth century, social concerns about animal suffering continued to grow, accompanied by a seemingly inexorable rise in animal
experimentation. Currently, the most accurate evidence-based estimates of
global laboratory animal use describe the year 2005. Approximately 126.9 million non-human vertebrates were used worldwide in that year (Knight, 2008a;
Taylor et al., 2008). Driven by increased development and use of geneticallymodified animals (Ormandy, Schuppli and Weary, 2009), and by large-scale
chemical-testing programs (Knight, 2011), laboratory animal use has steadily
increased in most developed countries, ever since.
The single largest category of research conducted today is fundamental biological research, much of which has no obvious application. The European
Union (EU) is the world’s largest region that publishes comprehensive analyses of its laboratory animal use. At the time of writing, the most recent published figures describe animal use in the 27 Member States of the EU in 2011
(with one state reporting for 2010). Within this period, 46.1% of the 11.5 million
animals were used for this purpose. However, barring 1.6% of animals used for
education and training, most of the remaining 52.3% were used in attempts
to advance public health—for research, development, or toxicity testing; for
quality control of products and devices for human or veterinary medicine and
dentistry; or for disease diagnosis and other purposes (European Commission,
2013). Most of these animals would have been used in attempts to advance human, rather than animal, health.
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2

Effectiveness of Laboratory Animal Use

Combined, this represents an enormous commitment of animal, scientific,
personnel, and financial resources, ostensibly dedicated primarily to the advancement of human health. But how effective has all this research been?
Advocates of such research have regularly claimed it is essential for preventing, curing, or alleviating human diseases (e.g., Brom, 2002; Festing, 2004);
and further, that the greatest achievements of medicine have only occurred
through the use of animals (e.g., Pawlik, 1998). However, those who champion
such claims frequently have careers dependent on such research. Furthermore, counter-narratives by others contest the contributions or necessity of
such research for the advancement of medical progress (e.g., Greek and Greek,
2002). To support their argument, advocates on either side regularly cite cases
in which animal and human outcomes are similar or different. However, only
small numbers of experiments are normally included in such reviews, and
their selection may be subject to bias. These are known as narrative reviews.
To provide more definitive conclusions, systematic reviews of the human
clinical or toxicological utility of large numbers of animal experiments are
necessary. A systematic review is “a review of a clearly formulated question
that uses systematic and explicit methods to identify, select, and critically appraise relevant research and to collect and analyze data from the studies that
are included in the review. Statistical methods (meta-analysis) may or may not
be used to analyze and summarize the results of the included studies” (Moher
et al., 2009). In recent years, systematic reviews have become widely utilized
to investigate a broad range of clinical and other research questions. Their
aims are to retrieve as much high-quality evidence as possible, relevant to the
research question, and to minimize bias during the selection, analysis, and
reporting of results. Any conclusions reached should, accordingly, be as close
as possible to biological, physical, chemical, or other truths.
A large number of systematic reviews of animal experiments within various
research fields have examined their utility for advancing human healthcare,
and the results have not been good. Of 20 published systematic reviews examining human-clinical utility located during a comprehensive literature search,
animal models demonstrated significant potential to contribute toward clinical interventions in only two cases, one of which was contentious. Included
were experiments approved by ethics committees on the basis of claims that
medical advances were likely to result; highly-cited experiments published
in leading journals; and chimpanzee experiments, utilizing the species most
generally predictive of human outcomes. Seven additional reviews failed to
demonstrate utility in reliably predicting human toxicological outcomes,
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including those associated with the greatest public health concerns, such as
carcinogenicity and teratogenicity. Results in animal models were frequently
equivocal or inconsistent with human outcomes (Knight, 2011). Since then,
numerous additional reviews have yielded similar results. Baker et al. (2014),
for example, examined human neurological disease, which has been extensively studied in animal models, resulting in relatively few human treatments
(Cheeran et al., 2009; Vesterinen et al., 2010). Similarly, despite reports of the
efficacy of more than 1,000 treatments in animal models of multiple sclerosis
(MS), very few treatments have progressed to the marketplace (Vesterinen et
al., 2010). This usually indicates failures of efficacy or safety concerns in humans. And, despite the widespread use of animal models within stroke research, virtually no interventions described as effective in animal models have
proven similarly effective in human patients (Cheeran et al., 2009). There are
many other examples.
Several studies have sought to determine the maximal human clinical utility that may be achieved by animal models, by examining chimpanzee experiments, given that chimpanzees are our closest relatives (Knight, 2007);
by examining experiments approved by ethics committees on the basis of
explicit claims of likely human healthcare benefits (Lindl, Völkel and Kolar,
2005); or by examining highly-cited animal experiments published in leading
scientific journals (Hackam and Redelmeier, 2006). Hackam and Redelmeier,
for example, located 76 animal experiments, each of which had been cited
well over 500 times and published in one of the world’s seven top scientific
journals when ranked by journal impact factor. Hence, these experiments represented some of the most important and scientifically-interesting animal research published at the time. In only 28 cases (36.8%), animal results were
later replicated in humans. Most animal research is neither highly cited nor
published in world-leading journals, and successful translation to humans is
far lower.
3

Limitations of Animal Models

A variety of factors appear responsible for the poor rates of translation of outcomes from animal studies into human patients and consumers. These relate
both to the animal models themselves and to the ways in which they are used.
Fundamental biochemical differences between species may result in differences in absorption, distribution, metabolism, and elimination pathways or
rates, which may alter toxico- or pharmaco-kinetics (i.e., bodily distribution).
Toxico- and pharmaco-dynamics (mechanisms of action and biological effects)
may also be altered. Jointly these factors may contribute to differences in o rgan
systems affected and in the nature and magnitude of those effects (Hartung,
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2008; Knight, 2011). Further problems arise from the characteristics of the animals used. Biological variability and predictivity for humans are frequently
compromised by restriction to single rodent strains, young animals, and single
sexes, usually without concurrent human risk factors, such as common comorbidities, that can alter human responses to exogenous (externally-derived)
compounds (Hartung, 2008; Knight, 2011).
Additional problems arise from the ways in which the animals are used.
Many toxicity tests, for example, rely on maximum tolerated doses (above
which acute, toxicity-related effects preclude further dosing), and chronic
dosing. These factors maximize sensitivity to toxins, with the result that false
negative results rarely occur. However, these conditions can also overwhelm
the physiological defenses that are effective at environmentally realistic doses,
resulting in false positive outcomes. As a result, many compounds that would
not normally be considered toxic are falsely indicated as such by animal tests;
this substantially decreases the reliability and relevance of any positive result.
Additionally, important human routes of exposure (e.g., inhaled) may differ
from those tested in animals, requiring extrapolation between routes of exposure, as well as between species, introducing further uncertainty (Gold, Slone
and Ames, 1998; Hartung, 2008; Knight, 2011).
Furthermore, animals used in laboratories commonly experience a significant array of stressors. These include stresses incurred during handling,
restraint, and other routine laboratory procedures; and, in particular, the
stressful routes of dose administration common to toxicity tests. Orogastric
gavaging, for example, involves the insertion of a tube into the esophagus for
the forced administration of test compounds. Combined with environmental
stressors (e.g., due to limited space and environmental enrichment) and social
stressors (e.g., due to aggressive interactions between conspecifics), these represent a significant body of stressors. These stressors can alter physiological,
hormonal, and immune statuses and even cognitive capacities and behavioral
repertoires, in ways that are not always predictable (Balcombe, Barnard and
Sandusky, 2004; Balcombe, 2006; Baldwin and Bekoff, 2007). The results may
include alterations in the progression of diseases, in bodily responses to chemicals and test pharmaceuticals, and in a range of other scientific outcomes, such
as those dependent on accurate determination of physiological, b ehavioral, or
cognitive characteristics (for further discussion see Herrmann, 2019, Chapter 1;
Jayne and See, 2019, Chapter 21).
4

Methodological Quality of Animal Studies

As if these were not problem enough, a sizeable body of recent studies and
systematic reviews have confirmed the existence of significant methodological
Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

326

Knight

flaws, in most published animal experiments (e.g., Knight, 2008b). Indeed, to
date, no systematic reviews appear to have been published in which a majority of animal studies, assessed against appropriate objective criteria, were
found to have been of good methodological quality. In particular, a variety of
design features must be included within animal experiments to minimize the
potential for bias. Hooijmans et al. (2014) described 10 types of bias that have
the potential to influence animal experimental results, which they grouped
into selection bias, performance bias, detection bias, attrition bias, reporting
bias, and other sources of bias. Many of these flaws are highly prevalent within
animal studies.
Kilkenny et al. (2009) conducted one of the largest and most comprehensive
systematic surveys to date, assessing the experimental design, statistical analysis, and reporting of published animal experiments. 271 papers were examined,
which included 72 studies using mice, 86 using non-human primates, and 113
using rats. Most (99%; 269/271) of these papers were published between 2003
and 2005. They covered a wide variety of experimental fields, were published in
a comprehensive range of journals, and were funded by leading grant agencies
within the United Kingdom and the United States. However, only 59% of these
studies clearly stated the hypothesis or objective of the study and the number
and characteristics of the animals used. Details, such as animal strain, sex, age,
and weight, are all scientifically important and can potentially influence results
(Alfaro, 2005; GV-Solas, 1985; Obrink and Rehbinder, 2000). Nevertheless, in
many cases these details were omitted.
Knowledge of planned treatment (or lack thereof) is one of a number of factors that can unconsciously influence the assignment of animals to treatment
groups, for example, when researchers sympathetically select animals they
consider weaker, to be used as controls, rather than test animals. The introduction of such confounding factors (in this case, variable animal fitness), can
potentially bias results (in this case, selection bias has occurred). Accordingly,
randomized selection of animals for treatment groups is mandated, to ensure
that outcome differences are most likely due to treatment effects (Festing and
Altman, 2002; Festing et al., 2002). Haphazard selection does not give sufficient
certainty that results are truly random, so a systematic approach is necessary,
such as the use of a random number generator (Kilkenny et al., 2009). Nevertheless, despite its well-acknowledged importance, randomized allocation of
animals to test groups was reported in only 12% of these studies.
Another crucial feature of good experimental design concerns the assessment of outcomes. Where qualitative assessments occur, which involve assessor
judgements, it is similarly crucial that assessors do not know (are blinded to)
the treatment (or lack thereof) of the animals assessed, lest such knowledge
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subtly affect their judgement (Festing and Altman, 2002). Because, as Cochrane (1972) noted, “When humans have to make observations there is always
the possibility of bias,” even unintentional bias. Nevertheless, only 14% (5/35)
of all papers in the survey by Kilkenny et al. (2009) that reported qualitative
assessment of outcomes, also reported the use of blinding.
Many factors can affect experimental outcomes, so the incorporation of
measures to minimize sources of bias is crucial to ensuring the reliability of research results. And yet, 87% of papers, examined by Kilkenny and colleagues,
failed to report randomization during animal selection; and 86% failed to
report blinded assessment of outcomes. Additionally, only 70% of the publications that used statistical methods described their methods and presented
the results with a measure of error or variability. More recently, similar results
were found in an even larger study. Vogt et al. (2016) determined the prevalence
of seven basic measures against bias (i.e., allocation concealment, blinding,
randomization, sample size calculation, inclusion/exclusion criteria, primary
outcome variable, and statistical analysis plan), within 1,277 experimental applications approved by Swiss authorities in 2008, 2010, and 2012 and within
50 subsequent publications. Measures against bias were reported at very low
rates, both in experimental applications (2%–19%) and in subsequent publications (0%– 34%).
The importance of randomization and blinding when comparing two or
more experimental groups has been highlighted by reviews of animal research
in the field of emergency medicine, which have found that estimates of treatment efficacy were significantly reduced in studies that incorporated these
mechanisms to reduce risks of bias (Bebarta, Luyten and Heard, 2003; Macleod
et al., 2008). Similar results have been found in numerous other studies. In
fact, studies incorporating the fewest measures to minimize sources of bias
tended to report the greatest effect sizes (Crossley et al., 2008; Hirst et al., 2014;
Macleod et al., 2005; Rooke et al., 2011; Vesterinen et al., 2010). The widespread
failure to utilize mechanisms, such as randomization and blinding, appears
to result in false expectations of treatment efficacy and reported outcomes
in animals often fail to translate into humans. Similar results were reported
following a literature review by Holman, Head, Lanfear and Jennions (2015).
They found that blind protocols are uncommon in the life sciences, and that
non-blind studies tend to report more significant outcomes and higher effect
sizes. They noted that: “Observer bias and other ‘experimenter effects’ occur
when researchers’ expectations influence study outcome. These biases are
strongest when researchers expect a particular result, are measuring subjective
variables, and have an incentive to produce data that confirm predictions. To
minimize bias, it is good practice to work ‘blind,’ meaning that experimenters
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are unaware of the identity or treatment group of their subjects while conducting research” (p. 1).
Another common problem observed by Kilkenny et al. (2009) concerned
the transparency of reporting, and the robustness of statistical analysis. Almost 60% of surveyed publications were deficient in these areas. Most studies failed to provide sample sizes or adequate justifications of them. And yet,
studies that use too many animals waste animal lives. Conversely, the results
of underpowered studies (with insufficient numbers of experimental subjects) cannot be extrapolated to wider populations with sufficient certainty.
Accordingly, power analyses or other simple calculations are widely used
in human clinical trials to ensure enough subjects (but not more) are present to detect biologically important effects. Indisputably, the same principles
should apply to animal studies (Dell, Holleran and Ramakrishnan, 2002; Festing and A
 ltman, 2002).
Unfortunately, methodological flaws appear to be prevalent even within animal research conducted at highly-ranked universities and published in leading journals. After studying 814 randomly-selected studies reporting primary
research, 2,671 publications reporting drug efficacy in eight disease models,
and 4,859 publications from five UK institutions ranked highest across six units
of assessment in biomedical sciences, in the 2008 National Research Assessment Exercise, Macleod et al. (2015) reported that severe deficiencies of experimental design remain the norm. These deficiencies were prevalent in research
conducted at leading uk research universities, in research funded by leading
UK funding organizations, and in research reported in high-impact journals.
5

Evidence-based Research within Human Clinical Trials

The importance of sound experimental design, and, particularly, the necessity of incorporating factors designed to minimize bias risks have long been
recognized within the field of human research. The Consolidated Standards
of Reporting Trials (consort) Statement for randomized controlled human
clinical trials was one of the first guidelines developed to ensure the quality
of human-based research. It provides an evidence-based, minimum set of recommendations, including a checklist of 25 recommended items that should
be included when reporting randomized human trials (Moher, Schulz and
Altman, 2001; Schulz, Altman and Moher, 2010). Since then, more than 90
guidelines have been developed for reporting different types of health research
(see Altman et al., 2008; Simera et al., 2010; www.equator-network.org).
An increasing number of leading journals have, subsequently, requested that
their authors comply with the consort guidelines (Altman, 2005; Hopewell
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et al., 2008). Organizations commending the use of such guidelines include,
the Committee on Publication Ethics (n.d.); the Nuffield Council on Bioethics
(2005); the Council of Science Editors (2018); and the International Committee
of Medical Journal Editors (2015). Subsequent to the widespread endorsement
of such guidelines, studies have indicated that the quality and transparency of
reports on human clinical trials have improved (Plint et al., 2006; Kane, Wang
and Garrard, 2007).
6

Application to Animal Studies

More recently, multiple attempts have been made to introduce similar standards within animal studies. In 2009, Kilkenny and colleagues observed that
most biomedical journals provided little or no guidance about the reporting
of animal research, other than the requirement to report ethical review of the
proposed protocols. They noted the contrast between biomedical journals and
those within other several research areas, particularly medical research, in this
respect. Accordingly, in 2010, Kilkenny and colleagues proposed the Animal
Research: Reporting of In Vivo Experiments (arrive) guidelines. Prepared in
consultation with scientists, statisticians, journal editors, and research funders,
these guidelines comprise a checklist of 20 items, designed to provide minimum information on items, such as the number and specific characteristics
of animals used (including species, strain, sex, and genetic background); housing and husbandry conditions; and the experimental, statistical, and analytical
methods used. The latter points included measures to reduce bias, such as the
random allocation of animals to experimental groups, blinded assessment of
outcome measures, statistical justifications of sample sizes, reporting of animals excluded from analyses, exclusion criteria, and any investigator conflicts
of interest. The intention was that these items should be included within all
scientific publications reporting animal research, thereby allowing critical assessment of methods used and results obtained.
Hooijmans et al. (2010) similarly proposed a Gold Standard Publication Checklist (gspc), which includes 74 items designed to improve the quality of animal
studies and to fully integrate 3Rs “(replacement, reduction and refinement)”
methods and facilitate their incorporation within systematic reviews and metaanalyses. In 2014, Hooijmans and colleagues also proposed a Risk of Bias (RoB)
tool to assess methodological quality and risk of bias within animal studies. The
tool is based on the similar Cochrane RoB tool (Higgins et al., 2011), which was
adjusted for particular aspects of bias that play a role in animal studies.
Other authors have proposed similar guidelines and checklists for the conduct and reporting of animal research. In 2009, Osborne and colleagues from
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the Royal Society for the Prevention of Cruelty to Animals (UK) proposed a
12-point assessment scheme for scoring biomedical journals’ policies on animal welfare and the 3Rs. And in 2015, Martins and Franco proposed their
Excellence in Editorial Mandatory Policies for Animal Research (exemplar)
scale, comprising four categories: regulatory compliance, quality of research
and reporting of results, animal welfare and ethics, and criteria for the exclusion of papers.
7

Poor Compliance of Animal Studies

Such guidelines provide indisputable benefits in ensuring the reporting of
methodological quality, reliability of results, and incorporation of the 3R
principles of animal research. The arrive guidelines of Kilkenny et al. (2010)
have been published or endorsed by more than 1,000 research journals, including those published by the N
 ature Publishing Group, PLoS, and BioMed Central (Reichlin, Vogt and Würbel, 2016). They have been similarly endorsed by
major UK funding agencies (including the Wellcome Trust, the Biotechnology
and Biological Sciences Research Council, and the Medical Research Council);
and they also form part of the US National Research Council Institute for Laboratory Animal Research guidelines (Baker et al., 2014). And yet, despite such
widespread endorsement, a number of studies have demonstrated that compliance with such guidelines remains poor.
Noting that, “Despite reports of over 1,000 treatments effective in animal
models of multiple sclerosis (MS), very few treatments have so far made it
to the marketplace following initial development in disease-related animal
models (Vesterinen et al., 2010),” Baker et al. (2014) investigated the general
adequacy of reporting within animal studies of MS. They uncovered significant inadequacies within the reporting of experimental design, including the
selection of appropriate statistical analyses and the application of key points
in the arrive guidelines. They observed that the arrive guidelines are not
being implemented by authors, reviewers, and journal editors (Baker and
Amor, 2012; Landis et al., 2012; Schwarz, Iglhaut and Becker, 2012).
Despite their very widespread publication and endorsement, lack of awareness of such guidelines appears to remain a major problem. After surveying all registered in vivo researchers in Switzerland recently, Reichlin et al.
(2016) reported that among 302 self-selected participants, 56.3% did not
know of the arrive Guidelines. A total of 1,891 researchers were surveyed,
but only 302 (16%) returned fully-completed questionnaires and, hence,
were not excluded. Even among those whose latest paper was published in
a journal that had endorsed the arrive guidelines, 51% had never heard
of them.
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The failure of biomedical journals to insist on compliance with quality
control standards is partly to blame. After surveying 236 biomedical journals’
policies on animal research, Osborne et al. (2009) found no mention of animal
use, within author guidelines or elsewhere, in 35% of journals studied. In 18%
of the journals, animals were mentioned, but no perceptible guidelines were
provided; and most of the remaining journals scored poorly, with 37% scoring three or fewer points out of 12 equally weighted items within their quality
checklist. Martins and Franco (2015) examined 170 journals that publish studies on animal models of three human diseases, namely Amyotrophic Lateral
Sclerosis (als, also known as Motor Neuron Disease); Type-1 Diabetes; and
Tuberculosis. Their results were broadly similar to the results of a survey by
Osborne et al.’s. (2009), when assessing studies using their exemplar scale.
They noted that, “little progress found regarding in-house policies on the ethical treatment of animals is worrisome” (p. 325).
8

Improving Study Quality

A range of measures are strongly warranted to increase the implementation of
the 3R principles, the methodological quality of animal research, and the reliability of results and to overcome some of the barriers that currently prevent
reliable extrapolation to human outcomes.
Compliance with each of the 3Rs and the arrive guidelines and other best
practice standards, during the design, conduct, and reporting of experiments,
must become mandatory. Such standards should cover animal sourcing, housing, environmental enrichment, socialization opportunities, appropriate use
of anesthetics and analgesics, handling, non-invasive endpoints, and a range
of measures designed to minimize sources of bias and to ensure methodological quality. Compliance with such standards should be a necessary condition
for securing research funding and ethical approval; licensing of researchers,
facilities, and experimental protocols; and publication of subsequent results.
Compliance would also facilitate subsequent systematic reviews.
Where journal space constraints limit the description of methodological
details, these should be included in supplementary online databases, which
are now widely available (Kilkenny et al., 2009). This would also facilitate the
transfer of alternative technologies, such as the development of new alternative methods, between institutions (Gruber and Hartung, 2004).
To enable animal researchers and technicians to meet the necessary standards, training and continuing professional development in 3R methodologies
and the design, conduct, and reporting of animal research should be compulsory. The existing lack of focus on replacement methods (in favor of refinement
methods) must be addressed.
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The adoption of measures, such as these, would increase the reliability of research results and would facilitate their use within systematic reviews. Prior to
designing any new animal study, researchers should conduct a systematic review
to collate, appraise, and synthesize all existing, good-quality evidence r elating to
their research questions. Such systematic reviews should be similarly required
by grant agencies, ethical review committees, other animal-experiment licensing bodies, and journals. Systematic reviews are studies in and of themselves. In
recognition of their intrinsic value, and their necessity for informing further research, they should also be readily funded by grant agencies.
To ensure that all such evidence is publicly available, greater efforts must
also be made by researchers and editors to publish negative results. Studies
that fail to show a treatment effect are often considered less interesting and
are, consequently, less likely to be published. The subsequent exclusion of such
results from systematic reviews leads to over-estimations of treatment efficacy
and partly explains the widespread failures in humans of treatments apparently efficacious in animals.
Within the field of human studies, clinical trial registers allow researchers
to learn about existing and prior clinical trials, including those with negative
outcomes, before results are formally published. A similar international initiative to register animal studies and their results is warranted (Hooijmans
et al., 2014).
Many of these measures will require cooperation and coordination between
researchers, regulators, licensing bodies, ethical review committees, funding bodies, journals, and authors. And of course, the necessary willingness,
among all parties, to change. If these measures were to be successfully implemented throughout the broad field of animal research, then we may be able
to predict treatment effects accurately within the animal species under study.
However, interspecies differences will remain in absorption, distribution, metabolism, and elimination pathways or rates, resulting in differing toxico- or
pharmaco-kinetics and dynamics and, subsequently, differences in the organ
systems affected and in the nature and magnitude of these effects. Such factors, which reflect the intrinsic complexity of living organisms, will continue to
pose b arriers to extrapolation to humans that will remain insurmountable, in
many cases.
9

Impacts on Laboratory Animals

Human patients are far from the only victims of poorly conducted, poorly
predictive, animal research. A wide variety of stressors have the potential to
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cause significant stress, fear, and possibly distress in laboratory animals. These
stressors may be associated with the capture of wild-sourced species, such
as primates, to supply laboratories or breeding centers; with transportation,
which may be prolonged for some animals; with laboratory housing and environments; and with both routine and invasive laboratory procedures (see
Knight, 2011). An invasive procedure is an intervention that interferes with bodily integrity through puncture, incision, or insertion of an instrument or foreign
material, as in surgical and some experimental procedures (Knight, 2011).
A large minority of all procedures are markedly invasive. These include procedures resulting in death (whether or not the animals are conscious); surgical
procedures (excluding very minor operative procedures); major physiological
challenges; and the production of genetically-modified animals. Few regions
report procedural invasiveness, but Canada does. From 1996–2008 inclusively,
the proportion of markedly invasive procedures reported in Canada ranged
between approximately 29%–44% (Canadian Council on Animal Care, 2009).
These procedures were defined by the Canadian Council on Animal Care
(2009) as resulting in moderate to severe stress or discomfort (Category D); or
in severe pain near, at, or above the pain tolerance threshold of unanesthetized
conscious animals (Category E) compared to procedures resulting in little or
no discomfort or stress (Category B) or minor stress or pain of short duration
(Category C).
A sizeable majority of all procedures utilize no anesthetics of any kind. Few
regions report anesthetic usage, but Britain does. During two recent decades
(1998–2009), the proportion of procedures conducted in the UK without anesthesia fluctuated between approximately 59%–69% (Home Office, 2010). For
example, in 2009, at the end of this period, 66.7% of cases did not utilize any
form of anesthesia. General anesthesia was provided throughout or at the end
of terminal procedures in 9.5% of cases. In 17.1% of cases, general anesthesia
with recovery was provided, and in 6.7% of cases, local anesthesia (Home
Office, 2010).
To assess animal impacts further, it is helpful to know the frequency of analgesic (pain-killer) use, and the level of correlation between markedly invasive
procedures and anesthetic or analgesic use (See Herrmann and Flecknell (2018)
for a review of original animal research proposals). Painful or invasive procedures warrant anesthesia and/or analgesia. Animal welfare is adversely affected when animals undergoing such procedures are denied these; or c onversely,
when they are provided without sufficient need (due to their p
 otential side
effects), although this is rare in practice. It would also be helpful to study the
prevalence of environmental enrichment and socialization opportunities. Unfortunately, such information remains largely unreported.
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Conclusions

Animal research is a mechanism by which we seek to increase our understanding of the biological world. The major useful applications of this knowledge lie
in the development of new therapies for combatting human diseases and in
predicting the human toxicity of chemicals used for a wide range of purposes.
As we have seen, however, the actual efficacy of animal research for these purposes is very low. This is due to a range of causes, some of which are, at least
theoretically, amenable to change and some of which are not.
When formulating social policy pertaining to animal research, the social
benefits realized are only part of the equation. The other major part that must
be considered concerns the resources consumed by this research. The very
substantial financial and scientific resources consumed by animal research
are consequently unavailable to other fields, some of which, such as preventative healthcare or human clinical research, may well be expected to produce
greater gains for public health. And as we have seen, the impacts on animals
are also severe. 127 million living non-human vertebrates were used worldwide
in 2005, the most recent year for which an evidence-based global estimate
was available. Based on figures from countries, such as Canada and the UK,
where these are published, a large minority of all procedures are markedly
invasive; and a sizeable majority utilize (or at least report) no anesthetics of
any kind.
The core ethical principle underpinning modern animal experimentation
regulation and policy is that the likely benefits of such research must outweigh its expected costs. This utilitarian harm-benefit analysis underpins all
fundamental regulation governing animal experimentation. For example, European Directive 2010/63/EU on the protection of animals used for scientific
purposes, which directs such animal use in all EU Member States, asserts that
it is “essential, both on moral and scientific grounds, to ensure that each use
of an animal is carefully evaluated as to the scientific or educational validity,
usefulness, and relevance of the expected result of that use. The likely harm to
the animal should be balanced against the expected benefits of the project”
(European Parliament, 2010, p. 37).
When considering harms and benefits overall, one cannot reasonably conclude that the benefits accrued for human patients or consumers, or those motivated by scientific curiosity or profit, exceed the harms incurred by animals
subjected to scientific procedures. On the contrary, evidence indicates that actual human benefit is rarely, if ever, sufficient to justify such harms. And those
harms are not limited to the many millions of animals used. Others potentially affected include patients and consumers. The social and ethical implications are profound, when consumers suffer serious toxic reactions to products
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assessed as safe in animal studies, or if patients with serious conditions are
denied effective clinical interventions, partly because potentially more efficacious research fields are under-resourced (Knight, 2011).
A paradigm change in scientific animal use is clearly warranted. Instead of
uncritically assuming the benefits of animal research, we must subject it to
much more rigorous and critical evaluation. Where animal research continues
to persist, a broad range of measures must be implemented to improve substantially its methodological quality and compliance with the 3Rs and to maximize the reliability of subsequent results (Knight, 2011). When such research
fails to meet the harm-benefit standards expected by society, which underpin legislative instruments, such as Directive 2010/63/EU, then such research
should cease; and the resources consumed by it directed into more promising
and justifiable fields of research and healthcare.
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The ethical arguments against animal experimentation remain ever-strong.
In addition, the scientific case against the use of animals in research grows
more compelling, with exponential progress in the development of alternative methods and new research technologies. The Dutch authorities recently
announced an ambitious, but welcome, proposal to phase out “the use of laboratory animals in regulatory safety testing of chemicals, food ingredients, pesticides and (veterinary) medicines” by 2025, as well as “the use of laboratory
animals for the release of biological products, such as vaccines” (Netherlands
National Committee for the protection of animals used for scientific purposes, NCad, 2016, p. 3). National government departments (e.g., the United
Kingdom, UK, Home Office) have stated that alternatives to animals are now
considered necessary for scientific as much as ethical reasons, also conceding
that pressure exists within the research community to use animals in order
to get published. Furthermore, only 20% of animal tests across the European
Union (EU) each year are conducted to meet regulatory requirements, with the
vast majority carried out as basic research (including basic medical research)
or breeding of genetically modified (GM) animals at academic institutions
(European Commission, 2013b).
Despite the strength of both scientific and moral arguments, animal research continues to increase worldwide, especially given the rising trend in use
of GM animals. A Catch 22 situation also exists, with regulators largely r efusing
to break with tradition and continuing to accept only animal data, even
when robust human-based data exists. Additionally, when new animal-free,
human-relevant methods are developed, regulators often insist that research
still be performed on animals; this is considered to be one of the major barriers to achieving change and, in turn, results in an industry reluctant to invest
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in non-animal research, if its results are unlikely to be accepted (Schiffelers
et al., 2012).
Whilst public engagement, via campaigns to highlight animal suffering,
remains vital, a renewed focus on scientific, political, and financial interests
is needed. This focus is needed to emphasize the fundamental message that
animal research simply does not deliver what is needed, in order to influence
those who regulate, finance, or approve animal experiments and have a meaningful impact on their ongoing reduction but primarily, their replacement. Scientific evidence is needed, on an ongoing basis, of the inadequacy of animal
experiments in predicting human outcomes, combined with a focus on the
modern, non-animal techniques that have the potential to replace them, to
drive an ongoing recognition of the need for genuine, significant investment
in human-relevant research. Additionally, not all animal tests need replacing,
many can simply end; so providing appropriate evidence of these types of tests
is also essential.
In striving to achieve a paradigm shift to end animal experimentation, for
scientific as much as ethical reasons, an evidence-based approach is required.
There remains a vital need for a combination of drivers in innovative, animalfree scientific research, training, and education, as well as continued lobbying
and campaigning to key stakeholders (i.e., scientists, regulators, and political
audiences).
Animal experimentation falls into two broad categories: basic research (including basic medical research) and a relatively smaller category, toxicity (or
safety) testing of new substances, which includes chemicals for use in personal
care, household products, industrial substances, foodstuffs, or pharmaceuticals
(the latter are also tested for efficacy). There is overlap, to some extent, in these
categories, with some animal procedures categorized as “fundamental toxicology”, for example. A two-fold strategy is suggested to end the use of animals
in all experimental research. The first should focus on how a large number of
procedures performed, both in basic research and product-safety testing, can
simply end today; in other words, they do not need non-animal replacements.
The second should focus on procedures that are considered to require replacement. This could be through intelligent and strategic combinations of existing
non-animal tests (integrated testing strategies) and/or further development of
new human-relevant models. Examples of these and their success in replacing
animals to date are discussed later in this chapter.
A popular argument in support of continuing animal research is that they
have been used for decades in the research and development of new medicines. The fact that millions of animals have been used over years, often in
the same repeated experiments, is not in dispute. However, their continued
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use does not prove necessity. It is also relevant to note that from early on in a
scientific career, one is discouraged from saying that experiments “didn’t work”
but instead, to conclude how further research or new approaches must be tried
next, in light of unsuccessful or unexpected results. The use of animals has
been grandfathered through, due to convention, anecdotal evidence or belief,
rather than robust scientific validity. “We must use a living system” … but it is
the wrong living system and no matter how many animals are used, they will
never provide an appropriate model for humans. This needs to change, particularly when considering the growing industry of breeding and supplying
millions of GM animals worldwide each year, in repeated attempts to mimic
the human condition.
The vast majority of animals are used either for basic research or breeding of GM strains. This is clear when reviewing recent official statistics for the
three highest animal-using countries in the EU; the UK, Germany, and France.
For example, more than 3.9 million procedures on animals (mice, rats, rabbits,
guinea pigs, dogs, horses, cats, non-human primates, pigs, sheep, cattle, birds,
xenopus, and fish, among other species) were carried out in the UK in 2016. Of
these, 729,390 were genetically modified, including more than 149,000 animals
deliberately bred to suffer a harmful phenotype (a deliberately induced condition, such as cancer, failed immune system, or organ failure to try to simulate
disease in humans). There were also increases in the number of experiments
across several species, and a significant number of experiments for ingredients
in household products (1700 procedures), to meet industrial chemicals legislation requirements, despite a policy on testing for such purposes (Home Office,
2017). In fact, of the total 3.9 million procedures conducted in the UK in 2016,
only 13% were carried out for regulatory purposes. Germany bred 1.2 million
GM animals in 2015 (with similar numbers of harmful phenotype animals to
the UK), representing 42% of the 2.8 million animals used annually (Federal
Ministry of Food and Agriculture, 2016). Figures reported for France in 2014
show that 1.8 million animals were used, however the proportion of GM animals was not reported (Ministry of Higher Education & Research, 2016).
Several thousand diseases affect humans. Of these, only 500 currently have
fda-approved treatments available (National Center for Advancing Translational Sciences, 2017). In every discipline of disease research, animals are used
on an ongoing basis, yet it is continually reported that mechanisms of human
conditions investigated in such animals are still not understood. This is because basic research in animals is a demand-driven and self-perpetuating system, with much research being proposed and licensed on the basis of being
repetitively performed on animals (often termed as “well established” or “well
documented” models). Such research is neither legally required, nor does it
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have to be relevant or applicable to human disease to be licensed. Another
key barrier to replacing animals, even when scientifically valid alternatives are
available, is awareness and acceptance of their use, both by researchers and
regulators (Ramirez et al., 2015).
The first part of this chapter provides an analysis of extrapolation of animal studies to humans, by sampling systematic reviews carried out to assess
evidence of clinical translation and incorporating a review of literature on
animal toxicity studies for some well-known, established case study drugs (e.g.,
paracetamol, aspirin, penicillin) and animal versus human findings. The second part addresses drivers for change and the development of animal-free (or
rather, human-relevant) research methods, as well as some examples of procedures that do not need replacing as they can simply stop, when considering
that they can logically be avoided or rejected on the basis of a correctly performed (and legally required) harm-benefit assessment. The chapter aims to
provide an overview of the above topics and suggestions for the way forward as
part of a new paradigm for a global, animal-research free future.
1

Part 1: Analysis of Abstracts from Systematic Reviews of Animal
Studies

To carry out an analysis of systematic reviews on animal experiments, a review of a sample of available literature was performed. The intention of this
analysis was to provide a generally qualitative review of the literature. To do so,
two separate sources were used. First, a search in PubMed (National Centre for
Biotechnology Information, 2016) was made using the keyword search of “systematic review animal studies.” This resulted in a total of 163,585 publications.
PubMed allows search by Article Type and selecting this as “systematic review”
further filtered results to 8,291 listings, also sorted by relevance. Second, the
Google Scholar database, using the same search terms, “systematic review animal studies,” for consistency, yielded 2,530,000 results (Google Scholar, 2016).
Dates of publications ranged from 1999–present. Generally, PubMed provided
more recent listings compared to Google Scholar, which resulted in older publications; but this was useful to provide a greater scope for review over the past
two decades as well as avoid duplication.
To account for time constraints, while still providing a reasonable sample
size, the first 50 abstract listings within each source were reviewed, giving a
sample total of 100 (see Table 15.1). If a publication appeared within both sources, this was also accounted for, although duplicates were relatively few. Where
publications were found to be not relevant, further listings were reviewed to
compensate for this and to maintain a total of 100.
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Table 15.1 Publications included in abstract review (n=100)

Number Reference

Source

1

PubMed

2

3

4

5

6

7

8

Andersen, K., Pedersen, T.K., Hauge, E.M., Schou, S. and Nørholt,
S.E. (2014). Effect of Mandibular Distraction Osteogenesis on
the Temporomandibular Joint: A Systematic Review of Animal
Experimental Studies. Oral Surgery, Oral Medicine, Oral Pathology,
Oral Radiology, 117(4), pp. 407–415
Belkouch, M., Hachem, M., Elgot, A., Van, A.L., Picq, M., Guichardant, M., Lagarde, M. and Bernoud-Hubac, N. (2016). The
Pleiotropic Effects of Omega-3 Docosahexaenoic Acid on the
Hallmarks of Alzheimer’s Disease. Journal of Nutritional Biochemistry, 38, pp. 1–11.
Bero, L., Anglemyer, A., Vesterinen, H. and Krauth, D. (2016).
The Relationship Between Study Sponsorship, Risks of Bias, and
Research Outcomes in atrazine Exposure Studies Conducted
in Non-human Animals: Systematic Review and Meta-analysis.
Environment International, 92–93, pp. 597–604.
Briel, M., Müller, K.F., Meerpohl, J.J., von Elm, E., Lang, B.,
Motschall, E., Gloy, V., Lamontagne, F., Schwarzer, G. and Bassler,
D. (2013). Publication Bias in Animal Research: A Systematic
Review Protocol. Systematic Reviews, 27(2), p. 23.
Carvalho-Lobato, P., Garcia, V.J., Kasem, K., Ustrell-Torrent, J.M.,
Tallón-Walton, V. and Manzanares-Céspedes, M.C. (2014). Tooth
Movement in Orthodontic Treatment with Low-level Laser
Therapy: A Systematic Review of Human and Animal Studies.
Photomedicine and Laser Surgery, 32(5), pp. 302–309.
Chiu, K., Robson, S., Devi, J., Woodward, A. and Whittem T.
(2016). The Cardiopulmonary Effects and Quality of Anesthesia After Induction with Alfaxalone in 2-hydroxypropyl-βcyclodextrin in Dogs and Cats: A Systematic Review. Journal of
Veterinary Pharmacology and Therapeutics, 39(6), pp. 525–538.
Disma, N., Mondardini, M., Terrando, N., Absalom, A. and Bilotta,
F. (2016). A Systematic Review Of Methodology Applied During
Preclinical Anesthetic Neurotoxicity Studies: Important Issues
and Lessons Relevant to the Design of Future Clinical Research.
Paediatric Anaesthesia, 26(1), pp. 6–36.
Emmens, R., Wouters, D., Zeerleder, S., van Ham, S., Niessen,
H. and Krijnen, P. (2016). On the Value of Therapeutic Interventions Targeting the Complement System in Acute Myocardial
Infarction. Translational Research, pp. S1931–5244.

PubMed

PubMed

PubMed

PubMed

PubMed

PubMed

PubMed
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Table 15.1 Publications included in abstract review (n=100) (cont.)

Number Reference

Source

9

PubMed

10

11

12

13

14

15

16

Faggion, C.M. Jr., Chambrone, L., Gondim, V., Schmitter, M. and
Tu, Y.K. (2010). Comparison of the Effects of Treatment of Periimplant Infection in Animal and Human Studies: Systematic
Review and Meta-analysis. Clinical Oral Implants Research, 21(2),
pp. 137–147.
Faggion, C., Giannakopoulos, N. and Listl, S. (2011). Risk of Bias
of Animal Studies on Regenerative Procedures for Periodontal
and Peri-implant Bone Defects. A Systematic Review. Journal of
Clinical Periodontology. 38(12), pp. 1154–1160.
Fliefel, R., Kühnisch, J., Ehrenfeld, M. and Otto, S. (2016). Gene
Therapy for Bone Defects in Oral and Maxillofacial Surgery: A
Systematic Review and Meta-analysis of Animal Studies. Stem
Cells Development, Epub ahead of print.
Gates, S., Smith, J.L., Ong, G.J., Brace, S.J. and Perkins, G.D. (2012).
Effectiveness of the lucas Device for Mechanical Chest Compression After Cardiac Arrest: Systematic Review of Experimental, Observational and Animal Studies. Heart, 98(12),
pp. 908–913.
Gulin, J.E., Rocco, D.M. and García-Bournissen, F. (2015). Quality
of Reporting and Adherence to arrive Guidelines in Animal
Studies for Chagas Disease Preclinical Drug Research: A Systematic Review. Public Library of Science Neglected Tropical Diseases,
20:9(11).
Hirst, T.C., Watzlawick, R., Rhodes, J.K., Macleod, M.R. and
Andrews, P.J. (2016). Study Protocol: A Systematic Review and
Meta-analysis of Hypothermia in Experimental Traumatic Brain
Injury: Why Have Promising Animal Studies Not Been Replicated
in Pragmatic Clinical Trials?. Evidence-based Preclinical Medicine,
3(2), p. e00020.
Krause Neto.W., Ciena, A.P., Anaruma, C.A., de Souza, R.R. and
Gama E.F. (2015). Effects of Exercise on Neuromuscular Junction
Components Across Age: Systematic Review of Animal Experimental Studies. BioMed Central Research Notes, 24(8), p. 713.
Krauth, D., Woodruff, T. and Bero, L. (2013). Instruments for
Assessing Risk of Bias and Other Methodological Criteria of
Published Animal Studies: A Systematic Review. Environmental
Health Perspectives, 121(9), pp. 985–992.

PubMed

PubMed

PubMed

PubMed

PubMed

PubMed

PubMed
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18
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20

21

22

23

24

25

Lee, S.H., van den Noort, M., Bosch, P. andLim, S. (2016). Sex
Differences in Acupuncture Effectiveness in Animal Models
of Parkinson’s Disease: A Systematic Review. BioMed Central
Complementary and Alternative Medicine, 3, 16(1), p. 430.
Leung, M.C., Yip, K.K., Ho, Y.S., Siu, F.K., Li, W.C. and Garner, B.
(2014). Mechanisms Underlying the Effect of Acupuncture on
Cognitive Improvement: A Systematic Review of Animal Studies.
Journal of Neuroimmune Pharmacology, 9(4), pp. 492–507.
Li, J., Hernanda, P.Y., Bramer, W.M., Peppelenbosch, M.P., van
Luijk, J. and Pan, Q. (2015). Anti-tumor Effects of Metformin
in Animal Models of Hepatocellular Carcinoma: A Systematic
Review and Meta-analysis. PLoS One, 1;10(6), p. e0127967.
Liao, Y., Zhang, X.L., Li, L., Shen, F.M. and Zhong, M.K. (2014).
Stem Cell Therapy for Bone Repair: A Systematic Review and
Meta-analysis of Preclinical Studies with Large Animal Models.
British Journal of Clinical Pharmacology, 78(4), pp. 718–726.
McClelland, J., Bozhilova, N., Campbell, I. and Schmidt, U. (2013).
A Systematic Review of the Effects of Neuromodulation on Eating
and Body Weight: Evidence from Human and Animal Studies.
European Eating Disorders Review, 21(6), pp. 436–455.
McDonald J., Eng, S., Dina, O., Schooling, C. and Terry, M. (2016).
Infection and Pubertal Timing: A Systematic Review. Journal of
Developmental Origins of Health and Disease, 7(6), pp. 636–651
Mueller, K.F., Briel, M., Strech, D., Meerpohl, J.J., Lang, B.,
Motschall, E., Gloy, V., Lamontagne, F. and Bassler, D. (2014).
Dissemination Bias in Systematic Reviews of Animal Research: A
Systematic Review. PLoS One, 26, 9(12), p. e116016.
Muhlhausler, B.S., Gibson, R.A. and Makrides, M. (2011). The Effect of Maternal Omega-3 Long-chain Polyunsaturated Fatty Acid
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Animal Studies. Prostaglandins, Leukotrienes, and Essential Fatty
Acids (plefa), 85(2), pp. 83–88.
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in specific procedures, but this was generally qualified with an advisory to interpret the findings with caution and the need for more clinical studies to provide better evidence in humans.
Species used in studies included rats, mice, rabbits, cats, dogs, sheep, pigs,
and non-human primates, among others. A wide range of disease areas were
covered, including several types of cancer, heart disease, stroke, neurological
disorders (e.g., Alzheimer’s and Parkinson’s disease), diabetes, bone defects
and facial disorders, dental research, gene therapy and stem cell research, to
provide some examples. Several publications were general reviews of how animal data translates to humans, as well as reviews of animal studies in specific
disease areas.
The large majority of reviews (75%) found that assessment of human response from animal data is significantly limited due to one or more of the
following factors: species differences, lack of clinical translation, poor quality
methodology, inconsistency, and publication bias, resulting in overstatement
of the benefits of animal use in predicting human disease outcomes or safety.
There was a distinct lack of evidence clinically, despite many therapies in use
based on animal studies. Numerous reviews highlighted the successes claimed
over basic research outcomes or new therapies in animal “models”, which have,
however, failed to translate to the clinic to help patients (Hirst et al., 2016).
Concerns over paucity of evidence, publication bias and consequently, overstatement of benefit in translating animal data to humans have led to many
systematic reviews (Briel et al., 2013).
A key finding from this review is that, not only is publication bias very common in animal research, but many additional results considered unsuccessful remain unpublished. This issue was raised in a number of the systematic
reviews analyzed, for example in animal models of stroke (Sena et al., 2010).
Several reviews also raised concerns over animal studies and human trials being carried out simultaneously (Horn et al., 2001; Lucas et al., 2002). Moreover,
this analysis found several studies (5% of the sample reviewed), highlighting
animal experiments that could have been entirely omitted and carried out directly and far more effectively and ethically in clinical or observational studies
in humans; for example, studies on dietary intake and cardiovascular health
(Reis et al., 2016; Raynor et al., 2015), or trials of substances already in human
use (Rogers et al., 2016). In many cases, human trials were carried out in parallel with animal experiments, representing examples of animal use that can be
abandoned. This is discussed later in this chapter in more detail.
The findings from the majority of publications reviewed are consistent
with other evidence on the problems of translating animal data to humans;
for example, the Review of Research Using Non-human Primates (jointly
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c ommissioned in 2006 by a number of major UK research councils and chaired
by Sir David Weatherall). A subsequent review in 2011 addressed one of the re
commendations in the Weatherall report, to review ten years of brain research
in monkeys retrospectively. Not only did the review reveal some disturbing insights into the routine suffering of non-human primates used in neurology, but
it reported the equally concerning finding that “In most cases, however, little
direct evidence was available of actual medical benefit in the form of changes
in clinical practice or new treatments” (Biotechnology and Biological Sciences
Research Council, 2011, p. 13). These findings were emphasized more recently
in the Review of the Assessment of Cumulative Severity and Lifetime Experience
in Non-human Primates Used in Neuroscience Research, published in November
2013 by the (then) Animal Procedures Committee (apc, now Animals in Science Committee) (apc, 2013).
Further evidence of increasing concern over the validity of animal research
was highlighted in a British Medical Journal review entitled, How Predictive
and Productive is Animal Research?, which concluded that “Funds might be
better directed towards clinical rather than basic research, where there is a
clearer return on investment in terms of effects on patient care” (Godlee, 2014,
p. 1). This article adds to a wealth of evidence on the poor performance of
animals in predicting human responses, with an accuracy of approximately
20%–60%, depending on reviews cited (Perel et al., 2007; van Meer et al., 2012).
Additionally, in a series of studies between 2013–2015, a collaboration between
the Fund for the Replacement of Animals in Medical Experiments and Cruelty
Free International involved the analysis of an unprecedented level of independent data from both preclinical toxicity studies and human clinical trials. The
studies revealed the inadequacies of animal toxicity studies in a number of
species (i.e., dog, rabbit, mouse, rat, and non-human primate) in predicting
human adverse events; and the urgency for more human-relevant methods to
be developed (Bailey et al., 2013, 2014, 2015).
To some extent the pharmaceutical industry recognizes that the models it
has been using are inadequate. There is encouraging research into alternative
approaches and further consideration of the problem in some areas (Bloomberg, 2013). In 2014, the National Institutes of Health (nih), Tissue Chip Program, began the investigation of more than 100 drugs that showed success in
rodents but went on to fail in human trials (nih, 2016).
With regard to the purpose of experiments covered by the reviews examined, the majority of publications focused on basic research in animals (66%).
This was expected, given that this is the largest area of animal use. The remaining 34% were concerned with reviewing safety or efficacy of substances,
including new and existing drugs, herbal therapies, or food related additives or
substances (e.g., low calorie sweeteners) (Rogers et al., 2016).
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Review of Toxicity Studies in Animals, Focusing on Three Wellknown Examples

A follow-up literature review was performed to further address publications of
toxicity tests in animals. This specific sample of the most recent literature was
chosen to provide meaningful case studies on three well-known and widelyused drugs worldwide: paracetamol (acetaminophen), aspirin and penicillin.
Information on these studies is presented in Table 15.2, and each drug is briefly
discussed below.
2.1
Paracetamol
Paracetamol was first marketed in the 1950’s (Sneader, 2005) and is well known
as one of the world’s most common household drugs, traded under many different brand names, including Tylenol and Panadol. Despite being marketed
for over five decades and the vast availability of data on global human use,
paracetamol continues to be routinely tested on animals, both for “blue sky”
research and attempts to market it for new purposes. Using a similar methodology to the previous review, the general key search terms of “paracetamol toxicity animals” resulted in 2,431 listings in PubMed. (Note: Using similar terms
“acetaminophen toxicity animals” provided 2,358 listings and a brief review
established, as expected, that many of these were the same results).
Review of the first five listings under the above search term, published
between 2014–2016, provided extensive evidence of ongoing experimental
research into paracetamol in animals. For example, hepatotoxicity has been well
known for decades as a risk of paracetamol overdose in humans, yet, inducing such effects in mice is still carried out routinely, worldwide (Pingili et al.,
2015). Further recent studies show that macaques are considered a poor model
due to their resistance to paracetamol poisoning when compared to humans
(Yu et al., 2015). Experimental dosing and killing of newborn mice continues
(Viberg et al., 2014), despite paracetamol’s widespread global use in children
and pregnant mothers, as shown by far more directly relevant clinical or observational studies to check for effects on offspring (Liew et al., 2014). Other experimental studies included, force feeding of GM mice with a drug to inhibit an
enzyme that activates the toxic response to paracetamol in order to investigate
resistance (Pu et al., 2016), and numerous similar, experimental testing in mice
(Hohmann et al., 2013), despite much earlier, advanced human-based studies
to investigate resistance to paracetamol toxicity (McCloskey et al., 1999).
Another publication investigated a widely-used industrial chemical that
humans are routinely exposed to in the environment via air, diet, and water: aniline. The aim of the study was to investigate aniline’s conversion to
paracetamol, and its effects on male fertility. Yet, instead of employing the
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Table 15.2 Review of publications relating to paracetamol, aspirin, and penicillin

Number Reference

Source

101

PubMed

102

103

104

105

106

107

Atli, O., Demir-Ozkay, U., Ilgin, S., Aydin, T., Akbulut, E. and
Sener, E. (2016). Evidence for Neurotoxicity Associated with
Amoxicillin in Juvenile Rats. Human & Experimental Toxicology,
35(8), pp. 866–876.
Cappon, G., Gupta, U., Cook, J., Tassinari, M. and Hurtt, M.
(2003). Comparison of the Developmental Toxicity of Aspirin
in Rabbits When Administered Throughout Organogenesis
or During Sensitive Windows of Development. Birth Defects
Research Part B: Developmental and Reproductive Toxicology,
68(1), pp. 38–46.
Chao, Y., Lee, C., Liu, K., Wang, Y., Wang, C. And Liu, S.(2015).
Sustained Release of Bactericidal Concentrations of Penicillin
in the Pleural Space via an Antibiotic-eluting Pigtail Catheter
Coated with Electrospun Nanofibers: Results from In Vivo and
In Vitro Studies. International Journal of Nanomedicine, 4(10),
pp. 3329–3336.
Feinstein, A., Heinemann, L., Curhan, G., Delzell, E.,
DeSchepper, P., Fox, J., Graf, H., Luft, F., Michielsen, P., M
 ihatsch,
M., Suissa, S., van der Woude, F. and Willichet, S. (2000).
Relationship Between Nonphenacetin Combined Analgesics
and Nephropathy: A Review. Kidney International, 58(6),
pp. 2259–2264.
Holm, J., Chalmey, C., Modick, H., Jensen, L., Dierkes, G., Weiss,
T., Jensen, B., Nørregard, M., Borkowski, K., Styrishave, B., Koch,
H., Severine, M., Jegou, B., Kristiansen, K. and Kristensen, D.
(2015). Aniline Is Rapidly Converted into paracetamol impairing Male Reproductive Development. Toxicological Sciences,
148(1), pp. 288–298.
Hueper, K., Elalfy, M., Laenger, F., Halter, R., Rodt, T., Galanski,
M. and Borlak, J. (2012). pet/CT Imaging of c-Myc Transgenic
Mice Identifies the Genotoxic N-nitroso-diethylamine as
Carcinogen in a Short-term Cancer Bioassay. PLoS One, 7(2),
p. e30432.
Huggett, A., Schilter, B., Roberfroid, M., Antignac, E. and
Koeman J.H. (1996). Comparative Methods of Toxicity Testing:
Consensus Document Following an International Life Sciences
Institute-ilsi Europe Workshop Held in May 1995. Food and
Chemical Toxicology, 34(2), pp. 183–192.

PubMed

PubMed

PubMed

PubMed

PubMed

PubMed
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109

110

111

112

113

114

115

116

Jefferies, S., Saxena, M. and Young, P. (2012). Paracetamol In
Critical Illness: A Review. Critical Care and Resuscitation, 14(1),
pp. 74–80.
Jegatheeswaran, S. and Siriwardena, A. (2010). Experimental
and Clinical Evidence for Modification of Hepatic Ischaemia—
reperfusion Injury by N-acetylcysteine During Major Liver
Surgery. The Official Journal of the International Hepato
Pancreato Biliary Association, 13, pp. 71–78.
Li, J., Yu, Y., Yang, Y., Liu, X., Zhang, J., Li, B., Zhou, X., Niu, J., Wei,
X. and Liu, Z. (2012). A 15-day Oral Dose Toxicity Study of Aspirin Eugenol Ester in Wistar Rats. Food and Chemical Toxicology,
50(6), pp. 1980–1985.
López-Ruiz, E., Vega-Flores, G., Contreras-Cisneros, B.,
Martínez, A. and Rivera-García, A. (2015). Effect of Partial and
Generalised Epileptic Seizures on Sleep Architecture in Rats.
Revista De Neurologia, 1,60(7),pp. 289–295.
McGill, M. and Jaeschke, H. (2014). Mechanistic Biomarkers in
Acetaminophen-induced Hepatotoxicity and Acute Liver Failure; From Preclinical Models to Patients Expert Opinion on Drug
Metabolism & Toxicology, 10(7), pp. 1005–1017.
Pingili, R., Pawak, A. and Challa, S. (2015). Systemic Exposure
of Paracetamol (Acetaminophen) Was Enhanced by Quercetin and Chrysin Co-administration in Wistar Rats and In Vitro
Model: Risk of Liver Toxicity. Drug Development and Industrial
Pharmacy, 41(11), pp. 1793–1800.
Pu, S., Ren, L., Liu, Q., Kuang, J., Shen, J., Cheng, S., Zhang,
Y., Jiang, W., Zhang, Z., Jiang, C. and He, J. (2016). Loss of
5-lipoxygenase Activity Protects Mice Against Paracetamolinduced Liver Toxicity. British Journal of Pharmacology, 173(1),
pp. 66–76.
Raza, H., John, A. and Shafarin J. (2014). nac Attenuates lpsinduced Toxicity in Aspirin-Sensitized Mouse Macrophages
via Suppression of Oxidative Stress and Mitochondrial
Dysfunction. PLoS One, 9(7), p. e103379.
Viberg, H., Eriksson P., Gordh, T. and Fredriksson, A. (2014).
Paracetamol (Acetaminophen) Administration During Neonatal Brain Development Affects Cognitive Function and Alters
Its Analgesic and Anxiolytic Response in Adult Male Mice.
Toxicological Sciences, 138(1), pp. 139–147.
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Table 15.2 Review of publications relating to paracetamol, aspirin, and penicillin (cont.)

Number Reference
117

Source

Yu, H., Barrass, N., Gales, S., Lenz, E., Parry, T., Powell, H.,
PubMed
Thurman, D., Hutchison, M., Wilson, I., Bi, L., Qiao, J., Qin,
Q. and Ren, J. (2015). Metabolism by Conjugation Appears
to Confer Resistance to Paracetamol (Acetaminophen)
Hepatotoxicity in the Cynomolgus Monkey. Xenobiotica, 45(3),
pp. 270–277.

d irectly relevant approach of investigating the vast amount of already available clinical and observational exposure data, groups of mice were injected,
before being killed and dissected along with their offspring, for examination
(Holm et al., 2015).
As well as review of specific experiments on paracetamol toxicity in animals, further publications published between 1996 and 2012 on systematic
reviews of paracetamol toxicity were analyzed (see Table 15.2). Included were
reviews of translating animal models of paracetamol toxicity to humans,
stating that “Considerable effort has been made to predict and model druginduced liver injury in humans using laboratory animals with only little success and even some controversy” (McGill and Jaeschke, 2014, p. 10). A further
review of paracetamol, and similar drugs in its class, concluded that there was
insufficient evidence based on animal (and human) tests to assess toxic effects
on the human kidney (Feinstein et al., 2000). An analysis of clinical treatment
for paracetamol-induced injury during liver surgery documented 19 different
studies carried out on mice, rats, dogs, and pigs with varying results, concluding that evidence was insufficient to suggest the therapy was clinically relevant
(Jegatheeswaran and Siriwardena, 2010).
The remaining reviews focused on how paracetamol, over two decades ago
(as one of a group of “well-studied” hepatoxicants), highlighted the need to
evaluate links between in vitro and in vivo testing strategies (Huggett et al.,
1996); and more recently, despite the extensive toxicity testing of paracetamol,
evidence supporting its use in specific groups of patients (e.g., the critically
ill) was considered lacking (Jefferies et al., 2012), highlighting the value of data
that can only be gathered in clinical research. When taken in normal regular doses, paracetamol is largely considered safe in humans for a number of
pain associated conditions. Yet, it causes a wide range of toxicities in many
species, for example, cancer in mice and rats (Hueper et al., 2012). In fact, given
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requirements today for extensive regulatory toxicity testing in animals, it is
highly likely that paracetamol would be denied approval based on its poor
safety profile in animals.
2.2
Acetylsalicylic Acid (Aspirin)
Acetylsalicylic acid, commonly known as Aspirin, has been in human use for
more than a century. It is still considered successful; and given its relatively
cheap production costs and widespread use for a number of indications, it is
still considered a “blockbuster” drug in terms of revenue (Hartung, 2009). Yet,
the human relevant dose of aspirin is lethal to rats and causes toxic effects in
many animal species, including embryonic deformities in dogs, cats, mice, rats,
monkeys, and rabbits (Barrow, 2002). Like paracetamol, given the poor safety
record of aspirin in animals, it would very likely be denied approval for human
use if newly marketed, according to today’s regulatory testing requirements
(Hartung, 2009). Aspirin continues to be routinely tested on animals, despite
availability of vast libraries of both historical and new human data.
With the same methodology and sampling as the previous reviews, the
search terms, “aspirin toxicity animals” were used. PubMed revealed experiments carried out between 2012–2016, including 15-day oral toxicity studies of
derivatives of aspirin in Wistar rats and subchronic toxicity studies in mice
(see Table 15.2). Searching for publications under the terms “acetylsalicylic acid
toxicity in animals” resulted in specific studies published between 2000–2013.
These included administration of large doses to pregnant rabbits, concluding
that aspirin is not teratogenic to them, and highlighting inconsistencies with
previous rabbit experiments and species differences with rats, having been “extensively studied” and exhibiting birth defects (Cappon et al., 2003).
2.3
Penicillin
Alexander Fleming’s pioneering work on penicillin is well known. Following
this, Florey and Chain won a Nobel Prize in the 1940’s for successful results in
mice with penicillin; yet, they considered themselves fortunate to have chosen
to test mice instead of guinea pigs, who showed lethal side effects to the drug,
as Florey later remarked: “Mice were used in the initial toxicity tests because
of their small size, but what a lucky chance it was, for in this respect man is
like the mouse and not the guinea pig. If we had used guinea pigs extensively
we should have said that penicillin was toxic and we probably should not have
proceeded to try and overcome the difficulties of producing the substance for
trial in man” (Florey, 1953, p. 12).
In fact, penicillin is safe, to some extent, in mice and rats but has severe,
often lethal, effects in hamsters and guinea pigs due to their very sensitive
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intestinal microbiota, making them particularly susceptible when compared
to other species. Animal users are quick to respond to this issue, stating that
multiple species are used to assess the most appropriate “model” for humans
and account for differences (heterogeneity) in animals. Again, no dispute is
made on this; indeed, this has been the tenet in toxicology for decades, testing
in different species and varying doses, modifying their condition either genetically, chemically or physically in an attempt to elicit the reaction needed. Yet,
the high attrition rate of new pharmaceuticals and lack of progress in key areas
of disease research should suggest that something is wrong. The use of animals
is the only area of scientific research where the same dated techniques are
still being used 60–70 years later, despite their limitations being well known.
No other area of science continues to use such a dogmatic approach. As evidence of this, a general literature review of the search terms “penicillin toxicity animals” results in numerous publications over decades, several of the
most recent listings (2011–2016, see Table 15.2) involving rats, rabbits, and other
animals; even using penicillin in repeated experiments to induce effects, including anxiety and depression (to try to mimic effects in rats already seen in
patients), weight loss, organ failure, and deliberate epilepsy to test the effects
of other drugs that, like penicillin, are already in extensive global use, with a
wealth of clinical toxicity data available.
3

Part 2: Drivers for Change—Development of Animal-free Testing
Methods

It should be noted that use of the term alternatives in this chapter refers only
to methods that replace the use of animals and their tissues. It is necessary to
make this distinction, given the widely-used terminology of the 3Rs (replacement, reduction and refinement), first proposed in The Principles of Humane
Experimental Technique (Russell and Burch, 1959). The ultimate goal of Russell
and Burch in establishing the 3Rs was replacement. While measures to refine
methods or reduce animal numbers are, of course, to be encouraged, much attention is devoted to these 2Rs and, to some extent, it has diverted focus from
replacement.
Given six decades of the 3R principles, dedicated attention to replacement
is long overdue. This is also reflected in European Directive 2010/63/EU on
animals used for scientific purposes (European Parliament, 2010, p. 2), which
states that it “represents an important step towards achieving the final goal of
full replacement of procedures on live animals for scientific and educational
purposes as soon as it is scientifically possible to do so. To that end, it seeks to
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facilitate and promote the advancement of alternative a pproaches.” Although
the Directive was implemented in January 2013, there has been relatively little
decrease and, in many cases, an increase in animal use across individual Member States. Therefore, there is still great scope for improvement, particularly
with regard to funding the development, acceptance, and adoption of animalfree, human-based methods.
Furthermore, the broad interpretation of the term alternatives under the
auspices of the 3Rs is used to describe the use of some animals as “alternatives”
to others, for example the use of zebrafish over rodents (Charles River, 2016);
transgenic mice to “replace” non-human primates (Home Office, 2014); and
even the use of minipigs, instead of dogs, as an “alternative” that may be more
acceptable to the public, because they are considered “food animals” (Forster
et al., 2010). Aside from the poor ethical argument, replacing one animal with
another still fails to address the wrong model problem.
Use of public opinion and political lobbying to drive legislative change
remains vital to fueling research and developments in animal-free science.
The clearest example in recent years is the phased-in bans on animal-tested
cosmetics across the EU between 2009–2013 (European Commission, 2013).
A testing ban on cosmetic ingredients was enforced from March 11, 2009, along
with a partial marketing ban for 10 animal-test requirements. This was eventually followed by a further marketing ban from March 11, 2013 for endpoints
considered more complex (i.e., repeat dose toxicity, skin sensitization, reproductive toxicity, carcinogenicity, and toxicokinetics). However, for safety data
requirements of cosmetic substances, some of these endpoints are rarely or not
required (Nohynek et al., 2010). Despite delays in implementing the bans and
legal challenges attempting to abolish them altogether, they had a monumental effect on the industry, with the development of numerous in vitro methods
to be ready in time. Despite loopholes with conflicting chemicals safety-testing
legislation, such as Registration, Evaluation, Authorisation and Restriction of
CHemicals (reach) (European Chemicals Agency, 2007), the bans have been
responsible for one of the most significant advances towards replacing animal
tests in decades.
The campaign to end cosmetics tests on animals began in the 1970s, and it
took until 1993 to see legislation amendments to mark the implementation of
official EU bans. After a further two decades of delays, the bans were finally enforced, with significant resistance amid claims that innovation would be stifled
and that the development of alternatives would not be possible. Instead, the
opposite was achieved. The development of in vitro methods was stimulated to
address a number of toxicological endpoints (the result of a study to determine
how toxic a substance is). The endpoints included skin irritation, eye irritation,
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skin corrosion, phototoxicity, skin absorption/penetration, acute toxicity, and
genotoxicity/mutagenicity. In preparation for the forthcoming bans, around
30 new in vitro assays were validated by 2007 (Hartung, 2008), with more
developed since and projections that the in vitro toxicity testing market will
be worth US$17,227 million by 2018 (PR Newswire, 2014). The bans have also
affected positive change outside EU borders, with similar bans now in place in
India, Israel, Norway, and New Zealand, as well as partial or full enforcements
in many other countries.
4

Methods Now Available, Previously Considered Only Possible in
Animals—Some Examples

Replacement can be (and is being) achieved by a number of approaches, including in vitro and in silico models. Some examples are discussed below.
In its 2014 Delivery Plan, Working to reduce the use of animals in scientific
research, the UK Home Office devoted much of the text to supporting the continuance of animal research. However, the plan also showcases human in vitro
methods, for example, using induced pluripotent stem cells (Yusa et al., 2011),
which it describes as “work that in the past could only have been modelled in
animal systems” (Home Office, 2014, p. 16).
Scientists at the University of Newcastle have developed human skin-based
assays, using cells isolated from the blood sample of healthy volunteers to assess new drugs, cosmetics and household products. The technology, now marketed as Skimune by Alcyomics Ltd, could have predicted the adverse effects
seen in the volunteers of the TGN1412 monoclonal antibody clinical trial in
2006 (Alcyomics, 2017).
Other high performance initiatives include physiologically-based pharmacokinetic modelling (pbpk), which quantitatively predicts the characteristics
of substances in the body (e.g., blood flow or effects on organs). The introduction of in vitro pbpk models over the past two decades is credited with reducing drug failure rates from over 40% to under 10% (McKim, 2010). Another
major area of replacement research uses devices, known as Multi Organ Chips
(moc), to mimic the human body’s response to chemicals and disease processes, with the ultimate goal being a human on a chip. Over the past few years,
advances in moc technology have been exponential. For example, the organ
on a chip devices developed at Harvard’s Wyss Institute can mimic events in
tissue function and disease, such as air flow, bacterial infection, immune system response, blood clotting, fluid leakage and, most recently, electrical activity across cells, to predict safety and disease mechanisms in patients (Wyss
Institute, 2017). For further discussion see Wilkinson, 2019, Chapter 26.
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At the United States nih Chemical Genomics Centre, a major testing program has been underway since 2004, involving a robotic-arm system that tests
thousands of chemicals, using patient donated cells. The high throughput
system performs approximately 3 million tests per week in relation to a different disease. The success of the system (also funded under the Toxicology in the
21st Century, Tox21, initiative) in screening and identifying suitable candidate
drugs has dramatically saved time, cost, and resources, resulting in human
clinical trials starting within a year.
A further groundbreaking concept is the Adverse Outcome Pathway (aop),
a key component of the paradigm shift towards human-relevant methods and
establishing a robust system for predicting human safety. An aop is a sequence
of events that starts by a chemical effect at the molecular level (termed a Molecular Initiating Event) and progresses through changes (termed Key Events)
in cells, tissues, and organs to produce an adverse effect in the body. aops act
as a bridge between emerging methods of safety testing and, ultimately, what
happens in the body in response to a particular substance (xenobiotic). With
increasing knowledge, aops can be linked to form networks, revealing adverse
outcomes that share pathways and vice versa. One example is the establishment of in vitro test methods that map the three key stages of the aop for skin
sensitization, now accepted at Organisation for Economic Co-Operation and
Development (oecd) level (2015). Before the EU cosmetic testing bans were
implemented, there was a high level of skepticism over the prospect of testing
substances for skin sensitization (and other complex endpoints) without the
use of animals; and while further work remains to be done, major progress has
been made. The aop program was established in 2012 and, including skin sensitization, there are now six aops approved at the oecd level; five relating to
human health effects and one to address potential ecotoxicological effects to
wildlife (fish, birds, and amphibians). A further 227 aops are in development
(oecd, 2017).
In addition to new in vitro and in silico models to address safety testing, other
areas of animal use previously considered essential, such as education, have
seen coordinated replacement initiatives. Although animals are still used extensively in this area, great successes have been achieved to date. For example,
campaigns by all involved in the International Network for Humane Education
(InterNICHE) project to provide training and disseminate information on humane methods in medicine, biology, and veterinary research (e.g., mannequins
and simulation techniques) continue to affect great change in universities and
schools worldwide (InterNICHE, 2017). Other progress is being made in education as well. In 2016, Washington University announced it would end its 25year use of cats for intubation training (the last university in the United States
still using cats in this way). Instead, it will now use mannequins and advanced
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simulators, following significant investment in its simulation center, which
made the decision possible, following sustained public awareness campaigns
(Physicians Committee for Responsible Medicine, 2016). Also in 2016, Johnson and J ohnson subsidiary, Ethicon, finally agreed to remove live pigs from its
medical-device training program, stating that it “discontinued live animal use in
salestrainingacrossourNorthAmericaregion”(PeoplefortheEthicalTreatmentof
Animals, 2016). For further discussion see Pawlowski, et al., 2019, Chapter 22.
In addition to the vast range of human-based technologies now available,
another sensible approach is to improve the use of data from clinical, epidemiological, and biomonitoring studies. All of these have been considerably
underused to date and could not only improve patient-safety and disease
research but avoid the unnecessary use of animals.
5

Abandonment of Redundant and Duplicative Animal Tests

The ethical arguments concerning use of animals and problems with scientific validity are compounded further by the issue of duplicative experiments,
which is a widespread problem. Many of the same tests are carried out over
and over again, often amid claims of needing to maintain confidentiality and
preserving intellectual property, despite mandates to share data. One example,
a robust analysis of safety data submitted under the reach program, recently
revealed that, incredibly, the Draize eye irritation test had been carried out on
rabbits for two chemicals, 90 times per substance. (Luechtefeld et al., 2016).
Not all tests need replacing. Many can end now as they are out of date or
have been found to be redundant. A recent case is the deletion of the singledose toxicity test from the European Medicines Agency guidelines, after it was
recognized that information from the test could be obtained elsewhere, and
that the test was of limited value (European Medicines Agency, 2010). Furthermore, there are many examples of animal tests that require a root and branch
analysis and retrospective assessment to not only assess whether scientific objectives were met but also whether such procedures should have been
approved at all. A case study to demonstrate this further is the European Coalition to End Animal Experiments (eceae). In 2014, eceae estimated that its
strategy of toxicological review and comment on animal testing proposals for
chemicals registered under the reach legislation saved at least 18,000 animals,
through rejected and withdrawn proposals. This was achieved on the basis of
existing data or evidence that the tests proposed were unnecessary or unjustified (eceae, 2014). Another recent example is the welcome decision that the
year-long chronic-toxicity test for pesticides is no longer required in dogs, on
the basis that it is not scientifically justified (Kobel et al., 2010). The test has
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been dropped in the EU, the United States, and Canada. Although there are
still requirements for the one-year test to be carried out in other countries,
the restrictions mark a change in attitudes and a meaningful review of testing
requirements. The campaign continues to see the test abolished worldwide as
soon as possible.
6

Conclusion

The aim of this chapter was to provide a qualitative overview of evidence
from systematic reviews and some individual studies of not only the flawed
approach to the continued use of animals in trying to predict mechanisms
of human disease; but also the success of existing and emerging animal-free
methods, the opportunities for intelligent use of human-based data, and the
distinction between animal tests that require replacement and those that can
simply end.
Advances in science, providing better technologies on an ongoing basis,
should pave the way for acceptance of non-animal methods. In some areas,
such as cosmetics testing, there is unprecedented change and global recognition that animal use must end. Yet, in other areas of animal research, despite a wealth of better science, the realities of some conventional attitudes,
resistance to change, and an industry reliant on the continuation of animal
experimentation (e.g., major establishments funded by long-term programs
of animal research, financial partnerships, GM animal breeding, commercial
breeders, suppliers, and transporters of animals) mean that political lobbying,
campaigning, and raising public awareness must continue to play a major role.
Fortunately, there are a number of animal protection, political, and scientific
stakeholders who continue to work in the field, actively pushing for change, to
increase recognition that animal research must end and to achieve the paradigm shift that is urgently needed for humans and animals.
Dedication
This chapter is dedicated to Andrew Tyler.
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Introduction

Since the second half of the twentieth century, non-human animals (hereinafter referred to as animals) have been widely used as models for researching
human disorders. Historically, this occurred for two main reasons: a) animals
are complex living systems; and b) it is considered less ethically-contentious
as well as easier, quicker, and cheaper to use animals than humans. Their benefit for biomedical advancement is assumed even though systematic evaluations, though uncommon, suggest otherwise. It is crucial to evaluate whether
animal-based biomedical research successfully benefits medical research—
even through indirect pathways—or if it is being used merely to justify further
animal-based research. In this chapter we demonstrate that there is a lack of
communication between animal-based research and clinical research. We discuss possible reasons for this and reflect on whether animal use in biomedical
research is, indeed, fulfilling its primary purpose.
Humans share a long evolutionary story with the rest of the animal kingdom, which explains common physiological and behavioral traits and adaptations. For example, basal ganglia, a set of subcortical nuclei involved in
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several motor functions, are present throughout vertebrate taxa and are largely
similar across species (Lee et al., 2015). Similarly, the rise of body temperature
as a response to infection is shared by humans and other mammals (Nesse and
Williams, 1996; Schaffner, 2006). Even poikilothermic (cold-blooded) animals,
such as lizards, tend to move to warmer places when they are ill, until their
body temperature is several degrees above normal (Nesse and Williams, 1996).
The relatively recent decoding of genomes had shown an impressive number
of genes shared between ourselves and taxonomically-distant species, such
as the frog (Hellsten et al., 2010). These similarities provided the basis for the
untested assumption that animals provide good research models for human
disorders.
However, we know that minimal biological changes can create significant
differences between species and individuals. For example, Darwin’s finches
comprise 14 closely-related species that vary dramatically in their feeding
habits, despite their biological proximity (Lack, 1947). Even amongst individuals of the same species, slight and almost undetectable differences can cause
very different adaptive responses. For example, human beings with sickle cell
trait may have increased protection from malaria but risk sudden death by
hypoxia, when visiting high altitudes or performing intense physical exertion
(Scheinin and Wetli, 2009; Webber et al., 2016), safe activities for most people.
Despite individual differences, it is obvious that human beings are the best
biomedical model for human disorders. However, clinical research is time
consuming and can have severe ethical constraints, which is one of the main
reasons why animals are widely used as models for human disorders. Recent
in vitro developments have allowed us to create cultures of human cells and
tissues (e.g., Petropolis et al., 2016; Wilson, Ahearne and Hopkinson, 2015) that
are considered superior to using animal samples for human-based research
(Clemedson et al., 1998; Huhtala et al., 2008; Petropolis et al., 2016). Nonetheless, among the scientific community, the main obstacle to the total replacement of animal use in biomedical research is not a desire to study cells, t issues,
or organs, but the desire to study entire, functioning bodily systems. This is
considered necessary when objectives include understanding a drug effect in
the whole organism or trying to understand the etiology and pathogenesis of
multifactorial disorders, such as mental disorders.
In silico techniques have been slowly addressing this issue, creating whole
body simulations (e.g., Viceconti, Clapworthy and Jan, 2008; Viceconti, Henney
and Morley-Fletcher, 2016). However, the availability of human data limits these
models. For example, if a new disease arises, models may fail to predict accurately the response of the human body to the new pathogen due to lack of data.
It should be noted that animal models also suffer from failure to predict human
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responses accurately. Despite the accepted potential of in silico techniques,
unvalidated animal models are still commonly believed to be the best available, so far, for studying the entire, functioning human body.
Throughout the years, various authors have asserted that animal research
has made only poor contributions to medical progress (e.g., Bailey, 2008;
Fadali, 1996; Greek and Greek, 2003; Shapiro, 1998), while others have asserted
the opposite (e.g., Illman, 2008; Shively and Clarkson, 2009; Perretta, 2009).
Such assertions are based upon historical analyses, investigations into the
development of various treatments, and critical reviews of animal model
use. Historical accounts are disputed. A classic example is the discovery of
the role of the pancreas in diabetes. Many claim that we owe this discovery
to experiments conducted by Minkowski and von Mering with dogs, in the
second half of the nineteenth century (cited in Bliss, 1982); whereas, others
argue that this medical breakthrough was achieved by Thomas Cawley, 100
years earlier, while performing autopsies on patients who died from diabetes
(cited in Fadali, 1996).
Investigations into the development of treatments are also controversial. A
good example is the development of the poliomyelitis vaccine. P
 oliomyelitis is
a viral disease that reached epidemic proportions in 1916. Some (e.g., Illman,
2008) state that it was the experiments performed on mice and monkeys that
allowed scientists to understand its pathogenesis and develop a vaccine. Furthermore, both poliomyelitis vaccines (Salk vaccine and Sabin vaccine) were
initially grown in monkey kidney tissue (Dowdle et al., 2003), reinforcing the
perception of the central role of animal experiments in the development of poliomyelitis treatment (Illman, 2008). However, others (e.g., Fadali, 1996) claim
that animal experiments delayed the vaccine’s development. Rhesus monkeys,
which provided a widely-used animal model for poliomyelitis, misled scientists
to believe that the virus was transmitted via the respiratory, rather than the
digestive route (Dowling, cited in Bailey, 2008), as earlier research on humans
had suggested (see Fadali, 1996, for a review). This mistake led to an erroneous clinical trial in 1937, in which exposed children suffered olfactory damage
(Parish, 1968). Also, the first poliomyelitis vaccines, grown on monkey kidney
cells, were responsible for the exposure of millions of American citizens to
simian virus 40, found in rare human cancers (Pennisi, 1997). When it comes
to non-human primates (nhps), these disputes are even more contentious,
because public opinion is less supportive of the use of nhps in research (European Commission, 2010). Furthermore, as technology evolves, better methods
become available, and the apparent historical necessity of animal experiments
becomes of less relevance. For example, vaccines that used to be developed using animal tissues—at times suboptimally due to poor efficiency (e.g., rubella
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vaccine developed through duck embryo cells and dog kidney cells) or zoonosis (e.g., the simian virus that reached humans through the first polio
vaccines)—are now being developed using human strains (Plotkin, 2017).
Recently more objective tools to assess the contribution of animal models
to biomedical progress have emerged. Such is the case of systematic reviews,
meta-analyses, and citation analyses. Systematic reviews are literature reviews
focused on a research question that aim to identify, appraise, and synthesize
all high-quality research evidence relevant to that question. They are generally
considered the best tool to produce evidence about the value of animal studies
(Pound et al., 2004), not only because they are designed to include all relevant
information, drastically reducing the potential for bias; but also because systematic reviews evaluate experimental designs through rigorous and objective peerreviewed protocols, such as the Animal Research: Reporting In Vivo Experiments
(arrive) guidelines that apply scientific method to the task of reviewing research evidence (Kilkenny et al., 2010). A meta-analysis can go even further
by incorporating a statistical representation of all the reviewed studies as well.
In the past decades, the number of systematic reviews shedding light on the
scientific value of animal studies has increased (e.g., Banwell, Sena and
Macleod, 2009; Corpet and Pierre, 2005; Lucas et al., 2002; Macleod et al., 2005;
Martić-Kehl et al., 2015; Perel et al., 2007). The systematic reviews have revealed:
a) poor transferability of animal outcomes to human clinical trials (e.g., Perel
et al., 2007); b) simultaneous occurrence of animal and clinical trials, rather
than sequentially, as expected given that the animal experiments should
be conducted first, to allow detection of possible toxicity (e.g., Lucas et al.,
2002); and, c) significant methodological and design flaws in a clear majority
of animal experiments (e.g., Martić-Kehl et al., 2015). Consequently, the use of
arrive or similar guidelines has become more common, which will hopefully
lead to better protocols and reduce redundant studies. As for the poor transferability of animal outcomes to human trials, it can be argued that this is either a
consequence of poor experimental design, and/or the fact that animal models
are not suitable models for human beings (Bailey and Taylor, 2016).
Another way to determine the value of animal studies is citation analysis,
which consists of determining the frequency with which a study is cited in subsequent papers. Several authors have conducted citation analyses on published
papers, reporting data from animals used as models for human disorders
(e.g., Carvalho et al., 2016; Knight, 2007; Long, Huang and Ho, 2014); results
show that these papers have received very few citations in human medical
papers. Again, it can be debated whether this occurs due to a false assumption that animal models are suitable models for human disorders or because
of methodological errors, or both.
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To try to address this issue, we performed a citation analysis on a small
sample of papers reporting data from animals used to model two complex
psychiatric disorders: attention deficit hyperactivity disorder (adhd) and major depressive disorder (mdd).
adhd is a chronic neurodevelopmental condition of multifactorial origin,
marked by persistent inattention; hyperactivity; and, occasionally, impulsivity (American Psychiatric Association, apa, 2013). It affects 2.2% of children
worldwide (Erskine et al., 2013); and it can be extremely disabling (apa, 2013).
mdd is a complex psychiatric mood disorder characterized by a persistent
feeling of sadness that seriously impairs normal day-to-day functioning and
may even lead to suicide (apa, 2013). Mental disorders are the leading cause
of years lived with disability worldwide, and 40.5% of this burden is caused by
mdd alone (World Health Organization, 2008).
In this study we categorized the citations obtained into animal versus human studies and determined whether human-based and animal-based papers
focused on the same disorder investigated by the animal study they were citing.
This form of analysis is valuable for shedding light on whether animal-based
research is being used to advance human healthcare, or whether it simply fuels
further animal-based research. If animal studies are contributing to human
healthcare advancements, then we would expect that:
1.
The citations made in human-based papers should be a substantial proportion of total citations.
2. The citations should be made mainly by studies focused on the same
disorder. Any substantial deviations would signal the possibility that animal-based research is not achieving its primary purpose.
2

Methods

We conducted a citation analysis as defined by Garfield and Merton (1979).
Briefly, in a citation analysis, one defines a number of target papers and conducts a search of all papers that cite these target papers. The information
obtained can include the total number of citations and patterns of citation.
We used a total of 50 target papers: 25 non-human animal studies on adhd,
and 25 non-human animal studies on mdd.
The adhd papers were selected from the citation analysis database created in the study by Carvalho et al. (2016). We included all papers reporting
data collected with primate models (7 papers) and randomly selected 18 papers from the remaining papers, using the free online tool, Research Randomizer (www.randomizer.org). The 25 studies were examined to determine the
proportion of citations each paper received in human-based papers focused
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on adhd, in human-based papers focused on other subjects, in animalbased papers focused on adhd, and in animal-based papers focused on other
subjects.
The mdd papers were obtained using PubMed to locate original articles
using animal models to investigate major depressive disorder (similar to the
protocol used in Carvalho et al., 2016). We searched PubMed using the following Medical Subject Heading (MeSH) search terms:
“Major Depressive Disorder” AND (title/abstract): “animal” OR “rat” OR
“mice” OR “mouse” OR “Rattus” OR “Mus” OR “pig” OR “Cavia” OR “Sus”
OR “rabbit” OR “Leporidae” OR “Drosophila” OR “primate” OR “monkey”
OR “Macaca” OR “macaque” OR “ape” OR “rhesus” OR “chimpanzee” OR
“bonobo” OR “gorilla” OR “Pan” OR “Orang Utan” OR “Pongo” OR “gibbon”
OR “Hylobates” OR “Colobus” OR “Baboon” OR “Papio” OR “Mandrillus” OR
“Mandrill” OR “Cebus” OR “Cebuella” OR “Brachyteles” OR “Loris” OR “Nycticebus” OR “Lemur” OR “dog” OR “Canis” OR “cat” OR “Felis.”
We found 33 published papers using nhps as models and randomly selected
seven, using the same randomizing tool. We found over 1,000 published papers
using other animals as models and proceeded, as above, to randomly select 18
papers for the citation analysis. We recorded the number of citations each paper received from subsequent animal research papers and subsequent human
research papers. We similarly analyzed the aim of the citing paper (whether
it was focused on the same disorder or another), in both animal and human
papers.
Using Fisher’s exact test (http://www.kisnet.or.jp/nappa/software/star-e/
freq/1x2.htm), we investigated whether there was a significant difference between the number of citations of the target animal articles in human research
papers and in animal research papers. We also verified whether there was a
significant difference between the number of citations in subsequent articles
addressing the same disorder and subsequent articles addressing different topics. Differences were considered statistically significant if p<0.05.
3

Results

Regarding our adhd sample, the 25 original animal studies were cited 660
times. As shown in Figure 16.1, animal studies were mainly cited in other animal research papers (315), of which 82 focused on adhd and 233 focused on
different subjects. The sample resulted in 69 citations in human research papers, of which 30 focused on adhd and 39 focused on different subjects. The
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remaining 345 citations were in review articles (198) or papers describing different methods, such as in silico or in vitro (147).
The columns represent the number of citations of the 25 target papers in
animal research papers (blue) and human research papers (orange). The t otal
number (left), as well as the number of citations in papers studying adhd
(middle) and other subjects (right) are presented. Fisher’s exact test p-values
are also presented for each comparison made (n.s.= non-significant).
The number of citations in animal research papers was far greater than the
number of citations in human research papers (p<0.0001). The number of citations in animal research papers focused on adhd was lower than the number
of citations in animal research papers focused on other subjects (p<0.0001).
The difference between the number of citations in human research papers on
adhd and human research papers focused on other subjects was not statistically significant (p=0.3355).
Seven of the target papers reported nhp studies. These papers received 274
citations, 94 of which were in subsequent animal research papers and 48 were
in human research papers. The remaining 138 citations were in review papers
(96) or papers describing different methods, such as in silico or in vitro (42). The
difference between citations in animal research papers and human research
papers was statistically significant (p=0.0001). Of the 94 citations in subsequent
animal papers, 21 were in papers focused on adhd, and 73 were in papers focused
on other issues. This difference was also statistically significant (p<0.0001).
Of the 48 citations in human research papers, 15 were in papers focused on
adhd, and 33 were in papers describing other disorders. Fisher’s exact test
showed that in the case of nhps there was a statistically significant difference
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between the number of citations in papers on adhd and papers focused on
other subjects (p=0.0132).
Regarding the mdd sample, the 25 target animal studies were cited 631
times. As shown in Figure 16.2, animal studies were mainly cited in other
animal research papers (353), of which 127 focused on mdd, and 226 focused
on different subjects. The sample received 51 citations in human research papers, of which 19 focused on mdd, and 32 focused on different subjects. The
remaining 227 citations were in review articles (163) or papers describing
different m
 ethods, such as in silico or in vitro (64).
The columns represent the number of citations in animal research papers
(blue) and in human research papers (orange) of the 25 cited papers. The total number (left), as well as the number of citations in papers studying mdd
(middle) and other subjects (right) are presented. Fisher’s exact test p-values
are also presented for each comparison made.
The number of citations in animal research papers was substantially greater
than the number of citations in human research papers (Fisher’s exact test,
p<0.0001). The number of citations in animal research papers focused on
mdd was lower than the number of citations in papers focused other subjects
(p<0.0001). The difference between the number of citations in human research
papers focused on mdd and papers focused on other subjects was not statistically significant (p=0.0919).
The seven papers reporting on nhp studies received 227 citations, 97 of
which were in subsequent animal research papers, and 19 were in human research papers. This difference was statically significant (p=0.001). Of the 97
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c itations in subsequent animal papers, 13 were in papers on mdd, and 84 were
in papers focused on other issues. This difference was statistically significant
(p<0.0001). Of the 19 citations in human medical papers, six were in papers on
mdd, and 13 were in papers focused on other subjects. This difference was not
statistically significant (p=0.1670).
4

Discussion

Our results suggest that animal data is mainly used by subsequent animal papers. Another trend that emerged is that papers citing animal research (whether they focus on human medical research or not) focus on disorders that differ
from the one targeted in the animal study cited. This trend is stronger in papers
focused on animal research.
The tendency for animal research to be cited more in subsequent animal
research has been previously described (e.g., Carvalho et al., 2016). This finding
contradicts the previously stated assumption that citations in human-focused
papers should constitute a substantial proportion of the total number of citations. Clearly, biomedical research focused on animal models does not seem
to be considered important by, or particularly visible to, the human medical
research community.
Our results also indicate that papers citing data collected from animal models do not necessarily target the disorder described in the animal paper. This
difference appears to be more significant in animal research papers citing
other animal research papers, than in human research papers that cite a nimal
research. This contradicts the second assumption we tested: that citations
should be made mainly by studies focused on the same disorder. This finding
reinforces the concern that animal-based research is failing to shape meaningful healthcare advances for humans.
It can be argued that if the same animal model is used for different disorders, it may contribute more to medical research than predicted by the second
assumption. For example, dat knock-out mice comprise a common model for
adhd but are also used to model Parkinson or schizophrenia (Gainetdinov,
2008). Nevertheless, the total citation frequency in human research papers
is still very low, regardless of the paper’s area of focus (Carvalho et al., 2016;
Knight, 2007; Long, Huang and Ho, 2014).
The fact that animal strains are used to model several disorders may help
explain the intriguing tendency for animal research papers to be cited more
often in papers addressing non-related subjects than in papers focused on the
same disorder. This tendency was also apparent in human-based papers that
cited animal-based papers focused on mdd. This may have occurred because
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there are 6–7 times more papers focused on mdd than on adhd, which may
mean that the 25 papers on mdd were not a representative sample of mdd research. If this phenomenon was to recur with a larger sample, one could argue
that this is due to the same animal strain being used for different purposes, as
previously mentioned. If the strains used in mdd research are commonly used
to model a greater number of disorders than strains used in adhd research, it
would be more probable that human studies focused on unrelated disorders
cite studies in these strains. We did not verify this, and it should be explored in
future studies.
Our data shows that even though the difference between the total frequency of citations by human papers focused on adhd and paper focused on other
subjects was not statistically significant, there was a bias regarding papers describing nhp models of adhd. A close examination of the data allowed us to
conclude that this bias was due to one paper, cited 18 times in human research
papers, 17 of which focused on disorders other than adhd. This particular paper described the behavioral changes caused by bicuculline microinjections
in external globus pallidus, a brain structure involved in pathogenesis of adhd
but also in Tourette’s syndrome. Most of the 18 citations this paper received in
human papers were actually from papers related to Tourette’s syndrome. If we
discard this outlier, the data on nhp follows the same pattern as other adhd
papers.
Since our two assumptions have been challenged, we must discuss their
causes and implications. One possible explanation for these results is that
animal models only attempt to model specific symptoms or traits of complex human disorders. This oversimplification may lead to results that are
non-applicable or of minimal use for human medicine. Another possible explanation is that funding is more easily attached to studies that claim to have
the potential to advance human health. This may lead animal researchers to
overestimate the applicability of their projects. A further possible explanation
is that communication and sharing of ideas between clinical and preclinical
research is insufficient. Moreover, previous studies have shown that clinical
and preclinical trials can occur simultaneously (Pound et al., 2004), which
emphasizes this lack of communication. Although it is difficult to define an
optimum communication level, this issue must be raised in both communities in order to maximize efficiency in scientific research as well as the promotion of animal welfare. An additional possibility is that a substantial amount
of animal research is needed in order to achieve a critical mass that can lead
to useful breakthroughs in human health. This is a theoretical possibility that
is difficult to measure and properly test. However, even if proven correct, the
financial and ethical implications of this assumption should be considered.
Other methods may prove to be more efficient or ethically acceptable, and this
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comparison could lead to a reevaluation of funding priorities. Finally, a conceivable possibility is that animal models are not suitable for biomedical research into complex human disorders. It may be possible that the uniqueness
of some human disorders is just not feasibly simulated in non-human animals.
If our last suggested explanation is indeed correct, the implications must
be considered. The funding currently allocated to these animal-based studies
should still be available for science. While most of it would likely be redirected
to other models of these disorders, some of it could be assigned either to other
basic research fields or to the care of surplus animals.
Regardless of the possible explanations, our results indicate that animalbased research is failing to reach the human medical community, at least in
the case of mental disorders, such as the ones we evaluated. This means that
considerable financial investment and considerable suffering inflicted on the
animals used for this purpose did not translate into direct medical advances. It
would be interesting to survey the practitioners working with mental disorders
to assess if this is due to lack of awareness of animal-based findings, or if they
consider animal-based data to be inadequate or lacking in relevance.
In conclusion, our analysis suggests that most animal-based research, at
least in the case of these mental disorders, is not currently being utilized by
human-based researchers. Regardless of the reasons for this, the profound financial and ethical implications should lead to a reevaluation of the current
research paradigm, which is heavily reliant on invasive animal use.
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1

Introduction

Every year, and in countries around the world, significant time and resources
are devoted to the noble cause of developing drugs to treat and cure human
disease. With rare exception, drug interventions cannot reach commercialization without safety and efficacy having first been demonstrated in animal
models. The intention of regulations, which require the use of animal models
in such contexts, is to ensure that only safe and effective drugs end up being
used by patients. Similarly, it is standard practice for researchers to employ
animal models in their attempts to understand the way diseases present and
progress in humans. Unfortunately, there exist serious theoretical and empirical concerns regarding the standard practice of using non-human animals to
model human response to perturbations, such as drugs and disease. These
concerns are important because conducting disease research and drug development in a manner that is not supported by science will have suboptimal
implications for the humans who rely on that research, which encompass the
entire population. Based on complexity science, modern evolutionary biology,
and empirical evidence, we demonstrate that animal models have failed as
predictors of human response. That is, animal models do not and cannot have
acceptably high predictive value for human response to drugs and disease. By
this we mean that animal modeling, as a methodology, is for all practical purposes not predictive of human response to drugs and disease; and hence it
should be abandoned in favor of human-based research and testing, such as
personalized medicine, a new field that takes into account the unique genetic
make-up of each individual patient.
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People are accustomed to hearing about the ethical issues arising from the
use of non-human animals in biomedical research, testing, and science in general. But there are scientific issues with the practice as well. Researchers who
employ animal modeling often attempt to justify the practice based on claims
of accurately predicting human response to drugs and disease. For example,
Giles (2006, p. 981) states: “In the contentious world of animal research, one
question surfaces time and again: how useful are animal experiments as a way
to prepare for trials of medical treatments in humans? The issue is crucial, as
public opinion is behind animal research, only if it helps develop better drugs.
Consequently, scientists defending animal experiments insist they are essential for safe clinical trials, whereas animal-rights activists vehemently maintain
that they are useless”.
One need not search hard to find examples claiming non-human animals
play an essential role in the quest to treat and cure human disease. For example, the American Physiological Society (apa) (2017) states on its website:
“Animals are used in research to develop drugs and medical procedures to treat
diseases.” Andrew B. Rudczynski, Yale University’s associate vice president for
research administration, stated in a letter to the editor (2011): “[T]he basic research model used by Yale University and its peer institutions is scientifically
valid and predictive of human disease”. Michael F. Jacobson, executive director of the Center for Science in the Public Interest (2008) stated: “We must
test animals to determine whether a substance causes cancer”. Huff, Jacobsen,
and Davis (2008, p. 1439) stated: “Chemical carcinogenesis bioassays in animals
have long been recognized and accepted as valid predictors of potential cancer
hazards to humans.” Lin (1995, p. 1008) stated: “Although the validity of animal
testing to predict efficacy and or safety in humans has been questioned, it is
generally believed that data from animal studies can be reasonably extrapolated to humans with the application of appropriate pharmacokinetic principles
[….] From an evolutionary point of view, all mammals are similar, because they
originate from a common ancestor, yet they differentiate because of their dissimilar environmental adaptations”.
While it can be argued that there may be scientifically justified grounds for
the use of non-human animals in some contexts, other than those that involve
predicting human responses, it is most common to see attempts to justify the
use of non-human animals for applications to human health (see Kramer
and Greek (2018), for additional discussion of this point). Therefore, it is appropriate to carefully examine the claimed validity of the animal model for
predicting human outcomes.
To that end, consider Trans-Species Modeling Theory (tsmt), a concept
that was formalized by Greek and Hansen (2013), based on a combination of
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e xtensive previous research on complex systems science and evolutionary biology, as summarized by authors, including Greek and Rice (2012), LaFollette
and Shanks (1996), LaFollette and Shanks (1998), Shanks and Greek (2008),
and Shanks and Greek (2009). tsmt states: “While trans-species extrapolation
is possible when perturbations concern lower levels of organization or when
studying morphology and function on the gross level, one evolved complex system will not be of predictive value for another when the perturbation affects
higher levels of organization” (Greek and Hansen, 2013, p. 254). That is, according
to science, the observation of a drug response in one species is uninformative
about the drug response in another species. This theory is based on complexity science, evolutionary biology, and empirical evidence. In the remainder of
this article, we explain why the fields of complexity science and evolutionary
biology are relevant to understanding animal modeling and evaluating the inability of animal models to predict human response to drugs and disease.
LaFollette and Shanks (1996) and the Medical Research Modernization
Committee (2006) were among the first to document systematically the methodological failure of using one evolved complex system to model another, in
terms of predicting outcomes. Subsequent work by Greek and Hansen (2013),
Greek and Rice (2012), Shanks and Pyles (2007), and Shanks and Greek (2009)
then led to the development of tsmt, which is the only theory (we intentionally use the word theory as opposed to hypothesis; see National Academies of
Science Engineering Medicine, 2016) that accounts for both past and present successes and failures of animal modeling. It is also the only theory that
explains why animal models will never offer practical predictive value for
disease and drug research. To be clear, the aforementioned authors did not
discover evolution, complexity science, or any aspect of probability. Rather,
they relied on what had been previously published in those disciplines and
combined various insights to formalize the case against the use of animal models to predict outcomes in other species.
tsmt was a paradigm shift in animal modeling analysis. Moreover, tsmt
was inclusive of valid past criticisms, while simultaneously explaining and
taking those criticisms further. For example, tsmt obviated the need to point
out that small differences in environments among lab animals influenced
results, as many anti-vivisectionists did and continue to do, because even
under perfect environmental conditions, one evolved complex system would
not be expected to have predictive value for another. Likewise, there is little
to no value in analyzing why one species has historically been inadequate for
predicting human response, because according to tsmt, no species, regardless of genetic similarity, will ever be similar enough to another to serve as a
valid predictive model. tsmt is also more precise and has more explanatory
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power than g eneral criticisms, such as species differ in their metabolisms. Furthermore, tsmt explains why increasing scientific rigor, the current mantra
for justifying the use of animal models, will have no effect on predictive value.
We now turn to examining the three pillars underlying tsmt, comprising
complex systems science, evolutionary biology, and empirical evidence.
2

Complex Systems

Advances in the field of complex systems have highlighted the poor predictive
value of animal modeling. The study of complex systems and chaotic systems,
currently usually classified under the general heading of complex systems,
dates back to the 1950s and began a revolution in physics, similar to that of
the early 1900s involving relativity and quantum mechanics (Gell-Mann, 1994;
Gleick, 2008; Goodwin, 2001).
The following are characteristics of simple systems:
– They are nothing more than the sum of their parts.
– They have predictable behaviors. (There are no unanticipated or unexpected
behaviors.)
– They are usually composed of just a few components.
– They can be intuitively understood.
– They are in equilibrium. (They are non-dynamic.)
– There are few interactions and feedback loops. (For example, compare a
primitive barter system in contrast to our modern market-based economy).
Rosen (1999, p. 392) states: “A system is simple if all its models are simulable.
A system that is not simple, and that accordingly must have a nonsimulable
model, is complex”. This should give us pause: A complex system is nonsimulable. Note that simulable may mean different things to different people. When
scientists state that biological complex systems are nonsimulable, they mean
nonsimulable at the complex level. The aim of researchers who use animal
models is not to gain insight into the simple systems that are basic building
blocks of the complex system. For example, at the simple level, we can rely
on knowledge about simple systems to extrapolate that the final outcome for
two different species will be the same when, for example, they are permanently deprived of water or they are thrown out of an airplane at 30,000-feet
elevation. R
 esearchers attempt to use non-human animals to model humans at
higher, complex levels of organization, because this is the level at which disease
and drug effects occur. So, when an animal modeler claims that their model
simulates a human, unless they are speaking of low levels of organization (much

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

395

The Scientific Problems with Using Non-human Animals

simpler than the levels at which drug and disease responses occur), this is not
possible.
In contrast to simple systems, complex systems are characterized by the following (see Figure 17.1 for a diagrammatic representation of a complex system):
– Complex systems are composed of many parts that themselves have hierarchal levels of organization.
– Complex systems have feedback loops.
– Complex systems exhibit self-organization.
– Complex systems respond to perturbations in a nonlinear fashion. Because
small changes in a complex system can result in outcomes that are not proportional to the input, one biological complex system can die because of
what, at first, appears to be a minor change or difference between it and
another almost identical complex system (Morange, 2001; Pearson, 2002).
For example, Northrop (2011, p. xiv) states: “Early bioengineers, biophysicists, and systems physiologists tried to characterize certain physiological
regulators as linear and stationary. Initially, linear systems analysis was
inappropriately applied to certain complex, physiological regulators and
Characteristics of Complex Systems
A'complex' system
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Figure 17.1 The characteristics of complex systems.
source: Marshall Clemens/Idiagram (https://www.idiagram.com)
Note: A complex system is built out of simple systems. As more and more
of these simple systems combine and form a complex system, the level of
organization increases and simulability decreases.
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control systems (e.g., pupil regulation and eye movement control), which
resulted in black-box, closed-loop models in which linear transfer function
modules were connected to a nonlinear module in a single feedback loop.
These were phenomenological input/output models that gave little insight
into the physiology and complexity of the systems”.
Complex systems demonstrate redundancy and robustness. Complex systems have redundant parts and, therefore, losing a part may not affect
function. Adding to this is robustness, which means that perturbations may
not result in dysfunction. Complex systems have emergent properties that
Aziz-Alaoui and Bertelle (2009, preface) define as follows: “Emergence and
complexity refer to the appearance of higher-level properties and behaviors
of a system that obviously comes from the collective dynamics of that system’s components. These properties are not directly deductable from the
lower-level motion of that system. Emergent properties are properties of
the “whole” that are not possessed by any of the individual parts making
up that whole. Such phenomena exist in various domains and can be described, using complexity concepts and thematic knowledges.”
Examples of emergent properties include the following from Van Regenmortel (2002):
– The three physical states of water and phase transitions, such as boiling
point.
– The viscosity of water (individual water molecules have no viscosity).
– The color of a chemical.
– A melody arising from notes.
– The saltiness of sodium chloride.
– The specificity of an antibody.
– The immunogenicity of an antigen.
The components of complex systems can be grouped as modules, and the
modules communicate with each other. Nevertheless, failure in one module
does not necessarily spread to the system as a whole because of redundancy
and robustness.
Complex systems are dynamic. They communicate with, and change in response to, their environment.
The whole of a complex system is greater than the sum of its parts, and
hence complex systems have properties that cannot be determined even
with total knowledge of the components of the system. This limits the validity of reductionism when studying complex systems.
Importantly for our discussion, complex systems are also very dependent on
initial conditions; for example, genetic make-up in the context of individuals
or species. This means that a very small change in the initial conditions of
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two otherwise identical complex systems (e.g., monozygotic twin humans),
may result in sickness for one but not the other. In strains of mice, k nocking
out one gene has been shown to result in death for one strain, while the
other thrives (Belmaker et al., 2012; Bell and Spector, 2011; Bruder et al., 2008;
Castillo-Fernandez et al., 2014; Chapman and Hill, 2012; Czyz et al., 2012;
Dempster et al., 2011; LeCouter et al., 1998; Raineri et al., 2001; Pearson, 2002).
The sensitivity of complex systems, also known as nonlinear dynamic systems,
to initial conditions, in general, was demonstrated in principle in the 1960s by
Massachusetts Institute of Technology mathematician, Edward Lorenz, while
he was studying a weather model using a computer. Lorenz found significant
differences in outcomes using his model, when the initial conditions were
changed by a very small amount:
On a particular day in the winter of 1961, Lorenz wanted to re-examine a
sequence of data coming from his model. Instead of restarting the entire
run, he decided to save time and restart the run from somewhere in the
middle. Using data printouts, he entered the conditions at some point
near the middle of the previous run and re-started the model calculation. What he found was very unusual and unexpected. The data from the
second run should have exactly matched the data from the first run.
While they matched at first, the runs eventually began to diverge dramatically — the second run losing all resemblance to the first within a
few “model” months.
Bradley, 2010

Figure 17.2 Plots of the data from two simulations of weather response over time.
Source: Bradley (2010)
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Plots of the time-series data from two of Lorenz’s weather simulations appear in Figure 17.2.
Lorenz rounded off a variable to three digits after the decimal instead of
six, and this resulted in the different values shown in Figure 17.2. While no one
knows which specific weather condition Lorenz recorded on the Y axis (it is
commonly assumed that time is shown on the X axis), we do know the fluctuations shown on the right-most portion of the Y axis are between extreme values,
and thus we see that a tiny perturbation in starting values (measured in units
smaller than three decimal places), eventually yielded opposite predictions in
the simulated weather. This experiment is the origin of expressions, such as, “a
butterfly flaps its wings in Brazil, and it rains in America.” Very small changes in
initial conditions can result in dramatically different outcomes in complex systems. In fact, this behavior is a defining characteristic of a complex or chaotic
system (Gleick, 2008). Obviously, Lorenz’s computer program was intended to
simulate weather, but because it lacked sufficiently detailed inputs, the model
yielded dramatically different outputs depending on very small changes in the
inputs — the initial conditions. This example demonstrates how a particular model, in this case a computer program, can be inadequate for simulating a complex system. Likewise, animal models are inadequate for predicting
human response to drugs and disease.
Examples of complex systems include cells, humans, non-human animals,
ecosystems, economies, ant colonies, social interaction, and the United States
electrical grid. For more on biological complex systems, see Ahn et al. (2006),
Gell-Mann (1994), Goodwin (2001), Greek (2013c), Greek and Rice (2012),
Kitano (2002); Morowitz (2002), Solé and Goodwin (2002), Van Regenmortel
(2004a, b), Van Regenmortel and Hull (2002), Vojinovic (2015a, b).
It is not easy to understand complex systems. Consider the following summary of the necessary background for understanding complex systems:
This introductory textbook is intended for use in a one-semester course
to acquaint biomedical engineers, biophysicists, systems physiologists,
ecologists, biologists, and other scientists, in general, with complexity and complex systems. I have focused on biochemical, genomic, and
physiological complex systems, and I have also introduced the reader to
the inherent complexity in economic systems [….] Reader background:
Readers should have had college courses in algebra, calculus, ordinary
differential equations, and linear algebra, and, hopefully, engineering
systems analysis. They should also have had basic college courses in
chemistry, biochemistry, cell biology, and ideally even in human physiology and anatomy. This is the broad background that is required in the
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interdisciplinary fields of biomedical engineering, biophysics, systems
physiology, and economics.
northrop, 2011, pp. xiii–xvii

Northrop (2011, p. xiii) also notes: “Broadly stated, we consider that complexity is a subjective measure of the difficulty in describing and modeling a s ystem
(thing or process), and thus being able to predict its behavior” (emphasis
added). Again we note the fact that complex systems are difficult to model in
terms of being able to predict outcomes to perturbations.
Vicsek (2002, p. 131) states:
In the past, mankind has learned to understand reality through simplification and analysis. Some important simple systems are successful idealizations or primitive models of particular real situations — for example, a
perfect sphere rolling down an absolutely smooth slope in a vacuum. This is
the world of Newtonian mechanics, and it ignores a huge number of other,
simultaneously acting factors. Although it might sometimes not matter
that details such as the motions of the billions of atoms dancing inside the
sphere’s material are ignored, in other cases reductionism may lead to incorrect conclusions. In complex systems, we accept that processes that occur
simultaneously on different scales or levels are important, and the intricate
behaviour of the whole system depends on its units in a nontrivial way. Here,
the description of the entire system’s behaviour requires a qualitatively new
theory, because the laws that describe its behaviour are qualitatively different from those that govern its individual units.” (Emphasis added)
Animal modeling seeks to use one complex system, be it a mouse or a monkey,
to predict responses to perturbations that occur at higher levels of organization, of another complex system — a human. To do so ignores the most basic
fundamental features of complex systems, discussed above. Given those features, it is outside the realm of science to use one complex system in expectation of its having predictive value for another, when the perturbation affects
higher levels of organization.
3

Evolutionary Biology

Informally, evolution can be thought of as small changes in genes (i.e., initial
conditions) that occur over long periods of time, resulting in new species with
traits different from those of the ancestor organism. In other words, chimpanzees
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and humans are both different from the primate that we descended from, and
we are different from each other. But the notion that differences among genes
can result in new species is separate from the fact that very small differences in
genes can also lead to members of the same species reacting quite differently
to drugs and disease. Humans and non-human animals are examples of complex systems that have evolved over time – their initial conditions changed
in the form of genetic make-up, and these changes affected the organism
in a nonlinear fashion, just as we saw in Lorenz’s computer model of weather.
Even for two individuals within the same species, small differences in dna
can mean the difference between life and death. A tiny difference of one amino acid within the human chromosome is all that separates a patient with
life-threatening sickle cell anemia from those of us who can live free of that
condition. Dramatic differences can exist across species without changes in
amino acid sequences. Genes are regulated, turned on and off, by other genes.
For example, mice and humans share the gene that allows mice to grow a tail
(Graham, 2002). The reasons humans do not normally grow a tail during development is that the gene is never turned on (or expressed). Differences in gene
regulation and expression vary within and between species and account for
differences in response to drugs and disease (Kasowski et al., 2010; Marchetto
et al., 2013; Morley et al., 2004; Pritchard et al., 2006; Rifkin, Kim and White,
2003; Rosenberg et al., 2002; Sandberg et al., 2000; Seok et al., 2013; Storey et al.,
2007; Suzuki and Nakayama, 2003; Warren et al., 2014; Zhang et al., 2008). So,
while it is a fact that humans share a large percentage of their genes with other
mammals, this fact is largely immaterial in terms of predicting how humans
will respond to perturbations, such as drugs and disease. For example, the progression of hiv to aids, which is common in humans, has been very rarely observed in great apes. On the matter of non-human primates, Varki and Altheide
(2005, p. 1746) write “[I]t is a striking paradox that chimpanzees are in fact not
good models for many major human diseases/conditions”.
Based on facts from the theory of evolution and complexity science, there
are robust theoretical reasons to conclude that, for all practical purposes, one
species will have no predictive value for the response to perturbations that
occur at higher levels of organization; and drugs and disease affect higher
levels of organization. Note that we are not saying humans and non-human
animals cannot ever respond similarly to the same drug or disease. They do
in some instances. However, in order for there to be scientific merit in using
non-human animals as predictive models for humans, the models would have
to have a high predictive value as calculated using concepts we discuss in the
following section. Consistent with theory, extensive empirical evidence shows
that animal models do not have high predictive value for human response to
drugs and disease, rendering their use in that context unscientific.
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Empirical Evidence: The Failure of the Animal Model in Terms of
Predictive Value for Humans

We now delve into empirical evidence regarding the inability of the animal
model to predict human response to drugs and disease. By comparing how well
an animal-based test or research method corresponds to human results, we
can determine how much predictive value the modality has. Predictive value
is measured in science by using the calculations summarized in Table 17.1. In
the discussion that follows, we refer to quantities from this table, such as gold
standard, false positive, and false negative. Any given test or system can generally be compared to a gold standard, which is the most accurate one available
under reasonable conditions.
For example, the gold standard for determining whether a patient has a collapsed lung is a computerized axial tomography (CT) scan of the chest. Even
clinically insignificant cases of a collapsed lung can be detected with a CT scan
and clinically significant collapses are detected essentially 100% of the time.
In reality, patients are assessed with a chest x-ray instead of a CT scan because
an x-ray is quicker, easier, and less expensive than a CT scan, and clinically
significant collapses are detected by x-ray a very, very high percentage of the
time. To determine the predictive value of the chest x-ray, one would perform
both diagnostic tests on a group of patients and the calculations in Table 17.1.
A positive chest x-ray (an x-ray that revealed a collapsed lung) in light of a
positive CT scan would be counted as a true positive (TP) and listed under
gold standard positive; while a negative chest x-ray (no collapsed lung) in light
of a negative CT scan would be listed as true negative (TN) and listed under
gold standard negative. Similarly, a negative x-ray in light of a positive CT scan
would be labeled a false negative (FN); and a positive chest x-ray in conjunction with a negative CT scan would be a false positive (FP) (see Nagarsheth and
Kurek, 2011, for an example of this).
In the case of evaluating animal models, outcomes in humans would be
the gold standard. These same calculations can be performed for any test or
modality where a gold standard can be known in contexts within and outside
of biomedical science, for example to determine whether a patient has cancer,
to determine whether a computer model can predict an outcome in engineering or business, or to determine the predictive value of drug sniffing dogs in
airports. For more details see Greek (2014b).
Not all tests or methods need to have a high predictive value to be useful.
For example, if you devised a method of winning at the blackjack table more
than 50% of the time and bet appropriately each time and played long enough,
probabilistically you would beat the house. But in medical science, we need
much higher predictive values than 0.5. Even a probability of 0.999 can be
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Table 17.1 Binary classification test and formulas for determining how well a test or practice
compares with the most accurate test available under reasonable conditions.

Gold Standard:

Test:

T+
T-

GS+
TP
FN

GSFP
TN

Calculations:
Sensitivity = TP/(TP+FN)
Specificity = TN/(FP+TN)
Positive Predictive Value (ppv) = TP/(TP+FP) = % of all positives that are true
positives
Negative Predictive Value (npv) = TN/(FN+TN) = % of all negatives that are true
negatives
Abbreviations:
T- = Test negative
T+ = Test positive
FP = False positive
TP = True positive
FN = False negative
TN = True negative
GS- = Gold standard negative
GS+ = Gold standard positive

inadequate. Drugs that harm even a very small percentage of patients, even
one out of 1,000, have been pulled off the market because of life-threating side
effects, such as total liver failure, heart attack, or stroke. Examples of widelymarketed drugs that have been withdrawn due to unanticipated fatalities include Vioxx (rofecoxib), Propulsid (cisapride), and Rezulin (troglitazone). See
Graham et al. (2005) and Attarwala (2010) for details on such instances.
So what is an acceptable level of predictive value to expect from animal
modeling? To answer this question, first we need to emphasize that acceptable predictive value, like many things in life, varies depending on the context,
as the blackjack example illustrates. Consider the case of deeming whether
a species exhibits the trait of sentience, which is highly valued in the animal
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protection movement as a feature to take into account when considering the
ethics of animal modeling. Sentience can be assessed using criteria for which
we could attempt to measure predictive value; but, nevertheless, a large gray
zone emerges. Chimpanzees are clearly sentient, as are mammals in general.
But when we consider invertebrates, the situation becomes less clear. Octopi
appear to be both sentient and sapient, but what about sponges, worms, jellyfish, and the common fruit fly? To date we do not have strong evidence that
these entities exhibit sentience, but we may simply lack the power to detect
sentience in all cases where it exists. Yet, our inability to conclude with certainty that sponges are sentient does not mean we can ignore the fact that
chimpanzees do demonstrably exhibit sentience. The precautionary principle
should be employed in cases where great suffering is at stake, meaning that
our ability to deem a particular species as sentient should not be predicated
on the requirement that there exists an assessment method with a predictive
value as high as 0.99.
Turning back to the matter at hand, predictive values for responses to drugs
in development typically cluster around or below 0.5, which makes them no
more useful for prediction than flipping a coin. Predictive values this low are of
no use in medical science. When values in the 0.7 to 0.9 range are seen, physicians and medical scientists cannot rely on the results, test, or modality alone,
without verifying the item in question with other tests or modalities. To do so
would be unethical; the patient deserves greater certainty before proceeding.
Science in general relies on consilience, and medical research is not an exception. In this case, when deciding which modality to use, one must consider
the mathematics of complex systems and the initial conditions in the form of
evolutionary biology. Because animal models are used to make the life-altering
decision of whether to take a drug to human trials or to abandon it, even values
greater than 0.9 can be deemed inadequate and unacceptably costly in terms
of the likelihood of adverse human consequences.
The way around this problem of identifying the right predictive value is
addressed by Greek and Greek (2004), Greek, Menache and Rice (2012), and
Shanks and Greek (2009), and is summarized by Kramer and Greek (2018).
The solution involves the use of human-based research and testing through
personalized medicine; that is, matching gene(s) to drugs and disease in each
patient. Based on the science of complex systems and evolutionary biology,
we know categorically that using non-human animal models has unacceptably low predictive value for human responses to drugs and disease. Thus, on
balance, the use of animal models in drug development and disease research
should be abandoned immediately for the same reasons that society has abandoned wrong or harmful medical practices such as phrenology, bloodletting,
and trephination; they were simply ineffective.
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We now turn to specific examples of the poor predictive value of animal
models, starting with early empirical evidence dating back as early as the 1990s
and ending with recent sets of evidence from 2016 that summarize decades of
findings.
Data from Suter (1990) and the 11th edition of the Catalog of Teratogenic
Agents (Shepard and Lemire, 2004) demonstrate the importance of using
predictive values. Suter reported on the development of six drugs where
humans and non-human animals shared 22 side effects. Suter’s data revealed
that animal models had a positive predictive value of 0.31. That is, if a side effect was seen in the animal models it had only a 31% chance of being seen in
humans for these six drugs. This prediction rate, which is below that expected
from a coin toss (heads we abandon the drug because of danger, and tails we
continue to develop the drug), illustrates the failure of these animal models as
predictors for human response. A naive but common retort to this fact is that if
animal models derailed any drug that would have harmed humans, it is worth
using animal models. The fallacy of this view becomes evident when considering the following assessment of empirical evidence on using animal models to
predict human birth defects.
The Catalog of Teratogenic Agents lists more than 3,100 agents, of which
about 1,500 can produce congenital anomalies (birth defects) in experimental
animals but not in humans. These are known as false positives. Furthermore,
only about 40 cause birth defects in both humans and non-human animals.
These are known as true positives. Based on these numbers and the formulas
in Table 17.1, one can calculate a value of 3% for the positive predictive value.
A positive predictive value of 3% tells us that for any given birth defect noted
in non-human animals, there is only a 3% chance that it will also be seen in
humans. A predictive value of 3% is obviously extremely poor but is consistent
with the general lack of predictive value in using animal models to determine
whether compounds are harmful to developing fetuses (see Greek, Shanks and
Rice, 2011, for more on teratogenicity and animal models). This means that for
any drug that tests positive for birth defects, when tested for teratogenicity in
animal models, there is about a 3% chance that it will harm human babies in
utero. Predictive value does not mean that 3% of drugs that would have caused
birth defects will be abandoned in development. Instead it means that of 100
drugs tested and shown to harm animal fetuses, about three may harm the
human fetus. Unfortunately, we do not know which three. So, abandoning a
drug in development based on a test that has a low predictive value does not
save babies. Moreover, when human health is involved, low predictive value
means anything below 90%–95%; and, often times, even a probability of 99%
is inadequate to base treatment on. The predictive value of animal modeling
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falls far below 99%; for example, 3% in the above teratogenicity example. For
more on this point, see Greek (2013a, b, 2014b), Greek and Greek (2010), and
Shanks, Greek, and Greek (2009).
Values this low mean animal modeling per se has, for all practical purposes, no
predictive value for human response to drugs and disease. Some researchers ar
gue that any predictive value greater than zero means animal models have some
predictive value. However, given the scope for serious adverse consequences,
including death, the threshold number required in medical science has to be
much higher than the typically observed 3% to 55% range of values seen when
calculating the predictive value of animal modeling (see previous references);
hence the paradigm of animal modeling cannot be justified scientifically in
this context. Medical science requires higher predictive values than one needs
for winning at the blackjack table.
In our discussion of the predictive value of animal models, we have focused
so far on the context of response to drugs. It is also illuminating to consider
predictive value in the context of disease research. Scientists are now matching gene response to disease, and great variation is being observed across
species. For instance, Seok et al. (2013) studied inflammatory processes, such
as sepsis, in mice and humans and found no correlation between what the
genes and responses did in mice versus what they did in humans. The following statement, by science journalist Dolgin (2013, p. 118), puts Seok’s and colleagues’ findings in context: “Yet, despite the fact that some compounds have
repeatedly reversed the symptoms of sepsis in animal tests, not a single drug
has proven effective in human clinical trials, even though more than 30,000
people have been included in randomized controlled studies, involving candidate antisepsis agents over the past 25 years”.
Thus, in searching for a treatment for sepsis, tens of thousands of people
were exposed to the risks of a new drug, and billions of dollars were wasted
based on animal studies, the results of which proved unrelated to human outcomes. Even more patients were unable to access a potentially effective drug
that might have been identified had the resources been dedicated instead to
human-based research.
The failure of animal models in these cases appears to be due to differences
in gene response between humans and mice (Seok et al., 2013; Warren et al.,
2014). Considering that humans and non-human animals are evolved complex
systems, there is no reason to expect other diseases or conditions would allow
animal models to have high predictive value. Indeed, many diseases have been
studied and similarity in responses among species found only at very low rates
and usually in retrospect (Enna and Williams, 2009; Hau, 2003; Lin, 1995). (Note
that basic science research is prone to the same critique. Many r esearchers now

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

406

Greek and Kramer

claim that basic research on non-human animals has high predictive value for
humans. See, for example, Devoy et al., 2012; Groenink, Folkerts and Schuurman,
2015; Katzner et al., 2009; National Science Foundation, 2011; Rudczynski, 2011;
van Meer, Graham and Schuurman, 2015. Such claims invite the same scrutiny
as claims about predictive value in drug development and disease research.)
Based on the track record of drugs that have been tested on non-human
animals to date, the poor predictive value of animal models used in preclinical
research, and the fact that humans and non-human animals are evolved
complex systems, there is every reason to believe yet-to-be-developed drugs
identified through the use of animal models will similarly exhibit profoundly
different responses in non-human animals versus humans. The exceptions to
this rule occur when the perturbation affects levels of organization where the
system under analysis is simple or where conserved processes are involved. But
even when conserved processes are being studied (e.g., the mechanism for cell
replication, the cytochrome P450s, and the presence of various receptors), the
outcomes to perturbations to these processes vary among species (Greek and
Rice, 2012).
Turning to other medical applications, around 100 vaccines have been
shown to be effective against hiv-like viruses in animal models, to date. None
have been effective in humans (Bailey, 2008; Editorial, 2007; Gamble and Matthews, 2010). More than a thousand drugs have been seen to protect against
nervous system damage in animal models of stroke. Again, none have been
protective in humans (Dirnagl, 2006; Dirnagl and Macleod, 2009; Macleod,
2004; O’Collins et al., 2011; O’Collins et al., 2006; Sena et al., 2007). Fouad, Hurd
and Magnuson (2013) identify over 10,000 publications modeling spinal cord
injury in rats and mice. Many treatments identified in those publications have
been effective in non-human animals but failed in humans, and spinal cord
injury resulting in paralysis remains incurable in humans.
The predictive value of the above-mentioned medical applications would
be roughly zero. In order to prove a test or practice has poor predictive value
(as opposed to predictive value numerically equal to zero), one only has to
show a relatively small number of failures compared to the successes. The
above examples are adequate. Conversely, proving a practice has high predictive value requires examples from a large number of studies. To the best of our
knowledge, there are no studies of any kind that show high predictive value
of animal models for drugs or disease. Drawing on knowledge from complex
systems and the theory of evolution, one can easily infer that the above examples are representative of all animal models and are not exceptions to the
rule. Moreover, the studies described above are a small sample of the many
such instances that have been recorded in the medical literature showing the
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animal model’s overall lack of predictive value. For more examples see Arrowsmith (2011a, b), Chiou et al. (2000), Ennever et al. (1987), Fletcher (1978), Grass
and Sinko (2002), Hughes (2008), Litchfield (1962), Igarashi et al. (1995, 1996),
Johnson et al. (2001), Kola and Landis (2004), Kummar et al. (2007), Lesko
and Woodcock (2004), Lumley (1990), Mahmood (2000), Smith and Caldwell
(1977), Spriet-Pourra and Auriche (1994), van Meer et al. (2012), and Weaver et
al. (2003). Despite the above, important international regulatory bodies still
require animal-based research and testing. See for example, the Organisation
for Economic Co-operation and Development (2018) and the International
Council for Harmonization of Technical Requirements for Pharmaceuticals
for Human Use (2011).
The overall consequence of continued reliance on animal models is evident when considering the costly failures seen in drug development. For the
past few decades, arguably the period when our advanced scientific sophistication should have been yielding the greatest progress in drug development,
the success rate in human clinical trials of drugs that entered those trials,
based on data from animals, was about 10% (see, e.g., bio, Biomedictracker
and Amplion, 2016; Smietana, Siatkowski and Moller, 2016). Safety/toxicity and
efficacy are the two characteristics researchers seek to evaluate when using
animal models in drug development. But drugs developed using animal models have systematically failed in human clinical trials for both safety/toxicity
reasons and efficacy reasons. Moreover, even more drugs have failed when
prescribed to large numbers of people, dropping the success rate below 10%.
Granted there are many reasons that drugs fail to enter the market, but these
are rare in comparison to the frequency with which efficacy and safety issues
have failed to be revealed by animal modeling.
Based on our discussion above of evolved complex systems, evolution, and
the empirical data, we conclude that animal models, overall, do not and cannot have a numeric predictive value above about 50%; and, hence, we conclude
that, for all practical purposes, they have no predictive value. By this we do not
mean the predictive value of any given animal model is exactly equal to zero,
but rather that the predictive value is so low that it is necessarily below any
reasonable threshold to be considered useful in medical science in general.
5

Summary

Drawing on theoretical principles, based on evolutionary biology and complex
systems, and based on extensive empirical evidence, the position that animal
modeling has predictive value for human response to drugs in general has
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been falsified. tsmt is a theory, and, like all scientific theories, it is consistent
with this definition from the National Academies of Science Engineering Medicine (2016): “In everyday usage, theory often refers to a hunch or a speculation.
When people say, ‘I have a theory about why that happened,’ they are often
drawing a conclusion based on fragmentary or inconclusive evidence. The formal scientific definition of theory is quite different from the everyday meaning
of the word. It refers to a comprehensive explanation of some aspect of nature
that is supported by a vast body of evidence”.
Researchers who aim to improve human outcomes cannot continue to treat
humans and non-human animals as simple systems and expect results based
on non-human animals to translate to human patients. tsmt is the first comprehensive theory that explains the past failures and apparent successes of
animal modeling and also explains why animal models will never achieve predictive value and, thus, should be abandoned.
We acknowledge that the scientific community as a whole is not yet familiar
with tsmt; but we are confident that, in time, a consensus will be reached.
Kramer and Greek (2018) explain the obstacles that must be overcome to
ensure that drug development and the study of diseases are based on sound
science. This will require changes to the regulations that currently mandate
the use of animal models. Furthermore, Kramer and Greek (2018) discuss
modern techniques that fall under the heading of personalized medicine,
which offer t reatments and cures that are customized to a patient’s individual
genetic make-up and, hence, sidestep the significant risks associated with the
continued blind reliance on methods arising from the use of animal models.
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1

Introduction

Animal safety testing for new medicines is arguably the most difficult use of
non-human animals (hereinafter referred to as animals) to challenge, for two
reasons: first, it is required by governments (regulatory testing); second, protecting patients is a vital goal, and it seems intuitively obvious that animal
tests must protect patients. Animal testing became institutionalized in the
mid twentieth century (Parke, 1994) in response to early drug disasters, with
the aim of preventing further tragedies. However, even the laudable aim of
protecting patients cannot justify animal testing, unless it is the most effective means to ensure the safety of medicines. European Union (eu) law (European Parliament, 2010, Directive 2010/63/EU) states that animals must not be
used if a non-animal method could achieve the same purpose. So, it is crucial
to know how well animal tests predict the safety of medicines, and whether
any other methods are equally or more predictive. In addition to the question
of predictive value, other important issues must also be taken into consideration, including the efficiency of different methods in terms of time and costs;
and the ethical acceptability of using animals, if their use is deemed to be of
irreplaceable value.
The issue of whether animals should be used as human surrogates for safety
testing is highly contentious; individual views range from no use of animals
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is acceptable, to any use is justified if it is ultimately for the benefit of human
health. In a 2016 Ipsos Mori poll for the United Kingdom government, 35% of
respondents felt that “animals should not be used in any scientific research
because of the importance I place on animal welfare”; and 51% felt that it is
unacceptable to use animals to test chemicals that could harm plants or the
environment (Clemence and Leaman, 2016). In the United States (us), a 2017
Gallup poll found that 44% of adults considered medical testing on animals to
be morally wrong (Jones and Saad, 2017). A 2015 survey by the us Pew Centre
found that 50% of citizens “oppose the use of animals in scientific r esearch”
(Pew Research Center, 2015). Thus, it is questionable whether the continued
use of animals in research or testing has a mandate from society. What is clear
is that their use should be replaced as soon as scientifically possible (European
Parliament, 2010, Recital 10), which brings us back to the question of their
effectiveness relative to other methods.
Before any new methods can be approved for use in regulatory safety testing,
they must be shown to be at least as effective as the methods they are designed
to replace, a logic that cannot be faulted. However, herein lie a number of
problems. First, we do not know how valuable existing animal-based methods
actually are, as none have ever been formally validated in the m
 anner required
for potential replacements. One reason for this is that the formal process of
test-method validation is so slow, expensive, and demanding, in its current
format, that it represents an effective block to testing existing accepted methods and a significant barrier to testing new methods. The situation is further
complicated by the fact that the “gold standard” with which new data must be
compared, is usually animal data that is of unknown value. We strongly believe
that the most relevant gold standard should be human data.
In this chapter, we propose a new, pragmatic approach that could accelerate
the replacement of most, if not all, regulatory animal tests with superior tests
based on human biology. We also propose that changes to the requirements
for safety testing, issued by the us Food and Drug Administration (fda), must
be made in order to enable the use of superior new tests, which are currently
disadvantaged by the outdated language of the regulations. But first, it is
imperative to establish some level of understanding of the efficacy of existing
animal-based methods in order to know whether any possible replacement is
better or worse.
2

Learning from Clinical Experience

In order to quantify, as best as we can, the effectiveness of animal tests for predicting the safety of medicines, we can begin by assessing about half a century
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of clinical experience. We have a significant amount of information gleaned
from the use of approved medicines in human subjects and can identify, for
such medicines, where animal-based testing failed to predict human safety
issues; and whether non-animal methods now exist that would be able to identify the toxic effects that were missed by animal tests.
Many medicines that have been judged safe enough for testing in humans,
following all the required safety tests in vitro, and in at least two species of
animals, have gone on to cause serious adverse reactions in the first volunteers to try them: participants in clinical trials. The most infamous examples
include the trials of the candidate medicines tgn1412 in the uk, bia 10-2474 in
France, and fialuridine in the us. TGN1412 is a monoclonal antibody that was
intended to treat B cell chronic lymphocytic leukemia and rheumatoid arthritis. The clinical trial, in London in 2006, hit headlines when all six young men
in the Phase I (safety assessment) trial were rushed to intensive care with multiple organ failure. Miraculously, they all survived; but they were told that they
face “a lifetime of contracting cancers and all the various autoimmune diseases
from lupus to ms, from rheumatoid arthritis to me” (Leppard, 2006). TGN1412
was shown to be safe in monkeys at doses 500 times higher than those that
nearly proved fatal to the volunteers (St. Clair, 2008).
In January 2016, a Phase I study of the drug bia 10-2474 conducted in Rennes,
France, left one initially healthy volunteer dead, and four volunteers with serious neurological damage (Sharav, 2016). The drug was intended to target a wide
range of conditions including pain, hypertension, multiple sclerosis, obesity,
and cancer. Experts convened by the French National Agency for Medicines
and Health Products concluded that the compound being tested had caused
an “astonishing and unprecedented” reaction in the brain. Why this was not
clear in early trials on animals is “inexplicable,” according to the expert panel’s
report (Bisserbe, 2016). The drug had been tested in mice, rats, dogs, and monkeys, with few ill effects, despite doses up to 650 times stronger than those given to the volunteers (Temporary Specialist Scientific Committee, tssc, 2016).
A subsequent study indicates that an off-target effect, which can be species
dependent, may explain why animal tests in multiple species did not identify
the deadly neurological effects (van Esbroeck et al., 2017). The off-target effect
could only be found using human cells in vitro and in humans.
In 1993, a combined Phase I/Phase ii clinical trial (to test both safety and
effectiveness) of fialuridine, a potential hepatitis B treatment, conducted by
the National Institutes of Health (nih) in the us, caused unexpected and devastating reactions, such as jaundice, liver failure, and multiple organ failure.
Five of the 15 participants died. Emergency liver transplants saved two others.
Previous toxicity tests in animals, including a six-month trial in dogs, had given
the drug the green light for testing in humans (Thompson, 1994).
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Many more medicines have passed both preclinical (mainly animal-based)
safety tests and human clinical trials and still gone on to cause serious a dverse
reactions in patients. This illustrates how difficult it is to predict safety for
humans, in general, and even more so for particular members of the human
population. There is enormous genetic variability between people, and individual reactions will vary with age, sex, ethnicity, health, diet, environment,
and unique genetic characteristics. Adverse drug reactions (adrs) are now a
leading cause of death, killing 197,000 people in the eu each year (European
Commission, 2008), and over 125,000 in the us (Light, 2015). In addition to this
devastating human cost, the financial cost of adrs is astronomical, calculated
at €79 billion per annum in the eu (European Commission, 2008). A study of
new drugs approved by the us fda between 2001 and 2010 found that 32%
were affected by a post market safety event (Downing et al., 2017). Another
study of all 454 drugs approved in the us and Canada from 1992 to 2011, found
that 52% (236 drugs) were either withdrawn from the market or restricted by
a serious safety (black box) warning within the 20-year period (Rawson, 2013).
Black box warnings are reserved for adrs that may lead to death or serious
injury. Half of them are detected and documented within seven years after
drug approval, during which time their market uptake and sales volume may
be explosive. There is a compelling argument that “when safe and effective the
rapies already exist, any new drug should be considered a black box” (Lasser et
al., 2002). When the costs of withdrawn and restricted drugs, as well as failures
during development, are factored into the total cost of developing a successful
new drug, this results in an estimated average of us$4 billion and could reach
as high as us$12 billion (Herper, 2012).
It is argued that most adrs that were not detected in clinical trials are very
rare and/or idiosyncratic, i.e. unique to the individuals who suffered them and,
therefore, impossible to identify until large numbers of people are exposed to
the drug, once it is on the market. The implication of this position, accepted
by our governments, is that we are powerless to prevent rare or idiosyncratic
adrs and must simply accept them as an unavoidable risk of medicine. The
problem is that even if an adverse reaction is rare, when millions of people
are taking a drug, large numbers will be affected. Not only are hundreds of
thousands of people killed, it is estimated that a total of over 80 million adrs
result in 2.7 million hospitalizations each year; in addition, pain, discomfort
and dysfunction affect physical or cognitive function and can lead to falls and
cause potentially fatal vehicle accidents (Light, 2015). While it can be argued
that responsibility for failing to protect participants in clinical trials from
dangerous drug candidates lies mainly with animal testing, neither animal
tests nor human trials have been able to prevent the large numbers of adrs
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d ocumented above. Clearly, it is imperative to examine all aspects of safety
testing, to find every weak point, and to take action to address them all.
3

Clinical Trial Flaws

Many problems with clinical trials have been identified, and are being
addressed to varying degrees (Evans, Thornton and Chalmers, 2006; Goldacre,
2012). For example, most volunteers in Phase I trials are young men, who are
not representative of the often elderly and/or female patients who will be
taking the medicines (Abadie, 2010; Johnson et al., 2014). The conduct and
reporting of trials are beset by a host of biases, such as selective reporting of
results, to emphasize benefits and disguise risks; and non-publication of trials
where the desired outcomes were not achieved (Goldacre, 2012; Harris, 2017).
In biomedical research as a whole, 235 types of bias have been documented
(Chavalarias and Ioannidis, 2010). Many doctors have been campaigning for
many years to tackle these biases, which make a mockery of the evidence base
for medical treatments. Doctors and patients are unable to choose the best
treatments without full, unbiased disclosure of the magnitude of their bene
fits as well as their risks. With un endorsement, the AllTrials campaign (2016)
has published a roadmap towards ensuring that all clinical trials are properly
reported to improve the evidence base for medicine, which is currently badly
incorrect and incomplete.
4

Preclinical Animal Tests

To assess the performance of preclinical animal tests, the most direct comparison is between data obtained during preclinical (animal) and clinical
(human) trials. We have already mentioned three extreme examples of disastrous clinical trials, where animal tests failed to predict toxicity with devastating consequences. But are these isolated examples, and do animal tests usually
predict serious toxicities before they manifest in people? This is difficult to
answer quantitatively because compounds that are shown to be toxic in animal tests do not usually progress to clinical trials. However, we do know that
95% of potential new drugs fail during clinical trials (Arrowsmith, 2012), either
because of toxicities that were not predicted, or because they lack the therapeutic efficacy that was predicted. Data obtained by Freedom of Information
legislation shows that from 2010–2014, 7,187 people in the uk suffered serious unexpected adrs during clinical trials and 761 died, although none of the
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deaths could be proven to have been “directly caused” by the test drug (Bagot,
2015). More than 2,600 patients participating in clinical trials in India died
between 2005 and 2012, and nearly 12,000 suffered serious adverse effects. Of
these, 80 deaths and more than 500 serious adverse effects were directly attributed to the drug being trialed (Nair, 2015). Clearly the record of animal tests in
predicting safety is poor.
Another example that illustrates the dangers of both misleading preclinical animal studies and non-publication of clinical trials is lorcainide, which
is estimated to have killed over 100,000 people in the us alone over the course
of the 1980s (Bruckner and Ellis, 2017). Lorcainide and other anti-arrhythmic
drugs (most of which have since been withdrawn) were prescribed routinely
to patients recovering from heart attacks, on an assumption, bolstered by the
strength of their effectiveness against experimentally induced arrhythmias in
animals, that they would help to prevent early deaths. A clinical trial in 1980
indicated that, in fact, they caused more deaths; but the trial was not published
until 13 years later, to the great regret of the authors, who realize that they could
have helped avert tens of thousands of unnecessarily early deaths (Hampton,
2015).
An important point that must be made is the difference between predicting the presence or the absence of toxicity. It seems intuitively obvious that
if a compound is overtly toxic for an animal, it is not unreasonable to suspect
that it will also be toxic in humans. In a series of studies, Bailey, Thew and Balls
(2013, 2014, 2015) examined the likelihood that such suspicions would be correct. They analyzed a data set of 2,366 drugs, for which both animal and human
data are available, in the most comprehensive analysis of publicly available
animal toxicity data ever compiled. Crucially, they used the appropriate statisti
cal metrics of likelihood ratios, for the first time, to question critically the value
of the use of the main preclinical animal species (i.e., rats, mice, rabbits, dogs,
and monkeys) in the testing of new human pharmaceuticals. They found that
the presence of toxicity in animal tests indeed shares some degree of correlation (above random chance) with the presence of toxicity in humans, although
such correlation is too variable to be regarded as predictive, as has been demonstrated by many previous studies (Fourches et al., 2010; Geerts, 2009; Green,
2015; Hackam and Redelmeier, 2006; Heywood, 1990; Igarashi, 1994; Ioannidis,
2012; Knight et al., 2006; Matthews, 2008; Pound et al., 2004; Pound and Bracken, 2014; Perel et al., 2007; Salsburg, 1983; Seouk et al., 2013; Spriet-Pourra and
Auriche, 1994; Wall and Shani, 2008, van Meer et al., 2012). More importantly,
they found that animal tests have essentially no ability to predict the absence
of toxicity, the very reason for their use in preclinical testing: candidate drugs
proceed to testing in humans when no toxicity shows up in tests on animals.
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So, while animal tests undoubtedly prevent some toxic compounds from reaching humans, they cannot predict safety for humans. Thus, as we have seen,
their use creates a false sense of security. A study published in 2012 found that
animal tests missed 81% of the serious side effects of 43 drugs that went on to
harm patients (van Meer, 2012). This is disastrous not only for patients but also
for the pharmaceutical industry, which is in crisis and urgently needs to stem
the unsustainable rate of late-stage attrition of new medicines.
In addition to letting dangerous medicines slip through the net (through
false negative results), promising medicines may be wrongly discarded due to
animal toxicities that do not affect humans (false positives). Clear examples of
this are few, as any compound causing adrs in animals is extremely unlikely to
progress to the clinic; therefore, its safety profile in humans remains unestablished. However, there are examples. Glivec, an effective cancer treatment,
was almost abandoned during development, as it caused liver damage in dogs.
Fortunately, its remarkable success in human cells in vitro and in early trials
in leukemia patients enabled its continued development (Capdeville, 2002).
Similarly, tamoxifen was almost lost as a cancer treatment because it causes
liver tumors in rats (Carthew, 1995). Evidence for this may also be gleaned
from drugs introduced before rigorous safety testing became mandatory. For
example, aspirin, introduced over a hundred years ago, has proved useful for
pain treatment ever since, but it is highly doubtful it would ever have appeared
had it been subjected to modern animal-based safety testing (Hartung, 2009).
Other such examples include, benzodiazepines, methylxanthines, such as
caffeine, and beta-blockers. It is a similar story with many foodstuffs, such as
chocolate and garlic, which are well tolerated by humans but prove toxic to
dogs and cats (Cortinovis and Caloni, 2016).
Furthermore, not all failures in animal studies involve adverse events. Many
reflect a lack of apparent efficacy in the chosen animal species, a finding that
usually consigns a prospective candidate to the waste bin. However, on occasion, a “failed” compound has a champion, sufficiently dogged to proceed
despite such a setback. A particularly good example of this are statins (Endo,
2010), the best selling drugs in history, which nearly never emerged from
preclinical testing. Based on the belief that elevated levels of cholesterol in
the body are, in some way, responsible for coronary heart disease, many approaches to reducing circulating cholesterol have been explored; one of these
was through inhibition of hmg-CoA reductase, a key enzyme in cholesterol
biosynthesis. In 1976, a report of the first statin, compactin, was published
(Endo et al., 1976), describing how it inhibited this key enzyme and reduced
cholesterol synthesis in isolated mammalian cells. Unfortunately, when tested
in rats, this compound proved to be without effect on serum cholesterol levels
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(Endo, 2010); and if not for the persistence of the scientists working on the
project, this would have been the end of the story. However, despite its lack
of effect in rats, compactin was, by chance, found to lower circulating levels
of cholesterol in chickens and, subsequently, in other animal species; and the
race to develop the ultimate statin was on. Although statins’ effectiveness in
saving lives is now controversial (de Lorgeril and Rabaeus, 2015), there is no
doubt of their e ffectiveness in lowering cholesterol in humans.
It is hard to imagine a world without antibiotics, the most life-saving class
of drugs ever discovered. Yet, the world’s first antibiotic, penicillin, was almost
lost to humanity because Alexander Fleming concluded that its rapid clearance
from the bloodstream in a rabbit would prevent it from being systemically
effective (Hare, 1982). For twelve years following his discovery of “mould juice”,
Fleming pursued its use merely as a topical antiseptic, until Florey and Chain
resurrected interest in its greater potential. Fleming later commented to his
student, Dennis Parke, who became an extremely influential pioneering toxicologist: “How fortunate we didn’t have these animal tests in the 1940s, for
penicillin would probably never have been granted a license, and possibly the
whole field of antibiotics might never have been realised” (Parke, 1994).
We have discussed, above, examples of false negatives and false positives for
safety, as well as false negatives for efficacy. Finally, there are many examples
of false positives for efficacy, i.e. drugs that were effective in animal tests but
turned out to be ineffective in humans. They include the vast majority of new
cancer treatments, which have one of the highest failure rates (96%) in clinical
trials (Hutchinson and Kirk, 2011); all putative disease-modifying treatments
(more than 300) for Alzheimer’s disease to date (Langley, 2014; Lowe, 2017);
more than 100 candidate aids vaccines, all of which were effective in non-
human primates, as well as other animal models (Sheets et al., 2016); more than
100 drugs for stroke (Collaborative Approach to Meta-Analysis and Review of
Animal Data from Experimental Studies, camarades, 2017); and 150 drugs for
sepsis, the leading cause of death in intensive care units (Seok et al., 2013).
The camarades group was founded to study the translatability of stroke
studies from animals to humans, and later expanded to include a number of
other diseases that share a high rate of translational failure. They have found
that the poor quality of animal studies confounds research in all areas they
have studied, so far (camarades, 2017). These failed treatments have been
tested on patients in clinical trials. When the director of the us nih, Dr. Francis Collins, learned of the poor quality of the animal studies that led to clinical
trials of treatments for amyotrophic lateral sclerosis (als, also known as motor
neuron disease), he said: “Humans were being put at risk based on that kind
of data, and that took my breath away” (Harris, 2017). This reproducibility crisis
is now receiving much attention, and many initiatives have begun to attempt
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to improve standards and the quality of animal research and reporting (Harris,
2017). However, a review of developments in the field of stroke found that, despite researchers’ adherence to recommendations intended to improve the
quality of preclinical stroke studies for over 10 years, there is no evidence of an
increased rate of successful translation (Sutherland et al., 2012). It is possible
that many years and many precious resources will be invested in attempts to
surmount a problem that may ultimately be insurmountable, due to inherent
interspecies differences in crucial genetic and biochemical systems. Dr. Fiona
Godlee, Editor of British Medical Journal, posed the pivotal question: “Where
would you place the balance of effort: investment in better animal research or
a shift in funding to more clinical research?” (Godlee, 2014).
5

Other Preclinical Tests in Current Use

Preclinical testing also includes a number of in vitro and in silico (computer
modeling) methods, whose record of predicting safety must also be acknowledged as lamentable. Indeed, the uk government always uses this argument
in defense of animal testing, stating that “prior to testing in animals, new
drugs are tested in batteries of in silico and in vitro tests, including, where
available and validated, tests using human tissue samples” (uk Department
of Health, 2012). However, many of these tests are based on animal cells and
tissues; and even the human-based ones generally do not represent the latest
state of the art models, which have long ago moved on from 2D to 3D models
and recognized the importance of incorporating more realistic physiological
features, such as multiple interconnected organs, metabolic activity, and fluid
circulation, among others. Technologies are now becoming available that can
identify toxic liabilities more accurately than animal tests and furthermore,
some of them are able to identify subtle signals of toxicities that only manifest
in rare individuals (Xu et al., 2008). This could enable the detection of potential rare ADRs that are currently unpredictable (Kenna, 2017). Thus, these human biology-based technologies should be recognized as a truly disruptive (i.e.
revolutionary) technology, with the potential to transform toxicology from an
imprecise science based on inter-species extrapolations to a predictive science
based on a deep understanding of human pathways of toxicity. A particularly
powerful approach has recently been described by Theil et al. (2017), in which
they use a system to “contextualize in vitro” data to reflect an in vivo situation
in patients through computer modeling, using data derived from both human
cells and clinical experience. A system such as this allows the identification of
potential biomarkers of toxicity, and the use of these biomarkers in an in vitro
setting to predict potential toxicity in clinical use.
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Non-animal Technologies

Remarkable scientific advances have created a new generation of more relevant and predictive toxicological tools. They include human tissue created by
reprogramming cells from people with the relevant disease (dubbed patient
in a dish); organ on a chip devices, where living human tissue samples on a
silicon chip are linked by a circulating blood substitute; a variety of computer modeling approaches, such as virtual organs, patients, and clinical trials;
and microdosing studies, where tiny doses of drugs given to volunteers allow
scientists to study their metabolism in humans, safely and with unsurpassed
accuracy. There are also humbler, but no less valuable, studies in ethically
donated “waste” tissue. Together, these innovations provide invaluable insight
into the functioning of the integrated human system. Such tests are frequently able to detect side effects that were missed by preclinical animal tests. For
example:
– A micro-liver (called HepatoPac) comprising human liver cells is able to
predict liver damage from fialuridine, the potential hepatitis B treatment
that killed five patients in the devastating 1993 clinical trial (Baker, 2011).
Furthermore, the same technology is able to identify many other liver-toxic
drugs that were missed by animal testing (Xu et al., 2008).
– Following the trial of TGN1412, a method using human cells was rapidly
developed to model the cytokine storm experienced by the volunteers (Stebbings et al., 2007).
– The us government’s initiative, Toxicology in the 21st Century (Tox21), has
tested 10,000 chemicals using a panel of human cell-based assays (National
Center for Advancing Translational Sciences, 2016). These are automated
high-throughput screening assays that expose cells to chemicals and then
screen them for changes that could suggest toxic effects. The use of this panel of assays enabled the identification of important safety aspects of drugs
and chemicals “markedly better” than toxicity tests in animals (Huang et al.,
2016). The human in vitro data were mainly assessed against rodent data, as
human in vivo data are sparse. As expected, the Tox21 data better predicted
human toxicity endpoints than rodent data.
Non-animal tests are often faster and cheaper, as well as more accurate and
reliable (Balijepalli and Sivaramakrishan, 2017; Bracken, 2009; Garner et al.,
2017; Krul, 2014; nih, 2008). Some of the more valuable technologies are expensive, but worth it—there is nothing more expensive than getting the wrong
answer. Human tissue company, Biopta (2017), estimates an average saving of
US$7 for every US$1 invested in predictive human assays. Director of the us
nih, Dr. Francis Collins, recently predicted before us Congress that within 10
years, human biochips “will mostly replace animal testing for drug toxicity and
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e nvironmental sensing, giving results that are more accurate, at lower cost,
and with higher throughput” (us Senate Committee on Appropriations, 2016).
However, new methods will not automatically implement themselves. Pharmaceutical companies would make much greater use of them if g overnments
encouraged it, but inflexible requirements for animal tests are a major deterrent. Reliance on animals is so entrenched and institutionalized, that the
system is “locked-in” (Frank, 2004). Intervention is necessary to overcome the
many factors contributing to entrenchment against change.
7

Validation

Quite correctly, new technologies must be shown to be robust, reliable, and fit
for purpose before they can be recommended for use in any regulatory safetytesting regime. The current validation process involves testing by several different laboratories and is tremendously demanding, taking an average of 10 years
and costing up to US$1 million (Hartung, 2013). This approach protects the status quo by making the bar for acceptance so high and so unaffordable for small
technology providers. Moreover, in this fast-moving field, by the time a new
technology has finally been validated, it will already have been superseded.
Most ironically, new technologies are assessed on how well they can predict
the “gold standard” animal data; thus ensuring that they cannot succeed, if the
drug affects animals differently from humans, which we now know is very often the case (Hartung, 2007, 2010; Leist et al., 2012). The very concept of the use
of animal data as a useful standard is fundamentally flawed, as no species is
truly representative of any other (Hartung, 2009; Wang & Gray, 2015; Perlman,
2016). Indeed the ability of rats to predict for carcinogenicity in mice has been
shown to be useful in less than 60% of cases (Gray et al., 1995).
8

A Way Forward: Pragmatic Evaluation

The need for better ways to protect the public from the ever-increasing epidemic of adrs is so urgent that a new approach to implementing more predictive
methods is critical. This is now widely recognized and much attention is
being devoted to making validation more flexible. The fda is considering accepting methods that have been through a process of “qualification”, rather
than traditional validation (Food and Drug Administration, fda, 2017). Others have suggested streamlining validation, through greater use of reference
chemicals and performance standards and the development of an objective,
transparent, online peer review process (Judson et al., 2013).
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We believe most strongly that any superior system must be based on
h uman biology, and if that aim is compromised, predictive value is bound to
fall. Advocates of animal testing say that this is unrealistic, and that it is not
possible to gain sufficient understanding of the intact human system from
isolated cells and tissues. However, if we look at other fields of technology,
such as computing, automotive manufacture, telephonic communication, or
space exploration, we see that yesterday’s impossibility becomes today’s challenge and tomorrow’s commonplace. There is no reason why this should not
equally apply to safety testing. In all other areas, technological advances are
made in a step-wise fashion, seldom, if ever, in a single leap. We argue that the
only practical way forward is a process of pragmatic evaluation of new technologies, whereby those that demonstrate success in predicting safety issues
for humans, where the current system failed (as well as where it succeeded),
should be accepted for use in appropriate circumstances and with sufficient
justification. This approach will be iterative, and as shortcomings of the new
tests are identified, further tests may be developed to overcome these problems. The truth is that we may never identify tests that will allow prediction
of all safety issues, but by tackling these in a manageable fashion, we will get
much closer than we can currently manage using animal-based approaches.
Of course, we cannot test potential new medicines on humans prospectively, using new methods in place of old ones, in case they perform less well.
Therefore, new methods must be evaluated using historical “legacy” data. By
studying the safety profiles of drugs that have been extensively used in human subjects, which will have necessarily passed the mandatory animal-based
safety tests, we can identify where those tests failed to detect safety issues in
human subjects. A selection of drugs whose toxicities were missed by animal
tests can then form the basis of a test panel, to be submitted to a range of nonanimal tests. In this way, the predictive performance of the new tests can be
compared to that of the animal-based methods. To increase the scientific rigor
of such studies, pairs of closely-related compounds should be used, where one
has a particular toxicity that the other does not share. This will identify tests
that are capable of differentiating between toxic and non-toxic compounds,
the key attribute of any desirable test. Rather than assessing each new test in
isolation, different types of tests will be combined in testing batteries, designed
to complement each other in their ability to detect a variety of toxicities. Different batteries will be appropriate for different types of compounds. We need
to forget the beguilingly simplistic approach of attempting to model humans
with one system, even when that system is an integrated whole animal. No
single test, however integrated, will ever be an adequate model for the breadth
of human genetic variability. Combinations of tests at the molecular, cellular, organ, and system levels will need to be performed to generate sufficient
Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

Replacing Animal Tests to Improve Safety for Humans

429

confidence to advance into cautious first-in-human testing, using safe approaches, such as microdosing, before proceeding to test therapeutic doses in
patients in carefully designed adaptive clinical trials.
The Evidence-Based Toxicology Collaboration (ebtc) at the Johns Hopkins
Bloomberg School of Public Health, is currently undertaking an evidencebased evaluation study, as described above. Using systematic reviews, they are
comparing drug-induced toxicity in humans to preclinical animal data and to
in vitro data from the Toxicity Forecaster (ToxCast) program of the us Environmental Protection Agency. The results will provide an objective comparison of the relative predictive abilities of animal versus non-animal methods.
If successful, this study will demonstrate that a limited compound set can be
used, if proper negative and positive controls are present, to compare the performance of a battery of tests relative to the current system. A clear demonstration of multiple successes, especially where the current regime has failed,
would create a powerful impetus for governments and pharmaceutical companies to allocate more resources to tackling this problem more urgently. Substantial funding is required, as is greatly increased access to data.
Pharmaceutical companies are sitting on a treasure trove of preclinical and
clinical data, which could yield immensely valuable information if made available for analysis. Former fda Commissioner, Robert Califf called for a preclinical database to be established (Scott, 2016). This initiative must be seized; it
has the potential to save time, money, and animals by avoiding futile repetitive
testing; and, more importantly, the potential to revolutionize the evaluation
of both old and new technologies, through statistical comparisons with a gold
mine of millions of data points.
9

Regulatory Change

Former nih Director, Elias Zerhouni, and former fda Commissioner, Margaret Hamburg, state that the “regulation of drugs can either grease the wheels
of progress or throw a wrench in the works” (Zerhouni and Hamburg, 2016).
Calling for global harmonization of regulatory requirements, they note that
differences between regulations in different countries create unnecessary
barriers to the efficient delivery of safe, innovative, and effective treatments
to patients. They acknowledge that regulatory authorities are struggling to
keep up with rapid advances in science and technology and advocate highlevel cooperation to ensure progress is not delayed by bureaucratic stagnation that promotes the status quo. Change needs to be driven by a top-down
strategy to drive harmonization forward, urgently (Zerhouni and Hamburg,
2016).
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Decades-old regulations have not been updated to reflect rapid advances
in science and technology. It is acknowledged that regulations requiring the
use of animal tests are a major barrier to adoption and use of more predictive human-relevant test methods (Malloy, 2016). Without regulatory updates
reflecting the acceptability of the most predictive test methods available, the
scientific advancements of the past decade will not be utilized.
International guidelines for preclinical testing remain focused on the use of
traditional animal tests and merely mention the availability of more predictive
human-relevant test methods. The International Council for Harmonisation of
Technical Requirements for Pharmaceuticals for Human Use (ich), Guidance
on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, states: “The development of a pharmaceutical is a stepwise process involving an evaluation of both animal and
human efficacy and safety information” (ich, 2009). While the ich guideline
states that consideration should be given to the 3Rs, specifically reduction of
the use of animals, and suggests consideration of the use of in vitro methods
that could possibly replace animals, it does not discuss specifics of acceptable
non-animal methods. This focus on reduction of animal use addresses only the
ethics of animal testing, not the safety of human patients. From a public health
perspective, the focus must be shifted to the replacement of animal tests with
human-relevant test methods to provide safer, more effective medicines.
One has only to look at the fda regulations on investigational new drugs and
devices to understand the regulatory barrier to acceptance and adoption of
modern test methods. fda claims that the regulations give them the flexibility
to accept modern, non-animal test methods (natms), such as in vitro studies,
or prior experience with the drug or biological product in humans (Dorsey,
2010); however, current fda regulations explicitly require animal testing. This
requirement discourages the use of natms, which may be more predictive of
human response. Twenty-nine fda regulations clearly require animal testing
and promote the status quo, creating an unreceptive environment that fails to
encourage innovation and development of more predictive test methods (Center for Responsible Science, 2015). Modification of regulatory language would
promote use of existing modern test methods and encourage further development to advance modernization of preclinical testing. Regulations must be
changed to state clearly that the test most predictive of human response should
(or even must) be used. In 2015, a coalition of non-profits, technology developers, and patient advocacy groups petitioned the fda to make modest, noncontroversial regulation amendments that would be an important first step
in advancing the use of natms (Center for Responsible Science, 2015). These
minor amendments to outdated existing regulations would have great impact
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on the use and development of better tools for drug and device d evelopment.
For example, when a current regulation states, “…extensive animal and clinical
tests are required as a condition of approval,” the petition proposes a change
of wording to state, “…extensive preclinical and clinical tests are required as a
condition of approval.” Adoption of these test-neutral, conservative regulatory
amendments would be an important first-step in moving forward. The fda has
yet to provide a substantive response to the petition.
While the us is a world leader in biomedical research and technology
development, it lagged behind the eu in developing a strategy and roadmap for the advancement and use of new technology, until very recently. In
December 2017, the fda’s Predictive Toxicology Roadmap was issued to advance
predictive toxicology in regulatory risk assessments (fda, 2017). In January
2018, after considering input from 16 federal agencies, the Interagency Coordinating Committee on the Validation of Alternative Methods (iccvam) issued
its Strategic Roadmap for Establishing New Approaches to Evaluate the Safety of
Chemicals and Medical Products in the United States (iccvam, 2018). Both roadmaps outline a way forward to successful implementation of new technology.
Crucially, they have been issued by government agencies, which should ensure
that real progress is achieved; indeed, many activities towards implementation
are already underway. The European roadmap calls for many things, including
a joint taskforce to gather all current data on a wide variety of compounds into
a toxicity database; abolition of useless tests; and, crucially, reasonable investment (Basketter et al., 2012). However, without an effective top-down (i.e., government-led) implementation strategy, advances in science and technology
will languish and the eu will lag behind.
Evidence shows that animal methods are often still used, both in the us
and the eu, even when superior validated methods are available. This is likely due to existing regulations that explicitly require animal tests. Applicants
worry that forgoing the inclusion of animal data in product submissions risks
rejection by regulatory reviewers, which would be costly in time and expense
for drug sponsors. For example, since 2005, the fda has informally stated
that Draize data are not required for primary skin and eye irritation testing;
yet, drug sponsors continue to submit Draize data. A review of the 137 New
Molecular Entities approved by the fda between 2011–2014 showed that the
Draize test was used in 94% of all skin irritation and 60% of all eye irritation
tests, d espite the availability of validated methods that are more predictive of
human response (Archibald, Drake and Coleman, 2015).
Regulatory submission reviewers require continuing education to be up
to date on available new technologies. Without reviewer education and uniform acceptance criteria, variability between reviewers’ acceptance of new
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technologies will discourage their use and cause confusion for sponsors on
their acceptability. It is essential that regulators become knowledgeable about
available natms to facilitate early communication with sponsors on their
acceptability.
10

Conclusions

There is a clear ethical imperative to replace unreliable animal-based safety
tests, not just for the animals but to protect human safety. Remarkable knowledge and tools are emerging from projects, such as ToxCast; Tox21; Innovative
Medicines Initiative; Safety Evaluation Ultimately Replacing Animal Testing
(seurat); Integrated European “Flagship” Program Driving Mechanism-based
Toxicity Testing and Risk Assessment for the 21st Century (EU-ToxRisk); and
the Precision Medicines Initiative. These initiatives have the potential to revolutionize our ability to advance and protect human health, but only if they
are implemented. A 2018 report by the uk BioIndustry Association and the
Medicines Discovery Catapult emphasizes that humanizing the process of drug
discovery and testing is the most important way to ease the productivity crisis
in pharmaceutical research.
We must acknowledge that predicting the safety of medicines is an enormous challenge, and that a major obstacle to paradigm change is lack of confidence in the new methods. To tackle this, we suggest that a new, pragmatic
approach to demonstrating that novel methods are more fit for purpose than
existing methods could help to accelerate the replacement of most, if not all,
animal toxicity tests with superior tests based on human biology. We believe
that only through utilizing human-based systems to evaluate new medicines
can we truly gain confidence in their clinical safety. In a 2014 debate on the
proposal that “Animal experimentation in toxicology can be phased out in
five-years’ time,” there was unanimous agreement that disruptive technologies must be properly funded and that more systematic, comparative data is
needed (van der Meer, 2014).
In 2007, the us National Research Council called for a “paradigm shift from
the use of experimental animals […] toward the use of more efficient in vitro
tests and computational techniques” in their landmark report, Toxicity Testing
in the 21st Century: A Vision and a Strategy. The authors expected the paradigm
shift to encounter resistance, as toxicological testing practices are “deeply ingrained.” They envisioned that “toxicity testing will be radically overhauled
over the next 10 years, with the animal testing component virtually, if not actually, eliminated within the next 20 years” (National Research Council, 2007).
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The science of toxicity testing has indeed been transformed over the past 10
years; but in the absence of any regulatory pressure, practical change has been
occurring at a glacial pace, while revolution rather than evolution is required
(Hartung, 2017). Deadlines create tremendous impetus for change, as can be
seen with the eu Cosmetic and Registration, Evaluation, Authorisation and Restriction of CHemicals (reach) regulations. If we are serious about reducing
the ever-increasing burden of death and disability caused by adrs, we must
agree on a deadline for the adoption of more human-relevant methods, and the
phasing out of methods whose predictive ability has not been proven. As with
the replacement of horses by cars, there will need to be a brief period of sharing the road, while confidence in the new methods grows. The Netherlands now
leads the world with its announcement that it intends to phase out all legally
prescribed, animal-based safety testing by 2025 (Netherlands National Committee for the protection of animals used for scientific purposes, NCad, 2016).
The Committee recognizes that the transition will not happen of its own accord and will require clear strategic direction to change attitudes and practices.
Crucially, the regulations that govern how drugs are tested must be updated
to encourage the adoption of the best new approaches. Current regulations are
stifling innovation by failing to keep pace with scientific progress. We argue
that several aspects of current practice can no longer be justified:
1.
The continued use of testing methods that have never been validated,
while novel methods must demonstrate a level of performance that current methods not only have never been asked to perform but are clearly
unable to perform.
2. Resistance to the adoption of non-animal methods that, although not
formally validated, show greater predictive performance than animal
tests.
3. The continued blind eye turned to the use of animal-based tests, where
viable non-animal methods exist, on the pretext that they may be
required by regulators at home or abroad.
4. The exposure of human patients and volunteers to potentially unsafe
substances on the basis of demonstrably unreliable animal data.
5. The risk of the loss of potentially life-saving/modifying treatments on the
basis of demonstrably unreliable animal data.
In March 2016, Safer Medicines Trust commissioned a survey of 2,500 uk
healthcare professionals. 79% agreed that pharmaceutical companies should
be legally obliged to test new medicines using methods demonstrated to be
the most predictive of safety for humans (Dods Information, 2016). Governments must act to protect the public by updating regulations, whose raison
d’etre is patient safety, that now prevent their own aim from being realized.
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1

Introduction

The scientific method demands a willingness to correct and integrate previous knowledge, based on observable, empirical, measurable evidence and
subject to laws of reasoning; yet, it has scarcely been applied to non-human
animal (hereinafter referred to as animal) research. Nevertheless, animal
use in science started declining in the mid 1970s, at least in the United Kingdom, resulting in a drop in the number of animals used approaching 50% between the mid-1970s and mid 1980s (UK Home Office, 2016)—perhaps a tacit
admission of problematic species differences that render animals poor models
for humans. This trend was, however, reversed with the advent of genetically
modified (GM) animals, animals whose genetic material has been deliberately
altered in some way by insertion, deletion, or substitution of dna. While the
decline in use of non-GM animals continued steeply well into the new millennium, overall numbers have been rising for some time, solely due to increased
utilization of GM animals (Ormandy, Schuppli and Weary, 2009). UK statistics
for 2015 show that more than two million procedures involved the creation and
breeding of GM animals, who were not subsequently used in further research
(around 50% of the total); and there were 720,000 procedures on GM animals
in further experiments, representing 35% of the total animals used in actual
experiments (Hendriksen and Spielmann, 2014; UK Home Office, 2016). Trends
in GM animal use for the rest of the world are difficult to determine due to
different reporting requirements, but they are likely to be similar, with up to
50% of the approximately 13 million animals used annually in research in the
European Union (EU) (Taylor and Rego, 2016), and the estimated 115 million
animals used globally (Taylor et al., 2008).
This chapter aims to summarize and analyze this shift in the use of animals
in experiments and, without being overly technical, to ask critically why GM
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animals have been so embraced in research. Is this justified? Have they fixed
problems with species differences and made animal research more human relevant? Are there still issues with species differences, and to what extent? Does
the new Clustered Regularly Interspaced Short Palindromic Repeats (crispr)
technique help? Can GM animals ever provide data sufficiently applicable to
humans? If so, what are the ethical costs? How much pain, suffering, and death
is involved?
2

What GM Animals Are, How They Are Made, and Problems of
Efficiency and Specificity

The genome—an organism’s complement of genetic material comprising its
entire collection of genes and associated elements—comprises long molecules of dna, present in almost all cells. There are many genes along its length,
each with a defined function(s), and serving as a template(s) for the manufacture of the proteins and enzymes that are the structural and chemical basis
of life. The genes themselves are made up of subunits, called nucleotides, the
exact sequence of which determines each gene’s function. The human genome
contains an estimated 20,000 genes and more than three billion nucleotides.
Between the genes are other regions of dna that serve, in various ways, to control the expression of those genes, i.e. when the genes are on or off, or to what
degree the proteins they produce are synthesized.
Because our genes are fundamental to many normal biological processes,
they are also at the root of perturbations of these processes that can cause
things to go wrong, resulting in illness and diseases. Genetic studies have,
therefore, been pivotal to much biomedical research, attempting to understand the basis of diseases and what can be done to prevent, treat, and cure
them. Because animal approaches increasingly appear to be of poor human
relevance, due to the very genetic differences that make species dissimilar and
unique, some scientists have modified genes in animals used in experiments
to attempt to overcome these differences and make them more relevant to
human biology.
Broadly speaking, genes may be inserted or knocked in to animals, their
own genes may be deleted or otherwise rendered non-functional or knocked
out, or existing genes may be modified or repaired to alter their function.
Creating GM animals has undoubtedly become more efficient and specific
since their emergence, with the first reports of GM mice in 1974 (Jaenisch
and Mintz, 1974). Much of what is involved is technical in nature, so it will
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not be d iscussed in detail here; suffice to say that various methods are available to introduce the dna of interest—the dna, synthesized in the laboratory,
which will induce the desired genetic modification—into the zygotes (fertilized eggs) or embryos of the animals to be modified. Briefly, it may be injected
into fertilized eggs (pronuclear microinjection) or into embryonic stem cells
(escs or ES cells)—cells in a developing embryo with the capacity to become
one of many different, specialized types of cell—that are removed from an
embryo for manipulation and, subsequently, re-injected into developing embryos. These are subsequently surgically implanted into surrogate mothers, in
which the embryos will develop, as intended, to term and result in live births
of GM offspring. There are many welfare issues throughout this process, which
are described later in this chapter. Initially, the technology was crude, with the
cutting and splicing of dna and insertion of new genes being fairly random
and with concomitant high wastage of animal lives due to its lack of precision
and efficiency. While gene editing in escs improved the process, it should be
noted that, “while it is commonly and frequently claimed that genome editing
has become significantly (perhaps radically) quicker, cheaper, more efficient,
easier to use, and therefore more accessible, care is needed when interpreting these claims” (Nuffield Council on Bioethics, 2016, Section 2.6); “progress
has often been technically challenging […] ES cells have not been obtained for
most species and, even in mice, where the technology is relatively refined, it is
time-consuming, expensive, variable, often highly inefficient, and requires a
special skill set” (Section 1.11 Skarnes, 2015).
One important welfare issue for GM animals, aside from the obvious outcome of their genetic modification, is the poor efficiency (on-target efficiency),
and associated undesired (off-target) effects, of the process. On-target efficiency has increased and off-target effects have decreased significantly with
the relatively recent discovery of new methods (Hsu, Lander and Zhang, 2014),
especially the rna-guided programable nuclease gene-editing platform,
c rispr (crispr/Cas9 system) (see e.g., Chandrasekaran, Song and Ramakrishna, 2017). crispr has generated particularly significant excitement, having “swept through labs around the world”, at a “breakneck pace [that] leaves
little time for addressing the ethical and safety concerns such experiments can
raise.” (Ledford, 2015, pp. 20–21). This is because, in relation to other methods,
it is less expensive (Ledford, 2015; various components of crispr experiments
can be bought for as little as US$30), less technically challenging, and less time
consuming (Caplan et al., 2015). It, therefore, deserves particular attention.
crispr derives from a bacterial immune system (Fineran and Charpentier,
2012), and has two components: a single guide rna molecule (sgRNA), which
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is specifically designed to seek and bind to precise targets in the genome that
are to be modified; and an associated enzyme, Cas9, which cuts the dna at the
target site and initiates the genetic modification process. Put simply, crispr
causes complete (double-stranded) breaks in the dna at (in theory) specific
targeted sites, which are subsequently repaired by the cell’s own dna-repair
systems.
However, the repair process is inherently error prone and generates small
insertions or deletions of dna at the break sites, which can be used to disrupt
gene function or, in the presence of engineered dna molecules introduced experimentally, to alter the dna specifically at that site. While this method is
generally considered to be much more efficient and specific compared to other
approaches, any accurate, definitive, quantitative estimation of the efficiency
of crispr is difficult to find, as estimates vary considerably and are affected by
many factors, including the nature of the target site and the crispr molecule
used. Generally, the method has improved over time, but there is a strong argument that crispr remains far from good enough, scientifically and ethically.
One 2017 review reported that “knock-in efficiencies are still low and highly
variable,” with different genetic loci in zebrafish embryos having genes successfully knocked in, in 45% and 70% of cases, though only in 1.7% and 3.5%
respectively, with any real precision. Associated successful germline modifications to produce founder fish for breeding occurred on average just 3.8% of the
time (Albadri, Del Bene and Revenu, 2017, p. 8). Another recent study found
an average of 9.2% of transferred embryos resulted in mouse pups, and an average of 76% of these had been successfully knocked out for a specific gene.
The generation of pups harboring specific point mutations was lower: 6.5%
of transferred embryos produced pups, though less than 8% of these had the
desired mutation (Nakagawa et al., 2016). In cell lines, mutation efficiencies are
generally higher, though they range from lower than 5% up to 90%, and gene
knock in less than 10% up to 66% (see Bortesi et al., 2016).
Regardless of on-target efficiency, one issue has plagued the creation of GM
animals: off-target effects, or mutations induced by the GM process that are
not intended but affect other non-specific sites in the genome (Fu et al., 2013;
Hsu et al., 2013; Pattanayak et al., 2013). This is a significant scientific and welfare issue, which raises serious concerns over the wider application of genetic
modification in science, medicine, and agriculture (Kanchiswamy et al., 2016;
Kleinstiver et al., 2016). These concerns include: the low birth rates of animals
with the desired genetic modification and the associated high “wastage”, or
animals that may suffer and/or be killed as a result; and many animals who
harbor off-target mutations adversely affecting the animal’s characteristics
(phenotype) (Guha, Wai and Hausner, 2017). Significant off-target dna cleavage
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and mutation results in toxicity to those cells in which it occurs (Kim et al.,
2009), and their repair causes chromosomal rearrangements, which can activate genes that can cause cancer (Cradick et al., 2013; see also Cho et al., 2014).
Not surprisingly, “major concerns of off-target mutations have been observed
in medical and clinical studies,” as well (Kanchiswamy et al., 2016, p. 564). This
leads to difficulty in interpreting data but may also cause these animals further
pain and suffering, due to the off-target effects, and death as they succumb to
adverse off-target effects or are killed because they are of no experimental use.
Despite the considerable effort put into improving the situation, the extent of off-target effects is still a matter of serious debate (Bassett, 2017).
Astoundingly, they are thought to be up to 50% more common than the
desired on-target mutation efficiency, and they may occur at sites quite different to the target site, both of which are of serious concern (Fu et al., 2013; see
also Bortesi et al., 2016; Komor, Badran and Liu, 2017). Many computational
approaches to assessing potential crispr off-target problems exist. Though
useful, each is biased regarding the type of off-target sites it may or may not
fail to predict. It is therefore widely accepted that other, unbiased methods
of assessment must be used to help avoid missing off-target effects that may
be seen experimentally (see Bolukbasi, Gupta and Wolfe, 2016; D’Agostino and
D’Aniello, 2017; Tsai et al., 2015). Some crispr experiments show more than 100
off-target mutations, while others appear to show none (Bolukbasi et al., 2016).
Some a nalyses have suggested little or no off-target activity for some crispr
molecules, though these analyses examined preselected genomic sites only
so are likely to suffer from bias (see Bortesi et al., 2016). Any single technique
will miss off-target sites that others will detect; and, unfortunately, the most
comprehensive method—whole genome sequencing—is technically difficult
and expensive. For example, a rare mutation (0.1% frequency) would require
sequencing 1,500 genomes to give a 95% probability of finding this mutation at
least once (Sluch et al., 2015).
A recent (2017) study attempted to complete a comprehensive whole-genome
analysis to determine the actual prevalence of all off-target mutations in a
crispr-edited mouse, not only the larger mutations, such as insertions and
deletions (indels) of dna but also the smaller, though no less important, single
nucleotide variants (snvs) that are often not sought. Schaefer and colleagues,
reported “an unexpectedly high number of snvs,” in addition to an average of
146 indels, with many of these in known genes (Schaefer et al., 2017, p. 547).
The authors concluded that “concerns persist” over the unpredictable nature
of crispr off-target mutation sites, which were likely to have a detrimental
impact on key cellular processes and would likely manifest in adverse phenotypes. This specific issue remains, however, highly controversial. In March
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2018, Schaefer and colleagues retracted their paper—in the face of pressure
from some members of the scientific community working on crispr—on the
grounds that the study results were irreproducible and unsupported by the
data, and the study lacked key controls (Editorial, 2018; Schaefer et al., 2018).
Retraction of this paper does not, of course, remotely prove or even suggest
that crispr is sufficiently free of off-target effects to be safely used in humans.
Most stakeholders who have opined in its wake have urged further progressive,
yet cautious, research to elucidate the situation and stopped short of inferring
an all clear from the authors’ most recent work (Schaefer et al., 2018). With
particular regard to their revision, Schaefer et al. are careful to note (correctly)
that their latest data suggest that, “in specific cases, crispr […] may not introduce numerous, off-target mutations” (Abstract). Others note that this simply
means that the concern over off-target effects “just isn’t perhaps as big as that
initial study suggested.” (Brown, 2018). More generally, all involved appear
to accept that far too little data exist to reach any robust, definitive conclusions about off-target effects associated with crispr, either way. This sensible,
evidence-based view is supported by the many studies that exist, with a full
spectrum of results (such as those referenced in this chapter), that serve only
to rubber stamp the view that this field is young, and the question of off-target
effects is still completely wide open.
Crucially, just before this Volume went to press, this caution was further justified by a detailed study published in Nature Biotechnology, which showed
that the specificity of crispr-induced genetic alternations had been overestimated to date, due to exploration of them being “limited to the immediate
vicinity of the target site and distal off-target sequences” (Kosicki et al., 2018).
The authors’ more thorough and detailed investigations revealed that—in two
different types of mouse cells and a differentiated h
 uman cell-line alike—mutagenesis at the target sites was often much more significant than intended/
expected. Instead of the aforementioned small insertions or deletions of dna,
the resulting crispr-mediated genetic alterations were frequently “large deletions and more complex genomic rearrangements”, often extending to many
kilobases. Further, off-target lesions often resulted in “genomic damage”, which
“may have pathogenic consequences.” The important warnings of their conclusions bear repeating here: extensive on-target genomic damage is a common outcome; consequences are not limited to the target locus but will affect
more distal genes; some repercussions may initiate neoplasia (cancer); it is
likely that some cells in each protocol would contain important pathogenic
lesions, some of which would become cancer-causing in time; and others.
Such frequent and extensive genetic damage is and has been undetectable
by the means often used to identify it, leading to its under-reporting and
under-appreciation, and so much more comprehensive analysis of the genetic
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consequences of crispr experiments is warranted and necessary. This may be
of urgent concern due to the fact that six clinical trials of crispr are currently
underway, for various malignancies/cancers, including esophageal, nasopharyngeal, gastric, non-small cell lung cancer, leukemias/lymphomas and other
hematological malignancies (see Clinicaltrials.gov).
Clearly, off-target mutations remain a major issue, with persistent targeting
of unintended genomic loci (Bisaria, Jarmoskaite and Herschlag, 2017, p. 21; see
also Tsai and Joung, 2016), even as steps are taken to mitigate their occurrence
and effects, such as using engineered/modified crispr components (see e.g.
Bayat et al., 2017; Chandrasekaran, Song and Ramakrishna, 2017; Combes and
Balls, 2014; Ding et al., 2016; Guha, Wai and Hausner, 2017). It is widely believed
that the factors controlling crispr’s precision and accuracy “are still not fully understood,” and obstacles remain on the path to any clinical application
(Jiang and Doudna, 2017, p. 524). “Much remains to be learned regarding the
efficiency and specificity of crispr/Cas9-mediated gene editing in human
cells, especially in embryos.” (Liang et al., 2015, p. 364) It is considered “necessary” to develop methods of detecting off-target mutations that are much
more sensitive (Tsai and Joung, 2016, p. 310); but it is also thought that these
will never be removed completely (Bassett, 2017), and that off-target effects
will still occur often, no matter how high the on-target specificity (Liang et
al., 2015). Off-target mutations remain stubbornly numerous and confounding
in spite of many, multi-faceted efforts to reduce them and their impact; and
this may have serious consequences for the use of crispr, even in laboratorybased r esearch, where there will be more acceptance of them. This means that
the role of off-target effects in any observations cannot be ruled out, but especially in clinical settings, where safety is paramount and even off-target mutation frequencies as low as 0.1% can have serious consequences (Tsai and Joung,
2016).
Finally, shortly before this Volume went to press, yet another, but different, clarion call for great caution came in the form of two papers published
in Nature (Ihry et al., 2018; Haapaniemi et al., 2018). The double-strand dna
breaks created by crispr/Cas9 as part of its mechanism of action activate a
gene called p53, which is known as the “guardian of the genome”—involved
in the repair of dna damage and, if that damage is sufficiently significant, in
apoptosis, or the destruction of the cell containing the damaged dna. It is
because of these functions that p53—a tumor suppressor gene—is known to
be mutated in more than half of all human cancers (Hollstein et al., 1991; Foronda and Dow, 2018); if p53 cannot carry out its normal activities, damaged
cells may go on to become tumorous (Ferrarelli, 2018). This is an issue because,
as one might expect, p53 blocks crispr/Cas9 activity; and it therefore follows
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that cells that are experimentally modified by crispr, must, thus, tolerate
dna damage, and so must have deficient p53. In selecting for crispr-modified
cells, therefore, one may be selecting for cells that could lead to tumor formation, which could be clinically catastrophic. As one of the authors opined, “By
picking cells that have successfully repaired the damaged gene we intended to
fix, we might inadvertently also pick cells without functional p53. If transplanted into a patient, as in gene therapy for inherited diseases, such cells could give
rise to cancer, raising concerns for the safety of crispr-based gene therapies.”
(Karolinska Institutet, 2018).
It has been suggested that such cells could be identified and eliminated by
in vitro screening (Foronda and Dow, 2018), but various problems remain. Just
one, single dna break seems to be sufficient to prime p53 activity, and lead to
cell arrest or death (Foronda and Dow, 2018; Ihry et al., 2018), so the problem
may be greater than first thought. Some have inferred or implied that this is a
new discovery, but it is not: almost quarter of a century ago, this was demonstrated in human fibroblasts (Di Leonardo et al., 1994). Further, crispr-editing
issues were reported in 2016 with some types of cells, including primary and
stem cells (Hockemeyer and Jaenisch, 2016; Carroll, 2018), the latter being the
type of cell involved in one of the recent Nature papers (Ihry et al., 2018)—so
this may be another illustration of lack of caution among some crispr researchers and advocates, and further reason to doubt that due caution and
critical approach are being applied widely enough—particularly as the underlying mechanism was not pursued (Carroll, 2018). As stated in a recent, highly
relevant review, “It is surprising that this phenomenon was not recognized
much earlier.” (Carroll, 2018). Because break-induced toxicity has not been detected in all cell types, but also due to it not being seen in some cell types that
do have functional p53, it means that “the induced arrest phenomenon will
have to be tested and addressed for each type of target cell” as “that pathway is
not the whole story” (Carroll, 2018). Finally, while selection is possible in vitro,
it is not an option for in vivo somatic gene correction, in which this would have
serious consequences for animals and humans (Foronda and Dow, 2018).
3

Current and Intended Uses of GM Animals

3.1
Biomedical
Many GM animals are used in basic research with no direct application (for
example, to a particular therapy for a specific disease), but with aims to investigate the functions of particular genes, for example, and the nature of their regulation. Others are used as specific models for many different human diseases,
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including multiple infectious diseases, such as hiv, immune system defects,
blood and metabolic disorders, muscular dystrophy, cancer immunotherapies,
among others (Cornu, Mussolino and Cathomen, 2017). Gene therapy interventions for some of these diseases have already reached clinical trials, such as
hiv/aids therapies (Cornu, Mussolino and Cathomen, 2017); though there are
some serious concerns over potential immune reactions in humans to two of
the most common proteins used in the crispr/Cas9 system. Recent analysis
of human blood samples revealed the presence of antibodies to Cas9 proteins
in 65%–79% of individuals; and around half of all the blood samples harbored
immune cells with the potential to destroy human cells, containing one of the
Cas9 proteins (Charlesworth et al., 2018). The potential severity of any immune
reaction in patients is unknown, but it could range from making crispr nonfunctional, to dangerous inflammatory reactions.
Efforts are being made to use crispr to deactivate and render some
viruses non-infectious and/or non-pathogenic, such as hepatitis B and C viruses
and hiv (Doerflinger et al., 2017; Huang et al., 2017; Li et al., 2017; Moyo et al.,
2017; Soppe and Lebbink, 2017). Serious caution has been advised, however,
due to the risk of causing mutations that increase, rather than decrease, virulence (Wang et al., 2016). It is claimed that crispr holds the key to translating
data from rodent models of psychiatric disorders and neurobehavioral traits
to humans, including disorders associated with anxiety, mood, and substance
and impulse-control (Baud and Flint, 2017, p. 373). crispr’s potential for cancer biology has been expounded, as it can recreate potential cancer-causing
mutations identified in human tumors, in both cell lines and GM animals
(Guernet and Grumolato, 2017). Some GM animals are used in attempts to produce medically important proteins, for example, in cows’ milk, which can be
generated in high volumes and purified from the milk for clinical use. Examples
include treatments for some blood disorders, osteoporosis, and emphysema
(Moura, Melo and de Figueiredo Freitas, 2011). GM animals are central to
efforts to use animals as a source of organs for human transplantation (xenotransplantation), targeting biological pathways involved in immune rejection
of transplanted organs.
3.2
Farm/Food Animals
A major application of GM technology (GM also can mean genetic modification
or manipulation, as well as genetically modified) is the engineering of animals
used for food (Ledford, 2015). Examples include, chickens producing only female offspring for egg-laying, cows producing only male offspring for better
meat yield, pigs who can be fattened with less food, cashmere goats producing
more meat from greater muscle mass and longer hair for greater wool yield;
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and efforts to facilitate greater stocking density, such as cattle without horns
and animals with greater resistance to disease (see Frewer et al., 2013; Nuffield
Council on Bioethics, 2016). Double-muscled pigs (Cyranoski, 2015), rabbits (Lv
et al., 2016), sheep and cows (Proudfoot et al., 2015; Luo et al., 2014) have been
created for human consumption, though many died early and were unhealthy,
and birthing difficulties occurred due to their size (Cyranoski, 2015). Cows without horns can be housed more densely with lower risk of goring injuries (Loria
K, 2016; Carlson et al., 2016). While there may be welfare benefits—millions
of cattle would no longer need to be dehorned, which can be very painful—
they would be farmed more intensively and have less space to live in, further
compromising their welfare. Other efforts include cows that produce milk that
does not induce allergies in humans (Yu et al., 2011); milk with altered fatty acid
content, and milk that contains high levels of lactoferrin (Yang et al., 2008a);
cows who produce “tastier beef” because their flesh contains more fat (Guo
et al., 2017); and pigs who bleed out more efficiently at slaughter (Hai et al., 2014)
and have omega-3 fatty acids in their flesh (Lai et al., 2006). GM salmon, modified so that they grow at twice the rate of normal salmon and can be housed
in tanks on land, have been approved for human consumption in the United
States (US) (Connor, 2015). Much of this is undoubtedly the result of lobbying
by vested interests that stand to profit from these projects, who assert that, for
instance, the Earth’s growing population and shifting appetites will necessitate
considerable increases in food production that cannot be achieved by any o ther
means alone; yet, there is strong counter evidence and opinion that alternative strategies could meet that need, such as reducing food wastage; changing
consumer demand and preferences for meat, dairy, and eggs; and improving
farming and production methods by other means (High Level Panel of Experts
on Food Security and Nutrition, 2014). Despite the potential for both direct and
indirect effects on animal welfare in this area, it is a cknowledged that too little
attention has been devoted to the genetic modification of “farm animals” and
to the regulation of the practice (Nuffield Council on Bioethics, 2016).
However, the creation of GM animals commonly used for food is not limited to making them easier to manage or more profitable for their meat and
milk. Pigs are touted as being more appropriate models of human diseases
than mice, for example, for cystic fibrosis, cancer, diabetes, neurological disorders, high cholesterol, and muscular dystrophy; while a gene associated with
achondroplasia has been targeted in cattle (Carlson et al., 2012; Petersen and
Niemann, 2015).
3.3
Dogs and Monkeys
Concerns that less strict regulations in countries outside of the EU and the
US may lead to GM projects that may not be approved elsewhere appear to
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have substance. Prior to crispr, a Chinese group created transgenic dogs who
emitted red fluorescent light (Hong et al., 2009). This was far from efficient. 344
embryos transferred to 20 surrogate mother dogs, resulted in seven pregnancies and six live births. More recently, another Chinese laboratory created GM
dogs using crispr, knocking out a gene controlling muscle growth, resulting
in dogs who were “much more muscular” (Doane, 2016; Zou et al., 2015). Their
work was defended via a tenuous link to the creation of future dogs who could
model, for example, Parkinson’s disease; but only two of 60 edited embryos
were “successful.” Elsewhere in China, GM monkeys have been created with
apparently similar characteristics to autism. Eight macaques (out of “dozens”
of GM embryos) were born with a gene (MECP2) linked to autism in humans,
who showed signs such as running “obsessively in circles”, ignoring their peers,
and grunting anxiously when stared at (Cyranoski, 2016b; Liu et al., 2016; Snowdon, 2016).
Interestingly, when espousing the use of “large animals” as GM models for
human diseases, those who may otherwise stoutly defend GM mice are open to
criticizing them. For example, one recent paper, authored by scientists creating
GM livestock, noted that “the drawbacks of using rodents to model humans
are well established […] mice make poor models for reproductive physiology,
pulmonary problems, metabolic regulation, and many other fields of inquiry”
(West and Gill, 2016). Unfortunately for such advocates, as discussed in this
chapter and in works referenced in it, it appears that “larger animals”, GM or
not, remain poor models for these areas and more, and can only ever be so.
This is compounded by the same, or even greater, confounding issues of low
efficiency and a variety of limitations and complications (see section on nonhuman primates, nhps, below).
4

Suffering, Welfare, and Ethical Issues with GM Animals

Many animal researchers acknowledge that creating GM animals involves suffering at every step, from generating sufficient eggs to embryos for modification,
through to the pain and suffering experienced by many progeny (Laboratory
Animal Science Association, 2008; Robinson, Jennings and Working, 2004).
4.1
Breeding and the GM Process
Producing eggs for the embryos used in the GM process involves drug-induced
superovulation of females, whose fertilized eggs are collected post-mating,
which may involve killing the females, a common practice in rodents, or at
least surgery under general anesthesia (more “valuable” species). Approved
killing methods for rodents are, commonly, neck dislocation or carbon dioxide
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suffocation, which can both (not surprisingly) cause distress (Robinson et al.,
2004). Both superovulation and fertilized-egg collection can cause discomfort, stress, and post-operative pain (Camara, et al., 2008). After modification,
embryos are implanted into surrogate mothers in the form of pseudopregnant
females, who have been previously mated with vasectomized males (The Boyd
Group, 1999). Pre- and post-natal death of offspring may be significant. One
report showed that an average of just 29% of implanted embryos survived to
weaning, and only a quarter of these (7% of implanted embryos) (Hubrecht,
1995), or an average of 15% ( Robinson et al., 2004), may be GM. Miscarriages
may cause pain and distress, and such poor efficiency means that many donor
and recipient animals must be used to produce a relatively small number of
desired GM individuals. Genotyping of resultant offspring may involve blood
sampling or tissue biopsy. Invasive methods are still common, including tail
snipping, ear snipping/punching, or even toe amputation, all causing pain
in mice (Robinson et al., 2004). The genetic modification process has been
documented, at least in larger animals, such as sheep and cattle, as a factor
in increased gestation length, greater body weight, risk of dystocia (difficult
birth), and various perinatal anomalies and loss. In mice, there is also evidence
of increased embryonic and fetal loss (Camar et al., 2008).
4.2
Animal Lives Wasted
The persistent inefficiency of the GM process is a serious welfare issue (Boyd
Group, 1999; Camara et al., 2008; Laboratory Animal Science Association, 2008;
Robinson et al., 2004). It is difficult to quantify, as many countries do not require the reporting of GM-animal statistics (Taylor et al., 2008). In the UK, statistics indicate a high degree of wastage (around 50% of a total of more than 4
million animal procedures in 2015, involved the creation and breeding of GM
animals not used in subsequent experiments), and specific GM license applications are revealing: seven projects from 2014–2015 proposed using a total of
almost 27,000 animals ( UK Home Office, 2014).
4.3
Effects of Genetic Modification
Inserted genetic material may have adverse effects on GM embryos/animals.
Some may be unpredictable, such the aforementioned off-target effects; while
others are expected and the result of on-target effects, such as GM mice who
will develop painful cancers. Naturally, the GM process may not necessarily
adversely impact welfare; but the critical point is that, frequently, the welfare
consequences of the GM process cannot be predicted in detail, nor can they
be assessed properly. Welfare assessments are by their nature wide open to
subjectivity and opinion, and much more research needs to be done in this
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area to increase objectivity, if indeed this is possible to any significant degree
(Hawkins et al., 2011, Wells et al., 2006). Therefore, it is acknowledged that
reduced viability or impaired health may be expected (Bundesamt für Veterinärwesen, 2006); while some estimates suggest around 20% of GM animals
suffer minor discomfort, 15% severe discomfort, and 30% increases in mortality
and susceptibility to disease (Thon et al., 2002).
Indications may include, for instance, developmental abnormalities, such as
cleft palate; perinatal and post-weaning mortality; skeletal abnormalities, including malformed limbs; discharge from eyes and ears; diarrhea; poor posture,
gait, and ataxia; stereotypies, such as lack of alertness, poor or over-grooming,
circling in cage; absence of teeth; poor mothering; poor thermoregulatory
ability; enhanced growth of tumors and development of metastases, often at
atypical sites; increased aggression; seizures; a range of diseases, including diabetes, osteoporosis, degenerative joint disease, inflammatory bowel disease,
and ulcerative colitis; sensory and locomotor abnormalities affecting sight,
hearing, smell, balance, and social interactions; and increased incidence of
infectious disease (Dennis, 2002). GM mice databases reveal progressive hearing loss and deafness; development of diabetes; impaired movement and
coordination, including tremors and involuntary movements, difficulty in initiating movement, abnormal posture, and paralysis; susceptibility to infectious
disease; colitis; progressive muscle weakness; kidney inflammation; premature
death; intestinal obstruction; respiratory distress; hyperactivity; heart failure;
internal bleeding/brain hemorrhage; self-harm; seizures; vision problems and
blindness; and many more (e.g., Mouse encode Consortium, mouseencode.
org; Mouse Genome Informatics, mgi, database, informatics.jax.org). The
Mouse Genome Informatics (mgi) database lists mice under the following categories (among others): with abnormality of blood, connective tissue, head or
neck, limbs, metabolism, prenatal development/birth, cardiovascular system,
digestive system, ear, eye, genitourinary system, immune system, musculature,
nervous system, respiratory system, skeletal system, and cancers. The scale
of this must also be mentioned: as of July 2017, the mgi database cites 51,000
mutant alleles in mice, with more than 3,100 human disease models; the International Mouse Strain Resource (findmice.org) lists around 40,000 strains as
available worldwide; the International Knockout Mouse Consortium has generated around 5,000 mutant mouse lines (Rosen, Schick and Wurst, 2015); and
the International Mouse Phenotyping Consortium intends to generate 20,000
knockout mouse strains (mousephenotype.org) (Koscielny et al., 2014).
Off-target modifications may induce mutations that abrogate gene function
and/or cause rearrangements of the genome with other, subsequent mutational effects on other genes. In assessing effects of GM on welfare, it has been
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cautioned that setting a “normal” baseline must be done carefully. For example,
it is normal for GM mice engineered to have vestibular abnormalities to spend
much time circling in their cages. This may be normal for these mice but should
not be considered normal from a welfare perspective (Hawkins et al., 2011).
4.4
Increasing Numbers of GM Animals
Many of these welfare issues are not exclusive to crispr and exist for other
GM methods. It has been argued that crispr should mitigate many of these,
with its simplicity and greater efficiency, and so should be welcomed by animal advocates. To some extent this may be true, in time. However, the corollary gives great cause for concern, that this simplicity and efficiency will also
“not only increase in the range and diversity of transgenic rodent strains but
will greatly expedite transgenesis in other species, including non-human primates” (Combes and Balls, 2014, p. 137). In this regard, crispr is described as a
mixed blessing (Hendriksen and Spielmann, 2014); and animal ethicist Bernard
Rollin (2015) accepts that easier GM techniques would undoubtedly lead to an
increase in the number of animals used “as more researchers engage in hitherto impossible animal research”. It has been said that crispr will revolutionize
mouse genetics by reducing the time it takes to create a new GM model from
years to months, or even weeks (Fellmann et al., 2017). In other words, for any
reduction and refinement in any specific GM experiment due to crispr, a
greater overall number of GM experiments will offset this, compounded by
more experiments on a wider range of species, including dogs and monkeys.
This is not mere speculation. Aside from being logical, and in addition to
multi-stakeholder enthusiasm for crispr and associated market projections,
it is clear from current scientific literature. Many speculative claims for crispr
reflect an excitement that, in part, is responsible for the great expansion of
interest in the technology and in the creation of greater numbers of GM animals in academe, biotech firms, and large pharmaceutical companies (Cornu et al., 2017). For example, it is estimated that by 2021, the GM market will
be worth US$6.28 billion (MarketsandMarkets, 2017). It has, therefore, been
strongly suggested that the welfare consequences of genetic modification
for all species should be monitored and explored in greater detail. Perhaps,
at least, an in-depth, systematic, critical assessment of the rationale for using
GM animals in human disease research is warranted; and projects involving GM
animals should be approved only in “extremely exceptional circumstances”
(Combes and Balls, 2014, p. 143; see also Mepham et al., 1998). Unfortunately,
interest in crispr is, at least for now, manifesting in substantial animal use.
The scientific literature shows (as of June 2017) more than 6,000 publications,
up from fewer than 4,000 just a year earlier (June 2016), and just over 600, 18
months prior to that (Nuffield Council on Bioethics, 2016).
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4.5
Increasing Numbers of Non-Human Primates (nhps)
There is, therefore, great, well-founded, concern that this interest will translate into greater creation of GM monkeys (e.g. Liu et al., 2014; Niu et al., 2014).
Examples of GM primates have already been mentioned (Cyranoski, 2016b;
Liu et al., 2016; Sasaki et al., 2009; Snowdon, 2016), following on from, for example, the first reports of GM macaques in 2001 (Chan et al., 2001), and a GM
nhp model of Huntington’s disease (Yang et al., 2008b). Some scientists are
calling for further increases. To illustrate, a 2016 paper lamenting the failure
of animal research (including nhps) to translate to a greater understanding
of human brain disorders and their treatment—largely due to “lack of good
animal models” and “profound differences in brain and behavior” between
humans and nonhumans—puts its weight firmly, and speculatively, behind
GM nhps as a solution (Jennings et al., 2016, p. 1123). Associated suffering is
justified by a brief assurance of veterinary oversight and intervention. While
accepting that greatly expanding GM nhp creation and use is challenging in
many ways, the authors propose a “concerted international effort” to overcome those c hallenges (Jennings et al., 2016, p. 1128), involving automated
methods for training the animals to comply with the researchers’ demands,
chronic use of intracranial electrodes, and the creation of an international
network of nhp centers and vendors. Overall, a horrifying vision for animal
advocates, and scientifically unjustifiable in any case. My colleagues (at Cruelty Free International, and indeed in the wider animal protection community) and I agree that there is a “dismal record of drug development for neurological and psychiatric disease over the past several decades” and that “basic
neuroscience has failed to deliver substantially new and effective treatments
for many brain disorders, partially because the animal modelling was done in
species whose brains are too dissimilar from those of humans” (Jennings et al.,
2016, p. 1128). However, we believe that modifying a gene or two in these poor
models cannot overcome these problems or lead to research that is any less
unethical.
GM nhp creation also suffers from the same problems as GM rodents, even
16 years after the first GM monkey was born (Chan et al., 2001); and so, widespread, efficient, successful, generation of human-relevant GM nhps may be
a forlorn hope anyway (Luo, Li and Su, 2016). Surprisingly little analysis had
been done of this until recently. Though crispr has intensified the generation of GM nhps, targeting efficiency in nhps is still low, “successful gene
replacement in monkeys via the cripsr/Cas9 system remains elusive, possibly
due to the complexity of dna repair mechanisms in monkeys” (Luo et al., 2016,
p. 242), and “there are still some technical limitations for its use in non-human
primates” (Guo and Li, 2015). A 2017 report acknowledges “the incidence of
undesirable outcomes has not been well characterized”. It states: “Most studies
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experienced very high rates of developmental arrest (can be 90%) … [which]
further raises concerns about non-genetic technical factors contributing to low
rates of survival” (Midic et al., 2017, p. 4). While this study claimed that the creation of GM nhp embryos could be 80%-100% efficient, this does not reflect on
the efficiency of generating otherwise healthy adult nhps with desired g enetic
modifications, and without confounding and/or welfare-compromising offtarget effects. The same study suggests that mosaicism (where offspring contain cells with different genes/gene variants) is “substantial” and is “a significant
limitation,” and accepts that the creation of GM nhps to date was “achieved at
a very high cost in terms of the number of embryos used,” due in part to the
“very limited (around 10%) viability of transferred embryos to term” (Midic
et al., 2017, p. 15; see also Chen et al., 2015). They conclude that inefficiency
remains “a major barrier to practical use of the technology in nonhuman primates” (Midic et al., 2017, p. 15); and that the entire process is financially costly.
To illustrate, one effort to generate GM nhps via crispr, with two disrupted
genes, reported that of 22 embryos injected, 15 (68%) survived culturing, while
on average just over one third of these contained the desired modification (Niu
et al., 2014). Subsequent attempts to generate GM monkeys involved injecting
186 zygotes; 83 (45%) were transferred to 29 surrogate females, establishing 10
pregnancies (34%), with 19 fetuses. The paper was published while 8/10 were
still pregnant; one miscarried, and the other gave birth to twins, whose genes
had been successfully modified, though mosaicism was confirmed, and phenotype had yet to be established.
This is all of particular concern because experimentation on monkeys is
opposed much more strongly than on rodents (Aldhous, Coghlan and Copley,
1999; Animal Aid, 2003; Clemence and Leaman, 2016; Leaman, Latter and Clemence, 2014; tns Opinion & Social, 2010); and genetic manipulation of “higher”
organisms evokes stronger concern from the public (Olsson and Sandøe, 2010).
The European Science Foundation’s European Medical Research Councils
group has stated: “Whether a species needs special protection should not be
based solely on its phylogenetic relations to humans, but on its potential for
suffering. nhps are distinguished by the very advanced nature of their social,
cognitive, sensory, and motor functions” (Olsson and Sandøe, 2010, p. 185).
5

Failure of GM Animals and Consequences for Animals
and Humans

Much has been published on the failures of GM animals to live up to their promise, though criticisms of GM animals are frequently understated, couched, for
example, as follows: they do not always accurately reflect the human condition;
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they have limitations; data must be interpreted carefully; and so on. Examples of
failures are numerous, and include Parkinson’s and Alzheimer’s diseases, cystic
fibrosis, type i and type ii diabetes, amyotrophic lateral sclerosis, Kallmann’s
syndrome, Lesch-Nyhan’s disease, ataxia-telangiectasia, sickle-cell anemia,
deafness, visual defects, Duchenne muscular dystrophy, Down’s syndrome, and
schizophrenia (Pratt et al., 2012), multiple sclerosis, cancers, and immunotherapy (Ruggeri, Camp and Miknyoczki, 2014), migraine (Storer, Supronsinchai and
Srikiatkhachorn, 2015), pain (Craig, 2009; Mogil, 2009), and depression (Benatar,
2007; Bhogal and Combes, 2006; Davis, 2008; McGonigle, 2014; Norgren, 2004;
Webb, 2014). It is, however, increasingly acknowledged in scientific literature
that GM animals are failing to deliver by any measure. For example, GM-based
“advances” in animal models of many human conditions and diseases “have not
made a significant increase in improving the rate of success in Phase ii proofof-concept studies”; in other words, GM animals are not leading to more, better, safer drugs and indeed may well be hindering the process because they are
misleading (Hunter, 2011, p. 1). GM-animal models of cns disorders “have been
increasingly criticized in the wake of numerous clinical trial failures of nces
[new chemical entities, or new drugs] with promising preclinical profiles”
(McGonigle, 2014, p. 140), and they are “criticized for their limited ability to predict nce efficacy, safety and toxicity in humans” (McGonigle and Ruggeri, 2014,
p. 162). Clinical trials of gene therapy for heart failure and muscular dystrophy,
despite early promise, have failed (Hulot, Ishikawa and Hajjar, 2016; Lu, Cirak
and Partridge, 2014). And despite many years of substantial effort in the field of
xenotransplantation, and early promises that successful transplantation of pig
organs into humans would be realized by 2010 and worth multiple billions of
dollars, the most recent developments claim no more success than a GM pig’s
heart surviving in a monkey for 51 days (Johnston, 2016), or in the abdomen of
a baboon in addition to its own heart for just over two years, until they were rejected when immunosuppressive drugs were reduced (Mohiuddin et al., 2016;
Servick, 2016).
Attempts to overcome other significant hurdles continue, such as porcine
endogenous retrovirus (perv) in pigs, which can cause problems in humans
(Yang et al., 2015); but there remain persistent issues, such as immune rejection; transmission of infectious agents; ethical problems and boundaries; aspects of physiological compatibility, such as discrepancies in coagulation and
metabolism; and others (Niemann and Petersen, 2016). Some argue xenotransplantation is not needed anyway. Prevention of much of the need for transplantation via education and health measures, improved donor recruitment,
and mandated choice and presumed consent/opt-out schemes, and others
have all had positive outcomes in countries that have adopted them (Perera,
Mirza and Elias, 2009).
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With specific regard to crispr, there is also evidence to question claims
that it can improve matters and facilitate more accurate and human-relevant
models. An approach utilizing Morpholino oligomers (MOs) has been widely
used to investigate gene function in zebrafish, but attempts to confirm findings
for specific genes using crispr have been extremely confounding. One study
reported that most genes altered by crispr failed to show similar phenotypes
to experiments that altered the expression of the same genes using MOs, which
the authors attributed to differing off-target effects from the techniques (Kok
et al., 2015). This is mirrored in a study comparing selected genes affected by
crispr and a gene-silencing method using short hairpin rnas (shRNA). These
methods were found to have similar precision; but each affected “numerous”
genes that the other did not, attributable to differences in off-target effects
and in the timing of each (Morgens et al., 2016). To illustrate, a recent study
revealed that previous research implicating the melk gene in certain breast
cancers—with sufficient certainty to prompt pharmaceutical companies to
develop drugs to block its activity, some of which proceeded to human trials—
may be unreliable. When the melk gene was knocked out using crispr, cancer cells multiplied unexpectedly, and drugs that targeted melk still stopped
their growth. This casts doubt on the role of melk, and suggests that drugs
targeting melk work through other targets (Lin et al., 2017).
It is often, perfectly reasonably, asked if such failures may be balanced
against any successes of GM technology. This is not the purpose of this chapter,
which is to highlight issues and caveats with it and to supply a more critical argument against its use. However, any claimed successes, in which it is implied
that the use of GM animals has resulted directly in human benefit, must fulfil
the following criteria: data from the GM animal experiments must be reliably
and sufficiently translatable to humans; these experiments must have provided data that could not have been obtained in any other way; and these data
must have been critical to the ultimate human benefit. Even if, for the sake
of argument, one assumes such examples exist, they still must be balanced
against an objective appraisal of the scale of failure and against the ethical cost
of the animal research involved.
6

Reasons for These Failures

Reasons proffered for this scale of failure include the evolutionary distance
of humans and non-human species—approximately 65 million years for
humans and mice—and all consequent differences in gene complement
and expression, the artificiality of induced diseases, and the inbred strains of
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a nimals often used (Davis, 2008). See also two comprehensive reviews of genetic differences between humans and chimpanzees (chimpanzees were used
in science in the US until very recently), and humans and monkeys (Bailey,
2011, 2014). Even with current knowledge, limited because such differences
have barely been sought, they are much more widespread and extensive, with
significant and varied consequences, than is generally accepted. There are significant differences in gene complement, but more importantly, in gene expression, i.e., how these genes are regulated and used in the organism, even
where they are common to both species. These differences affect all biological systems, but notably the immune system, the brain, and the liver, which
are fundamental to much biomedical research involving infectious agents and
disease, autoimmunity and inflammation, neuroscience and neurological diseases, and drug safety and efficacy. It is these differences that underpin the
failures of animal research, whether GM or not, discussed in this chapter.
Of course, genetic differences between humans and nhps, as appreciable as
they are, are not as great as those between humans and mice, who constitute
the greatest numbers of GM animals used in science. These differences have
not yet been elucidated in detail, but illustrative examples exist. For example,
a systematic comparison of the mouse and human genomes has revealed that
there is significant conservation of functional genes themselves, with around
half of human dna aligning with mouse dna when directly compared; however, this of course means that half of it does not. Furthermore, there are,
crucially, “wide ranging differences” in many biological pathways and cellular
functions, which show “considerable divergence”; and the areas of the genome
that control and regulate gene expression are substantially different (Yue et al.,
2014, p. 355). Indeed, many disease-causing mutations are in these areas, rather
than in the main protein-coding parts of genes themselves. Because these differ, particularly between species, this can make direct animal-human comparisons not just difficult and uncertain, but impossible (Bassett, 2017). Even when
humans and mice share genes, they can show functional differences: a study
of 120 genes that are known to be essential for life in humans, revealed that
almost one quarter of them are not essential for life in mice (Liao and Zhang,
2008).
The problem with a shift toward GM nhps, in the hope of greater human
relevance, is that there is little or no evidence to support this, even if nhps
are evolutionarily less removed from humans. While it is true to some extent
that nhps “are genetically and phenotypically closer to humans, particularly in
regards to anatomy, physiology, cognition, and gene sequences,” it does not follow that they are, therefore, “optimal animal models for genetic modification
in an attempt to understand human biology” (Luo et al., 2016, p. 241,). This is
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only valid if this results in better translation of nhp data to human benefit.
I argue that it does not, because there is simply no evidence that it does.
One positive for animal advocates, while reading myriad literature on the
burgeoning creation of GM animals, is that there now appears to be more honesty about, and criticism of, the human relevance of non-GM animals. A paper
in the prestigious journal, Nature, cited the wholesale failure of new drugs to
treat amyotrophic lateral sclerosis (als), a fatal neurodegenerative condition,
known as Lou Gehrig’s or motor neuron disease, despite success in animal
models of the disease, as well as similar failures in Alzheimer’s and cancer,
among others (Perrin, 2014). Contemporary criticisms of animal research are
welcome because they have been scant from the scientific community for
decades. Ironically, many criticisms are akin to those made by animal a dvocates
for many years, which were roundly dismissed. What seems commonplace,
however, is the unfortunate and groundless assertion that genetic modification will instantly make failed animal models more human relevant. Evidence
suggests otherwise.
7

Alternatives to GM Animals—The Way Forward

If not GM animals, what is the way forward to understand the myriad human
diseases and realize treatments and cures for them? Modeling human diseases
in cultured human stem cells continues to take great leaps forward and will
surely become a mainstay of biomedical research that “could rival the use of GM
mice in popularity” (Musunuru, 2013. p. 901). Somatic cells (cells from various
parts of the body, other than reproductive cells, such as sperm and eggs, often
skin biopsies or blood) can now be reprogrammed to act as cells in e arly-stage
embryos, able to develop into many different specialized cell types (Takahashi
et al., 2007; Takahashi and Yamanaka, 2006). Immense collaborative efforts
now collect and characterize cells from many thousands of healthy and diseased human individuals, many with a wide variety of disorders, and use these
induced pluripotent stem cells (iPSCs) for comparative studies of normal and
diseased states and screening of potential new drugs and therapies, including
the study of polygenic disorders (diseases involving many genes). The development of 3D cell cultures and organoids (cultured miniature o rgans) is likely to
increase the in vivo relevance of this approach, with more faithful and accurate
cellular phenotypes (see Bassett, 2017). Organoids successfully developed to
date include, brain, intestine, stomach, salivary gland, esophagus, pancreas,
liver, breast, lung, prostate, fallopian tube, and taste bud (see Driehuis and Clevers, 2017). Genetically modifying such iPSCs and organoids adds another level
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of sophistication, allowing potential causative gene variants or mutations to
be introduced for further study, for example, to validate mutations implicated
in causing disease and/or for attempts at repairing faulty genes.
Cell lines for these studies have been generated for many diseases, including Parkinson’s, Alzheimer’s, Huntington disease, various immune disorders,
cardiomyopathy, and cystic fibrosis (Brookhouser et al., 2017; Nishizaki and
Boyle, 2017); and efforts at repairing mutated genes in these systems have been
promising in, for example, cystic fibrosis and cancers (Driehuis and Clevers,
2017), and retinopathies (Quinn, Pellissier and Wijnholds, 2017). The combined
use of genome editing and iPSCs offers the ability to study genes and mutations in different human genetic backgrounds, which is especially important
for the study of complex neurological disorders. This approach has been found
to “closely mimic cellular and molecular features of human diseases.” (Heidenreich and Zhang, 2016, p. 42) crispr has also aided the derivation of retinal
ganglion cells from human pscs, to model human optic nerves in vitro for research into optic nerve disease (Sluch et al., 2015). The very high efficiency of
these types of methods, coupled with the relative ease and speed of the process, and the ability to use and screen many thousands of cell lines in parallel,
means that this type of approach to understanding the basis of human disease
and to identify therapeutic targets and therapies must be the way forward, in
place of creating GM animals (see Bassett, 2017). While the aforementioned
off-target effects are a confounding factor, they matter much less in cell lines
than in animals, because there are no ethical problems; and cell lines can be
produced, screened, and evaluated much more quickly and efficiently.
8

Summary

Acknowledgement of the suffering of GM animals has, at least, led to some
efforts to reduce it, even if these have not, to date, led to overall reductions
in their creation and experimental use. Guidelines for the use and care of
GM animals, for example, are welcome. Working Groups and international
guidelines have been commissioned to this end (Wells et al., 2006) and are at
least intended to reduce the number of GM animals created and improve the
welfare of those who are. These include requiring attempts to establish the
appropriateness of generating any GM animal, both scientifically and with regard to welfare, involving a harm-benefit analysis; and a stipulation that new
animals should not be generated if similar suitable lines already exist, and/
or if an in vitro method could be used instead (Rose et al., 2013). These guidelines need to be widely adopted and enforced, but also greater training of staff
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responsible for care, for example, can only make little or no impact on the
welfare of the many millions of GM animals that will end up in laboratories
worldwide. Ultimately, guidelines or not, GM animals suffer greatly, in their
tens of millions each year. Controversially, one developing effort to address
this, already attempted in rats, is to make GM animals who—while still able
to sense pain—are incapable of finding its sensation unpleasant (Shriver,
2015).
Yet, the public demands that such pain and suffering is avoided or controlled at all costs for them to accept animal research, GM or not (Aldhous et
al., 1999; Animal Aid, 2003; Clemence and Leaman, 2016; Leaman, Latter and
Clemence, 2014; tns Opinion & Social, 2010). Generally, people are much less
accepting of GM animals than they are of GM plants and GM food compared to
other GM applications. While perceptions of risk are offset by perceived benefits (Frewer et al., 2013), there is evidence that the EU populace has in the past
“morally rejected genetic engineering of animal models of disease,” which is
incompatible with the direction in which worldwide attitudes and laws are
moving (Rollin, 2015, p. 114). Utilitarians may argue that human benefit outweighs this pain and suffering. But, given the degree of animal pain and suffering involved, both qualitatively and quantitatively, the relatively small number
of people who stand to benefit from any breakthrough for many of the rare
genetic diseases that may be modelled, and how unlikely GM animals are to
contribute to breakthroughs given the burgeoning evidence against them, how
can this be so? This is especially true if any harm-benefit analyses applied to
license applications for animal experimentation are conducted properly and
more stringently, as there are calls for authorities to ensure (Würbel, 2017).
Even if one presumes sufficient human benefit from research on GM animals, which I (and many others) believe is not supported by evidence, there
remain serious scientific issues with, and ethical/welfare consequences of,
genetic engineering. Despite the best currently available method of crispr
having “swept through labs around the world” recently, and being touted as a
“revolution” (Ledford, 2015, pp. 20–21), it is still considered as being “in an immature phase of development” and “not yet ready for therapeutic applications
in humans given the low editing efficiency” (<15%) (D’Agostino and D’Aniello,
2017, p. 4). This is also due to the persistent concerns over the stubborn nature of off-target mutations, occurring at frequencies of up to 60%, more than
the best efficiency of intended on-target modifications. Even if off-target issues can be greatly reduced, which is questionable, they are still of concern
clinically, as “Even low-frequency events could potentially be dangerous if they
accelerate a cell’s growth and lead to cancer” (Ledford, 2015, p. 22).

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

Genetic Modification of Animals

465

The efficiency of crispr translation to clinical applications is also of concern. Scientists using crispr to correct a disease-causing mutation in mice in
a gene therapy experiment had to “pump large volumes of liquid into blood
vessels—something that is not generally considered feasible in people” and
this corrected the mutation in just 0.4% of the mice’s cells, not enough to be
effective (Ledford, 2015, p. 21). Delivery methods for introducing the crispr
apparatus to cells also need optimizing (Peng, Lin and Li, 2016). Carrier dna
used to introduce crispr to target cells may become integrated into the host
genome, causing off-target effects, which may disrupt the genome editing process and can cause toxicity. Alternative methods may be stressful to cells, altering gene expression, or leading to high off-target effects (Peng, Lin and Li, 2016).
Despite these concerns, the first clinical trial involving crispr commenced in
October 2016, when knockout immune cells were injected into patients as potential therapy for metastatic non-small cell lung cancer (Cyranoski, 2016a);
and now crispr is already part of ten clinical trials just a few years after it
became mainstream (clinicaltrials.gov). It remains to be seen if they will be
successful, and if so, how much they rely on GM animal research.
9

Conclusion

GM animal creation and experimentation takes the lives of tens of millions of
animals each year and involves considerable suffering at every stage. Its scientific value is extremely poor, to the point of it being unnecessary, misleading and therefore harmful not just to the animals involved, but also to people,
who depend on good science to understand, treat, and cure the diseases that
affect us all. The continued insistence of many who practice and fund GM research that animals must be used is without foundation. Non-human animals
have always been bad models for humans due to species differences, and no
amount of genetic modification can remedy that, even if it were perfect. GM
processes are far from perfect, however. Even the best is extremely inefficient,
and confounded not just by those species differences, but also by off-target
effects of the GM process. These issues are at the root of animal research failing to be relevant and reliable for humans, of animals being poor models for
disease right across the spectrum, and of the failure of 90%-95% of new drugs
in human trials that were successful in animal tests (Bailey, Thew and Balls,
2013; Bailey, Thew and Balls, 2014; Bailey, Thew and Balls, 2015). Moving away
from animal research, including the use of GM animals, has never been more
imperative.
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1

Introduction
This is a uniquely human disease, with impairments in abstract reasoning and judgment. We’ve cured mice engineered with this disease over
500 times. The mouse models don’t translate into humans. We know for a
fact that mice don’t write books.
howard fillit, Chief Science Officer, Alzheimer’s Drug Discovery Foundation,
in Shakoor et al., 2017

Perhaps the most impactful and foreboding development in chronic diseases in recent decades has been the increasing prevalence and awareness of
dementia. The various dementias, especially Alzheimer disease (AD), have derailed and ended the lives of tens of millions in America and worldwide. It is
a truism that AD patients die twice. First the mind dies, and only later does
the body. AD uniquely and unremittingly affects not only patients, but their
families, caregivers, and communities. In recent years, AD may have displaced
cancer as the most feared disease among Americans. As with other diseases
that have no meaningful methods for prevention and treatment, research targeting AD has primarily focused on preclinical approaches, predominantly using animals. Nonetheless, decades of animal research have failed to translate
into significant advances in the prevention or treatment of AD. In view of this
failure, a different and human-relevant approach is critically needed.
© john j. pippin et al., ���9 | doi:10.1163/9789004391192_021
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This chapter addresses the epidemiology and current understanding of AD
as a scientific and societal challenge, reviews the uses and results of animal
research in basic science and drug development, and discusses risk factors and
funding. Important follow-up topics, including current and in-development,
human-relevant approaches for replacement of the failed animal research paradigm, deserve comparable treatment and hence are not addressed here. The
reader is referred to the list of recommended readings at the end of the chapter
for further discussion of these topics.
The ethics of continued use of the animal-based approach in AD is troublesome in at least two respects. First, regardless of where one stands on the ethical spectrum of animal use for medical research, certainly the inhumane and
lethal use of animals for demonstrably faulty research is unethical. Second, the
ethical responsibility to AD patients, their families, and the larger community
demands reliable and useful results, which in turn demand a revised research
approach, emphasizing human-relevant methods.
2

Epidemiology and Current Status

Dementia can be defined as a disorder of mental capabilities caused by brain
disease or injury and marked by memory disorders, impaired thought and
reasoning, diminished judgment, social withdrawal, and altered personality.
Except for several reversible causes, dementia is a chronic and unremitting
disease with a fatal outcome. AD is the most common form of dementia, accounting for 60%–80% of all dementia diagnoses in the United States (US)
(Alzheimer’s Association, 2017). The next four most prevalent categories of
dementia (vascular dementia, dementia with Lewy bodies, frontotemporal
dementia, and mixed dementia) account for all but a small percentage of the
other diagnoses. Vascular and mixed dementia overlap considerably with AD;
nearly all cases of vascular dementia display characteristics of AD (Thal, Grinberg and Attems, 2012), and prevalence figures do not include the AD precursor, mild cognitive impairment (mci), making the percentage of dementia and
incipient dementia attributable to AD even higher (Lopez et al., 2012; Mitchell
and Shiri-Feshki, 2009; Roberts et al., 2014a; Ward et al., 2013). AD prevalence
increases with age and varies based on diagnostic criteria and death records.
It can only be definitively diagnosed by postmortem examination of the brain,
though recent advances in neuroimaging and cerebrospinal fluid analysis offer strong clinical evidence and presumptive diagnosis. AD is almost certainly
underdiagnosed and underreported, both among persons who die of AD and
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those who die with AD (James et al., 2014; Taylor et al., 2017; Wachterman, Kiely
and Mitchell, 2008; Weuve et al., 2014).
A reasonable estimate of AD prevalence in the US is 3% of persons aged
65–74 years, 17% of persons aged 75–84 years, and 32% of persons aged 85
years and older (Hebert et al., 2013), though some sources estimate the risk for
persons 85 years and older as nearly 50% (Alzheimer’s Association, 2012; Chai,
2007; Gatz et al., 2006). About 5.5 million Americans (two-thirds of whom are
women) currently have AD, and this number is expected to increase to nearly
14 million by 2050 (Hebert et al., 2013). The number of people living with dementia worldwide is estimated at 47.5 million and is projected to increase to
75.6 million by 2030 and more than triple by 2050 (World Health Organization,
2015). The estimated global cost of AD in 2015 was US$818 billion (McDade and
Bateman, 2017), which according to the International Monetary Fund (2017)
and the World Bank (2017), would rank as the 18th highest national gross domestic product worldwide.
Conversely, evidence has emerged in recent years suggesting that the incidence and prevalence of AD and other less common dementias have been
decreasing in some populations, perhaps for more than three decades (Langa
et al., 2017; Satizabal et al., 2016). Improved risk factor management has been
suggested as mitigating AD incidence and prevalence. However, a recent report from the US Centers for Disease Control and Prevention, using state- and
county-level death certificate data from the National Vital Statistics System
for the period 1999–2014, demonstrates that the AD death rate increased by
54% between 1999 and 2014 (Taylor et al., 2017). Between 2000–2014, the annualized number of deaths from AD in the US increased by a remarkable 89%
(Alzheimer’s Association, 2017); while deaths from heart disease, stroke, and
hiv decreased by 14%, 21%, and 54%, respectively (Shakoor et al., 2017). The
reported increases in AD deaths and death rate are likely partly attributable to
more careful reporting of the disease.
AD is the sixth leading cause of death in the US, the fifth leading cause of
death for persons 65 years old and older, and among the leading causes of disability and chronic poor health. Among the ten most common causes of death,
AD is the only one with no effective approach for prevention, slowing disease
progression, or cure. AD ranked 25th among diseases in the US, in terms of
disability-adjusted life-years lost in 1990 and 12th in 2010, the largest change
among the 30 leading diseases (US Burden of Disease Collaborators, 2013). It
is not surprising that the public’s fear of AD is escalating. In 2012, a Marist poll
of 1,247 US adults found that AD was the most feared disease, chosen by 44%
of participants compared to 33% for cancer, the second most feared disease
(Help for Alzheimer’s Families, 2012).
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3

Animal Basic Science Research and Correlations

Most basic science research of AD has used animals, predominantly mice
(transgenic, inbred, and wild-type), but also rats and, to a lesser degree, other
species, such as rabbits, dogs, and non-human primates. Numerous genetic
mutations have been suggested to contribute to the pathological changes in
the brains of AD patients, resulting in the selective breeding and research utilization of many transgenic strains of mice and rats expressing those mutations
(Cavanaugh, Pippin and Barnard, 2014; Do Carmo and Cuello, 2013; Jackson
Laboratory, 2017; Webster et al., 2014). Because gene-disease links have been
associated predominantly with autosomal dominant, early-onset familial
AD (accounting for fewer than 5% of cases), transgenic animal models have
been based on early-onset disease; and the resultant data have been extrapolated to relate to the much more common, late-onset sporadic AD. Researchers thus seek to recapitulate the genetic and pathological elements of human
AD, thereby deriving mechanistic and therapeutic knowledge that is hoped to
translate to the human condition.
The business of breeding transgenic animal strains for AD research has
flourished, and there are several commercial sources for these animals (Alzforum, 2017; Charles River, 2017; Jackson Laboratory, 2017; Taconic Biosciences,
2017). Extensive lists of animal models for AD basic science research and drug
development have been published, including information on specific genetic
configurations and how these animals have been used (Cavanaugh, Pippin and
Barnard, 2014; Kumar et al., 2016; Neha et al., 2014; Puzzo et al., 2014).
Because postmortem studies have identified specific brain pathologies
among AD patients, most notably extracellular beta-amyloid (Aß) plaques
and intracellular neurofibrillary tangles (nft), the great majority of basic science research has used genetically modified animals to produce similar brain
pathologies. Aß plaques have been associated with localized inflammation,
contributing to the neuronal and synaptic network damage believed to be
related to AD symptoms and disease progression (Eikelenboom et al., 1989;
Eikelenboom and Veerhuis, 1996; Rosenberg, 2005; Veerhuis, 2011). The ability
to produce Aß plaques and nft in animal models has been available for more
than three decades (Glenner and Wong, 1984; Kosik, Joachim and Selkoe, 1986;
Wood et al., 1986). Aß plaques are also formed, then often broken down and removed in healthy human brains; but they persist and accumulate in AD brains.
Further complicating the relationship between Aß plaques and AD, studies
have shown that 14%–21% of clinically diagnosed patients have zero or minimal brain Aß plaques on postmortem examination (Beach et al., 2012; Beekly
et al., 2007; Serrano-Pozo et al., 2014).
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Tau proteins serve an essential role in the structure and function of microtubules that regulate intracellular transport of important nutrients. nft consist
of hyperphosphorylated tau proteins, resulting in characteristic fibrillar structures and microtubule dysfunction, contributing to neuronal destruction as
well as disruption of axonal growth and plasticity (Kosik, Joachim and Selkoe,
1986; Wood et al., 1986). Both extracellular Aß and intracellular nft are believed to extend damage to the brain’s connecting network of dendrites and
axons, thereby disrupting intercellular communication and contributing to
loss of neurons and neuronal networks. The postulated causative role for Aß
and nft in clinical AD is further confounded by findings that both pathologies
have been identified in the brains of patients with frontotemporal dementia,
Parkinson disease, Huntington disease, Down syndrome, and amyotrophic
lateral sclerosis, as well as in normal brains (Cavanaugh, Pippin and Barnard,
2014; Masters et al., 1985; Ross and Poirier, 2004).
Mutations in genes encoding amyloid precursor protein (app), as well as
the gamma secretase catalytic proteins presenilin 1 (psen1) and presenilin 2
(psen2), have also been linked to familial AD and have been employed in the
study of the disease in animals (Borchelt, et al., 1997; Chartier-Harlin et al., 1991;
Goate et al., 1991; Levy-Lehad et al., 1995; Mullan et al., 1992). Inheritance of the
apolipoprotein E type 4 allele (ApoE4) has been linked to an increased risk for
late-onset AD, though the gene-disease link is weakened by the fact that the
ApoE4 allele is neither necessary nor sufficient to predict AD (Corder et al., 1993;
Rossor et al., 1996; Sadigh-Eteghad et al., 2012; Strittmatter et al., 1993). Numerous
transgenic or double-transgenic animal models have induced and accelerated
the development of Aß plaques and have produced associated brain inflammation with cognitive and behavioral pathologies. These models have not produced nft, but nft have been produced in conjunction with cognitive deficits
by animal models expressing mutated tau protein. A triple transgenic mouse
model expressing mutated human Aß precursor protein, psen1, and tau protein
was developed to generate both Aß plaques and nft; this model also produced
associated gliosis, synaptic pathology, and impaired memory (Oddo et al., 2003).
The senescence-accelerated mouse prone 8 (samp8) strain with a mean
lifespan of 9.7 months is considered by researchers to be more suitable to
investigate late-onset AD (Pallàs, 2012). samp8 mice exhibit dendritic spine
loss, spongiosis, gliosis, and forebrain cholinergic deficits, while developing Aβ deposits and aberrant hyperphosphorylated tau-like nfts (Cheng,
Zhou and Zhang, 2014). Despite extensive characterization of samp and the
samp8-app/psen1 mouse model (i.e., double transgenic for amyloid precursor protein and psen1 in the senescence-accelerated background of
samp8) (Lok et al., 2013; Porquet et al., 2015), the genes responsible for senescence and the observed pathological traits are largely unknown. Moreover,
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samp8-app/ps1 mice exhibit significant differences in Aβ plaque formation
and cognitive abnormalities when compared with human AD (Porquet et al.,
2015).
Further information, regarding the specific animal models, their phenotypic results, and their contributions to the knowledge base for animal surrogates
of human AD and some important biological and outcome differences, is available (e.g., Cavanaugh, Pippin and Barnard, 2014; Esquerda-Canals et al., 2017;
Geerts, 2009; Kumar et al., 2016).
Many of the animal experiments have been successful in determining the
pathogenesis and progression of simulated AD-like disorders at the molecular,
cellular, and behavioral levels for the transgenic species studied. Some topics,
such as steps in amyloid and tau pathways, have prospered from transgenic
animal studies. However, though various transgenic models develop specific phenotypical aspects of AD— not only Aß plaques and nft, but also related gliosis, synaptic alterations, neurodegeneration, behavioral changes,
and memory deficit—no individual animal model or combination of models replicates the clinicopathological complexity of human Alzheimer or
translates to improved outcomes for Alzheimer patients (Dodart et al., 2002;
Duyckaerts, Potier and Delatour, 2008).
What are the correlations between the extensive animal-derived knowledge
and the etiology, risk factors, clinical course, pathophysiology, treatments, and
outcomes of AD, and what is the payoff expected from basic science research?
It is now well understood that, despite the plethora of Alzheimer animal
models in use, the interspecies translation is poor for genetic, physiological,
and technical reasons (Neha et al., 2014). No matter how close two species,
or even two strains within a species, may be genetically, there are immutable
differences in gene function, gene expression, protein production, and phenotypic or physiological results that render translation unpredictable and unreliable. Description and explanation of many animal-human discrepancies
specific to AD are available (see Cavanaugh, Pippin and Barnard, 2014; Langley,
2014). The demonstrated inability to modify animal models to improve translation provides further evidence that only a shift to human-derived and, thus
human-relevant, research methods can improve the applicability of basic science research to human AD.
4

Animal Drug Development Research and Outcomes

The translational goal of basic science research for medical diseases is to
provide the knowledge required to predict, prevent, identify, treat, and hopefully cure these diseases. As such, the success of this approach for AD can be
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 easured, in substantial part, by assessing the role of animal research in pharm
maceutical development. Over the past three decades, basic and applied science research have identified mechanisms leading to the discovery of drug
targets and the development of drugs customized for those targets. An extensive review of these targets, drugs, and clinical trial results is beyond the scope
of this chapter but may be found elsewhere (see Berk and Sabbagh, 2013; Cavanaugh, Pippin and Barnard, 2014; Langley, 2014; Schneider et al., 2014).
Though the current discussion is limited to AD, context is also important
in fairly assessing the success of preclinical animal research for drug development. For the past eight decades, preclinical testing methods for the safety and
efficacy of drugs have relied heavily on the use of animals, not least b ecause
this has been the default approach of the US Food and Drug Administration (fda) and regulatory agencies in most other regions of the world. This
animal-testing paradigm has never been subjected to a systematic validation
of translation to human medicine or consistency among or within non-human
species and different laboratories. Former fda pharmacology and toxicology
reviewer, Anita O’Connor, confirmed this situation in 1998, stating that: “Most
of the animal tests we accept have never been validated. They evolved over the
past 20 years, and the fda is comfortable with them.” Similarly, in the United
Kingdom, Parliamentary Under-Secretary of State, Caroline Flint stated, in
2004, that: “The Home Office has not commissioned or evaluated any formal
research on the efficacy of animal experiments” (UK Parliament, 2004). This
situation persists not only in these two nations.
As far back as 2003, the fda reported a clinical trial failure rate of 92% for
drugs deemed safe and effective based on preclinical animal studies, a marked
increase from the already high 86% attrition rate in 1985, despite purported
advances in preclinical drug testing (fda, 2004; Mitka, 2006; Singh and Henske, 2003). The most recent phase-specific data for drugs tested safe and effective in preclinical animal studies identified clinical trial attrition rates of
56% for Phase i (designed to assess drug safety and estimate dosing); 82% for
Phase ii (designed to assess proof of concept); and 50% for Phase iii (designed
to assess safety and effectiveness for humans) (Arrowsmith, 2011a; Arrowsmith,
2011b; Lovell-Badge, 2013)—a cumulative 96% failure rate. When drug withdrawals, duplicative “me too” drugs, and low patient response rates are included, only about one in one hundred drugs that are tested successfully in animals
becomes a unique, effective, and safe medication; and then it is very likely to
be effective for only a minority of patients and often marginally so. This is certainly the case with the four drugs licensed to treat AD.
There could hardly be stronger evidence that animal use for drug testing
is very unreliable and poorly contributes to drug efficacy or safety in the real
world. Added to this serious false-positive problem are the missed opportunities
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for useful drugs, due to false-negative animal testing and adverse effects that
would not translate to humans. The cause-effect relationship between animal
testing and clinical trial results was succinctly stated by Stanford’s Joseph Garner (Garner, 2014, p. 440):
The logic tying failures in clinical trials to basic research in animals is
seductively straightforward. Every drug entering human trials, by definition, “worked” in an animal model in terms of both safety and efficacy,
and efficacy is the primary reason drugs fail in human trials. Thus, the
primary reason for these failures can be traced back directly to false
positives in animal models committing the pipeline to develop a drug
that will ultimately fail. Straightforward data can be used to make this
case. For instance, as reviewed by Zahs and Ashe (2010), over 200 different
interventions have been reported to be effective in the app mouse model
of Alzheimer’s disease, yet none has proven effective in human trials.
Animal research addressing drug development for AD is even worse than the
overall pattern described above. Despite the 2,204 AD clinical trials (including
1,329 completed, terminated, suspended, and withdrawn drug studies) listed at
ClinicalTrials.com on July 24, 2017, only four drugs are currently FDA-approved
for treatment of the disease alone or in combination (Table 20.1). Three of
these are acetylcholinesterase inhibitors (AChEI), which inhibit the depletion
of the crucial neurotransmitter acetylcholine in AD. The fourth drug is a Nmethyl-D-aspartate (nmda) receptor antagonist that inhibits the destructive
excitatory action of glutamate at the cellular level.
It is perhaps a measure of the dearth of therapies to address AD that the
fda has approved even these few drugs, which only scratch the surface of AD
therapy. The drugs produce very small changes, of dubious clinical relevance,
on cognitive and behavioral measurement scales (Delrieu et al., 2011); they typically have mild impact on symptoms in only a minority of patients, have no
effect on disease progression or mortality, often lose any effectiveness within
several months, and may produce serious adverse effects.
Despite the low bar for fda approval of AD drugs, the pharmaceutical industry trade group, Pharmaceutical Research and Manufacturers of
America (PhRMA), reported that between 1998–2014, 123 drugs failed in AD
clinical trials (2015), further supporting the organization’s comments in its
2012 report: “The limited utility of current models of the human disease is a
huge barrier in preclinical testing of drug candidates [….] Unfortunately, these
medical treatments do not always work, they cannot cure the disease or stop
its progression, and when they work their efficacy often wears off over time”
(PhRMA, 2012).
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Table 20.1 fda-approved drugs for Alzheimer disease (2019)

Drug name

Brand name Category fda
Approved
approval disease stages

Approved
generic

Donepezil
Rivastigmine

Aricept
Exelon

AChEIa
AChEI

Yes
Yes

Galantamine
Memantine
Donepezil +
memantine

Razadyne
Namenda
Namzaric

AChEI
2001
nmdaric 2003
AChEI + 2014
nmdari

1996
2000

All stages
Mild-moderate
Moderate-severeb
Mild-moderate
Moderate-severe
Moderate-severe

Yes
Yes
Yes

a Acetylcholinesterase inhibitor
b Patch is approved for moderate-severe
c N-methyl-D-aspartate receptor inhibitor.
The AChEI tacrine was approved for mild-moderate AD in 1993 and withdrawn in 2013 due to
severe toxicities

Cummings, Morstorf and Zhong (2014) reported on all registered AD drug
trials for the period between 2002–2012, using nih’s ClinicalTrials.gov database to extract drug and trial data. They found that during this period, 244
candidate AD drugs were tested in 413 clinical drug trials. There was a 72%
attrition rate for Phase i trials, which reached 92% when Phase ii trials were
added. Only one drug succeeded in Phase iii to achieve fda approval (memantine in 2003). The failure rate was 99.6% (243 of 244 the drugs tested). An
analysis of AD clinical drug trials reported from January 1, 2004 (after memantine approval) through to July 19, 2017, reveals 1,273 completed or closed trials
and no approved drugs (ClinicalTrials.gov, n.d.).
PhRMA reported 77 AD drugs in clinical trials in 2016, 21 of which were in
Phase iii studies (PhRMA, 2016). By May 2017, nine of these drugs had already
failed at least one late-stage trial, none had a successful outcome, and numerous others no longer had trials registered on ClinicalTrials.gov. In January
2016, ClinicalTrials.gov listed 93 agents in 115 open AD trials: 24 agents in 36
Phase iii trials, 45 agents in 52 Phase ii trials, and 24 agents in 27 Phase i trials
(Cummings, Morstorf and Lee, 2016). In July 2017, none of these had achieved
a successful outcome. Data from the July 2017 Alzheimer’s A
 ssociation
International Conference reported 58 Phase ii and 32 Phase iii AD drugs in
development, including 8 Phase ii and 27 Phase iii drugs expected to launch
in the next five years (Henriques, 2017; Us Against Alzheimer’s, 2017).
Table 20.2 displays notable drugs that have failed late-stage clinical trials in
the past six years. Some drugs have failed several clinical trials and some have
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continued to be evaluated in additional late-stage clinical trials. Among drug
candidates currently in Phase iii trials are Aß antibodies aducanumab (Biogen) and crenezumab (Hoffmann-La Roche); BACE1 inhibitors elenbecestat
(Biogen) and JNJ-54861911 (Janssen); 5-HT6 antagonist SUVN-502 (Suven Life
Sciences); and nmda receptor antagonist AVP-786 (Avanir).
Cumulatively, Cummings et al.’s (2014) results from 2002–2012 data and
results for 2013–2018, shown in Table 20.2, demonstrate that at least 265
AD drugs have failed in clinical trials in the past 15 years. The race between
translatable research and burgeoning disease is being lost, with no clear path
Table 20.2 Notable Alzheimer drug failures from 2013–2018

Failed drug

Category

LY 2886721
Intravenous Ig
Begacestat

BACE1 inhibitor
Lilly
Immune modulator Baxter, Intl.
γ secretase inhibitor Bristol-Myers
Squibb
Aß antibody
Pfizer
Aß vaccine
AFFiRiS AG
PDE9A inhibitor
Pfizer
Aß antibody
Hoffmann-La
Roche
BACE1/2 inhibitor Boehringer
Ingelheim
Dietary supplement University
Hospital, Toulouse,
France
MAO-B inhibitor
Roche
α7 NAR agonist
forum

2013
2013
2013

Toxicity
Ineffective
Ineffective

2014
2014
2014
2014
2015
2015

Ineffective
Ineffective
Ineffective
Ineffective
Toxicity

2015

Ineffective

2015
2015

Tyrosine kinase
inhibitor
Aß vaccine

AB Science

2015

Ineffective
Toxicity (fda
halted)
Ineffective

Novartis
Lundbeck &
Otsuka
Pfizer
Cleveland Clinic

2016
2016

Ineffective
Ineffective

2016
2016

Ineffective
Ineffective

Bapineuzumab
Affitope AD02
PF04447943
Gantenerumab
BI 1181181
ω-3 fatty acid

Sembragiline
Encenicline
Masitinib

CAD 106
Idalopirdine
PF05212377
Bexarotene

5-HT6 antagonist
5-HT6 antagonist
Anti-neoplastic

Sponsor

Most recent Reason for failure
failed trial
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Table 20.2 Notable Alzheimer drug failures from 2013–2018 (cont.)

Failed drug

Category

Sponsor

Most recent Reason for failure
failed trial

lmtx

TauRx

2016

Ineffective

Bryostatin
AC-1204
Intepirdine
BAN2401
Solanezumab
Pioglitazone
BI 409306

Tau aggregation
inhibitor
pkc modulator
Ketosis inducer
5-HT6 antagonist
Aß antibody
Aß antibody
antiglycemic
PDE9A inhibitor

2017
2017
2017
2017
2018
2018
2018

Ineffective
Ineffective
Ineffective
Ineffective
Ineffective
Ineffective
Ineffective

Verubecestat
Azeliragon
Pimavanserin
Atabecestat
Lanabecestat
Elenbecestat

BACE1 inhibitor
rage inhibitor
5-HT2A antagonist
BACE1 inhibitor
BACE1 inhibitor
BACE1 inhibitor

Neurotrope
Accera
Axovant Sciences
Biogen/Eisai
Lilly
Takeda/Zinfandel
Boehringer
Ingelheim
Merck
vTv
Acadia
Johnson & Johnson
Lilly
Biogen/Eisai

2018
2018
2018
2018
2018
2018

Ineffective
Ineffective
Ineffective
Toxicity
Ineffective
Ineffective

bace1=beta-site amyloid precursor protein-cleaving enzyme 1; Ig=immunoglobulin;
rage=receptor for advanced glycation endproducts; PDE9A=phosphodiesterase 9A;
mao-B= monoamine oxidase B; α7 nar=α7 nicotinic acetylcholine receptor; 5-HT6=5hydroxytryptamine (serotonin) type 6 receptor; pkc=protein kinase C; 5-HT2A=5hydroxytryptamine (serotonin) type 2A receptor.

to improvement other than the replacement of the failed animal research paradigm by a commitment to human-relevant research methods.
5

Whither the Amyloid Cascade Hypothesis?

The amyloid cascade hypothesis, in its initial description (Hardy and Allsop,
1991; Hardy and Higgins, 1992) and in its reappraisal (Hardy, 2006; Hardy and
Selkoe, 2002), has been foundational for AD preclinical and clinical research for
a quarter of a century. Early and widespread acceptance of the hypothesis has
impacted research gatekeepers, such as funding agencies, journal editors, peer
reviewers, and pharmaceutical companies. The amyloid cascade hypothesis,
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derived from human autopsy studies, identifying the presence and presumed
causative roles for Aß plaques and tau proteins, proposes that sequential enzymatic cleavage of mutated app by secretase enzymes results in deposition of
soluble Aß protein oligomers that coalesce into plaques, and that downstream
events include tau protein and nft formation and cell death. The specifics of
inflammation and destruction of neuronal networks were identified with further investigation. This entire process is termed, neurodegeneration.
In the pursuit of AD research, abundant information has been obtained
casting doubt on the amyloid cascade hypothesis. Paramount among contrary information is the finding that a meaningful percentage of young adult
(Baker-Nigh et al., 2015) and older persons (Armstrong et al., 1996; Esparza
et al., 2013; Haroutunian et al., 2008; Monsell et al., 2013; Price et al., 2009),
without dementia, have substantial Aß plaque deposition demonstrated in
brain imaging and postmortem studies. In one large review, amyloid biomarkers increased with age and were present in 10%–44% of cognitively
normal participants aged 50–90 years (Jansen, et al., 2015). Lon Schneider of
the University of Southern California, Keck School of Medicine, stated that:
“There are people who die with a head full of amyloid and have no cognitive impairment whatsoever” (Mullin, 2017). Conversely, Aß plaques may be
absent or minimally present in clinically diagnosed AD patients (Monsell
et al., 2015; Morris, Clark and Vissel, 2014; Terry et al., 1991). A recent report
demonstrates that tau oligomers, produced subsequent to Aß deposition, are
also present in the sera of aged normal controls as well as AD patients (Kolarova et al., 2017). It has been reported that some degree of tau pathology is
ubiquitous in postmortem human brains (Braak and Braak, 1997; Braak and
Del Tredici, 2011).
Since some drugs have successfully removed brain Aß plaque without producing improvement in cognition and other symptoms and without improving clinical course or mortality, it has been proposed that Aß plaques may not
be causative for AD. Tau pathology not only is triggered by Aß plaques but also
appears to progress unabated even after the removal of Aß plaques, suggesting
that therapies targeting Aß are unlikely to succeed in controlling AD (Hampel
et al., 2010; Wang et al., 2016). Some recent basic science and drug development
research has focused on a possible AD causative role for tau proteins rather than
Aß plaques, but the only completed tau-targeting Phase iii drug trial (a tau
protein aggregation inhibitor known as lmtx, lmtm, or TRx0237) failed to show
benefits (Alzforum, 2016a). The true AD target may be the synaptic and neuronal network destruction that is the common final pathway to dementia. An
alternative interpretation is that the timing of Aß-targeted therapies may be
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key: Once Aß plaque has formed, it may be too late to reverse the pathological
consequences.
AD has appropriately been described as late-life phenotypes, beginning as
midlife pathologies with a two-decade or more latency period. There is now
a corresponding move towards identifying and validating biomarkers to aid
in detecting AD in its earliest stages, or even before symptoms appear, so that
the neuronal network damage may be prevented rather than treated (Donohue et al., 2017; Schneider et al., 2014). Foremost among these approaches
may be prevention trials enrolling asymptomatic persons, with characteristic neuroimaging pathology or with specific cerebrospinal fluid biomarkers (Donohue et al., 2017; Jansen et al., 2015; Olsson et al., 2016; Ramachandran, 2016), and targeting subsequent cognitive loss and the development of
mci or AD.
Earlier intervention is a logical approach derived from the failure of later
clinical intervention, but its value is debatable for at least three reasons. First,
the biomarkers indicating risk for AD are not yet sufficiently accurate to exclude persons who would never develop AD or even mci from clinical trials.
Second, fewer than half of persons with mci will progress to AD, making even
this indicator of limited utility and suggesting that earlier biomarkers may be
fraught with low specificity and positive predictive value (Mitchell and ShiriFeshki, 2009; Richard and Brayne, 2014; Roberts et al., 2014a; Ward et al., 2013).
Third, this approach does not directly address the failure of animal research to
identify disease-modifying therapies, though it is postulated that some failed
therapies may be effective if applied earlier.
So, the fate of the amyloid cascade hypothesis remains unknown but appears tenuous; and its demise would seriously compromise decades of basic
science, clinical, and pharmaceutical efforts. Outcomes to date have not confirmed, and generally do not support, the amyloid cascade hypothesis; and
if current and pending early-stage and presymptomatic Aß-targeted studies
fail to impact outcomes, it must be presumed to be incorrect. It is axiomatic
that the first step in understanding, characterizing, and addressing disease
is to determine the cause(s). We have not demonstrably done this for AD,
arguably because basic science research, predominantly using transgenic
animals, has been unable to accomplish the task despite more than three
decades of effort.
6

The Expanding Role of Lifestyle Factors for AD Prevention

Concomitant with the emphasis on earlier detection and preventive measures for AD, there is a need to identify factors that are predictive of,
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c ontributory to, or protective for the development of cognitive impairment
and AD. In particular, modifiable lifestyle factors associated with risk for
cognitive impairment and AD offer a particularly appealing approach to
prevention—lifestyle modifications without adding heretofore failed drug
treatments.
Blood pressure—pressure variability rather than absolute systolic, diastolic,
or mean blood pressure—has been associated with risk for subsequent cognitive decline and AD in a unique manner. The same pattern of greater cognitive
decline with greater blood pressure variability has been established for office
(Alpérovitch et al., 2014; Sabayan et al., 2013); ambulatory (McDonald et al.,
2017); and home (Matsumoto et al., 2014; Oishi et al., 2017) blood pressure measurements and for day-to-day or month-to-month variability. Though blood
pressure variability has also been shown to correlate with cardiovascular event
risk and target organ damage (Kikuya et al., 2008; Rothwell et al., 2010); it is unknown whether there are shared mechanisms with cognitive decline, and it is
also unknown whether specific blood pressure control efforts impact the cognitive risk (Palatini, 2014). Observational studies of hypertension and cognitive
risk have been heterogeneous, but the evidence is strongest for risk correlation
between mid-life hypertension and late-life AD and all cause dementia (Kennelly, Lawlor and Kenny, 2009a; Kennelly, Lawlor and Kenny, 2009b; Purnell et
al., 2009; Qiu, Winblad and Fratiglioni, 2005), with an estimated relative risk of
1.6 (Barnes and Yaffe, 2011).
Regular exercise is a topic of great interest for potential reduction of the
risk for cognitive decline and AD. A prospective study of 200 persons with
mild dementia evaluated cognitive outcomes of a group receiving 16 weeks
of supervised exercise and a non-exercise control group. No differences were
seen in objective measures of cognition, quality of life, or ability to perform
activities of daily living (Hoffman et al., 2016). This outcome was confirmed
in a Swedish study of 186 persons with dementia who participated in an intensive four-month exercise program (Toots et al., 2017). A Western Australia
prospective trial evaluated exercise effect on cognition among 138 at-risk older
adults, randomized to either 24 weeks of supervised physical activity or no exercise. This methodologically problematic study showed minimal and dubious improved cognitive measures over 18 months (Lautenschlager et al., 2008).
In a secondary analysis of the randomized prospective life trial, a 24-month
physical activity intervention involving 1,635 sedentary older adults, no exercise-related improvements were seen in global or domain-specific cognitive
function (Sink et al., 2015).
In contrast, a 2009 meta-analysis of 16 studies including 163,797 nondemented participants showed an approximate 45% reduced risk for AD and
28% reduction in all-cause dementia, between the highest and lowest physical
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activity groups, with a relative risk among inactives of 1.82 for AD (Hamer and
Chida, 2009). Another systematic review reported that physical inactivity was
linked to an increased risk for cognitive impairment in 20 of 24 included studies (Rolland, Abellan van Kan and Vellas, 2008). A 2010 meta-analysis of 15 prospective studies, including 33,816 nondemented subjects, who were followed
for 1 to 12 years, showed a decreased risk for subsequent cognitive decline at
all exercise levels (Sofi et al., 2010). These meta-analysis findings were compromised by conflicting results and methodological heterogeneity among the
studies reviewed. A secondary analysis of a 30-year questionnaire-based study
of midlife exercise found no relationship to subsequent cognitive impairment
or dementia (Gross et al., 2017).
The majority of studies evaluating exercise or uncharacterized physical
activity as predictors of subsequent cognitive impairment, AD, or all-cause
dementia are observational cohort studies, variably compromised by methodological limitations. These limitations include poorly characterized or unsupervised exercise, inconsistent exercise and activity patterns, self-reporting by
subjects, questionnaire-based data collection (subject to recall bias), researcher bias, variable influence of the observers on participant performance, and
short interventional and observational periods, among other disadvantages.
Cumulative findings to date show no significant evidence for exercise benefit
regarding progression among persons with dementia, and conflicting evidence
for benefit regarding future development of cognitive decline, AD, or all-cause
dementia.
The relationship of diet to risk for cognitive decline and AD or uncharacterized dementia is a revealing area of investigation. Studies of specific dietary
supplements have predominantly failed to show decreased risks for prevalent
or incident cognitive decline and dementia, excluding replacement therapy
for severe nutritional deficiencies, such as vitamin B12 and niacin. Dietary supplement animal research supports beneficial effects for vitamins C, D, and E
(Anastasiou, Yannakoulia and Scarmeas, 2014; Guerrero et al., 1999; Joseph et
al., 1998; Socci, Crandall and Arendash, 1995; Yamada et al., 1999). Human studies of dietary vitamin intake have shown inconsistent results. Prospective observational studies in Chicago (Morris et al., 2002) and Rotterdam (Engelhart
et al., 2002) showed lower AD risk with greater dietary vitamin E intake, while
a similar study in New York showed no association (Luchsinger et al., 2003).
The Rotterdam study showed lower AD risk with greater vitamin C intake, but
the other two studies did not. The Chicago study also found a worrisome positive correlation between vitamin C intake and the risks for hypertension and
stroke. None of the three studies showed benefit from vitamin C or vitamin E
supplements.
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In a 2014 study of elderly hospitalized patients, blood levels of 25-hydroxy
vitamin D did not discriminate among cognitively normal (200); mci (46); and
demented (182) patients, nor did the levels predict conversion to dementia
(Graf et al., 2014). Conversely, another observational study showed a relative
risk for incident AD of 1.69 for deficient and 2.22 for severely deficient vitamin
D levels among 1,658 healthy ambulatory adults (Littlejohns et al., 2014). Overall, human vitamin D study outcomes have been heterogeneous, but the highest quality evidence (clinical trials) does not support vitamin D-related benefit
(Anastasiou, Yannakoulia and Scarmeas, 2014).
Dietary saturated fat and trans fat intake have been associated with higher
AD risks in human studies (Kalmijn et al., 1997; Luchsinger et al., 2002; Morris et al., 2003), though this correlation disappeared during follow-up in one
study (Kalmijn et al., 1997). A more recent systematic review revealed mixed
evidence among four observational studies of saturated fat and trans fat intake and mci or dementia (Barnard, Bunner and Agarwal, 2014). A study of 444
Finnish men linked elevated midlife blood cholesterol with increased subsequent AD risk (Notkola et al., 1998). Observational studies have reported lower
AD risk with statin therapy (Jick et al., 2000; Wolozin et al., 2000); but a 2016
Cochrane review found no benefit on five cognitive tests in two randomized
placebo-controlled trials of statins, including 26,340 participants (McGuinness, et al., 2016). Diets consisting substantially of meat, dairy, processed and
fatty foods, snack foods (often high in trans fats), and high caloric content contribute to known AD risk factors as well as other health risks.
The pattern of accelerated AD and all-cause dementia after adoption of the
American-style diet is widely evident, including in Japan (Grant, 2014), China
(Chan et al., 2013), rural India (Chandra, et al., 1998), eight developing nations
(Grant, 2014), and among participants in the Adventist Health Study (Giem,
Beeson and Fraser, 1993). A recent comprehensive review of dietary data and
cognitive risks from 2014–2016 presented updated data regarding seafood
intake and lines of evidence against cognitive protection, despite the purported favorable effects of the omega-3 fatty acids, eicosapentaenoic acid, and
docosahexaenoic acid (Solfrizzi et al., 2017).
Type 2 diabetes mellitus (T2DM) is an AD risk factor, resulting predominantly from the combined and cumulative effects of poor diet, sedentary
lifestyle, and obesity. T2DM and AD are known to share pathologies, such
as cerebrovascular disease, brain atrophy and diminished brain volume, impaired brain glucose metabolism, and cns insulin resistance (Asih et al., 2017;
Bharadwaj et al., 2017; Sutherland et al., 2017); and both disorders have been
linked to tau pathology and neurodegeneration (Sutherland et al., 2017). At the
clinical level, T2DM and AD both increase in incidence with age; and risks for
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both have been shown for sedentary lifestyle, hypertension, poor diet, obesity,
dyslipidemia, and smoking. Overlapping features, including the role of insulin
resistance in the brain, have resulted in the designation of AD as “type 3 diabetes” (De La Monte and Wands, 2008).
Observational cohort studies, systematic reviews, and meta-analyses have
predominantly identified T2DM in cognitively normal persons as a risk factor for mci, AD, and all-cause dementia (Barnes and Yaffe, 2011; Biessels
et al., 2006; Biessels et al., 2014; Cheng et al., 2012; Cukierman, Gerstein and
Williamson, 2005; Exalto et al., 2012; Gudala et al., 2013; Kopf and Frolich, 2009;
Lu, Lin and Kuo, 2009; Roberts, et al., 2014b; Yaffe, et al., 2012; Zhang et al., 2017),
though some of these studies have methodological flaws and unaccounted bias
(Sutherland et al., 2017). This correlation was not confirmed for the progression
of cognitive decline among AD patients (Li et al., 2017). Several investigators
have estimated the relative risk for AD from T2DM as 1.5 (Chatterjee et al., 2016;
Cheng et al., 2012; Gudala et al., 2013), including recent population-based studies of more than 2.3 million (Chatterjee, et al., 2016) and more than 1.7 million
persons (Zhang et al., 2017). A combined systematic review and m
 eta-analysis
of eight studies of T2DM and AD risk reported that seven studies found a positive correlation, but only two reached statistical significance, and overall relative risk was 1.4. (Lu, Lin and Kuo, 2009).
The risk for development of mci, AD, and all-cause dementia increases with
T2DM duration (Asih et al., 2017; Bruce et al., 2014). Dementia risk appears to
be proportional to diabetes severity (Yaffe, et al., 2012), to occur at a younger
age when T2DM is present (Zilkens et al., 2013), and to display shorter survival
when combined with T2DM (Helzner et al., 2008; Zilkens et al., 2013). The rapidly increasing worldwide prevalence of T2DM, thus, suggests not only more
prevalent AD, but also younger onset and shortened survival for AD patients.
Conversely, improved T2DM prevention would be expected to have a beneficial effect on AD prevalence, onset, and mortality.
Based on the preceding and similar findings, certain recommendations can
be made to minimize modifiable risks for cognitive decline and AD. These recommendations are built on the preponderance of evidence from human studies and the overall beneficial effects for cardiovascular disease, T2DM, obesity, hypertension, and other AD risk factors as well as for the hard endpoints
of cognitive decline and dementia. Elements of the lifestyle prescription include, regular exercise or other physical activities; adoption of heart-healthy
diets, such as the Mediterranean diet and other plant-based diets emphasizing
fruits, vegetables, whole grains, and legumes (with consideration for excluding seafood consumption due to cholesterol content and uncertain benefit);
preference for food sources rather than supplement sources of potentially
protective dietary components; maintenance of normal body weight, blood
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 ressure, blood glucose and lipids; and other factors not discussed here, such
p
as not smoking and attainment of at least a high school level of education. As
a bonus, and in contrast to drug therapies, the side effects of this prescription
are beneficial.
7

Brief Overview of Research Funding

During the first decade of the twenty-first century, AD research funding from
nih was strikingly low, compared to other widespread, lethal, and costly diseases. Passage of the US National Alzheimer’s Project Act (napa) by Congress
in January 2011, focused greater emphasis on AD research, and federal funding
increased slowly until the 2016 and 2017 fiscal years showed large increases.
In 2012, nih research funding for AD and AD-related dementias was half a
billion dollars, compared to US$1.3 billion for heart disease, US$3.1 billion for
hiv/aids, and US$5.6 billion for cancers. AD research funding did not exceed
US$600 million until 2015, but it received a 60% increase in 2016 and a 40%
increase in 2017 (Alzforum, 2016b; Moore, 2017; nih, 2016). Projected nih AD
research funding for 2017 is nearly US$1.4 billion, almost triple the funding of
the past five years, while funding for heart disease, hiv/aids, and cancers has
remained unchanged.
While this is very good news for AD research, the devil is in the details. nih
funding in this area has been heavily weighted towards animal research for at
least the past decade, supporting three times as many animal research protocols as human-specific protocols, and spending more than twice as many tax
dollars for animal research (Figure 20.1). Total nih expenditures for AD and
AD-related dementia research since 2011 is more than US$5 billion, with no
clinical return on this investment. If this pattern of dependence on animal research is unchanged, genetic principles, interspecies differences, and history
tell us that the AD animal research paradigm will continue to fail in producing
advances in AD prevention and treatment, regardless of how much money is
directed towards that goal.
Some private funding sources, which collectively distribute tens of millions of dollars annually for AD research, have shown a broader perspective
regarding the directions for AD research. For example, in 2016 the Alzheimer’s Association partnered with philanthropist Michaela Hoag to announce
its Part the Cloud Challenge and grants totalling US$7 million to fund clinical
trials investigating brain inflammation in AD (Alzheimer’s Association, 2016).
The Alzheimer’s Drug Discovery Foundation (2017) funds many non-amyloid,
non-tau research approaches. The Paul G. Allen Family Foundation’s US$7 million award in 2015 sought innovative AD research approaches, e mphasizing the
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focused on the use of animal models (black bars) versus projects accounting
only for human-relevant models/methods (white bars). (A) and (B) present
relative funding provided by the nih from 2007 to 2017. (Updated from
Pistollato et al., 2016)

 uman disease, and the Microsoft cofounder stipulated that at least one memh
ber of each of the five recipient research teams must not be an AD researcher
(Begley, 2016; Paul G. Allen Philanthropies, 2015). Similarly, the Darrell K. Royal
Research (dkr) Fund for Alzheimer’s Disease (2016) “is interested in novel,
innovative and cutting-edge approaches to Alzheimer’s disease, dementia,
Traumatic Brain Injury, and related disorders. Additionally, the dkr Fund
is particularly interested in non-amyloid and non-tau approaches that may
not receive funding through traditional mechanisms. Studies that pilot novel
mechanisms and novel therapeutic interventions are particularly encouraged.”
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(Underline in original.) It is through innovative and nontraditional research
design, specifically human-relevant research, that the inability to translate basic science discoveries to AD prevention, treatment, and successful drug development may be overcome.
8

Conclusions: The Process and the Ethics

Perhaps as starkly as for any other disease, AD research ethics must address
both animal use and human outcomes. This is because the animals suffer captive breeding and genetic alteration, community disruption, confinement,
handling, fear, and painful procedures—and because AD research animals
always die. It is also because the human disease is prevalent, frightening,
and debilitating and its victims also always die from or with the disease. The
animal-use ethical question involves a spectrum of viewpoints, ranging from
no concern for the animals to strong objection to any harmful animal use for
research purposes. Public surveys over the past few decades have shown a shift
towards the latter position or towards restricting animal use to essential and
unavoidable circumstances, the definition of which is also variable. But wherever one stands on the animal-use ethical spectrum, hopefully all can agree
that the conduct of frightening, painful, and lethal experiments on sentient
beings—whether mice, dogs, or monkeys—is unacceptable when the research
translates in no significant way to human benefits, despite decades of effort.
The authors of this chapter have been animal researchers, and they have firsthand knowledge that the process is unavoidably cruel, painful, unreliable,
and ultimately unrewarding. Nonetheless, we have not argued that no useful
knowledge ever results from animal experiments, but we have demonstrated
that such knowledge is restricted in practical terms to the genetically manipulated experimental species. That is, it is unreliable for human medicine and
does not result in meaningful treatments for AD.
In view of the billions of dollars of federal and private research support for
AD, now more than one billion dollars annually of taxpayer funds alone, meaningful clinical results are an ethical expectation. Yet, such results remain absent,
and there are no current animal research approaches p
 romising t ranslational
basic science revelations or improved drug development in the foreseeable future. Spiraling costs related to basic science and clinical research, clinical diagnostics, acute and especially chronic patient care, caregiver support, and the
economic consequences facing families, communities, and businesses are on
track to decimate federal and private insurance programs and further impair
economic productivity.
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Arguably the most immediate ethical question regards accountability to
AD patients, those at risk for AD, their families and communities. The costs
of a failed animal research underpinning for AD are not limited to money
spent and strained research resources, and include irretrievable losses in
time, hope, and human lives. Of all the ethical accompaniments of AD animal research, the deferred and unrealized obligations to those impacted by
AD, the persistence in pursuing a failed research model, the recurring hype
surrounding drugs that cannot affect AD or its outcome, the advances perennially “just around the corner” are the real-world human consequences.
As a corollary, preclinical researchers in the field have spent years or decades performing productive bench work without contributing to improving
quality of life, delaying disease progression, or prolonging the lives of AD
patients.
For now, and likely years ahead, there will be nothing more than the four
largely inconsequential AD drugs currently available. Neurobiologist, George
Perry, Dean of the College of Sciences at the University of Texas at San Antonio, summed this up: “The field has known for over 10 years, probably 15 years,
that the models were not Alzheimer disease and could not predict therapeutic efficacy” (Begley, 2016). This paralyzing mindset must be overcome to gain
ground on AD, and the replacement of animal research with human-relevant
research methods is the path forward.
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Modeling Wild Animal Behavior in the Laboratory:
Scientific Concerns
– Kimberley Jayne –

Behavioral research on non-human animals (hereinafter referred to as animals)
can involve the study of their evolution and natural behavior, cognitive abilities and psychological constructs, or welfare and response to stressors, among
other areas of natural animal behavior. Behavioral research on animals is also
carried out to model human behavior, for example in psychological studies
and pharmacological models, as well as for comparative purposes to understand differences and similarities between species. This chapter focuses on the
former—where ethology moves into the laboratory environment to model the
behavior of free living animals—however, some of the discussion is also relevant to the laboratory animal model in general because of the very nature of
using laboratory animals as “models”. For further discussion on animals used to
model disease or within pharmacology in particular, see the following chapters
in this Volume: Archibald, Coleman and Drake (2019, Chapter 18); Bailey (2019,
Chapter 19); Carvalho et al., (2019, Chapter 16); Greek and Kramer (2019, Chapter 17); Pippin, Cavanaugh and Pistollato (2019, Chapter 20); and Ram (2019,
Chapter 15). For more on animal models within psychology, see Shapiro (1998).
In comparison to other scientific procedures, such as those within biomedical research, modeling the behavior of wild animals in the laboratory can involve
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methods that are physically non-invasive. While it is true that some behavioral
studies are accompanied by invasive measures (which can be a nything from
injecting dye for identification purposes, to drilling into the skull to insert brain
implants), for those that are not, physical and psychological suffering may be
overlooked. This can also affect the rigor with which the 3Rs are applied, with
the implementation of replacement in behavioral research being of particular
concern. Nevertheless, the welfare of animals used for behavioral research can
suffer as a direct result of: experimental manipulations (e.g., simulating prolonged presence of predators); marking methods (Association for the Study of
Animal Behaviour, 2018); from being wild-trapped and transported to a laboratory; or simply living in a laboratory environment can result in various degrees
of suffering by impeding an animal from performing natural behavior, imposing a chronic state of fear, or observing them at close proximity (particularly if
they are a prey or territorial species). Moreover, research in the name of animal
welfare brings about scientific concerns with studying wild animal behavior in
the laboratory, as well as problems with the animal model in general.
The first half of this chapter focuses exclusively on animals that are used
in laboratory behavioral research to model wild behavior, what is typically involved, problems associated with this practice, and how behavioral research
has revealed scientific problems in the animal model. The second half of this
chapter then addresses the ethical questions of whether scientific curiosity of
animal behavior in general provides any justification for carrying out this research in this first place, with specific focus on non-human primates (nhps).
1.1
The Origins of Laboratory Behavioral Research
The study of animal behavior has a long history, dating back over 2000 years;
however laboratory behavioral research became popular in the twentieth
century with the rise of behaviorism, with research using animal models to
understand more about the human processes of learning and memory and
the comparative abilities of animals (Klopfer, 1993). Food deprivation was
frequently used as a method to motivate laboratory animals to “perform” and
is still frequently used today across behavioral research. For example, early
studies by Thorndike in 1898 deprived cats of food and confined them in a
“puzzle box”, from which they had to work out how to escape for a food reward
(Chance, 1999). In the 1920s, Pavlov used dogs to demonstrate the principals of
classical conditioning: a dog was restrained and isolated in a room for use in a
series of trials where food was presented with a neutral event (e.g., flashing of
a light), so that their salivation response could be recorded (Pavlov, 1927). Still
used today (e.g., Meier, Lea and McLaren, 2016), and developed in the 1920s
by Skinner, the Skinner Box (sometimes referred to as an “operant chamber”)
confines p
 artially food-deprived animals (often pigeons or rats) inside of a box
Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

Behavioral Research on Captive Animals

519

with a device they must operate to obtain a food reward. Sometimes animals
were also given amphetamines to assess the impact on their behavior under
these conditions (Dews, 1955). Laboratory research has also used animals to
model other aspects of human behavior: Seligman and colleagues gave dogs
electric shocks they could not escape to model learned helplessness associated with human depression (Abramson, Seligman and Teasdale, 1978); Harlow (1958) isolated infant rhesus macaques from their mothers to raise them in
complete social isolation, or with a “cloth mother” or “wire mother” surrogate.
Despite studies with humans being carried out, which reveal human-relevant
data, six decades later this type of research continues with infant monkeys
(e.g., Massart et al., 2014). So has the use of animal models of learned helplessness, which have been going on for five decades, particularly with rodents
(e.g., Greenwood, Strong and Fleshner, 2010; for review see Maier and Seligman, 2016).
Alongside the rise in laboratory behavioral research, a contrasting method
of studying the natural behavior of animals, known as ethology, gained popularity during the mid-twentieth century through the work of Lorenz, Tinbergen and von Frisch (Bolhuis and Geraldaue, 2008; Klopfer, 1993). The purpose
of ethology was to ask questions about animals in their natural environment,
using non-intrusive observational methods or environmental manipulations
(Klopfer, 1993). However, for the opportunity to study them close up and/or
under controlled conditions, ethologists have frequently brought animals into
the laboratory—now common practice in modern behavioral research—and
used invasive techniques with free-living, wild animals. For example, early
ethological studies used chronically implanted electrodes to stimulate areas of
the brain (Klopfer, 1993); and homing pigeons were fitted with contact lenses
(Schmidt-Koenig and Schlichte, 1972) and, more recently, had their olfactory
nerve cut to study the impact upon their ability to navigate (Gagliardo et al.,
2008).
1.2
Ethology in the Laboratory
In modern ethology research, animals are studied in the wild and in captivity.
Animals that are used in laboratories are either captive bred or caught from the
wild in order to study behavior seen in their wild counterparts, but in an environment where they are in closer visual proximity and where their behavior
can be observed and manipulated under controlled conditions. The number of
animals involved in behavioral research worldwide is unknown because many
are not documented and, in the UK, only research that is considered to cause
an animal “pain, suffering, distress, or lasting harm” (UK Home Office, 2012) is
subject to licensing and therefore reported. However, potentially, a large number of undocumented behavior studies could be carried out that could still
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cause an animal a degree of d istress, even if the distress is simply a result of the
captive environment or being observed. And even more animals may simply
be housed in laboratories but not the subject of current procedures (e.g., University College London, 2017). While some countries do not report behavioral
research in their statistics, the most recent United Kingdom statistics show
that out of 3,936,723 procedures, involving the use of live animals, 55,475 come
under the category of behavioral research that causes, “pain, suffering, distress,
or lasting harm” (accounting for approximately 1.4% of procedures) (UK Home
Office, 2017a). This includes research on mice, rats, other rodents, carnivores,
pigs, sheep, birds, amphibians, and fish.
Laboratory studies of wild animal behavior cover a wide range of research
questions, including questions about their evolution and adaptations, development, cognitive abilities, social behavior, and even how their behavior
is affected by captivity, among many other areas. For example, fish are used
in large numbers in laboratories (78% of behavioral research in the UK) (UK
Home Office, 2017a); and even more fish are bred to maintain genetic lines
(e.g., Greenwood et al., 2013), with some taken from the wild to test under laboratory conditions (e.g., Burns et al., 2016). Research can involve exposing animals to aversive stimuli, such as simulating predator presence to observe their
anti-predator behavior (e.g., Brilot and Bateson, 2012); manipulating different
social conditions, for example, to monitor how males harass females (Killen
et al., 2015); and assessing whether specific behaviors are indicative of pain or
suffering (Braithwaite and Boulcott, 2007). Both nhps and birds are frequently
used for comparative cognition studies to study how abilities that are characteristically human may have adaptive qualities for animals. For example, to
study concepts, such as numerosity, theory of mind, language, economic decision making, tool use, and memory (Call and Tomasello, 2008; Clayton and
Emery, 2005; Pepperberg, 2017). In laboratory studies of this nature, an animal will typically be within a confined space and given a problem to solve, for
example, using an apparatus or on a computer screen, for which they would
receive food as a reward (e.g., Meier, Lea and McLaren, 2016). Some cognition
research also involves invasive procedures, such as fixing recording chambers
to an animal’s skull (e.g., Schechtman et al., 2016); or being restrained in stereotactic frames (e.g., Neubert et al., 2015), to take brain recordings alongside
behavioral measures.
1.3
Laboratory Animal Welfare Research
Animals who live in laboratories are affected by their environment in ways
that makes their behavior different from free-living animals. These behavioral
changes can be negative for the animal, as well as for the scientific output.
For this reason, there is a separate field of behavioral research that studies the
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welfare of laboratory housed animals, where animals are observed and experimented upon to ascertain how they deviate from their wild counterparts, as a
result of the conditions of their captive environment. Therefore, not only do
animals suffer as a direct result of experimental procedures but, because the
stress and deprivation of a laboratory environment is known to cause welfare
concerns, additional animals are housed and experimented upon in order to
examine the effects that a laboratory can have upon behavior, welfare, and,
ultimately, scientific results.
For animals who live within captive environments the ecological pressures
are significantly different from the environment in which their wild counterparts have evolved. Their surroundings are smaller, uncontrollable, and less
complex than their natural habitat. They engage in social interaction that is
distinct from what they would naturally experience (e.g., in terms of group
size, proximity, sex ratio, or hierarchy). Furthermore, they are prevented from
performing many of their natural behaviors, such as in preparation for feeding,
but are exposed to unnatural routines imposed by their carers (Bassett and
Buchanan-Smith, 2007), including: being caught and handled (Gouveia and
Hurst, 2017; Hosey, 2005); unfamiliar sounds (including ultrasonic noise from
computers); lighting and temperature (Gaskill, 2016; Reardon, 2016); and even
cage cleaning, which has been found to disrupt olfactory communication and
increase aggressive behavior (Arakawa et al., 2008). The presence of abnormal
behaviors is common in captive animals and is considered a direct result of living in these environments. These behaviors can develop as a result of unavoidable stress or fear, as a frustrated response to being prevented from performing
a behavior, or through lack of stimulation. The presence of abnormal behavior is considered a significant indicator of reduced welfare. These behaviors
can include repetitive locomotor stereotypies, such as somersaulting, pacing
or body-rocking, bar-mouthing, and self-injurious behavior (reviewed in Mason and Rushen, 2006). Laboratory animals can even experience “contagious
anxiety” physiological changes that occur as a result of observing conspecifics
undergoing procedures (Gewin, 2011; Lutz et al., 2016; Novak et al., 2013). The
presence of such behavior is absent in free-living animals, making the justification for studying wild-like behavior in laboratory animals questionable, and
problematic when animals are used to model human behavior (for further discussion of how laboratory animal behavior and welfare impacts on modeling
the human condition, see Herrmann, 2019, Chapter 1 in this Volume).
Nevertheless, to understand more about abnormal behaviors prevalent in
existing laboratory animals, experiments are carried out on more animals to
investigate factors that influence the occurrence of these behaviors and ways
to reduce or eliminate them in laboratory-confined animals. For example,
to determine whether wild-caught animals might be more susceptible to
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laboratory stressors, infant animals are taken from the wild to compare their
behavioral responses with those that have been hand-reared in the laboratory
(Jayne, Feenders and Bateson, 2013); to assess the effects of different enrichments, some animals are forced to live in barren cages (Abou-Ismail and Mahboub, 2011); and to examine the effect of different social conditions, animals
are exposed to various stressors, such as predator cues, to measure their stress
response (Zoratto et al., 2014).
Welfare research has shown that even small differences across laboratory
environments can have varying effects upon stress and the expression of abnormal behavior and development. For example, monkeys that are separated
from their mothers and raised by their peers display abnormal behaviors
later in life, as well as long lasting effects on their stress hormones, compared
to those who do not experience early maternal separation (Feng et al., 2011).
Differences in housing and husbandry, such as introducing an artificial burrow, can impact the expression of abnormal behavior (Waiblinger and Koenig, 2007). Having visual access to conspecifics has even been shown to affect
stress levels and cognitive performance (Harris, D’Eath and Healy, 2010).
Research has shown that stress of the laboratory environment is not only
associated with abnormal behavioral development, but also has long-term
effects on abnormal physiological development and even brain functioning,
with abnormal behaviors actually thought to reflect permanent brain dysfunction (Knight, 2001). For example, the basal ganglia, responsible for motor control, show altered responding in rodents and birds displaying abnormal
behavior (Garner and Mason, 2002; Garner, Mason and Smith, 2003); sensory
and motor deprivation are thought to be associated with impaired brain development (van Praag, Kempermann and Gage, 2000); and abnormal repetitive
behaviors are considered to originate from chronically thwarted attempts to
perform specific behaviors or to gain access to resources (Würbel, 2001). Psychological stress can also affect the body in other physiological ways. For example, sporadic noise stress administered to rats can encourage the display of
abnormal rearing behavior, as well as impact their gut morphology (Baldwin,
Primeau and Johnson, 2006) and the functioning of their autonomic nervous
system (Burwell and Baldwin, 2006), among other stress-related diseases (Gaskill, 2016). In addition, being prevented from performing one’s natural behavior can result in reduced physiological condition (Makowska and Weary, 2016).
Overall, animals living in the laboratory are vulnerable to abnormal behavior,
physiology, and brain development. They do not represent “healthy” models of
free-living individuals of their species, thereby questioning the validity of research using these animals to model natural animal behavior within the laboratory (Würbel, 2007). (Note that there are areas of research that indeed require
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a nimal models to display conditions not present in healthy wild p
 opulations,
such as in disease research, but critique of these models is beyond the scope
of this chapter.)
The Validity, Reliability, and Replicability of Modeling Wild Animal
Behavior in the Laboratory
For research where “abnormal models” are undesirable, as is the case for modeling wild behavior, the presence of abnormal behaviors has been identified
as a scientific problem that can compromise a study’s validity, reliability, and
replicability; thereby questioning the wider knowledge that can be gained
from such models. Experimental validity measures the degree to which a test
measures what it is supposed to test, including whether the effects were indeed caused by the treatment (internal validity); and whether the sample used
is representative of a target population (external validity). When ethological
studies are brought into the laboratory, threats to both internal and external
validity are particularly problematic when using abnormally behaving animals
to model “normal” behavior (Würbel, 2001, 2007). Reliability in an experiment
means that the same result would be obtained from repeated observations
or from multiple measurement devices. The likelihood that the outcome is
reliable is reduced by using animals that show abnormal behaviors in experiments. This increases the amount of interindividual variation in an
experiment (Garner, 2005), particularly if that variation affects the natural behavior being modeled. The replicability of an experiment refers to the extent
to which the results can be repeated, for example, across different laboratories,
which is affected by the variability in abnormal behaviors from atypical
models seen between different laboratories (Garner, 2005). Garner (2005)
describes how the brain mechanism that produces abnormal behavior “can
and does” affect experimental outcomes in behavioral studies that measure
response latencies, cage activity, behavioral switching, and extinction learning; he shows that different types of housing and laboratory environments can
affect the prevalence of these behaviors and, therefore, the validity, reliability, and replicability of a behavioral experiment (p. 112). What is even more
concerning from a scientific point of view is the prevalence of abnormal behaviors in laboratory animals; for example, it is estimated that 50% of laboratory mice display abnormal behaviors, which they start to develop right after
weaning at 21 days old (Würbel and Stauffacher, 1994; Würbel, Stauffacher and
von Holst). Therefore, a potentially large number of animals are being used,
which are unsuitable for modeling behavior of the same species living in their
natural environments, and providing results that are invalid, unreliable, and
unreplicable.
1.4
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1.5
Other Scientific Concerns
Some experiments, such as those within animal cognition (e.g., exploring innovative problem solving), over-rely on using a small number of individuals,
typically raised in unnatural, barren or restrictive environments, as an exemplar of their species’ cognitive capacities (Allen, 2002; Boesch, 2007, 2008;
Leavens, Bard and Hopkins, 2010). This is particularly true for research using
great apes. These experiments can involve the repetitive use of a small number
of the same individuals, animals that have been exposed to countless numbers
of trials with different variations of problems they must solve. While measures
are taken to try to control for the effect of learning or environment, it is not
possible to eliminate these variables as reasons for the findings in these studies; and, hence, they could explain individual differences apparent in studies
using animals who have been used many times in previous research (e.g., Tecwyn, 2013; Tecwyn, Thorpe and Chappell, 2012). In particular, there is debate
regarding the epistemic legitimacy of drawing species-level generalizations
from studies that use captive primates. For example, Tomasello and Call (2008)
controversially assert that the cognitive capacities of captive chimpanzees are
not affected negatively by their unnatural environment. To the contrary, they
note that captive chimpanzees have repeatedly demonstrated a range of impressive abilities not observed in their wild counterparts. In response, Boesch
(2007, 2008) argues that the cognitive potential of enculturated chimpanzees
is beside the point; the issue lies in making fair cross species comparisons.
Boesch (2007) states: “The recent acceptance of experimental studies, with
captive individuals considered as fully representative of an entire species,
is based on the assumption that socioecological factors play a minimal role
in the development of the cognitive and cultural abilities of the individual”
(p. 3). Despite legitimate concerns of this nature, the results of experiments
on captive populations are often considered—whether tacitly (e.g., Povinelli
et al., 2000; Silk et al., 2005) or explicitly (e.g., Tomasello and Call, 1997, 2008)—
to be indicative of the cognitive capacities (or lack thereof) of conspecifics
across all developmental contexts. Indeed, extensive evidence already exists
that different environmental experiences affect not only the cognitive development of nhps, and other non-human animals (see Nelson, de Haan and
Thomas, 2006, for a review), but that of humans as well. For example, human
infants raised in different environments perform differently on tests designed
to evaluate capacities for spatial reasoning, theory of mind, and numerical
ability (see Boesch, 2008, for a review). Furthermore, Boesch (2007) points out
that the acceptance of captive studies as representative of species’ abilities
can strongly discourage more ecologically relevant cognitive studies with wild
populations.
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A laboratory environment can never adequately simulate the natural life
of a wild animal in an ecologically realistic way and with the same ecological pressures; frequently, the experiments they are exposed to, even for ethology laboratory research, do not represent real problems for which they have
evolved to solve (Jayne, 2014). While controlling variables under laboratory
conditions allows their effects to be studied in isolation from one another, as
well as enabling behavior to be studied close up, these measures do not realistically represent how they would appear in wild populations (Leavens, Bard,
and Hopkins, 2010), and thus affect the external validity or ecological relevance
of a study (Bailoo, Reichlin and Würbel, 2014). For this reason, some experiments that are carried out to model wild behavior cannot always be replicated
under controlled laboratory conditions (Jayne, 2014). For example, Boesch and
Boesch-Achermann (2000) argue precisely this in relation to theory of mind
research carried out in captive chimpanzees:
No captive study has so far attempted to study the chimpanzee’s theory
of mind, but all have confronted the chimpanzees with totally new situations to pass tests to show the human’s theory of mind. This may a ddress
the question of [the] chimpanzee[s’] potential, but does not answer
questions about the theory of mind that chimpanzees use in their daily
lives. If some of these tests did not demonstrate a theory of mind in captive chimpanzees, we should not be surprised but rather ask ourselves
“What kind of theory of mind is adaptive for chimpanzees to acquire?”
and “When do they use it?”. (p. 243)
1.6
The Utility of Ethological Research in the Laboratory
In relation to the scientific concerns of modeling wild animal behavior in
the laboratory, a further problem is the extent to which the findings are even
desirable in advancing our knowledge of behavior in wild-living individuals,
given the methods used to obtain them. This is of particular relevance for
determining whether the gains of the research, in terms of human knowledge about a species and their behavior, outweigh the harms to the animal,
which appears to be played down when planning a laboratory study of wild
animal behavior (personal analysis of UK non-technical summaries; UK
Home Office, 2017b), although it should be a vital part of all harm-benefit
analyses.
Furthermore, while the 3Rs must be addressed for any laboratory animal
study that takes place—at least under European Union (EU) regulations,
among other systems—the urgency with which they are applied to this type
of behavioral research is minimal, in comparison to other fields of a nimal
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research, particularly for replacement (personal analysis of EU funding
dedicated to the 3Rs for laboratory behavioral/ethology research, 2017). Any
legal requirement to seek non-animal replacements is easily disregarded in
behavioral research because animals are the target species (Cuthill, 2007).
Some non-animal methods are available for behavioral research and have
been around for decades, such as computer modeling for analyzing shoaling and flocking behavior (Huston, 1988; Mwaffo, Butail and Porfiri, 2017); or
computer programs with virtual animals that can be used for educational purposes (Graham, Alloway and Krames, 1994; Behavior on a Disk, n.d.); however,
these may not be suitable replacements for many types of behavioral study.
Thus, because the behavioral studies discussed here are specifically designed
to model wild behavior, in close proximity and under controlled conditions
not always possible in an animal’s natural environment, the requirement for
replacement is undermined and, as a consequence, the scientific concerns are
given minimal weight.
Although studying the behavior of wild animals in the laboratory is a small
field of research, relative to other areas where animals are modeled, phasing
out the use of animals for this nature of research is particularly favorable: first,
because of the scientific reasons already outlined; and second, because there
is an obvious replacement available for researchers to ask the same questions
(or at the very least, similar and refined questions) about behavior, namely,
observing the natural behavior of wild and free-living animals. And where
the study of free-living animals is not feasible, researchers need to consider
whether the scientific knowledge gained from using laboratory models is even
desirable. In terms of harm-benefit assessment, more critical scrutiny by researchers and licensing bodies should find that the harms do not outweigh the
gains to scientific knowledge from attempting to model wild behavior in the
laboratory, not least the ethical concerns (which are addressed in the second
part of this chapter). This is a field of research where it is practicable to end
animal use under these conditions and could be applied with minimal negative outcomes for researchers, who should still be able to continue their study
under more scientifically favorable conditions, namely, with wild, free-living
animals.
1.7
Concluding Remarks
Due to the smaller numbers of animals used, and with typically less invasive
procedures, ethology laboratory studies often receive little attention when the
3Rs are discussed. The necessity of the research, however, is a different matter; for example, in cognition research, efforts to test whether animals are
“intelligent” focus on their abilities to show human-like capabilities, which is
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irrelevant to their evolutionary history or ecological needs (see Bekoff, 2013a,
2013b; and the second part of this chapter, for further discussion).
The Association for the Study of Animal Behaviour (asab) states that: “[i]f
procedures used in research or teaching involve animals’ exposure to painful,
stressful or noxious stimuli, whether through acts of commission or omission,
the investigator must consider whether the knowledge that may be gained is
justified” (2018, p. iii). Ultimately, laboratory behavioral research shows us
that the stress animals experience as a result of living in a laboratory impacts
the outcomes of experiments in such a way that the information gained from
these experiments may not be reliable or valid and, therefore, not justified.
asab (2018, p. i) also state that “Behavioural studies are of great importance
in increasing our understanding and appreciation of nonhuman animals”.
Behavioral welfare studies reveal that laboratory animals are a poor scientific
model for increasing our understanding of animal behavior and welfare and,
particularly, for modeling behavior seen in wild animals (Garner, 2005; Würbel, 2007). In terms of furthering our knowledge and understanding of other
animals, there are far more non-intrusive methods, such as ethological field
studies where an animal’s natural behavior can be appreciated for its own
worth, rather than using animals for hypothetical human gains. The study of
the natural behavior of animals is fascinating, and none more so than when
they are free to express their full behavioral repertoire in their own habitat.
Furthering our understanding of animal behavior is entirely possible using
non-intrusive approaches whilst still being grounded in the scientific method,
such as through direct observations, or even experimentally by incorporating
environmental manipulations (e.g., Jayne, Lea and Leaver, 2015; Klopfer, 1993).
Although laboratory behavioral research may rarely come under the category of causing “severe” suffering (unless being carried out alongside invasive procedures), for ethology studies; we have seen, from the first part of
this chapter, that some experimental methods cause animals to experience
psychological stress to such a degree that it can affect their long-term physiological development. Even simply living in a laboratory environment can
result in a sufficient amount of stress to bring about permanent changes in
behavior, physiology, and brain development (e.g., Makowska and Weary, 2016;
van Praag, Kempermann and Gage, 2000; Würbel, 2001). Ultimately, a laboratory can never adequately provide an environment for an animal to behave in
an ecologically relevant way for experimental findings to inform about natural behavior or evolved abilities. Accordingly, the continued use of laboratory
animals for ethology research is not scientifically desirable or necessary, as
well as being fraught with ethical problems, as the second part of this chapter
illustrates.
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Behavioral Research on Captive Animals: Ethical Concerns
– Adam See –

The remainder of this chapter focuses on underrepresented ethical issues arising from behavioral research in comparative cognition or, more generally, the
study of animal minds. As the range of potential topics of interest here is immense, discussion is limited to the following: 1. behavioral research conducted
in captive environments, i.e., zoos and research centers; 2. controlled studies
on non-human primates (nhps); and 3. research motivated solely by scientific
curiosity, i.e., pure or basic research as opposed to applied research, such as
theory of mind debates. Research in this vein has, to our knowledge, never
been subject to sustained ethical scrutiny. The primary aim of what follows is
to motivate this conversation.
2.1
Behavioral Research on Non-human Primates
Great ape and monkey species have long been staples of both behavioral and
biomedical research in the United States (US) and in the European Union. Biomedical research on great apes has been (mostly) banned in the EU (European
Parliament, 2010, Directive 2010/63/EU, Article 8; though see various safeguard
clauses in Article 55); and in the US, where the Fish and Wildlife Services recently granted chimpanzees endangered species status (2015; more on this law below). However, so-called “non-invasive” or “behavioral” research on great apes,
and especially other nhps, continues largely untouched in these countries.
In the US, the Ape Cognition and Conservation Initiative in Des Moines,
Iowa, continues to house, breed, and conduct behavioral studies on bonobos,
many of which focus on multi-modal communication (e.g., Taglialatela et al.,
2015). The Yale Comparative Cognition Laboratory in New Haven, Connecticut,
conducts behavioral research on the origins of human cognitive abilities in
a “naturalistic” indoor enclosure, “equipped with natural branches and other
toys” (Leimgruber, Rosati, and Santos, 2016; see also Cohen and Santos, 2016;
Rosati and Santos, 2016). Behavioral research on monkeys, involving functional
magnetic resonance imaging (fMRI), is also being conducted at Rockefeller
University in New York City (e.g., Sliwa and Freiwald, 2017). The Yerkes Research Center (Yerkes) houses and breeds nhps at both Emory University and
a second location in Lawrenceville, Georgia. Their current population of nhps
is approximately 3,400, though it is unclear what percentage is used exclusively
for behavioral research (Yerkes, n.d.). Much of the behavioral research at Yerkes takes place in “sound attenuating booths” with computer touch screens,
as well as a “foraging room” where monkeys “explore and learn in a large area
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where food can be hidden and puzzles presented” (Laboratory of Comparative
Primate Cognition, n.d.). Recent behavioral research at Yerkes involves monkeys (e.g., Brown, Templer, and Hampton, 2017; Hassett and Hampton 2017),
orangutans (e.g., Diamond et al., 2016), and chimpanzees (e.g., Krachun et al.,
2016). What is more, the Comparative Intelligence and Cognition Laboratory
at the Language Research Center at Georgia State University conducts a wide
range of comparative experiments on chimpanzees, capuchin monkeys, rhesus monkeys, and human infants and adults. Nearly a dozen such experiments
were conducted in 2016, with comparable numbers in previous years, focusing
on topics, such as numerical cognition, metacognition, strategic economic interactions, prospective memory and planning, self-control and delay of gratification, and perceptual and cognitive illusions (Comparative Intelligence and
Cognition Laboratory, n.d.).
Behavioral research on theory of mind, cognitive bias, cooperation, and
fairness, among other areas, is also regularly conducted at zoos, such as Zoo
Atlanta, which houses the largest population of gorillas, orangutans, and drill
monkeys in the US (Zoo Atlanta, n.d.); and the Lester E. Fisher Center for the
Study and Conservation of Apes at the Lincoln Park Zoo, which publishes a
wealth of studies on sociocognitive abilities in chimpanzees (e.g., Brosnan
et al., 2015; Hopper et al., 2015). Finally, behavioral research on nhps in the
US is also performed at field stations, such as the National Institutes of Health
(nih) Animal Center at the Laboratory of Comparative Ethology in Poolesville,
Maryland (e.g., Dettmer et al., 2016b; Wooddell et al., 2017). This field station is
a five acre “naturalistic” environment from which primates are temporarily removed for reasons, such as manipulating group dynamics (e.g., “rank changes
and troop stability”) in their absence (e.g., Wooddell et al., 2017). Some studies
involve separation of infant macaques from their mothers (e.g., Ferrari et al.,
2009) for up to five intervals during the first month of their lives, while others
do not (e.g., Dettmer et al., 2016a).
In the EU, the most prominent institution for behavioral research is the Wolfgang Köhler Primate Research Center (Pongoland) in Leipzig, Germany, which
houses 41 great apes. Notable recent studies include, the false-belief experiments of Krupenye et al. (2016) and Kano et al. (2017), which are the first tests
in over 40 years of research on this subject, to demonstrate that apes possess
an understanding of reality-incongruent mental states in others. The capacity
to attribute false beliefs has long been the litmus test for whether chimpanzees
possess a theory of mind, making these studies particularly significant.
The above survey of contemporary behavioral research on nhps is hardly
exhaustive, but it gives the reader a sufficient idea of the types of research under discussion here. Behavioral research is not easy to define. It can range from
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“purely-observational” research in the field, to controlled experimental trials in
captive environments involving touch screens, “non-invasive” neural imaging,
and competitive and collaborative activities with humans and conspecifics.
It mostly occurs in zoos, sanctuaries, and research centers (laboratories with
“naturalistic” enclosures). A great advantage of the mode of argumentation
that follows is that concrete definitions are unnecessary. Both the moral principle presented below as well as the challenge that results from this principle are
intended to apply to behavioral research in all of its iterations. As will become
clear, certain behavioral research may be readily justifiable in accordance with
this principle, while other behavioral research will not, and a great many cases
will remain up for debate.
2.2
Scientific Curiosity and the Ethics of Behavioral Research
In comparative cognition, the vast majority of behavioral research has been,
and continues to be, conducted on nhps bred and raised in captivity (Andrews, 2015, p. 164). As mentioned above, chimpanzees continue to be widely
used in behavioral research. Yet, as Birkett and Newton-Fisher (2011, p. 6) state,
there is an “urgent need to understand how the chimpanzee mind copes with
captivity, an issue with both scientific and welfare implications that will impact potential discussions concerning whether such species should be kept in
captivity at all”. Indeed, we share the concerns of Boesch (2007, 2008, 2015)
and Leavens, Bard and Hopkins (2010) that there is a desperate need to grapple with serious epistemic and methodological issues that arise from making population-to-species generalizations, based entirely on the behavior of
captive chimpanzees. However, the focus in this discussion is on an even less
represented issue: the welfare implications of behavioral research on these individuals. While biomedical research on chimpanzees and other non-human
primates is a widely contentious issue amongst philosophers, scientists, and
the general public alike, behavioral research has rarely been subject to moral scrutiny. Nonetheless, Malone and Palmer (2014, p. 33) are quite right that
“although ‘purely observational’ research in the field and the zoo is often regarded as inherently good and only minimally problematic, complex ethical
issues accompany research in both these settings”. The same can be said for
more hands on behavioral experiments in “naturalistic” indoor and outdoor
environments at primate research centers. Over the past few years, behavioral
research on chimpanzees has, thankfully, been the subject of several excellent
papers (Baker and Dettmer, 2016; Fedigan, 2010; Gruen, Fultz and Pruetz, 2013;
Hosey, 2005, 2008; Mackinnon and Riley, 2010; Malone, Fuentes and White, 2010;
Malone and Palmer, 2014). This discussion does not summarize the myriad of
issues that they raise but rather concludes by highlighting a crucial challenge
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to behavioral studies on captive nhps, which has been largely marginalized by
philosophers and primatologists alike.
In the opening pages of her popular primer, Fundamentals of Comparative
Cognition (2013, pp. 1–2), Shettleworth highlights two motivations for studying
the animal mind. First, there are various “practical considerations” for “addressing issues in conservation and animal welfare,” as well as for the construction
of animal models for application in fields, such as neuroscience and genetics.
Research motivated by these concerns is directly relevant to challenges discussed in the early sections of this chapter. Of special interest in the current
discussion, however, is the second motivation that Shettleworth discusses: behavioral research motivated strictly by “sheer scientific curiosity.” It is clear, for
example, that the longest running and most popular issues regarding animal
minds, tackled by philosophers and scientists alike, are chiefly addressed at
questions of human uniqueness. As Shettleworth (2013, p. 2) claims, “What unifies this diverse field is the overarching question with which the modern study
of comparative cognition began, how true is Darwin’s (1871) assertion that
humans’ ‘mental powers’ are ‘different in degree but not in kind’ from those
of other species?” The question as to whether Darwin was right to challenge
this age-old, and still dominant, notion of human uniqueness is commonly
thought justifiable for its own sake. Povinelli’s work (2000; 2012) on chimpanzee
“folk physics” offers a prime example of such research. Based on a series of experiments on captive chimpanzees at the New Iberia Research Center (nirc),
Povinelli argues that chimpanzees understand the physical world in a way that
is fundamentally different from humans. It is worth noting, in line with the
first part of this chapter, that the ecological validity of Povinelli’s findings has
been subject to great scrutiny. Within a year of publication, three scathing reviews of Povinelli’s first book on the subject, by high-profile figures, appeared
in comparative cognition (Hauser, 2001; Whiten, 2001; Allen, 2002). This second
class of behavioral research (henceforth referred to as sheer curiosity-based behavioral research or scbb research) presents a unique ethical challenge that is
not faced by other common forms of animal experimentation.
scbb research can be defined as, experimental, or purely observational,
behavioral research with no expected, or foreseeable, practical consequences.
The motivations of the researchers are essential to this definition. Povinelli’s
experiments on the nirc chimpanzees were not motivated by welfare concerns, nor were they motivated by future use in constructing animal models;
rather, Povinelli and collaborators quite simply sought to gain knowledge as
to whether chimpanzees understand the physical properties of objects in the
same way that humans do (or, in many other of their experiments, whether
chimpanzees possess a theory of mind). The majority of behavioral research
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on chimpanzees in comparative cognition is guided, first and foremost, by this
basic desire to know for the sake of knowing (not to mention, of course, academic eminence, research grants, and the desire to publish). Further research
and commentary is encouraged on this final point, as these overarching goals
and features of academic culture are clearly relevant to the issue at stake.
When Shettleworth (2013, p. 2) claims that while “practical considerations
motivate some research in animal cognition,” an “equally important impetus
for studying comparative cognition is sheer scientific curiosity,” she is evoking
the classic dichotomy between pure and applied science. In so doing, Shettleworth is aligning scbb research with the former. Indeed, much of the animal
minds literature tacitly operates under the banner of so-called, pure science,
i.e., science without clear or direct practical implications. However, as is frequently argued in the philosophy of science, a strong case can be made that
science is never entirely pure, insofar as the practice of doing science is never
entirely value neutral. The costs and benefits of research at every step of the
way—from motivating the research program to deciding upon the means
to conduct it—are the result of tacit or explicit value judgments, including
“a prior judgment to which moral considerations are pertinent” (Kitcher, 2001,
p. 90; see also Gonzalez, 2013, for further commentary). With respect to scbb
research, for many experimenters who work in field, zoo, and research centers,
traditional ethical criteria (such as the 3Rs) appear “puzzling and irrelevant”
(Fedigan, 2010, p. 755); occasionally going “so far as to identify their projects
as exempt from the entire oversight process” (Malone and Palmer, 2014, p. 25).
While much of the current ethics literature on chimpanzee behavioral research (such as those cited above) provides strong reasons to reject this perspective (i.e., zoological institutions and field research clearly come with their
own ethical concerns), in what follows we take a different critical approach
by challenging the very basis for conducting some of this research in the first
place. As these issues are broken down, scientific curiosity alone emerges as an
extremely weak reason for breeding and confining animals.
2.3
A Moral Challenge
Practically all discussions of the ethics of animal experimentation (under any
guise, context, motivation, or environment) involve some form of utilitarian
calculus, i.e., “one that tries to weigh the beneficial consequences of experimentation with the costs associated with it” (Gruen, 2011, p. 118). The challenge that we pose to pure research facilities that breed and maintain animals
solely to satisfy scientific curiosity is that such practices are incredibly difficult to justify on ethical grounds. There is even a crucial sense in which, given
a utilitarian calculus, breeding and maintaining animals in captivity for the
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sole purpose of studying their behavior is more difficult to justify with reasoned arguments than invasive biomedical experiments. Invasive biomedical
research clearly evokes more welfare concerns than behavioral research, but
the welfare concerns in the former can be, and often are, argued away on the
basis of anticipated practical benefit. scbb research, on the other hand, may
be legitimately said to evoke fewer welfare concerns. However, without any expected or foreseeable practical benefit to fall back on, convincing justification
for breeding and maintaining chimpanzees in captivity—rather than placing
extant chimps in sanctuary—is by no means obvious. Therefore, despite the
wealth of knowledge attained from captive studies, a large amount (perhaps
even the majority) of behavioral research conducted on chimpanzees (past,
present, and future) is far from easy to justify. There is clearly a very real challenge present here worthy of serious consideration.
Those who conduct scbb research in zoological institutions, such as Frans
de Waal at the Arnhem Zoo (e.g., de Waal, 1998) and Michael Tomasello at the
Wolfgang Köhler Primate Research Center in collaboration with the Leipzig
Zoo (e.g., Tomasello et al., 2007), are capable of offering additional justifications for captivity, e.g., the conservation efforts of their host institutions
(see later discussion). However, it is very difficult to make a strong case that
breeding and maintaining nhps at pure research facilities, such as New Iberia Primate Research Center or the Yerkes National Primate Research Center,
is morally justified. There are currently eight National Primate Research Centers in the US, not including many other similar federally-funded institutions,
such as the nirc. Some of these institutions have conducted scbb research
on chimpanzees, in addition to more common biomedical studies. Both the
Yerkes facility (Guha and Sullivan, 2015) and, more infamously, the New Iberia
facility (Gruen, 2011, p. 116) have been subject to charges of ethics violations by
the Humane Society of the United States, ultimately leading to the retirement
of 220 New Iberia chimpanzees to the Project Chimps sanctuary in 2016 (New
Iberia Research Center, n.d.). Crucially, the line of argumentation presented
here is not contingent upon these more egregious cases, but rather applies
more broadly to challenging the ethical basis for keeping chimpanzees in captivity (even in “enriched” or “naturalistic” conditions) purely to satisfy scientific
curiosity.
2.4
A Moral Principle
Let us proceed via demonstrative reasoning by agreeing to what we take to
be an uncontroversial principle: interests motivated by the desire to satisfy intellectual curiosity (with no foreseeable or expected practical benefit) should
not compromise or outweigh the welfare interests of others, because the former
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type of interests are comparably trivial relative to the latter. This principle is
non-speciesist; it applies to research on humans as well as any sentient being
capable of having interests. Importantly, it does not make all behavioral research unethical. For many animals raised in captivity, releasing them into the
wild would clearly not be in their interests (Gruen, 2011). As such, for many animals already in social groups at zoological institutions, with conservation and/
or welfare-directed mission statements, this principle may readily promote
their continued existence at the zoo, alongside other welfare interests of the
nhp populations in question. For example, the Wolfgang Köhler Primate Research Center website claims that, “The breeding program at the zoo is framed
within the global strategy of the European Endangered Species Program (eep);
and some research focuses on the husbandry and care of great apes in captivity”. What is more, so long as the experiments themselves conducted in these
environments can be convincingly argued to not violate the welfare of the test
subjects, the principle is likewise not violated. The principle simply states that
X’s interests in bodily mobility, choice of social and sexual relations, general
psychological well-being, and so forth, always outweigh Y’s interests in satisfying their intellectual curiosity. It, therefore, follows that whenever X’s interests
and Y’s interests are at odds, it is Y’s obligation to explain why their interests to
conduct scbb research are not trivial when compared to X’s welfare interests;
or, that Y’s interests do not actually supersede any of X’s welfare interests (as
researchers in zoological institutions may claim). That said, the challenge that
we have posed, based on this principle, is vital to future research programs
because, if the above reasoning is sound, it seems to follow that none of the
scbb research conducted on the New Iberia chimpanzees, for example, was
morally justified.
2.5
Counter Argumentation
Let us now consider several logical counter-arguments. To begin, some might
take issue with the liberal use of the word practical and suggest, rightly, that
while it is true that individual researchers may take themselves to be merely
scratching an intellectual itch, the scientific enterprise as a collective effort almost always bears practical fruit, even from the most obscure research programs. If that is true, then the utilitarian calculus suggested here starts to look
a lot more complicated. It requires the estimation of possible future utility of
discoveries arising from research programs that, when undertaken, do not
seem to have any practical value. As such, it is far from clear how such a utility
calculation could be performed in any rigorous way.
Our response is as follows. When defining the parameters of scbb research,
we stressed the importance of researcher motivations because almost any
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pure research could be justified on the basis of ad hoc practical applications.
Consider the theory of mind research. One foreseeable response to our conclusions is that work on theory of mind in chimpanzees does clearly have practical
repercussions in the sense that this debate has been “central” to discourse on
whether apes should be considered moral or legal persons (Lurz, 2011, p. 4).
As such, a potential counter-argument might run along the following lines: as
Malone and Palmer (2014, p. 34) note, “caregivers to orangutans at Auckland
Zoo expressed the idea that zoo animals serve as ‘martyrs’ for their species,
suggesting that individual sacrifice is justified for the sake of the ‘greater good’
of conservation. Similar ideas are often raised in discussions about the b enefits
of field research, alongside the notion that ‘knowing more’ makes such research inherently good”. With respect to theory of mind research, those who
breed and maintain chimpanzees at research facilities could argue that these
individuals were, in some sense, “martyrs” for scientific knowledge that has,
or may foreseeably have, practical applications regarding the welfare of their
entire species.
This potential response is strongly unappealing for a number of reasons.
First, there is no clear evidence that theory of mind research has led to
progress for chimpanzees attaining legal personhood. Second, there is already
sufficient evidence that chimpanzees have at least a “minimal” theory of mind
(Call and Tomasello, 2008), which should satisfy any salient ethical concerns
regarding the concept. Third, it is hypocritical for anyone who is motivated to
defend theory of mind studies at research facilities, such as the nirc, due to
concern for the personhood status of chimpanzees, because any presumed or
potential personhood status owed to those research subjects would be violated
by their being bred and kept in such an environment. Fourth, the chimpanzees themselves quite clearly had no say in their presumed status as “martyrs”.
Fifth, as Gruen (2011, p. 129) notes, “Virtually every scientific article ends by
claiming ‘that more research is needed’. This is how research scientists make
their living”. Theory of mind research is no different; in fact, the theory of mind
debate has long been subject to a well-known gridlock since decades worth
of experimental and ethological research have failed to mitigate widespread
skepticism under the guise of the so-called logical problem. Proponents of the
logical problem claim that all approaches, past and present, that have been
used to evaluate cognitive capacities, such as the presence of theory of mind
in animals, “cannot provide evidence for this ability even in principle” (Halina,
2015, p. 474). In its basic form, the logical problem states that since all we can
observe is an animal’s behavior, it is difficult (if not impossible) to determine
whether an animal is predicting the behavior of others by means of mental
state attribution (e.g., of their underlying intentions and beliefs), or by means

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

536

Jayne and See

of associative or conditioned response-mechanisms. Since there is little reason
to believe that the logical problem will be solved (Andrews, 2015), ad hoc justifications of scbb research based on foreseeable ethical consequences of the
theory of mind debate are clearly weak. Therefore, this same conclusion applies to any other research program commonly pursued at pure research centers for the sole purpose of scientific curiosity.
Another foreseeable counter argument would evoke the “naturalistic” or
enriched conditions provided by research centers, such as Yerkes. It could be
argued that, given these enriched conditions the ethics of captivity for primates
in research centers deserves to be situated on a moral continuum with the
apparent “naturalistic” conditions at zoological institutions, rather than in a
separate category. We agree. Our response is that zoological institutions, such
as Pongoland, are certainly not off the hook morally. We have excluded zoos
from the heart of this discussion because the costs and benefits of their supposed conservation value is under scrutiny elsewhere (e.g., Alroy, 2015; Keulartz, 2015; Marino et al., 2010; Princée, 2016); but we readily grant that zoos and
research centers exist on the same moral spectrum. With respect to this issue,
we direct the reader to literature that explicitly considers the ethical weighing of zoological conservation efforts and welfare concerns brought upon by
captivity (e.g., Davey, 2007; Gruen, 2011; Hosey, 2005, 2008; Keulartz, 2015) and
grant that the challenges raised here apply to scbb research across the map.
Nonetheless, in the absence of any clear benefits for the animals themselves,
it is evident that scbb research conducted at institutions, such as nirc and
Yerkes, cannot readily satisfy the self-evident moral principle that we have provided nor can any given utilitarian calculus that one may apply to justify this
kind of research. Finally, it must be noted that the above is intended strictly
as grounds for positing an important, yet critically underdiscussed, challenge
for researchers to contend with—a moral dilemma that naturally arises when
one attempts to justify scbb studies—rather than a direct indictment of any
particular researchers or institutions.
2.6
Concluding Remarks
Those who engage in or otherwise defend scbb research necessarily face a
unique challenge not confronted by other forms of animal experimentation. All
debates over animal experimentation evoke some sort of messy utilitarian or
consequentialist calculus, wherein some foundation (firm or not) is provided to
weigh the costs and benefits of breeding, maintaining, and experimenting on animals for research. However, when it comes to breeding primates (or any species,
for that matter) purely for scientific curiosity at research centers, the calculus
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appears to come out the same every time: scbb research is unjustified across the
board. The extent to which this conclusion may also apply to similar research
programs at zoos is far beyond the scope of this chapter but certainly one for further discussion. Also crucial for future discussion are the difficulties associated
with justifying continued behavioral research by means of the conservation efforts of particular non-sanctuary research institutions, where such research is
conducted (e.g., the Ape Cognition and Conservation Initiative in Iowa).
The following proposal is a corollary of the basic moral principle put forth
and defended above; those who study animals in captivity must demonstrate
either that:
1.
The welfare interests of their research subjects are not compromised or outweighed in favor of interests derived solely from satisfying intellectual curiosity; and/or that
2. The dominant reasons for breeding and maintaining animals in captivity
derive more from the welfare interests of the animals themselves than from
purely intellectual interests.
The traditional act of breeding and maintaining non-human primates at research centers cannot readily satisfy these fair-minded conditions.
In terms of logistics, what exactly is being recommended here? We propose
that the US Fish and Wildlife Services (fws) may have already, in part, paved
the way. On September 14, 2015, the fws officially granted endangered species
status to chimpanzees living in the wild and in captivity. As a result, in order
to use chimpanzees for biomedical research, one must apply for a special permit from the fws. To date, only one permit has been applied for, which was
granted in the interest of developing an Ebola vaccine for wild chimpanzees
(Walsh et al., 2017). According to the fws, however, behavioral research does
not require such a permit. Such research would only require one, if it involves
“actions that harm, stress, harass, or noticeably change the animal’s behavior”
(Grimm, 2015). If it can be convincingly argued via a combination of investigative journalism and welfare research on captive primates that these consequences do arise in captive chimpanzees, especially at pure research centers,
a double standard could fairly be demonstrated here. Furthermore, “endangered species status” is largely irrelevant to the key issue at stake. One could
readily expand this general proposal in the following way: All biomedical and
behavioral research—not only that which involves nhps, but all research involving captive canids, birds, bears, rodents, and others—should require such a permit. Research at zoological institutions would very likely be granted one, but it
seems unlikely that future breeding and research programs conducted at more
laboratory-oriented types of research institutions would.
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1

Introduction

Hands-on skills training in biomedical education has traditionally relied on
the use of more than 9 million live vertebrate animals each year in the United
States (US) alone (Patronek and Rauch, 2007), and more in other countries
around the world, ranging from performing minor surgical manipulations and
pharmacological interventions to managing major traumatic gunshot wounds,
burn injuries, and dismemberments. Recently, however, a paradigm shift has
taken place that has seen the full replacement of animal use in civilian medical
school curricula and skills-training programs in various countries, along with
significant reductions and replacements of animal use in comparable military
training drills. The embrace of simulation-based biomedical training has been
spurred, in part, by improvements in technological realism that accurately
mimics human anatomy and physiology, financial burdens involved with running animal laboratories, heightened public awareness and ethical objections
© john pawlowski et al., ���9 | doi:10.1163/9789004391192_023
This is an open access chapter distributed under the terms of theKathrin
prevailing
cc-by-nc License at the time
Herrmann and Kimberley Jayne - 978-90-04-39119-2
of publication.
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

552

Pawlowski et al.

to the use of animals in experiments, and unique pedagogical advantages inherent in simulation-based training and assessment capabilities.
This chapter reviews the global trend towards a modernization of biomedical education in favor of simulation-based training methods, which studies
confirm improve student learning and transference of applied skills to clinical
practice, reduce laboratory costs, and spare animals from harmful procedures.
2

Animals Used in Military Medical Training

2.1
Live Tissue Training
The first published curtailing of the US military’s use of dogs, cats, and nonhuman primates in invasive wound experiments occurred in 1983. That year,
animal protection organization People for the Ethical Treatment of Animals
(peta) publicized plans by the US Department of Defense (dod) to shoot
live dogs to create life-threatening injuries, during a so-called, “wound lab” so
that military personnel could practice trauma management. Subsequently, the
dod temporarily halted all animal use for this practice before banning the use
of cats, dogs, and non-human primates and allowing for the use of pigs and
goats that continues today in, so-called, “live tissue training” (ltt) (Associated Press, 1984). The dod’s present-day incarnation of ltt involves creating
penetrating gunshot and stab wounds, burn injuries, and limb amputations in
more than 8,500 live pigs and goats each year (Klimas, 2017). Bipartisan legislation has been introduced in the US Congress (Battlefield Excellence Through
Superior Training Practices Act, 2017) to replace the use of animals in ltt with
superior human simulation technology, a transition supported by the New York
Times Editorial Board and national physicians’ organizations, among others
(Johnson, 2016; Editorial Board, 2016).
Two peta eyewitness video investigations of these military drills—one in
2012, showing live goats having their limbs cut off with tree trimmers (Kimberlin, 2012); and one in 2013, showing live pigs enduring gunshot wounds to their
faces (Shiffman, 2015)—have exposed ltt to the scrutiny of the public, spurring protests and congressional inquiries (Kheel, 2016). Due in part to these
developments, in 2013 the US Army required all non-medical personnel, and
certain medical personnel, to use human simulation training methods exclusively, instead of ltt (Brooks, 2013). In 2014, the US Coast Guard cut its use of
animals for ltt by more than half (Vergakis, 2014). In 2014, the dod directed
all military service branches to cease using animals for six areas of medical
education, including Advanced Trauma Life Support training, obstetrics and
gynecology residency training, pediatric intubation training, and certain types
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of trauma training among other areas (US Department of Defense, 2014).
In 2017, the US Coast Guard fully ended all use of animals for ltt in favor of
human simulation models (Seck, 2017).
Internationally, a survey published in 2012 found that 22 of 28 North Atlantic Treaty Organization (nato) nations, nearly 80% percent, do not use any
animals for military medical training programs and instead use human simulation models exclusively (Gala et al., 2012). Of note, animal advocates filed
complaints with German authorities about ltt permit applications by the US
Army in Germany. In 2010, German officials repeatedly denied requests by the
US military to proceed with this activity, concluding that the procedures would
“violate host nation animal protection laws” because “effective alternatives to
animals are available” (Vandiver and Kloeckner, 2010). Similarly, after animal
advocates provided information to military officials about human simulators
and other non-animal trauma training methods, in 2013, the Polish Ministry of
National Defense ended ltt; and in 2014, the Norwegian Animal Research Authority rejected an ltt application by the Norwegian Armed Forces, since they
did not provide evidence that non-animal training methods were inadequate
(Baker, 2015).
2.2
Chemical Casualty Training
The US Army’s Aberdeen Proving Ground regularly conducted training in the
medical management of biological and chemical casualties by exposing as
many as 48 live monkeys annually to simulated nerve agents, which can cause
uncontrollable twitching, seizures, vomiting, and difficulty breathing (Vastag,
2011). The release of video footage in 2009 from this training by the Physicians
Committee for Responsible Medicine (pcrm) (Lawrence, 2009)—followed by
public protests, congressional inquiries, and a deluge of letters to military officials by animal advocates—led to the Army’s announcement in 2011 that it
would replace the use of animals with trained actors, computer programs, and
high-tech human patient simulators (Vastag, 2011). In effect, the animals were
replaced with more anatomically correct and physiologically relevant human
models, which established a credible gravity to the educational experience
(Vastag, 2011).
2.3
Pediatric Intubation Training
According to documents obtained by peta via the US Freedom of Information Act from 2010 through 2014, physicians, pediatric residents, nurses, and
medical technicians traditionally learned neonatal intubation by forcing hard
plastic tubes down ferrets’ delicate airways, as many as six times per animal each session at both Lackland Air Force Base (afb) (2007) and Madigan
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Health System (2010); as many as five times per animal each session at both
Travis afb (2008) and Keesler afb (2010); and as many as 10 times per animal
each session at Naval Medical Center Portsmouth (Sizemore, 2012). This procedure can cause bleeding, swelling, pain, scarring, collapsed lungs, and even
death. Indeed, the approved protocols at these facilities acknowledge that
there is pain associated with this procedure, given that in these protocols as
many as 100 animals or more were listed in the US Department of Agriculture’s Column D, which is reserved for animals experiencing pain or distress
(Keesler afb, 2010; Lackland afb, 2007; Madigan Health System, 2010; Travis
afb, 2008).
Following numerous letters to the leadership of each military installation
by concerned members of the public and military physicians, each facility
ended its use of animals for pediatric intubation training. Per a dod memorandum, by the year 2015, all military facilities fully transitioned to infant
simulators, which are able to better represent human anatomy as well as
physiological vital signs, to teach pediatric intubation skills (US dod, 2014).
3

Animals Used in Civilian Medical Training

3.1
Undergraduate Medical Curricula
Medical students in the US have historically participated in classroom animal
laboratories, such as injecting pharmaceuticals into live dogs to observe adverse side effects and performing invasive procedures on live pigs. However, a
confluence of various factors, including sustained advocacy efforts by organizations such as pcrm, constricted institutional educational budgets, and the
technological advancement of simulation models, helped to clear the path for
the complete end of animal use in the US medical curricula in the year 2016
(Simkin et al., 2017). Canadian medical schools accomplished this feat five
years earlier (Blackwell, 2011).
Perhaps one of the largest animal use policy changes in global biomedical
training came from India, which for decades required medical students in
Bachelor of Medicine and Bachelor of Surgery (mbbs) programs to perform
pharmacology and physiology experiments on approximately 1.5 to 2 million
live animals each year (Akbarsha, 2012). In part, following meetings with animal advocates, government officials, physicians, and academics, the Medical
Council of India amended its mbbs regulations to replace the use of animals
with non-animal training methods (dna Correspondent, 2014). This decision
that was replicated by the Pharmacy Council of India (tnn, 2014) for pharmacy training; the Dental Council of India for dental training (Singh, 2013);
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and the University Grants Commission for life science and zoology training
(Pulla, 2014). These actions, now taken by many of the governing bodies of
the educational systems in India, may result in saving millions of animals
each year.
3.2
Neonatal Procedure Training
Neonatal procedural skills include the practice of infant intubation; neonatal
umbilical view cannulation; neonatal chest tube insertion; and cerebrospinal
fluid sampling (spinal taps). These procedures have traditionally been taught
using live animals. However, the American Academy of Pediatrics (in 2005);
the Emergency Nurses Association (in 2008); and the American Heart Association (in 2013) wrote to peta to embrace the use of animal-free training methods involving human simulation. In 2011, the National Association of Neonatal
Nurses (nann) announced that they would replace their use of animals in
training for these procedures with a human simulator-based curriculum, a
transition facilitated by peta, which donated newborn patient simulators
(nurse.com, 2011).
At another civilian facility, Washington University in St. Louis, the Pediatric
Advanced Life Support (pals) course announced that it was replacing its use
of live cats with simulation-based mannequin training. The program’s decision
followed complaints by pcrm and peta’s release of eyewitness video footage
showing students at times struggling repeatedly to insert breathing tubes in
the animals’ throats (Salter, 2016).
3.3
Advanced Trauma Life Support (atls) Training
The American College of Surgeons’ (acs) Advanced Trauma Life Support
(atls) program was introduced in 1978 and has become the standard of care
for initial assessment and treatment of trauma patients. During this course,
physicians historically practiced cricothyroidotomy, chest-tube insertion, pericardiocentesis, venous cutdown, and diagnostic peritoneal lavage by cutting
crude holes into the chests, throats, abdomens, and limbs of live dogs, pigs,
sheep and goats. In 2001, the acs approved the use of human cadavers and the
TraumaMan system (Simulab Corporation, 2017), as full replacements to the
use of animals during the surgical laboratory session of the atls course (acs,
2001). The TraumaMan system allows atls programs to avoid animal use by allowing students to practice surgical procedures on an anatomically-correct human torso that features lifelike skin, tissue, internal organs and bones, as well
as simulated bleeding when cut into and airway response using a ventilator.
Due in part to advocacy efforts by pcrm and others, and given the numerous
studies confirming the efficacy of simulation-based training, today more than
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99% of the 276 atls training facilities in the US (pcrm, 2018), and all of the 32
atls programs in Canada (Blackwell, 2011), now exclusively use TraumaMan
and other acs-approved non-animal training methods.
Starting in 2012, Peta surveyed international atls programs regarding their
use of animals or simulators as part of the course’s surgical skills laboratory.
Numerous international atls officials from countries that use animals for this
course expressed a desire to switch to non-animal simulation models, yet cited
financial constraints as the primary transition barrier. To solve this issue, peta
established a successful groundbreaking program with Simulab Corporation
and atls leaders in 22 countries to cost-effectively replace their use of animals with TraumaMan models, sparing thousands of animals from undergoing
terminal surgical procedures while also improving trauma-skills training for
physicians around the world (McNeil, 2014; Belisomo, 2015; People for the Ethical Treatment of Animals, 2017).
4

Use of Animals in Veterinary Medical Training

Concurrent with the advances in the use of simulation for human medical
education, a surge of knowledge, curricula, and simulation technologies have
been applied to the field of veterinary medicine. In addition to using simulators to teach physical diagnosis skills, these devices have been employed to
teach clinical procedures (Hodgson and Pelzer, 2017). In 2010, researchers described the use of simulation-based training to teach the bovine rectal exam
(Baillie et al., 2010). Simulators have been used to instruct veterinary students
in procedures as well as in laparoscopic surgical techniques (Kilkenny, 2016).
Industries (n.d.) has expanded to develop species-specific, whole body simulators for horses, cattle, sheep, dogs, cats, and a variety of other animals. These
simulators have the advantage of species-specific physiological and pharmacological models, as well as relevant anatomical structures.
In addition to task and procedural training, veterinary simulators have been
applied to teach team training and aspects of professionalism (Caraballo et al.,
n.d.; Scalese and Issenberg, 2005). Mossop (2012) described the teaching of
certain professional traits using veterinary simulators. These traits included
communication, ethical reasoning, reflective practice, and learning skills.
Communication skills and professionalism are among the most common reasons for failure during clinical rotations and for the filing of malpractice suits
(Hoffman, 2016).
Similar to the professional development goals articulated by the Accreditation Council for Graduate Medical Education, the American Veterinary
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 edical Association maintains a list of required standards for all graduates
M
from accredited veterinary medical schools. These traits of integrity, teamwork, communication, and honesty can be brought out and discussed during
simulated exercises. The simulation encounters can be altered to be more difficult for advanced students or repeated for students who need remediation.
In summary, the field of veterinary medicine has seen a recent expansion of
animal simulators and simulation curricula to teach the practical and professional aspects of a veterinary practice. These new simulation-based developments provide humane teaching tools that allow replacement of the harmful
use of live animals in veterinary science education.
5

Non-animal Training Methods

Numerous curricular reforms have led to a dramatic decrease in the use of
live animals for biomedical training around the world. In most cases, some
form of whole body simulation and/or task trainer devices are used as educational tools in place of animals. Implicit in the replacement of animal
use is that the simulation-based methods have equal or better pedagogical
outcomes for the learners, and several studies confirm this point (Patronek
and Rauch, 2007).
5.1
High-fidelity Simulation Accurately Models Human Patients
Many whole body mannequins and partial task trainers can bleed, breathe,
and simulate realistic surgical procedures. Examples include, Multiple Amputation Trauma Trainer simulator (Kforce Government Solutions, Inc., 2014);
high-fidelity SimMan Essential simulator (Laerdal Medical, 2017); Caesar trauma patient simulator (cae Healthcare, 2017); hyper-realistic Cut Suit model
(Strategic Operations, 2015); and TraumaMan model (Simulab Corporation,
2017). Simulators can adapt to medications with changes in heart rate, blood
pressure, and respiratory rate. The physiological responses are based on hemodynamic models of humans and, therefore, are well suited to teach medical
students. During clinical training, medical students can practice asking questions that probe a patient’s medical history, and the mannequin’s response to
these questions can facilitate further inquiries by the student. This way, the
student can piece together essential information to compile a detailed history
and differential diagnosis. Far from being limited to simple signs and sounds,
whole body simulators can evoke complex cognitive issues and require synthesis, analysis, and processing of medical information to determine the various
disease entities. To teach trainees to recognize different pathophysiological
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states, the mannequin can demonstrate a number of disease symptoms. For
example, the mannequin can wheeze, develop a murmur, or produce muffled
bowel sounds. Acute airway obstruction or tension pneumothorax can prompt
an emergent clinical response from students, years before they would be ready
to treat a patient with assurance.
Surgical procedures can also be taught using either virtual reality simulation
or task trainers in conjunction with whole body mannequins. For example,
an entire laparoscopic cholecystectomy can be performed in virtual reality,
with students manipulating laparoscopic instruments in an environment that
mimics the surgical anatomy, duplicates bleeding vessels, and features flaming
cautery to coagulate hemorrhage. Task trainers can similarly depict abdominal
structures that the student must identify and retract in order to expose and
remove the gall bladder. These simulator options can also be used to measure
reduction in time to perform a task as a measure of proficiency, record surgical errors, and be accompanied by real-time feedback and deliberate practice
(Reznick and MacRae, 2006).
5.2
Simulators Improve Technical Proficiency
In a randomized study on emergency procedures, Hall (2011) assigned trainees
to complete procedural tasks on human simulators or on live animal tissue
models. Results demonstrated that trainees’ acquisition of procedural skills
were significantly better when simulators were used. Most of the perceived
benefits came from the human anatomical features of the simulators. This
preference for the human anatomical model was also demonstrated in a study
by McCarthy et al. (2002), who compared cricothyroidotomy sessions using canine versus human cadaver models. They found that trainees performed procedures more accurately on the latter.
Simulation technologies exist for many levels and subjects in biomedical
education. Early training with whole body simulators has been shown to be
effective in teaching the principles of physiology to first year medical students.
Tan et al. (2002) described the range of simulation-based sessions in preclinical medical school courses, which include introduction of clinical situations
and diseases; elements of history taking and empathetic styles; formation of
a differential diagnosis; and corroboration of physical examination findings.
5.3
Simulators Improve Patient and Medical Provider Safety
Medical students learning either internal medicine or general surgery can benefit from simulation-based teaching. All simulation training avoids the potential risks to the patient of medical trainee-induced complications (Friedrich,
2002). For example, the first needle insertion, suture repair, or incision by a
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medical student can be done using a simulator. A hallmark of simulation allows students to perform numerous medical procedures and receive satisfactory assessment by skilled instructors, before any attempts on a live human
patient, thereby minimizing patient injury and complications during the period of early training. In addition, the use of simulation can prove to be safer
for the medical student. Needle punctures can result in the transmission of
disease, such as hepatitis or hiv. Therefore, avoidance of early needle punctures for infected patients using simulators, allows students to gain some proficiency and avoid the risk of self-inflicted needle injury with a contaminated
needle. For both the patient and the student, early use of simulators can provide important safety benefits.
5.4
Simulators Foster Development of Higher-Order Cognitive Skills
Simulation-based training can also teach a host of higher-order cognitive
lessons. In 2006, Takayesu and colleagues examined the use of high-fidelity
patient simulation in medical student learning. Participants were asked to report on their experience following a simulation-based clinical exercise. Aside
from the simulators’ “learning by doing” paradigm that fosters technical skills
development, 46 percent of the students felt that simulators are superior to
other methods in teaching “clinical decision making” and “communication
and teamwork”. These subjects are considered more conceptual and complex
and require higher-order cognitive skills; and they are often associated with
essential elements of professionalism. The authors concluded that simulation
exercises help students to integrate pathophysiological concepts into clinical
situations in a risk-free environment (Takayesu et al., 2006).
Students Benefit from Immersive Simulation-Based Training that
Mimics Realistic Clinical Scenarios
Not only do simulators allow for a fairly realistic depiction of anatomic
structures, but they can also allow students to be immersed in a realistic environment that resembles an operating room. Surgical equipment, anesthesia machines, gowns, and gloves can bring the learner into an engaging and
realistic clinical space. The level of engagement simulation offers has been
well-described, and such levels of activation are crucial to learning (Oriol et
al., 2011). In surgical literature, Kaufman (2003) described how simulation not
only allows for deliberate technical practice but can also be integrated into
the clinical environment. Kaufman described the use of simulation to teach
and coordinate the care of military patients in a multi-casualty setting; however, the lessons learned can likely apply to civilian circumstances. All surgical
operations involve teams and communication. All surgical procedures have
5.5
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periods of technical challenge, and other times may include logistical problems.
Simulation-based training can provide a realistic situation of urgency, emotional stress, and technical demand that require quick decisions, precise
actions, and coordinated follow-up. With trained clinical raters, the participants can receive valuable feedback about their decision making, technical
surgical skill proficiency, teamwork, and communication. It is important
to note that only a small portion of medical learning objectives involve task
completion. Indeed, most of the skills are non-technical and include effective
communication, an organized approach, management of resources and people, and maintenance of global awareness. The conversion from animal-based
training to the use of simulators allows for a preservation of effective learning
and an increase in patient safety (Balcombe, 2004).
5.6
Simulation Shortens Medical Trainees’ Learning Curve
Issenberg et al. (2005) systematically reviewed the best clinical evidence for
the use of simulation in medical education and found that the majority of
studies demonstrate the utility of simulation in providing faster learning with
better retention of concepts over time. Almost all of the reviewed papers
showed that simulation was as least as good as, if not better than, conventional
teaching methods. Another study showed that simulation-based training accelerated or shortened the learning curve that any novice or trainee experiences by allowing for ongoing coaching, evaluation, feedback, and correction
through deliberate practice (Patel, et al., 2006). In both civilian medicine and
military medical training, the use of simulation has become a key component
of the curriculum (Hauck, 2016).
6

Harmonization of Best Training Practices

There is a global lack of policy harmonization between countries and locally
between laboratories, regarding the use of animals in biomedical education.
For example, the United Kingdom prohibits surgical training on live animals,
yet other countries still allow the use of animals for this purpose. The US Army
has banned the use of animals in trauma training drills by non-medical personnel, yet other US military service branches continue to allow non-medical
personnel to use animals in these exercises. Twenty-two nato nations, including 19 European Union (EU) Member States, have confirmed that they do
not use any animals for military medical training (Gala et al., 2012). Yet, six
nato nations continue to use animals for ltt, some of which are EU countries
bound by Directive 2010/63/EU (European Parliament, 2010) that requires the
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use of non-animal training methods whenever available. Also, many medical
schools around the world continue to use animals in physiology and pharmacology training, among other disciplines, even though this practice has been
abandoned by all medical schools in the US, Canada, and India.
Efforts should be made to identify procedures, skills, or concepts that are
currently taught at certain facilities using simulation technology and advocate for their adoption by comparable training programs still using animals
for these lessons. Numerous countries mandate that animal use in biomedical training be justified to obtain animal ethics committee approval. However,
when similar procedures, skills, or concepts are taught in one facility with simulation models and at another facility using animals, the latter may encounter difficulty in justifying its use of animals upon scrutiny. Times are changing, with more and more training facilities taking up non-animal methods
for the training of their students. In time, it will become more difficult for other training institutions to continue to justify their use of animals in biomedical
training, resulting in a new generation of medically trained professionals, who
are distanced from the antiquated use of animals in education.
7

Conclusion

The modernization of biomedical education has gone hand-in-hand with an
embrace of advanced human simulation technology and a reduction in the
use of animals for training. Just as a century ago, the decline in the number
of buggy whips produced could portend the acceptance of the automobile,
the world-wide decline in the use of live animals used in medical training can
provide evidence for the value of simulation training in science and medicine.
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Introduction

Despite the predominance of traditional teacher-centered approaches, educators are constantly changing paradigms and social boundaries, by stimulating criticism with active learning based approaches, which are centered on
contexts and experiences. Viewing students as individuals enables paradigm
changes and inspires new perspectives on established theories and facts. This
chapter discusses education in Brazil, with a focus on humane education. Humane education strives to foster compassion and respect for humans, nonhuman animals (hereinafter referred to as animals), and the environment by
creating awareness of the needs of others and the effects of our actions. In
this chapter we describe the process of humane education in the context of
animals used for teaching. We explore the possibilities of replacing animals
and including ethical discussions in the curriculum; the history of Brazilian
humane education, considering the Environmental Crimes Act that forbids
animal use when alternative methods exist; and the legislation that controls
the use of animals for research and teaching purposes in Brazil.
2

Moving towards Humane Education

In the context of animals used for experimentation, education, and training
purposes, humane education is a process that leads to a more egalitarian,
critical, and fair society that has ethical consideration towards animals (Faver,
2010). To achieve this, we have to consider approaches that include an educational and moral revolution. However, for such a revolution to happen effectively, two common reasons for the justification of animal use need to be
considered. First, maintenance of the current paradigm, whereby both academic staff and students use and harm animals. Second, the social speciesism
that exists in regarding animals as instruments or tools for science. In terms
of maintenance of the current animal experimentation paradigm, harmful
animal use puts students in a kill-to-save dilemma, encouraging thinking that
animal use in practical classes is necessary. This conflict can result in the exclusion of students who are ideologically oriented against animal experimentation, ultimately leading to their exclusion as potential researchers who could
work towards animal replacement methods. Even in situations where academic staff are not comfortable with using animals, the maintenance of this
system represents a negative feedback loop for the advancement of scientists
favoring animal research. Speciesism is also rife within the current paradigm,
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for example, many scientists avoid using some animal species, such as dogs, for
training surgery and favor the use of pigs. This situation is common in some
veterinary and medical courses in Brazil. The choice for species to be “protected” from experimentation can also originate from social pressure (e.g., the
use of animals regarded as “pets”) as well as from ethical restraints. In this situation, the choice of species does not consider nervous system development,
the existence of a conscience, or the experience of pain and suffering.
From an anti-speciesist standpoint, animal objectification is a recognized
feature of human-animal relations that should be tackled as an unjust social
tendency in all areas where it occurs. Education courses that involve animal
handling may result in students’ desensitization toward animals’ pain and suffering, as a mechanism to resolve the cognitive dissonance generated by the
unpleasant experience of witnessing animal discomfort (Amiot and Bastian,
2015; Woon, 2011; Zanetti, 2010). Thus, students are often led to deny the subjectivity of animals, as well as their cognitive and emotional capacities, regarding
them as “things”.
Many students feel uncomfortable when engaging in practices that may
cause an animal pain or discomfort however, they are not encouraged to express their concerns (Capilé et al., 2015). In this situation, students should be
informed about their right to object, and how they can exercise this right; this
is a significant pursuit of humane education (Knight, 2014). Recognizing students’ objections to participating in harmful animal use is essential to the goal
of replacing animals in education and training (Seixas et al., 2010). In Brazil,
there is a legal provision, whereby one is allowed to be exempt from participating in such acts that offend one’s moral positions or beliefs by expressing consciousness objection (República Federativa do Brasil, 1988). Practicing humane
education of students right to withdraw enables protection mechanisms for
students to avoid classes that cause mental conflict, encouraging an academic
mind shift based on morals and ethics. Furthermore, on a long-term basis, this
could nurture students’ interaction with animals more as individuals, enabling
these future professionals to participate in building a more ethical mindset in
the way humans treat other animals.
3

Animal Replacement for a Humane Science

In analyzing the moral limits of science in human experimentation, Edgar
Morin (1990) described the ethics of this science as based on social control
and scientists’ awareness of moral barriers. Thus, although biotechnology is
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constantly advancing new ways for carrying out research and testing without
animals, it is moral barriers and empathic education that can protect animals
from the harms of “scientific exploration”. Without a critical animal ethics
curriculum for science in schools and higher education, the mindset of the
current paradigm of animal use is maintained.
By observing instances where humans have been the subject of experimentation in the past century, we can identify (in addition to political, legal, and
regulatory changes) a positive ethical paradigm change based on humane education. Ethical concerns over the use of human experimentation are frequently
traced back to the Nuremberg Trials, which resulted in the Nuremberg Code,
making informed consent in human experimentation compulsory (Nuremberg Military Tribunals, 1946). However, the existence of this guideline can be
traced back as early as the nineteenth century. The Prussian Regulation, published by the Minister for Religious, Educational, and Medical Affairs in 1900,
was based on the principle of personal autonomy and presented an early model
of informed medical consent (Annas and Grodin, 1992). By 1931, during the political reform of criminal law in Germany, the Dritte Reich government issued
the Guidelines for New Therapy and Human Experimentation, differentiating between therapeutic and non-therapeutic human experimentation. These regulations were based on patient autonomy and reinforced the doctrine of informed
consent (Jochen-Vollmann, 1995; Vollmann and Winau, 1996; Reich Minister
of the Interior, 1931). Unfortunately, these legal parameters were not enough
to protect vulnerable humans during the Nazi period, as described in the
Nuremberg Trials (Nuremberg Military Tribunals, 1946); nor did they prevent
other unethical human experimentation across the Western world (Comisión-
técnica, 2011; Frieden and Collins, 2010; Horner, 1999; Seidelman, 2012). These
historical accounts bring to mind the power relations involved in human and
animal experimentation, where sentient beings are transformed into scientific
instruments (Comisión-técnica, 2011; Horner, 1999; Teixeira, 2011; Torrey and
Yolken, 2010). After the establishment of Nuremberg Code, obtaining data from
animal tests became compulsory to protect human volunteers and patients in
clinical trials. However, the placement of animal models as simply a protection mechanism for humans, and not because they are an advanced scientific
model, demonstrates that the animal experimentation paradigm exists primarily because animals act as a moral barrier to prevent human experimentation.
The criticism around human experimentation, and the public dissemination
of examples where humans have been experimented on, ensures consideration
of ethical concerns before starting any type of scientific project involving humans. In this case, moral progress is the only factor capable of stopping unethical research. The same should apply to animal experiments. To work towards
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a much-needed change of paradigm away from using animals for research,
education, and training, we need to start by recognizing that animals are not
mere objects for research, but their own individual agents. A humane education system has the potential to deconstruct the speciesism present in current
scientific education and training, helping us to consider the basic rights of
animals.
4

History of Brazilian Humane Education

At the beginning of the 1990s, the use of animals at Brazilian universities was
the norm, particularly for biomedical teaching, continuing the paradigm in
which learning is entirely dependent on animal use. Students were coerced
into participating in classes using animals and were reluctant to discuss the
matter and express their opinions. An investigation carried out at the beginning of the 1990s in Brazil, with students across different education levels,
revealed that vivisection was an unpleasant practice for the majority; 68% of
university students referred to it as a “necessary evil” and 72.4% explicitly talked about their dislike of the method (Lima, 1995).
The debate about animal use for education and training in Brazil started
in the late 1990s and has grown ever since. An important landmark was the
Brazilian Environmental Crimes Act, Law 9605 of February 12, 1998 (República
Federativa do Brasil, 1998). According to this law, a crime can be considered
commissive, when somebody uses an animal in a way that causes them intentional pain and suffering; or omissive, when somebody acts in a neglectful
manner towards an animal. Both crimes can be applied to animals that are
used for experimentation and education. In the case of omissive crimes, the
law considers causing animals painful or cruel experiences a crime, even for
educational or scientific purposes, when non-animal alternatives are available.
With this law, two important shifts occurred: 1. a previously invisible social
movement became visible to the media and government in Brazil; and 2. the
need to replace the use of animals in education and training became evident.
In 2002, a few years after the publication of the Environmental Crimes Act,
a study was conducted to investigate the use of animals and their alternatives
in medical education, as well as teachers’ attitudes towards the use of animals
for teaching purposes (Bastos et al., 2002). Seven medical schools in the cities of Rio de Janeiro and Niterói were selected to survey teachers who used
animals in their courses. The results revealed that four in seven institutions
used animals in various courses. Most of the participants were unaware of laws
relating to animal use and did not believe in discontinuing these practices. The
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study indicated that there was need to raise greater awareness of innovative
educational methods and increase discussions about animal ethics in medical education. As a result of increasing awareness of the ethics surrounding
animal use and the replacements available, bioethics courses were introduced
in Brazil by the end of the 1990s. With the inclusion of bioethics subjects in
biological and biomedical courses, the debate on animal use could begin.
However, despite these early efforts, a recent study investigating the curricular
integration of bioethics and similar learning opportunities in undergraduate
biology programs at Brazilian federal institutions found that of 36 programs,
only 19 (53%) included bioethics or similar courses for biology degrees (Dória
and Moreira, 2011). Furthermore, increased emphasis on bioethics is strongly
linked to medical practice, for example, the choice of subjects of study and
the academic and professional trajectory of researchers (Diniz and Guilherm,
2002). It is clear that a more holistic approach is needed, one that covers human, animal, and environmental issues in bioethics. Moreover, we need to
expand the public discussion of bioethics and include students of veterinary
medicine and pharmacy, as well as biology, among others.
Regarding the regulation of animals used in research, education, and training in Brazil, it is noteworthy that the Animal Use Ethics Committees (auecs),
Comissões de Ética no Uso de Animais in Portuguese, were only officially esta
blished in 2008 (República Federativa do Brasil, 2008). Although auecs exist
in several institutions in Brazil, and their numbers are increasing, several conflicts have occured in these committees. For example, if a teacher justifies the
use of animals as relevant for learning in their course and tells the auec that
they cannot be replaced, the course will be authorized. However, it is difficult
for auecs members to know if a certain practice is, in fact, performed according to their approval because the actual activities are not monitored. Therefore,
once a project is approved by an auec, the teaching staff can act as they wish;
and proponents of animal use often do not follow auec recommendations
for the replacement of animals in their teaching. Adding to this issue, there is
still no way to gather information about and assess, officially, the situation of
animal use in Brazil. Information on numbers, species, procedures, and degree
of invasiveness is not publicly available, although a database for this kind of
information may be under construction (Bachinski et al., 2015).
5

Implementation of Alternative Methods Following the Publication
of the Brazilian Environmental Crimes Act

After the publication of the Brazilian Environmental Crimes Act (República Federativa do Brasil, 1998), several Brazilian institutions and university
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d epartments took a stand against the harmful use of animals in teaching and
training, fully replacing this practice in some courses. As such, it is worthwhile
to mention some examples:
– In 1990, Federal Fluminense University (uff) replaced harmful animal use
in the physiology classes of the biomedical program with the use of cell
cultures; and since then, they have been teaching the relevance of in vitro
assays as alternatives to animal use (Silva et al., 2012). In 2012, the uff, together with the Brazilian National Network on Alternative Methods, hosted
the Latin American Congress on Alternative Methods, a biannual event that
gathers researchers from around the world to discuss developments in alternatives to animal use in science, industry, and education.
– The Federal Rural University of Pernambuco, in the State of Pernambuco, abolished the use of live animals for surgical training, as part of their
veterinary medicine training, over 16 years ago. They now use preserved
ethically-sourced cadavers, synthetic models, and in-house created simulators and are developing many other materials (Souza, 2014). [The term ethically sourced cadaver refers to cadavers and tissue obtained from animals
who died of natural causes or in accidents, or were euthanized because of a
terminal disease or non-recoverable injury; and, from humans who, prior to
their death, gave persmission for their body and tissue to be used (Martinsen and Jukes, 2007)].
– The University of Brasilia, in Distrito Federal, replaced the harmful use of animals with computer simulations in practical classes in 1998. Their microsurgical techniques training was replaced by simulators that use a pvc mouse
attached to a computer simulator as a teaching interface (Souza, 2014).
– The team at the Faculty of Veterinary Medicine and Animal Science at University of São Paulo achieved an important milestone for more humane education by gaining international recognition for developing a preservation
technique that employs a modified Larssen solution (da Silva, 2003; da Silva
et al., 2004). This solution is based on a higher concentration of glycerin
and lower concentration of formaldehyde and allows the preservation of
ethically-sourced cadavers for up to one year and their thawing between six
and 10 times without the loss of organoleptic characteristics. The reduced
concentration of formaldehyde makes the modified Larssen solution less
toxic, which benefits students, technicians, and teachers. The preserved material retains adequate color and texture, ideal for practical classes in anatomy, surgical techniques, and other disciplines, such as orthopedics. More
recently, the research group published a refinement of the first developed
model, which consists of adding artificial blood to the system to simulate
situations, such as bleeding and the use of hemostatic techniques (de Souza
and Matera, 2015).
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– In 2007, the Federal University of Pelotas completely banned the harmful
use of live animals in all courses.
– Since 2006, the Higher Education Center of Campos Gerais at Paraná State
has involved veterinary medicine students in helping develop non-animal
models as part of their physiology classes to increase their knowledge and
problem-solving skills. In 2015, 27 low-cost models were presented by students to their classmates, including models of renal circulation, respiratory
homeostasis, the digestive system of ruminants and non-ruminants, ovulation, spermatogenesis, and synapses (Bachinski et al., 2015; Ruiz, 2014).
– In 2007, the Faculty of Medicine of the Federal University of Rio Grande
do Sul implemented the Laboratory Practice of Surgical Techniques and promoted the full replacement of harmful animal use for medical training.
– Still in 2007, and as a result of an internal initiative, the Faculty of Medicine
at the abc Foundation, in the State of São Paulo, prohibited the harmful
use of live animals. The animals used in practical classes of physiology and
pharmacology were replaced by interactive software and ethically-sourced
animal cadavers.
– The Catholic University of Pelotas, in the State of Rio Grande do Sul, replaced harmful animal use in practical classes of physiology and pharmacology in 2008.
– At the Regional University of Northwest of the State of Rio Grande do Sul
(unijuí) initiatives to replace animals in education started with the opening of the veterinary medicine program in 2008. For example, in the veterinary surgical course, students practice suturing on foam tissue models or
other available non-animal materials. Students then perform surgeries on
live animal patients who need certain procedures or who are to be neutered
or spayed. The same process has been utilized by other Brazilian universities. Since 2016, the unijuí also started using other alternative methods,
such as artificial bones that simulate fractures and their reconstruction, as
well as chemically preserved cadavers using Thiel solution (Thiel, 1992). As
part of veterinary anesthesiology classes, students have the opportunity to
learn how to restrain an animal and provide drugs using dog mannequins.
Furthermore, in 2016, students developed models of different body systems
in their physiology class.
– In 2009, the veterinary medicine degree at the University Center Monte Serrat (Unimonte) abolished the harmful use of animals and received the Brás
Cubas Merit Medal in April of that year for this move.
– In 2013, the Federal University of Vales do Jequitinhonha e Mucuri at Minas
Gerais State provided students the opportunity to develop alternative
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 ethods to animal use in their animal anatomy and physiology classes
m
for agricultural science degrees. The animal anatomy course now allows
students to develop anatomical pieces based on ethically-sourced animal
cadavers. Animal replacements for students studying animal physiology include, physiological models with molecular and macroscopic levels, such as
dynamic models of myosin-actin protein molecule interactions, and models
that demonstrate circulation. There are also models that display biophysical components, such as surface tension and pressure variations in vascular
beds.
– In the past six years, students and researchers have developed models for
veterinary training at the Federal University of Paraná at Paraná State. Alternative methods include, mannequins as a scaffold for training models of
different systems, such as cystocentesis, blood collection in dogs and cats,
and prostatic palpation.
– More recently, in 2015, a project aiming to develop and implement humane
teaching techniques for veterinary and biology courses was carried out at
the Rural Federal University of Rio de Janeiro, in Rio de Janeiro State. This
project includes the use of ethically sourced cadavers, developing models,
as well as interacting with local state schools for the dissemination of humane research methods and scientific communication.
6

Policy Development Related to Animals Used in Research and
Teaching in Brazil and Its Relevance to Humane Education

In addition to the Environmental Crimes Act, Brazil regulates animal production and use for research and education purposes by Federal Act 11894/2008,
protecting vertebrate animals (República Federativa do Brasil, 2008). This Act
restricts animal breeding and use for higher education and professional training in biomedical sciences. The Act also created the National Council for the
Control of Animal Experimentation (concea), which is a government organization related to the Ministry of Science, Technology, Innovations, and Communications. Invertebrate animals, however, were not included in this Act,
which is a critical omission in the protection of animals in Brazil, in comparison to other nations where certain classifications of non-vertebrates, such as
cephalopods, are protected (European Parliament, 2010, Article 1).
According to Federal Act 11894/2008 (República Federativa do Brasil, 2008),
concea formulates standards for animal use in research and teaching, monitors and evaluates the introduction of alternative techniques that replace their
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use, and maintains an updated register of research and teaching procedures
and of researchers involved in animal use, among other responsibilities. All institutions with teaching or research activities using animals are obliged to set
up auecs, which are composed of veterinarians and biologists, professors and
researchers in specific scientific fields, and a representative of a Brazilian animal protection society. All animal teaching and research procedures must be
approved by auecs and reported to concea. From an organizational standpoint, concea has permanent structures to deliberate about animals used in
research, education and training, breeding, and development and use of alternative methods, as well as providing parliamentary and media assistance.
The decisions of all chambers are voted on in a plenary meeting of the council,
consisting of 14 delegates and their alternate members, totaling 28 councilors:
12 from federal public agencies, 12 from civil non-profit organizations linked
mainly to research, and only 4 non-profit civil associations for animal protection. Considering the institutional interests, in general terms, the majority
(24 individuals) are interested in the “ethical use of animals” and only 4 individuals, from animal protection groups, aim to recognize and protect animals’
interests.
All concea delegates are appointed by their institutions, but animal protection delegates are not elected by direct designation. Delegates from animal
protection groups are subjected to an evaluation by an ad hoc committee, composed of three concea external members. The final decision regarding the
council’s composition is made by the Minister of Science, Technology, Innovation, and Communication. Unfortunately, the process of selection may allow
the election of delegates with no history of interest in animal protection. For
example, a researcher from a Primatology Center has been a representative of
animal protection groups at concea, implicating a possible conflict of interest. Nevertheless, animal protection delegates do have the opportunity to be
part of the discussions and decisions regarding the use of animals in research
and education, although their delegates rarely participate in auecs. This lack
of local representation often comes from a lack of knowledge of the concea
legislation and background suited to the ethical and technical discussions.
Nonetheless, this should not be considered a barrier to the inclusion of animal
protection representatives in auecs, as many come from scientific and technology backgrounds.
In 2016, concea’s teaching chamber organized the first Symposium on
Alternative Methods for the Use of Animals in Education, generating a space
for discussion and exchange of knowledge on alternative methods used
for teaching in Brazil. The event welcomed students, professors, and third
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s ector organizations. The teaching chamber is also involved in the proposition of regulations for the evaluation of the welfare of animals; promotion of
humane education in scientific activities; the establishment of values, principles, and guidelines for animals used in research and education; and support for the development and use of alternative methods in surgical training.
It is of utmost importance that the auecs, in line with concea’s actions,
are kept informed about all available alternative methods and new learning approaches. With this information, projects proposing the use of animals
for education and training can be evaluated according to their merits and
whether animal replacement methods are available. Often, harmful animal
use is proposed by teachers who have repeated a “tried-and-tested” practice
for decades without searching for more technologically advanced methods
that do not used live animals; and they do not seek to base their classes on
humane, ethical values. To increase consideration and implementation of the
3Rs (replacement, reduction, and refinement) (Russell and Burch, 1959), the
auecs should require that project applications provide a detailed scientific
literature review, including search strategy, list of databases used, keywords,
and scientific citations (Shapiro, 1999).
7

Final Considerations and Perspectives

Souza (2014) described the evolution of moral and social thinking about the
status of animals in Brazil, especially addressing their use as a scientific and
training instrument. Following a detailed analysis of literature on humane education and animal use in education and of academics’ and students’ opinions,
Souza concluded that the use of animals in teaching could not be accepted for
ethical, legal, and pedagogical reasons. There are economic reasons to avoid
their use as well. Research shows that the use animals for research, education,
and training costs more than the use of alternative methods (Bones et al., 2015;
Feijó et al., 2008; Fox et al., 2013; Neto, 2011; Ribeiro et al., 2013; Sathyanarayana,
2009; Tudury et al., 2009).
Despite awareness that animals should not be used for education and
training purposes, their use continues in some institutions in Brazil. With
this consideration, it is important to analyze the main reasons for retaining
their use. For example, in a study focusing on animal use for rabies diagnosis, the proportion of tests that used mice was higher in Brazil (75%) than in
other countries (32%). Moreover, barriers to the replacement of animal use
most frequently cited by respondents in a 2014 study by Bones and colleages
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included: lack of structure, equipment, and materials in the laboratories; lack
of financial resources; lack of human resources and professional qualifications;
resistance to change; regulatory obstacles, and lack of incentive by the government (Bones et al., 2014). Although this study refers to the use of animals
for testing purposes, its findings on barriers to for implementing non-animal
methods are indicative to other areas of animal use, including education and
training.
Within teaching, resistance to change is one of the most difficult problems
at universities in Brazil. Barriers to the replacement of animal procedures
could be addressed by focusing on humane education, using a novel tool: a
decision tree (DT) approach (Bones et al., 2016). The DT approach discusses
barriers that hinder replacement and helps to address the main obstacles. If
followed in a step-by-step manner, the DT approach can lead to the uptake of
alternative methods or their development when alternatives do not already exist. For example, for the resistance barrier, the DT approach suggests the need
to obtain financial resources, to develop courses on the 3Rs and courses on the
ethics of animal use, and to provide people with information about the Environmental Crimes Act (República Federativa do Brasil, 1998). The DT approach
can be applied to laboratory animal use scenarios, where alternative methods
already exist, and could contribute to increased compliance with the legal requirement of the 3Rs principles in Brazil.
In addition to the application of DT methods, we suggest other actions
to accelerate the process of preventing harmful use of animals in education and training. For example, strengthening student movements that value
ending the harmful use of animals; pressuring the government to increase
funding for the development of alternative methods; and implementing
more humane education discussions. Alongside these actions, both teachers
and students need to monitor the availability of alternative methods and
legal mechanisms for greater protection of animals used in education. Approaches that involve students in the development of animal-free methods
should be a vital part of academic and vocational training (Bachinski et al.,
2015).
As a final note, the work of the Brazilian Network for Humane Education
(RedEH) needs to be acknowledged. Starting in 2015, this network provides a
platform to connect researchers and teachers from various science and educa
tional institutions across the country to engage in promoting scientific edu
cation on the replacement of animals used in education and training activities
(RedEH: Bachinski et al., 2015). RedEH’s main objective is the development
and dissemination of new teaching methods and public policies in Brazil
and sharing teaching experiences without the involvement of animal harm.
RedEH also constitutes a link between teachers and researchers, providing
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opportunities for collaboration using new techniques and methods developed
by the members. As a result of these actions, several institutions have already
stopped harmful animal use in favor of humane approaches. RedEH is gradually expanding its actions in Brazil, each year counting the collaboration of
an increasing number of educators. Initiatives involving teacher and student
collaboration and including more active engagement can enable a humane
scientific paradigm shift among educators and students. As well as working for
the replacement of harmful animal use and increasing the ethical regard for
animals as individuals, and not as tools, RedEH also works on issues of social
equality and justice.
In this chapter we have discussed actions based on social participation in
scientific-political decisions. Considering science as a social production, with
social limits and social demands, we encourage ideological pluralism in scientific development and looking for new opportunities for a non-speciesist scientific paradigm. Humane education, social participation, and defense for new
scientific perspectives that respect basic animal rights are important for any
society interested in the development of humane science.
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1

Introduction to Alternative Methods

At least 115 million animals are thought to be used for scientific purposes every
year, worldwide (Taylor et al., 2008). Animals are typically used to test whether
an intervention will cause harm to humans or other animals of the same or
different species, i.e. safety testing; or whether it will work, i.e. efficacy testing. Interventions can include testing substances (such as cosmetic products,
industrial chemicals, drugs, pesticides, food additives, and biocides); medical
devices; surgical techniques; environmental changes; or other ways of altering
the physiology and/or behavior of a live animal. Safety testing is highly regulated and is often done after any efficacy testing, if necessary, to finally check
that an intervention is safe for humans and/or other animals to use. Efficacy
testing is less formalized and often occurs in universities as ideas are tested in
live animals as a “proof of concept”, often prior to the development of actual
interventions to help humans or other animals.
Methods that replace techniques that use live animals, or methods of testing substances without live animal use, are known as alternatives, replacements
or non-animal methods. Some prefer the term advanced technologies given the
fact that they often rely on more sophisticated technology and are more human-relevant than the animal test they replace (see Langley et al., 2015). There
have been efforts to replace animal tests since the 1960s. Significant progress
initially came in replacing animals used to diagnose human disease; to produce
biological drugs (such as vaccines); and to safety test batches of these drugs
as they were produced. Concerns about safety were the initial driver for this,
as drugs produced using animal material could be contaminated with animal
diseases. However, cost, efficiency, and the need for swifter and more accurate
predictions also played a part. Some of the earliest replacements are, in fact, no
longer referred to as such, as they are now standard practice. For example, the
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polio vaccine used to be produced in primary monkey kidney cells, resulting in
the death of tens of thousands of monkeys every year. However, by the 1970s,
the use of long-lived human or monkey cells in culture was common place
and the risk of contamination with animal viruses was also eliminated
(Bookchin and Schumacher, 2005). Batches of the vaccine against yellow fever
used to be tested for efficacy (potency) on animals in lethal dose tests, but
these tests were replaced by a cell culture test, the plaque-reduction neutralization test, in the 1970s (World Health Organization, who, 2007).
As analytical techniques improved, as well as scientific understanding,
animals were no longer used as indicators of disease because disease-causing
agents were now both understood and could be measured directly. For example,
every batch of insulin used to be checked using 600 mice and tens of thousands
were used in the United Kingdom alone every year. The mouse convulsion test
was a particularly unpleasant test, as the number of mice that went into convulsions following injection was used as a measure of the strength of vials of
insulin. Now, analytical methods can measure the components of insulin directly (Underhill et al., 1994). Similarly, rabbits were used in the diagnosis of
pregnancy. A rabbit was injected with the urine from a potentially pregnant
woman, and if the rabbit’s ovaries swelled (detected upon killing and dissecting the rabbit), this was considered a good predictor of pregnancy (Friedman,
1939). Now, of course, we know that the substance indicative of pregnancy is
gonadotrophin, which can be detected directly using chemical tests.
Nowadays, alternative methods can include a range of techniques, including
cell-based tests (in vitro); tests using tissue taken from dead humans or animals
(ex vivo); chemical-based analytical tests (in chemico); computer-based modelling (in silico); and ethical human studies (in vivo). Using examples of these
types of methods used for regulatory safety testing, this chapter illustrates the
difficulties seen in replacing animals and how they can be overcome.
2

Recent Developments in Alternatives to Toxicity Testing

The past 30 years have seen a dramatic increase in the development of alternatives to animals (see Liebsch et al., 2011). Advances in replacements are more
recognized in the field of toxicology because it is this area that has received the
most attention. Regulatory, typically toxicity testing, is only a small proportion
of the global testing on animals (8% in Europe according to Daneshian et al.,
2015); but due to the standardized nature of the tests, replacement of just one
test has a permanent effect on the use of animals in that area and is, therefore,
seen as particularly worthwhile.
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Table 24.1 outlines the status of alternatives for the most common tests
used for chemical safety testing, which traditionally and in most cases still use
animals. Two things stand out in this table. First, that replacement of topical
endpoints (i.e., tests that measure effects on the external parts of the body)
are almost completely replaced. However, alternative tests for systemic, broad
effects, such as repeated dose, do not yet feature in the regulatory acceptance
column. Second, there has been significant progress in the past 10 years in regulatory acceptance. Many tests have gained approval from the Organisation for
Economic Co-operation and Development (oecd), even if they can only be
used in combination with other tests.
Table 24.1 Alternatives for standard toxicity tests for chemical safety

Endpoint

Animal test

Alternative tests

Skin
absorption

The substance is rubbed
onto the shaved backs of
rats, and they are killed
the next day (oecd TG
427).
Rats are exposed to a
very high dose of the
substance, such that
a number of them
are expected to die
(oecd TG 402,403,
420,423,425,436).
Substance is rubbed onto
the shaved backs of rabbits, and they are killed
2 weeks later (oecd TG
404).
Substance is placed into
the eyes of live rabbits
who are monitored for
up to 3 weeks (oecd TG
405).

Ex vivo skin-based tests that
oecd TG 428
measure the amount of
(2004). Standalone
substance that passes through replacement.
excised skin.

Acute
toxicity

Skin
irritation/
corrosion

Eye
irritation/
corrosion

Regulatory
acceptance

Cell-based tests, in particular
the NRU3T3, which measures
the extent of cell death in the
presence of the substance.

Not formally accepted, can be used
in combination with
other information
only.

Reconstituted in vitro human
skin models that measure
the extent of cell death in the
presence of the substance.

oecd TG 431 (2004)
and 439 (2010), plus
others. Testing strategy accepted (oecd,
2014a).
oecd TG 437 and
438 (ex vivo, 2009);
oecd TG 492 (hce,
2015). Testing strategies yet to be formally
accepted.

Excised eyes from hens and
cattle killed for food (ex vivo)
can detect non-irritants and
severe irritants; human corneal epithelial (hce) models
based on excised human skin
or corneas that measure the
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Table 24.1 Alternatives for standard toxicity tests for chemical safety (cont.)

Endpoint

Animal test

Skin
The substance is rubbed
sensitization onto the shaved skin
of guinea pigs who are
subjectively assessed for
allergy (Buehler or the
guinea pig maximization test, gpmt; oecd
TG 406); or painted onto
the ears of mice who
are killed 6 days later to
assess the immune response (local lymph node
assay, llna test), (oecd
TG 429, 442a/b).
MutaThe substance is forcegenicity/
fed or injected into mice
genotoxicity or rats for 14 days; they
are then killed to look at
the effects on their cells
(oecd TG 474, 475, 483,
486, 488, 489).

Repeated
dose

Alternative tests

extent of cell death in the
presence of the substance can
detect non-irritants.
Several tests exist that cover
the adverse outcome pathway
(aop) for skin allergy. The
direct peptide reactivity assay
(dpra) measures the binding
of the substance to proteins
(in chemico); and the
in vitro keratinocyte assay and
the human Cell Line Activation Test (h-clat), which are
based on human skin cells,
measure part of the immune
response.

Several in vitro tests, including
bacteria (Ames) tests, in vitro
chromosome aberration, cell
micronucleus, and gene mutation tests are available.
A battery of two or three cellbased tests is always carried
out before conducting an
animal test.
Rats (occasionally
In silico techniques, such as
rabbits, mice, or dogs)
read across, can be used if the
are force-fed, forced to
substance is similar to existing
inhale, or have the sub- ones that have already been
stance rubbed onto their tested.
shaved skin every day
A battery of in vitro tests or lab
for 28 or 90 days, before on a chip models are still in
being killed (oecd TGs the development phase.
407–413).

Regulatory
acceptance

oecd TG 442c
(dpra, 2015); 442d
(keratinocyte assay,
2015); and 442e (hclat, 2016). Testing
strategies yet to be
formally accepted.

oecd TG 471 (1997);
473 (1997); 476
(1997); 487 (2010);
490 (2015). Positive
results, however still
lead to follow up in
vivo.

Read across is accepted on a case-bycase basis (see oecd,
2014b); battery of
in vitro tests or lab
on a chip are not yet
accepted.
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Carcinogenicity

Rats or mice are fed the
substance for two years
to see if they get cancer
(oecd TG 451, 452).

Reproductive Pregnant female rabbits
toxicity
or rats are force-fed the
substance and then killed
along with their unborn
babies (oecd TG 414).

Cell transformation assays
(cta) based on cellular
changes to rodent cells have
been in use for 50 years and
can detect 90% of known human carcinogens.
In silico techniques, such as
read across, can be used if the
substance is similar to existing
ones that have already been
tested.The in vitro Embryonic
Stem cell (est) test is based on
mouse stem cells. Substances
are classed as toxic if they
block development into beating heart cells.
Other in vitro tests are still in
the development phase.
Receptor binding assays are
in vitro assays that can detect
activation of genes involved in
hormone production.

cta assays have failed
to gain international
regulatory acceptance
and are used for
screening purposes
only (oecd 2015,
2016).
Read across is accepted on a case-bycase basis (see oecd,
2014b). est has
failed to gain international regulatory
acceptance. Receptor
binding assays (oecd
TG 455, 2012; 457,
2012; 456, 2011) are
accepted to screen for
potential endocrine
disrupting properties.

For a list of all oecd Test Guidelines referred to in this table, see http://www.oecd.org/chemica
lsafety/testing/oecdguidelinesforthetestingofchemicals.htm.

It is widely acknowledged that public pressure has played a significant part in
encouraging these developments. Public outrage at animal testing for cosmetics started in the 1970s and gained momentum in the 1980s. In Europe, the outcry turned into calls for an actual ban on cosmetics testing on animals, even in
the absence of alternatives for all relevant animal tests. From 1993, and finally
ending in 2013, a series of deadlines were negotiated and re-negotiated within
the European Union (EU) by which the testing had to end, first for the testing
of products and then for the testing of ingredients (European Commission,
2017). During this period, the cosmetics industry foresaw that testing any new
substances on animals would soon have to end, and they invested in alternatives, as did the European Commission (EC).
The formal encouragement to use alternatives in the EU was set in stone
by the EU Directive on animal testing in 1986 (Council of the European
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Communities, 1986, Directive 1986/609/EEC) and revised in 2010 (European
Parliament, 2010, to Directive 2010/63/EU). Directive 2010/63/EU states that an
animal test must not be conducted if an alternative method is available. This
rule is unique to the EU; and while not enforced as well as one might hope,
it has nonetheless helped encourage the promotion of alternatives internationally. Finally, the overhaul of EU chemicals’ legislation in 2006 also played
a part in driving the need for alternative methods. The new chemical regulation, R
 egistration, Evaluation, Authorisation and Restriction of CHemicals
(reach) is interesting in that it requires the testing of all new and existing
chemicals on animals, unless alternative methods or data already exist (European Parliament and the Council of the European Union, 2006, Regulation
1907/2006). The fact that this could result in the use of up to 38 million animals
(Joint Research Centre, 2006), has encouraged both regulators and industry to
look for alternatives to keep costs and animal numbers down.
3

Implementation of Alternative Methods

The replacement of an animal test is a laborious and lengthy, scientific and bureaucratic process. Figure 24.1 outlines the steps that typically need to be taken
before an animal test can be finally considered replaced by another method.
Unfortunately, the outlined process is often repeated for each sector of use. For
example, the method needs to be validated and accepted for replacing animals
to test chemicals and then repeated in order for the method to be considered
acceptable to replace animals used in drug testing. This is because the types of
chemicals differ in each sector, and there is a fear that the alternative may not
work on different chemistries. There is also an element of distrust in alternatives not developed for that sector, and so the industry tends to want to reevaluate the alternative itself rather than transfer it across immediately.
Development is the stage in which the alternative is created, optimized, and
initially tested. Academe plays a large role at this stage. Alternative centers,
such as the UK National Centre for the 3Rs and alternatives charities, are vital
in funding this kind of work. Researchers may develop spin-off companies to
further develop a method. Larger chemical, medical, and cosmetics companies
Development
Figure 24.1

Validation

Formal test
method

Regulatory
acceptance

Deletion of
animal test

The process of acceptance of an alternative test method. Steps in black are
primarily science driven, steps in white are primarily regulatory driven.
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may also develop alternatives, even creating their own spin-off companies or
buying existing ones. For example, L’Oréal purchased the rights to EpiSkin in
1997 and bought the SkinEthic company in 2006, so that they could d evelop
and use their own human skin irritation models (Auplat, 2012). Unfortunately,
academics may be satisfied by the publication of their method in scientific
journals and often leave it to others to ensure it is used more widely. More proactive, academic-driven development may still struggle to grasp the r egulatory
hurdles that need to be overcome before the method can be used. Unfortunately, industry-driven development can also be rather inward looking. Companies
may be satisfied if the method is considered suitable for their own in-house
purposes for screening substances; and, often, they have little incentive to donate the method to the wider community, particularly if they have invested
heavily in its development, and competitors could gain from its use.
Validation is the stage in which the method is independently assessed to ensure it is reliable and accurate. This step is vital if the method is to progress to
acceptance. There are internationally agreed principles for the way a method
should be validated; but they are rather vague and not always well understood.
The key requirements include, showing that the method produces the same
results when tested at different times in the same laboratory and when used
by other naive laboratories, and that the results are consistent with what is
expected, i.e. the test does what it is designed to do. The process is laborious,
requires collaboration between several laboratories, and can be expensive. If
things go wrong, the validation stage may have to be repeated. In most cases,
historical animal test data is used as the gold standard by which an alternative method is assessed, so no new animal tests have to be done; but there can
be problems in ensuring the old animal data is of good quality. Quite often,
the fact that the animal test itself was never validated causes problems during validation, as the assessors realize that the animal data is so unreliable or
inaccurate that they cannot trust it (Balls, 2006). Species differences also play
a significant role in making comparisons between human-based cell tests and
animal test results very difficult (Hartung, 2007).
Official bodies are seen as a good way of ensuring a method is correctly validated. In Europe, the European Commission’s European Centre for the Validation of Alternative Methods (ecvam) is an important validation body. There
are now equivalent bodies in other countries, such as the United States (US)
(Interagency Coordinating Committee on the Validation of Alternative Methods, iccvam), and Japan (Japanese Centre for the Validation of Alternative
Methods, JaCVAM). Unfortunately, the process of validation and regulatory
acceptance is still a bit of a black box. Methods do not have to go through
these validation centers to be accepted, but it often helps. Companies with
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new methods are often unsure about the process, whether they need to submit
their method for official validation or directly to the regulatory body, who they
should contact, and what information they need to provide.
Formal test method. Once there is sufficient evidence that an alternative method is valid, the next stage is to write up how the method should be
performed as a formal test method. In Europe, the policy is to gain wider agreement on the method via large international collaborations, such as the oecd
or the International Council on Harmonization (ich). This is so that the method, in theory, will be accepted outside Europe and European companies will
not be disadvantaged by having to conduct other tests. Negotiating how to conduct the method is often combined with further analysis of the validity of the
method and can take several years. This stage can also provide false hope that
a method is acceptable in all regions; this is because, although an agreement
may be sought in principle, at an international level, the regional acceptance
process can be prolonged as regulators still have to decide that the method is
relevant and acceptable to the legal framework in their region.
Regulatory acceptance does not automatically happen following the publication of a formal test method, a fact that is often not widely appreciated. Following adoption of a formal test method, typically several regional regulatory
agencies have to assess independently whether the method can be used for
their sector (e.g., chemical, medicines, or cosmetics). Unfortunately, there is often no official mandate for them to do this, and they may need political pressure
to act. Regulators do not have to wait until the method is formally recognized
internationally to decide whether they will accept it for their purposes, but they
frequently do. Negotiations within each regulatory body can take many months,
or even years; and currently, these have to happen separately for each sector
and region. Regulators typically accept methods by updating their guidelines,
but it is often only when a corresponding legislation is changed that industry
becomes aware of the need to use the alternative in place of the animal test.
Deletion of the animal test. Changing sector specific legislation to replace
any requirement for a specific animal test with the alternative takes several
years and the process is usually not started until the very end of the process.
Political pressure is usually needed to instigate the deletion of the animal
test, often following pressure from animal protection organizations. For example, there was a delay of seven years from the point in which there was a
formal method alternative to the rabbit skin irritation test (Commission of the
European Communities, 2009) until the rabbit test was deleted from reach
requirements and replaced with the skin irritation methods (European Commission, 2016a). The process was not initiated until 2012, following a complaint
from Cruelty Free International. To date, the rabbit test is still performed in
Europe and elsewhere, and the formal test method for the rabbit test (oecd
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TG 404) still exists. The only standard regulatory animal test that has been deleted from oecd requirements is the LD50 acute toxicity test (oecd, TG 401)
in 2001, which was “replaced” by other animal tests that cause slightly less suffering or equivalent suffering to fewer animals.
Regulatory acceptance is not usually required for methods that replace animals in basic research conducted in academe. Here, the route to acceptance is
a less defined, unofficial, and often very slow process. The scientific community may gradually move towards alternative methods, usually through the common scientific channels of publications, conferences, and workshops. There is
no body within the medical research establishment tasked with coordinating
this process, although national 3R centers may facilitate more rapid progress
on a case-by-case basis. Regulators of animal experiments could play a role in
ensuring that no animal-based projects are conducted in their region if there
is an alternative; but as the line between what is and what is not an accepted
alternative is less clear for basic research, they currently do not appear to do so.
In summary, the development and validation stages are primarily sciencedependent processes, which can be sped up through appropriate funding and
coordination. The stages of formal test method, regulatory acceptance, and deletion of the animal tests are primarily regulation dependent and can be accelerated by political will and regulatory enforcement.
4

The Future of Alternatives

The difficulties of replacing animal tests, combined with increasing frustration with the lack of reliability of animal tests, have forced scientists, in recent
years, to consider whether a paradigm shift is needed. A ground-breaking report to this effect was published by the National Academy of Sciences (nas)
in the US in 2007. Rather than criticizing the ethics of testing on animals, the
report focused on better science and set out a future vision for toxicity testing.
The idea is that society should move away from using black box animal models,
where tests depend on simply counting how many animals die rather than on
understanding why they die. Instead, toxicology should seek to map human
reactions at a more molecular and cellular level, something entirely possible
in vitro. The Toxicology Testing in the 21st Century (Tox21) concept was funded
on a practical level by the US government under the ToxCast project, which is
screening thousands of chemicals using simple in vitro tests to help start the
process of identifying toxicity pathways (Richard et al., 2016).
The nas report has helped accelerate the concept of Adverse Outcome
Pathways (aops) which provides the biological explanation for a single toxic
event. Some toxic events, such as skin irritation and skin sensitization, may
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only have one biological explanation. For example, the aop for skin sensitization has been described (oecd, 2012) and is made up of four steps: reaction
of the substance with proteins in the skin, inflammatory responses in keratinocyte skin cells, activation of dendritic cells, and lastly the proliferation of Tcells. The first three steps now have oecd approved in chemico or in vitro tests
(see Table 24.1); the fourth step is measured in the mouse llna.
Unfortunately, some animal tests capture many different types of toxicity,
including some that are not relevant to humans. For example, repeated dose
toxicity tests assess long term toxicity, which can manifest in a number of ways
(e.g. cancer, liver disease, and heart disease, among others). To replace animals
for these tests will require the identification of many aops and the development of tests for the steps within them. The thinking is that if all possible aops
relevant to repeated dose toxicity can be mapped, then in chemico or in silico
tests for only some of the key steps will need to be created. The risk is that finding all of these aops will take time, and animal tests will not be replaced until
that happens. Nonetheless, the concept has now taken hold in Europe, and the
oecd is supporting the population of a database of aops (oecd, n.d.).
Another development in toxicology that seeks to overcome the criticism
that cell cultures are too simplistic, is the lab on a chip concept: body or organ
on a chip models vary in size and complexity but essentially use engineering
technology to combine small cultures of cells (e.g., liver, brain, and kidney)
into a single, tiny device with fluid running between the compartments of
each type of cell. The idea is to recreate some of the key organs and processes
that occur within a human on a miniature scale (Marx et al., 2012). The concept
is proving not as easy as it seems though, with issues regarding how to r emove
waste products, how to keep cells alive, and how to mimic realistic pressures
within the fluidic channels. The lab on a chip and/or the aop approach will
also likely lead to the replacement of animal models for basic research (Langley et al., 2017). In a way, it should be easier to replace animal tests for drug
development, since drug discovery itself is already very reductionist. New
drugs are usually developed to interact with cell-based mechanisms inside the
body that trigger disease. This is similar to the aop approach, and it should
be possible to model it in vitro. It is, therefore, rather incomprehensible that
researchers look to a more holistic, whole animal approach to demonstrate
both the efficacy and safety of a new drug, with all the added complications
of lack of relevance and species differences that this brings. Encouraging
researchers to justify efficacy based on human cell-based approaches and then
testing the drug on a few patients in, so called futility trials (see Creanor et al.,
2015, for example of a futility trial), could be one approach to speed up drug
development and reduce the high number of drugs that fail in clinical trials.
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Another approach is to use technology to enable humans to be used safely
in studies that would otherwise use animals in a harmful manner. Microdosing exploits the technological advances in analytical techniques to enable
volunteers to be injected with novel substances at such low levels, that even
potentially harmful substances do not to pose a threat (Lappin, 2015). Similarly, improvements in brain imaging technology are enabling researchers to
measure human brain activity non-invasively, and at a high level of precision,
so that invasive tests in monkeys will soon be considered redundant (Bailey
and Taylor, 2016).
5

Barriers to the Implementation of Alternatives and How to
Overcome Them

5.1
The Current Scientific Paradigm
A major stumbling block when it comes to replacing animals is the current way
that hypotheses are tested in science. Figure 24.2 outlines the typical process
scientists go through when testing either the safety or efficacy of a substance,
or indeed any hypothesis. The process is one of testing in models of increasing
complexity with growing confidence in the hypothesis, as it successfully passes
each hurdle.
The most common justification for using animals is the apparent need to
test a substance or idea in a “complex, whole being” before there is enough
confidence that it can be tested safely in humans. The assumption behind this
is that the complex, whole being will capture all possible, unforeseen ways in
which the substance or idea could be harmful (or not work), avoiding harm
to (or wasting time on) human volunteers. This “complexity” argument is
one reason for the lack of support for in vitro based techniques, as these are
seen as less complex and, therefore, inferior. The desire to capture all possible
interactions appears to override the very real possibility that many of these
interactions are wrong by the very nature of testing in the wrong species. This
is very frustrating for those who support alternative approaches; and there appears to be a real gap between the two groups in terms of what is more important, complexity or relevance. Added to that is the fact that demonstration of
Idea or
drug or
chemical
Figure 24.2

Test in a simple
model (computer/in
vitro/DNA screening)

Test in more
complex model
(animal)

Test in
a
human

Idea is ‘proved’,
drug is effective,
chemical is safe

The standard approach to testing medical hypotheses. Confidence increases as
you move from left to right.
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the predictivity of alternative methods often fails to convince those who cannot get past the fact that the alternative is simply not a live, complex animal.
If an alternative method is found to be 90% predictive of effects in humans,
this does not seem to provide confidence. The answer is always, “what if?” This
caution has undoubtedly raised the standard by which alternative methods
are measured; but some believe that the bar is, in fact, now too high and is still
being unfairly applied.
The complexity versus relevance debate may be resolved by greater understanding and uptake of the aop approach. This approach seeks to break down
the complexity of biological processes on a more scientific basis. Alternative
methods can be chosen that measure a distinct part of a mechanistic process
that leads to an adverse effect (i.e., toxicity). Using an alternative method that
is known to predict even just one step in the aop should give confidence that
it is relevant. Combining several methods that test different parts of the aop
should also help address the complexity issue. Lab on a chip methods, as well
as more complex in vitro methods, such as 3D tissue constructs and mini-brains
(see Caruso, 2017), are also another solution to increase both relevance and
complexity.
5.2
Interface with Legislation
Scientists developing alternative methods have historically designed them
to give simple answers to the question, is the substance being tested safe or
toxic, yes or no? This was seen as a good first step to assist in their validation and initial adoption, even if the animal test they are designed to replace
actually produces quantitative (numerical) answers on the extent of toxicity.
However, failure of alternative methods to produce equivalent results to the
animal tests has been one reason for the delay to their full implementation. For example, the in vitro skin irritation/corrosion methods were initially
validated to give a yes/no result on whether a substance would cause skin
corrosion in 1998 (ecvam Scientific Advisory Committee, esac, 1998). This
limited their use because chemical sector regulators actually required these
methods to present the result as not irritant, irritant, or severely irritant/
corrosive. This is because the results of the animal test are used not only for
risk management purposes but for classification and labelling of substances,
which is governed by different legislation. It was not until 2007 that a slightly
different protocol, using the same skin methods, was validated to provide
this information on irritation (esac, 2007). Even then, it was not until 2009
(esac, 2009)—when a third, more rapid validation was completed because
the classification and labelling requirements had changed since the start of
the process—that the rabbit test was finally replaced using a combination
of two methods.
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Since the issue surrounding the validation of the skin irritation methods,
there is now greater recognition of the need to be aware of classification and
labelling requirements, but problems still occur. For example, the in vitro skin
sensitization methods were also validated to provide yes/no answers; but the
regulators require three answers: no effect, weak effect, or strong sensitizing. It
was for this reason that the EC and Member States recently refused to remove
the mouse llna test from reach requirements, as they are of the opinion that
full replacement for classification and labelling is not yet possible using the in
vitro methods (European Commission, 2016b).
The issue is further complicated by countries around the world that have
different requirements for the classification of substances based on the same
toxicity test results. The alternatives are often only validated against one
scheme. For chemicals, this is often the United Nations Globally Harmonized
System (UN ghs) of Classification and Labelling of Chemicals, but this is not
recognized by all countries and all legislations that may have different requirements. So, two additional hurdles are getting those involved in the validation
of alternative methods to appreciate the regulatory use of the method and
validate it accordingly and getting countries to harmonize their regulatory requirements, irrespective of the methods used, to satisfy the requirements. Lack
of international harmonization of classification and labelling requirements is
one of the reasons why rabbit skin irritation tests are still being conducted in
Europe for non-EU regulators, even though the alternatives are now accepted
within Europe.
5.3
Bureaucracy
Bureaucracy plays a large part in the delay to the implementation of alternatives, in my view, particularly at the regulatory acceptance stage. Much of
this bureaucracy could be avoided as illustrated below. It is, in my opinion,
in part caused by inertia amongst regulators and a failure to incentivize and
reward them for evaluating new methods. The process still largely relies on the
goodwill of a few experts from a few countries. Industry are not specifically
rewarded for developing alternatives and, indeed, run some risk if the alternative is not accepted (due to wasted development costs). Regulators also run the
risk of accepting a method that could fail in the real world, potentially causing
harm to humans. Hiding behind bureaucratic delays avoids having to make a
decision.
There are bureaucratic delays caused by the desire to harmonize testing requirements internationally. Harmonization is seen as a good thing, as it means
that, in theory, a single (animal) test conducted in a laboratory in one country
will be accepted for regulatory submission of that substance in all countries
that sign on the agreement. This is called Mutual Acceptance of Data (mad).
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There have been tremendous efforts in the past 20 years to encourage the
chemical and drug sectors to harmonize their requirements. As alternatives
have been developed, they too have had to go through this harmonization process. In theory, this is also a good thing, because once accepted no more animal
tests would be required around the world for that specific substance. However,
in reality the process of negotiation takes a long time; and to speed up the
process, loopholes are placed in documents that can give a false sense that harmonization has actually been achieved. A recent example is skin sensitization,
where the alternative methods gained oecd acceptance relatively easily, but
on the understanding that they cannot be used as standalone replacements.
Therefore, there is no requirement for countries to accept these methods to
replace the corresponding animal test, until perhaps another formal document is agreed on at some point in the future that shows how they can be used
together.
In the EU the situation is further complicated. The EU defers to the oecd
on the basis that international harmonization is preferable to EU acceptance
(ignoring the fact that the EU is already a grouping of 28 countries). This causes
on average two years’ delay to a method that was validated in Europe. They
then require that the test method, as agreed by the oecd, be published in the
official EU regulations (Commission of the European Communities, 2008, Test
Methods Regulation EC440/2008,) in an almost completely bureaucratic process that takes, on average, a further two to three years. For example, the first
version of the reconstituted skin model was validated by ecvam for detecting
corrosive substances in 1998 (esac, 1998); but it was not adopted by the oecd
until 2004 (oecd, TG 431). The first version of the model for skin irritation
was validated in 2007 (esac, 2007); but it was not adopted by the oecd until
2010 (oecd TG 439). Due to political pressure at the time, the EU adopted an
unusual procedure and accepted the skin methods before the oecd in 2000 for
corrosion (European Parliament and the Council of the EU, 2000), and in 2009
for irritation (Commission of the European Communities, 2009). The EU has
not done this since, even though similar delays have occurred for other methods. For example, the dpra for skin sensitization was validated in 2012 (esac,
2012); but it was not published as oecd TG 44C until 2015. Over two years after
its publication in the oecd, it was published in the EU Test Methods Regulation (Commission of the European Communities, 2017).
One could argue that the bureaucratic delay between validation and regulatory acceptance gives industry time to advance their knowledge of the new
methods, get them into place and gain confidence in their use. In reality, companies, other than those directly involved in the development and validation
of the new method, tend to remain unaware of these methods until they are
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accepted. If they do become aware of them, they tend to wait for confirmation
that they will be accepted, before investing in using them. One of the reasons
for the delays at both the oecd and the EU’s Test Methods Regulation is the
timing of the cycle for revising test guidelines. The process is annual at the
oecd; if you miss the deadline for submitting methods, you lose one year. Given sufficient political will, it should be entirely possible to speed up the process
by increasing the cycle of meetings and, in Europe, by accepting that as most
EU members are also members of the oecd, there is little need for a second
round of negotiation to update the Test Methods Regulation.
5.4
Lack of Funding
Obtaining funds to develop replacements for animal tests is still very difficult,
despite a few high profile, one-off, significant projects. For example, in response
to the imminent cosmetics testing bans in 2009, the EC and the cosmetics industry each contributed €25 million towards the development of alternatives
to animals for long-term toxicity testing (SEURAT-1, n.d.). Furthermore, the EC
claims it has funded replacement methods in the last main scientific-funding
stream, Framework Project 7 (2007–2013), to a total of €180 million (European
Commission, 2013). However, compared to overall science funding, the levels
of investment are relatively low. The total Framework Project 7 budget was
€45.3 billion; as such, the Commission dedicated only 0.4% of its science budget to alternatives to animal testing.
National funding levels are even lower than central funding, perhaps reflecting a general apathy about the need to improve the humanity and reliability of
scientific methods. We recently compiled a survey of EU countries and found
that direct funding of alternative (3Rs) methods was reported to total only
€18.7 million in 2013 (Taylor, 2014). Only seven countries provided this funding:
Austria, Belgium, Denmark, Finland, Germany, Sweden, and the UK. Much of
this budget was dedicated to support national centers for the 3Rs rather than
the development of new methods. Funding by the most generous country, the
UK (approximately €11 million), was still only 0.04% of its national science research and development expenditure for that year.
Central and national funding of alternatives, therefore, exists but is relatively very low and ad hoc. This compares poorly to the funding given to equally
ambitious big picture projects. For example, former US President Obama’s project to map the human brain was funded by US$100 million (The White House,
President Barak Obama, n.d.); and the human genome project by US$3.8 billion (Human Genome Research Institute, n.d.). However, these are single projects. Replacing all animal tests, even only in the field of regulatory toxicology
comprises many, many projects. Clearly, the rate of change is likely to be slow
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unless levels of funding significantly increase and are proportionate to the
scale of the problem being addressed.
5.5
Entrenchment
Many of the remaining animal tests to be replaced, particularly for regulatory
testing, have remained unchanged since they were first developed many decades ago. For example, the pyrogenicity test in rabbits (used to establish if
injectable drugs are contaminated) was developed in 1912 (Hort and Penfold,
1912); the Draize skin irritation test on rabbits in 1944 (Draize et al., 1944); and
the Buehler guinea pig skin sensitization test in 1965 (Buehler, 1965).
Entrenchment is common in science (Kuhn, 1962). This may seem counter
intuitive when one considers that what defines science is its questioning nature. But even those who use animals in research will attest to the difficulty
in getting funding for new approaches, as well as the difficulty in publishing
research that uses a method that is different from the one everyone else is using. Behind closed doors, researchers will complain about journal editors even
asking for their idea to be demonstrated in an animal model before they will
publish it (see Cronin, 2017; discussions at the recent EC conference on alternatives). This situation is partly caused by the fact that those who are conducting research, reviewing papers, and reviewing funding applications are usually
from within the same scientific peer group. New ideas that threaten the status
quo can struggle to gain support; and researchers who are unhappy about their
treatment are often afraid to speak up, in case it affects their university tenure
or funding.
Preferentially funding scientists who want to use different methods is a
system that could work to promote change. However, apart from occasional
large projects, such funding is still only taken on by specialist replacement
charities with small budgets. Once they are a part of a project to replace
animals, however, scientists can create a support network that can help to
foster change; but it is crucial that funding is dependable for this to be sustained. Another solution is finding a way to include fresh perspectives on the
types of projects being funded. Including experts who are more motivated
to challenge the need to test on animals in the ethical review of projects
involving animals, such as individuals with expertise in alternatives or in
animal protection, could have a big impact. Currently, funding and licensing bodies only tend to include token lay persons in their discussions, who
can feel out of depth and overwhelmed. Making applications or, at the very
least, the funding policies of granting bodies open to regular public scrutiny
could also help.
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5.6
Lack of Enforcement
If improved funding of alternatives is the carrot, then enforcement is probably the stick. Although, most would say the carrot is the best approach for
entrenched issues such as this, enforcement still has a role to play. In Europe,
since 1986, it has been illegal, on paper, to conduct an animal test “if another
scientifically satisfactory method of obtaining the result sought, not entailing
the use of an animal, is reasonably and practicably available” (Council of the
European Communities, 1986, Directive 86/609/EEC). Unfortunately, in 2010
this was watered down, to some extent, with a stricter onus being placed on
methods that are “recognized under the legislation of the Union,” although the
general premise remains. “Member States shall ensure that, wherever possible,
a scientifically satisfactory method or testing strategy, not entailing the use of
live animals, shall be used instead of a procedure” (European Parliament, 2010).
Technically the onus is on the Member State to not authorize animal tests
where alternatives exist, rather than on the researcher. Our experience has
shown, however, that if Member States can divest themselves of this, they will.
Laboratories are granted multiple generic licenses that do not cover the specific
substances being tested, which makes it impossible for the authorizing body
to make decisions as to whether an alternative method is suitable. This is a
particular issue with quality control tests, where the alternative can often be
used for some substances and not others. Following an undercover investigation, Cruelty Free International recently demonstrated that a contract testing
facility in the UK was testing substances for pyrogens on rabbits, for which
the alternative bacterial endotoxin test was suitable, according to the European Pharmacopeia (see Cruelty Free International, n.d.). It was not until we
challenged the UK competent authority that they began asking for substancespecific information in advance (Animals in Science Regulation Unit, 2014).
Enforcement of the use of alternatives for basic research is more complex
and is currently being largely overlooked by regulators of animal experiments.
Due to the myriad of ways in which animals can be used to test medical hypotheses, and the lack of formal standardized approaches, regulators tell us
that they cannot really enforce the use of alternatives as they would for safety
testing. Currently, in the UK, the onus is on the researcher, rather than the regulator to demonstrate the absence of an alternative approach. The regulator, assessing a potential project that intends to use animals, is not usually an expert
in the area; and it is not clear to what extent researchers are really being challenged in their statements that alternatives are not available. The solution is
for regulatory bodies to simply take responsibility for upholding the law when
an alternative method is available that can prevent animal experiments or at
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least partially replace them. Currently, some animal protection o rganizations
see it as part of their role to hold regulators accountable to encourage them
to do this. A better solution would be if a tougher stance was accepted internally by the regulators, perhaps as a consequence of a directive from their
governments.
6

Targets for Change

It is clear from Table 24.1 that prior to the EU cosmetics testing bans, there was
very little regulatory approval of alternative methods. There is a clear acceleration from 2003, the date of the implementation of the first testing ban (for
products). But now that Europe has a complete ban on cosmetics testing on
animals, it is important that this momentum is not lost. It is possible that, with
public support, new bans or deadlines could be put in place. There are already
calls for bans on the testing of household products and all testing on dogs and
monkeys. Using prohibitions on testing as an incentive for the development
of alternatives is, however, hitting a hurdle in these areas. Animal testing for
medical purposes is seen as something that cannot end until alternatives are
available, and setting a timeline for science to replace animal experiments is
not considered by some to be possible or even desirable. In a Nature survey of
its readers (over half of whom conducted animal experiments), 63% thought
ending animal experiments was a desirable but unachievable goal (Ainsworth,
2006).
The absence of viable alternatives has, however, not hindered political agreement in a number of other areas, where the ability to realize the promise relies
to some extent on science and technology, such as the case of climate change.
Internationally, the Kyoto Protocol was signed by 37 industrialist countries as
well as Europe, in 1997, and set the goal of a 5% reduction in carbon emissions
below 1990 levels by 2012. The target was met (United Nations Climate Change,
n.d.). Europe has a further commitment to reduce levels by 20% by 2020 (European Commission, n.d.). Although countries have signed up to reduce their
emissions, no one is suggesting that they cease manufacturing cars or turn the
power off in order to do so. Instead, goals to reduce in emissions are being met
by increased efficiency and innovation (see European Commission, n.d.). One
can see that a reduction in animal testing could also be achieved through more
efficient use of animals (e.g., not authorizing the more “blue sky” type of basic
research and using less animals for any given purpose) and investment in technology. Setting a target of, for example, a reduction of 50% in national animal
experiments by 2025 will enable countries to exert power over experiments
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that they feel they could perhaps do without and to prioritize for replacement
those that they cannot. Targets will feed into the ethical review committees
for animal experiments, who will have to make harder decisions and actually
reject some applications. Targets will also seep into the mindset of scientists,
who will have to think more carefully about whether they are likely to be accepted before putting forward applications for new animal experiments. There
will be more political will to fund alternatives and put in place the necessary
governmental and institutional schemes to fund, develop, promote, and implement alternatives.
It is important to remember that reduction in animal experimentation will
not always rely on replacement. It is unfortunate that this view, however, prevails even in Directive 2010/63/EU, which states that “this Directive represents
an important step towards achieving the final goal of full replacement of procedures on live animals for scientific and educational purposes as soon as it
is scientifically possible to do so” (European Parliament, 2010). In the area of
basic research in particular, where the majority of animals are actually used
(Daneshian et al., 2015), there is much more of an element of choice in conducting an animal experiment. In a world with infinite questions about human biology, there are equally important questions that can be tackled that
do not require resorting to animal experiments. Some scientists choose to use
animals, but they could choose to study humans, or cells, or computer models
and still contribute to the pool of medical knowledge. If we change the goal to
one of improving the humanity and quality of medical knowledge, rather than
replacing like for like, then, in my opinion, a significant proportion of animal
research could end today.
7

Conclusion

The field of alternatives research has accelerated in the past 30 years, largely
as a result of legislative pressures on specific sectors to end testing and/or use
alternatives. There are now alternatives for a significant proportion of the standard “battery” of animal tests, which are typically required to test the safety
of new chemicals and drugs. Unfortunately, the corresponding removal of the
animal tests that these new alternatives replace is still forthcoming. There are
many reasons why animal testing persists even, when there are alternatives,
which have little to do with the scientific limitations of the new tests. Human
limitations, including bureaucracy, political malaise, and entrenchment in the
scientific establishment are as great, if not greater, barriers to the replacement
of animals in testing.
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There needs to be a paradigm change in the way science approaches many
of its questions. The classic approach of test your idea or substance in a simple
model, such as a cell culture; and then if successful test it in a more complex model, such as an animal, needs to change. Funding bodies and journals need to
stop requiring proof of concept in animal models but in more human-relevant
approaches. A more mechanistic approach is one possible way to facilitate the
use of alternatives. Breaking down the question you need to answer into questions that can be tested in simpler models would facilitate a speedier uptake of
alternatives. Another approach is to employ technology to overcome some of
the current problems of using humans ethically or to increase the complexity
of cell-based systems. Whether these two approaches will complete or complement each other remains to be seen.
What will encourage science to change its paradigm? Political will needs
to be amplified and targets for a reduction of animal experiments are needed.
This, in turn, will help increase levels of funding to speed up the development
of new approaches and reduce regulatory malaise, so that they are implemented as soon as they appear.
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1

Toxicology in the 21st Century

Toxicology is one of the sciences that have slowly but surely embraced technology and new methods, focusing on high throughput and high content screenings, omics technologies, and mathematical modeling. Thus, a transition in
toxicology—from a traditional reductionist paradigm towards 21st century
methods based on human biology and holistic multi-omics studies—is now
becoming a reality. With the recent advances in human-cell cultivation techniques, allowing in vivo-like in vitro long-term functionality, there is a shift in
focus towards the mechanistic details of the adverse effects “over time” aimed
at a better understanding of the dynamics of biological processes.
In vitro methods, based on human primary cells, cell lines, and genetically
modified reporter cell lines, have greatly expanded the scope of in vitro toxicology. Other significant progress in the area of human-induced pluripotent
stem cells (hiPSCs) (Asgari et al., 2010; Schwartz et al., 2014; Shinde et al., 2016;
Shtrichman, Germanguz and Itskovitz-Eldor, 2013) is allowing the application
of patient and disease-specific hiPSCs (Ghodsizadeh et al., 2010; McCracken et
al., 2014; Siller et al., 2013). Moreover, the tools of precise genome editing with
engineered nucleases, such as the zinc finger nucleases (zfns), the transcription activator-like effecter nucleases (talens) and, more recently, the Clustered Regularly Interspaced Short Palindromic Repeats (crispr) associated
Cas9 technology (Gaj, Gersbach and Barbas, 2013; Kim, 2016; Komor, Badran
and Liu, 2017) have opened up tremendous opportunities for the development
of cell lines, especially those of human origin (Tobita, Guzman-Lepe and de
L’Hortet, 2015). crispr/Cas9 technology was reported for genome editing in
hiPSCs (Flaherty and Brennand, 2015; Li et al., 2014; Seah et al., 2015; Suzuki
et al., 2014). Another study reported on the simultaneous reprogramming and
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gene correction of patient fibroblasts (Howden et al., 2015). Since 2015, more
than 3,000 articles were published on studies using crispr/Cas9 genome editing, including more than 900 articles using the technology in mammalian cells
(PubMed, accessed June 11, 2017). With further technological developments,
these human in vitro cellular models shall be highly useful in the screening
of compounds for personalized medicine, allowing optimum therapy with
minimum or no adverse effects, and in the study of adverse outcomes in different strata of population. In addition to high-content screening, where several
parameters are measured as simultaneous readouts in single cells (Gasparri,
2009), high-content imaging will play an important complimentary role in systems biology approaches (van Vliet et al., 2014). High-content platforms have
been already used for the screening of compounds (Bale et al., 2014; Sirenko
et al., 2014; Tolosa et al., 2014).
Modern technologies of omics and high-content imaging are resulting in
immense data sets which require large-scale data-processing tools. Powerful
bioinformatics’ tools are also required for data integration and the overarching interpretation of biological data from disparate sources. The inherent complexity of biological systems is a challenge that is expected to be overcome by
computational modeling of biological systems. Toxicology is, therefore, aiming
at the integration of a tremendous amount of diverse information—at various
levels of biological hierarchy (genome, transcriptome, proteome, and metabolome) and biological structure (organelles, cells, tissues, organs, and organism)—with computational tools for understanding and predicting biological
behavior (e.g., adverse effect) under given conditions (e.g., perturbation due to
a toxin). This rejuvenated toxicology in modern terms is referred to as systems
toxicology (see Figure 25.1).
1.1
Systems Toxicology
The term systems toxicology is derived from systems biology and could be defined as the study of biological systems, using omics technologies, with a focus
on the mechanisms underlying complex biological processes, their interactions and perturbations in response to a toxin combined with mathematical
data integration and modeling. Systems toxicology, therefore, aims at understanding and exploring the way that different biological components are orchestrated as an ensemble in cells, tissues, and organisms.
A biological system usually consists of a large number of functionally diverse
and/or multitasking components interacting together in a nonlinear fashion
in, so-called, biological networks spread over several levels of biological organization (Kitano, 2002). Systems biology aims at understanding the structural
and functional connectivity in biological networks or simply the biological
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Modern toxicology leaning towards the systems biology approach to understanding and predicting adverse effects by integrating traditional endpoint
measurements and pharmacokinetics/pharmacodynamics information with
omics data and computational modeling.

homeostasis. Almost 150 years ago, the French physiologist, Claude Bernard,
put forward the idea that free life is based on the constancy of the internal environment. Later, in 1922, the American physiologist, Walter Canon, described
homeostasis as the key principle of life. According to Hans Seyle (1956), since
systems are robust, a system under stress will try to achieve a new homeostasis
to maintain its functions, until the stress crosses a certain threshold, and the
system collapses. Similarly, biological systems exposed to a stressor/toxin will
try to adapt and survive. Acute exposure for a short period may constitute a
temporary stress that may, or may not, manifest as a toxic effect(s), while the
biological system tries to adapt or compensate. However, acute exposure at a
very high dose may lead to acute exhaustion of the system’s resources to cope
and may lead to rapid system breakdown. On the other hand, upon repeated or
chronic exposure to low levels of stress, the system inevitably acquires a new
homeostasis. This new homeostasis may be accompanied by adverse effects
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or disease development (e.g., depression, cancer) over the period of exposure.
Upon accumulation of long-term stress, when the system’s capacity to maintain altered homeostasis is exhausted, the system will break down, ultimately
leading to the extinction of the system.
Understanding biological processes means a step towards understanding
the mechanisms of adverse effects, which in turn means understanding the molecular and functional changes in a system upon perturbation of the system’s
homeostasis. A mechanistic understanding requires system-wide quantitative
measurements of these molecular and functional changes. Recent progress in
omics technologies is playing a decisive role in linking system-level understanding to quantitative molecular knowledge (Ideker, Galitski and Hood, 2001). An
essential part of systems toxicology is the mathematical modeling of biological
responses based on mechanisms and the use of such computational models
for predicting responses by changing the parameters of perturbation. Systems
toxicology is, therefore, the integration of traditional toxicology with modern
techniques of integrated testing strategies, high-throughput screenings, pharmacokinetics/pharmacodynamics knowledge, high-content screenings, omics
technologies, in silico tools and modeling. Recent advances in cell-culture
techniques, mimicking in vivo organs, are allowing for the acquisition of
physiologically relevant information that will enhance pathways-based understandings for the discovery of novel targets and prediction of risks of adverse
outcomes.
1.2
Pathways of Toxicity
The concept of pathways of toxicity (PoTs) evolved after the famous report
from the United States National Research Council in 2007, titled Toxicology
in the 21st Century, which recommended a shift in testing from animals to
human-cell systems for the assessment of toxicity pathways (Krewski et al.,
2010). Other terms, such as the mode of action (moa) and the adverse outcome
pathways (aop) are currently used to structure and describe biological processes over biochemical pathways leading to adverse effects. This information
can be mapped on various levels of biological organization (e.g., from cells to
populations and even ecologies) (see Figure 25.2).
A PoT is a cellular response pathway, which upon sufficient perturbation
will lead to an adverse health effect. A PoT should describe the molecular basis
of the adverse response. It is assumed that a limited number of PoTs are conserved over cell types, organs, and even species, and should mediate the same
adverse outcome (Bouhifd et al., 2015). PoTs aim at molecular annotations of
network perturbations and their causes from high-content phenotyping (Hartung and McBride, 2011). It should be possible to derive PoTs from simple in vitro
tests, as in the ToxCast program in the US, which evaluated 2,000 compounds
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Organization of scientific information at different levels of biological
complexity with commonly used terminologies, such as PoT, moa, and aop.
Adapted from gocht et al. (2015)

in more than 700 assays and around 300 signaling pathways (Attene-Ramos
et al., 2013; Hsieh et al., 2017).
The molecular mechanisms over a series of causal events can be described as
the moa. It is important to distinguish a mechanism of action from the mode
of action. A mechanism of action describes the primary chemico-biological interaction between a compound and a structural moiety in a biological system
(Blaauboer and Andersen, 2007). This is more or less equivalent to the molecular initiating event in an aop. The moa describes functional and structural
changes that follow the primary interaction of a compound with its biological
target and result in quantifiable changes at the organism level (Blaauboer and
Andersen, 2007). The moa-based paradigm is based on the concept of toxicity
pathways. A PoT represents a set of molecular events that ultimately lead to a
measurable adverse outcome associated with the stressor/toxin. As such, moa
and aop are sometimes used in similar contexts.
1.3
Adverse Outcome Pathways
The concept of aop was developed in the field of ecotoxicology. Ankley et al.
(2010, p. 730) defined aop as “a conceptual construct that portrays existing
knowledge concerning the linkage between a direct molecular initiating event
and an adverse outcome at a biological level of organization relevant to risk
assessment”. The term aop is a misnomer, since pathways are not intrinsically
adverse or non-adverse but they may lead to adverse effects or disease after perturbation. The aop framework allows the organization and structuring of information for improved decision making in risk assessment (Edwards et al., 2016).
The concept of aop is now embraced by scientists all over the world, with
international efforts for harmonization and guidance on aop construction and
development, such as the Organisation for Economic Co-operation and Development (oecd) guideline (2013) and recently published aop development
strategies, principles, and best practices (Villeneuve et al., 2014a,b). aops have
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been described for skin sensitization, liver cholestasis, liver steatosis, and
fibrosis (oecd, 2012; Vinken et al., 2013; Willett et al., 2014). More recently,
there are suggestions that the aop framework can also be used for organizing,
structuring, and describing the pathways involved in diseases (Langley et al.,
2017; Noor, 2015).
An aop will begin upon exposure to a compound. The interaction of that
compound with the biological target will depend on its physico-chemical
properties and could be analyzed using methods of quantitative structureactivity relationships (qsars). The interaction of the compound with its biological target is the molecular initiating event. This will in turn lead to causal
chain of events at different levels of biological organization, with effects at the
organelle, cellular, and tissue levels. Depending on the intensity and duration
of the exposure, these effects will affect the function(s) of the organ, which
will initially try to adapt to the perturbation to achieve a new homeostasis.
However, persistent stress will ultimately lead to adverse effect(s) at the organ
level (see Figure 25.3). With time, organ level effects can spread to the whole
organism. In epidemiology, many affected organisms will lead to population
and ecology effects.
Initially, aops were thought to be linear constructs with key events causally linked with each other and occurring at different levels of biological organization (Landesmann et al., 2013). However, biological systems are highly
complex and interconnected, in addition to being very robust, and show adaptive responses to stress stimuli. Biological processes are nonlinear and highly
wired together with feedback loops and cross regulation. Modern aops are
chemically independent, modular, and connected over networks (Villeneuve
et al., 2014a). The concept of key event relationships has been used to explain
quantitative connections between several aops and more than one adverse
Adverse outcome pathway
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An aop framework to explain multilevel effects beginning with an initial triggering event (molecular initiating event), followed by a series of intermediary
events (key events) that lead to an adverse outcome.
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outcome (Figure 25.4). These connections help to identify gaps and uncertainties in an aop. An adverse outcome may also lead to another adverse outcome.
For prediction, quantitative response relationships among key events within
an aop are required and make use of weighting and probabilistic and mechanistic a pproaches (Becker et al., 2015; Perkins et al., 2015). It is expected that
quantitative aop and quantitative aop networks will have quantitative key event
relationships and this may help define an aop score for the prediction.
Although an aop is a pragmatic way of organizing information of biological relevance and facilitates causal links with multilevel information, there
are many challenges to their wide application. An aop should not only give
information about the structure of the system but also provide important clues
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Adverse outcome pathways. (A) a linear AOP showing molecular initiating
event (MIE) as the interaction between chemical and its biological target leading to a chain of causal key events (KE) resulting in an adverse outcome (AO).
(B) an AOP network with multiple pathways and key events (KE) leading to
one or more adverse outcomes. The quantitative correlation between two
key events (KER) would determine the intensity of the involvement of that
pathway.
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on the dynamics of the system. It is highly recommended for an aop to have
direct human relevancy, and an aop based only on animal data is insufficient.
The relationships between molecular initiating events, key events, and adverse
outcomes should be predictable. The successful application and adaption of
aops in toxicology (especially regulatory toxicology) will depend on the effectiveness of an aop to predict adverse outcomes. Since aops are considered
living documents that will change with the progressive availability of knowledge, the development of aops will proceed in parallel with their use; which
will inevitably, in some cases, pose uncertainties. The more nonlinear linkages
there are over multiple pathways, the more challenging the task of deriving
correlations for prediction. As with other sciences, there is an urgent need for
standardization, harmonization, and development of common language(s) to
connect and understand different application domains.
2

Preclinical Drug Development

From the discovery of new therapeutic entities to the marketing of the final
product, the drug development process mainly deals with preclinical development and clinical trials of, so-called, investigational new drugs. Preclinical
drug development focuses on the proof of efficacy and safety of new drugs. The
immense technological advancements of recent years have rendered the drug
discovery and development process more expensive than ever. At the same
time, the success rates have fallen, the regulatory requirements are becoming
stricter, and the competition has become fierce. According to the Tufts Center for the Study of Drug Development, in 2014, the cost of drug development
was around US$2.6 billion, with preclinical development costs surpassing
US$1 billion (Mullin, 2014). Only one in ten drugs entering the clinical phase
is approved by the US Food and Drug Administration (fda), according to a
recent report (Hay et al., 2014). The failure of an investigational new drug in the
clinical trials may cost billions of dollars (Horton 2004; Lang 2005). Most
investigational new drug failures are due to lack of efficacy and/or clinical toxicity. Human safety issues result in about 20% of failed drugs (Kola and Landis,
2004). In 2010, a 10-year survey showed that safety issues remained one of the
major bottlenecks in drug development (Waring et al., 2015). The woes of the
pharmaceutical industry can continue even after the approval and marketing
of a drug, as there is around 5% risk of post-marketing withdrawal due to adverse effects (Smith and Schmid, 2006).
Liver and cardiac toxicity are the major issues in drug development. Liver toxicity alone (until 2014) has resulted in most drug withdrawals. The
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r egulatory agencies require the testing of acute and repeated-dose toxicity in
animals. Although, the pharmaceutical industry is, at present, using a range
of high-throughput in vitro assays (some accepted by regulatory bodies) in
the initial screening of compounds, there are no accepted in vitro models for
repeated-dose, long-term toxicity. The next part of the chapter focuses on the
limitations of animal models and emerging new models and technology in the
assessment of liver toxicity, followed by in silico computational methods in
drug development.
3

Limitations of Animal Models in Liver Toxicity Evaluations

Although in vivo animal testing gives direct evidence of toxicity in a living “intact” organism and allows experiments not possible in humans, it is limited by
several serious drawbacks of scientific, economical, and ethical nature. A major limitation is the poor predictive power of animal studies. This poor translation of animal results to humans is mainly due to species-specific differences
(Martignoni, Groothuis and de Kante, 2006). Animals predict only 40% of human liver toxicities (Ewart et al., 2014; Olson et al., 2000). Even among different animal species, the correlation is about 60% (Hartung and Daston, 2009),
showing differences among test species and the limitation of prediction. The
intrinsic differences in animals within the same species provide inconsistent
results, especially in the case of oral-dose chronic toxicity. Testing in animals
is usually carried out in the highest tolerable doses, which do not reflect human exposure. Equally important, even after standard animal testing, 19% of
compounds presumably safe in animals, show toxic effects in human clinical
trials and are not pursued further (Sacks et al., 2014). In addition, many drugs
proved safe in animal tests and clinical trials, are withdrawn from the market
or labeled with black box warnings due to serious side effects. In the past 60
years, there have been more than 450 post-marketing withdrawals of drugs due
to hepatotoxicity (Onakpoya, Heneghan and Aronson, 2016).
Species-specific differences are mainly due to differences in the pharmacokinetic parameters, namely absorption, distribution, metabolism, and elimination. Screening in animals is carried out with the assumption that similar
reactions of biotransformation and clearance will occur in animals as in humans. However, animals differ from humans in the biotransformation of xenobiotics from Phase 0 (uptake of compounds mainly via transporters), to Phase i
(cyp450 metabolism), Phase ii (conjugation reactions), and Phase iii (excretion/eliminations of the parent compound or metabolites or their conjugates
mainly via the transporters). It is now well known that not only are there

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

The Changing Paradigm in Preclinical Toxicology

619

d ifferences in the metabolism of substances between animals and humans,
but also many molecular mechanisms of human cellular injury are different
(Woolbright et al., 2015).
In addition, due to the characteristics inherent to in vivo testing, such testing is excessively precautionary; and, therefore, many potential therapeutic
compounds are screened out. One such example is aspirin, which is considered safe for human beings; it would not have been possible to market aspirin
with current methods and criteria for safety (Hartung, 2009). This means that
the current methods of screening may also possibly screen out compounds
that could otherwise be useful in the therapy of human ailments. Other technical limitations include, low throughput of animal studies, in addition to
prolonged study periods in some cases (e.g., carcinogenicity study) (Bucher,
2002).
Although animal testing has provided significant insights into biological
processes and has contributed to human safety, the scientific goal of the 21st
century should be a move towards human-based in vitro methods, with modern tools of systems biology, to bypass the species barrier and to allow better
translation.
4

In vitro Models of Liver Toxicity in Preclinical Drug Development

Traditionally, in vitro models refer to cell-cultivation methods of primary cells
and cell lines, commonly involving plastic or glass cultivation vessels with a
cell-culture medium suitable for a given cell type. Wilhelm Roux, a German
zoologist, established the basic principles of tissue culture in 1885, by maintaining tissues in a warm saline solution for several days. Julius Richard Petri, a
German microbiologist, owns the credit of inventing the Petri dish in the early
1900s. Modern two-dimensional (2D) cell culture is usually carried out in polymer culture flasks and dishes of multitude formats. Ross Granville Harrison, an
American embryologist, is considered the pioneer of 3D cell culture using the
hanging drop method (Nicholas, 1961).
Today, 2D cultivation techniques are well established and cells (mostly cell
lines) of almost all tissues of human or animal origin are available. There are
many advantages to the 2D cultivation of cells, such as simplicity; expertise
required; low costs; high number of replicates; and, most importantly, application in high-throughput screening in multi-well plates, with the possibility of
miniaturization and robotic automation, minimizing human bias and error as
well as ensuring high precision. In addition, less material (cells and culture media as well as test substance) is required with fewer ethical concerns. A battery
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of simple and complex 2D in vitro assays can predict up to 80% of human hepatotoxicity (Noor et al., 2009; Vernetti et al., 2017).
Nevertheless, 2D cultivation of cells involves maintaining the cells in an
unnatural and artificial environment, whereby they lose their organ- and
tissue-specific architecture and organization. Other factors, such as medium
change, cell density to surface ratios, lack of flow and sheer tension, and unphysiological oxygen supply are other major limitations. Another commonly
encountered problem is the rapid de-differentiation of primary cells, such as
the hepatic cells, in 2D cultures, resulting in the loss of functions.
In vivo, cell-to-cell contacts and communication across the extracellular matrix are ensured within a three-dimensional (3D) arrangement. The extracellular matrix regulates cell morphology and gene expression in vivo (Bissell, 2007;
Bissell, Hall and Parry, 1982; Le Beyec et al., 2007). A 3D environment influences
the epigenetic plasticity of the cells (Spencer,Xu and Bissell, 2007; Xu, Spencer and Bissell, 2007). Conventional 2D hepatic cultures rapidly lose liver-like
functionality (Godoy et al., 2013; Paine and Andreakos, 2004), leading to poor
concordance between experimental in vitro data and in vivo data, especially
with respect to xenobiotic metabolism and transporter activities. Optimization of the culture medium may help in the maintenance of functions for some
time (Klein et al., 2014; Mueller et al., 2012). However, modern in vitro methods
are more and more focused on the 3D cultivation of cells as organoids or micro tissues that ensure cell-to-cell contacts, cells to be surrounded completely
by extracellular matrix, facilitating cell-to-cell communication and signaling
(Alepée et al., 2014; Mueller, Heinzle and Noor, 2013).
3D cultures of primary human hepatocytes and human-cell lines, such
as HepRG and HepG2, retain long-term viability and maintain liver-specific
functions in vitro (Mueller, Koetemann and Noor, 2011a; Mueller et al., 2011b;
Gunness et al., 2013; Mueller et al., 2014; van Grunsven, 2017). 3D cultures (also
called 3D micro tissues, organoids, and organotypic cultures) in microfluidic
devices, are termed biochips (Baudoin et al., 2007), organs on a chip (Bhatia
and Ingber, 2014) or body on a chip, where several tissues or organ systems are
represented (Marx et al., 2012; Materne et al., 2015a; Materne et al., 2015b; Sung
et al., 2014). These emerging technologies allow the study of human physiology and adverse effects in vitro, as they enable analysis of the biochemical
and metabolic activities of living cells in functional tissue and organ contexts,
while allowing high-resolution, real-time imaging (Bhatia and Ingber, 2014).
Although, such advanced 3D culture techniques demand expertise, and usually special equipment/setups, in addition to comparatively h
 igher costs and
lower throughputs, they seem to be indispensable for meaningful humanbiology based science in future.
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Much development effort is underway for a high-throughput generation of
the 3D cultures as aggregates (Gevaert et al., 2014), micro-patterned co-cultures
(Khetani and Bhatia, 2008) and 3D printing (Billiet et al., 2014). High-content
platforms are already used in drug development for the screening of compounds (Bale et al., 2014; Tolosa et al., 2014). At the same time, highly-advanced
imaging and other techniques (including automated methods for assessing
multiple readouts, such as cell viability, shape of the nuclei, cell area, mitochondrial membrane potential, phospholipids accumulation, cytoskeleton
integrity, and apoptosis) are playing an important role in the study of biological pathways (Ramaiahgari et al., 2014; Sirenko et al., 2014). Such high-content
and high-throughput platforms are changing the toxicity screening paradigm
(Patlewicz et al., 2013), paving the way towards pathway-based, in vitro only,
safety assessment (Adeleye et al., 2014; Kleensang et al., 2014).
5

Computational in silico Tools

In silico methods such as quantitative structure activity relationships (qsars)
in predictive toxicology are not new. More than 150 years ago, Cros (1863) linked
the toxicity of primary alcohols to their water solubility. Crum-Brown and Fraser (1869) advanced the idea that the biological activity of a compound was
linked to its chemical structure. In the 1980s, when pharmaceutical companies
were creating libraries of thousands of compounds, methods of qsars were
refined, automatized, and extensively applied. The idea was that the toxicity
of a chemical is dependent on specific features of the structure of that chemical. Therefore, similar chemical features are expected to share similar mechanisms of action and could be used for the prediction of activity. Basically, a set
of compounds of known activities are used to train computer algorithms to
differentiate between active and inactive compounds (Johnson and Maggiora,
1990). qsars provide a mathematical relationship between a biological activity and one or more molecular descriptors able to predict the activity. These
molecular descriptors are quantifiable and, therefore, give a quantitative relation to the toxicity. Modern qsars are multidimensional (mqsar) and include
multiple representations of the ligand or protein (Tseng et al., 2012; Vedani,
Dobler and Lill, 2006).
qsars are often used in combination with other methods, such as read-across
and weight-of-evidence assessments. Read-across is defined by the European
Chemicals Agency (2017, p. 6) as “a technique for predicting endpoint information for one substance (target substance), by using data from the same endpoint from (an)other substance(s), (source substance(s))”. A range of in silico
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tools are available for grouping the chemicals and read-across (Enoch, Cronin
and Ellison, 2011). Publicly available software include, toxicity estimation software tool (test), the oecd qsar toolbox, high-throughput virtual molecule
docking (htvmd), MetaCore, and the topkat model. qsar methods are increasingly predictive in hazard identification for acute toxicity, genotoxicity,
mutagenicity, and bioaccumulation. Nevertheless, qsars and read-across are
limited in the prediction of the pharmacokinetic properties of compounds.
Other in silico methods include computational methods for modeling
the pharmacokinetics of compounds and linking this to the biological response. Pharmacokinetics deals with the quantification of drug absorption,
distribution, and elimination for the investigation and prediction of blood
concentration-time profiles. Pharmacokinetic models can be simple to complex, depending on the level and the quality of information available. Simple
models are empirical and can be used for the estimation of clearance and
half-life, allowing dosage-regimen calculations (Jones, Mayawala and Poulin,
2013; Klein et al., 2015; Wetmore et al., 2012). Models that are more complex are
Physiologically Based Pharmaco-Kinetic (pbpk) models, which are compartment models. These compartments represent tissues and organ spaces and
their volumes. As early as 1937, Toerell, one of the pioneers of pharmacokinetics, described the basic principles of a pbpk approach (Teorell, 1937). However,
its mathematical complexity and the lack of physiological data needed for the
model were significant challenges to its widespread application for many years.
At present, pbpk models are mechanism based and allow extrapolation
from high doses to lower doses, from one species to another, and between dose
routes. Traditionally, data is generated from in vivo animal and in vitro animal
and human studies (see Figure 25.5), in an approach originally described by
Sobels for anticancer drugs (Sobels, 1977).
Since pbpk models are based on physiological parameters, it is possible to
use them to predict in vivo absorption, distribution, metabolism, and excretion. pbpk modeling is still heavily dependent on animal studies, and very few
clinical applications of pbpk models have appeared. The major reason is the
lack of human data for validation. However, in vitro systems can be used, to
some extent, for the prediction of distribution, metabolism, and elimination
(Poulin, 2013; Poulin et al., 2013a, b; Poulin and Haddad, 2013). Using a pbpk
model, in vitro tests can also provide parameters that allow the prediction of
dose-response in vivo. pbpk modeling not only allows simulation of human
pharmacokinetics, it also enables in vitro to in vivo extrapolation. For this
purpose, quantitative in vitro data, such as data on tissue distribution, rates
of metabolism, rates of interactions with biological macromolecules such
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Traditional approach for risk assessment using animal data.
Adapted from sobels (1977)

as receptors, changes in cell function and viability, is needed. pbpk modeling combined with other in silico (chemical-related) and in vitro (biologyrelated) parameter estimations allows for prediction of in vivo exposure
equivalent to the in vitro assay concentrations producing an adverse effect. For
reliable predictions u
 sing such methods, a thorough experimental design with
the characterization of the biological system, including the cell model and
its characteristics, is essential. Recently, simple pbpk models were combined
with acute and long-term dose-response data to calculate oral equivalent doses (Chang et al., 2015; Hamon et al., 2015; Klein et al., 2015; Rotroff et al., 2010;
Wetmore et al., 2012; Yoon et al., 2014).
Models based on a systems biology approach are also being developed (Ideker et al., 2001) to allow firm anchorage of pbpk/pharmacodynamic models
on a mechanistic basis. This new developing area, currently also referred to as
quantitative systems pharmacology, focuses on the drugability of targets in biological systems. Quantitative systems pharmacology, in fact, follows a systems
biology approach to drug discovery, aimed at the underlying mechanisms of
drug actions on multiscale systems, using iterative computational modeling
(Knight-Schrijver et al., 2016; Vernetti et al., 2017).
In general, the advantages of in silico methods are low costs, standardization, equipment needs, throughput, and the tremendous possibility of virtual
expansion in terms of chemical space, numbers, and biological response scenarios. However, these methods have their own limitations, such as reliability
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and robustness. These limitations are mainly based on data quality (and in
some cases quantity) and the complexity of biological systems. Gene expression and metabolic network models, along with integrated, large multiscale
models, are computationally demanding, data intensive, and time consuming.
6

Toxicology in the Coming Years: Challenges and Perspectives

Systems biology—with next generation technologies, such as integrated omics
techniques, advanced cell-culture methods, and assays, along with better and
faster computational in silico methods—is playing a key role in changing the
global mindset towards toxicology. This shift in paradigm will allow for the integration of a human knowledgebase, including network information and in
vitro assays providing critical key event parameter values, with less emphasis
on in vivo animal data (Edwards and Preston, 2008). For optimal application of
systems biology tools, the fundamental construct is to develop adequate and
fit-for-purpose in vitro assays to characterize pathway perturbations and predict adverse outcomes due to these perturbations. Future in vitro assays will be
based on human cells derived from pluripotent stem cells and human reporter
cell lines.
The two most important corner stones of risk assessment are exposure and
concentration response. Systems biology provides the framework for bridging
exposure to a compound and its causal adverse outcome (Sheldon and Cohen
Hubal, 2009). It is essential that in vitro data provide relevant information on
the concentration response over time. The perturbations and the concentration in which they occur should reflect human in vivo exposure and effects.
However, extrapolation of in vitro results to humans in vivo is sometimes
limited due to the fact that nominal concentrations in the in vitro assays are
used without consideration of the exposure magnitude, timing, and duration
(Coecke et al., 2013). Other factors such as in vivo bioavailability and metabolic
clearance are not taken into account, in addition to other in vitro specific parameters, such as plastic binding, cell-surface binding, compound degradation
and evaporation (Groothuis et al., 2015).
Furthermore, better tools for the characterization of the biological perturbations leading to adverse effects are needed for a mechanistic understanding
of the perturbed pathways. This will require a recapitulation of the toxicity
pathway(s) by in vitro assays. In this context, the systems biology approach
provides molecular information and key event networks for the comparison
of moa-based pathways. Systems biology measurements will also provide information on overlapping events across multiple pathways. Given that there
is often a temporal shift in various omics readouts, it is imperative to conduct
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An ideal shift in paradigm where human-relevant, advanced mechanismbased in vitro cells, such as primary human hepatocytes, hiPSCs, derived
functional hepatocytes, or cardiomyocytes will provide high-quality data for
in vitro to in vivo extrapolation (ivive) of human pharmacokinetics (PK)/
pharmacodynamics (PD), identification of targets, and mechanisms that will
ultimately lead to the prediction of adverse effects in humans in vivo.

k inetic studies, so that time resolved data could be obtained. Careful design
and control of the system is necessary to obtain high-quality data and to reduce
uncertainties inherent to in vitro systems. A fully integrated systems approach
would reduce many uncertainties associated with current risk assessment approaches. The aim is to obtain human-specific, high-quality data at different
molecular levels and integrate these with in silico tools for the extrapolation
and prediction of human adverse effects (see Figure 25.6).
Thus, a systems biology approach could help define moa, species extrapolation, in vitro to in vivo extrapolation and provide a mechanistic basis for describing the susceptibility of certain subpopulations. An integrated approach
of human in vitro and in silico methods for in vivo exposure is expected to provide a reliable prediction of toxicity. An in vitro system that is designed and
characterized to provide human in vivo relevant information will be the key to
successful prediction. Combined with qualitative and quantitative knowledge
on perturbations in biological pathways over time, this integrated approach
could be a powerful tool for in vivo relevant toxicity assessment. Finally, the
concept of aop remains to be developed beyond its limitations and deficiencies
to be successful and to gain acceptance by the regulatory agencies in humanrisk assessment.
Microfluidic systems, using 3D organotypic cultures for compound screening, is another area with great promise. In the case of liver, it will additionally
allow measurements of pharmacokinetic and pharmacodynamic parameters
in vitro. A challenge will be to include more than one organ on such a platform. Although some systems (see Figure 25.7) are already reported, they are
still limited in their wide application. A pragmatic solution will be to combine
organ-type cells, according to the scientific need and the data needed.
The establishment of complex cellular models based on co-cultures is another active research area with promise in the quantitative understanding of
mechanisms in human health and disease. Organs are complex structures and
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Body on a chip.
Image courtesy of the Wyss Institute, Harvard University

their response (manifested as adverse effects or disease) is a joint response of
many cell types in communication. Combining different cell types is no trivial
task, due to the complex environmental needs of each cell type. The in vivo
relevance of these systems will have to be validated. Advanced microfluidic
systems, in future, will include liver zonation (Vernetti et al., 2017).
The application of hiPSC-derived models in human disease research, in
future, will move in vitro systems from mostly proliferating cell lines towards
patient-specific cells and will, thus, facilitate personalized systems medicine.
Human-induced pluripotent stem cells have great potential in toxicological screening, since they provide patient-specific pharmacological responses.
Hepatocyte-like cells, derived from hiPSCs cultured on a micropatterned coculture system are reported to predict the hepatotoxicity of test compounds
with 65% sensitivity and 100% specificity (Ware et al., 2015). In addition,
crisper/Cas9 technology provides a range of modified induced pluripotent
stem cells (iPSCs), which will allow discovery of novel targets and biomarkers.
A whole range of modified iPSCs, after differentiation, could serve not only in
regenerative therapy but could be applied in mechanistic research and in the
screening of therapeutics (see Figure 25.8).
It is hoped that this shift in paradigm will progress towards evidence-based
science and personalized medicine, where clinical observations will be used to
design advanced in vitro methods based on 3D models, with patient-specific
primary or iPSC-derived cellular models (see Figure 25.9). The omics data from
these models is expected to allow biological target identification and validation. This information will facilitate personalized therapy for a specific patient
depending on the patient’s genetic background.
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Figure 25.9

Modern cell reprogramming and gene editing tools, allowing modifications of
patient-specific iPSCs for use in disease research, toxicology, and screening, in
addition to the possibility of cell therapy.
Image taken from Seah et al. (2015)
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The paradigm shift towards clinical, observations-based, mechanistic investigations in vitro, using advanced tools of cell culture and omics. These should
provide potential biomarkers and targets for exploitation in evidence-based
personalized therapy and follow-up.
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Clinical observations combined with the omics information, mechanisms,
and biomarkers will iterate the whole process in modern systems toxicology.
The impact of this approach is, no doubt, beyond toxicology in other fields of
health, medicine, drug development, and basic sciences.
References
Adeleye, Y., M. Andersen, R. Clewell, M. Davies, M. Dent, S. Edwards, P. Fowler, S. Malcomber, B. Nicol, A. Scott, B. Sun, C. Westmoreland, A. White, Q. Zhang and P.L. Carmichael (2014). Implementing Toxicity Testing in the 21st Century (TT21C): Making
Safety Decisions Using Toxicity Pathways, and Progress in a Prototype Risk Assessment. Toxicology, 332, pp. 102–111.
Alepee, N., A. Bahinski, M. Daneshian, De B. Wever, E. Fritsche, A. Goldberg, J. Hansmann, T. Hartung, J. Haycock, H. Hogberg, L. Hoelting, J.M. Kelm, S. Kadereit, E.
McVey, R. Landsiedel, M. Leist, M. Lübberstedt, F. Noor, C. Pellevoisin, D. Petersohn,
U. Pfannenbecker, K. Reisinger, T. Ramirez, B. Rothen-Rutishauser, M. SchäferKorting, K. Zeilinger and M.G. Zurich (2014). State-of-the-art of 3D Cultures (Organs
on a Chip) in Safety Testing and Pathophysiology. Alternatives to Animal Experimentation, 31, pp. 441–477.
Ankley, G.T., R.S. Bennett, R.J. Erickson, D.J. Hoff, M.W. Hornung, R.D. Johnson, D.R.
Mount, J.W. Nichols, C.L. Russom, P.K. Schmieder, J.A. Serrrano, J.E. Tietge and D.L.
Villeneuve (2010). Adverse Outcome Pathways: A Conceptual Framework to Support Ecotoxicology Research and Risk Assessment. Environmenal Toxicology and
Chemistry, 29(3), pp. 730–741.
Asgari, S., B. Pournasr, G.H. Salekdeh, A. Ghodsizadeh, M. Ott and H. Baharvand (2010).
Induced Pluripotent Stem Cells: A New Era for Hepatology. Journal of Hepatology,
53, pp. 738–751.
Attene-Ramos, M.S., N. Miller, R. Huang, S. Michael, M. Itkin, R.J. Kavlock, C.P. Austin,
P. Shinn, A. Simeonov, R.R. Tice and M. Xia (2013). The Tox21 Robotic Platform for
the Assessment of Environmental Chemicals: From Vision to Reality. Drug Discovery Today, 18(15–16), pp. 716–723.
Bale, S.S., L. Vernetti, N. Senutovitch, R. Jindal, M. Hegde, A. Gough, W.J. McCarty, A.
Bakan, A. Bhushan, T.Y. Shun, I. Golberg, R. DeBiasio, B.O. Usta, D.L. Taylor and M.L.
Yarmush (2014). In Vitro Platforms for Evaluating Liver Toxicity. Experimental Biology and Medicine (Maywood), 239, pp. 1180–1191.
Baudoin, R., A. Corlu, L. Griscom, C. Legallais, and E. Leclerc (2007). Trends in the Development of Microfluidic Cell Biochips for In Vitro Hepatotoxicity. Toxicology In
Vitro, 21, pp. 535–544.

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

The Changing Paradigm in Preclinical Toxicology

629

Becker, R.A., G.T. Ankley, S.W. Edwards, S.W. Kennedy, I. Linkov, B. Meek, M. Sachana,
H. Segner, B. Van Der Burg, D.L. Villeneuve, H. Watanabe and T.S. Barton-Maclaren
(2015). Increasing Scientific Confidence in Adverse Outcome Pathways: Application
of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence. Regulatory Toxicology and Pharmacology, 72, pp. 514–537.
Bhatia, S.N., and D.E. Ingber (2014). Microfluidic Organs on Chips. Nature Biotechnology, 32, pp. 760–772.
Billiet, T., E. Gevaert, T. De Schryver, M. Cornelissen and P. Dubruel (2014). The 3D
Printing of Gelatin Methacrylamide Cell-laden Tissue-engineered Constructs with
High Cell Viability. Biomaterials, 35, 49–62.
Bissell, M.J. (2007). Architecture Is the Message: The Role of Extracellular Matrix and
3D Structure in Tissue-specific Gene Expression and Breast Cancer. Pezcoller Foundation Journal, 16(29), pp. 2–17.
Bissell, M.J., H.G. Hall, and G. Parry (1982). How Does the Extracellular Matrix Direct
Gene Expression?. Journal of Theoretical Biology, 99(1), pp. 31–68.
Blaauboer, B.J. and M.E. Andersen (2007). The Need for a New Toxicity Testing and Risk
Analysis Paradigm to Implement REACH or Any Other Large Scale Testing Initiative. Archives of Toxicology, 81(5), pp. 385–387.
Bouhifd, M., M.E. Andersen, C. Baghdikian, K. Boekelheide, K.M. Crofton, A.J. Fornace
Jr., A. Kleensang, H. Li, C. Livi, A. Maertens, P.D. McMullen, M. Rosenberg, R. Thomas, M. Vantangoli, J.D. Yager, L. Zhao and T. Hartung (2015). The Human Toxome
Project. Alternatives to Animal Experimentation, 32(2), pp. 112–124.
Bucher, J.R. (2002). The National Toxicology Program Rodent Bioassay: Designs, Interpretations, and Scientific Contributions. Annals of the New York Academy of Sciences, 982, pp. 198–207.
Chang, X., N. Kleinstreuer, P. Ceger, J. Hsieh, D. Allen and W. Casey (2015). Application
of Reverse Dosimetry to Compare In Vitro and In Vivo Estrogen Receptor Activity.
Applied In Vitro Toxicology, 1(1), pp. 33–44.
Coecke, S., O. Pelkonen, S.B. Leite, U. Bernauer, J.G. Bessems, F.Y. Bois, U. GundertRemy, G. Loizou, E. Testai and J.M. Zaldivar (2013). Toxicokinetics as a Key to the
Integrated Toxicity Risk Assessment Based Primarily on Non-animal Approaches.
Toxicology In Vitro, 27, pp. 1570–1577.
Cros, A.F.A. (1863). Action de L’alcool Amylique sur L’organism. Faculté de Médecine
Strasbourg.
Crum-Brown, A., and T.R. Fraser (1869). On the Connection Between Chemical Constitution and Physiological Action. Part i. Transactions of the Royal Society of Edinburgh, 25, pp. 257–274.
Edwards, S.W. and R.J. Preston (2008). Systems Biology and Mode of Action Based Risk
Assessment. Toxicological Sciences, 106, pp. 312–318.

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

630

Noor

Edwards, S.W., Y.M. Tan, D.L. Villeneuve, M.E. Meek and C.A. McQueen (2016). Adverse
Outcome Pathways-organizing Toxicological Information to Improve Decision
Making. Journal of Pharmacology and Experimental Therapeutics, 356(1), pp. 170–181.
Enoch, S.J., M.T. Cronin, C.M. Ellison (2011). The Use of a Chemistry-based Profiler for
Covalent DNA Binding in the Development of Chemical Categories for Read-Across
for Genotoxicity. Alternatives to Laboratory Animals, 39(2), pp. 131–145.
European Chemicals Agency (2017). Read-Across Assessment Framework (RAAF).
[online] Available at: https://echa.europa.eu/documents/10162/13628/raaf_en.pdf
[Accessed 9 March 2018].
Ewart, L., M. Aylott, M. Deurinck, M. Engwall, D.J. Gallacher, H. Geys, P. Jarvis, H. Ju, D.
Leishman, L. Leong, N. McMahon, A. Mead, P. Milliken, W. Suter, A. Teisman, K. Van
Ammel, H.M. Vargas, R. Wallis and J.P. Valentin (2014). The Concordance Between
Nonclinical and Phase i Clinical Cardiovascular Assessment from a Cross-company
Data Sharing Initiative. Toxicological Sciences, 142(2), pp. 427–435.
Flaherty, E.K. and K.J. Brennand (2015). Using hiPSCs to Model Neuropsychiatric Copy
Number Variations (Cnvs) Has Potential to Reveal Underlying Disease Mechanisms.
Brain Research, 1655, pp. 283–293.
Gaj, T., C.A. Gersbach, and C.F. Barbas 3rd (2013). ZFN, TALEN, and CRISPR/Casbased Methods for Genome Engineering. Trends in Biotechnology, 31, pp. 397–405.
Garcia-Reyero, N. (2015). Are Adverse Outcome Pathways Here to Stay? Environmental
Science and Technology, 49, pp. 3–9.
Gasparri, F. (2009). An Overview of Cell Phenotypes in HCS: Limitations and Advantages. Expert Opinions in Drug Discovery, 4, pp. 643–657.
Gevaert, E., L. Dolle, T. Billiet, P. Dubruel, L. van Grunsven, A. van Apeldoorn and R.
Cornelissen (2014). High Throughput Micro-well Generation of Hepatocyte Microaggregates for Tissue Engineering. PLoS One, 9, p. e105171.
Ghodsizadeh, A., A. Taei, M. Totonchi, A. Seifinejad, H. Gourabi, B. Pournasr, N.
Aghdami, R. Malekzadeh, N. Almadani, G.H. Salekdeh and H. Baharvand (2010).
Generation of Liver Disease-specific Induced Pluripotent Stem Cells Along with
Efficient Differentiation to Functional Hepatocyte-like Cells. Stem Cell Reviews, 6,
pp. 622–632.
Gocht, T., E. Berggren, H.J. Ahr, I. Cotgreave, M.T. Cronin, G. Daston, B. Hardy, E. Heinzle,
J. Hescheler, D.J. Knight, C. Mahony, M. Peschanski, M. Schwarz, R.S. Thomas, C. Verfaillie, A. White and M. Whelan (2015). The SEURAT-1 Approach Towards Animal
Free Human Safety Assessment. Alternatives to Animal Experimentation, 32(1), pp.
9–24.
Godoy, P., N.J. Hewitt, U. Albrecht, M.E. Andersen, N. Ansari, S. Bhattacharya, J.G. Bode,
J. Bolleyn, C. Borner, J. Bottger, A. Braeuning, R.A. Budinsky, B. Burkhardt, N.R. Cameron, G. Camussi, C.S. Cho, Y.J. Choi, R.J. Craig, U. Dahmen, G. Damm, O. Dirsch,
M.T. Donato, J. Dong, S. Dooley, D. Drasdo, R. Eakins, K.S. Ferreira, V. Fonsato, J.

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

The Changing Paradigm in Preclinical Toxicology

631

Fraczek, R. Gebhardt, A. Gibson, M. Glanemann, C.E. Goldring, M.J. Gómez-Lechón,
G.M. Groothuis, L. Gustavsson, C. Guyot, D. Hallifax, S. Hammad, A. Hayward, D.
Häussinger, C. Hellerbrand, P. Hewitt, S. Hoehme, H.G. Holzhütter, J.B. Houston,
J. Hrach, K. Ito, H. Jaeschke, V. Keitel, J.M. Kelm, B. Kevin, C. Kordes, G.A. Kullak-
Ublick, E.L. LeCluyse, P. Lu, J. Luebke-Wheeler, A. Lutz, D.J. Maltman, M. Matz-Soja,
P. McMullen, I. Merfort, S. Messner, C. Meyer, J. Mwinyi, D.J. Naisbitt, A.K. Nussler, P.
Olinga, F. Pampaloni, J. Pi, L. Pluta, S.A. Przyborski, A. Ramachandran, V. Rogiers, C.
Rowe, C. Schelcher, K. Schmich, M. Schwarz, B. Singh, E.H. Stelzer, B. Stieger, R. Stöber, Y. Sugiyama, C. Tetta, W. Thasler, T. Vanhaecke, M. Vinken, T.S. Weiss, A. Widera,
C.G. Woods, J.J. Xu, K.M. Yarborough and J.G. Hengstler (2013). Recent Advances in
2D and 3D In Vitro Systems Using Primary Hepatocytes, Alternative Hepatocyte
Sources and Non-parenchymal Liver Cells and Their Use in Investigating Mechanisms Of Hepatotoxicity, Cell Signaling and ADME. Archives of Toxicology, 87, pp.
1315–1530.
Groothuis, F.A., M.B. Heringa, B. Nicol, J.L. Hermens, B.J. Blaauboer and N.I. Kramer
(2015). Dose Metric Considerations in In Vitro Assays to improve Quantitative In
Vitro-In Vivo Dose Extrapolations. Toxicology, 332, pp. 30–40.
Gunness, P., D. Mueller, V. Shevchenko, E. Heinzle, M. Ingelman-Sundberg and F. Noor
(2013). 3D Organotypic Cultures of Human HepaRG Cells: A Tool for In Vitro Toxicity Studies. Toxicological Sciences 133(1), pp. 67–78.
Hamon, J., M. Renner, M. Jamei, A. Lukas, A. Kopp-Schneider and F.Y. Bois (2015).
Quantitative In Vitro to In Vivo Extrapolation of Tissues Toxicity. Toxicology In Vitro,
30(1A), pp. 203–216.
Hartung, T. (2009). Per Aspirin Ad Astra. Alternatives to Laboratory Animals, 37(2), pp.
45–47.
Hartung, T. and G. Daston (2009). Are In Vitro Tests Suitable for Regulatory Use?. Toxicological Sciences, 111, pp. 233–237.
Hartung, T. and M. McBride (2011). Food for Thought ... on mapping the human toxome.
Alternatives to Animal Experimentation, 28 (2), pp. 83–93.
Hay, M., D.W. Thomas, J.L. Craighead, C. Economides and J. Rosenthal (2014). Clinical
Development Success Rates for Investigational Drugs. Nature Biotechnology, 32, pp.
40–51.
Horton, R. (2004). Vioxx, The Implosion of Merck and Aftershocks at the FDA. Lancet,
364, pp. 1995–1996.
Howden, S.E., J.P. Maufort, B.M. Duffin, A.G. Elefanty, E.G. Stanley, and J.A. Thomson
(2015). Simultaneous Reprogramming and Gene Correction of Patient Fibroblasts.
Stem Cell Reports, 5(6), pp. 1109–1118.
Hsieh, J.H., R. Huang, J.A. Lin, A. Sedykh, J. Zhao, R.R. Tice, R.S. Paules, M. Xia and S.S.
Auerbach (2017). Real-time Cell Toxicity Profiling of Tox21 10K Compounds Reveals
Cytotoxicity Dependent Toxicity Pathway Linkage. PLoS One, 12(5), p. e0177902.

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

632

Noor

Ideker, T., T. Galitski and L. Hood (2001). A New Approach to Decoding Life: Systems
Biology. Annual Review of Genomics and Human Genetics, 2, pp. 343–372.
Johnson, M.A. and G.M. Maggiora, eds. (1990). Concepts and applications of molecular
similarity. 1st ed. Wiley.
Jones, H.M., K. Mayawala and P. Poulin (2013). Dose Selection Based on Physiologically
Based Pharmacokinetic (PBPK) Approaches. American Association of Pharmaceutical Scientists Journal, 15(2), pp. 377–387.
Khetani, S.R. and S.N. Bhatia (2008). Microscale Culture of Human Liver Cells for Drug
Development. Nature Biotechnology, 26, pp. 120–126.
Kim, J.S. (2016). Genome Editing Comes of Age. Nature Protocols, 11(9), pp. 1573–1578.
Kitano, H. (2002). Computational Systems Biology. Nature, 420, pp. 206–210.
Kleensang, A., A. Maertens, M. Rosenberg, S. Fitzpatrick, J. Lamb, S. Auerbach, R. Brennan, K.M. Crofton, B. Gordon, A.J. Fornace Jr., K. Gaido, D. Gerhold, R. Haw, A. Henney, A. Ma’ayan, M. McBride, S. Monti, M.F. Ochs, A. Pandey, R. Sharan, R. Stierum,
S. Tugendreich, C. Willett, C. Wittwehr, J. Xia, G.W. Patton, K. Arvidson, M. Bouhifd,
H.T. Hogberg, T. Luechtefeld, L. Smirnova, L. Zhao, Y. Adeleye, M. Kanehisa, P. Carmichael, M.E. Andersen and T. Hartung (2014). T4 Workshop Report: Pathways of
Toxicity. Alternatives to Animal Experimentation, 31(1), pp. 53–61.
Klein, S., S. Maggioni, J. Bucher, D. Mueller, J. Niklas, V. Shevchenko, K. Mauch, E.
Heinzle and F. Noor (2015). In Silico Modeling for the Prediction of Dose and Pathway Related Adverse Effects in Humans from In Vitro Repeated-dose Studies. Toxicological Sciences, 149(1), pp. 55–66.
Klein, S., D. Mueller, V. Schevchenko and F. Noor (2014). Long-term Maintenance of
HepaRG Cells in Serum-free Conditions and Application in a Repeated Dose Study.
Journal of Applied Toxicology, 34(10), pp. 1078–1086.
Knight-Schrijver, V.R., V. Chelliah, L. Cucurull-Sanchez and N. Le Novère (2016). The
Promise of Quantitative Systems Pharmacology Modelling for Drug Development.
Computational and Structural Biotechnology Journal, 14, pp. 363–370.
Kola, I. and J. Landis (2004). Can the Pharmaceutical Industry Reduce Attrition Rates?.
Nature Reviews Drug Discovery, 3(8), pp. 711–716.
Komor, A.C., A.H. Badran and D.R. Liu (2017). CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes. Cell, 168(1–2), pp. 20–36.
Krewski, D., D. Acosta Jr., M. Andersen, H. Anderson, J.C. Bailar 3rd, K. Boekelheide,
R. Brent, G. Charnley, V.G. Cheung, S. Green Jr., K.T. Kelsey, N.I. Kerkvliet, A.A. Li, L.
McCray, O. Meyer, R.D. Patterson, W. Pennie, R.A. Scala, G.M. Solomon, M. Stephens,
J. Yager and L. Zeise (2010). Toxicity Testing in the 21st Century: A Vision and a Strategy. Journal of Toxicology and Environmental Health Part B Critical Reviews, 13(2–4),
pp. 51–138.
Landesmann, B., M. Mennecozzi, E. Berggren and M. Whelan (2013). Adverse Outcome
Pathway-based Screening Strategies for an Animal-free Safety Assessment of Chemicals. Alternatives to Laboratory Animals, 41, pp. 461–471.
Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

The Changing Paradigm in Preclinical Toxicology

633

Lang, L. (2005). Valdecoxib (Bextra) Withdrawal Leaves Pain Relief Treatment Gap.
Gastroenterology, 128, pp. 1769–1770.
Langley, G.R., I.M. Adcock, F. Busquet, K.M. Crofton, E. Csernok, C. Giese, T. Heinonen,
K. Herrmann, M. Hofmann-Apitius, B. Landesmann, L.J. Marshall, E. McIvor, A.R.
Muotri, F. Noor, K. Schutte, T. Seidle, A. van de Stolpe, H. Van Esch, C. Willett and
G. Woszczek (2017), Towards a 21st-century Roadmap for Biomedical Research and
Drug Discovery: Consensus Report and Recommendations. Drug Discovery Today,
22(2), pp. 327–339.
Le Beyec, J., R. Xu, S.Y. Lee, C.M. Nelson, A. Rizki, J. Alcaraz and M.J. Bissell (2007). Cell
Shape Regulates Global Histone Acetylation in Human Mammary Epithelial Cells.
Experimental Cell Research, 313(14), pp. 3066–3075.
Li, M., K. Suzuki, N.Y. Kim, G.H. Liu and J.C. Izpisua Belmonte (2014). A Cut Above the
Rest: Targeted Genome Editing Technologies in Human Pluripotent Stem cells. Journal of Biological Chemistry, 289, pp. 4594–4599.
Martignoni, M., G.M. Groothuis and R. de Kanter (2006). Species Differences Between
Mouse, Rat, Dog, Monkey, and Human CYP-mediated Drug Metabolism, Inhibition,
and Induction. Expert Opinion on Drug Metabolism and Toxicology, 2, pp. 875–894.
Marx, U., H. Walles, S. Hoffmann, G. Lindner, R. Horland, F. Sonntag, U. Klotzbach, D.
Sakharov, A. Tonevitsky and R. Lauster (2012). “Human on a Chip Developments”:
A Translational Cutting-edge Alternative to Systemic Safety Assessment and Efficiency Evaluation of Substances in Laboratory Animals and Man?. Alternatives to
Laboratory Animals, 40, pp. 235–257.
Materne, E.M., I. Maschmeyer, A.K. Lorenz, R. Horland, K.M. Schimek, M. Busek, F.
Sonntag, R. Lauster and U. Marx (2015a). The Multi-organ Chip. A Microfluidic Platform for Long-term Multi-tissue Coculture. Journal of Visualized Experiments, p.
e52526.
Materne, E.M., A.P. Ramme, A.P. Terrasso, M. Serra, P.M. Alves, C. Brito, D.A. Sakharov,
A.G. Tonevitsky, R. Lauster and U. Marx (2015b). A Multi-Organ Chip Co-culture of
Neurospheres and Liver Equivalents for Long-term Substance Testing. Journal of
Biotechnology, 205, pp. 36–46.
McCracken, K.W., E.M. Cata, C.M. Crawford, K.L. Sinagoga, M. Schumacher, B.E. Rockich, Y.H. Tsai, C.N. Mayhew, J.R. Spence, Y. Zavros and J.M. Wells (2014). Modeling
Human Development and Disease in Pluripotent Stem-cell-derived Gastric Organoids. Nature, 516(7531), pp. 400–404.
Mueller, D., E. Heinzle and F. Noor (2013). 3D Hepatic In Vitro Models as Tools for Toxicity Studies. Current Tissue Engineering, 2, pp. 78–89.
Mueller, D., A. Koetemann and F. Noor (2011a). Organotypic Cultures of HepG2 for In
Vitro Toxicity Studies. Journal of Bioengineering and Biomedical Science, S2:002.
Mueller, D., L. Kramer, E. Hoffmann, S. Klein and F. Noor (2014). 3D Organotypic HepaRG Cultures as In Vitro Model for Acute and Repeated Dose Toxicity Studies. Toxicology In Vitro, 28, pp. 104–112.
Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

634

Noor

Mueller, D., U. Muller-Vieira, K.M. Biemel, G. Tascher, A.K. Nussler and F. Noor (2012).
Biotransformation of Diclofenac and Effects on the Metabolome of Primary Human Hepatocytes upon Repeated Dose Exposure. European Journal of Pharmaceutical Sciences, 45, pp. 716–724.
Mueller, D., G. Tascher, U. Muller-Vieira, D. Knobeloch, A.K. Nuessler, K. Zeilinger, E.
Heinzle and F. Noor (2011b). In-depth Physiological Characterization of Primary
Human Hepatocytes in a 3D Hollow-fiber Bioreactor. Journal of Tissue Engineering
and Regenerative Medicine, 5(8), pp. e207–e218.
Mullin, R. (2014). Tufts Study Finds Big Rise in Cost of Drug Development. Chemical and
Engineering News. [online] Available at: http://cen.acs.org/articles/92/web/2014/11/
Tufts-Study-Finds-Big-Rise.html [Accessed 9 March 2018].
Nicholas, J.S. (1961). Ross Granville Harrison. Biographical Memoirs National Academy
of Sciences, 35, pp. 132–162.
Noor, F. (2015). A Shift in Paradigm Towards Human Biology-based Systems for
Cholestatic-liver Diseases. The Journal of Physiology, 593(23), pp. 5043–5055.
Noor, F., J. Niklas, U. Muller-Vieira and E. Heinzle (2009). An Integrated Approach to Improved Toxicity Prediction for the Safety Assessment During Preclinical Drug Development Using Hep G2 Cells. Toxicolology and Applied Pharmacolology, 237, pp. 221–231.
OECD (2013). Guidance Document on Developing and Assessing Adverse Outcome
Pathways. Series on Testing and Assessment, 184. Paris: OECD Publishing. [online] Available at: http://www.oecd.org/chemicalsafety/testing/series-testing
-assessment-publications-number.htm [Accessed 9 March 2018].
Olson, H., G. Betton, D. Robinson, K. Thomas, A. Monro, G. Kolaja, P. Lilly, J. Sanders, G.
Sipes, W. Bracken, M. Dorato, K. Van Deun, P. Smith, B. Berger and A. Heller (2000).
Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals. Regulatory Toxicology and Pharmacolology, 32(1), pp. 56–67.
Onakpoya, I.J., C.J. Heneghan and J.K. Aronson, (2016). Post-marketing Withdrawal of
462 Medicinal Products Because of Adverse Drug Reactions: A Systematic Review
of the World Literature. BMC Medicine 14, pp. 10–21.
Organisation for Economic Co-operation and Development (OECD) (2012). The Adverse Outcome Pathway for Skin Sensitization Initiated by Covalent Binding to
Proteins. Part I: Scientific Evidence. Series on Testing and Assessment, 168. Paris:
OECD Publishing. [online] Available at: http://www.oecd.org/officialdocuments/
publicdisplaydocumentpdf/?cote=env/jm/mono(2012)10/part1&doclanguage=en
[Accessed 9 March 2018].
Paine, A.J. and E. Andreakos (2004). Activation of Signalling Pathways During Hepatocyte Isolation: Relevance to Toxicology In Vitro. Toxicology In Vitro, 18, pp. 187–193.
Patlewicz, G., T. Simon, K. Goyak, R.D. Phillips, J.C. Rowlands, S.D. Seidel and R.A.
Becker (2013). Use and Validation of HT/HC Assays to Support 21st Century Toxicity
Evaluations. Regulatory Toxicology and Pharmacology, 65, pp. 259–268.

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

The Changing Paradigm in Preclinical Toxicology

635

Perkins, E.J., P. Antczak, L. Burgoon, F. Falciani, N. Garcia-Reyero, S. Gutsell, G. Hodges,
A. Kienzler, D. Knapen, M. McBride and C. Willett (2015). Adverse Outcome Pathways for Regulatory Applications: Examination of Four Case Studies with Different
Degrees of Completeness and Scientific Confidence. Toxicological Sciences, 148(1),
pp. 14–25.
Poulin, P. (2013). Prediction of Total Hepatic Clearance by Combining Metabolism,
Transport, and Permeability Data in the In Vitro-In Vivo Extrapolation Methods:
Emphasis on an Apparent Fraction Unbound in Liver for Drugs. Journal of Pharmaceutical Sciences, 102, pp. 2085–2095.
Poulin, P. and S. Haddad (2013). Toward a New Paradigm for the Efficient In Vitro-In
Vivo Extrapolation of Metabolic Clearance in Humans from Hepatocyte Data. Journal of Pharmaceutical Sciences, 102, pp. 3239–3251.
Poulin, P., D.M. Dambach, D.H. Hartley, K. Ford, F.P. Theil, E. Harstad, J. Halladay, E.
Choo, J. Boggs, B.M. Liederer, B. Dean and D. Dolores (2013a). An Algorithm for
Evaluating Potential Tissue Drug Distribution in Toxicology Studies from Readily Available Pharmacokinetic Parameters. Journal of Pharmaceutical Sciences, 102,
pp. 3816–3829.
Poulin, P., C.E. Hop, L. Salphati and B.M. Liederer (2013b). Correlation of Tissue-plasma
Partition Coefficients Between Normal Tissues and Subcutaneous Xenografts of
Human Tumor Cell Lines in Mouse as a Prediction Tool of Drug Penetration in Tumors. Journal of Pharmaceutical Sciences, 102, pp. 1355–1369.
Ramaiahgari, S.C., M.W. den Braver, B. Herpers, V. Terpstra, J.N. Commandeur, B. van
de Water and L.S. Price (2014). A 3D In Vitro Model of Differentiated HepG2 Cell
Spheroids with Improved Liver-like Properties for Repeated Dose High-throughput
Toxicity Studies. Archives of Toxicology, 88, pp. 1083–1095.
Rotroff, D.M., B.A. Wetmore, D.J. Dix, S.S. Ferguson, H.J. Clewell, K.A. Houck, E.L.
Lecluyse, M.E. Andersen, R.S. Judson, C.M. Smith, M.A. Sochaski, R.J. Kavlock, F.
Boellmann, M.T. Martin, D.M. Reif, J.F. Wambaugh and R.S. Thomas (2010). Incorporating Human Dosimetry and Exposure into High-throughput In Vitro Toxicity
Screening. Toxicological Sciences, 117, pp. 348–358.
Sacks, L.V., H.H. Shamsuddin, Y.I. Yasinskaya, K. Bouri, M.L. Lanthier and R.E. Sherman
(2014). Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of
Initial Applications for New Drugs, 2000–2012. Journal of the American Medical Association, 311(4), pp. 378–384.
Schwartz, R.E., H.E. Fleming, S.R. Khetani and S.N. Bhatia (2014). Pluripotent Stem
Cell-derived Hepatocyte-like Cells. Biotechnology Advances, 32(2), pp. 504–513.
Seah, Y.F.S., C.A. EL Farran, T. Warrier, J. Xu and Y.H. Loh (2015). Induced Pluripotency
and Gene Editing in Disease Modeling: Perspectives and Challenges. International
Journal of Molecular Sciences, 16(12), pp. 28614–28634.
Selye, H. (1956). The stress of life. New York: McGraw-Hill Book Co.

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

636

Noor

Sheldon, L.S., and E.A. Cohen Hubal (2009). Exposure as Part of a Systems Approach
for Assessing Risk. Environmental Health Perspectives, 117, pp. 119–1194.
Shinde, V., P. Sureshkumar, I. Sotiriadou, J. Hescheler and A. Sachinidis (2016). Human
Embryonic and induced Pluripotent Stem Cell Based Toxicity Testing Models: Future Applications in New Drug Discovery. Current Medicinal Chemistry, 23(30), pp.
3495–3509.
Shtrichman, R., I. Germanguz and J. Itskovitz-Eldor (2013). Induced Pluripotent Stem
Cells (iPSCs) Derived from Different Cell Sources and Their Potential for Regenerative and Personalized Medicine. Current Molecular Medicine, 13, pp. 792–805.
Siller, R., S. Greenhough, I.H. Park and G.J. Sullivan (2013). Modelling Human Disease
with Pluripotent Stem Cells. Current Gene Therapy, 13, pp. 99–110.
Sirenko, O., J. Hesley, I. Rusyn and E.F. Cromwell (2014). High-content Assays for Hepatotoxicity Using Induced Pluripotent Stem Cell-derived Cells. Assay and Drug Development Technologies, 12(1), pp. 43–54.
Smith, D.A. and E.F. Schmid (2006). Drug Withdrawals and the Lessons Within. Current
Opinion in Drug Discovery and Development, 9 (1), pp. 38–46.
Sobels, F.H. (1977). Some Problems Associated with the Testing for Environmental
Mutagens and a Perspective for Studies in “Comparative Mutagenesis”. Mutation
Research, 46(4), 2, pp. 245–260.
Spencer, V.A., R. Xu and M.J. Bissell (2007). Extracellular Matrix, Nuclear, and Chromatin Structure and Gene Expression in Normal Tissues and Malignant Tumors: A
Work in Progress. Advances in Cancer Research, 97, pp. 275–294.
Sung, J.H., B. Srinivasan, M.B. Esch, W.T. McLamb, C. Bernabini, M.L. Shuler and J.J.
Hickman (2014). Using Physiologically-based Pharmacokinetic-guided “Body on a
Chip” Systems to Predict Mammalian Response to Drug and Chemical Exposure.
Experimental Biological and Medicine (Maywood), 239, pp. 1225–1239.
Suzuki, K., C. Yu, J. Qu, M. Li, X. Yao, T. Yuan, A. Goebl, S. Tang, R. Ren, E. Aizawa, F.
Zhang, X. Xu, R.D. Soligalla, F. Chen, J. Kim, N.Y. Kim, H.K. Liao, C. Benner, C.R. Esteban, Y. Jin, G.H. Liu, Y. Li and J.C. Izpisua Belmonte (2014). Targeted Gene Correction
Minimally Impacts Whole-genome Mutational Load in Human-disease-specific Induced Pluripotent Stem Cell Clones. Cell Stem Cell, 15(1), pp. 31–36.
Teorell, T. (1937). Kinetics of Distribution of Substances Administered to the Body. Archives Internationales de Pharmacodynamie et de Thérapie, 57, pp. 205–240.
Tobita, T., J. Guzman-Lepe and A.C. de l’Hortet (2015). From Hacking the Human Genome to Editing Organs. Organogenesis, 11(4), pp. 173–182.
Tolosa, L., A. Carmona, J.V. Castell, M.J. Gomez-Lechon and M.T. Donato (2014). Highcontent Screening of Drug-induced Mitochondrial Impairment in Hepatic Cells: Effects of Statins. Archives of Toxicology, 89(10), pp. 1847–1860.
Tseng, Y.J., A.J. Hopfinger and E.X. Esposito (2012). The Great Descriptor Melting Pot:
Mixing Descriptors for the Common Good of QSAR Models. Journal of Computer
Aided Molecular Design, 26(1), pp. 39–43.
Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

The Changing Paradigm in Preclinical Toxicology

637

van Grunsven, L.A. (2017). 3D In Vitro Models of Liver Fibrosis. Advanced Drug Delivery
Reviews, 121, pp. 133–146.
van Vliet, E., M. Daneshian, M. Beilmann, A. Davies, E. Fava, R. Fleck, Y. Jule, M. Kansy,
S. Kustermann, P. Macko, W.R. Mundy, A. Roth, I. Shah, M. Uteng, B. van de Water, T.
Hartung and M. Leist (2014). Current Approaches and Future Role of High Content
Imaging in Safety Sciences and Drug Discovery. Alternatives to Animal Experimentation, 31(4), pp. 479–493.
Vedani, A., M. Dobler, M.A. Lill (2006). The Challenge of Predicting Drug Toxicity In
Silico. Basic and Clinical Pharmacology and Toxicology, 99(3), pp. 195–208.
Vernetti, L.A., A. Vogt, A. Gough and D.L. Taylor (2017). Evolution of Experimental Models of the Liver to Predict Human Drug Hepatotoxicity and Efficacy. Clinics in Liver
Disease, 21(1), pp. 197–214.
Villeneuve, D.L., D. Crump, N. Garcia-Reyero, M. Hecker, T.H. Hutchinson, C.A. LaLone,
B. Landesmann, T. Lettieri, S. Munn, M. Nepelska, M.A. Ottinger, L. Vergauwen and
M. Whelan (2014a). Adverse Outcome Pathway (AOP) Development i: Strategies
and Principles. Toxicological Sciences, 142(2), pp. 312–320.
Villeneuve, D.L., D. Crump, N. Garcia-Reyero, M. Hecker, T.H. Hutchinson, C.A. LaLone,
B. Landesmann, T. Lettieri, S. Munn, M. Nepelska, M.A. Ottinger, L. Vergauwen and
M. Whelan (2014b). Adverse Outcome Pathway Development ii: Best Practices. Toxicological Sciences, 142(2), pp. 321–330.
Vinken, M., B. Landesmann, M. Goumenou, S. Vinken, I. Shah, H. Jaeschke, C. Willett,
M. Whelan and V. Rogiers (2013). Development of an Adverse Outcome Pathway
from Drug-mediated Bile Salt Export Pump Inhibition to Cholestatic Liver Injury.
Toxicological Sciences, 136(1), pp. 97–106.
Ware, B.R., D.R. Berger and S.R. Khetani (2015). Prediction of Drug Induced Liver Injury
in Micropatterned Co-cultures Containing iPSC-derived Human Hepatocytes. Toxicological Sciences, 145(2), pp. 252–262.
Waring, M.J., J. Arrowsmith, A.R. Leach, P.D. Leeson, S. Mandrell, R.M. Owen, G.
Pairaudeau, W.D. Pennie, S.D. Pickett, J.B. Wang, O. Wallace and A. Weir (2015). An
Analysis of the Attrition of Drug Candidates from Four Major Pharmaceutical Companies. Nature Reviews Drug Discovery, 4(7), pp. 475–486.
Wetmore, B.A., J.F. Wambaugh, S.S. Ferguson, M.A. Sochaski, D.M. Rotroff, K. Freeman,
H.J. Clewell 3rd, D.J. Dix, M.E. Andersen, K.A. Houck, B. Allen, R.S. Judson, R. Singh,
R.J. Kavlock, A.M. Richard and R.S. Thomas (2012). Integration of Dosimetry, Exposure, and High-throughput Screening Data in Chemical Toxicity Assessment. Toxicological Sciences, 125(1), pp. 157–174.
Willett, C., J. Caverly Rae, K.O. Goyak, B. Landesmann, G. Minsavage and C. Westmoreland (2014). Pathway-based Toxicity: History, Current Approaches and Liver Fibrosis
and Steatosis as Prototypes. Alternatives to Animal Experimentation, 31, pp. 407–421.
Woolbright, B.L., K. Dorko, D.J. Antoine, J.I. Clarke, P. Gholami, F. Li, S.C. Kumer, T.M.
Schmitt, J. Forster, F. Fan, R.E. Jenkins, B.K. Park, B. Hagenbuch, M. Olyaee and H.
Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

638

Noor

Jaeschke (2015). Bile Acid-induced Necrosis in Primary Human Hepatocytes and in
Patients with Obstructive Cholestasis. Toxicology and Applied Pharmacology, 283,
pp. 168–177.
Xu, R., V.A. Spencer and M.J. Bissell (2007). Extracellular Matrix-regulated Gene Expression Requires Cooperation of SWI/SNF and Transcription Factors. Journal of
Biological Chemistry, 282, pp. 14992–14999.
Yoon, M., A. Efremenko, B.J. Blaauboer and H.J. Clewell (2014). Evaluation of Simple In
Vitro to In Vivo Extrapolation Approaches for Environmental Compounds. Toxicology In Vitro, 28, pp. 164–170.

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

Chapter 26

The Potential of Organ on Chip Technology for
Replacing Animal Testing
Malcolm Wilkinson

Chief Executive Officer, Kirkstall Ltd., Rotherham, United Kingdom
malcolm.wilkinson@kirkstall.com

1

What Is Organ on a Chip Technology?

The term organ on a chip is used to describe the latest stage of development of
in vitro cell culture technology. Figure 26.1 shows its steady development since
the 1960s. Each step forward has improved our ability to model human-clinical
response to new drugs or therapies and has enabled safety risk assessment of
existing cosmetics, personal care products, or other chemicals in the environment. Scientific evidence that the predictive power of in vitro tests is superior
to the use of animals will trigger a major shift in the way that medical research,
in many areas, is carried out. In this emerging field, some researchers also refer
to organ on a chip as a microphysiological system. As yet, there are few agreed
upon standards or definitions for the latest developments.
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In this chapter, the following definitions are used:
2D cell culture. This is the conventional plating of cells in a plastic or glass
plate, such as a petri dish, that contains the liquid culture media. In this format, the cells basal side is in contact with the base wall (glass or plastic); and
the top or apical side is in contact with the media. A major limitation of this
method is that cell-to-cell contact is very limited. The cell-culture dish can be
a classic petri dish or, more likely, one of the highly-miniature versions known
as microtiter plates. These have been scaled from 6 wells to 24, 96, 384, or even
1,024, configured as regular arrays in a way that allows robotic equipment to
load cells and media and sample media for analysis.
3D cell culture. Having recognized the limitation of 2D cell culture, many
approaches have been developed to increase the proportion of cell-to-cell contact to create a more physiologically relevant model of the structure of tissue
in the human body. Cells can be provided with a soft or rigid matrix or scaffold
in which to grow. Many cells have a natural tendency to adhere to the cellculture dish plastic; but if the plastic is coated with a low adhesion surface,
then the cells can clump together to form spheroids containing between 1,000
and 10,000 cells. There are now several well-established commercial systems
for producing spheroids in microtiter plates. The main limitation with this
method is that cells in the center of larger spheroids are starved of oxygen and
media and become necrotic.
Perfusion. In the human body the vascular network links organs and transports oxygen and nutrients to the cells. It is also a vital communication highway for metabolic signaling between tissues. A major current goal of advanced
in vitro models is to be able to recapitulate the physiological interactions bet
ween tissues in the body connected by the bloodstream. This has enormous
potential, as it will enable studies on specific two-way or higher-order organto-organ and tissue interactions. Perfusion or flow of media across the cell culture is a first step in realizing this objective. Unfortunately, the flow of media
past cells can induce flow stress, if the flow is higher than the cells might experience in the body. Hence, control of flow rate is critical. Optimized flow levels
(which vary from tissue to tissue) can remove the necrosis in spheroids of tissue slices and upregulate cell activity back to levels observed in freshly isolated
human primary cells (Vinci et al., 2011).
Organoids. In vitro culture of whole human organs is difficult and expensive. An intense research effort is underway to see if the main functions of a
whole organ can be replicated by a much smaller number of cells, perhaps as
few as 10,000. When provided with the right physical, biochemical, and other
cues, these cells will often spontaneously differentiate into a morphology that
can replicate the features of tissue in specific organs. These small samples
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of biological material are known as organoids. One example is hepatocytes,
where bile ducts form (Ramachandran et al., 2015).
Organ on a chip. This is a commonly used term in the popular press that
would benefit from a clearer definition. The term chip is borrowed from the
semiconductor industry and is a shortening of the term microchip, which is
a small (typically fingernail-sized) crystal of silicon that contains millions of
transistor circuits. The implication is that biological circuits will be capable of
similar scaling in complexity. Unfortunately, the laws of physics apply. Biological cells and liquid fluids do not continue to function correctly as the size is
reduced. This is in stark contrast to electrons on transistor circuits, which operate faster and use less power as they are scaled to smaller geometries. Another
feature of microelectronic chips is that they are manufactured thousands at a
time on a large wafer of silicon, which is one reason why the cost per-chip can
be very low. In contrast, organs on a chip are currently manufactured singly or
in small batches. There is very little standardization in the manufacturing processes used between the different laboratories making them, apart from the
widespread use of silicone, a flexible rubber-like material, to mold the small
channels. The chips in this case are typically 2 cm or more per side (i.e., much
larger than silicon chips); and many have fluid connections glued in place to
allow cell-culture media or test chemicals to be passed over the cells under
culture.
Organ on a plate. This is a larger format approach than organ on a chip and
typically has multiple cell-culture chambers molded in a plastic plate. The fluid connections between different chambers can be formed as part of the plate
or added by connecting flexible tubing, as in the Quasi Vivo® Interconnected
Cell Culture System (Yoon et al., 2015). The plastic plate is often designed to
meet the industry standard format for 6 well or 24 well to facilitate handling by
robotic equipment. Such multi-chamber plates can be used to connect different cell types or run multiple replicates in the same flow system. An integrated
systemic view can, thus, be constructed piecewise; and, in the Quasi Vivo® advanced cell culture flow systems, allometry can be used to set up physiologically-relevant connected culture models of biotransformation, distribution,
adsorption, and gas exchange (Haycock, Ahluwalia and Wilkinson, 2014).
Microphysiological system (mps). This terminology was first used by the Defense Advanced Research Projects Agency (darpa) in the United States that
launched the mps program of research. mps research aims to develop a reconfigurable platform that permits simultaneous study of 10 or more in vitro
physiological systems, arranged in any sequence. The goal is to design a flexible, user-friendly, and reliable platform that will allow biological components
to interact in a physiologically-relevant manner and will sustain the resident
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tissues for up to four weeks. Researchers developing the in vitro mimics aim to
demonstrate that the engineered tissues function together to reproduce each
of the human physiological systems. As these system mimics are integrated
into a platform of increasing complexity, researchers must demonstrate that
the platform reproduces the physiologically-relevant crosstalk between the
systems that normally occurs in humans. To validate its behavior, and its potential value for evaluating drugs and vaccines, test compounds with known
effects in humans will be applied to the platform. The effects that the test compounds have on the physiological system mimics will then be extrapolated to
humans via computer modeling and compared to the health effects previously
observed in humans. Many of the current organ on a chip developments are
targeted to meet the requirements of the darpa program.
2

The Opportunity for Better in vitro Methods

Although technological capability has now reached the point where multiple
cell types can be cultured together in a single miniature plate, it is important to
recognize that routine testing of chemical or drug safety lags behind the state
of the art by many years. It is only now, after 10 years in development, that 3D
cell culture, in the form of spheroids, is being used routinely by industry. However, 2D cell culture, in 96 or 384 well plates, is still the dominant technology.
Considerable evidence of the benefits of any new technique has to be accumulated before industry will adopt it, and it takes even longer before regulatory
bodies accept new methods.
One of the driving forces behind the development of the microtiter plate,
with 96, 384, or even 1,536 small cavities for cell culture, has been the need to
screen very large numbers of chemical compounds for safety or, in the case
of the pharmaceutical industry, for their potential as drugs. Historically, the
pharmaceutical industry has had access to tens of thousands of chemical compounds that may, potentially, be active drugs. Hence, the need for a very simple
go/no go test that could quickly screen a large number of compounds to a more
manageable number. Despite the high throughput of tests using microtiter
plates, the High Throughput Screening (hts) assays give very little, if any, information about mechanisms of action. Current hts assays are very narrowly
focused (e.g., receptor binding) and usually use animal-derived cells or subcellular components. If advanced hts could use human cells/components, they
may reveal much more information. Because hts in vitro testing has only provided poor prediction of what is likely to happen in clinical trials, regulatory
bodies still demand testing of drug candidates on animals. However, because
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Figure 26.2

Summary of the drug development process.
clerk and villien, 2017, reprinted with permission

testing on animals is so expensive, pharmaceutical companies try to screen
out the more obvious failures before that stage. The drug development process
is shown in Figure 26.2. hts is mainly used in the first stage of drug discovery
when the number of candidate drugs to be screened may be as high as 10,000.
There is still considerable opportunity to improve the efficiency of this process despite the billions of dollars invested in it each year. The primary motivation for industry is the immense waste of resources, because around 90%
of the drug candidates that enter clinical trials fail to reach the market (Mullard, 2016). This is because both current in vitro testing and animal methods are
poor predictors of what will happen in clinical trials. It is this need for a more
predictive method that is driving the development of organ on a chip and organ on a plate technology.
3

The Functional Requirement for Improved in vitro Methods

There is a growing body of knowledge that shows that the use of animal
cells in in vitro testing is a factor in the poor performance of current methods. Even the use of whole animal models does not replicate what happens
in the human body, so it is hardly surprising that animal cells placed in an in
vitro environment will also give misleading results (Chandrasekera and Pippin, 2014; Cook, Clerk and Sugden, 2009; Mestas and Hughes, 2004; Potashkin,
Blume and Runkle, 2011).
The choice to use animal cells is often driven by convenience rather than
scientific reasons for further discussion see Redmond, 2019, Chapter 27. Human cells are difficult to obtain, often come from a single diseased patient,
and are not representative of a larger pool of donors. Cell lines derived from
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human cells are more readily available, but there are issues with the cell lineage. Tumor-derived cell lines readily proliferate; but their functionality may
be quite different from healthy tissue; and their very robustness may be a problem, if we are trying to achieve a sensitive test for toxicity of a chemical or drug.
Even when a representative supply of cells has been secured, there are other
reasons why the models can be inadequate. Current research indicates that 2D
static cell culture (no flow of media) is not as good at predicting toxicity as 3D
cell culture (Eglen, 2017). There is also a growing body of evidence that perfusion (flow) of media over or through the cells produces a better prediction of
IC50 (half maximal inhibitory concentration) levels of drug toxicity than static
medium (Davidge and Bishop, 2017).
Using this wealth of research, we can set out a list of requirements that
should be met by any advanced in vitro method, including organ on a chip:
Biological requirements
– Use of human cells
– Culture conditions that produce physiologically relevant organoid models
– Connected organoids, so that the system models the whole organism
– Long-term culture/homeostasis for repeat-dose testing or low clearance
compounds
Practical requirements
– Easy to use and fast to set up in the laboratory
– Robust/repeatable across multiple laboratories
– No air bubbles disrupting flow or blockages caused by biological material
Scale requirements
– Better hts tests and high-content methods to replace animals
– Ability to test thousands of compounds for improving hts assays
– Ability to test tens of compounds and replace hundreds of animals used in
preclinical screening
Economical requirements
– Capital and consumable cost lower than animal testing
– Even lower cost per test to replace hts.
The last points in this list suggest that the market for advanced cell culture
could become segmented into high throughput approaches and high-content
(lower throughput) methods.
4

History and Current Status of Organ on a Chip Methods

The concept of combining of microtechnology and biology to reconstitute the
physiological and mechanical functions of human organs is not a new one.
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 ichael Shuler at Cornell University was one of its pioneers. In 1994, Shuler
M
filed patents on a macro scale in vitro system for the physiological and metabolic evaluation of substances for use in living beings. The system included one
or more cell culture chambers, each containing cells in a culture medium and
a gas-liquid exchange device for contacting the culture medium with oxygencontaining gas. By 2003, Shuler was developing a micro-scale version (Park and
Shuler, 2003), which was closely followed by Arti Ahluwalia at the University of
Pisa (Ahluwalia, 2004), who filed her first patent in 2004. These pioneers were
then followed by a surge of researchers, including Luke Lee at the University of
California, Linda Griffith at the Massachusetts Institute of Technology, Donald
Ingber at Harvard University, Shuichi Takayama at the University of Michigan,
and many more. Sung and Shuler (2010) provide an excellent review of this
area of research.
Progress between 2004 and 2014 was slow because of the significant technical challenges encountered in the application of microfluidics to biological
systems. Few of the start-up companies that emerged from the early academic
laboratories managed to get products to market. Despite these early setbacks
there has been a resurgence of interest in the area following significant funding allocated to organ on a chip developers by the US darpa and the US National Institutes of Health (nih), who have awarded US$140 million and US$76
million, respectively, over a 5-year period, to support developments. In parallel,
technology developers have raised more than US$80 million since 2012 with
equity investors. These investments caught the attention of market analysts;
and in 2016, the first market forecast specifically aimed at this sector was published (Accuray Research llp, 2016). In 2017, a more detailed analysis of the
market was provided by Yole Research (Clerk and Villien, 2017). Yole’s analysts
estimated the combined sales of organ on a chip devices and service offerings
at no more than US$7.5 million in 2016.
Most companies in this area are spin offs from university laboratories and
are currently developing their organ on a chip devices through projects sponsored by industrial players. Pharmaceutical and cosmetics companies are interested in the emerging technology but remain skeptical about its potential in
the short term. Given the experience with 3D spheroid technology, it could be
many years before the technology is ready for widespread adoption. However,
the belief that such technologies could become a multibillion dollar market
in the mid- to long-term future has the potential to accelerate progress, given
the billions of dollars they could help the pharmaceutical industry save every
year. Ethical concerns are also one of the potential drivers at the heart of this
new market. Around the world, at least 115 million vertebrates are estimated
to be used for scientific purposes annually (Taylor et al., 2008). Many of these
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Leading contenders in the race to develop organs on a chip and organs on a
plate.

animals could be replaced by alternative methods, which may include some
elements of microfluidic technology.
Some of the leading developments in organ on a chip are summarized in
Figure 26.3.
Summarizing the current developments, we can observe that there is little standardization. Each team is developing its own approach, with its own
unique technology. The players are mainly start-up companies commercializing prototypes developed in the local universities. There is widespread use of
silicone plastic to fabricate chambers and channels; but Mimetas and Kirkstall have opted to use acrylic-type plastic that can be injection molded and,
hence, is amenable to volume production. There are widely differing chamber and plate sizes. Hurel, CN Bio, and Mimetas use 96 well plate size; TissUse
and Kirkstall use 24 well plate size; and Wyss/Emulate has custom plates for
each organ. Another point of divergence is the way that cell-culture media is
fed into the chambers and over the cells. Pneumatic, peristaltic, and syringe
pumps, as well as gravity fed flow, are all in use. Although some of the cellculture chambers look simple, many require complex control systems to set
up and maintain the temperature and gas ambient environment. Mimetas,
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 issUse, and Kirkstall have all opted to use conventional cell-culture incubaT
tors into which their systems are loaded.
Returning to the functional requirements listed in the previous section,
we can gage how well each of the contenders are faring in their endeavor to
achieve a technology that will be capable of replacing some of the animal testing in the drug discovery process.
4.1
Biological Requirements
Animal cells may be easier to obtain and keep alive than human primary cells,
but they are not moving us forward. Human tumor-derived cell lines are easy
to culture but are not representative of healthy tissue. Human-induced pluripotent stem cells (hipscs) look promising but are currently expensive and need
long, complex protocols to create the differentiated cells needed for organ
models. Human donor tissue could be considered the gold standard, but cryopreservation is needed to store tissue from donors to match the time window
for experiments. Unfortunately, cryopreservation compromises the function of
the cells. Esch, Bahinski and Huh (2015) provide a review of the cell types used
in organ on chip models.
4.2
Practical Requirements
In order for any new technology to achieve regulatory acceptance, it must
demonstrate that it is a robust and repeatable method. Many of the organ on
a chip methods are a long way from this goal. They are so complex to set up
and operate that they are only running in the host developer’s laboratory and
offered as a service. In contrast, Kirkstall has designed its Quasi Vivo® organ
on a plate platform to be easy to use and fast to set up in the laboratory. It is
well on the way to demonstrating that it can be robust and repeatable across
multiple laboratories with a current academic-user base of more than 70
universities.
4.3
Scale Requirements
Figure 26.2 shows the different points in the drug discovery and development
process where organs on a chip could be used. There is a clear divergence between the requirement to screen thousands of compounds and improve hts
assays, and the lower throughput needs to test in-depth tens of compounds
and replace hundreds of animals used in preclinical screening. Most of the
current organ on chip developments have indicated that the former is their
commercial goal. In contrast, TissUse and Kirkstall have opted for 24 well plate
size chambers that should be more suited to the latter and a focus on animal
replacement.
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4.4
Economical Requirements
Since so few of the organ on a chip projects have offered products to the market as yet, it is difficult to assess the likely costs involved. Many of the technologies are suitable for scaling to volume production and so, in theory, should be
capable of meeting customers’ expectations on cost. The economics of animal
replacement have been thoroughly researched by Hartung and his team at
Johns Hopkins University (Bottini and Hartung, 2009). The cost targets (capital and consumable cost) to replace animal testing are probably easier to meet
than those to replace existing hts.
5

Barriers and Drivers for Change

There is a clear market need for improvements in the drug discovery and development process, and this is validated by the eagerness with which pharmaceutical and cosmetics companies are evaluating new technologies, one
of which is organ on a chip and in silico modeling another. However, inertia
among researchers is recognized as a barrier to moving away from existing animal methods (Innovate UK, 2015). In addition, they are conservative and will
need time to complete evaluation, validation, and adoption of the technology.
Regulatory approval, if required, will take even longer. Apart from the technical challenges yet to be solved, the start-up companies that are championing
the new methods face commercial issues. Some have raised significant equity
investment to complement government grants and customer-sponsored research and development projects. Government grants to individual companies and to organizations supporting the 3Rs have been particularly helpful.
In the United Kingdom, such grants have been part of the Innovate UK’s roadmap to support the development of non-animal technologies (Innovate UK,
2015).
The current worldwide market for animal testing is estimated to be in excess of US$30 billion (Bottini and Hartung, 2010); and it is most likely that the
companies involved in that market (including contract research organizations
offering animal testing) will fight hard to defend their current business, despite the ethical and scientific pressures for change. It is not only businesses
that will fight to defend the status quo. Many academic careers are based on
animal models, and it is not easy to make changes late in a career. In contrast,
early-career researchers will be highly motivated to learn about new methods,
but the peer review system for awarding grants will make it tough for them
to get approval for ground-breaking and disruptive ideas. Centers of excellence are emerging to support animal replacement technologies. The Center
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for Alternatives to Animal Testing (caat) at Johns Hopkins University in the
US was one of the first and now has a satellite at the University of Konstanz in
Germany. The UK has the Animal Replacement Centre of Excellence (arc) at
Queen Mary University, London; and Canada has just launched the Canadian
Centre for Alternatives to Animal Methods (ccaam) at the University of Windsor, Ontario. These centers will act as nuclei for further awareness creation,
research funding, technology evaluation, and industry support. Their most effective action may be to train a new generation of researchers who are aware of
the disruptive technology and are willing to become agents for change.
The conservatism of regulators is often cited as one of the most difficult
barriers to overcome (Innovate UK, 2015). The production of an overwhelming
body of scientific evidence may be the best long-term approach. After all, the
regulators’ role is to protect the public from the risks of exposure to harmful
drugs and chemicals. In the absence of good in vitro models and data, they will
always revert to what their colleagues have done for years before them, i.e.,
insist on animal testing. In the short term, there are other ways to introduce
the new technology that do not need regulatory approval but utilize in vitro
tests in parallel to reduce the number of drug candidates before they enter the
expensive animal and clinical-testing phases. In vitro methods are then effectively being used to cause compounds to fail early, and the potential economic
savings are immense. Additionally, as in vitro assays are implemented, they will
be validated by improved success in subsequent clinical trials.
Figure 26.4 shows a representative comparison of the economic benefits of
using advanced in vitro testing to reduce the number of drug compounds going forward into animal testing. By testing 25 compounds and eliminating 10
that have shown some adverse activity, only 15 go forward. The potential saving
is US$226 million, justifying a significant investment in the additional in vitro
tests. This approach does not need regulatory approval because animal testing
will still be used in the later stages, albeit on a reduced number of compounds.
With these potential savings per drug candidate reaching the market, Yole
Research’s projection that the organ on a chip market could reach between
US$60 million and US$176 million by 2022 does not seem unreasonable.
6

A Strategy for Accelerating the Paradigm Change Away
from Animal Use

The previous sections described the technology, market opportunity, status of
current developments, and barriers and incentives for change. Is there any way
that we can accelerate this process and speed the adoption of methods that
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Figure 26.4

Potential cost benefits of using advanced in vitro methods, such as organ on a
chip (ooc).

will save the lives of countless animals and reduce their suffering? Many years
of research in the high technology industry show us that incremental change
is much easier to push forward than disruptive change. Clearly, the full replacement of animals is a disruptive change. The candidate technology presented
here is also disruptive, as it is not a natural outgrowth of existing biology or
microtechnology but a fusion of the two. The technical challenges are enormous and require a multidisciplinary effort from biologists, pharmacologists,
statisticians, computer modelers, plastic material and fabrication engineers,
and many other experts. It is interesting that the challenge of bringing together
scientists from different disciplines to work on, so-called, grand challenges has
been addressed in several universities. Pisa University created the Centro Piaggio and Sheffield University the Kroto Centre with this express goal. Technical
brilliance is not enough. The new technology has to be translated into a sustainable business, and that takes a whole different skill set. Entrepreneurship
is needed.
The roadmap and strategy presented in Figure 26.5 describes an innovative
approach to synthesizing disruptive change from a number of smaller, almost
incremental steps. The foundation starts with good science from a few o pinion

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

651

The Potential of Organ on Chip Technology

University
Research

· Unregulated market
· Circa 50% of animal use
· Technical endorsement
· Peer reviewed papers

Animal
Replacement
Centres

· Training of young researchers
· Individual technical breakthroughs
· Key opinion leaders
· Peer reviewed papers

Widespread
Adoption in
Academie
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Validation

· Sensitivity and specificity established
· Robustness/repeatibility
· Cost performance established

Regulatory
Approval
Figure 26.5

· Target high value
and difficult tests

A roadmap and strategy for accelerating the adoption of alternative methods,
showing parallel adoption in academia and industrial research.

leaders in the academic sector but leads on to the creation of centers of excellence that eventually drive widespread adoption of the new paradigm through
academe. It is important to note that academic research accounts for about
half of the total number of animals used in the UK. Industry adoption follows
but is slower at first because of the need for extensive evidence to support
claims of superiority for the emerging new technology. The early evidence
comes from academics followed by the development of robust protocols by
contract research organizations. The pharmacological industry is increasingly
using contract research organizations to do validation and development work
that may previously have been done in their own research and development
laboratories.
Much of the current interest and excitement about organ on a chip technology is fueled by marketing hype and will soon be replaced by disillusionment
unless practical working systems are delivered. Many of the venture capitalists
investing in organ on a chip will expect immense financial return from the
10% of their portfolio that succeed. There are some very exciting technology
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developments under way. Although some of these are several years away from
the market, there is no doubt that within the next 3 to 5 years, we will see the
start of a significant shift away from the use of animals.
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1

Introduction

Despite a great deal of talk about “alternatives” to animal testing, and “replacing” animal use, there are no clearly agreed upon definitions for these terms.
This has led to extensive numbers of animals used and accepted as “alternatives”—including zebrafish, invertebrates, animal tissues, embryos, sera, and
animals’ eyes—despite the obvious fact that they will suffer and/or be killed
for these methods. Instead, there is a confusing array of reference to live animals, vertebrates, and mammals being termed as “less sentient” or “conscious”
species.
Much of the discussion on alternatives is still based around Russell and
Burch’s (1959) 3Rs; although few, if any, of the definitions currently in use
match their original writings, which were designed to be a foundation for future discussions. In the European Union (EU), Directive 2010/63/EU on the
protection of animals used for scientific purposes defines its aim as representing “an important step towards achieving the final goal of full replacement of
procedures on live animals for scientific and educational purposes, as soon as
it is scientifically possible to do so” (European Parliament, 2010, Recital 10). Although this is a progressive step forward compared to previous legislation, use
of the word live is often overlooked, as are so many other obstacles to a true end
to all animal use in laboratory research. Talk of “replacing animal testing” and
“alternatives” comes with little discussion about what those phrases actually
mean; while researchers continue to use animal sera, tissues, and live animals
that are perceived as less sentient.
This chapter addresses some of the areas in which animals are still used
within “alternatives”-based research and calls on animal welfare and in vitro organizations to lead the debate and encourage absolute replacement of animal
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use in research. Without this, progress to end animal research will always remain limited, despite the paradigm shift seen in recent decades.
2

Russell and Burch

Russell and Burch’s concept of the 3Rs was no doubt radical when their book,
The Principles of Humane Experimental Technique, was published in 1959
(hereinafter referred to as The Principles). Alan Goldberg (2010, p. 25), Founding Director of the Center for Alternatives to Animal Testing (caat), called it,
“a monumental contribution”. A special edition, containing the original text,
was reissued in 1992; and an abridged version was translated into Mandarin
and provided to Chinese public libraries and universities for free in 2014. The
3Rs have also been enshrined into EU legislation on animal experimentation.
While The Principles has undoubtedly been vital to the discussion on animal
research over the past 60 years, how relevant is it to the current situation? Has
the scientific community, which often refers to the 3Rs, actually taken much of
Russell and Burch’s advice on board? These questions are pertinent because,
as Tannenbaum and Bennett (2015, p. 120) commented, “The Principles was
presented not as the final word of this science but as a foundation for future
developments”.
Russell and Burch (1959/1992) defined the 3Rs as replacement: “the substitution for conscious living higher animals of insentient material”; reduction:
“reduction in the numbers of animals used to obtain information of a given
amount and precision”; and refinement: “any decrease in the incidence or severity of inhumane procedures applied to those animals which still have to be
used”. This chapter focuses on replacement, and how the terms replacement
and alternatives to animal experimentation are defined across the scientific and
non-governmental organization sectors.
3

Replacement: Relative and Absolute

Russell and Burch defined replacement as “any scientific method employing non-sentient material” that may replace the use of “conscious living vertebrates”. Tannenbaum and Bennett (2015, p. 126) add that replacement, “is
defined as the use of insentient (or non-sentient) material instead of sentient material. Russell and Burch do not define replacement as not using
animals because they classify the use of insentient animals as instances of
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replacement. They distinguish between what they call relative and absolute
replacement.”
3.1
Relative Replacement
“In relative replacement, animals are still required, though […] they are exposed, probably or certainly, to no distress at all. In absolute replacement,
animals are not required at all at any stage. It follows from what has been said
earlier that absolute replacement may be regarded as the absolute ideal” (Russell and Burch, 1959/1992). Relative replacement may include: “non-recovery
experiments on living and intact but completely anesthetized animals”;
“experiments in which animals are still required but only to furnish preparations after being painlessly killed”; and “work on the isolated cells, tissues, or
organs of vertebrates” (Russell and Burch, 1959/1992). The Institute for Laboratory Animal Research (ilar) (ilar, 2011, p. 5) refers to relative replacements as
“replacing animals such as vertebrates with animals that are lower on the phylogenetic scale”. ilar is not unique in its deviation from Russell and Burch’s
definition, as it appears common for species of “lower sentience” to be considered as (relative) “replacements”, without any obvious consideration or discussion of what less sentient means or what evidence it is based on. This is perhaps
one of the reasons why, in recent years, zebrafish have been promoted as an alternative, as the following example shows: “another 3Rs approach involves the
replacement of more sentient vertebrates with animals thought to have a lower potential for pain perception, such as the amoeba Dictyostelium discoideum,
fruit fly Drosophila melanogaster and zebrafish” (Tanner and McShane, 2016,
p. 3). The examples that Russell and Burch gave of species they considered
to be replacements (“the more degenerate metazoan endoparasites”) were
included because they believed “that they are completely non-sentient, not
because they are less sentient” (Tannenbaum and Bennett, 2015, p. 127).
3.2
Absolute Replacement
“Turning to absolute replacement, we may distinguish four main subdivisions: the use (outside the vertebrate body) of metazoan endoparasites; higher
plants; microorganisms (protozoa, bacteria, molds, etc.); and nonliving physical and chemical systems. First, there is the study of metazoan endoparasites
(nematodes, cestodes, and trematodes) in vitro, as opposed to their study in
the living vertebrate host” (Russell and Burch, 1959/1992). Provisions were still
made in The Principles for the use of members of the animal kingdom within absolute replacement, whereas the more widely accepted opinion now is
that no animal or animal-derived material be involved (Gunatilake, 2016; Lidbury and Richardson, 2012). The replacement models that have so far been
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introduced by the scientific community are mostly relative, not absolute, and
more encouragement needs to be given to progress further in this area. Scientific conferences on alternatives to animal use often seem to focus on reduction and refinement, with very little discussion on replacement. Michael Balls,
of the Fund for the Replacement of Animals in Medical Experiments (frame)
noted that, “it is impossible to avoid the conclusion that it [replacement] is
the forgotten R, even though Russell and Burch saw it as of great importance”
(2010, p. 21). Balls added that there is “a danger that refinement can be used
as a convenient way of showing commitment to the 3Rs, whilst ensuring that
animal experimentation is seen as respectable and can be allowed to continue,
while the fundamental ethical questions raised by it are avoided”.
4

What Is an Alternative?

Are “alternatives” and “replacement” the same thing? The United States Department of Agriculture (usda) (2017) refers to alternatives as “a term that has
different meanings to different people and this difference largely depends on
which side of the issue one is found”. “Alternatives” are generally based on the
3Rs, although the terms “alternatives” and “alternative methods” never occur
in The Principles. The word “alternatives” should be considered to only refer to
Replacement, yet this is not how it is always viewed.
The European Union Reference Laboratory for Alternatives to Animal Testing (eurl ecvam) (2017) defines “alternative” as “generally associated with
the Principles of the 3Rs […] In this context an alternative method serves to
fully replace an animal test, to reduce the number of animals needed in a test,
or to refine an animal testing procedure in order to reduce pain and suffering.” In its “step-by-step approach to an alternatives search,” caat suggests
that, in addition to cell culture and tissue culture, researchers “might look
for non-mammalian animal models—fish or invertebrates, for example—
that would still give you the data you need” (Center for Alternatives to Animal Testing, n.d.). However, even using mammals is not always ruled out.
The UK Government has referred to transgenic mice being used “to replace
non-human primates” in oral polio vaccine safety tests (Home Office, 2014,
p. 14). The EU-funded, rethink project evaluated the potential for minipigs
“as an alternative approach” to using dogs and non-human primates in regulatory toxicity testing that can contribute to the 3Rs. Although the argument
was made that this met the criteria for refinement, Forster et al. (2010) noted
that, “the concept of replacement does not embrace the notion of replacing
one class of s entient mammal (e.g. primates) by another (minipigs)” (p. 239).
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Others c onsider a non-animal approach to be one that does not use live animals (Clippinger et al., 2016, p. 453). AltTox.org (2017), “a website dedicated to
advancing non-animal methods of toxicity testing” lists “alternative methods”
for assessing eye irritation/serious eye damage for regulatory testing purposes,
some of which still use animals, including cow, rabbit, and chicken eyes.
So, does the term “alternative” apply to any of the 3Rs, all live animals, mammals only, or perhaps just vertebrates? The terms “alternatives to animal testing”, as well as “replacement”, appear to be used very loosely by stakeholders
on all sides of the discussion. While the general public are often led to believe,
or at least not corrected when they do believe, that these terms mean that no
animal use whatsoever is involved, this is all too often not the case. Philosopher Joel Marks (2012, p. S18) writes that “the so-called alternatives movement
commonly contains a fatal loophole. For while a layperson may assume that
the term ‘alternative’ refers to the use of some wholly nonanimal method of
research […] in fact, it often means an animal ‘down the phylogenetic scale’”.
Marks believes that, “it is really only full replacement of animals in biomedical
research that merits the name ‘alternative’. Any alternative to that understanding of ‘alternatives’ is unjustified, not only in word but in deed.” (2012, p. S18).
5

Which Animals Are Protected?
animal […] a. A living organism which feeds on organic matter, typically
having specialised sense organs and a nervous system and able to respond rapidly to stimuli; any living creature, including man. […]
b. In ordinary or non-technical use: any such living organism other than
a human being.
Oxford English Dictionary, 2016

Legislation to protect animals used in laboratory experimentation does not
protect all animals. Directive 2010/63/EU (European Parliament, 2010), the
key EU legislation relating to animals used for scientific purposes, applies to
the following animals (Article 1 (3)): “1. (a) live non-human vertebrate animals, including: (i) independently feeding larval forms; and (ii) foetal forms of
mammals as from the last third of their normal development; 2. (b) live cephalopods.” The Animal Welfare Act (awa) regulates the use of animals in laboratories in the United States as well as other animal use, including zoos and
circuses. The term animal in the awa includes specific species in some, but
not all, situations and specifically excludes rats of the genus rattus and mice of
the genus mus as well as birds used in research (usda, 2017). awa also e xcludes
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cold-blooded animals (fish, reptiles, and amphibians), as well as farmed animals used in agricultural research (e.g., cows and pigs); as such fewer than
10% of animals in US laboratories are covered by the awa (New England AntiVivisection Society, 2017). Mice alone make up more than three-quarters of the
animals used by the top federally-funded US test centers (Kaiser, 2015). Other
countries have different legislation on what species (if any) are protected in
experimentation.
6

“Alternatives” that Still Exploit Animals

6.1
Fish
There has been a greater increase in the use of fish in research in the EU than
any other species (European Commission, 2013, p. 9). In the United Kingdom,
fish are the second most used animals after mice (Home Office, 2015, p. 11).
Zebrafish (Danio rerio) have been the focus of much attention, and they now
account for 50% of all fish used in UK laboratories, partly due to the availability of genetically altered zebrafish for use in basic and applied biomedical
research (Home Office, 2015, p. 23). A major reason for the increase in the use
of zebrafish is their reduced cost compared to mammals (Reed and Jennings,
2011, p. 14; maintenance costs are less than 1/1,000th of the cost for mice); and
a pair of zebrafish can produce 100–300 eggs per week, making their embryos
a “suitable model” for high throughput screening (van Vliet, 2011, p. 24). Zebra
fish have now become established as a “widely accepted relative replacement
model” (Gunatilake, 2016).
Researchers at the University of British Columbia reviewed existing literature on public acceptance of using particular species in laboratories and found
that fish and invertebrates were “typically rated below mammals, and, as such,
are often considered an appropriate replacement for mammals in research”
(Ormandy, Schuppli and Weary, 2012, p. 321). Although their own study found
that when the research was deemed to cause pain to zebrafish (specifically
when it came to enu mutagenesis) survey participants objected to it (p. 331), it
may explain why even some in vitro organizations promote the use of zebrafish
(Gunatilake, Busquet and Akbarsha, 2014; M’Barek et al., 2015). Sweeping statements are often made in support of using fish instead of mammals in research,
with no real attempt to back them up. Planchart et al. (2016, p. 435) claim that,
“Small freshwater fish models, especially zebrafish, offer advantages over traditional rodent models, including […] reduced animal welfare concerns”. An
article on the website of the British Association of Zebrafish Husbandry claims
that, “their mental and physical concerns may be deemed less than those of
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a rodent for example […] Because of the widespread use of the unprotected
larval form of zebrafish there is currently little emphasis on replacing aspects
of this use” (Nicholls, 2012).
In the UK, the Royal Society for the Prevention of Cruelty to Animals
(r spca) has highlighted concerns over zebrafish use in research (Reed and
Jennings, 2011), including:
– Specific husbandry requirements are still poorly understood.
– The majority of experiments, which involve embryonic and early larval (less
than six days post-hatching) stages, would not be covered and reported by
legislation.
– Some practices do not require reporting in the annual Home Office statistics, including the humane killing of zebrafish by an approved method in
order to obtain tissues, organs, sperm or eggs; and the use of zebrafish in
breeding programs (unless they are genetically modified).
Evidence that fish, like all vertebrate animals, feel pain was first presented almost 40 years ago (rspca, 1980). The UK government’s Farm Animal Welfare
Committee (1996) subsequently acknowledged that fish experience fear, stress,
and pain when removed from water; and that the physiological mechanisms in
fish for experiencing pain are very similar to those in mammals. More recently,
fisheries professor, Victoria Braithwaite (2010) wrote that, “I have argued that
there is as much evidence that fish feel pain and suffer as there is for birds and
mammals—and more than there is for human neonates and preterm babies”.
Fish behavior and welfare scientist, Yue Cottee, added (2010) that, “We now
have logical reason and scientific evidence to start treating fish as sentient creatures” (p. 13); and “it now seems that the question to be asking is not ‘Do fish
have conscious awareness’ but ‘What is the level and nature of their conscious
awareness?’” (p. 12). The rspca conclude that, “Although there has been little
specific study involving zebrafish, given the above [evidence that fish feel pain],
zebrafish should be given the benefit of any doubt” (Reed and Jennings, 2011,
p. 41).
6.2
Vertebrates in Early Developmental Stages/Use of Animal Embryos
Under Directive 2010/63/EU (European Parliament, 2010), vertebrates only become protected animals at a particular stage in their development: the last
third of gestation (mammals); incubation (birds and reptiles); or the stage
when independent feeding occurs (amphibians and fish), for example, early
chicken embryos in reproductive toxicity tests. Such cut-off points have been
criticized as “arbitrary and unsatisfactory” and not based on any strong scientific basis (Balls, 1994, p. 197).
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The fish embryo toxicity (fet) test is considered “a possible alternative to
the acute fish [toxicity] test” (peta International Science Consortium, 2015a).
This test exposes at least seven fish to the test substance for a period of 96 hours
to record the concentrations that kill 50% of them (LC50) (Organisation for
Economic Cooperation and Development, oecd, 1992). fet uses 20 freshlyfertilized embryos per treatment or control (Chemical Watch, 2015), mostly
zebrafish, fathead minnow, rainbow trout, bluegill, and Medaka. At an international symposium on using fish and amphibian embryos as alternative models,
it was stated that, “In compliance with international animal welfare regulations, the fish and amphibian embryo models provide an ethically acceptable
small scale analysis system with the complexity of a complete organism […]
The ultimate goal of the symposium is to promote the development of the fish
and frog embryo models as potential alternatives to animal testing.” (Helmholtz Centre for Environmental Research, 2016). A footnote to an article on
the Chemical Watch website (2015) about fet highlights some of the ongoing
confusion: “This article was amended on 17 April to clarify that the fish embryo toxicity (fet) test is not considered a replacement to animal testing, as
fish embryos are animals. However, the use of fish embryos up to a certain age
does not fall under Directive 2010/63/EU on the protection of animals used for
scientific purposes.”
6.3
Body Parts
Animal parts used as “alternatives” to animal testing (or classed as a “non-animal
method” (Clippinger et al., 2016), include the eyes of animals slaughtered for
consumption. Examples are the Bovine Corneal Opacity and Permeability assay (bcop), seen as a substitute for the Draize eye irritation test that uses live
rabbits (in which a substance is instilled into one of the rabbit’s eyes to assess injury for up to 21 days). The bcop test method can be used to identify
chemicals causing serious eye damage. The oecd (Organisation for Economic
Co-operation and Development, 2017) states that the test “uses isolated corneas from the eyes of cattle slaughtered for commercial purposes, thus avoiding the use of laboratory animals”. Along with the isolated chicken eye (ice)
and Isolated Rabbit Eye (ire) tests, the bcop assay is validated by regulatory
bodies, including the oecd and Interagency Coordinating Committee on the
Validation of Alternative Methods (iccvam), as well as promoted by in vitro
and animal protection organizations (Humane Society International, 2013;
Institute for In Vitro Sciences, 2014; peta International Science Consortium,
2015b), although again there appears to be no discussion over the ethical considerations of this.

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

662

Redmond

6.4
Invertebrates
Invertebrates are generally exempt from any animal welfare legislation, and
little consideration is given to their animal care requirements or suitability for
captive conditions (Carere, Wood and Mather, 2011), with one exception. Since
2013, all cephalopod species (e.g., octopus, squid, and cuttlefish) used in research have been regulated within the EU by Directive 2010/63/EU (European
Parliament, 2010), giving them the same legal protection as vertebrates because of their capacity to experience pain and suffering. Several other non-EU
countries also regulate their use. Some reviewers believe that decapod crustacea (e.g., crabs, lobsters) may receive similar protection in the future “because
of the continuing debate about their pain perception” (Fiorito et al., 2014, p. 15).
The horseshoe crab, Limulus polyphemus, is used in the Limulus amoebocyte
lysate (lal) assay to replace the rabbit pyrogen test for the detection of endotoxin in Hepatitis B vaccines (Park et al., 2005). The rabbit test involves injecting the test substance into the ears of three rabbits (who, 2016). However, the
lal assay uses blood cells from the horseshoe crab, with up to 30% mortality
due to bleeding (Leschen and Correia, 2010, p. 144).
Russell and Burch (1959/1992) stated that replacement means using completely insentient material, animal or non-animal. Tannenbaum and Bennett
(2015, p. 127) noted that, “using animals that are less sentient […] is inconsistent
with their definition […] They explicitly argue that, because of more limited
mental capacities that prevent them from understanding and dealing with distressful experiences, for lower vertebrates a given level of distress is probably
worse than it is for a higher vertebrate species.”
6.5
Animal-based Sera
Fetal calf serum (also known as fetal bovine serum) is the most widely-used
serum supplement for in vitro cell culture (Seralab, 2017). Bovine fetal blood is
collected by cardiac puncture, performed by inserting a needle directly into the
heart of the unanesthetized fetus in a specially provided area in the slaughterhouse (International Serum Industry Association, 2017). Other products are sold
as a lower cost alternative and for veterinary vaccines, such as horse, goat, rabbit, porcine, and chicken serum (Thermo Fisher Scientific, 2017). Blood may be
taken at the time of slaughter for consumption or obtained from what is euphemistically called “donor” animals, from whom blood is taken more than once.
In a survey of companies and laboratories involved with the collection and
use of fetal calf serum (fcs), Jochems et al. (2002) concluded that:
– The time that elapses between death of the mother cow and the puncture
was found to be up to 30 minutes, with the procedure of bleeding itself lasting another 2–5 minutes. So, a bleeding procedure may last up to 35 minutes
after the death of the mother (pp. 4–5).
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– It is very likely that the fetus is alive at the time of blood collection and “will
experience pain and/or suffering at the moment of heart puncture for blood
collection and possibly for a period after that, until it actually dies” (p. 8).
– “Exsanguination and cardiac puncture (penetrating skin, internal and external intercostal muscles, costal pleura, heart muscle, and heart pleura)
are both graded as severe discomfort in unanesthetized post-natal bovines.
From this, we have to conclude that the current practice of blood collection
from fetal bovines causes suffering to these animals” (p. 11).
– The global number of bovine fetuses used annually is 1–2 million (p. 5).
Oredsson (2013), a researcher at Lunds University, stated that, “The very use of
fetal calf serum actually defeats the purpose of using cell culturing as replacement for animals in research”. Jochems et al. (2002, p. 13) similarly argue that,
“The thought that cell culture techniques requiring fbs are a replacement to
the use of animals is a misconception.”
6.6
Antibodies
Traditionally, antibodies against a specified target are produced by injecting
the antigen into an animal and initiating an immune response (Afability, 2017).
Animals are repeatedly injected with the molecule to be detected, initiating a
hyperimmune response. An unknown number of animals (millions) are used
worldwide to generate the antibodies that are extracted at a later stage for the
detection of the molecule. Gray et al. (2016) note that, although the extracted
antibodies are incorporated into an in vitro test, this traditional method is not
a replacement of animal testing but simply buries the animal use “several layers deep in the production process, and our ultimate aim, to replace needless
animal use, is not achieved” (p. 961). Gray and colleagues have called for the
proper implementation of Directive 2010/63/EU, which requires that animals
not be used when a non-animal alternative exists. They also recommend that
the European Union Reference Laboratory for Alternatives to Animal Testing (eurl ecvam) extends its activities to include the production of animalfriendly affinity reagents (afas) and their subsequent use (p. 967). In addition,
there are reported concerns about the quality and unreliability of commercial,
animal-derived antibodies (Groff, Brown and Clippinger, 2015, p. 1788); and scientists are being encouraged to use the non-animal affinity reagents that are
available.
6.7
Tissues
Living material for vertebrate tissue culture has to be obtained from animals
or humans. Although it may be sourced from animals killed for food (which,
in itself, is an ethical issue to consider), it is more likely to be obtained from
animals specifically-bred and killed for the purpose because of requirements,
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such as a sterile technique (Balls, 1994, p. 197). Data collected for EU Member States excludes animals killed solely to supply tissues for ex vivo or in vitro
use; but for the six countries that Taylor et al. (2008, p. 331) obtained data, the
average percentage of animals killed for their tissues was 21.1%. Philosopher
Joel Marks (2012, p. S18) considers it absurd that “the very same animal (both
species and individual) can be used as an ‘alternative’. This is due to two additional ambiguities. One of them is between an experiment on a whole animal
and an experiment on tissue taken from an animal of the same species. The
latter can be considered an ‘alternative’ but of course the animal is still bred,
confined, and subject to various procedures”.
7

The Role of Regulatory Bodies in Promoting Animal-based Testing

It has been shown that “alternatives” to animal testing do not always mean that
no animals or animal substances are used. Many of the “alternatives” endorsed
by eurl ecvam, iccvam, and/or the oecd still use animals in some way, for
example (peta International Science Consortium, n.d.):
– Rat skin transcutaneous electrical resistance (ter) test for skin corrosion
– Murine local lymph node assay (llna) for skin sensitization
–	Bovine corneal opacity and permeability (bcop) test method and Isolated Chicken Eye (ice) test method for eye corrosion/eye irritation
– Whole rat embryo toxicity assay for reproductive toxicity
–	
f et test and Daphnia sp., acute immobilization test for aquatic toxicity.
Scientists and organizations working on promoting absolute replacement of
animal tests need to be proactive in ensuring that regulatory bodies are fully
aware of these alternatives, and why their validation is preferable to those that
currently exploit animals. This may involve training regulatory reviewers in the
new methods.
A review of companies manufacturing antimicrobial cleaning products to
discover why so few were submitting non-animal data for regulatory purposes
(Clippinger et al., 2016, p. 455) found there was a lack of global regulatory acceptance (meaning that animal tests would likely be conducted anyway, since
it was required by other countries or authorities); and uncertainty within industry about regulatory reviewers’ familiarity with the framework and their
ability to evaluate and interpret non-animal studies, which could influence
the likelihood of acceptance. The authors concluded that, “Overcoming institutional inertia at companies and regulatory agencies requires collaboration
among a motivated group of people across multiple sectors.” (p. 455). The multistep process of implementation includes education of regulatory and industry personnel before a non-animal method is finally accepted.
Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

When is an Alternative Not an Alternative?

8

665

Encouraging True Replacement: Lush Prize

The Lush Prize is an annual prize fund supporting initiatives across science,
campaigns, and regulatory lobbying to end the use of animals in research, particularly toxicology. A joint project between Lush Cosmetics and the Ethical
Consumer Research Association, it provides £250,000 in funding each year in
the main prize categories, with additional funds provided through regional
awards in Asia and the Americas (Lush Prize, 2017a).
Unique in being a 1R award (focusing on absolute replacement as opposed
to 3Rs), the Lush Prize has strict eligibility guidelines (Lush Prize, 2017b),
including:
– “Non-animal research in this sense means no use of non-human animals (including all vertebrates and invertebrates) or primary animal cells, embryos,
tissues, organs and serums. Human biology-based approaches are strongly
encouraged, although the use of established cell lines of non-human animal
origin shall not necessarily be excluded.” (Immortalized cell lines can keep
undergoing division, so no new animals are killed for them).
– “The prize money shall be ring-fenced for non-animal use so that it cannot
be used to fund any animal testing whatsoever.”
– “In awarding the prize to academic institutions, priority will be given to research teams or groups which deal exclusively with non-animal research.”
The five categories of prize are designed to complement each other in breaking
down the barriers to end animal testing. It supports science, so that scientist
can come up with new tests; training, so that scientists can learn how to use
the new tests, and young researchers can learn how to discover new tests early
in their careers; lobbying, so that governments can be persuaded to make the
new tests compulsory; public awareness, so that the governments can be pressured to make these changes (Lush Prize, 2016).
In addition to the financial support, the Lush Prize raises the profile of
absolute replacement through an annual conference and a special edition
of the Alternatives to Laboratory Animals journal, highlighting the work of
awarded scientists who are helping to achieve the paradigm shift towards true
replacement.
9

Conclusions

Whilst the issue of animal testing is the subject of a great deal of public discourse, there has been little discussion about what defines “replacement” or
“alternatives”. Regulatory bodies and many scientists working in “alternatives”
are not particularly concerned about some of the animal use mentioned here.
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Their focus, as highlighted in Directive 2010/63/EU (European Parliament,
2010), is the use of live animals. What is of greater concern is the quiet acceptance, or even active promotion, of animal-based research by animal welfare
and in vitro organizations. They should be setting the standards and always
pushing for absolute replacement; otherwise, progress will remain limited.
The Lush Prize has begun to put this discussion on the agenda, not only with
its strict eligibility criteria, but also through its conferences. Its 2014 conference
was titled, Is One R the new Three Rs?, and asked “Does the consensus building
around 21st Century Toxicology—a wholly replacement model (1R)—mean
that the 3Rs framework (refinement, reduction, replacement) is an idea that
has had its day?” (Lush Prize, 2014). There needs to be honesty among regulators and the research community that the use of any animal product is not a
complete replacement or an alternative, only then can there be encouragement to fully replace animal testing with ethical and reliable human-relevant
models.
Russell and Burch’s 3Rs have played a crucial role in developing ideas on
replacing the use of animals in experimentation, and much of what they wrote
in 1959 is still valid today. However, we need to update the terms “alternative”
and “replacement” to reflect our goal of completely ending the use of all animals in research and stop being complacent in thinking that partially replacing
animal use is sufficient. It will be the role of non-governmental organizations
and those scientists who truly believe in the goal of complete replacement to
lead this progression, to agree on definitions and ensure that they begin to be
used across all sectors, including industry and academia. As Tannenbaum and
Bennett (2015, p. 120) commented, Russell and Burch did not see their writings
as the final word on this but “a foundation for future developments”.
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Research and Testing Without Animals: Where Are
We Now and Where Are We Heading?
Thomas Hartung

Director, Center for Alternatives to Animal Testing, John Hopkins University,
Baltimore, MD, United States

1

Introduction
I don’t think there’s much point in bemoaning the state of the world unless there’s some way you can think of to improve it. Otherwise, don’t
bother writing a book; go and find a tropical island and lie in the sun.
peter singer

Experiments involving non-human animals (hereinafter referred to as animals)
were the predominant technology in the life sciences from the 1920s to the
1970s. Increasingly, animal-based procedures have been complemented and
superseded by other approaches; yet, they still have an enormous reputation
as an apparent definitive answer to many scientific and, especially, regulatory
questions. They have been questioned first for ethical reasons: Can we justify
making animals suffer for scientific inquiry? Simply said, people have different
views on this question, but the general public views animal experimentation
more and more critically. The animal research community has sought a compromise between those who would like to see the end to the use of animals
sooner rather than later, and those who think animal research is indispensable.
The societal response has included regulation and oversight of animal experiments (e.g., requiring formal justifications and permission), as well as support
for the development of alternative methods.
2

Progress in Legislation

Building on the legislation of some of the more progressive Member States,
the European Union (EU) has twice advanced the legislative oversight of animal experimentation and the push for alternative methods. Already in 1986,
European lawmakers reasoned that harmonized animal testing legislation
© thomas hartung, ���9 | doi:10.1163/9789004391192_029
This is an open access chapter distributed under the terms of theKathrin
prevailing
cc-by-nc License at the time
Herrmann and Kimberley Jayne - 978-90-04-39119-2
of publication.
Downloaded from Brill.com11/11/2019 09:57:08PM
via free access

674

Hartung

was needed within the common market, both to level the playing field and
to limit animal testing. Since then, and revised and strengthened as Directive
2010/63/EU, the EU requires that practically available alternatives to animal
experiments have to be used (European Parliament, 2010). The EU also tasked
the European Commission and the Member States with furthering the development and validation of alternatives. The 2010 Directive continued to expand
the scope of the legislation and added enforcements. It also included an important reversal of the burden of proof: the legislation does not restrict the
free use of animals in science, but it grants an exemption from the prohibition
of animal tests upon sufficient justification (Hartung, 2010a). Noteworthy, the
scope of Directive 2010/63/EU was extended to include the entire animal life
cycle, from breeding to the conclusion of the experiments; and it was extended
to late stages (last trimester) of embryonic development as well as to cephalopods, such as octopus and squid. The legislation also requires the application
of the 3Rs and encourages their further development, as well as requiring the
systematic evaluation of projects, including prospective and, for certain experiments, retrospective assessments of pain, suffering, and distress caused to
animals.
While these general provisions apply for basic research as well as the applied use of animals for product development and safety testing, it is quite
remarkable that the safety testing part (i.e. toxicology) has become the primary battleground over animal experimentation and its alternatives. This area
accounts for only about 10% of overall animal use in science (Daneshian et al.,
2015), according to statistics from the EU and elsewhere; yet, it is probably fair
to say that 90% of the work to develop alternative methods, in the sense of
one-for-one replacement, has taken place in this field (see Stephens and Mak,
2013) for a comprehensive look at the history of pursuing alternative methods
in toxicology). Consequently, toxicology has a lighthouse function for other
areas. If we can substitute for animals in the area of human safety, we can undoubtedly do the same in other areas.
3

Problems with Animal Models Increasingly Acknowledged

A key recent development is that animal experiments are being challenged on
more than just ethical grounds (Hartung, 2017a, b). Animal experimentation
is resource intensive, in terms of both expense and duration (Bottini and Hartung, 2009), and we are increasingly realizing the limited predictivity of animal
models for humans based on both the limited reproducibility of their results,
and the differing results across animal species (Hartung, 2013; Pound et al.,
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2004; Pound and Bracken, 2014). Humans are obviously not 70kg rats (Hartung,
2009a). Within toxicology research, the costs have become particularly evident
as companies start to tackle the backlog of testing of industrial chemicals under the European Registration, Evaluation, Authorisation and Restriction of
CHemicals (reach) program (Hartung and Rovida, 2009). The comprehensive assessment of a single substance amounts to several million US dollars of
testing costs. We simply cannot afford to test tens of thousands of substances
using the usual methods, and we also do not even have the laboratory capacities to do so. Often overlooked, we also need about 20kg of a substance to
run a comprehensive toxicity profile; for novel and costly substances such an
amount is often impractical to synthesize.
The most important issue—the limited predictivity of animal experimentation—was underscored by recent findings that the high failure rate of new
substances in the pharmaceutical industry is based, at least in part, on the misleading findings of the animal models used during the course of development
(Hartung, 2013). Two major assessments by pharmaceutical companies, one
by Amgen and one by Bayer, showed that animal-based research studies were
reproducible in only 11% of 53 projects (Begley and Ellis, 2012) and in about
20%–25% of 67 studies (Prinz, Schlange and Asadullah, 2011). This and similar
findings have fueled a more general discussion about the reproducibility crisis
in science (Baker, 2016). It is important to note that this issue is simply one
of replicating the findings of earlier animal studies in later animal studies of
similar design; this is quite apart from the issue of extrapolating such results
to humans. The reproducibility crisis increasingly calls into question whether
animal studies should serve as the ultimate gold standard of scientific work
in the life sciences. Indeed, more than 95% of substances that show promise
in animal experiments (Arrowsmith, 2011a, b, 2012) fail in later stages of drug
development when assessed in human trials (Hartung, 2013). To be sure, the
drug development process continues to deliver new entities but at costs in the
billion US dollar range (DiMasi, Grabowski and Hansen, 2016), making it more
and more difficult to sustain this business model.
4

Regulatory Testing as a Role Model for Moving Away from Animal
Experimentation as a Whole

A scientific discussion challenging animal experimentation would be fruitless if there were no alternatives. When acknowledging the shortcomings
of animal experimentation, many animal researchers will essentially argue
that it is better to have something imperfect than nothing at all. But are they
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just imperfect, or are they downright misleading? Nobody knows how many
promising drugs have never made it to human trials because the animal tests
wrongly sorted them out as inefficient or harmful. It is somewhat frightening
to realize that aspirin would probably not make it to the market today because
it fails a number of animal-based safety tests (Hartung, 2009b).
As stated above, formal replacement of animal-based procedures by alternatives has been pioneered mainly in the field of regulatory testing, i.e. the
toxicological assessment of drugs, medical devices, chemicals, pesticides,
cosmetics, and other consumer products prior to marketing, as well as the
batch-release testing for vaccines. Why the focus here on alternatives to animal-based tests? Governments tend to fund the development of alternatives to
the animal procedures they prescribe (safety sciences); and legislation, such as
the European cosmetics test ban (Hartung, 2008) and reach (Hartung, 2010b),
have spurred these developments. Hence, regulatory toxicology has the potential to be an important driver for animal replacement research more generally.
Noteworthy, the cosmetic ban was the consequence of public pressure voiced
by animal protection groups to policy makers, not a consequence of scientific
progress or perceived regulatory needs. Much of the new science came after
the legislative ban took effect; and after the ban was embraced by industry and
regulators, first in the EU and then elsewhere.
Regulatory testing has formed a bit of an island because, until recently,
it has been outside of the normal competition of ideas, failing to keep pace
with technological advances. In contrast, there is pressure to employ the latest
technologies in drug development. After patenting a lead compound, there
is a race to bring the drug to the market, as a single day of delay costs the
company, on average, US$1 million to recuperate the almost US$3 billion of
average development costs (DiMasi et al., 2016). This means that drug deve
lopment companies readily explore and apply technologies that hasten decision making and may bring a competitive advantage. It has been suggested
that our knowledge in these areas doubles every seven years. In comparison,
many approaches in regulatory science are decades old: acute and repeateddose testing originate from the 1920s, skin and eye irritation from the 1940s,
and reproductive toxicity testing from the 1960s. This unusually static situation has inadvertently allowed the long-term, systematic targeting of these
assays in recent decades. In other areas of biomedical research, development
and validation projects of 10–20 years (not uncommon in the testing arena)
would be quite pointless, because the technology changes so much over time
that the validated test becomes obsolete. So, to some extent the development
of alternatives for regulatory animal tests has become the sparring partner
for other areas of research, as it elucidates general needs for addressing the
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d efinition and reporting of experiments, their combined use, and their relevance, quality assurance, and validation. This also helps to transform, more
generally, the mindset of researchers, creating awareness of the availability
and the need of alternatives.
Education plays a key role here. By training the next generation of scientists
with an openness to the new technologies and with a critical eye towards the
use of animals—certainly not hailing them as the ultimate tool of generating
knowledge—the basis for a balanced use of different tools is set (Daneshian et al., 2011; Hartung, Blaauboer and Leist, 2009). Internet-based teaching
and training is facilitating this sea change. The emerging professorships for
alternative methods in Konstanz, and other places in Germany; Baltimore;
Utrecht; and elsewhere, and their collaboration with each other, represent an
enormous opportunity. An important element is the parallel replacement of
animals in the teaching of all areas of the life sciences. Nowadays, alternative
teaching models, computer simulations, and movies can effectively substitute
for repeatedly carrying out the same demonstration of an animal test. The
non-animal approaches help to underscore a mindset of avoiding animal use.
But it is not only about the next generation. Especially important is the continuous education of regulators, which at the moment often form a bottleneck for the broader use of new approaches. Such continuing education plays
an important role in accelerating change across all areas of animal-based
research.
The obvious principal alternatives to animal use are in vitro and in silico
approaches, i.e. methods based on cell culture or on computer modeling. Although not without their own scientific limitations, these approaches can at
least be focused on human biology, and they are typically cheaper and faster
than animal tests. We also have increasingly technical solutions (Marx et al.,
2016) and quality assurance tools (Coecke et al., 2005) to overcome the limitations of the early cell-culture technologies. Stem-cell technologies now make
high-quality human cells more broadly available, and bioengineering allows the
reproduction of organ architecture and function in cell culture. Such advanced
organotypic cell models are now often called microphysiological systems. They
promise to provide all life sciences, including safety sciences (Andersen et al.,
2014; Marx et al., 2016; Smirnova et al., 2018), with more meaningful functional
organ models, overcoming many of the shortcomings of traditional cell culture
(Pamies and Hartung, 2017) and, thereby, making them more competitive to
animal experimentation. Our own development of human mini-brains from
stem cells (Pamies et al., 2017) may serve as an example for the many models
mushrooming as a consequence of stem-cell technologies and advances in
bioengineering.
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Validating Animal Models and Their Alternatives

The ultimate quality control and the basis for replacing an animal method is
formal validation of alternative methods (Leist et al., 2012). This started with
the creation of the first validation body, the European Centre for the Validation
of Alternative Methods (ecvam) in 1991 (which the author headed between
2002 and 2008). Since then, validation has been internationally harmonized
and also required for new animal test methods by the Organisation for Economic Co-operation and Development (oecd) (2005). The validation process
was developed for regulatory tests (mainly originating from drug safety testing,
but with a focus on their application to cosmetics and industrial chemicals),
where safety is at stake, and is not generally considered necessary for other areas of the life sciences. However, the elements and principles of validation are
very much advisable to any type of experimental work (i.e., the clear definition
of the method—its purpose, execution, and applications—and the assessment of its reproducibility and relevance) and are vital to moving away from
animal experiments. Successful examples of validation include testing for skin
and eye corrosion and irritation, phototoxicity, skin sensitization, pyrogenicity,
and batch testing for several vaccines in international test guidelines from the
oecd and different pharmacopoeias. The reader is referred to the websites
of validation bodies, such as ecvam and its US counterpart, the Interagency
Coordinating Committee on the Validation of Alternative Methods (iccvam);
and the independent website, AltTox.org, which keep track of the status of the
validation and acceptance of testing methods.
Validation has taught us, first of all, that clear definitions of a test and its
purpose are needed. It is astonishing to see how often these are not clearly
stated in scientific literature and the whole field of animal research. Second,
validation formally addresses reproducibility. While requiring ring trials of a
new method is certainly going too far, a more formal reporting on reproducibility (starting with a clear distinction between what was done repeatedly, and
what was done in parallel technical replicates only) is an important element of
addressing the prevailing reproducibility crisis. The most overlooked element
of validation within the life sciences is to formally establish the relevance of a
test. This might sound odd to a lay audience, but in science we often produce
results in a model system and then uncritically translate them to the system
being modeled (usually humans).
Often lacking in our scientific papers are formal assessments of the scientific basis of the new methods (are the relevant mechanisms reflected?) and their
interspecies predictivity, as well as a demonstration that the model gives meaningful results with well-known reference compounds. The “cherry-picking” of
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the literature backing our results creates enormous bias. A change in scientific paradigm is needed towards evidence-based approaches. Here too, within
the preclinical sciences, it is toxicology and the search for alternatives that are
spearheading relevant developments, i.e., the creation of evidence-based toxicology (Hoffmann and Hartung, 2006), with systematic reviews of the literature (Stephens et al., 2016).
6

Alternative Technologies in Toxicology as a Roadmap for Basic
and Applied Research

Much of what has been written above is centered on in vitro methods. In silico
methods have undergone similar developments making them a central tool
in the life sciences and regulatory assessments (Ekins, 2014). Ever-increasing
computer-power allows more and more applications of these methods. However, their limitations so far prohibit regulatory use on a large scale (Hartung
and Hoffmann, 2009); this seems to result from the fact that most approaches
have looked for an exact formula to describe parts of the chemical universe
from the structures of the chemicals. This has proven to be difficult owing to
the quality problems of the animal input data and the quite small datasets generally available. More recently, however, in silico methods have gained ground,
especially the very pragmatic area of data-gap filling by read-across. Readacross is based on the principle that similar chemicals have similar toxicological effects; i.e., it suggests taking over the results from similar chemicals with
the respective reasoning about similar chemistry, chemicophysical properties,
uptake, metabolism, and biological effect. The use of read-across flourished
in the context of reach (Patlewicz et al., 2014), but the extent of its applicability and how to conduct and report it are under debate. This has prompted
the development of Good Read-Across Practices (Ball et al., 2016) and ideas for
a more automated read-across (Hartung, 2016). The latter development also
makes use of the emerging large toxicological databases (Luechtefeld et al.,
2016). These machine-learning approaches are agnostic to the biological effect
studied and are similarly useful in drug discovery. Other in silico approaches,
which are mushrooming, include modeling from receptor binding to cells, organs, and organisms. In short, the informatics revolution fuels the replacement
of animal tests with increasing pace (Ekins, 2014).
Increasingly, in vitro and in silico methods are combined, forming integrated
testing strategies, acknowledging that one method alone does not satisfy all
information needs (Hartung et al., 2013; Rovida et al., 2015a). While the idea
is rather simple, the systematic composition, optimization, and validation of
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such strategies are still in their infancy. Again, the safety sciences are spearheading the concept, also combining it with a more mechanistic approach
(Tollefsen et al., 2014); but the needs and opportunities are not very different
for other areas of the life sciences. Mechanistic toxicology has been boosted
by the recent cataloging of mechanisms as adverse outcome pathways (aop)
(Leist et al., 2017), which have been systematically developed under the umbrella of the OECD and which help the discussion and design of integrated
testing strategies, among others. Similarly, modern drug development integrates different testing tools, though this could often benefit from a more formal integration of tests. It is interesting what can be learned from the mass
testing of environmental chemicals. Simply said, for tests, 1+1 is more than 2
when well integrated.
In the life sciences, the increases in molecular and mechanistic understanding—as exemplified by the mapping of the human genome—have given rise
to mechanistic models throughout experimental medicine (Langley et al.,
2015). The new approaches do not simply replace or complement animal tests;
they are enabling technologies that outperform the animal-based procedures
as soon as sufficient mechanistic understanding shows their physiological
relevance. The increasing use of non-animal methods corresponds with this
stronger mechanistic emphasis of research: biochemistry and molecular biology have dramatically changed how we understand physiology and disease.
It is very difficult to identify a mechanism leading to disease in the whole animal organism, and it is very difficult to test selectively for a certain mechanism
employed by a test substance using a complex animal model. An understanding of pathways increasingly allows the modeling of (patho-) physiology as
a systems biology (systems toxicology) approach (Hartung et al., 2012, 2017,
Smirnova et al., 2018). The scientific progress that is demanding more tailored
experimental systems has been automatically making animal testing superfluous to needs (Rovida et al., 2015b). Figure 28.1 illustrates these developments.
7

Barriers to Non-animal Methods

The major obstacle for the development of new non-animal models is the prevailing over-reliance on the value of animal-based procedures as an information source in the life sciences. As long as researchers believe that they cannot
produce the high-level publications needed to enhance their career without
a new gene knock-out mouse, many researchers will choose animal experiments. A transparent and objective assessment of animal research’s shortcomings is, therefore, key for opening the scientific community to change. The
reproducibility crisis noted in the life sciences is, therefore, a godsend for those
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Early Alternatives

Today
Organo-typic
Cell Culture
(Coculture, Organ function,
often Perfusion)

Cell Culture
(one cell type,
few parameters)

Cell Culture + Omics
or Image Analysis
(high-content)
Automated Cell
Culture
(high-throughput
Screening)

Structure / ActivityRelationships
(Correlations)

Figure 28.1

Future

Integrated
Test Strategies
(combined tests)

Human-on-chip
(Multi-Organ Models
With Micro fluidics)

Toxicity Mechanisms
(“Adverse Outcome Pathways”,
“Human Toxome”)

Systems Toxicology
(“Virtual Patient”)

Modeling
(Receptor binding,
Virtual Organs, Kinetics)

The technological developments in alternative methods in toxicology
(Busquet and Hartung, 2017; reproduced with permission). Technologies
listed as today refer to the more broadly available new technologies, while
those only emerging are listed as future.

who want such a discussion about the shortcomings and misdirection of animal tests and models.
For decades, our desire to study the complexity of the human organism
and its diseases seemed feasible only through using animals. Increasingly,
however, very different complex systems are now used. These new approaches challenge the value of costly and time-consuming animal models and
erode the justification for causing animal suffering. In vitro and in silico tools
are cheaper and faster and, thus, can usually be carried out more readily and
with greater ease of quality control. With such quality control, sometimes
supported by validation, they represent robust methods for data generation. They are simplistic and partial, i.e. only reflecting a small fraction of
(patho-) physiology. However, this is overcome by two principal approaches:
reproducing complexity in the models (e.g., [multi-] organs on a chip); and
combining pieces of information in integrated testing strategies or modeling (e.g., systems biology). Ultimately, all alternative approaches come with
limitations too; but compared to animal models, these limitations can be
surmounted by combining these new advanced animal-free models. With
the ongoing improvements of these technologies and their (combined) use,
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we will be able to rely less and less on the evidently unsound animal component in this mix.
8

Concluding Thoughts

Many developments summarized here hint at an upcoming scientific revolution, changing the paradigm and predominance of animal experimentation in
the life sciences. In his influential book, The Structure of Scientific Revolutions
(1962), Thomas Samuel Kuhn (1922–1996) laid out some principles that nurture
this expectation (Hartung, 2008). Our current belief system is being shattered
by, among other things, the reproducibility crisis. Kuhn (1962) remarked that
“normal science […] often suppresses fundamental novelties because they are
necessarily subversive of its basic commitments” (p. 5); a good description of
how alternatives have been perceived by many in the scientific establishment.
The revolution takes place when “the tradition-shattering complements to the
tradition-bound activity of normal science” (p. 6) hit. This is exactly what we
observe with accelerated technological opportunities to transition into mechanistic, cellular, and even molecular understanding. The old (animal) model
simply does not fully meet the needs of scientific and economic progress; it
fails in cost, speed, level of detail of understanding, and human relevance. On
top of this, animal experimentation lacks acceptance by an ethically evolving
society. So let us embrace the revolution.
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After years of science education, teaching experience, and research practice,
which focused on the use of non-human primates as potential models of human psychological disorders, a young student in my primate behavior class
amiably, but insistently, suggested my preparation was incomplete. She asked
me to read Peter Singer’s book Animal Liberation, which had been published
two years earlier, in 1975. I had been lecturing in class about the effects of early
experience on the rhesus monkey’s (Macaca mulatta) social and intellectual
development, and my descriptions of the invasive research interventions and
behavioral consequences encouraged her to make the book suggestion. I said
I would try to find the time, but that I was busy. She handed me a fresh new
copy of the book saying, “This is for you.” She made it clear that she was not
loaning me her copy but wanted the book to be part of my professional library.
Over the following weeks while describing this event to colleagues, many also
involved in animal research, I asked them if they had read Professor Singer’s
book. While some had heard of it, no one had actually read it. “Why should
I do that?” was a common tone of the comments. After all, our experimental standards were quite clear and seemed self-evidently valid. That is, if any
interesting and, therefore, valuable research question could not be tested in
humans for ethical reasons, then it could be evaluated in animal models. Pro
gress required risk, and progress was urgently needed. This powerful drive to
know and understand nature, so as to improve the welfare of human beings,
was what the bioethicist Paul Ramsey (1976) called, the research imperative, to
emphasize its motivational dominance.
In response to the student’s questioning looks as we saw one another in
class, and out of respect for her serious intention, I did finally read Animal
Liberation. The chapter titled, Tools for research or what the public doesn’t know
it is paying for, quickly trapped my attention. Three of the assertions of the
chapter were: (1) The raw descriptions of the experimental manipulations
done to animals revealed a shocking emotional callousness on the part of investigators; (2) The extent of the harms, which the animals were required to
absorb, seemed excessive in comparison with the many obvious or even trivial
facts discovered; (3) It was estimated that after all the experimental effort and
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a nimal suffering, approximately one quarter of the studies actually made it
into the open scientific literature. I thought the number was significantly less
than 25%. More personally, a significant part of the chapter raised specific ethical questions about the research of Harry F. Harlow, which also involved studying the effects of socially isolating infant rhesus monkeys from their mothers
and peers. Harlow was once one of my central mentors in graduate school and
continued to support me by providing monkey subjects and experimental advice. Singer described the laboratory where I was educated, and he sounded
morally disgusted. While I mostly rejected the implication, it was clear that the
basic assertion of Animal Liberation was that our vague and rarely articulated
ethical assumptions, when placed under the light of a sophisticated utilitarian
ethical analysis, revealed themselves to be simplistic, self-serving, and mostly
indifferent to science-generated animal harm and suffering.
As my colleagues and I began to see an increase in the number of pointed
questions about the validity and justification of animal models from students,
a few scientists, and from the public after 1975, curiosity about the controversy
and the issues raised turned to hardened defensiveness and something approaching contempt for the questioners. We bolstered our dismissiveness by
making forceful statements about the demands of the research imperative and
the extent of human clinical need. We remained blind or just mute about the
dangers that can accrue when an imperative becomes an omnipotent and unassailable directive.
More subtle, but perhaps more dangerous, is that there is evidence that
many researchers have neglected and continue to neglect the notion that science is not just based on acts of direct perception of nature, followed by the
straightforward description of facts. Rather, it is a process strongly influenced
by psychological, social, and cultural forces. Ludwik Fleck, a microbiologist
who wrote as early as 1935 about how different sides of many scientific controversies evolved into thought collectives that demanded loyalty to the beliefs
of the collective and disdain for outsiders. Fleck showed that the collectives
were capable of shaping thought styles that could have the effect of limiting the
ability of members to actually understand divergent perspectives and to take
alternative research paths. The magisterial work of Thomas Kuhn (1962), in
The Structure of Scientific Revolutions, which built on Fleck (1935), articulated
how, what he termed, “normal science” could actively deny incorporating experimental findings that had the potential to disconfirm entrenched methods
and explanations. More recently, historians of science, such as David Wootton
(2007) in his book Bad Medicine: Doctors Doing Harm since Hippocrates, further
elaborate how the tendency of scientists to confer authority to “established”
theories and methods have been the central factor in the delay of medical
progress, and so it is now with much of the work in animal research.
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Animal Experimentation: Working Towards a Paradigm Change illustrates
how these crucial cautions about doing science, and the necessity to understand the complex nature of methodological choices, have remained surprisingly weak in encouraging checks on the tribal-like loyalty to the continued use
of animal models in the face of contrary evidence. It is as if Claude Bernard’s
(the father of modern physiology) brash nineteenth century assurance that
“experiments on animals are entirely conclusive for the toxicology and hygiene
of man” (Hajar, 2011) is in no need of modification. This trust is maintained
even in the face of the moral demands left by our increased knowledge of the
cognitive and emotional capabilities of the “other”, and the scientific understanding of physiological processes taking place below the level of magnification of the common microscope. By the time you, the readers, are at this point
in this volume, you have been exposed to an incredible variety of evidence of
the empirical failure of animal models to protect humans and to control many
diseases and maladies. You have seen the existence of regulatory dysfunction,
along with good faith attempts to structure legal systems that confront outmoded, ineffective, and pain-provoking research traditions. You have had a
look at parts of the incentive structure of science and its unfortunate facilitation of the good soldier keeping in line with traditional, safe expectations in
order to produce long vitas that are likely to be short on breakthroughs and
revolutionary excursions.
This carefully constructed and edited book needs to be held close by those
with brave-thinking hearts. I will place my copy right next to my well-worn edition of Animal Liberation given to me many years ago.
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